(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 May 2023 (11.05.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/081687 A1

(51) International Patent Classification:
C12N 15/113 (2010.01) *C12N 9/22* (2006.01)
C12N 15/11 (2006.01) *C12N 15/88* (2006.01)

(21) International Application Number:
PCT/US2022/079121

(22) International Filing Date:
02 November 2022 (02.11.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/275,426 03 November 2021 (03.11.2021) US
63/352,161 14 June 2022 (14.06.2022) US

(71) Applicant: **INTELLIA THERAPEUTICS, INC.** [US/US]; 40 Erie Street, Cambridge, Massachusetts 02139 (US).

(72) Inventors: **MULEPATI, Sabin**; 40 Erie Street, Cambridge, Massachusetts 02139 (US). **STRETZ, Lindsey, Jean**; 40 Erie Street, Cambridge, Massachusetts 02139 (US). **YOUNG, Michelle**; 40 Erie Street, Cambridge, Massachusetts 02139 (US). **CHOI, Sung Hee**; 40 Erie Street, Cambridge, Massachusetts 02139 (US). **PARMAR, Rubina, Giare**; 40 Erie Street, Cambridge, Massachusetts 02139 (US).

(74) Agent: **BAUR, Amelia, Feulner** et al.; McNeill Baur PLLC, 125 Cambridge Park Drive, Suite 301, Cambridge, Massachusetts 02140 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,

(54) Title: MODIFIED GUIDE RNAS FOR GENE EDITING



Fig. 37

(57) Abstract: This disclosure relates to modified guide RNAs having improved *in vitro* and *in vivo* activity in gene editing methods. This disclosure also relates to *N. meningitidis* Cas9 (NmeCas9) gene editing systems with modified guide RNAs.

[Continued on next page]

WO 2023/081687 A1

SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

MODIFIED GUIDE RNAS FOR GENE EDITING

[001] This application claims the benefit of priority to United States Provisional Application No. 63/275,426 filed on November 3, 2021, and United States Provisional Application No. 63/352,161 filed on June 14, 2022, the contents of both of which are incorporated by reference in their entirety.

[002] The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on November 1, 2022, is named 01155-0048-00PCT_ST26 and is 1,429,694 bytes in size.

[003] This disclosure relates to the field of gene editing using CRISPR/Cas9 systems, a part of the prokaryotic immune system that recognizes and cuts exogenous genetic elements.

[004] The CRISPR/Cas9 system relies on a single nuclease, termed CRISPR-associated protein 9 (Cas9), which induces site-specific breaks in DNA. Cas9 is guided to specific DNA sequences by small RNA molecules termed guide RNA (gRNA). A complete guide RNA comprises tracrRNA (trRNA) and crisprRNA (crRNA). A crRNA comprising a guide region may also be referred to as a gRNA, with the understanding that to form a complete gRNA it should be or become associated covalently or noncovalently with a trRNA. The trRNA and crRNA may be contained within a single guide RNA (sgRNA) or in two separate RNA molecules of a dual guide RNA (dgRNA). Cas9 in combination with gRNA is termed the Cas9 ribonucleoprotein complex (RNP).

[005] CRISPR/Cas9 systems exist in various bacterial species, and can have different properties, including with respect to gRNA length and degree of sequence-specificity in cleavage. *Neisseria meningitidis* Cas9 (NmeCas9) has an advantageously low off-target cleavage rate but uses relatively long gRNAs, which complicates *in vitro* gRNA synthesis.

[006] Oligonucleotides, and in particular RNA, are sometimes degraded in cells and in serum by non-enzymatic, endonuclease or exonuclease cleavage. Oligonucleotides can be synthesized with modifications at various positions to reduce or prevent such degradation. Given the cyclic nature and imperfect yield of oligonucleotide synthesis, shortening the gRNA while retaining or even improving its activity would be desirable, e.g., so that the gRNA can be obtained in greater yield, or compositions comprising the gRNA have greater homogeneity or fewer incomplete or erroneous products. Additionally, improved methods

and compositions for preventing such degradation, improving stability of gRNAs and enhancing gene editing efficiency is desired, especially for therapeutic applications. The present disclosure aims to meet one or more of these needs, provide other benefits, or at least provide the public with a useful choice.

SUMMARY

[007] The present disclosure relates to gene editing using *Neisseria meningitidis* CRISPR/Cas9 systems. NmeCas9 is smaller than *Streptococcus pyogenes* Cas9 (SpyCas9), allowing NmeCas9 to be suitable for messenger RNA (mRNA)-based delivery methods. However, NmeCas9 forms an RNP with a gRNA that is longer than a SpyCas9 guide RNA. Conventionally used gRNA for NmeCas9 has a length of 145 or more nucleotides (Ibraheim et al. Genome Biology (2018) 19:137) and shortening the gRNA while retaining or even improving its activity would be desirable for preventing degradation and improving stability of gRNAs and enhancing gene editing efficiency.

[008] In some embodiments, genome editing tools are provided comprising guide RNA (gRNA) with one or more shortened regions as described herein. The shortened regions described herein may facilitate synthesis of the gRNA with greater yield or homogeneity, or may improve the stability of the gRNA and the gRNA/Cas9 complex, or improve the activity of Cas9 to cleave target DNA.

[009] In some embodiments, crisprRNA (crRNA) or tracrRNA (trRNA) with one or more shortened regions or substitutions as described herein are provided. In some embodiments, a dual guide RNA (dgRNA) comprises the modified crRNA or modified trRNA. In some embodiments, a single guide RNA (sgRNA) comprises the modified crRNA or modified trRNA. The shortened regions or substitutions described herein may facilitate synthesis of the gRNA with greater yield or homogeneity or may improve the stability of the gRNA and the gRNA/Cas9 complex, or improve the activity of NmeCas9 to cleave target DNA. Compared to NmeCas9 145-mer sgRNAs, synthesis of the presently disclosed gRNAs may increase crude yield of a gRNA. Similarly, gRNA sample purity as measured by the proportion of full length product, e.g., crude purity, can be increased. Guide RNA can be obtained in greater yield, or compositions comprising the gRNA can have greater homogeneity or fewer incomplete or erroneous products. Guide RNA purity may be assessed using ion-pair reversed-phase high performance liquid chromatography (IP-RP-HPLC) and ion exchange HPLC methods, e.g., as in Kanavarioti et al, Sci Rep **9**, 1019 (2019) (doi:10.1038/s41598-018-37642-z). Using UV spectroscopy at a wavelength of 260 nm,

crude purity and final purity can be determined by the ratio of absorbance of the main peak to the cumulative absorbance of all peaks in the chromatogram. Synthetic yield is determined as the ratio of the absorbance at 260 nm of the final sample compared to the theoretical absorbance of input materials.

[0010] The following embodiments are encompassed.

[0011] In some embodiments, a guide RNA (gRNA) is provided, the guide RNA comprising a guide region and a conserved region, the conserved region comprising one or more of:

(a) a shortened repeat/anti-repeat region, wherein the shortened repeat/anti-repeat region lacks 2-24 nucleotides, wherein

(i) one or more of nucleotides 37-48 and 53-64 is deleted and optionally one or more of nucleotides 37-64 is substituted relative to SEQ ID NO: 500; and

(ii) nucleotide 36 is linked to nucleotide 65 by at least 2 nucleotides; or

(b) a shortened hairpin 1 region, wherein the shortened hairpin 1 lacks 2-10, optionally 2-8 nucleotides, wherein

(i) one or more of nucleotides 82-86 and 91-95 is deleted and optionally one or more of positions 82-96 is substituted relative to SEQ ID NO: 500; and

(ii) nucleotide 81 is linked to nucleotide 96 by at least 4 nucleotides; or

(c) a shortened hairpin 2 region, wherein the shortened hairpin 2 lacks 2-18, optionally 2-16 nucleotides, wherein

(i) one or more of nucleotides 113-121 and 126-134 is deleted and optionally one or more of nucleotides 113-134 is substituted relative to SEQ ID NO: 500; and

(ii) nucleotide 112 is linked to nucleotide 135 by at least 4 nucleotides;

wherein one or both nucleotides 144-145 are optionally deleted relative to SEQ ID NO: 500;

wherein at least 10 nucleotides are modified nucleotides.

[0012] In some embodiments, a guide RNA (gRNA) is provided, the guide RNA comprising a guide region and a conserved region, the conserved region comprising one or more of:

(a) a shortened repeat/anti-repeat region, wherein the shortened repeat/anti-repeat region lacks 18-22 nucleotides relative to SEQ ID NO: 500, wherein

(i) nucleotides 37-48 and 53-64 are deleted; and

(ii) nucleotide 36 is linked to nucleotide 65 by 6-10 nucleotides; or

(b) a shortened hairpin 1 region, wherein the shortened hairpin 1 lacks 2 nucleotides, wherein nucleotides 86 and 91 are deleted or nucleotides 85 and 92 are deleted relative to SEQ ID NO: 500; or

(c) a shortened hairpin 2 region, wherein the shortened hairpin 2 lacks 18 nucleotides, wherein nucleotides 113-121 and 126-134 are deleted relative to SEQ ID NO: 500; and

wherein nucleotides 144-145 are deleted relative to SEQ ID NO: 500;

wherein at least 10 nucleotides are modified nucleotides.

[0013] The guide RNA (gRNA) of the previous embodiment comprising a guide region and a conserved region, the conserved region comprising:

(a) a shortened repeat/anti-repeat region, wherein the shortened repeat/anti-repeat region lacks 18-22 nucleotides, wherein

(i) nucleotides 37-48 and 53-64 are deleted relative to SEQ ID NO: 500; and

(ii) nucleotide 36 is linked to nucleotide 65 by 6-10 nucleotides;

(b) a shortened hairpin 1 region, wherein the shortened hairpin 1 lacks 2 nucleotides relative to SEQ ID NO: 500, wherein nucleotides 86 and 91 are deleted or nucleotides 85 and 92 are deleted;

(c) a shortened hairpin 2 region, wherein the shortened hairpin 2 lacks 18 nucleotides, wherein nucleotides 113-121 and 126-134 are deleted relative to SEQ ID NO: 500; and

(d) wherein nucleotides 144-145 are deleted relative to SEQ ID NO: 500;

wherein at least 10 nucleotides are modified nucleotides.

[0014] In further embodiments, the shortened repeat/anti-repeat region, wherein the shortened repeat/anti-repeat region lacks 22 nucleotides relative to SEQ ID NO: 500. In further embodiments, nucleotide 36 is linked to nucleotide 65 by a sequence comprising the nucleotide sequence UGAAAC. In further embodiments, nucleotide 36 is linked to nucleotide 65 by 10 nucleotides. In further embodiments, the nucleotide 36 is linked to nucleotide 65 by a sequence comprising the nucleotide sequence UUCGAAAGAC (SEQ ID NO: 950).

[0015] In some embodiments, the gRNA comprises a 5' end modification. In some embodiments, the gRNA comprises a 3' end modification. In some embodiments, the gRNA comprises a 5' end modification and a 3' end modification. In some embodiments, the gRNA comprises a modification in the upper stem region of the repeat/anti-repeat region. In some embodiments, the gRNA comprises a modification in the hairpin 1 region. In some embodiments, the gRNA comprises a modification in the hairpin 2 region.

[0016] In some embodiments, any of the foregoing modification is a modified nucleotide is selected from 2'-O-methyl (2'-OMe) modified nucleotide, 2'-O-(2-methoxyethyl) (2'-O-

moe) modified nucleotide, a 2'-fluoro (2'-F) modified nucleotide, a phosphorothioate (PS) linkage between nucleotides, or an inverted abasic modified nucleotide, optionally wherein the gRNA comprises at least two modifications independently selected from a 2'-O-methyl (2'-OMe) modified nucleotide, 2'-O-(2-methoxyethyl) (2'-O-moe) modified nucleotide, a 2'-fluoro (2'-F) modified nucleotide, a phosphorothioate (PS) linkage between nucleotides, and an inverted abasic modified nucleotide.

[0017] In some embodiments, the 5' end modification comprises a modified nucleotide selected from (i) 2'-O-methyl (2'-OMe) modified nucleotide, (ii) 2'-O-(2-methoxyethyl) (2'-O-moe) modified nucleotide, (iii) a 2'-fluoro (2'-F) modified nucleotide, (iv) a phosphorothioate (PS) linkage between nucleotides, or (v) an inverted abasic modified nucleotide, optionally, wherein the gRNA comprises at least two 5' end modifications independently selected from (i)-(v).

[0018] In some embodiments, the 3' end modification comprises a modified nucleotide selected from (i) 2'-O-methyl (2'-OMe) modified nucleotide, (ii) 2'-O-(2-methoxyethyl) (2'-O-moe) modified nucleotide, (iii) a 2'-fluoro (2'-F) modified nucleotide, (iv) a phosphorothioate (PS) linkage between nucleotides, or (v) an inverted abasic modified nucleotide, optionally, wherein the gRNA comprises at least two 3' end modifications independently selected from (i)-(v).

[0019] In some embodiments, the 5' end modification comprises:

i. a modification of one or more of the first 1-4 nucleotides, wherein the modification is a PS linkage, inverted abasic nucleotide, 2'-OMe, 2'-O-moe, or 2'-F;
ii. a modification to the first nucleotide with 2'-OMe, 2'-O-moe, or 2'-F, and an optional one or two PS linkages to the next nucleotide or the first nucleotide of the 3' tail;
iii. a modification to the first or second nucleotide with 2'-OMe, 2'-O-moe, or 2'-F, and optionally one or more PS linkages;
iv. a modification to the first, second, or third nucleotides with 2'-OMe, 2'-O-moe, or 2'-F, and optionally one or more PS linkages; or
v. a modification to the first, second, third, or forth nucleotides with 2'-OMe, 2'-O-moe, or 2'-F, and optionally one or more PS linkages,

optionally, wherein the gRNA comprises at least two 5' end modifications independently selected from (i)-(v).

[0020] The gRNA of any one of the preceding claims, wherein the 3' end modification comprises:

i. a modification of one or more of the last 1-4 nucleotides, wherein the modification is a PS linkage, inverted abasic nucleotide, 2'-OMe, 2'-O-moe, or 2'-F;
ii. a modification to the last nucleotide with 2'-OMe, 2'-O-moe, or 2'-F, and an optional one or two PS linkages to the next nucleotide or the first nucleotide of the 3' tail;
iii. a modification to the last or second to last nucleotide with 2'-OMe, 2'-O-moe, or 2'-F, and optionally one or more PS linkages;
iv. a modification to the last, second to last, or third to last nucleotides with 2'-OMe, 2'-O-moe, or 2'-F, and optionally one or more PS linkages; or
v. a modification to the last, second to last, third to last, or fourth to last nucleotides with 2'-OMe, 2'-O-moe, or 2'-F, and optionally one or more PS linkages,

optionally wherein the gRNA comprises at least two 3' end modifications independently selected from (i)-(v).

[0021] In some embodiments, the modification in the repeat/anti-repeat region, the hairpin 1 region, or the hairpin 2 region comprises a modified nucleotide selected from (i) 2'-O-methyl (2'-OMe) modified nucleotide, (ii) 2'-O-(2-methoxyethyl) (2'-O-moe) modified nucleotide, (iii) a 2'-fluoro (2'-F) modified nucleotide, or (iv) a phosphorothioate (PS) linkage between nucleotides, optionally wherein the modification in the repeat/anti-repeat region, the hairpin 1 region, or the hairpin 2 region comprises at least two modifications independently selected from (i)-(iv).

[0022] In some embodiments, the modification in the repeat/anti-repeat region, the hairpin 1 region, or the hairpin 2 region comprises a modified nucleotide selected from (i) 2'-O-methyl (2'-OMe) modified nucleotide, (ii) a 2'-fluoro (2'-F) modified nucleotide, or (iii) a phosphorothioate (PS) linkage between nucleotides, optionally wherein the repeat/anti-repeat

region, the hairpin 1 region, or the hairpin 2 region comprises at least two modifications independently selected from (i)-(iii).

[0023] In some embodiments, the modification in the repeat/anti-repeat region, the hairpin 1 region, or the hairpin 2 region comprises a modified nucleotide selected from (i) 2'-O-methyl (2'-OMe) modified nucleotide, or (ii) a phosphorothioate (PS) linkage between nucleotides, optionally wherein the repeat/anti-repeat region, the hairpin 1 region, or the hairpin 2 region comprises at least two modifications independently selected from (i) and (ii).

[0024] In some embodiments, a composition comprising a gRNA associated with a lipid nanoparticle (LNP) disclosed herein is provided. In some embodiments, an LNP composition comprising a gRNA disclosed herein is provided. In some embodiments, the composition further comprises a nuclease or an mRNA which encodes the nuclease.

[0025] The following additional embodiments are provided herein.

[0026] Embodiment 1 is a guide RNA (gRNA) comprising a guide region and a conserved region, the conserved region comprising one or more of:

(a) a shortened repeat/anti-repeat region, wherein the shortened repeat/anti-repeat region lacks 2-24 nucleotides, wherein

(i) one or more of nucleotides 37-48 and 53-64 is deleted and optionally one or more of nucleotides 37-64 is substituted relative to SEQ ID NO: 500; and

(ii) nucleotide 36 is linked to nucleotide 65 by at least 2 nucleotides; or

(b) a shortened hairpin 1 region, wherein the shortened hairpin 1 lacks 2-10, optionally 2-8 nucleotides, wherein

(i) one or more of nucleotides 82-86 and 91-95 is deleted and optionally one or more of positions 82-96 is substituted relative to SEQ ID NO: 500; and

(ii) nucleotide 81 is linked to nucleotide 96 by at least 4 nucleotides; or

(c) a shortened hairpin 2 region, wherein the shortened hairpin 2 lacks 2-18, optionally 2-16 nucleotides, wherein

(i) one or more of nucleotides 113-121 and 126-134 is deleted and optionally one or more of nucleotides 113-134 is substituted relative to SEQ ID NO: 500; and

(ii) nucleotide 112 is linked to nucleotide 135 by at least 4 nucleotides;

wherein one or both nucleotides 144-145 are optionally deleted relative to SEQ ID NO: 500;

wherein at least 10 nucleotides are modified nucleotides.

[0027] Embodiment 2 is the gRNA of Embodiment 1, wherein the gRNA is a single-guide RNA (sgRNA) and wherein the gRNA comprises (a) a shortened repeat/anti-repeat region, wherein the shortened repeat/anti-repeat region lacks 2-24 nucleotides, wherein

(i) one or more of nucleotides 37-48 and 53-64 is deleted and optionally one or more of nucleotides 37-64 is substituted relative to SEQ ID NO: 500; and

(ii) nucleotide 36 is linked to nucleotide 65 by at least 2 nucleotides.

[0028] Embodiment 3 is the gRNA of Embodiment 1 or 2, wherein the guide region has (i) an insertion of one nucleotide or a deletion of 1-4 nucleotides within positions 1-24 relative to SEQ ID NO: 500, or (ii) a length of 24 nucleotides.

[0029] Embodiment 4 is the gRNA of Embodiment 3, wherein the guide region has a length of 25, 24, 23, 22, 21, or 20 nucleotides, optionally wherein the guide region has a length of 25, 24, 23, or 22 nucleotides.

[0030] Embodiment 5 is the gRNA of Embodiment 4, wherein the guide region has a length of 23-24 nucleotides.

[0031] Embodiment 6 is the gRNA of any one of Embodiments 1-5, wherein the gRNA further comprises a 3' tail.

[0032] Embodiment 7 is the gRNA of Embodiment 6, wherein the 3' tail comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides.

[0033] Embodiment 8 is the gRNA of Embodiment 7, wherein the 3' tail comprises 1, 2, 3, 4, or 5 nucleotides.

[0034] Embodiment 9 is the gRNA of any one of Embodiments 6-8, wherein the 3' tail terminates with a nucleotide comprising a uracil or modified uracil.

[0035] Embodiment 10 is the gRNA of any one of Embodiments 6-9, wherein the 3' tail is 1 nucleotide in length.

[0036] Embodiment 11 is the gRNA of any one of Embodiments 6-10, wherein the 3' tail consists of a nucleotide comprising a uracil or a modified uracil.

[0037] Embodiment 12 is the gRNA of any one of Embodiments 6-11, wherein the 3' tail comprises a modification of any one or more of the nucleotides present in the 3' tail.

[0038] Embodiment 13 is the gRNA of any one of Embodiments 6-12, wherein the modification of the 3' tail is one or more of 2'-O-methyl (2'-OMe) modified nucleotide and a phosphorothioate (PS) linkage between nucleotides.

[0039] Embodiment 14 is the gRNA of any one of Embodiments 6-13, wherein the 3' tail is fully modified.

[0040] Embodiment 15 is the gRNA of any one of Embodiments 1-14, wherein the 3' nucleotide of the gRNA is a nucleotide comprising a uracil or a modified uracil.

[0041] Embodiment 16 is the gRNA of any one of Embodiments 1-5, wherein one or more of nucleotides 144 and 145 are deleted relative to SEQ ID NO: 500.

[0042] Embodiment 17 is the gRNA of any one of Embodiments 1-5, wherein both nucleotides 144 and 145 are deleted relative to SEQ ID NO: 500.

[0043] Embodiment 18 is the gRNA of any one of Embodiments 1-5, wherein the gRNA does not comprise a 3' tail.

[0044] Embodiment 19 is the gRNA of any one of Embodiments 1-18, wherein the shortened repeat/anti-repeat region lacks 2-24 nucleotides.

[0045] Embodiment 20 is the gRNA of any one of Embodiments 1-19, wherein the shortened repeat/anti-repeat region has a length of 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides.

[0046] Embodiment 21 is the gRNA of any one of Embodiments 1-20, wherein the shortened repeat/anti-repeat region lacks 12-24, optionally 18-24 nucleotides, optionally 20-22 nucleotides.

[0047] Embodiment 22 is the gRNA of any one of Embodiments 1-21, wherein the shortened repeat/anti-repeat region has a length of 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides.

[0048] Embodiment 23 is the gRNA of any one of Embodiments 1-22, wherein the shortened repeat/anti-repeat region has a length of 28, 29, 30, 31, 32, 33, or 34 nucleotides, or 30, 31, or 32 nucleotides.

[0049] Embodiment 24 is the gRNA of any one of Embodiments 1-23, wherein nucleotides 37-64 of SEQ ID NO: 500 form the upper stem, and one or more base pairs of the upper stem of the shortened repeat/anti-repeat region are deleted.

[0050] Embodiment 25 is the gRNA of any one of Embodiments 1-24, wherein the upper stem of the shortened repeat/anti-repeat region comprises no more than one, two, three, or four base pairs.

[0051] Embodiment 26 is the gRNA of any one of Embodiments 1-25, wherein all of positions 39-48 and all of positions 53-62 of the upper stem of the shortened repeat/anti-repeat region are deleted, and optionally nucleotide 38 or 63 is substituted.

[0052] Embodiment 27 is the gRNA of any one of Embodiments 1-26, wherein all of positions 38-48 and all of positions 53-63 of the upper stem of the shortened repeat/anti-repeat region are deleted, and optionally nucleotide 37 or 64 is substituted.

[0053] Embodiment 28 is the gRNA of any one of Embodiments 1-27, wherein all of nucleotides 37-48 and 53-64 of the upper stem of the shortened repeat/anti-repeat region are deleted, and optionally nucleotides 36 or 65 is substituted.

[0054] Embodiment 29 is the Grna of any one of Embodiments 1-28, wherein the shortened repeat/anti-repeat region has a duplex portion 11 base paired nucleotides in length.

[0055] Embodiment 30 is the gRNA of any one of Embodiments 1-29, wherein the shortened repeat/anti-repeat region has a single duplex portion.

[0056] Embodiment 31 is the gRNA of any one of Embodiments 1-29, wherein the shortened repeat/anti-repeat region has a first duplex portion and a second duplex portion.

[0057] Embodiment 32 is the gRNA of Embodiment 31, wherein the second duplex portion is 2-3 base paired nucleotides in length.

[0058] Embodiment 33 is the gRNA of Embodiment 31, wherein the first duplex portion is 11 base paired nucleotides in length and the second duplex portion is 3 base paired nucleotides in length.

[0059] Embodiment 34 is the gRNA of any one of Embodiments 1-33, wherein the upper stem of the shortened repeat/anti-repeat region includes one or more substitutions relative to SEQ ID NO: 500.

[0060] Embodiment 35 is the gRNA of any one of Embodiments 1-34, wherein one or more of nucleotides 49-52 is substituted relative to SEQ ID NO: 500.

[0061] Embodiment 36 is the gRNA of any one of Embodiments 1-33, wherein the shortened repeat/anti-repeat region is unsubstituted.

[0062] Embodiment 37 is the gRNA of any one of Embodiments 1-36, wherein the shortened repeat/anti-repeat region has 12-22 modified nucleotides

[0063] Embodiment 38 is the gRNA of Embodiment 37, wherein the shortened repeat/anti-repeat region does not comprise a modification at nucleotide 76.

[0064] Embodiment 39 is the gRNA of Embodiment 37, wherein the shortened repeat/anti-repeat does not comprise a phosphorothioate (PS) modification at nucleotide 76.

[0065] Embodiment 40 is the gRNA of any one of Embodiments 1-39, wherein the shortened hairpin 1 region lacks 2-10 nucleotides, optionally 2-8 or 2-4 nucleotides.

[0066] Embodiment 41 is the gRNA of any one of Embodiments 1-40, wherein the shortened hairpin 1 region has a length of 13, 14, 15, 16, 17, 18, 19, 20, or 21 nucleotides.

[0067] Embodiment 42 is the gRNA of Embodiment any one of Embodiments 1-41, wherein the shortened hairpin 1 region has a duplex portion 4-8, optionally 7-8 base paired nucleotides in length.

[0068] Embodiment 43 is the gRNA of Embodiment any one of Embodiments 1-41, wherein the shortened hairpin 1 region has a single duplex portion.

[0069] Embodiment 44 is the gRNA of any one of Embodiments 1-43, wherein one or two base pairs of the shortened hairpin 1 region are deleted.

[0070] Embodiment 45 is the gRNA of any one of Embodiments 1-44, wherein the stem of the shortened hairpin 1 region is seven or eight base paired nucleotides in length.

[0071] Embodiment 46 is the gRNA of any one of Embodiments 1-45, wherein one or more of positions 85-86 and one or more of nucleotides 91-92 of the shortened hairpin 1 region are deleted.

[0072] Embodiment 47 is the gRNA of any one of Embodiments 1-46, wherein nucleotides 86 and 91 or nucleotides 85 and 92 of the shortened hairpin 1 region are deleted.

[0073] Embodiment 48 is the gRNA of any one of Embodiments 1-47, wherein one or more of nucleotides 82-95 of the shortened hairpin 1 region is substituted relative to SEQ ID NO: 500.

[0074] Embodiment 49 is the gRNA of any one of Embodiments 1-48, wherein one or more of nucleotides 87-90 is substituted relative to SEQ ID NO: 500.

[0075] Embodiment 50 is the gRNA of any one of Embodiments 1-48, wherein the shortened hairpin 1 region is unsubstituted.

[0076] Embodiment 51 is the gRNA of any one of Embodiments 1-49, wherein the shortened hairpin 1 region has 6-15 modified nucleotides.

[0077] Embodiment 52 is the gRNA of any one of Embodiments 1-50, wherein the shortened hairpin 2 region lacks 2-18, optionally 2-16 nucleotides.

[0078] Embodiment 53 is the gRNA of any one of Embodiments 1-51, wherein the shortened hairpin 2 region has a length of 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides.

[0079] Embodiment 54 is the gRNA of any one of Embodiments 1-52, wherein the shortened hairpin 2 region has a length of 28, 29, 30, 31, 32, 33, or 34 nucleotides.

[0080] Embodiment 55 is the gRNA of any one of Embodiments 1-53, wherein one or more of nucleotides 113-121 and one or more of nucleotides 126-134 of the shortened hairpin 2 region are deleted.

[0081] Embodiment 56 is the gRNA of any one of Embodiments 1-54, wherein the shortened hairpin 2 region comprises an unpaired region.

[0082] Embodiment 57 is the gRNA of any one of Embodiments 1-55, wherein the shortened hairpin 2 region has two duplex portions.

[0083] Embodiment 58 is the gRNA of any one of Embodiments 1-56, wherein the shortened hairpin 2 region has a duplex portion of 4 base paired nucleotides in length.

[0084] Embodiment 59 is the gRNA of any one of Embodiments 57-58, wherein the shortened hairpin 2 region has a duplex portion of 4-8 base paired nucleotides in length.

[0085] Embodiment 60 is the gRNA of any one of Embodiments 57-59, wherein the shortened hairpin 2 region has a duplex portion of 4-6 base paired nucleotides in length.

[0086] Embodiment 61 is the gRNA of any one of Embodiments 1-60, wherein nucleotides 109-138 of SEQ ID NO: 500 form the upper stem, and the upper stem of the shortened hairpin 2 region comprises one, two, three, or four base pairs.

[0087] Embodiment 62 is the gRNA of any one of Embodiments 1-61, wherein at least one pair of nucleotides 113 and 134, nucleotides 114 and 133, nucleotides 115 and 132, nucleotides 116 and 131, nucleotides 117 and 130, nucleotides 118 and 129, nucleotides 119 and 128, nucleotides 120 and 127, and nucleotides 121 and 126 are deleted.

[0088] Embodiment 63 is the gRNA of any one of Embodiments 1-62, wherein all of positions 113-121 and 126-134 of the shortened hairpin 2 region are deleted.

[0089] Embodiment 64 is the gRNA of any one of Embodiments 1-63, wherein one or more of nucleotides 113-134 of the shortened hairpin 2 region is substituted relative to SEQ ID NO: 500.

[0090] Embodiment 65 is the gRNA of any one of Embodiments 1-64, wherein one or more of nucleotides 122-125 is substituted relative to SEQ ID NO: 500.

[0091] Embodiment 66 is the gRNA of any one of Embodiments 1-64, wherein the shortened hairpin 2 region is unsubstituted.

[0092] Embodiment 67 is the gRNA of Embodiment any one of Embodiments 1-66, wherein the shortened hairpin 2 region has 6-15 modified nucleotides.

[0093] Embodiment 68 is the gRNA of any one of Embodiments 1-67, wherein the guide region of the gRNA comprises at least two modified nucleotides, optionally at least four modified nucleotides.

[0094] Embodiment 69 is the gRNA of any one of Embodiments 1-68, wherein the guide region of the gRNA comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 modified nucleotides, optionally 1, 2, or 3 modified nucleotides.

[0095] Embodiment 70 is the gRNA of any one of Embodiments 1-69, wherein the guide region of the gRNA comprises 4, 5, 6, 7, 8, 9, 10, 11, or 12 modified nucleotides.

[0096] Embodiment 71 is the gRNA of any one of Embodiments 1-70, wherein the guide region of the gRNA comprises 6, 7, 8, 9, 10, 11, or 12 modified nucleotides.

[0097] Embodiment 72 is the gRNA of any one of Embodiments 1-71, wherein the guide region does not comprise a modified nucleotide 3' of the first three nucleotides of the guide region.

[0098] Embodiment 73 is the gRNA of any one of Embodiments 1-66, wherein the guide region does not comprise a modified nucleotide.

[0099] Embodiment 74 is the gRNA of any one of Embodiments 1-72, wherein the gRNA comprises a 5' end modification.

[00100] Embodiment 75 is the gRNA of any one of Embodiments 1-74, wherein the gRNA comprises a 3' end modification.

[00101] Embodiment 76 is the gRNA of any one of Embodiments 1-75, wherein the gRNA comprises a 5' end modification and a 3' end modification.

[00102] Embodiment 77 is the gRNA of any one of Embodiments 1-76, comprising a modification in the upper stem region of the repeat/anti-repeat region.

[00103] Embodiment 78 is the gRNA of any one of Embodiments 1-77, comprising a modification in the hairpin 1 region.

[00104] Embodiment 79 is the gRNA of any one of Embodiments 1-78, comprising a modification in the hairpin 2 region.

[00105] Embodiment 80 is the gRNA of Embodiment 79, wherein the modification in the hairpin 2 region comprises a modification at 1, 2, 3, or 4 nucleotides of nucleotides 106-109.

[00106] Embodiment 81 is the gRNA of Embodiment 80, wherein the modification in the hairpin 2 region comprises a modification at each of nucleotides 106-109.

[00107] Embodiment 82 is the gRNA of any one of Embodiments 80 or 81, wherein the modification comprises a 2'-O-methyl (2'-O-Me) modification.

[00108] Embodiment 83 is the gRNA of any one of Embodiments 1-82, comprising a 3' end modification, and comprising a modification in the upper stem region of the repeat/anti-repeat region.

[00109] Embodiment 84 is the gRNA of any one of Embodiments 1-83, comprising a 3' end modification, and a modification in the hairpin 1 region.

[00110] Embodiment 85 is the gRNA of any one of Embodiments 1-83, comprising a 3' end modification, and a modification in the hairpin 2 region.

[00111] Embodiment 86 is the gRNA of any one of Embodiments 1-85, comprising a 5' end modification, and comprising a modification in the upper stem region of the repeat/anti-repeat region.

[00112] Embodiment 87 is the gRNA of any one of Embodiments 1-86, comprising a 5' end modification, and a modification in the hairpin 1 region.

[00113] Embodiment 88 is the gRNA of any one of Embodiments 1-87, comprising a 5' end modification, and a modification in the hairpin 2 region.

[00114] Embodiment 89 is the gRNA of any one of Embodiments 1-88, comprising a 5' end modification, a modification in the upper stem region of the repeat/anti-repeat region, and a 3' end modification.

[00115] Embodiment 90 is the gRNA of any one of Embodiments 1-89, comprising a 5' end modification, a modification in the hairpin 1 region, and a 3' end modification.

[00116] Embodiment 91 is the gRNA of any one of Embodiments 1-90, comprising a 5' end modification, a modification in the hairpin 1 region, a modification in the hairpin 2 region, and a 3' end modification.

[00117] Embodiment 92 is the gRNA of any one of Embodiments 1-91, comprising a 5' end modification, a modification in the repeat/anti-repeat region, a modification in the hairpin 1 region, a modification in the hairpin 2 region, and a 3' end modification.

[00118] Embodiment 93 is the gRNA of any one of Embodiments 1-92, wherein the modification in the repeat/anti-repeat region does not comprise a phosphorothioate (PS) modification at nucleotide 76.

[00119] Embodiment 94 is the gRNA of any one of Embodiments 1-93, wherein the modification in the repeat/anti-repeat region does not comprise a modification at nucleotide 76.

[00120] Embodiment 95 is the gRNA of any one of Embodiments 74-94, wherein the 5' end modification comprises a modified nucleotide selected from a 2'-O-methyl (2'-OMe) modified nucleotide, 2'-O-(2-methoxyethyl) (2'-O-moe) modified nucleotide, a 2'-fluoro (2'-F) modified nucleotide, a phosphorothioate (PS) linkage between nucleotides, or an inverted abasic modified nucleotide.

[00121] Embodiment 96 is the gRNA of any one of the Embodiments 74-95, wherein the 3' end modification comprises a modified nucleotide selected from a 2'-O-methyl (2'-OMe) modified nucleotide, 2'-O-(2-methoxyethyl) (2'-O-moe) modified nucleotide, a 2'-fluoro (2'-F) modified nucleotide, a phosphorothioate (PS) linkage between nucleotides, or an inverted abasic modified nucleotide .

[00122] Embodiment 97 is the gRNA of any one of the Embodiments 74-96, wherein the 5' end modification comprises any of:

i, a modification of any one or more of the first 1, 2, 3, or 4 nucleotides;

ii. one modified nucleotide;

iii. two modified nucleotides;
iv. three modified nucleotides; and
v. four modified nucleotides.

[00123] Embodiment 98 is the gRNA of any one of Embodiments 74-97, wherein the 5' end modification comprises one or more of:

i. a phosphorothioate (PS) linkage between nucleotides;
ii. a 2'-OMe modified nucleotide;
iii. a 2'-O-moe modified nucleotide;
iv. a 2'-F modified nucleotide; and
v. an inverted abasic modified nucleotide.

[00124] Embodiment 99 is the gRNA of any one of Embodiments 74-98, wherein the 3' end modification comprises any of:

i. a modification of any one or more of the last 4, 3, 2, or 1 nucleotides;
ii. one modified nucleotide;
iii. two modified nucleotides;
iv. three modified nucleotides; and
v. four modified nucleotides.

[00125] Embodiment 100 is the gRNA of any one of Embodiments 74-99, wherein the 3' end modification comprises one or more of:

i. a phosphorothioate (PS) linkage between nucleotides;
ii. a 2'-OMe modified nucleotide;
iii. a 2'-O-moe modified nucleotide;
iv. a 2'-F modified nucleotide; and
v. an inverted abasic modified nucleotide.

[00126] Embodiment 101 is the gRNA of any one of Embodiments 74-100, wherein the 5' end modification comprises at least one PS linkage, and wherein one or more of:

i. there is one PS linkage, and the linkage is between the first and second nucleotides;
ii. there are two PS linkages between the first three nucleotides;
iii. there are PS linkages between any one or more of the first four nucleotides; and

iv. there are PS linkages between any one or more of the first five nucleotides.

[00127] Embodiment 102 is the gRNA of Embodiment 101, wherein the 5' end modification further comprises at least one 2'-OMe, 2'-O-moe, inverted abasic, or 2'-F modified nucleotide.

[00128] Embodiment 103 is the gRNA of any one of Embodiments 1-102, wherein the 5' end modification comprises:

i. a modification of one or more of the first 1-4 nucleotides, wherein the modification is a PS linkage, inverted abasic nucleotide, 2'-OMe, 2'-O-moe, or 2'-F;

ii. a modification to the first nucleotide with 2'-Ome, 2'-O-moe, or 2'-F, and an optional one or two PS linkages to the next nucleotide or the first nucleotide of the 3' tail;

iii. a modification to the first or second nucleotide with 2'-Ome, 2'-O-moe, or 2'-F, and optionally one or more PS linkages;

iv. a modification to the first, second, or third nucleotides with 2'-Ome, 2'-O-moe, or 2'-F, and optionally one or more PS linkages; or

v. a modification to the first, second, third, or forth nucleotides with 2'-Ome, 2'-O-moe, or 2'-F, and optionally one or more PS linkages.

[00129] Embodiment 104 is the gRNA of any one of Embodiments 1-103, wherein the 3' end modification comprises at least one PS linkage, and wherein one or more of:

i. there is one PS linkage, and the linkage is between the last and second to last nucleotides;

ii. there are two PS linkages between the last three nucleotides; and

iii. there are PS linkages between any one or more of the last four nucleotides.

[00130] Embodiment 105 is the gRNA of Embodiment 104, wherein the 3' end modification further comprises at least one 2'-Ome, 2'-O-moe, inverted abasic, or 2'-F modified nucleotide.

[00131] Embodiment 106 is the gRNA of any one of Embodiments 1-105, wherein the 3' end modification comprises:

i. a modification of one or more of the last 1-4 nucleotides, wherein the modification is a PS linkage, inverted abasic nucleotide, 2'-OMe, 2'-O-moe, or 2'-F;

ii. a modification to the last nucleotide with 2'-OMe, 2'-O-moe, or 2'-F, and an optional one or two PS linkages to the next nucleotide or the first nucleotide of the 3' tail;
iii. a modification to the last or second to last nucleotide with 2'-OMe, 2'-O-moe, or 2'-F, and optionally one or more PS linkages;
iv. a modification to the last, second to last, or third to last nucleotides with 2'-OMe, 2'-O-moe, or 2'-F, and optionally one or more PS linkages; or
v. a modification to the last, second to last, third to last, or fourth to last nucleotides with 2'-OMe, 2'-O-moe, or 2'-F, and optionally one or more PS linkages.

[00132] Embodiment 107 is the gRNA of any one of Embodiments 1-106, wherein the modification in the repeat/anti-repeat region, the hairpin 1 region, or the hairpin 2 region comprises a modified nucleotide selected from 2'-O-methyl (2'-OMe) modified nucleotide, 2'-O-(2-methoxyethyl) (2'-O-moe) modified nucleotide, a 2'-fluoro (2'-F) modified nucleotide, or a phosphorothioate (PS) linkage between nucleotides.

[00133] Embodiment 108 is the gRNA of any one of Embodiments 1-106, wherein the modification in the repeat/anti-repeat region, the hairpin 1 region, or the hairpin 2 region comprises a modified nucleotide selected from 2'-O-methyl (2'-OMe) modified nucleotide, a 2'-fluoro (2'-F) modified nucleotide, or a phosphorothioate (PS) linkage between nucleotides.

[00134] Embodiment 109 is the gRNA of any one of Embodiments 1-106, wherein the modification in the repeat/anti-repeat region, the hairpin 1 region, or the hairpin 2 region comprises a modified nucleotide selected from 2'-O-methyl (2'-OMe) modified nucleotide or a phosphorothioate (PS) linkage between nucleotides.

[00135] Embodiment 110 is the gRNA of any one of Embodiments 1-109, wherein the modification in the repeat/anti-repeat region does not comprise a phosphorothioate modification at nucleotide 76.

[00136] Embodiment 111 is the gRNA of any one of Embodiments 1-110, wherein the modification in the repeat/anti-repeat region does not comprise a modification at nucleotide 76.

[00137] Embodiment 112 is the gRNA of any one of Embodiments 1-111, wherein at least 20%, 30%, 40%, or 50% of the nucleotides are modified nucleotides.

[00138] Embodiment 113 is the gRNA of Embodiment 112, wherein the gRNA comprises modified nucleotides selected from 2'-O-methyl (2'-OMe) modified nucleotide, 2'-O-(2-

methoxyethyl) (2'-O-moe) modified nucleotide, a 2'-fluoro (2'-F) modified nucleotide, a phosphorothioate (PS) linkage between nucleotides, or combinations thereof.

[00139] Embodiment 114 is the gRNA of any one of Embodiments 1-113, wherein the modification comprises a modification at 1, 2, 3, or 4 nucleotides of nucleotides 106-109.

[00140] Embodiment 115 is the gRNA of any one of Embodiments 113 or 114, wherein the modification comprises a modification at each of nucleotides 106-109.

[00141] Embodiment 116 is the gRNA of any one of Embodiments 114-115, wherein the modification comprises a 2'-O-methyl modification.

[00142] Embodiment 117 is the gRNA of any one of Embodiments 112-116, wherein the gRNA comprises modified nucleotides selected from 2'-O-methyl (2'-Ome) modified nucleotide, a 2'-fluoro (2'-F) modified nucleotide, a phosphorothioate (PS) linkage between nucleotides, or combinations thereof.

[00143] Embodiment 118 is the gRNA of any one of Embodiments 1-117, wherein nucleotides 1-3 of the guide region are modified and nucleotides in the guide region other than nucleotides 1-3 are not modified.

[00144] Embodiment 119 is the gRNA of any one of Embodiments 1-118, wherein a 3' tail of nucleotide 144 is present in the gRNA, and comprises 2'-O-Me modified nucleotides at nucleotides 141-144 and two PS linkages between nucleotides 141-142 and 142-143 respectively.

[00145] Embodiment 120 is the gRNA of any one of Embodiments 1-120, wherein one or more positions of 49-52, 87-90, or 122-125 is substituted.

[00146] Embodiment 121 is a single guide RNA (sgRNA) comprising any one of SEQ ID NOs: 1-19 and 21-42.

[00147] Embodiment 122 is the gRNA of any one of Embodiments 1-121, comprising a nucleotide sequence having at least 99, 98, 97, 96, 95, 94, 93, 92, 91, 90, 85, 80, 75, or 70% identity to the nucleotide sequence of any one of SEQ ID Nos: 1-19 and 21-42.

[00148] Embodiment 123 is the gRNA of any one of Embodiments 1-121, comprising a nucleotide sequence having at least 99, 98, 97, 96, 95, 94, 93, 92, 91, 90, 85, 80, 75, or 70% identity to the nucleotide sequence of any one of SEQ ID Nos: 1-19 and 21-42, wherein the modification at each nucleotide of the gRNA that corresponds to a nucleotide of the reference sequence identifier in Table 1 is identical to or equivalent to the modification shown in the reference sequence identifier in Table 2.

[00149] Embodiment 124 is the gRNA of any one of Embodiments 1-122, comprising a nucleotide sequence having at least 99, 98, 97, 96, 95, 94, 93, 92, 91, or 90% identity to the

sequence from X to the 3' end of the nucleotide sequence of any one of SEQ ID Nos: 1-5, 7, 8, 11, 12, 13, 15, 16, 18, 19, 21, 23, 24, 26, 27, 28, 30, 31, 33, 34, 35, 37, 39, 41, 101-291, 301-494, 931-946, 951, and 952, where X is the first nucleotide of the conserved region.

[00150] Embodiment 125 is the gRNA of any one of Embodiments 121-124, further comprising a 3' tail comprising a 2'-O-Me modified nucleotide.

[00151] Embodiment 126 is the gRNA of any one of Embodiments 1-125, wherein the gRNA directs a nuclease to a target sequence for binding.

[00152] Embodiment 127 is the gRNA of any one of Embodiments 1-126, wherein the gRNA directs a nuclease to a target sequence for inducing a double-strand break within the target sequence.

[00153] Embodiment 128 is the gRNA of any one of Embodiments 1-127, wherein the gRNA directs a nuclease to a target sequence for inducing a single-strand break within the target sequence.

[00154] Embodiment 129 is the gRNA of any one of Embodiments 126-129, wherein the nuclease is a Nme Cas9.

[00155] Embodiment 130 is the gRNA of any one of Embodiments 1-129, wherein the gRNA comprises a conservative substitution, optionally wherein the conservative substitution maintains at least one base pair.

[00156] Embodiment 131 is a composition comprising a gRNA of any one of Embodiments 1-130, associated with a lipid nanoparticle (LNP).

[00157] Embodiment 132. An LNP composition comprising a gRNA of any one of Embodiments 1-130.

[00158] Embodiment 133 is a composition comprising the gRNA of any one of Embodiments 1-130, or the composition of any one of Embodiments 131-132, further comprising a nuclease or an mRNA which encodes the nuclease.

[00159] Embodiment 134 is the composition of Embodiment 133, wherein the nuclease is a Cas protein.

[00160] Embodiment 135 is the composition of Embodiment 134, wherein the Cas protein is a Nme Cas9.

[00161] Embodiment 136 is the composition of Embodiment 135, wherein the Nme Cas9 is an Nme1 Cas9, an Nme2 Cas9, or an Nme3 Cas9.

[00162] Embodiment 137 is the composition of any one of Embodiments 133-136, wherein the nuclease has a double strand cleaving activity.

[00163] Embodiment 138 is the composition of any one of Embodiments 133-137, wherein the nuclease has a nickase activity.

[00164] Embodiment 139 is the composition of any one of Embodiments 133-138, wherein the nuclease has a dCas DNA binding domain.

[00165] Embodiment 140 is the composition of any one of Embodiments 133-139, wherein the nuclease is modified.

[00166] Embodiment 141 is the composition of Embodiment 140, wherein the modified nuclease comprises a heterologous functional domain.

[00167] Embodiment 142 is the composition of Embodiment 141, wherein the heterologous functional domain is a deaminase.

[00168] Embodiment 143 is the composition of Embodiment 142, further comprising a UGI or a mRNA encoding a UGI.

[00169] Embodiment 144 is the composition of any one of Embodiments 142-143, wherein the heterologous functional domain is a cytidine deaminase.

[00170] Embodiment 145 is the composition of any one of Embodiments 140-144, wherein the modified nuclease comprises a nuclear localization signal (NLS).

[00171] Embodiment 146 is the composition of any one of Embodiments 133-145, comprising an mRNA which encodes the nuclease.

[00172] Embodiment 147 is the composition of Embodiment 146, wherein the mRNA comprises the sequence of any one of SEQ ID NOs: 636-638.

[00173] Embodiment 148 is a pharmaceutical formulation comprising the gRNA of any one of Embodiments 1-130 or the composition of any one of Embodiments 131-147 and a pharmaceutically acceptable carrier.

[00174] Embodiment 149 is a method of modifying a target DNA comprising, delivering a Cas protein or a nucleic acid encoding a Cas protein, and any one or more of the following to a cell:

i. the gRNA of any one of Embodiments 1-130;
ii. the composition of any one of Embodiments 131-147; and
iii. the pharmaceutical formulation of Embodiment 148.

[00175] Embodiment 150 is the method of Embodiment 149, wherein the method results in an insertion or deletion in a gene.

[00176] Embodiment 151 is the method of Embodiment 149 or 150, wherein the method results in at least one base edit.

[00177] Embodiment 152 is the method of any one of Embodiments 149-151, further comprising delivering to the cell a template, wherein at least a part of the template incorporates into a target DNA at or near a double strand break site induced by the Cas protein.

[00178] Embodiment 153 is the gRNA of any one of Embodiments 1-130, the composition of Embodiments 131-147, or the pharmaceutical formulation of Embodiment 148 for use in preparing a medicament for treating a disease or disorder.

[00179] Embodiment 154 is use of the gRNA of any one of Embodiments 1-130, the composition of Embodiments 131-147, or the pharmaceutical formulation of Embodiment 148 in the manufacture of a medicament for treating a disease or disorder.

FIGURE LEGENDS

[00180] FIG. 1 shows mean editing results with standard deviation in HEK-Blue™ cells using truncated gRNAs.

[00181] FIG. 2 shows mean percent editing results for dual guide RNA (dgRNA) targeting VEGFA in HEK-Nme2 cells.

[00182] FIG. 3 shows the mean percent editing results of chemically modified sgRNA in HEK-Nme2 cells targeting the VEGFA gene at site T47.

[00183] FIG. 4 shows the mean percent editing results of modified sgRNA in HEK-293 cells targeting the VEGFA gene at site T47.

[00184] FIG. 5 shows mean percent editing at the TTR locus in PMH with increasing doses of Nme2Cas9 mRNA and chemically modified sgRNA.

[00185] FIG. 6 shows mean percent editing at PCSK9 locus in PMH with modified sgRNAs.

[00186] FIG. 7 shows mean percent editing in PMH of several Nme2Cas9 mRNAs with a modified sgRNA.

[00187] FIG. 8A shows mean percent editing at the TTR locus in PMH using varying ratios of sgRNA and Nme2Cas9 mRNA.

[00188] FIG. 8B shows mean percent editing at the TTR locus in PMH using varying ratios a pgRNA and Nme2Cas9 mRNA.

[00189] FIG. 9 shows mean percent editing at the TTR locus in PMH for pgRNAs with Nme2Cas9 mRNA.

[00190] FIG. 10A shows mean percent editing at the VEGFA TS-25 locus in HEK-Nme2 cells for combinations of modified crRNAs and trRNAs with Nme2Cas9 mRNA.

[00191] FIG. 10B shows mean percent editing at the VEGFA TS-47 locus in HEK-Nme2 cells for combinations of modified crRNAs and trRNAs with Nme2Cas9 mRNA.

[00192] FIG. 11 shows mean percent editing at the VEGFA TS-47 locus in HEK-Nme2 cells dgRNAs consisting of different crRNA and tracrRNA combinations for combinations of modified crRNAs and trRNAs with Nme2Cas9 mRNA.

[00193] FIG. 12A shows mean percent editing at TTR exon 1 in PMH for pgRNAs with 2'-OMe modification in the guide sequence.

[00194] FIG. 12B shows mean percent editing at TTR exon 3 in PMH for pgRNAs with 2'-OMe modification in the guide sequence.

[00195] FIG. 12C shows mean percent editing at TTR exon 1 in PMH for pgRNAs with light 2'-OMe modification in the guide sequence.

[00196] FIG. 12D shows mean percent editing at TTR exon 3 in PMH for pgRNAs with light 2'-OMe modification in the guide sequence.

[00197] FIG. 13 shows mean editing percentage in at the PCSK9 locus in PMH.

[00198] FIG. 14A shows mean editing results at the VEGFA locus in HEK cells treated with mRNA C (SEQ ID NO: 622).

[00199] FIG. 14B shows mean editing results at the VEGFA locus in HEK cells treated with mRNA I (SEQ ID NO: 627).

[00200] FIG. 14C shows mean editing results at the VEGFA locus in HEK cells treated with mRNA J (SEQ ID NO: 628).

[00201] FIG. 14D shows mean editing results at the VEGFA locus in PHH cells treated with mRNA C (SEQ ID NO: 622).

[00202] FIG. 14E shows mean editing results at the VEGFA locus in PHH cells treated with mRNA I (SEQ ID NO: 627).

[00203] FIG. 14F shows mean editing results at the VEGFA locus in PHH cells treated with mRNA J (SEQ ID NO: 628).

[00204] FIG. 15 shows mean percent editing at the mouse TTR locus in PMH cells treated with NmeCas9 constructs designed with 1 or 2 nuclear localization sequences.

[00205] FIG. 16 shows mean percent editing at the mouse TTR locus in PMH cells treated with pgRNA and various Nme2Cas9 mRNAs.

[00206] FIG. 17 shows fold change in Nme2Cas9 protein expression compared to SpyCas9 protein expression in PMH, PRH, PCH and PHH cells.

[00207] FIGS. 18A-18F show fold change in Nme2Cas9 protein expression compared to SpyCas9 protein expression in T cells from 2 donors assayed at 24 hours, 48 hours and 72 hours after treatment.

[00208] FIG. 19 shows mean percent editing at the TTR locus in mouse liver treated with sgRNA and Nme2Cas9.

[00209] FIG. 20A shows mean percent editing at the TTR locus in mouse liver following treatment with pgRNA and Nme2Cas9.

[00210] FIG. 20B shows mean serum TTR protein following treatment with pgRNA and Nme2Cas9.

[00211] FIG. 20C shows mean percent TTR knockdown following treatment with pgRNA and Nme2Cas9.

[00212] FIG. 20D shows mean percent editing at the TTR locus in mouse liver following treatment with pgRNA and various Nme2Cas9.

[00213] FIG. 20E shows serum TTR protein knockdown following treatment with pgRNA and various Nme2Cas9.

[00214] FIG. 21 shows mean percent editing in mouse liver following treatment with various Nme2Cas9 constructs.

[00215] FIG. 22 shows mean percent editing in mouse liver following treatment with pgRNA and various Nme2Cas9

[00216] FIG. 23 shows mean percent editing in mouse liver following treatment with various base editors.

[00217] FIG. 24 shows an exemplary schematic of Nme2 sgRNA in a possible secondary structure, including the repeat/anti-repeat region and the hairpin region which includes hairpin 1 and hairpin 2 regions and further indicates the guide region (or targeting region) (denoted with a gray fill with dashed outline), bases not amenable to single or pairwise deletion (denoted with a gray fill with solid outline), bases amenable to single or pairwise deletion (open circles).

[00218] FIG. 25 shows an exemplary sgRNA (G021536; SEQ ID NO: 490) in a possible secondary structure. The methylation is shown in bold; phosphorothioate linkages are indicated by '*'. Watson-Crick base pairing is indicated by a '—' between nucleotides in duplex portions. Non-Watson-Crick base pairing is indicated by a '•' between nucleotides in duplex portions.

[00219] FIG. 26 shows the percent editing at the TTR locus in primary mouse hepatocytes.

[00220] FIG. 27 shows serum TTR levels in mice.

[00221] FIG. 28 shows percent editing at the TTR locus in mouse liver samples.

[00222] FIG. 29 shows serum TTR measurements following treatment in mice.

[00223] FIG. 30 shows percent editing at the TTR locus in mouse liver samples.

[00224] FIG. 31 shows the mean percent CD3 negative T cells following TRAC editing with Nme1Cas9.

[00225] FIG. 32 shows the mean percent CD3 negative T cells following TRAC editing with Nme3Cas9.

[00226] FIG. 33 shows the expression of Nme-HiBiT constructs in T cells at 24 hours.

[00227] FIG. 34 shows the CD3-negative cell population as a function of NmeCas9 mRNA amount.

[00228] FIG. 35 shows the dose response curve for select gRNAs in PCH.

[00229] FIG. 36 shows the dose response curve for LNP dilution series in PCH.

[00230] FIG. 37 shows an exemplary sgRNA (Guide ID G032572; SEQ ID NO: 951) in a possible secondary structure. The unmodified nucleotides are shown in bold and methylation is shown in light fonts; phosphorothioate linkages are indicated by '*'. Watson-Crick base pairing is indicated by a '—' between nucleotides in duplex portions. Non-Watson-Crick base pairing is indicated by a '•' between nucleotides in duplex portions.

[00231] FIG. 38 shows an exemplary sgRNA (Guide ID G031771; SEQ ID NO: 952) in a possible secondary structure. The unmodified nucleotides are shown in bold and methylation is shown in light fonts; phosphorothioate linkages are indicated by '*'. Watson-Crick base pairing is indicated by a '—' between nucleotides in duplex portions. Non-Watson-Crick base pairing is indicated by a '•' between nucleotides in duplex portions.

[00232] FIG. 39 shows serum TTR levels in mice.

[00233] FIG. 40 shows percent editing at the TTR locus in mouse liver samples.

[00234] FIG. 41 shows the dose response curve for select gRNAs in PMH.

[00235] FIG. 42 shows the dose response curve for select gRNAs in PMH.

DETAILED DESCRIPTION

[00236] Provided herein are shortened gRNAs for use in gene editing methods. Examples of sequences of engineered and tested gRNAs are shown in Tables 1-2.

[00237] Certain of the gRNAs provided herein are single guide RNAs (sgRNAs) for use in gene editing methods.

[00238] Certain of the gRNAs provided herein are dual guide RNAs (dgRNAs) for use in gene editing methods.

[00239] This disclosure further provides exemplary uses of these gRNAs to alter the genome of a target nucleic acid *in vitro* (e.g., cells cultured *in vitro* for use in *ex vivo* therapy or other uses of genetically edited cells) or in a cell in a subject such as a human (e.g., for use in *in vivo* therapy).

Table 1. Exemplary Sequences for gRNAs

Length (nt)	SEQ ID NO:	Sequence
145	**500**	NNNNNNNNNNNNNNNNNNNNNNNGUUGUAGCUCCCUUUCUCAUUUCGGAAACGAAAUGAGAACCGUUGCUAC AAUAAGGCCGUCUGAAAAGAUGUGCCGCAACGCUCUGCCCCUUAAAGCUUCUGCUUUAAGGGGCAUCGUUUA
101	**1**	$(N)_{20-25}$ GUUGUAGCUCCCUGAAACCGUUGCUACAAUAAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCUUCUGGCAU CGUU
105	**2**	$(N)_{20-25}$ GUUGUAGCUCCCUGAAACCGUUGCUACAAUAAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCUUCUGGCAU CGUUUAUU
107	**3**	$(N)_{20-25}$ GUUGUAGCUCCCUGGAAACCCGUUGCUACAAUAAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCUUCUGGC AUCGUUUAUU
101	**4**	mN*mNNNNNNNNmNNNmNNNNNNNNNNNNNmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmC AAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmGCmA mUC*mG*mU*mU
97-102	**5**	$(N)_{20-25}$ mGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGm AmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmGCmAmUC*mG*mU*mU
77	**6**	mGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGm AmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmGCmAmUC*mG*mU*mU
101	**7**	mN*mN*mN*mNmNNNmNmNNmNNmNNNNNmNNNNmNNNmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGU UmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCm UGGCAUCG*mU*mU
97-102	**8**	$(N)_{20-25}$ mGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGm AmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU
77	**9**	mGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGm AmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU
105	**10**	$(N)_{20-25}$ GUUGUAGCUCCCUUCGAAAGACCGUUGCUACAAUAAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCUUCUG GCAUCGUU

Length (nt)	SEQ ID NO:	Sequence
105	11	mN*mN*mN*mNmNNNmNmNNNmNNNNmNNNmGUUGmUmAmGmCUCCCmUmUmCmGmAmAmAmG mAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmC CmUmUmCmUGGCAUCG*mU*mU
101	12	mN*mNNNNNNNNNmNNNNmNNNNNNNNNmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmC AAUAAGmGmCCmGmUmCmGmAmAmGmAmUGUGCmCGCmCmAmAmCmGCUCUmGmCCmUmUmCmUGmGCmAm UC*mG*mU*mU
97-102	13	$(N)_{20\text{-}25}$ mGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAUAAGmGmCCmGmUmCmGmAmAmAmGmA mUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmGCmAmUC*mG*mU*mU
77	14	mGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAUAAGmGmCCmGmUmCmGmAmAmAmGmA mUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmGCmAmUC*mG*mU*mU
101	15	mN*mN*mN*mNmNNNmNmNNNmNNNNmNNNmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGU UmGmCUAmCAAUAAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmU GGCAUCG*mU*mU
97-102	16	$(N)_{20\text{-}25}$ mGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAUAAGmGmCCmGmUmCmGmAmAmAmGmA mUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU
77	17	mGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAUAAGmGmCCmGmUmCmGmAmAmAmGmA mUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU
105	18	mN*mN*mN*mNmNNNmNmNNNmNNNNmNNNmGUUGmUmAmGmCUCCCmUmUmUmCmGmAmAmAmAmG mAmCmCGUUmGmCUAmCAAUAAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCC mUmUmCmUGGCAUCG*mU*mU
101	19	mN*mNNNNNNNNNmNNNNmNNNNNNNNNmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmC AAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGCmAmAmCmGmCmUmUmCmUGm GCmAmUC*mG*mU*mU
97-102	21	$(N)_{20\text{-}25}$ mGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGm AmUGUGCmCGCmAmAmCmGmCCmUmUmCmUGmGCmAmUC*mG*mU*mU
77	22	mGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGm AmUGUGCmCGCmAmAmCmGmCCmUmUmCmUGmGCmAmUC*mG*mU*mU
101	23	mN*mN*mN*mNmNNNmNmNNNmNNNNmNNNmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGU UmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGmCmUmUmCmUGmCCmUm UmCmUGGCAUCG*mU*mU

Length (nt)	SEQ ID NO:	Sequence
97-102	**24**	(N) $_{20\text{-}25}$ mGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmGm AmUGUGCmCGmCAAmCGmCmUmCmUmGmCCmUmUmCmUGGCAUCG*mU*mU
77	**25**	mGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGm AmUGUGCmCGmCAAmCGmCmUmCmUmGmCCmUmUmCmUGGCAUCG*mU*mU
105	**26**	mN*mN*mN*mNmNNNmNmNNNmNNNNmNNNNmGUUGmUmAmGmCUCCCmUmUmCmGmAmAmAmG mAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGmCmUmCmUmCmU mGmCCmUmUmCmUGGCAUCG*mU*mU
101	**27**	mN*mNNNNNNNNmNNNmNNNNNNNNNmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmC AAUAAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGCmAmAmCmGmCmUmUmCmUmGmG CmAmUC*mG*mU*mU
97-102	**28**	(N)$_{20\text{-}25}$mGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAUAAGmGmCCmGmUmCmGm AmAmAmGmAmUGUGCmCGCmAmAmCmGmCmUmUmCmUGmGCmAmUC*mG*mU*mU
77	**29**	mGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAUAAGmGmCCmGmUmCmGmAmAmAmGmA mUGUGCmCGCmAmAmCmGmCmUmUmCmUmGmGCmAmUC*mG*mU*mU
101	**30**	mN*mN*mN*mNmNNNmNmNNNmNNNNmNNNNmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGU UmGmCUAmCAAUAAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGmCmUmUmCmUmGmCCmUmU mCmUGGCAUCG*mU*mU
97-102	**31**	(N) $_{20\text{-}25}$ mGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAUAAGmGmCCmGmUmCmGmAmAmAmGmA mUGUGCmCGmCAAmCGmCmUmUmCmUmGmGCmAmUC*mG*mU*mU
77	**32**	mGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAUAAGmGmCCmGmUmCmGmAmAmAmGmA mUGUGCmCGmCAAmCGmCmUmUmCmUmGmGCAUCG*mU*mU
97-102	**33**	(N)$_{20\text{-}25}$mGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAUAAGmGmCCmGmUmCmGmAmAmAmGm AmUGUGCmCGCmAmAmCmGmCmUmUmCmUmGmGCmAmUC*mG*mU*mU
105	**34**	mN*mN*mN*mNmNNNmNmNNNmNNNNmNNNNmGUUGmUmAmGmCUCCCmUmUmCmGmAmAmAmG mAmCmCGUUmGmCUAmCAAUAAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGmCmUmCmUm GmCCmUmUmCmUGGCAUCG*mU*mU
101-106	**35**	(N)$_{20\text{-}25}$ mGUUGmUmAmGmCUCCCmUmUmCmGmAmAmAmGmAmCmCGUUmGmCUAmCAAUAAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGmCAAmCGmCmUmUmCmUmGmCCmUmUmCmGGCAUCG*mU*mU

Length (nt)	SEQ ID NO:	Sequence
81	**36**	mGUUGmUmAmGmCUCCCmUmUmCmGmAmAmAmGmAmCmCGUUmGmCUAmCAAUAAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGmCAAmCGmCmUmCmUmGmCCmUmUmCmUGGCAUCG*mU*mU
101-106	37	(N)20-25 mGUUGmUmAmGmCUCCCmUmUmCmGmAmAmAmGmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGm AmAmAmGmAmUGUGCmCGmCAAmCGCUCUUmGmCCmUmUmCmUGGCAUCG*mU*mU
81	38	mGUUGmUmAmGmCUCCCmUmUmCmGmAmAmAmGmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGm AmAmAmGmAmUGUGCmCGmCAAmCGCUCUUmGmCCmUmUmCmUGGCAUCG*mU*mU
101-106	39	(N)20-25 mGUUGmUmAmGmCUCCCmUmUmCmGmAmAmAmGmAmCmCGUUmGmCUAmCAAUAAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGmCAAmCGCUCUUmGmCCmUmUmCmUGGCAUCG*mU*mU
81	40	mGUUGmUmAmGmCUCCCmUmUmCmGmAmAmAmGmAmCmCGUUmGmCUAmCAAUAAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGmCAAmCGCUCUUmGmCCmUmUmCmUGGCAUCG*mU*mU
101-106	41	(N)20-25 mGUUGmUmAmGmCUCCCmUmUmCmGmAmAmAmGmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGm AmAmAmGmAmUGUGCmCGmCAAmCGmCmUmCmUmGmCCmUmUmCmUGGCAUCG*mU*mU
81	42	mGUUGmUmAmGmCUCCCmUmUmCmGmAmAmAmGmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGm AmAmAmGmAmUGUGCmCGmCAAmCGmCmUmCmUmGmCCmUmUmCmUGGCAUCG*mU*mU

Table 2. Exemplary sgRNAs

Guide ID	SEQ ID NO.	sgRNA unmodified sequence	SEQ ID NO.	sgRNA modified sequence
G017564	101	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGGAAACC CGUUGCUACAAUAAGGCCGUCG AAAGAUGUGCCGCAACGCUCUG CCUUCUGGCAUCGUUUAUU	301	mG*mUGUGUCCCmUCUmCCCCACCCGUCCmGUUGmUmAmGmCUCCCmU mGmGmAmAmAmCmCmCGUUmGmCUAmCAAUAAGmGmCCmGmUmCmG mAmAmAmGmAmUGUGCmCGCAACGCUCUmGmCCmUmUmCmUGGCAUC GUUUAmU*mU
G017565	102	GGCCUGGCUGAUGAGGCCGCAC AUGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCUGA AAAGAUGUGCCGCAACGCUCUG CCUUCUGGCAUCGUUUAUC	302	mG*mG*mC*CUGGCUGAUGAGGCCGCACAUGUUGUAGCUCCCU*mG*mA *mA*mA*CCGUUGCUACAAUAAGGCCGUmC*mU*mG*mA*mA*mA*mA*m GAUGUGCCGCAACGCUCUGCCmU*mU*mC*mUGGCAUCGUUU*mA*mU* mC
G017566	103	GGCCUGGCUGAUGAGGCCGCAC AUGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUUUAUC	303	mG*mG*mC*CUGGCUGAUGAGGCCGCACAUGUUGUAGCUCCCU*mG*mA *mA*mA*CCGUUGCUACAAUAAGGCCGUmC*mG*mA*mA*mA*mGAUGU GCCGCAACGCUCUGCCmU*mU*mC*mUGGCAUCGUUU*mA*mU*mC
G020031	104	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGGAAACC CGUUGCUACAAUAAGGCCGUCG AAAGAUGUGCCGCAACGCUCUG CCUUCUGGCAUCGUUUAUU	304	GUGUGUCCCUCUCCCCACCCGUCCGUUGUAGCUCCCUGGAAACCCGUU GCUACAAUAAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCUUCUGG CAUCGUUUAUU
G020032	105	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGGAAACC CGUUGCUACAAUAAGGCCGUCG AAAGAUGUGCCGCAACGCUCUG CCUUCUGGCAUCGUUUAUU	305	mG*mU*mG*UGUCCCUCUCCCCACCCGUCCGUUGUAGCUCCCUGGAAAC CCGUUGCUACAAUAAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCU UCUGGCAUCGUUU*mA*mU*mU
G020033	106	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGGAAACC CGUUGCUACAAUAAGGCCGUCG	306	mG*mU*mG*UGUCCCUCUCCCCACCCGUCCGUUGUAGCUCCCUGGAAAC CCGUUGCUACAAUAAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCU UCUGGCAUCGUUUA*mU*mU

Guide ID	SEQ ID NO.	sgRNA unmodified sequence	SEQ ID NO.	sgRNA modified sequence
		AAAGAUGUGCCGCAACGCUCUG CCUUCUGGCAUCGUUUAUU		
G020034	107	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGGAAACC CGUUGCUACAAUAAGGCCGUCG AAAGAUGUGCCGCAACGCUCUG CCUUCUGGCAUCGUUUAUU	307	mG*mUGUGUCCCUCUCCCCACCCGUCCGUUGUAGCUCCCUGGAAACCC GUUGCUACAAUAAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCUUC UGGCAUCGUUUAmU*mU
G020035	108	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGGAAACC CGUUGCUACAAUAAGGCCGUCG AAAGAUGUGCCGCAACGCUCUG CCUUCUGGCAUCGUUUAUU	308	mG*mUGUGUCCCUCUCCCCACCCGUCCdGUUGdTdAdGdCUCCCdTdGdGd AdAdAdCdCdCGdTUdGdCUdAdCAAUAAGdGdCdCdGdUdCdGdAdAdAdGdAd UGdUGCdCGdCdAdAdCdGCUCUdGdCCdUdUdCdUGdGCdAdUCGdUdUUAm U*mU
G0020036	109	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGGAAACC CGUUGCUACAAUAAGGCCGUCG AAAGAUGUGCCGCAACGCUCUG CCUUCUGGCAUCGUUUAUU	309	mG*mUGUGUCCCUCUCCCCACCCGUCCGUUGUAGCUCCCUGGAAACCC GUUGCUACAAUAAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCUUC UGGCAUCGUUUAU*mU
G0020037	110	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGGAAACC CGUUGCUACAAUAAGGCCGUCG AAAGAUGUGCCGCAACGCUCUG CCUUCUGGCAUCGUUUAUU	310	mG*mUGUGUCCCUCUCCCCACCCGUCCGUUGUAGCUCCCUGGAAACCC GUUGCUACAAUAAGGCCGUCGAAAGAUGUGCCGCAACGmCmUmCUGCC UUCUGGCAUCGUUUAmU*mU
G0020038	111	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGGAAACC CGUUGCUACAAUAAGGCCGUCG AAAGAUGUGCCGCAACGCUCUG CCUUCUGGCAUCGUUUAUU	311	mGmUGUGUCCCUCUCCCCACCCGUCCGUUGUAGCUCCCUGGAAACCCG UUGCUACAAUAAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCUUCU GGCAUCGUUUAmU*mU
G0020039	112	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGGAAACC CGUUGCUACAAUAAGGCCGUCG AAAGAUGUGCCGCAACGCUCUG CCUUCUGGCAUCGUUUAUU	312	mG*mUGUGUCCCmUCUmCCCCACCCGUCCmGUUGmUmAmGmCUCCCmU mGmGmAmAmAmCmCmCGUUmGmCUAmCAAUAAGmGmCCmGmUmCmG mAmAmAmGmAmUGUGCmCGCAACGCUCUmGmCmUmUmCmUGGCAUC GUUUAmU*mU

Guide ID	SEQ ID NO.	sgRNA unmodified sequence	SEQ ID NO.	sgRNA modified sequence
G020040	113	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGGAAACC CGUUGCUACAAUAAGGCCGUCG AAAGAUGUGCCGCAACGCUCUG CCUUCUGGCAUCGUUUAUU	313	mG*mUG*UGU*CCCmUCUmCCC*CACCCGUCCmGUUGmUmAmGmCU*C* C*C*mUmGmGmAmAmAmCmCmCGUUmGmCUAmCA*A*U*A*AG*mGmCC *mGmUmCmGmAmAmAmGmAmUGUGCmCGCAACG*C*U*C*U*mGmCCm UmUmCmUG*GCAU*C*G*UUU*AmU*mU
G020041	114	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGGAAACC CGUUGCUACAAUAAGGCCGUCG AAAGAUGUGCCGCAACGCUCUG CCUUCUGGCAUCGUUUAUU	314	mG*mUGUGUCCCmUCUmCCCCACCCGUCCmGUUGmUmAmGmCUCCCmU mGmGmAmAmAmCmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCm GmAmAmAmGmAmUGUGCmCGCAACGCUCUmGmCCmUmCmUGGCAU CGUUU*AmU*mU
G020042	115	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGGAAACC CGUUGCUACAAUAAGGCCGUCG AAAGAUGUGCCGCAACGCUCUG CCUUCUGGCAUCGUUUAUU	315	mG*mUGUGUCCCmUCUmCCCCACCCGUCCmGUUGmUmAmGmCUCCCmU mGmGmAmAmAmCmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCm GmAmAmAmGmAmUGUGCmCGCAACGCUCUmGmCCmUmCmUGGCAU GCAUCGUUU*AmU*mU
G020043	116	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGGAAACC CGUUGCUACAAUAAGGCCGUCG AAAGAUGUGCCGCAACGCUCUG CCGAAAGGCAUCGUUUAUU	316	mG*mUGUGUCCCmUCUmCCCCACCCGUCCmGUUGmUmAmGmCUCCCmU mGmGmAmAmAmCmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCm GmAmAmAmGmAmUGUGCmCGCAACGCUCUmGmCCmGmAmAmAGGCA UCGUUU*AmU*mU
G020044	117	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGGAAACC CGUUGCUACAAUAAGGCCGUCG AAAGAUGUGCCGCAACGCUCUG CCUUCUGGCAUCGUU	317	mG*mUGUGUCCCmUCUmCCCCACCCGUCCmGUUGmUmAmGmCUCCCmU mGmGmAmAmAmCmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCm GmAmAmAmGmAmUGUGCmCGCAACGCUCUmGmCCmUmCmUGGCAU CGmU*mU
G020045	118	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUUUAUU	318	GUGUGUCCCUCUCCCCACCCGUUGUAGCUCCCUGAAACCGUUGC UACAAUAAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCUUCUGGCA UCGUUUAUU

Guide ID	SEQ ID NO.	sgRNA unmodified sequence	SEQ ID NO.	sgRNA modified sequence
G020046	119	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUUUAUU	319	mG*mU*mG*UGUCCCUCUCCCCACCCGUUGUAGCUCCCUGAAACC GUUGCUACAAUAAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCUUC UGGCAUCGUUU*mA*mU*mU
G020047	120	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUUUAUU	320	mG*mU*mG*UGUCCCUCUCCCCACCCGUUGUAGCUCCCUGAAACC GUUGCUACAAUAAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCUUC UGGCAUCGUUUA*mU*mU
G020048	121	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUUUAUU	321	mG*mUGUGUCCCUCUCCCCACCCGUCCGUUGUAGCUCCCUGAAACCGU UGCUACAAUAAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCUUCUG GCAUCGUUUAmU*mU
G020049	122	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUUUAUU	322	mG*mUGUGUCCCUCUCCCCACCCGUCCdGUUGdTdAdGdCUCCCdTdGdAd AdAdCdCGdTUdGdCUdAdCAAUAAGdGdCdCdGdUdCdGdAdAdAdGdAdUGd UGCdCGdCdAdAdCdGCUCUdGdCCdUdUdCdUGdGCdAdUCGdUdUUAmU*m U
G020050	123	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUUUAUU	323	mG*mUGUGUCCCUCUCCCCACCCGUUGUAGCUCCCUGAAACCGU UGCUACAAUAAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCUUCUG GCAUCGUUUAU*mU
G020051	124	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUUUAUU	324	mG*mUGUGUCCCUCUCCCCACCCGUUGUAGCUCCCUGAAACCGU UGCUACAAUAAGGCCGUCGAAAGAUGUGCCGCAACGmCmUmCUGCCUU CUGGCAUCGUUUAmU*mU

Guide ID	SEQ ID NO.	sgRNA unmodified sequence	SEQ ID NO.	sgRNA modified sequence
G020052	125	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUUUAUU	325	mGmUGUGUCCCUCUCCCCACCCGUCCGUUGUAGCUCCCUGAAACCGUU GCUACAAUAAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCUUCUGG CAUCGUUUAmUmU
G020053	126	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC GAAAGGCAUCGUUUAUU	326	mG*mUGUGUCCCUCUCCCCACCCGUCCGUUGUAGCUCCCUGAAACCGUU UGCUACAAUAAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCUUCUGG GCAUCGUUUAmU*mU
G020054	127	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	327	mG*mUGUGUCCCUCUCCCCACCCGUCCGUUGUAGCUCCCUGAAACCGUU UGCUACAAUAAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCUUCUG GCAUCGmU*mU
G020055	128	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUUUAUU	328	mG*mUGUGUCCCmUCUmCCCCACCCGUCCmGUUGmUmAmGmCUCCCmU mGmAmAmAmCmCGUUmGmCUAmCAAUAAGmGmCCmGmUmCmGmAmA mAmGmAmUGUGCmCGCAACGCUCUmGmCCmUmUmCmUGGCAUCGUUU AmU*mU
G020056	129	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUUUAUU	329	mG*mUGUGUCCCmUCUmCCCCACCCGUCCmGUUGmUmAmGmCUCCCmU mGmAmAmAmCmCGUUmGmCUAmCAAmUAAGmGmCCmGmUmCmGmAm AmAmGmAmAmUGUGCmCGCAmACGCUCUmGmCCmUmUmCmUmGmGCAUC GmUmUUAmU*mU
G020057	130	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUUUAUU	330	mG*mUmGmUmGmUCCCmUmCmUmCCCCmAmCCCGUCCmGUUGmUmAm GmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAUAAGmGmCCmGm UmCmGmAmAmAmGmAmUGUGCmCGCAACGCUCUmGmCCmUmUmCmU GGCAUCGUUUAmU*mU
G020058	131	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG	331	mG*mUmGmUmGmUCCCmUmCmUmCCCCmAmCCCGUCCmGUUGmUmAm GmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAmUAAGmGmCCmG

Guide ID	SEQ ID NO.	sgRNA unmodified sequence	SEQ ID NO.	sgRNA modified sequence
		UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUUUAUU		mUmCmGmAmAmAmGmAmUGUGCmCGCAmACGCUCUmGmCCmUmUmC mUmGmGCAUCGmUmUUAmU*mU
G020059	132	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC GAAAGGCAUCGUUUAUU	332	mG*mUmGmUmGmUCCCmUmCmUmCCCCmAmCCCGUCCmGUUGmUmAm GmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAmUAAGmGmCCmG mUmCmGmAmAmAmGmAmUGUGCmCGCAmACGCUCUmGmCCmGmAmA mAmGmGCAUCGmUmUUAmU*mU
G020060	133	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	333	mG*mUmGmUmGmUCCCmUmCmUmCCCCmAmCCCGUCCmGUUGmUmAm GmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAmUAAGmGmCCmG mUmCmGmAmAmAmGmAmUGUGCmCGCAmACGCUCUmGmCCmUmUmC mUmGmGCAUCGmU*mU
G020061	134	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUUUAUU	334	mG*mUG*UGU*CCCUCUCCC*CACCCGUCCGUUGUAGCU*C*C*C*UGAA ACCGUUGCUACA*A*U*A*AG*GCC*GUCGAAAGAUGUGCCGCAACG*C* U*C*U*GCCUUCUG*GCAU*C*G*UUU*AmU*mU
G020062	135	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUUUAUU	335	mG*mUGUGUCCCUCUCCCCACCCGUCCGUUG*UAGCU*C*C*C*UGAAAC CGUUGCUACA*A*UA*AG*GCC*GUCGAAAGAUG*UGCCGCAACG*C*U* C*U*GCC*UUCUGGCAU*C*G*UUU*AmU*mU
G020063	136	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUUUAUU	336	mG*mU*GUGUCCCUCUCC*CCACCCGUCCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCUUCU GGCAUCGUUUAmU*mU
G020064	137	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA	337	mG*mU*GUGUCCCUCUCC*CCACCCGUCCGUUG*UAGCU*C*C*C*UGAA ACCGUUGCUACA*A*UA*AG*GCC*GUCGAAAGAUG*UGCCGCAACG*C* U*C*U*GCC*UUCUGGCAU*C*G*UUU*AmU*mU

Guide ID	SEQ ID NO.	sgRNA unmodified sequence	SEQ ID NO.	sgRNA modified sequence
		AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUUUAUU		
G020065	138	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUUUAUU	338	mG*mUGUGUCCCUCUCCC*CACCCGUCCGUUGUAGCUCCCUGAAACCGU UGCUACAAU*AAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCUUCU GGCAUCGUUU*AmU*mU
G020066	139	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC GAAAGGCAUCGUUUAUU	339	mG*mUGUGUCCCUCUCCC*CACCCGUCCGUUGUAGCUCCCUGAAACCGU UGCUACAAU*AAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCUUCU GGCAUCGUUU*AmU*mU
G020067	140	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	340	mG*mUGUGUCCCUCUCCC*CACCCGUCCGUUGUAGCUCCCUGAAACCGU UGCUACAAU*AAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCUUCU GGCAUCGmU*mU
G020068	141	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUUUAUU	341	mG*mUG*UGU*CCCmUCUmCCC*CACCCGUCCmGUUGmUmAmGmCU*C* C*C*mUmGmAmAmAmCmCGUUmGmCUAmCA*A*U*A*AG*mGmCC*mGm UmCmGmAmAmAmGmAmUGUGCmCGCAACG*C*U*C*U*mGmCCmUmUm CmUG*GCAU*C*G*UUU*AmU*mU
G020069	142	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUUUAUU	342	mG*mUGUGUCCCmUCUmCCCCACCCGUCCmGUUG*mUmAmGmCU*C*C* C*mUmGmAmAmAmCmCGUUmGmCUAmCA*A*mUA*AG*mGmCC*mGmU mCmGmAmAmAmGmAmUG*UGCmCGCAmACG*C*U*C*U*mGmCCmUmU mCmUmGmGCAU*C*G*mUmUU*AmU*mU
G020070	143	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUUUAUU	343	mG*mUmGmUmGmUCCCmUmCmUmCCCCmAmCCCGUCCmGUUG*mUmA mGmCU*C*C*C*mUmGmAmAmAmCmCGUUmGmCUAmCA*A*mUA*AG*m GmCC*mGmUmCmGmAmAmAmGmAmUG*UGCmCGCAmACG*C*U*C*U*m GmCCmUmUmCmUmGmGCAU*C*G*mUmUU*AmU*mU

Guide ID	SEQ ID NO.	sgRNA unmodified sequence	SEQ ID NO.	sgRNA modified sequence
G020071	144	GUGUGUCCCUCUCCCCACCCGU CCGUUUGUAGCUCCCCUGAAACCG UUGCUACACAAUAAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUUUAUU	344	mG*mUGUGUCCCmUCUmCCCCACCCGUCCmGUUGmUmAmGmCUCCCmU mGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAm AmAmGmAmAmUGUGCmCGCAACGCUCUmGmCCmUGGCAUCGUU U*AmU*mU
G020072	145	GUGUGUCCCUCUCCCCACCCGU CCGUUUGUAGCUCCCCUGAAACCG UUGCUACACAAUAAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC GAAAGGCAUCGUUUAUU	345	mG*mUGUGUCCCmUCUmCCCCACCCGUCCmGUUGmUmAmGmCUCCCmU mGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAm AmAmGmAmAmUGUGCmCGCAACGCUCUmGmCCmGmAmAmAGGCAUCGUU U*AmU*mU
G020073	146	GUGUGUCCCUCUCCCCACCCGU CCGUUUGUAGCUCCCCUGAAACCG UUGCUACACAAUAAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	346	mG*mUGUGUCCCmUCUmCCCCACCCGUCCmGUUGmUmAmGmCUCCCmU mGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAm AmAmGmAmAmUGUGCmCGCAACGCUCUmGmCCmUmUmCmUGGCAUCGmU *mU
G020361	147	GGCCUGGGCUGAUGAGGCCGCAC AUGUUUGUAGCUCCCUCGAAAGC CGUUGCUACAAUAAGGCCGUCG AAAGAUGUGCCGCAACGCUCUG CCUUCUGGCAUCGUUUAUU	347	mG*mGC*CUGGGCUmGAUmGAGGCCGCACAUmGUUGmUmAmGmCUCCCU mCmGmAmAmAmAmGCCGUUmGmCUAmCAAU*A*AGmGmCCmGmUmCmGm AmAmAmGmAmUGUGCmCGCAACGCUCUmGmCCmUmUmCmUGGCAUCG UUU*AmU*mU
G020711	148	GUGUGUCCCUCUCCCCACCCGU CCGUUUGUAGCUCCCCUGAAACCG UUGCUACACAAUAAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	348	GUGUGUCCCUCUCCCCACCCGUUUGUAGCUCCCCUGAAACCGUUGC UACAAUAAAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCUUCUGGCA UCGUU
G020712	149	GUGUGUCCCUCUCCCCACCCGU CCGUUUGUAGCUCCCCUGAAACCG UUGCUACACAAUAAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	349	GUGUGUCCCmUCUmCCCCACCCGUCCmGUUGmUmAmGmCUCCCmUmG mAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAm AmGmAmUGUGCmCGCAACGCUCUmGmCCmUmUmCmUGGCAUCGUU

Guide ID	SEQ ID NO.	sgRNA unmodified sequence	SEQ ID NO.	sgRNA modified sequence
G020713	150	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	350	G*UGUGUCCCUCUCCCCACCCGUCCGUUGUAGCUCCCUGAAACCGUUGC UACAAUAAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCUUCUGGCA UCGU*U
G020714	151	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	351	mGmUGUGUCCCUCUCCCCACCCGUCCGUUGUAGCUCCCUGAAACCGUU GCUACAAUAAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCUUCUGG CAUCGmUmU
G020715	152	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	352	mGmUGUGUCCCUCUCCCCACCCGUCCGUUGUAGCUCCCUGAAACCGUU mGmAmAmAmCmCGUUmGmCUAmCAAUAAGmGmCCmGmUmCmGmAmA mAmGmAmUGUGCmCGCAACGCUCUmGmCCmUmUmCmUGGCAUCGmUm U
G020716	153	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	353	mGmUGUGUCCCUCUCCCCACCCGUCCGUUGUAGCUCCCUGAAACCGUU mGmAmAmAmCmCGUUmGmCUAmCAAUAAGmGmCCmGmUmCmGmAmA mAmGmAmUGUGCmCGCAACGCUCUmGmCCmUmUmCmUGGCAUCGmU* mU
G020717	154	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	354	mG*mUGUGUCCCUCUCCCCACCCGUCCGUUGUAGCUCCCUGAAACCGUU mGmAmAmAmCmCGUUmGmCUAmCAAUAAGmGmCCmGmUmCmGmAmA mAmGmAmUGUGCmCGCAACGCUCUmGmCCmUmUmCmUGGCAUCGmUm U
G020718	155	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	355	mG*mU*mG*UGUCCCmUCUmCCCCACCCGUCCmGUUGUAGCUCCCUGAAA CCGUUGUAGCUCCCUGAAACCGUUGCUACAAUAAGGCCGUCGAAAGA UGUGCCGCAACGCUCUGCCUUCUGGCAUCGUU
G020719	156	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG	356	mG*mUGUGUCCCmUCUmCCCCACCCGUCCmGUUGUAGCUCCCUGAAA CCGUUGUAGCUCCCUGAAACCGUUGCUACAAUAAGGCCGUCGAAAGA UGUGCCGCAACGCUCUGCCUUCUGGCAUCGUU

Guide ID	SEQ ID NO.	sgRNA unmodified sequence	SEQ ID NO.	sgRNA modified sequence
		UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU		AmAmGmAmUGUGCmCGCAACGCUCUmGmCCmUmUmCmUGGCAUC*mG *mU*mU
G020720	157	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	357	mG*mU*mG*UGUCCCmUCUmCCCCACCCGUCCmGUUGmUmAmGmCUCC CmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmG mAmAmAmGmAmUGUGCmCGCAACGCUCUmGmCCmUmUmCmUGGCAUC *mG*mU*mU
G020721	158	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	358	mG*mU*GUGUCCCmUCUmCCCCACCCGUCCmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmAmUGUGCmCGCAACGCUCUmGmCCmUmUmCmUGGCAUCG* mU*mU
G020722	159	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	359	mG*UGUGUCCCmUCUmCCCCACCCGUCCmGUUGmUmAmGmCUCCCmUm GmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmA mAmGmAmUGUGCmCGCAACGCUCUmGmCCmUmUmCmUGGCAUCGU*m U
G020723	160	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC GAAAGGCAUCGUU	360	mG*mUGUGUCCCmUCUmCCCCACCCGUCCmGUUGmUmAmGmCUCCCmU mGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAm AmAmGmAmUGUGCmCGCAACGCUCUmGmCCmGmAmAmAGGCAUCGmU *mU
G020724	161	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	361	mG*mUGUGUCCCmUCUmCCCCACCCGUCCmGUUGmUmAmGmCUCCCmU mGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAm AmAmGmAmUGUGCmCGCAACGmCmUmUmCmUGGCAUC GmU*mU
G020725	162	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA	362	mG*mUGUGUCCCmUCUmCCCCACCCGUCCmGUUGmUmAmGmCUCCCmU mGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAm AmAmGmAmUGUGCmCGCAACGC*U*C*UmGmCCmUmUmCmUGGCAUCG mU*mU

Guide ID	SEQ ID NO.	sgRNA unmodified sequence	SEQ ID NO.	sgRNA modified sequence
		AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU		
G020726	163	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	363	mG*mUGUGUCCCmUCUmCCCCACCCGUCCmGUUGmUmAmGmCUCCCmU mGmAmAmAmCmCGUUmGmCUAmCAAUAAGmGmCCmGmUmCmGmAmA mAmGmAmUGUGCmCGCAACGCUCUmGmCCmUmCmUGGCAUCGmU* mU
G020727	164	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	364	mG*mUGUGUCCCUCUCCCCACCCGUCCGUUGUAGCUCCCUGAAACCGU UGCUACAAU*AAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCUUCU GGCAUCGmU*mU
G020728	165	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	365	mG*mU*GUGUCCCmUCUmCC*CCACCCGUCCmGUUGmUmAmGmCUCCC mUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGm AmAmAmGmAmUGUGCmCGCAACGCUCUmGmCCmUmUmCmUGGCAUCG mU*mU
G020729	166	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	366	mG*mUGUGUCCCmUCUmCCCCACCCGUCCmGUUG*mUmAmGmCU*C*C* C*mUmGmAmAmAmCmCGUUmGmCUAmCA*A*UA*AG*mGmCC*mGmUm CmGmAmAmAmGmAmUG*UGCmCGCAACG*C*U*C*U*mGmCC*mUmUmC mUGGCAU*C*G*mU*mU
G020730	167	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	367	mG*mUGUGUCCCmUCUmCCCCACCCGUCCmGUUG*mUmAmGmCU*C*C* C*mUmGmAmAmAmCmCGUUmGmCUAmCA*A*U*A*AG*mGmCC*mGmU mCmGmAmAmAmGmAmUG*UGCmCGCAACG*C*U*C*U*mGmCC*mUmUm CmUGGCAU*C*G*mU*mU
G020731	168	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	368	mG*mU*GUGUCCCmUCUmCC*CCACCCGUCCmGUUG*mUmAmGmCU*C* C*C*mUmGmAmAmAmCmCGUUmGmCUAmCA*A*UA*AG*mGmCC*mGm UmCmGmAmAmAmGmAmUG*UGCmCGCAACG*C*U*C*U*mGmCC*mUmU mCmUGGCAU*C*G*mU*mU

Guide ID	SEQ ID NO.	sgRNA unmodified sequence	SEQ ID NO.	sgRNA modified sequence
G020732	169	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	369	mG*mU*GUGUCCCmUCUmCC*CCACCCGUCCmGUUG*mUmAmGmCU*C* C*C*mUmGmAmAmAmCmCGUUmGmCUAmCA*A*U*A*AG*mGmCC*mGm UmCmGmAmAmAmGmAmUG*UGCmCGCAACG*C*U*C*U*mGmCC*mUmU mCmUGGCAU*C*G*mU*mU
G020733	170	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	370	mG*mUG*UGU*CCCmUCUmCCC*CACCCGUCCmGUUGmUmAmGmCUCCC mUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGm AmAmAmGmAmAmUGUGCmCGCAACGCUCUmGmCCmUmUmCmUGGCAUCG mU*mU
G020734	171	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	371	mG*mUGUGUCCCmUCUmCCCCACCCGUCCmGUUGmUmAmGmCU*C*C*C *mUmGmAmAmAmCmCGUUmGmCUAmCA*A*U*A*AG*mGmCC*mGmUm CmGmAmAmAmGmAmUGUGCmCGCAACG*C*U*C*U*mGmCCmUmUmUmCm UG*GCAU*C*G*mU*mU
G020735	172	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	372	mG*mUG*UGU*CCCmUCUmCCC*CACCCGUCCmGUUGmUmAmGmCU*C* C*C*mUmGmAmAmAmCmCGUUmGmCUAmCA*A*U*A*AG*mGmCC*mGm UmCmGmAmAmAmGmAmUGUGCmCGCAACG*C*U*C*U*mGmCCmUmUmUm CmUG*GCAU*C*G*mU*mU
G020736	173	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUUU	373	mG*mUGUGUCCCmUCUmCCCCACCCGUCCmGUUGmUmAmGmCUCCCCmU mGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAm AmAmGmAmAmUGUGCmCGCAACGCUCUmGmCCmUmUmCmUGGCAUCGmU *mUmU
G020737	174	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUUUA	374	mG*mUGUGUCCCmUCUmCCCCACCCGUCCmGUUGmUmAmGmCUCCCCmU mGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAm AmAmGmAmAmUGUGCmCGCAACGCUCUmGmCCmUmUmCmUGGCAUCGmU *mUmU*mA
G020738	175	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG	375	mG*mUGUGUCCCmUCUmCCCCACCCGUCCmGUUGmUmAmGmCUCCCCmU mGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAm

Guide ID	SEQ ID NO.	sgRNA unmodified sequence	SEQ ID NO.	sgRNA modified sequence
		UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUUUAU		AmAmGmAmUGUGCmCGCAACGCUCUmGmCCmUmUmCmUGGCAUCGmU *mUmU*mA*mU
G020739	176	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUUGGAAAC CACGUUGCUACAAUAAGGCCGU CGAAAGAUGUGCCGCAACGCUC UGCCUUCUGGCAUCGUU	376	mG*mUGUGUCCCmUCUmCCCCACCCGUCCmGUUGmUmAmGmCUCCCmU mUmGmGmGmAmAmAmCmCmAmCGUUmGmCUAmCAAU*AAGmGmCCmGm UmCmGmAmAmAmGmAmUGUGCmCGCAACGCUCUmGmCCmUmUmCmU GGCAUCGmU*mU
G020740	177	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCGAAACGUU GCUACAAUAAGGCCGUCGAAAG AUGUGCCGCAACGCUCUGCCUU CUGGCAUCGUU	377	mG*mUGUGUCCCmUCUmCCCCACCCGUCCmGUUGmUmAmGmCUCCCmG mAmAmAmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAm GmAmUGUGCmCGCAACGCUCUmGmCCmUmUmCmUGGCAUCGmU*mU
G020741	178	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCGAAACUUGC UACAAUAAGGCCGUCGAAAGAU GUGCCGCAACGCUCUGCCUUCU GGCAUCGUU	378	mG*mUGUGUCCCmUCUmCCCCACCCGUCCmGUUGmUmAmGmCUCCmG mAmAmAmCUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmG mAmUGUGCmCGCAACGCUCUmGmCCmUmUmCmUGGCAUCGmU*mU
G020742	179	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	379	mG*mUGUGUCCCmUCUmCC*CCACCCGUCCmGUUG*mUmAmGmCU*C*C *C*mUmGmAmAmAmCmCGUUmGmCUAmCA*A*U*A*AG*mGmCC*mGmU mCmGmAmAmAmGmAmUG*UGCmCGCAACG*mCmUmCU*mGmCC*mUm UmCmUGGCAU*C*G*mU*mU
G020743	180	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	380	mG*mU*mG*UGUCCCmUCUmCC*CCACCCGUCCmGUUG*mUmAmGmCU* C*C*C*mUmGmAmAmAmCmCGUUmGmCUAmCA*A*U*A*AG*mGmCC*m GmUmCmGmAmAmAmGmAmUG*UGCmCGCAACG*mCmUmCU*mGmCC* mUmUmCmUGGCAU*C*G*mU*mU
G020744	181	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA	381	mG*mUGUGUCCCmUCUmCC*CCACCCGUCCmGUUG*mUmAmGmCU*C*C *C*mUmGmAmAmAmCmCGUUmGmCUAmCA*A*U*A*AG*mGmCC*mGmU mCmGmAmAmAmGmAmUG*UGCmCGCAACG*mCmUmCU*mGmCC*mGm AmAmAGGCAU*C*G*mU*mU

Guide ID	SEQ ID NO.	sgRNA unmodified sequence	SEQ ID NO.	sgRNA modified sequence
		AGAUGUGCCGCAACGCUCUGCC GAAAGGCAUCGUU		
G020745	182	GUGUGUCCCUCUCCCCACACCGU CCGUUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC GAAAGGCAUCGUU	382	mG*mU*mG*UGUCCCmUCUmCC*CCACCCGUCCmGUUG*mUmAmGmCU* C*C*C*mUmUmGmAmAmAmCmCGUUmGmCUAmCA*A*U*A*AG*mGmCC*m GmUmCmGmAmAmAmGmAmUG*UGCmCGCAACG*mCmUmCU*mGmCC* mGmAmAmAGGCAU*C*G*mU*mU
G020746	183	GUGUGUCCCUCUCCCCACACCGU CCGUUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	383	mG*mUmGmUmGUCCmCmCmUmCUmCCCCAmCCCGmUCCmGUUGmUmAm GmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGm UmCmGmAmAmAmGmAmUGUGCmCGCAACGCUCUmGmCCmUmUmCmU GGCAUCCGmU*mU
G0020747	184	GUGUGUCCCUCUCCCCACACCGU CCGUUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	384	mG*mUGUGUCCCmUCUmCCCCACCCGUCCmGUUGmUmAmGmCUCCCmU mGmAmAmAmCmCGUUmGmCUmAmCAAU*AAGmGmCCmGmUmCmGm AmAmAmGmAmUGUGCmCGCAACGCUCUmGmCCmUmUmCmUGGCAUCG mU*mU
G0020748	185	GUGUGUCCCUCUCCCCACACCGU CCGUUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	385	mG*mUGUGUCCCmUCUmCCCCACACCGUCCmGUUGmUmAmGmCUCCCmU mGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCmCmGmUmCmGmA mAmAmGmAmUGUGCmCGmCAACGCUCUmGmCCmUmUmCmUGGCAUC GmU*mU
G0020749	186	GUGUGUCCCUCUCCCCACACCGU CCGUUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	386	mG*mUGUGUCCCmUCUmCCCCACACCGUCCmGUUGmUmAmGmCUCCCmU mGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAm AmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmGC mAmUCGmU*mU
G0020750	187	GUGUGUCCCUCUCCCCACACCGU CCGUUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	387	mG*mUGUGUCCCmUCUmCCCCACACCGUCCmGUUGmUmAmGmCUCCCmU mGmAmAmAmCmCGmUUmGmCUmAmCAAU*AAGmGmCmCmGmUmCmG mAmAmAmGmAmUGmUGCmCGmCmAmAmCmGCUCUmGmCCmUmUmUmCm UGmGCmAmUCCGmU*mU

Guide ID	SEQ ID NO.	sgRNA unmodified sequence	SEQ ID NO.	sgRNA modified sequence
G020751	188	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCUGA AAAGAUGUGCCGCAACGCUCUG CCUUCUGGGCAUCGUU	388	mG*mUGUGUCCCmUCUmCCCCACCCGUCCmGUUGmUmAmGmCUCCCmU mGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmUmGm AmAmAmAmGmAmUGUGCmCGCAACGCUCUmGmCCmUmUmCmUGGCAU CGmU*mU
G020752	189	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC CUUCUGGGCAUCGUU	389	mG*mUGUGUCCCmUCUmCCCCACCCGUCCmGUUGmUmAmGmCUCCCmU mGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAm AmAmGmAmUGUGCmCGCAACGCUCUmGmCCCmUmUmCmUmGGGCAUC GmU*mU
G020753	190	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCUGA AAAGAUGUGCCGCAACGCUCUG CCCUUCUGGGCAUCGUU	390	mG*mUGUGUCCCmUCUmCCCCACCCGUCCmGUUGmUmAmGmCUCCCmU mGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmUmGm AmAmAmAmGmAmUGUGCmCGCAACGCUCUmGmCCCmUmUmCmUmGG GCAUCGmU*mU
G020754	191	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCUGA AAAGAUGUGCCGCAACGCUCUG CCUUCUGGGCAUCGUU	391	mG*mU*mG*UGUCCCCmUCUmCCCCACCCGUCCmGUUGmUmAmGmCUCC CmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmU mGmAmAmAmAmGmAmUGUGCmCGCAACGCUCUmGmCCmUmUmCmUG GCAUCGmU*mU
G020755	192	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC CUUCUGGGCAUCGUU	392	mG*mU*mG*UGUCCCCmUCUmCCCCACCCGUCCmGUUGmUmAmGmCUCC CmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmG mAmAmAmGmAmUGUGCmCGCAACGCUCUmGmCCCmUmUmCmUmGGGC AUCGmU*mU
G020756	193	GUGUGUCCCUCUCCCCACCCGU CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCUGA AAAGAUGUGCCGCAACGCUCUG CCCUUCUGGGCAUCGUU	393	mG*mU*mG*UGUCCCCmUCUmCCCCACCCGUCCmGUUGmUmAmGmCUCC CmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmU mGmAmAmAmAmGmAmUGUGCmCGCAACGCUCUmGmCCCmUmUmCmU mGGGCAUCGmU*mU
G020848	194	UGAGGACCGCCCUGGGCCUGGG AGGUUGUAGCUCCCUCGAAAGC	394	mU*mGA*GGACCGmCCCmUGGGCCUGGGAGmGUUGmUmAmGmCUCCCU mCmGmAmAmAmGCCGUUmGmCUAmCAAU*A*AGmGmCCmGmUmCmGm

Guide ID	SEQ ID NO.	sgRNA unmodified sequence	SEQ ID NO.	sgRNA modified sequence
		CGUUGCUACAAUAAGGCCGUCG AAAGAUGUGCCGCAACGCUCUG CCUUCUGGCAUCGUUUAUU		AmAmAmGmAmUGUGCmCGCAACGCUCUmGmCCmUmUmCmUGGCAUCG UUU*AmU*mU
G021237	195	GGGGCCAGCUUCAGACACAAAU ACGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	395	mG*mGGGCCAGCmUUCmAGACACAAAUACmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021238	196	UUUUCACAGCCAACGACUCUGG CCGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	396	mU*mUUUCACAGmCCAmACGACUCUGGCCmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021239	197	CAUCAGAGGACAUUUGGAUUCU CCGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	397	mC*mAUCAGAGGmACAmUUUGGAUUCUCCCmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021240	198	CAUGGAACGGGGAAAUGCCAAG UGGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	398	mC*mAUGGAACGmGGGmAAAUGCCAAGUGmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021241	199	AAAUCGUACUGGAAGACACUUG GCGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	399	mA*mAAUCGUACmUGGmAAGACACUUGGCmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021242	200	AAUCGUACUGGAAGACACUUGG CAGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA	400	mA*mAUCGUACUmGGAmAGACACUUGGCAmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU

Guide ID	SEQ ID NO.	sgRNA unmodified sequence	SEQ ID NO.	sgRNA modified sequence
		AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU		
G021243	201	UCUGGCCAUCGCCACUACACCA UCGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	401	mU*mCUGGCCAUmCGCmCACUACACCAUCmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmUmCmUGmG CmAmUC*mG*mU*mU
G021244	202	CUGGCCAUCGCCACUACACCAU CGGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	402	mC*mUGGCCAUCmGCCmACUACACCAUCGmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmUmCmUGmG CmAmUC*mG*mU*mU
G021245	203	ACCAUCGCAGCCCUGCUCAGCC CAGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	403	mA*mCCAUCGCAmGCCmCUGCUCAGCCCAmGUUGmUmAmGmCUCCCmU mGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAm AmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmUmCmUGmGC mAmUC*mG*mU*mU
G021246	204	UGGACUGGUAUUUGUGUCUGAA GCGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	404	mU*mGGACUGGUmAUUmUGUGUCUGAAGCmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmUmCmUGmG CmAmUC*mG*mU*mU
G021247	205	CUGCCUCGGACAGCAUCCAGGA CUGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	405	mC*mUGCCUCGGmACAmGCAUCCAGGACUmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmUmCmUGmG CmAmUC*mG*mU*mU
G021248	206	CUACAAGCUUACCCAGAGGCAA AGGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	406	mC*mUACAAGCUUmUACmCCAGAGGCAAAGmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmUmCmUGmG CmAmUC*mG*mU*mU

Guide ID	SEQ ID NO.	sgRNA unmodified sequence	SEQ ID NO.	sgRNA modified sequence
G021249	207	CAGAAUUGAGAGACUCAGCCCA GGGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	407	mC*mAGAAUUGAmGAGmACUCAGCCCAGGmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021250	208	GAUCCACAAGCUCCUGACAGGA UGGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	408	mG*mAUCCACACAAmGCUmCCUGACAGGAUGmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021251	209	AUCCACAAGCUCCUGACAGGAU GGGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	409	mA*mUCCACACAAGmCUCmCUGACAGGAUGGmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021252	210	GGACUGGUAUUUGUGUCUGAAG CUGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	410	mG*mGACUGGUAmUUUmGUGUCUGAAGCUmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021253	211	UGCUGAUCCCCUGCCAAGCUGAC UCGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	411	mU*mGCUGAUCCCmCUGmCCAAGCUGACUCmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021254	212	CAGCAACCCCCAGAAUUGAGAG ACGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	412	mC*mAGCAACCCmCCAmGAAUUGAGAGACmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021255	213	GCUUCUCCCUGGUGAAGGGGCUU UUGUUGUAGCUCCCCUGAAACCG	413	mG*mCUUCUCCCUmGGUmGAAGGGGCUUUUmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA

Guide ID	SEQ ID NO.	sgRNA unmodified sequence	SEQ ID NO.	sgRNA modified sequence
		UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU		mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021256	214	CCAAGUGUCUUCCAGUACGAUU UGGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	414	mC*mCAAGUGUCmUUCmCAGUACGAUUUGmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021257	215	CGAUGGCCAGAGUCGUUGGCUG UGGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	415	mC*mGAUGGCCAmGAGmUCGUUGGCUGUGmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021258	216	GUUUAAUAAGAAUGCUUCACGG CAGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	416	mG*mUUUAAUAAmGAAmUGCUUCACGGCAmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021259	217	UUGGAGUCAGCUUGGCAGGGAU CAGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	417	mU*mUGGAGUCAmGCUmUGGCAGGGAUCAmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021260	218	GGAAGGAGGGGGUAUAAAAGCC CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	418	mG*mGAAGGAGGGmGGmUAUAAAAGCCCCmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021261	219	ACAGGAUGGCUUCCCUUCGACU CUGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA	419	mA*mCAGGAUGGmCUUmCCCUUCGACUCUmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU

Guide ID	SEQ ID NO.	sgRNA unmodified sequence	SEQ ID NO.	sgRNA modified sequence
		AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU		
G021262	220	CUGGACUGGUAUUUGUGUCUGA AGGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	420	mC*mUGGACUGGmUAUmUUGUGUCUGAAGmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021263	221	CUCUGAUGGUCAAAGUCCUGGA UGGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	421	mC*mUCUGAUGGmUCAmAAGUCCUGGAUGmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021264	222	GAAGGAGUGUACAGAGUAGAAC UGGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	422	mG*mAAGGAGUGUACmAGAGUAGAACUGmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021265	223	AGGUGGUUUUCACAGCCAACGA CUGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	423	mA*mGGUGGUUUUmUCAmCAGCCAACGACUmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021266	224	GCCAACGACUCUGGCCAUCGCC ACGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	424	mG*mCCAACGACmUCUmGGCCAUCGCCACmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021267	225	UACAGCACCACGGCUGUCGUCA GCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	425	mU*mACAGCACCmACGmGCUGUCGUCAGCmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU

Guide ID	SEQ ID NO.	sgRNA unmodified sequence	SEQ ID NO.	sgRNA modified sequence
G021268	226	ACAGCACCACGGCUGUCGUCAG CAGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	426	mA*mCAGCACCACGGmCUGUCGUCAGCAmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021269	227	UAAACCGUGUUAGCAGCUCAGG AAGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	427	mU*mAAACCGUGmUUAmGCAGCUCAGGAAmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021270	228	GAAGAUGCCGUGAAGCAUUCUU AUGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	428	mG*mAAGAUGCCmGUGmAAGCAUUCUUAUmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021271	229	GAUGCCGUGAAGCAUUCUUAUU AAGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	429	mG*mAUGCCGUGmAAGmCAUUCUUAUUAAmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021272	230	UCCUGGUGAAGGGGCUUUUAUA CCGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	430	mU*mCCUGGUGAmAGGmGGCUUUUAUACCmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021273	231	UUCUCCUGGUGAAGGGGCUUUU AUGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	431	mU*mUCUCCUGGmUGAmAGGGGCUUUUAUmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021274	232	CUUCUCCUGGUGAAGGGGCUUU UAGUUGUAGCUCCCCUGAAACCG	432	mC*mUUCUCCUGmGUGmAAGGGGCUUUUAmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA

Guide ID	SEQ ID NO.	sgRNA unmodified sequence	SEQ ID NO.	sgRNA modified sequence
		UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU		mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021275	233	UCUACAGCAGGGCUGCCUCGGA CAGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	433	mU*mCUACAGCAmGGGmCUGCCUCGGACAmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021276	234	UUUGGUGUCCAGUUCUACUCUG UAGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	434	mU*mUUGGUGUCCAGmUUCUACUCUGUAGmUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021277	235	CAGGGCUGCGAUGGUGUAGUGG CGGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	435	mC*mAGGGCUGCGmAUGGUGUAGUGGCGmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021278	236	GAUGCUACUGCUUUGGCAAGAU CCGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	436	mG*mAUGCUACUmGCUmUUGGCAAGAUCCmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021279	237	CUGACAGGAUGGGCUUCCCCUUCG ACGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	437	mC*mUGACAGGAmUGGmCUUCCCCUUCGACmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021280	238	GCGGAGUCUGGAGAGCUGCACG GGGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA	438	mG*mCGGAGUCUmGGAmGAGCUGCACGGGmGUUGmUmAmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU

Guide ID	SEQ ID NO.	sgRNA unmodified sequence	SEQ ID NO.	sgRNA modified sequence
		AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU		
G021281	239	GCCACUACACCAUCGCAGCCCU GCGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	439	mG*mCCACUACACCAUCGCAGCCCUGCmGUUGmUmAmGmCUCCCmU mGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAm AmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmGC mAmUC*mG*mU*mU
G021282	240	CCUACAGCACCACGGCUGUCGU CAGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	440	mC*mCUACAGCAmCCAmCGGCUGUCGUCAmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021283	241	CUACAGCACCACGGCUGUCGUC AGGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	441	mC*mUACAGCACCACGGCUGUCGUCAGmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021284	242	CCCCCUCCUUCCAACCCAGGCU GCGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	442	mC*mCCCCUCCUUCCAACCCAGGCUGCmGUUGmUmAmGmCUCCCmU mGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAm AmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmGC mAmUC*mG*mU*mU
G021285	243	AAGGGGCUUUUAUACCCCCUCC UUGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	443	mA*mAGGGGCUUmUUAmUACCCCCUCCUUmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021286	244	GAGCUUGUGGAUCUGUGUGACG GCGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	444	mG*mAGCUUGUGmGAUmCUGUGUGACGGCmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU

Guide ID	SEQ ID NO.	sgRNA unmodified sequence	SEQ ID NO.	sgRNA modified sequence
G021287	245	ACCGCGGGGGCCAGCUUCAGACA CAGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	445	mA*mCCGCGGGGGmCCAmGCUUCAGACACAmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmAmUC*mG*mU*mU
G021288	246	AUCGCUCACAGGAUCACUCACC GCGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	446	mA*mUCGCUCACmAGGmAUCACUCACCGCmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmAmUC*mG*mU*mU
G021289	247	UUUUACAGCCACGUCUACAGCA GGGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	447	mU*mUUUACAGCmCACmGUCUACAGCAGGmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmAmUC*mG*mU*mU
G021290	248	UCCCAUGGUGGGCUUUCUACAA GCGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	448	mU*mCCCAUGGUmGGGmCUUUCUACAAGCmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmAmUC*mG*mU*mU
G021291	249	GUGGUGAGCCCGUGCAGCUCUC CAGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	449	mG*mUGGUGAGCmCCGmUGCAGCUCUCCCAmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmAmUC*mG*mU*mU
G021292	250	CUCAUCUGUGGUGAGCCCGUGC AGGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	450	mC*mUCAUCUGUmGGUmGAGCCCGUGCAGmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmAmUC*mG*mU*mU
G021293	251	UUCUACAAACUUCUCAUCUGUG GUGUUGUAGCUCCCCUGAAACCG	451	mU*mUCUACAAAmCUUmCUCAUCUGUGGUmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA

Guide ID	SEQ ID NO.	sgRNA unmodified sequence	SEQ ID NO.	sgRNA modified sequence
		UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU		mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021294	252	CUUCUACAAACUUCUCAUCUGU GGGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	452	mC*mUUCUACAAmACUmUCUCAUCUGUGGmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021295	253	AUCCGCGAAUUCAUGGAACGGG GAGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	453	mA*mUCCGCGAAmUUCmAUGGAACGGGGAmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021296	254	CCAAACAACUUGGUGUGUCCAC UUGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	454	mC*mCAAACAACmUUGmGUGUGUCCACUUmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021297	255	UCUCAAUUCUGGGGGUUGCUGA CGGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	455	mU*mCUCAAUUCmUGGmGGGUUGCUGACGmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021298	256	GCUACUGCUUUGGCAAGAUCCU GGGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	456	mG*mCUACUGCUmUUGmGCAAGAUCCUGGmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021299	257	UUCUUUCUUUAAAAAGUUUGAU CGGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA	457	mU*mUCUUUCUUUmUAAmAAAGUUUGAUCCGmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU

Guide ID	SEQ ID NO.	sgRNA unmodified sequence	SEQ ID NO.	sgRNA modified sequence
		AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU		
G021300	258	CCAUGACCUCCCCAAGAUGGAA AGGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	458	mC*mCAUGACCUCmCCCmCAAGAUGGAAAGmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021301	259	GCAAGUUGCCAGGAGCACCCAU GAGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	459	mG*mCAAGUUGCmCAGmGAGCACCCAUGAmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021302	260	AGCAAGUUGCCAGGAGCACCCA UGGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	460	mA*mGCAAGUUGmCCAmGGAGCACCCAUGmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021303	261	UCAAGCAAGUUGCCAGGAGCAC CCGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	461	mU*mCAAGCAAGmUUGmCCAGGAGCACCCmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021304	262	UCUUCCUCAAGCAAGUUGCCAG GAGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	462	mU*mCUUCCUCAmAGCmAAGUUGCCAGGAmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021305	263	AUCUUCCUCAAGCAAGUUGCCA GGGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	463	mA*mUCUUCCUCmAAGmCAAGUUGCCAGGmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU

Guide ID	SEQ ID NO.	sgRNA unmodified sequence	SEQ ID NO.	sgRNA modified sequence
G021306	264	UGGUCCACUCUGCUUUCUGACC UAGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	464	mU*mGGUCCACUmCUGmCUUUCUGACCUAmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021307	265	UGAACGGUUGGUCCACUCUGCU UUGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	465	mU*mGAACGGUUmGGUmCCACUCUGCUUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021308	266	CAGAUUGUGUGCUUUUAAUAGC UAGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	466	mC*mAGAUUGUGUGmCUUUUAAUAGCUAmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021309	267	UGGGAAAACACUACUGUGCAUC UAGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	467	mU*mGGGAAAACmACUmACUGUGCAUCUAmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021310	268	AGGAAGAUAGGUCAGAAAGCAG AGGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	468	mA*mGGAAGAUAGGUmCAGAAAGCAGAGmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021311	269	CUGGGAAAACACUACUGUGCAU CUGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	469	mC*mUGGGAAAACmCACmUACUGUGCAUCUmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021312	270	GGCCUACUUUUUCAGUAUUGUGA UUGUUGUAGCUCCCCUGAAACCG	470	mG*mGCCUACUUmUUCmAGUAUUGUGAUUmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA

Guide ID	SEQ ID NO.	sgRNA unmodified sequence	SEQ ID NO.	sgRNA modified sequence
		UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU		mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021313	271	UGGCCUACUUUUUCAGUAUUGUG AUGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	471	mU*mGGCCUACUmUUUmCAGUAUUGUGAUmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmAmUC*mG*mU*mU
G021314	272	UUAGUCACUAAAGGUUAUAAAA AAGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	472	mU*mUAGUCACUmAAAmGGUUAUAAAAAmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmAmUC*mG*mU*mU
G021315	273	UUUAGUCACUAAAGGUUAUAAA AAGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	473	mU*mUUAGUCACmUAAmAGGUUAUAAAAAmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmAmUC*mG*mU*mU
G021316	274	CCUGGGUUGGAAGGAGGGGGUA UAGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	474	mC*mCUGGGUUGmGAAmGGAGGGGGUAUAmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmAmUC*mG*mU*mU
G021317	275	CUGGGUUGGAAGGAGGGGGUA UAAGUUGUAGCUCCCCUGAAACC GUUGCUACAAUAAGGCCGUCGA AAGAUGUGCCGCAACGCUCUGC CUUCUGGCAUCGUU	475	mC*mUGGGUUGmGmAAGmGAGGGGGUAUAAmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmAmUC*mG*mU*mU
G021318	276	GGUAUAAAAGCCCCUUCACCAG GAGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA	476	mG*mGUAUAAAAmGCCmCCUUCACCAGGAmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmAmUC*mG*mU*mU

Guide ID	SEQ ID NO.	sgRNA unmodified sequence	SEQ ID NO.	sgRNA modified sequence
		AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU		
G021319	277	UUUGCUUGUAAAACAUUGAACG GUGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	477	mU*mUUGCUUGUmAAAmACAUUGAACGGUmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021320	278	CUUCACCAGGAGAAGCCGUCAC ACGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	478	mC*mUUCACCAGmGAGmAAGCCGUCACACmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021321	279	GAGAAGCCGUCACACAGAUCCA CAGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	479	mG*mAGAAGCCGmUCAmCACAGAUCCACAmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021322	280	UGCCCAGGGUGCUGGAGAAUCC AAGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	480	mU*mGCCCAGGGmUGCmUGGAGAAUCCAAmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021323	281	GACGUGGGCUGUAAAAGUGUUCA AAGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	481	mG*mACGUGGGCUmGUAmAAAGUGUUCAAAmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021324	282	CAAAAAGACCUCUGAGGGAUCC UGGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	482	mC*mAAAAAGACmCUCmUGAGGGAUCCUGmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU

Guide ID	SEQ ID NO.	sgRNA unmodified sequence	SEQ ID NO.	sgRNA modified sequence
G021325	283	AAAAAGACCUCUGAGGGAUCCU GGGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	483	mA*mAAAAGACCmUCUmGAGGGAUCCUGGmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021326	284	CUCUGGACUUGUGUGCCCUCCA GGGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	484	mC*mUCUGGACUmUGUmGUGCCCUCCAGGmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021327	285	UCCUUCCAACCCAGGCUGCUGA UCGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	485	mU*mCCUUCCAAmCCCmAGGCUGCUGAUCmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021328	286	CCCCUCCUUCCAACCCAGGCUG CUGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	486	mC*mCCCUCCUUmCCAmACCCAGGCUGCUmGUUGmUmAmGmCUCCCmU mGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAm AmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmGC mAmUC*mG*mU*mU
G021329	287	AGCAACCCCCAGAAUUGAGAGA CUGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	487	mA*mGCAACCCCCmCAGmAAUUGAGAGACUmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021330	288	ACCAGGAUCUUGCCAAAGCAGU AGGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	488	mA*mCCAGGAUCmUUGmCCAAAGCAGUAGmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021331	289	UUGCCAAAGCAGUAGCAUCCCA UUGUUGUAGCUCCCCUGAAACCG	489	mU*mUGCCAAAGmCAGmUAGCAUCCCAUUmGUUGmUmAmGmCUCCCm UmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmA

Guide ID	SEQ ID NO.	sgRNA unmodified sequence	SEQ ID NO.	sgRNA modified sequence
		UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU		mAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmG CmAmUC*mG*mU*mU
G021536	290	CCAAGUGUCUUCCAGUACGAUU UGGUUGUAGCUCCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	490	mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmA mGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmG mUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmUm CmUGGCAUCG*mU*mU
G021845	291	CUUCACCAGGAGAAGCCGUCAC ACGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	491	mC*mU*mU*mCmACCmAmGGmAGmAAGCCmGUCAmCACmGUUGmUmA mGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmG mUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmUm CmUGGCAUCG*mU*mU
G020927	292	AUCACGAUGCCUUUAUAGGGCA CCGUUUUAGAGCUAGAAAUAGC AAGUUAAAAUAAGGCUAGUCCG UUAUCAACUUGAAAAAGUGGCA CCGAGUCGGUGCUUUU	492	mA*mU*mC*UGCCUUUUAUAGGGCACCGUUUUAGAmGmCmUmAmGmAm AmAmUmAmGmCAAGUUAAAAUAAGGCUAGUCCGUUAUCAmAmCmUmU mGmAmAmAmAmAmGmUmGmGmCmAmCmCmGmAmGmUmCmGmGmUm GmCmU*mU*mU*mU
G020928	293	AGUGAUAUCACGAUGCCUUUAU AGUUUUAGAGCUAGAAAUAGC AAGUUAAAAUAAGGCUAGUCCG UUAUCAACUUGAAAAAGUGGCA CCGAGUCGGUGCUUUU	493	mA*mG*mU*CACGAUGCCUUUAUAGGUUUUAGAmGmCmUmAmGmAmA mAmUmAmGmCAAGUUAAAAUAAGGCUAGUCCGUUAUCAmAmCmUmU mGmAmAmAmAmAmGmUmGmGmCmAmCmCmGmAmGmUmCmGmGmUm GmCmU*mU*mU*mU
G020929	294	GGUGCAAGGAAUGAGAACCGUU UUAGAGCUAGAAAUAGCAAGUU AAAAUAAGGCUAGUCCGUUAUC AACUUGAAAAAGUGGCACCGAG UCGGUGCUUUU	494	mG*mG*mU*UGCAAGGAAUGAGAACCGUUUUAGAmGmCmUmAmGmAm AmAmUmAmGmCAAGUUAAAAUAAGGCUAGUCCGUUAUCAmAmCmUmU mGmAmAmAmAmAmGmUmGmCmAmCmCmGmAmGmUmCmGmGmUm GmCmU*mU*mU*mU

Table 2 (Continued)

G029377	290	CCAAGUGUCUUCCAGUACGAUU UGGUUGUAGCUCCCCUGAAACCG	931	mC*mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmA mGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAUAAGmGmCCmG

		UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU		mUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUm CmUGGCAUCG*mU*mU
G029378	290	CCAAGUGUCUUCCAGUACGAUU UGGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	932	mC*mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmA mGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCmAmAUAAGmGmCC mGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUm UmCmUGGCAUCG*mU*mU
G029379	290	CCAAGUGUCUUCCAGUACGAUU UGGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	933	mC*mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmA mGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCmAmAUAAGmGmCCm GmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmU mCmUGGCAUCG*mU*mU
G029380	290	CCAAGUGUCUUCCAGUACGAUU UGGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	934	mC*mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmA mGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCmAmAU*AAGmGmCC mGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUm UmCmUGGCAUCG*mU*mU
G029381	290	CCAAGUGUCUUCCAGUACGAUU UGGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	935	mC*mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmA mGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAdTAAGmGmCCmG mUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUm CmUGGCAUCG*mU*mU
G029382	290	CCAAGUGUCUUCCAGUACGAUU UGGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	936	mC*mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmA mGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmG mUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCmGCUCUmGmCCmUmU mCmUGGCAUCG*mU*mU
G029383	290	CCAAGUGUCUUCCAGUACGAUU UGGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	937	mC*mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmA mGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmG mUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCmUmGmCCmUmU mCmUGGCAUCG*mU*mU
G029384	290	CCAAGUGUCUUCCAGUACGAUU UGGUUGUAGCUCCCUGAAACCG	938	mC*mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmA mGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmG

		UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU		mUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGmCmUmCmUmGmCCm UmUmCmUGGCAUCG*mU*mU
G029385	290	CCAAGUGUCUUCCAGUACGAUU UGGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	939	mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmA mGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmG mUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCmGmCmUmCmUmGmCCmU mUmCmUGGCAUCG*mU*mU
G029386	290	CCAAGUGUCUUCCAGUACGAUU UGGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	940	mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmA mGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmG mUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCmGmCmUmCmUmGmCC mUmUmCmUGGCAUCG*mU*mU
G029387	290	CCAAGUGUCUUCCAGUACGAUU UGGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	941	mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmA mGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmG mUmCmGmAmAmAmGmAmUGUGCmCGmCmAmAmCmGmCmUmCmUmGm CmCmUmUmCmUGGCAUCG*mU*mU
G029388	290	CCAAGUGUCUUCCAGUACGAUU UGGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	942	mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmA mGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmG mUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUm CmUGGCAUmCmG*mU*mU
G029389	290	CCAAGUGUCUUCCAGUACGAUU UGGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	943	mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmA mGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmG mUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUm CmUGGCmAmUmCmG*mU*mU
G029390	290	CCAAGUGUCUUCCAGUACGAUU UGGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	944	mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmA mGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmG mUmCmGmAmAmAmGmAmUGUGCmCGmCmAmAmCmGmCmUmUmCmUmGm CmCmUmUmCmUGGCmAmUmCmG*mU*mU
G029391	290	CCAAGUGUCUUCCAGUACGAUU UGGUUGUAGCUCCCUGAAACCG	945	mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmA mGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmG

		UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU		mUmCmGmAmAmAmGmAmUGUGCmCGmCmAmAmCmGmCmUmCmUmGm CmCmUmUmCmUGGCAUmCmG*mU*mU
G029392	290	CCAAGUGUCUUCCAGUACGAUU UGGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	946	mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmA mGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmG mUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCmGmCmUmCmUmGmCC mUmUmCmUGGCAUmCmG*mU*mU
G032572	290	CCAAGUGUCUUCCAGUACGAUU UGGUUGUAGCUCCCUGAAACCG UUGCUACAAUAAGGCCGUCGAA AGAUGUGCCGCAACGCUCUGCC UUCUGGCAUCGUU	951	mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmA mGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAUAAGmGmCCmG mUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGmCmUmCmUmGmCCm UmUmCmUGGCAUCG*mU*mU
G031771	295	CCAAGUGUCUUCCAGUACGAUU UGGUUGUAGCUCCCUUCGAAAG ACCGUUGCUACAAUAAGGCCGU CGAAAGAUGUGCCGCAACGCUC UGCCUUCUGGCAUCGUU	952	mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmA mGmCUCCCmUmUmCmGmAmAmAmGmAmCmCGUUmGmCUAmCAAUAA GmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGmCmUmC mUmGmCCmUmUmCmUGGCAUCG*mU*mU

[00240] N represents a nucleotide having any base, e.g., A, C, G, or U. $(mN^*)_3$ represents three consecutive nucleotides each having any base, a 2'-OMe, and a 3' PS linkage to the next nucleotide, respectively. $(N)_{20\text{-}25}$ represent 20-25, i.e., 20, 21, 22, 23, 24, or 25 consecutive N. A, C, G, and U represent nucleotides having adenine, cytosine, guanine, and uracil bases, respectively.

[00241] Nucleotide modifications are indicated in Tables 1-2 as follows: m: 2'-OMe; *: PS linkage; f: 2'-fluoro; (invd): inverted abasic; moe: 2'-moe; e: ENA; d: deoxyribonucleotide (also note that T is always a deoxyribonucleotide); x: UNA. In the sgRNA modified sequences, in certain embodiments, each A, C, G, U, and N is independently a ribose sugar (2'-OH). In certain embodiments, each A, C, G, U, and N is a ribose sugar (2'-OH). Thus, for example, mA represents 2'-O-methyl adenosine; xA represents a UNA nucleotide with an adenine nucleobase; eA represents an ENA nucleotide with an adenine nucleobase; and dA represents an adenosine deoxyribonucleotide.

[00242] sgRNA designations are sometimes provided with one or more leading zeroes immediately following the G. This does not affect the meaning of the designation. Thus, for example, G000282, G0282, G00282, and G282 refer to the same sgRNA.

Table 3 exemplary NmeCas9 sgRNA (SEQ ID NO: 500)

1-24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48
NNNNNNNNNNNNNNNNNNNNNNN	G	U	U	G	U	A	G	C	U	C	C	C	U	U	U	C	U	C	A	U	U	U	C	G
	Lower stem													Upper stem										
Guide region	**Repeat/Anti-Repeat region**																							

49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77
G	A	A	A	C	G	A	A	A	U	G	A	G	A	A	C	C	G	U	U	G	C	U	A	C	A	A	U	A
Loop				Upper stem													Lower Stem											
Repeat/Anti-Repeat region																												

78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107	108
A	G	G	C	C	G	U	C	U	G	A	A	A	A	G	A	U	G	U	G	C	C	G	C	A	A	C	G	C	U	C
Stem									Loop				Stem (96: unpaired)											Lower stem				Bulge		
Hairpin 1																								**Hairpin 2**						

109	110	111	112	113	114	115	116	117	118	119	120	121	122	123	124	125	126	127	128	129	130	131	132	133	134
U	G	C	C	C	C	U	U	A	A	A	G	C	U	U	C	U	G	C	U	U	U	A	A	G	G
Upper Stem													Loop				Upper Stem								
Hairpin 2																									

135	136	137	138	139	140	141	142	143	144	145
G	G	C	A	U	C	G	U	U	U	A
Upper Stem				Bulge	Lower Stem					
Hairpin 2									**Tail**	

Definitions

[00243] The articles "a" and "an" are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element, e.g., a plurality of elements.

[00244] The term "including" is used herein to mean, and is used interchangeably with, the phrase "including but not limited to," such that recitation of items in a list is not to the exclusion of other like items that can be substituted or added to the listed items.

[00245] The term "or" is used herein to mean, and is used interchangeably with, the term "and/or," unless context clearly indicates otherwise. For example, "sense strand or antisense strand" is understood as "sense strand or antisense strand or sense strand and antisense strand."

[00246] The term "about" is used herein to mean within the typical ranges of tolerances in the art. For example, "about" can be understood as about 2 standard deviations from the mean. In certain embodiments, about means +10%. In certain embodiments, about means +5%, +2%, or +1%. When about is present before a series of numbers or a range, it is understood that "about" can modify each of the numbers in the series or range. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.

[00247] The term "at least" prior to a number or series of numbers is understood to include the number adjacent to the term "at least", and all subsequent numbers or integers that could logically be included, as clear from context. For example, the number of nucleotides in a nucleic acid molecule must be an integer. For example, "at least 17 nucleotides of a 20 nucleotide nucleic acid molecule" means that 17, 18, 19, or 20 nucleotides have the indicated property. When at least is present before a series of numbers or a range, it is understood that "at least" can modify each of the numbers in the series or range.

[00248] As used herein, "no more than" or "less than" is understood as the value adjacent to the phrase and logical lower values or integers, as logical from context, to zero. For example, a duplex region of "no more than 2 nucleotide base pairs" has 2, 1, or 0 nucleotide base pairs. When "no more than" or "less than" is present before a series of numbers or a range, it is understood that each of the numbers in the series or range is modified.

[00249] As used herein, ranges include both the upper and lower limits.

[00250] As used herein, it is understood that when the maximum amount of a value is represented by 100% (e.g., 100% inhibition) that the value is interpreted in light of the method of detection. For example, 100% inhibition is understood as inhibition to a level below the level of detection of the assay.

[00251] "Editing efficiency" or "editing percentage" or "percent editing" as used herein is the total number of sequence reads with insertions, deletions, or base changes of nucleotides into the target region of interest over the total number of sequence reads following cleavage or nicking by a Cas RNP.

[00252] "Regions" as used herein describes portions of nucleic acids. Regions may also be referred to as "modules" or "domains." Regions of an sgRNA may perform particular functions, e.g., in directing endonuclease activity of the RNP, for example as described in Briner AE et al., *Molecular Cell* 56:333–339 (2014), or have predicted structures. Exemplary regions of an sgRNA are described in Table 3.

[00253] "Hairpin" or "hairpin structure" as used herein describes a duplex of nucleic acids that is created when a nucleic acid strand folds and forms base pairs with another section of the same strand. A hairpin may form a structure that comprises a loop or a U-shape. In some embodiments, a hairpin may be comprised of an RNA loop. Hairpins can be formed with two complementary sequences in a single nucleic acid molecule bind together, with a folding or wrinkling of the molecule. In some embodiments, hairpins comprise stem or stem loop structures. In some embodiments, a hairpin comprises a loop and a stem. As used herein, when two hairpins are present in a gRNA, a "hairpin region" can refer to hairpin 1 and hairpin 2 and the intervening sequence (e.g., "n") between hairpin 1 and hairpin 2 of a conserved region of an sgRNA.

[00254] As used herein, "form a duplex portion" is understood as being capable of forming an uninterrupted duplex portion or predicted to form an uninterrupted duplex portion, e.g., by base pairing. A duplex portion may comprise two complementary sequences, e.g., a first hairpin stem region and a second hairpin stem region complementary to the first. As used herein, a duplex portion has a length of at least 2 base pairs. A duplex portion optionally comprises 2-10 base pairs, and the two strands that form the duplex portion may be joined, for example, by a nucleotide loop. Base pairing in a duplex can include Watson-Crick base pairing, optionally in combination with base stacking. As used herein, a duplex portion can include a single nucleotide discontinuity on one strand wherein each contiguous nucleotide on one strand is based paired with a nucleotide on the complementary strand which may have a discontinuity of one non-base paired nucleotide, e.g., as in nucleotide 96 of

SEQ ID NO: 500 in hairpin 1, wherein the discontinuity is flanked immediately 5' and 3' with Watson-Crick base pairs. This is distinct from non-paired nucleotides 36 and 65 in the repeat-anti-repeat region, and non-paired nucleotides 106-108 and 139 in hairpin 2, which constitute a discontinuity resulting in two duplex portions, as defined herein. RNA structures are well known in the art and tools are available for structural prediction of RNAs (see, e.g., Sato et al., Nature Comm. 12:941 (2021); RNAstructure at rna.urmc.rochester.edu/RNAstructureWeb/Servers/Predict1/Predict1.html and RNAfold WebServer at rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi). Bridging lengths and structural flexibility required to permit a fold and form a loop to allow nucleobases to come into sufficiently close proximity to base pair are well known in the art.

[00255] As used herein, an "RNA-guided DNA binding agent" means a polypeptide or complex of polypeptides having RNA and DNA binding activity, or a DNA-binding subunit of such a complex, wherein the DNA binding activity is sequence-specific and depends on the sequence of the RNA. Exemplary RNA-guided DNA binding agents include Cas cleavases (which have double strand cleaving activity), Cas nickases (which have single strand cleaving activity), and inactivated forms thereof ("dCas DNA binding agents"). "Cas nuclease", as used herein, encompasses Cas cleavases, Cas nickases, and dCas DNA binding agents. The dCas DNA binding agent may be a dead nuclease comprising non-functional nuclease domains (RuvC or HNH domain). In some embodiments the Cas cleavase or Cas nickase encompasses a dCas DNA binding agent modified to permit DNA cleavage, e.g., via fusion with a FokI domain. In some embodiments, the RNA-guided DNA binding agent has nuclease activity, e.g., cleavase or nickase activity.

[00256] Exemplary nucleotide and polypeptide sequences of Cas9 molecules are provided below. Methods for identifying alternate nucleotide sequences encoding Cas9 polypeptide sequences, including alternate naturally occurring variants, are known in the art. Sequences with at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to any of the Cas9 nucleic acid sequences, amino acid sequences, or nucleic acid sequences encoding the amino acid sequences provided herein are also contemplated. Exemplary open reading frames for Cas9 are provided in Table 4A.

[00257] As used herein, "ribonucleoprotein" (RNP) or "RNP complex" refers to a guide RNA together with an RNA-guided DNA binding agent, such as a Cas nuclease, e.g., a Cas cleavase, Cas nickase, or dCas DNA binding agent (e.g., Cas9). In some embodiments, the guide RNA guides the RNA-guided DNA binding agent such as Cas9 to a target sequence,

and the guide RNA hybridizes with and the agent binds to the target sequence; in cases where the agent is a cleavase or nickase, binding can be followed by cleaving or nicking.

[00258] "Stem loop" as used herein describes a secondary structure of nucleotides that form a base-paired "stem" that ends in a loop of unpaired nucleic acids. A stem may be formed when two regions of the same nucleic acid strand are at least partially complementary in sequence when read in opposite directions. "Loop" as used herein describes a region of nucleotides that do not base pair (i.e., are not complementary) that may cap a stem. A "tetraloop" describes a loop of 4 nucleotides. As used herein, the upper stem of an sgRNA may comprise a tetraloop.

[00259] "Guide RNA", "gRNA", and "guide" are used herein interchangeably to refer to, the combination of a crRNA (also known as CRISPR RNA) and a trRNA (also known as tracrRNA). The crRNA and trRNA may be associated as a single RNA molecule (single guide RNA, sgRNA) or in two separate RNA molecules (dual guide RNA, dgRNA). "Guide RNA" or "gRNA" refers to each type. The trRNA may be a naturally occurring sequence, or a trRNA sequence with modifications or variations compared to naturally-occurring sequences. Guide RNAs can include modified RNAs as described herein. In some embodiments, a guide RNA as used herein does not include a non-nucleotide linker to join two nucleotides within the guide RNA. Unless otherwise clear from the context, guide RNAs described herein are suitable for use with an Nme Cas9, e.g., an Nme1, Nme2, or Nme3 Cas9. For example, FIG. 24 shows an exemplary schematic of Nme2 sgRNA in a possible secondary structure.

[00260] As used herein, a nucleotide that is, for example, 6 nucleotides from the 5' end of a particular sgRNA segment is the sixth nucleotide of that segment, or "nucleotide 6" from the 5' end, e.g., XXXXXN, where N is the 6th nucleotide from the 5' end. A range of nucleotides that is located "at or after" 6 nucleotides from the 5' end begins with the 6th nucleotide and continues down the chain toward the 3' end. Similarly, a nucleotide that is, for example, 5 nucleotides from the 3' end of the chain is the 5th nucleotide when counting from the 3' end of the chain, e.g., NXXXX. A numeric position or range in the guide region refers to the position as determined from the 5' end unless another point of reference is specified; for example, "nucleotide 5" in a guide region is the 5th nucleotide from the 5' end.

[00261] The term a "conserved region" refers to a conserved region of an *N. meningitidis* Cas9 ("NmeCas9") gRNA as shown in Table 3. The first row shows the numbering of the nucleotides; the second row shows an exemplary sequence (e.g., SEQ ID

NO: 500); and the third and fourth rows show the regions. Shortened conserved regions lack at least one nucleotide shown in Table 3, as discussed in detail below.

[00262] As used herein, a "shortened" region in a gRNA is a conserved region of a gRNA that lacks at least 1 nucleotide compared to the corresponding conserved region shown in Table 3. Similarly, "shortened" with respect to an sgRNA means that its conserved region comprises fewer nucleotides than the sgRNA conserved region shown in Table 3. Under no circumstances does "shortened" imply any particular limitation on a process or manner of production of the gRNA.

[00263] "Substituted" or "substitution" as used herein with respect to a polynucleotide refers to an alteration of a nucleobase that changes its preferred base for Watson-Crick pairing or disrupts a base stacking interaction. When a certain region of a guide RNA is "unsubstituted" as used herein, the sequence of the region can be aligned to that of the corresponding conserved region of a NmeCas9 sgRNA (e.g., SEQ ID NO: 500) or any other gRNAs (e.g., part of SEQ ID NO: 1-19, 21-42, 301-494, and 931-946) with gaps and matches only (i.e., no mismatches), where bases are considered to match if they have the same preferred standard partner base (A, C, G, or T/U) for Watson-Crick pairing or have the paired base stacking interactions as shown in FIG. 25.

[00264] As used herein, a "conservative substitution" with respect to a polynucleotide refers to an alteration of a nucleobase means exchanging positions of base paired nucleotides such that base pairings may be maintained. For example, a G-C pair becomes a C-G pair, an A-U pair for a U-A pair, or other natural or modified base pairing.

[00265] As used herein, "substituted" and the like, in regard to unpaired nucleotides (e.g., loops of the repeat/anti-repeat, hairpin 1, or hairpin 2 regions, i.e., nucleotides 49-52, 87-90, and 122-125 in SEQ ID NO: 500, respectively, or other unpaired nucleotides) refers to the replacement of one or more nucleotides, e.g., 1, 2, 3, or 4 nucleotides, of the nucleotide sequence with a different nucleotide that does not interfere with the formation of a structure by the unpaired nucleotides (e.g., a bulge or a loop) which may thus permit formation of one or more duplex portions, e.g., in the repeat/anti-repeat, hairpin 1, or hairpin 2 regions.

[00266] In some embodiments, a gRNA comprises nucleotides that "match the modification pattern" at corresponding or specified nucleotides of a gRNA described herein. This means that the nucleotides matching the modification pattern have the same modifications (e.g., phosphorothioate, 2'-fluoro, 2'-OMe, etc.) as the nucleotides at the corresponding positions of the gRNA described herein, regardless of whether the nucleobases at those positions match. For example, if in a first gRNA, nucleotides 5 and 6, respectively,

have 2'-OMe and phosphorothioate modifications, then this gRNA has the same modification pattern at nucleotides 5 and 6 as a second gRNA that also has 2'-OMe and phosphorothioate modifications at nucleotides 5 and 6, respectively, regardless of whether the nucleobases at positions 5 and 6 are the same or different in the first and second gRNAs. However, a 2'-OMe modification at nucleotide 6 but not nucleotide 7 is not the same modification pattern at nucleotides 6 and 7 as a 2'-OMe modification at nucleotide 7 but not nucleotide 6. Similarly, a modification pattern that matches at least 75% of the modification pattern of a gRNA described herein means that at least 75% of the nucleotides have the same modifications as the corresponding positions of the gRNA described herein. Corresponding positions may be determined by pairwise or structural alignment.

[00267] As used herein, a "guide sequence" or "guide region" and the like refer to a sequence within a guide RNA that is complementary to a target sequence and functions to direct a guide RNA to a target sequence for binding or modification (e.g., cleavage) by NmeCas9A "guide sequence" may also be referred to as a "targeting sequence," or a "spacer sequence." A guide sequence can be 20-25 nucleotides in length, e.g., in the case of Nme Cas9, e.g., 20-, 21-, 22-, 23-, 24-or 25-nucleotides in length.

[00268] Target sequences for RNA-guided DNA binding agents include both the positive and negative strands of genomic DNA (i.e., the sequence given and the reverse complement of the sequence), as a nucleic acid substrate for an RNA-guided DNA binding agent is a double stranded nucleic acid. Accordingly, where a guide sequence is said to be "complementary to a target sequence", it is to be understood that the guide sequence may direct a guide RNA to bind to the sense or antisense strand (e.g. reverse complement) of a target sequence. Thus, in some embodiments, where the guide sequence binds the reverse complement of a target sequence, the guide sequence is identical to certain nucleotides of the target sequence (e.g., the target sequence not including the PAM) except for the substitution of U for T in the guide sequence.

[00269] As used herein, the "5' end" refers to the first nucleotide of the gRNA, including a dgRNA (typically the 5' end of the crRNA of the dgRNA) and sgRNA, i.e., the 5' end of the guide sequence, in which the 5' position is not linked to another nucleotide.

[00270] As used herein, a "5' end modification" refers to a gRNA comprising a guide region having modifications in one or more of the one (1) to about seven (7) nucleotides, optionally to about four (4) nucleotides at its 5' end, optionally wherein the first nucleotide (from the 5' end) of the gRNA is modified.

[00271] As used herein, the "3' end" refers to the end or terminal nucleotide of a gRNA, in which the 3' position is not linked to another nucleotide. In some embodiments, the 3' end is in the 3' tail. In some embodiments, the 3' end is in the conserved region of a gRNA.

[00272] As used herein, a "3' end modification" refers to a gRNA having modifications in one or more of the one (1) to about seven (7) nucleotides, optionally about four (4) nucleotides, at its 3' end, optionally wherein the last nucleotide (i.e., the 3' most nucleotide) of the gRNA is modified. If a 3' tail is present, the 1 to about 7 nucleotides, optionally about four (4) nucleotides, may be within the 3' tail. If a 3' tail is not present, the 1 to about 7 nucleotides, optionally about four (4) nucleotides, may be within the conserved region of a sgRNA.

[00273] The "last," "second to last," "third to last," etc., nucleotide refers to the 3' most, second 3' most, third 3' most, etc., nucleotide, respectively in a given sequence. For example, in the sequence 5'-AAACTG-3', the last, second to last, and third to last nucleotides are G, T, and C, respectively. The phrase "last 3 nucleotides" refers to the last, second to last, and third to last nucleotides; more generally, "last N nucleotides" refers to the last to the Nth to last nucleotides, inclusive. "Third nucleotide from the 3' end of the 3' terminus" is equivalent to "third to last nucleotide." Similarly, "third nucleotide from the 5' end of the 5' terminus" is equivalent to "third nucleotide at the 5' terminus."

[00274] As used herein, a "protective end modification" (such as a protective 5' end modification or protective 3' end modification) refers to a modification of one or more nucleotides within seven nucleotides, optionally four nucleotides, of the end of an sgRNA that reduces degradation of the sgRNA, such as exonucleolytic degradation. In some embodiments, a protective end modification comprises modifications of at least two or at least three nucleotides within seven nucleotides, optionally four nucleotides, of the end of the sgRNA. In some embodiments, the modifications comprise phosphorothioate linkages, 2' modifications such as 2'-OMe or 2'-fluoro, 2'-H (DNA), ENA, UNA, or a combination thereof. In some embodiments, the modifications comprise phosphorothioate linkages and 2'-OMe modifications. In some embodiments, at least three terminal nucleotides are modified, e.g., with phosphorothioate linkages or with a combination of phosphorothioate linkages and 2'-OMe modifications. In some embodiments, at least two terminal nucleotides are modified, e.g., with phosphorothioate linkages or with a combination of phosphorothioate linkages and 2'-OMe modifications. Modifications known to those of skill in the art to reduce exonucleolytic degradation are encompassed.

[00275] In some embodiments, a "3' tail" comprising about 1-10 nucleotides, optionally about 1-4 nucleotides, following the conserved region of a sgRNA at its 3' end.

[00276] Several Cas9 orthologs have been obtained from *N. meningitidis* (Esvelt et al., NAT. METHODS, vol. 10, 2013, 1116 - 1121; Hou et al., PNAS, vol. 110, 2013, pages 15644 - 15649) (Nme1Cas9, Nme2Cas9, and Nme3Cas9). The Nme2Cas9 ortholog functions efficiently in mammalian cells, recognizes an N4CC PAM, and can be used for in vivo editing (Ran et al., NATURE, vol. 520, 2015, pages 186 - 191; Kim et al., NAT. COMMUN., vol. 8, 2017, pages 14500). Nme2Cas9 has been shown to be naturally resistant to off-target editing (Lee et al., MOL. THER., vol. 24, 2016, pages 645 - 654; Kim et al., 2017). See also e.g., WO/2020081568 (e.g., pages 28 and 42), describing an Nme2Cas9 D16A nickase, the contents of which are hereby incorporated by reference in its entirety. Further, NmeCas9 variants are known in the art, see, e.g., Huang et al., Nature Biotech. 2022, doi.org/10.1038/s41587-022-01410-2, which describes Cas9 variants targeting single-nucleotide-pyrimidine PAMs.

[00277] As used herein, "NmeCas9" (sometimes referred to as "Cas9") encompasses NmeCas9, e.g., Nme1Cas9, Nme2Cas9, and Nme3Cas9; the variants of NmeCas9 listed herein, and equivalents thereof. See, *e.g.*, Edraki et al., Mol. Cell 73:714-726, 2019. "Cas nuclease", also called "Cas protein", as used herein, encompasses Cas cleavases, Cas nickases which further have RNA-guided DNA cleavases or nickase activity, and dCas DNA binding agents, in which cleavase/nickase activity is inactivated. In some embodiments, NmeCas9 has double strand cleavage activity. In some embodiments, NmeCas9 has nickase activity. In some embodiments, NmeCas9 comprises a dCas DNA binding domain.

[00278] As used herein, a first sequence is considered to "comprise a sequence with at least X% identity to" a second sequence if an alignment of the first sequence to the second sequence shows that X% or more of the positions of the second sequence in its entirety are matched by the first sequence. For example, the sequence AAGA comprises a sequence with 100% identity to the sequence AAG because an alignment would give 100% identity in that there are matches to all three positions of the second sequence. The differences between RNA and DNA (generally the exchange of uridine for thymidine or vice versa) and the presence of nucleoside analogs such as modified uridines do not contribute to differences in identity or complementarity among polynucleotides as long as the relevant nucleotides (such as thymidine, uridine, or modified uridine) have the same complement (e.g., adenosine for all of thymidine, uridine, or modified uridine; another example is cytosine and 5-methylcytosine, both of which have guanosine or modified guanosine as a complement). Thus, for example, the sequence 5'-AXG where X is any modified uridine, such as pseudouridine, N1-methyl

pseudouridine, or 5-methoxyuridine, is considered 100% identical to AUG in that both are perfectly complementary to the same sequence (5'-CAU). Exemplary alignment algorithms are the Smith-Waterman and Needleman-Wunsch algorithms, which are well-known in the art. One skilled in the art will understand what choice of algorithm and parameter settings are appropriate for a given pair of sequences to be aligned; for sequences of generally similar length and expected identity >50% for amino acids or >75% for nucleotides, the Needleman-Wunsch algorithm with default settings of the Needleman-Wunsch algorithm interface provided by the EBI at the www.ebi.ac.uk web server is generally appropriate.

[00279] "mRNA" is used herein to refer to a polynucleotide that is RNA or modified RNA and comprises an open reading frame that can be translated into a polypeptide (i.e., can serve as a substrate for translation by a ribosome and amino-acylated tRNAs). mRNA can comprise a phosphate-sugar backbone including ribose residues or analogs thereof, e.g., 2'-methoxy ribose residues. In some embodiments, the sugars of a nucleic acid phosphate-sugar backbone consist essentially of ribose residues, 2'-methoxy ribose residues, or a combination thereof. In general, mRNAs do not contain a substantial quantity of thymidine residues (e.g., 0 residues or fewer than 30, 20, 10, 5, 4, 3, or 2 thymidine residues; or less than 10%, 9%, 8%, 7%, 6%, 5%, 4%, 4%, 3%, 2%, 1%, 0.5%, 0.2%, or 0.1% thymidine content). An mRNA can contain modified uridines at some or all of its uridine positions. A modified mRNA comprises at least one nucleotide in which one or more of the phosphate, sugar, or nucleobase differ from that of a standard adenosine, cytidine, guanidine, or uridine nucleotide.

[00280] As used herein, a "subject" refers to any member of the animal kingdom. In some embodiments, "subject" refers to humans. In some embodiments, "subject" refers to non-human animals. In some embodiments, "subject" refers to primates. In some embodiment, "subject" refers to non-human primates. In some embodiments, subjects include, but are not limited to, mammals, birds, reptiles, amphibians, fish, insects, or worms. In certain embodiments, the non-human subject is a mammal (e.g., a rodent, a mouse, a rat, a rabbit, a monkey, a dog, a cat, a sheep, cattle, a primate, or a pig). In some embodiments, a subject may be a transgenic animal, genetically-engineered animal, or a clone. In certain embodiments of the present invention the subject is an adult, an adolescent or an infant. In some embodiments, terms "individual" or "patient" are used and are intended to be interchangeable with "subject" wherein the subject is a human subject.

[00281] As used herein, "treatment" refers to any administration or application of a therapeutic for disease or disorder in a subject, and includes slowing or arresting disease

development or progression, relieving one or more signs or symptoms of the disease, curing the disease, or preventing reoccurrence of one or more symptoms of the disease.

[00282] As used herein, "delivering" and "administering" are used interchangeably, and include *ex vivo* and *in vivo* applications.

[00283] Co-administration, as used herein, means that a plurality of substances are administered sufficiently close together in time so that the agents act together. Co-administration encompasses administering substances together in a single formulation and administering substances in separate formulations close enough in time so that the agents act together.

[00284] As used herein, the phrase "pharmaceutically acceptable" means that which is useful in preparing a pharmaceutical composition that is generally non-toxic and is not biologically undesirable and that are not otherwise unacceptable for pharmaceutical use. Pharmaceutically acceptable generally refers to substances that are non-pyrogenic. Pharmaceutically acceptable can refer to substances that are sterile, especially for pharmaceutical substances that are for injection or infusion.

I. Guide RNAs with one or more shortened conserved regions

[00285] Provided herein are guide RNAs (gRNAs) comprising one or more shortened conserved regions.

[00286] In some embodiments, a gRNA provided herein comprises a guide region and a conserved region comprising a repeat/anti-repeat region, a hairpin 1 region, and a hairpin 2 region, wherein one or more of the repeat/anti-repeat region, the hairpin 1 region, and the hairpin 2 region are shortened. In some embodiments, the gRNA is from *N. meningitidis Cas9* (NmeCas9).

[00287] In some embodiments, the conserved region comprises one or more of:

(a) a shortened repeat/anti-repeat region, wherein the shortened repeat/anti-repeat region lacks 2-24 nucleotides, wherein

(i) one or more of nucleotides 37-48 and 53-64 is deleted and optionally one or more of nucleotides 37-64 is substituted relative to SEQ ID NO: 500; and

(ii) nucleotide 36 is linked to nucleotide 65 by at least 2 nucleotides; or

(b) a shortened hairpin 1 region, wherein the shortened hairpin 1 lacks 2-10, optionally 2-8 nucleotides, wherein

(i) one or more of nucleotides 82-86 and 91-95 is deleted and optionally one or more of positions 82-96 is substituted relative to SEQ ID NO: 500; and

(ii) nucleotide 81 is linked to nucleotide 96 by at least 4 nucleotides; or

(c) a shortened hairpin 2 region, wherein the shortened hairpin 2 lacks 2-18, optionally 2-16 nucleotides, wherein

(i) one or more of nucleotides 113-121 and 126-134 is deleted and optionally one or more of nucleotides 113-134 is substituted relative to SEQ ID NO: 500; and

(ii) nucleotide 112 is linked to nucleotide 135 by at least 4 nucleotides;

wherein one or both nucleotides 144-145 are optionally deleted relative to SEQ ID NO: 500; and

wherein at least 10 nucleotides are modified nucleotides.

[00288] In some embodiments, the conserved region comprises:

a shortened repeat/anti-repeat region, wherein the shortened repeat/anti-repeat region lacks 2-24 nucleotides, wherein

(i) one or more of nucleotides 37-48 and 53-64 is deleted and optionally one or more of nucleotides 37-64 is substituted relative to SEQ ID NO: 500; and

(ii) nucleotide 36 is linked to nucleotide 65 by at least 2 nucleotides;

wherein one or both nucleotides 144-145 are optionally deleted relative to SEQ ID NO: 500;

wherein at least 10 nucleotides in the conserved region are modified nucleotides.

[00289] In some embodiments, the conserved region comprises:

a shortened hairpin 1 region, wherein the shortened hairpin 1 lacks 2-10, optionally 2-8 nucleotides, wherein

(i) one or more of nucleotides 82-86 and 91-95 is deleted and optionally one or more of positions 82-96 is substituted relative to SEQ ID NO: 500; and

(ii) nucleotide 81 is linked to nucleotide 96 by at least 4 nucleotides;

wherein one or both nucleotides 144-145 are optionally deleted relative to SEQ ID NO: 500;

wherein at least 10 nucleotides in the conserved region are modified nucleotides.

[00290] In some embodiments, the conserved region comprises:

a shortened hairpin 2 region, wherein the shortened hairpin 2 lacks 2-18, optionally 2-16 nucleotides, wherein

(i) one or more of nucleotides 113-121 and 126-134 is deleted and optionally one or more of nucleotides 113-134 is substituted relative to SEQ ID NO: 500; and

(ii) nucleotide 112 is linked to nucleotide 135 by at least 4 nucleotides;

wherein one or both nucleotides 144-145 are optionally deleted relative to SEQ ID NO: 500;

wherein at least 10 nucleotides in the conserved region are modified nucleotides.

[00291] In some embodiments, the conserved region comprises:

(a) a shortened repeat/anti-repeat region, wherein the shortened repeat/anti-repeat region lacks 2-24 nucleotides, wherein

(i) one or more of nucleotides 37-48 and 53-64 is deleted and optionally one or more of nucleotides 37-64 is substituted relative to SEQ ID NO: 500; and

(ii) nucleotide 36 is linked to nucleotide 65 by at least 2 nucleotides; and

(b) a shortened hairpin 1 region, wherein the shortened hairpin 1 lacks 2-10, optionally 2-8 nucleotides, wherein

(i) one or more of nucleotides 82-86 and 91-95 is deleted and optionally one or more of positions 82-96 is substituted relative to SEQ ID NO: 500; and

(ii) nucleotide 81 is linked to nucleotide 96 by at least 4 nucleotides; or

wherein one or both nucleotides 144-145 are optionally deleted relative to SEQ ID NO: 500;

wherein at least 10 nucleotides in the conserved region are modified nucleotides.

[00292] In some embodiments, the conserved region comprises:

(a) a shortened repeat/anti-repeat region, wherein the shortened repeat/anti-repeat region lacks 2-24 nucleotides, wherein

(i) one or more of nucleotides 37-48 and 53-64 is deleted and optionally one or more of nucleotides 37-64 is substituted relative to SEQ ID NO: 500; and

(ii) nucleotide 36 is linked to nucleotide 65 by at least 2 nucleotides; and

(b) a shortened hairpin 2 region, wherein the shortened hairpin 2 lacks 2-18, optionally 2-16 nucleotides, wherein

(i) one or more of nucleotides 113-121 and 126-134 is deleted and optionally one or more of nucleotides 113-134 is substituted relative to SEQ ID NO: 500; and

(ii) nucleotide 112 is linked to nucleotide 135 by at least 4 nucleotides;

wherein one or both nucleotides 144-145 are optionally deleted relative to SEQ ID NO: 500;

wherein at least 10 nucleotides in the conserved region are modified nucleotides.

[00293] In some embodiments, the conserved region comprises:

(a) a shortened hairpin 1 region, wherein the shortened hairpin 1 lacks 2-10, optionally 2-8 nucleotides, wherein

(i) one or more of nucleotides 82-86 and 91-95 is deleted and optionally one or more of positions 82-96 is substituted relative to SEQ ID NO: 500; and

(ii) nucleotide 81 is linked to nucleotide 96 by at least 4 nucleotides; and

(b) a shortened hairpin 2 region, wherein the shortened hairpin 2 lacks 2-18, optionally 2-16 nucleotides, wherein

(i) one or more of nucleotides 113-121 and 126-134 is deleted and optionally one or more of nucleotides 113-134 is substituted relative to SEQ ID NO: 500; and

(ii) nucleotide 112 is linked to nucleotide 135 by at least 4 nucleotides;

wherein one or both nucleotides 144-145 are optionally deleted relative to SEQ ID NO: 500;

wherein at least 10 nucleotides in the conserved region are modified nucleotides.

[00294] In some embodiments, the conserved region comprises:

(a) a shortened repeat/anti-repeat region, wherein the shortened repeat/anti-repeat region lacks 2-24 nucleotides, wherein

(i) one or more of nucleotides 37-48 and 53-64 is deleted and optionally one or more of nucleotides 37-64 is substituted relative to SEQ ID NO: 500; and

(ii) nucleotide 36 is linked to nucleotide 65 by at least 2 nucleotides;

(b) a shortened hairpin 1 region, wherein the shortened hairpin 1 lacks 2-10, optionally 2-8 nucleotides, wherein

(i) one or more of nucleotides 82-86 and 91-95 is deleted and optionally one or more of positions 82-96 is substituted relative to SEQ ID NO: 500; and

(ii) nucleotide 81 is linked to nucleotide 96 by at least 4 nucleotides; and

(c) a shortened hairpin 2 region, wherein the shortened hairpin 2 lacks 2-18, optionally 2-16 nucleotides, wherein

(i) one or more of nucleotides 113-121 and 126-134 is deleted and optionally one or more of nucleotides 113-134 is substituted relative to SEQ ID NO: 500; and

(ii) nucleotide 112 is linked to nucleotide 135 by at least 4 nucleotides;

wherein one or both nucleotides 144-145 are optionally deleted relative to SEQ ID NO: 500;

wherein at least 10 nucleotides of the conserved region are modified nucleotides.

[00295] In some embodiment, the gRNA disclosed herein is a sgRNA.

[00296] In some embodiments, one or both nucleotides 144-145 are deleted relative to SEQ ID NO: 500.

[00297] In some embodiments, at least 10 nucleotides of the conserved region are modified nucleotides.

[00298] In some embodiments, a repeat/anti-repeat region of a gRNA is a shortened repeat/anti-repeat region lacking 2-24 nucleotides, e.g., any of the repeat/anti-repeat regions indicated in the numbered embodiments above or Tables 1-2 or described elsewhere herein, which may be combined with any of the shortened hairpin 1 region or hairpin 2 region described herein, including but not limited to combinations indicated in the numbered embodiments above and represented in the sequences of Tables 1-2 or described elsewhere herein. In some embodiments, one or more of positions 49-52, 87-90, or 122-125 is substituted relative to SEQ ID NO: 500. In some embodiments, all of positions 49-52, 87-90, or 122-125 are substituted relative to SEQ ID NO: 500. In some embodiments, the 3' tail provided in Tables 1-2 or described herein is deleted.

[00299] In some embodiments, the shortened repeat/anti-repeat region of the gRNA lacks 18 nucleotides. In some embodiments, the shortened repeat/anti-repeat region of the gRNA lacks 22 nucleotides.

[00300] In some embodiments, in the shortened repeat/anti-repeat region of the gRNA, nucleotide 36 is linked to nucleotide 65 by 6 nucleotides. In some embodiments, in the shortened repeat/anti-repeat region of the gRNA, nucleotide 36 is linked to nucleotide 65 by 7 nucleotides. In some embodiments, in the shortened repeat/anti-repeat region of the gRNA, nucleotide 36 is linked to nucleotide 65 by 8 nucleotides. In some embodiments, in the shortened repeat/anti-repeat region of the gRNA, nucleotide 36 is linked to nucleotide 65 by 9 nucleotides. In some embodiments, in the shortened repeat/anti-repeat region of the gRNA, nucleotide 36 is linked to nucleotide 65 by 10 nucleotides.

[00301] In some embodiments, in the shortened repeat/anti-repeat region of the gRNA, nucleotides 38-48 and 53-63 are deleted relative to SEQ ID NO: 500. In some embodiments, in the shortened repeat/anti-repeat region of the gRNA, nucleotides 38, 41-48, 53-60, and 63 are deleted relative to SEQ ID NO: 500.

[00302] In some embodiments, in the shortened repeat/anti-repeat region of the gRNA, nucleotide 36 is linked to nucleotide 65 by 6 nucleotides. In some embodiments, in the shortened repeat/anti-repeat region of the gRNA, nucleotides 38-48 and 53-63 are deleted relative to SEQ ID NO: 500, and nucleotide 36 is linked to nucleotide 65 by nucleotides 37, 49-52, and 64.

[00303] In some embodiments, in the shortened repeat/anti-repeat region of the gRNA, nucleotide 36 is linked to nucleotide 65 by 10 nucleotides. In some embodiments, in the

shortened repeat/anti-repeat region of the gRNA, nucleotides 38, 41-48, 53-60, and 63 are deleted relative to SEQ ID NO: 500, and nucleotide 36 is linked to nucleotide 65 by nucleotides 37, 39, 40, 49-52, 61, 62, and 64.

[00304] In some embodiments, all of nucleotides 38-48 and nucleotides 53-63 of the upper stem of the shortened repeat/anti-repeat region are deleted relative to SEQ ID NO: 500.

[00305] In some embodiments, all of nucleotides 39-48 and nucleotides 53-62 of the upper stem of the shortened repeat/anti-repeat region are deleted relative to SEQ ID NO: 500, and nucleotides 38 and 63 is substituted.

[00306] In some embodiments, the shortened repeat/anti-repeat region has 14 modified nucleotides. In some embodiments, the shortened repeat/anti-repeat region has 15 modified nucleotides. In some embodiments, the shortened repeat/anti-repeat region has 16 modified nucleotides. In some embodiments, the shortened repeat/anti-repeat region has 17 modified nucleotides. In some embodiments, the shortened repeat/anti-repeat region has 18 modified nucleotides. In some embodiments, the shortened repeat/anti-repeat region has 19 modified nucleotides. In some embodiments, the shortened repeat/anti-repeat region has 20 modified nucleotides.

[00307] In some embodiments, the shortened hairpin 1 region lacks 2 nucleotides. In some embodiments, the shortened hairpin 1 region lacks 21 nucleotides. In some embodiments, the shortened hairpin 1 region lacks 2 nucleotides, and nucleotides 86 and 91 are deleted relative to SEQ ID NO: 500. In some embodiments, the shortened hairpin 1 region lacks 2 nucleotides, and nucleotides 85 and 92 are deleted relative to SEQ ID NO: 500. In some embodiments, in the shortened hairpin 1 region, nucleotide 81 is linked to nucleotide 96 by 12 nucleotides. In some embodiments, in the shortened hairpin 1 region, nucleotide 81 is linked to nucleotide 96 by 12 nucleotides. In some embodiments, in the shortened hairpin 1 region, nucleotides 86 and 91 are deleted relative to SEQ ID NO: 500, and nucleotide 81 is linked to nucleotide 96 by nucleotides 82-85, 87-90, and 92-95. In some embodiments, in the shortened hairpin 1 region, nucleotides 85 and 92 are deleted relative to SEQ ID NO: 500, and nucleotide 81 is linked to nucleotide 96 by nucleotides 82-84, 86-91, and 93-95.

[00308] In some embodiments, the shortened hairpin 1 region has a duplex portion of 7 base paired nucleotides in length. In some embodiments, the shortened hairpin 1 region has a duplex portion of 8 base paired nucleotides in length.

[00309] In the stem of the shortened hairpin 1 region is seven base paired nucleotides in length. In some embodiments, nucleotides 85-86 and nucleotides 91-92 of the shortened hairpin 1 region are deleted.

[00310] In some embodiments, the shortened hairpin 1 region has 13 modified nucleotides.

[00311] In some embodiments, the shortened hairpin 2 lacks 18 nucleotides. In some embodiments, the shortened hairpin 2 has 24 nucleotides. In some embodiments, in the shortened hairpin 2 nucleotides 113-121 and 126-134 are deleted relative to SEQ ID NO: 500. In some embodiments, the shortened hairpin 2 lacks 18 nucleotides, and nucleotides 113-121 and 126-134 are deleted relative to SEQ ID NO: 500. In some embodiments, in the shortened hairpin 2 region, nucleotide 112 is linked to nucleotide 135 by 4 nucleotides. In some embodiments, in the shortened hairpin 2 region, nucleotides 113-121 and 126-134 are deleted relative to SEQ ID NO: 500 and nucleotide 112 is linked to nucleotide 135 by nucleotides 122-125.

[00312] In some embodiments, the shortened repeat/anti-repeat region has a length of 28 nucleotides. In some embodiments, the shortened repeat/anti-repeat region has a length of 32 nucleotides.

[00313] In some embodiments, the upper stem of the shortened repeat/anti-repeat region comprises no more than one base pair. In some embodiments, the upper stem of the shortened repeat/anti-repeat region comprises no more than three base pairs.

[00314] In some embodiments, the shortened hairpin 2 region has 8 modified nucleotides.

[00315] In some embodiments, a guide RNA (gRNA) comprises a guide region and a conserved region, the conserved region comprising:

(a) a shortened repeat/anti-repeat region, wherein the shortened repeat/anti-repeat region lacks 18-22 nucleotides relative to SEQ ID NO: 500, wherein

(i) nucleotides 38-48 and 53-63 are deleted; and

(ii) nucleotide 36 is linked to nucleotide 65 by 6-10 nucleotides;

(b) a shortened hairpin 1 region, wherein the shortened hairpin 1 lacks 2 nucleotides, wherein nucleotides 86 and 91 are deleted or nucleotides 85 and 92 are deleted relative to SEQ ID NO: 500; and

(c) a shortened hairpin 2 region, wherein the shortened hairpin 2 lacks 18 nucleotides, wherein nucleotides 113-121 and 126-134 are deleted relative to SEQ ID NO: 500;

and wherein nucleotides 144-145 are deleted relative to SEQ ID NO: 500; wherein at least 10 nucleotides are modified nucleotides.

[00316] In some embodiments, a guide RNA (gRNA) comprises a guide region and a conserved region, the conserved region comprising:

(a) a shortened repeat/anti-repeat region, wherein the shortened repeat/anti-repeat region lacks 18-22 nucleotides relative to SEQ ID NO: 500, wherein

(i) nucleotides 38, 41-48, 53-60, and 63 are deleted; and

(ii) nucleotide 36 is linked to nucleotide 65 by 6-10 nucleotides;

(b) a shortened hairpin 1 region, wherein the shortened hairpin 1 lacks 2 nucleotides, wherein nucleotides 86 and 91 are deleted or nucleotides 85 and 92 are deleted relative to SEQ ID NO: 500;

(c) a shortened hairpin 2 region, wherein the shortened hairpin 2 lacks 18 nucleotides, wherein nucleotides 113-121 and 126-134 are deleted relative to SEQ ID NO: 500; and

wherein nucleotides 144-145 are deleted relative to SEQ ID NO: 500;

wherein at least 10 nucleotides are modified nucleotides.

[00317] In some embodiments, a guide RNA (gRNA) is provided, the gRNA comprising a guide region and a conserved region, the conserved region comprising one or more of:

(a) a shortened repeat/anti-repeat region, wherein the shortened repeat/anti-repeat region lacks 18-22 nucleotides relative to SEQ ID NO: 500, wherein

(i) nucleotides 37-48 and 53-64 are deleted; and

(ii) nucleotide 36 is linked to nucleotide 65 by 6-10 nucleotides; or

(b) a shortened hairpin 1 region, wherein the shortened hairpin 1 lacks 2 nucleotides, wherein nucleotides 86 and 91 are deleted or nucleotides 85 and 92 are deleted relative to SEQ ID NO: 500; or

(c) a shortened hairpin 2 region, wherein the shortened hairpin 2 lacks 18 nucleotides, wherein nucleotides 113-121 and 126-134 are deleted relative to SEQ ID NO: 500; and

wherein nucleotides 144-145 are deleted relative to SEQ ID NO: 500;

wherein at least 10 nucleotides are modified nucleotides.

[00318] In further embodiments, the shortened repeat/anti-repeat region, wherein the shortened repeat/anti-repeat region lacks 22 nucleotides relative to SEQ ID NO: 500. In further embodiments, nucleotide 36 is linked to nucleotide 65 by a sequence comprising the nucleotide sequence UGAAAC. In further embodiments, the nucleotide 36 is linked to nucleotide 65 by 10 nucleotides. In further embodiments, the nucleotide 36 is linked to

nucleotide 65 by a sequence comprising the nucleotide sequence UUCGAAAGAC (SEQ ID NO: 950).

[00319] In some embodiments, the guide RNA (gRNA) of the previous embodiment comprising a guide region and a conserved region, the conserved region comprising:

(a) a shortened repeat/anti-repeat region, wherein the shortened repeat/anti-repeat region lacks 18-22 nucleotides, wherein

(i) nucleotides 37-48 and 53-64 are deleted relative to SEQ ID NO: 500; and

(ii) nucleotide 36 is linked to nucleotide 65 by 6-10 nucleotides;

(b) a shortened hairpin 1 region, wherein the shortened hairpin 1 lacks 2 nucleotides relative to SEQ ID NO: 500, wherein nucleotides 86 and 91 are deleted or nucleotides 85 and 92 are deleted;

(c) a shortened hairpin 2 region, wherein the shortened hairpin 2 lacks 18 nucleotides, wherein nucleotides 113-121 and 126-134 are deleted relative to SEQ ID NO: 500; and

(d) wherein nucleotides 144-145 are deleted relative to SEQ ID NO: 500;

wherein at least 10 nucleotides are modified nucleotides.

[00320] In further embodiments, the shortened repeat/anti-repeat region, wherein the shortened repeat/anti-repeat region lacks 22 nucleotides relative to SEQ ID NO: 500. In further embodiments, nucleotide 36 is linked to nucleotide 65 by a sequence comprising the nucleotide sequence UGAAAC. In further embodiments, the nucleotide 36 is linked to nucleotide 65 by 10 nucleotides. In further embodiments, the nucleotide 36 is linked to nucleotide 65 by a sequence comprising the nucleotide sequence UUCGAAAGAC (SEQ ID NO: 950).

A. Shortened Repeat/Anti-repeat region

[00321] In some embodiments, a gRNA described herein comprises a conserved region comprising a shortened repeat/anti-repeat region. In some embodiments, the repeat-anti-repeat region comprises a hairpin structure between a first portion and a second portion of the repeat-anti-repeat region, wherein the first portion and the second portion of the repeat-anti-repeat region together form a duplex portion.

[00322] In some embodiments, a gRNA described herein comprises a conserved region comprising a shortened upper stem region of the repeat/anti-repeat region. In some embodiments, the repeat/anti-repeat region comprises a loop (e.g., a tetraloop).

[00323] In some embodiments, the shortened repeat/anti-repeat region lacks 2-24 nucleotides. In some embodiments, (i) one or more of nucleotides 37-48 and 53-64 is deleted

and optionally one or more of nucleotides 37-64 is substituted relative to SEQ ID NO: 500; and (ii) nucleotide 36 is linked to nucleotide 65 by at least 4 nucleotides.

[00324] In some embodiments, the shortened repeat/anti-repeat region lacks 2-24 nucleotides.

[00325] In some embodiments, the shortened repeat/anti-repeat region has a length of 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides.

[00326] In some embodiments, the shortened repeat/anti-repeat region lacks 12-24 nucleotides, optionally 18-24 nucleotides. In some embodiments, the shortened repeat/anti-repeat region has a length of 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides. In some embodiments, the shortened repeat/anti-repeat region has a length of 28, 29, 30, 31, 32, 33, or 34 nucleotides. In some embodiments, the shortened repeat/anti-repeat region has a length of 28 nucleotides. In some embodiments, the shortened repeat/anti-repeat region has a length of 29 nucleotides. In some embodiments, the shortened repeat/anti-repeat region has a length of 30 nucleotides. In some embodiments, the shortened repeat/anti-repeat region has a length of 31 nucleotides. In some embodiments, the shortened repeat/anti-repeat region has a length of 32 nucleotides. In some embodiments, the shortened repeat/anti-repeat region has a length of 33 nucleotides. In some embodiments, the shortened repeat/anti-repeat region has a length of 34 nucleotides.

[00327] In some embodiments, nucleotides 37-64 of SEQ ID NO: 500 form the upper stem, and one or more base pairs of the upper stem of the shortened repeat/anti-repeat region are deleted. In some embodiments, the upper stem of the shortened repeat/anti-repeat region comprises no more than one, two, three, or four base pairs. In some embodiments, all of positions 38-48 and all of positions 53-63 of the upper stem of the shortened repeat/anti-repeat region are deleted. In some embodiments, all of nucleotides 37-48 and 53-64 of the upper stem of the shortened repeat/anti-repeat region are deleted. As used herein, "base pairs" or "base paired nucleotides" or "Watson-Crick pairing nucleotides" include any pair capable of forming a Watson-Crick base pair, including A-T, A-U, T-A, U-A, C-G, and G-C pairs, and pairs including modified versions of any of the foregoing nucleotides that have the same base pairing preference. As used herein, base pairs or base paired nucleotides also include base pairs generated by base stacking, e.g. nucleotides 25 and 76, 33 and 68, 34 and 67, and 37 and 64 in the repeat/anti-repeat region; and nucleotides 78 and 100, and 83 and 94 in the hairpin 1 region.

[00328] In some embodiments, one or more of positions 37-48 is deleted. In some embodiments, position 37 is deleted. In some embodiments, position 38 is deleted. In some embodiments, position 39 is deleted. In some embodiments, position 40 is deleted. In some embodiments, position 41 is deleted. In some embodiments, position 42 is deleted. In some embodiments, position 43 is deleted. In some embodiments, position 44 is deleted. In some embodiments, position 45 is deleted. In some embodiments, position 46 is deleted. In some embodiments, position 47 is deleted. In some embodiments, position 48 is deleted.

[00329] In some embodiments, one or more of positions 53-63 is deleted. In some embodiments, position 53 is deleted. In some embodiments, position 54 is deleted. In some embodiments, position 55 is deleted. In some embodiments, position 56 is deleted. In some embodiments, position 57 is deleted. In some embodiments, position 58 is deleted. In some embodiments, position 59 is deleted. In some embodiments, position 60 is deleted. In some embodiments, position 61 is deleted. In some embodiments, position 62 is deleted. In some embodiments, position 63 is deleted. In some embodiments, position 64 is deleted.

[00330] In some embodiments, the shortened repeat/anti-repeat region has a duplex portion 11 base paired nucleotides in length. In some embodiments, the shortened repeat/anti-repeat region has a single duplex portion.

[00331] In some embodiments, one or more of base paired nucleotides in the repeat/anti-repeat region is deleted. In some embodiments, one or more of based paired nucleotides chosen from positions 37 and 53, positions 38 and 54, position 39 and 55, positions 40 and 56, positions 41 and 57, positions 43 and 58, positions 43 and 59, positions 44 and 60, positions 45 and 61, positions 46 and 62, positions 47 and 63, and positions 48 and 64.

[00332] In some embodiments, the upper stem region of the repeat/anti-repeat region comprises 1- 5 base pairs.

[00333] In some embodiments, the upper stem of the shortened repeat/anti-repeat region includes one or more substitution relative to SEQ ID NO: 500.

[00334] In some embodiments, one or more substitutions are conservative substitutions that maintain base pairing(s). For example, a G-C pair becomes a C-G pair or other natural or modified base pairing, or an A-U pair becomes a U-A pair or other natural or modified base pairing. In some embodiments, one or more substitutions are conservative substitutions that exchange positions of base paired nucleotides (e.g., a G-C pair becomes a C-G pair, or an A-U pair for becomes a U-A pair).

[00335] In some embodiments, one or more of nucleotides 49-52 is substituted relative to SEQ ID NO: 500. In some embodiments, the shortened repeat/anti-repeat region is unsubstituted.

[00336] In some embodiments, the shortened repeat/anti-repeat region has 12-22 modified nucleotides.

B. Shortened Hairpin 1 region

[00337] In some embodiments, a gRNA described herein comprises a conserved region comprising a shortened hairpin 1 region. In some embodiments, the hairpin 1 region comprises a hairpin structure between a first portion and a second portion of the hairpin 1 region, wherein the first portion and the second portion together form a duplex portion.

[00338] In some embodiments, a gRNA described herein comprises a conserved region comprising a shortened upper stem region of the hairpin 1 region. In some embodiments, the hairpin 1 comprises a loop (e.g., a tetraloop).

[00339] In some embodiments, the shortened hairpin 1 lacks 2-10 nucleotides. In some embodiments, the shortened hairpin 1 lacks 2-8 nucleotides. In some embodiments, the shortened hairpin 1 lacks 2-4 nucleotides. In some embodiments, the shortened hairpin lacks 2 nucleotides. In some embodiments, the shortened hairpin lacks 3 nucleotides. In some embodiments, the shortened hairpin lacks 4 nucleotides. In some embodiments, the shortened hairpin lacks 5 nucleotides. In some embodiments, the shortened hairpin lacks 6 nucleotides. In some embodiments, the shortened hairpin lacks 7 nucleotides. In some embodiments, the shortened hairpin lacks 8 nucleotides. In some embodiments, the shortened hairpin lacks 9 nucleotides. In some embodiments, the shortened hairpin lacks 10 nucleotides. In some embodiments, (i) one or more of nucleotides 82-86 and 91-95 is deleted and optionally one or more of positions 82-95 is substituted relative to SEQ ID NO: 500; and (ii) nucleotide 81 is linked to nucleotide 96 by at least 4 nucleotides.

[00340] In some embodiments, wherein the shortened hairpin 1 region lacks 2-10 nucleotides. In some embodiments, wherein the shortened hairpin 1 region has a length of 13, 14, 15, 16, 17, 18, 19, 20 or 21 nucleotides. In some embodiments, wherein the shortened hairpin 1 region has duplex portion 7-8 base paired nucleotides in length. As used herein, nucleotide 96 is not considered to interrupt the duplex portion of hairpin 1 when one or more of base pairs 82 and 95, 83 and 94, 85 and 93, and 86 and 92 are present.

[00341] In some embodiments, the shortened hairpin 1 region has a single duplex portion. In some embodiments, in the shortened hairpin 1 region, positions 78 and 100, and

positions 83 and 94 have base stacking interactions and do not constitute a discontinuity in the duplex portion.

[00342] In some embodiments, one or two base pairs of the shortened hairpin 1 region are deleted. In some embodiments, the stem of the shortened hairpin 1 region comprises one, two, three, four, five, six, seven, or eight base pairs. In some embodiments, the stem of the shortened hairpin 1 region is seven or eight base paired nucleotides in length.

[00343] In some embodiments, one or more of positions 85-86 and one or more of nucleotides 91-92 of the shortened hairpin 1 region are deleted. In some embodiments, nucleotides 86 and 91 of the shortened hairpin 1 region are deleted. In some embodiments, nucleotides 85 and 92 of the shortened hairpin 1 region are deleted. In some embodiments, one or more of nucleotides 82-95 of the shortened hairpin 1 region is substituted relative to SEQ ID NO: 500. In some embodiments, one or more of nucleotides 87-91 is substituted relative to SEQ ID NO: 500.

[00344] In some embodiments, the shortened hairpin 1 region is unsubstituted. In some embodiments, wherein the shortened hairpin 1 region has 6-15 modified nucleotides.

C. Shortened Hairpin 2 region

[00345] In some embodiments, a gRNA described herein comprises a conserved region comprising a shortened hairpin 2 region. In some embodiments, the hairpin 2 region comprises a hairpin structure between a first portion and a second portion of the hairpin 2 region, wherein the first portion and the second portion together form a duplex portion.

[00346] In some embodiments, (c) a shortened hairpin 2 region, wherein the shortened hairpin 2 lacks 2-16 nucleotides. In some embodiments, (i) one or more of nucleotides 113-121 and 126-134 is deleted and optionally one or more of nucleotides 113-134 is substituted relative to SEQ ID NO: 500; and (ii) nucleotide 112 is linked to nucleotide 135 by at least 4 nucleotides.

[00347] In some embodiments, a conserved region of a gRNA described herein comprises a shortened upper stem region of the hairpin 2 region. In some embodiments, the hairpin 1 comprises a loop (e.g., a tetraloop). In some embodiments, the shortened hairpin 2 region lacks 2-16 nucleotides. In some embodiments, the shortened hairpin 2 region has a length of 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides. In some embodiments, the shortened hairpin 2 region has a length of 28, 29, 30, 31, 32, 33 or 34, nucleotides. In some embodiments, one or more of positions 113-121 and one or more of nucleotides 126-134 of the shortened hairpin 2 region are deleted.

[00348] The shortened hairpin 2 region comprises an unpaired region The unpaired region, nucleotides 106-108 and nucleotide 139 on the opposite strand, result in a discontinuity of the duplex portion within hairpin 2, providing two duplex portions, nucleotides 102-105 and 140-143, and nucleotides 109-112 and 135-138.

[00349] In some embodiments, the shortened hairpin 2 region has two duplex portions. In some embodiments, the shortened hairpin 2 region has one duplex portion of 4 base paired nucleotides in length. In some embodiments, the shortened hairpin 2 region has one duplex portion of 4-8 base paired nucleotides in length.. In some embodiments, the shortened hairpin 2 region has one duplex portion of 4-6 base paired nucleotides in length. In some embodiments, the upper stem of the shortened hairpin 2 region comprises one, two, three, or four base pairs. In some embodiments, at least one pair of nucleotides 113 and 134, nucleotides 114 and 133, nucleotides 115 and 132, nucleotides 116 and 131, nucleotides 117 and 130, nucleotides 118 and 129, nucleotides 119 and 128, nucleotides 120 and 127, and nucleotides 121 and 126 are deleted. In some embodiments, all of positions 113-121 and 126-134 of the shortened hairpin 2 region are deleted.

[00350] In some embodiments wherein one or more of nucleotides 113-134 of the shortened hairpin 2 region is substituted relative to SEQ ID NO: 500. In some embodiments one or more of nucleotides 122-125 is substituted relative to SEQ ID NO: 500.

[00351] In some embodiments the shortened hairpin 2 region is unsubstituted. In some embodiments the shortened hairpin 2 region has 6-15 modified nucleotides.

D. 3' tail

[00352] In some embodiments, the gRNA comprises a 3' tail. In some embodiments, the 3' tail is 1-20 nucleotides in length and is linked by a phosphodiester or a phosphorothioate linkage, to the 3' end of the conserved region of a gRNA. In some embodiments, the 3' tail comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides. In some embodiments, the 3' tail comprises 1, 2, 3, 4, or 5 nucleotides. In some embodiments, the 3' tail comprises 1 or 2 nucleotides.

[00353] In some embodiments, the 3' tail has a length of 1-10 nucleotides, 1-5 nucleotides, 1-4 nucleotides, 1- 3 nucleotides, and 1-2 nucleotides. In some embodiments, the 3' tail comprises about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides. In some embodiments, the 3' tail has a length of 1 nucleotide. In some embodiments, the 3' tail has a length of 2 nucleotides. In some embodiments, the 3' tail has a length of 3 nucleotides. In some

embodiments, the 3' tail has a length of 4 nucleotides. In some embodiments, the 3' tail has a length of 1-2, nucleotides.

[00354] In some embodiments, the 3' tail terminates with a nucleotide comprising a uracil or modified uracil. In some embodiments, the 3' tail is 1 nucleotide in length. In some embodiments, the 3' tail consists of a nucleotide comprising a uracil or modified uracil. In some embodiments, wherein the 3' tail comprises a modification of any one or more of the nucleotides present in the 3' tail. In further embodiments, wherein the modification of the 3' tail is one or more of 2'-O-methyl (2'-OMe) modified nucleotide and a phosphorothioate (PS) linkage between nucleotides.

[00355] In some embodiments, the 3' tail is fully modified.

[00356] In some embodiments, the 3' nucleotide of the gRNA is a nucleotide comprising a uracil or modified uracil.

[00357] In some embodiments, one or more of nucleotides 144 and 145 are deleted relative to SEQ ID NO: 500. In some embodiments, both nucleotides 144 and 145 are deleted relative to SEQ ID NO: 500.

[00358] In some embodiments, the gRNA does not comprise a 3' tail. In some embodiments, the 3' end of the guide, that does not comprise a 3' tail, terminates with a nucleotide comprising a uracil or modified uracil. In some embodiments, the 3' tail consists of a nucleotide comprising a uracil or modified uracil. In some embodiments, the 3' terminal nucleotide is a modified nucleotide. In some embodiments, the modification of the 3' end is one or more of 2'-O-methyl (2'-OMe) modified nucleotide and a phosphorothioate (PS) linkage between nucleotide the terminal nucleotide and the penultimate nucleotide.

[00359] In some embodiments, the 3' end, i.e., the end of hairpin 2 with no further tail or the end of the 3' tail, comprises or further comprises one or more modifications, e.g., a phosphorothioate (PS) linkage between nucleotides, a 2'-OMe modified nucleotide, a 2'-O-moe modified nucleotide, a 2'-F modified nucleotide, an inverted abasic modified nucleotide, and a combination thereof. In some embodiments, the 3' end comprises or further comprises one or more modifications, e.g., a phosphorothioate (PS) linkage between nucleotides, a 2'-OMe modified nucleotide, a 2'-F modified nucleotide, and a combination thereof. In some embodiments, the 3' end comprises phosphorothioate (PS) linkage between nucleotides 141 and 142, and 142 and 143; a 2'-OMe modified nucleotide at each of positions 142 and 143.

[00360] In some embodiments, the 3' end, i.e., the end of hairpin 2 with no further tail or the end of the 3' tail, comprises or further comprises one or more phosphorothioate (PS) linkages between nucleotides. In some embodiments, the 3' end comprises or further

comprises one or more 2'-OMe modified nucleotides. In some embodiments, the 3' end comprises or further comprises one or more 2'-O-moe modified nucleotides. In some embodiments, the 3' end comprises or further comprises one or more 2'-F modified nucleotide. In some embodiments, the 3' end comprises or further comprises one or more an inverted abasic modified nucleotides. In some embodiments, the 3' end comprises or further comprises one or more protective end modifications. In some embodiments, the 3' end comprises or further comprises a combination of one or more of a phosphorothioate (PS) linkage between nucleotides, a 2'-OMe modified nucleotide, a 2'-O-moe modified nucleotide, a 2'-F modified nucleotide, and an inverted abasic modified nucleotide.

E. Guide sequence

[00361] In some embodiments, the gRNA further comprises a guide sequence. In some embodiments, the guide sequence comprises 20, 21, 22, 23, 24, or 25 nucleotides, optionally 22, 23, 24, or 25 nucleotides 5' to the most 5' nucleotide of the repeat/anti-repeat region. In some embodiments, the guide sequence comprises 22, 23, 24, 25, or more nucleotides. In some embodiments, the guide sequence has a has a length of 24 nucleotides. In some embodiments, the guide sequence has a length of 23 nucleotides. In some embodiments, the guide sequence has a length of 22 nucleotides. In some embodiments, the guide sequence has a length of 21 nucleotides. In some embodiments, the guide sequence has a length of 20 nucleotides.

[00362] In some embodiments, the guide region has (i) an insertion of one nucleotide or a deletion of 1-4 nucleotides within positions 1-24 relative to SEQ ID NO: 500, or (ii) a length of 24 nucleotides.

[00363] In some embodiments, the selection of the guide sequence is determined based on target sequences within the gene of interest for editing. For example, in some embodiments, the gRNA comprises a guide sequence that is complementary to target sequences of a gene of interest.

[00364] In some embodiments, the target sequence in the gene of interest may be complementary to the guide sequence of the gRNA. In some embodiments, the degree of complementarity or identity between a guide sequence of a gRNA and its corresponding target sequence in the gene of interest may be about 90%, 95%, or 100%. In some embodiments, the guide region of a gRNA and the target region of a gene of interest may be 100% complementary or identical. In other embodiments, the guide sequence of a gRNA and the target sequence of a gene of interest may contain at least one mismatch. For example, the

guide sequence of a gRNA and the target sequence of a gene of interest may contain 1, optionally 2, or 3 mismatches, where the total length of the target sequence is at least about 22, 23, 24, or more nucleotides. In some embodiments, the guide sequence of a gRNA and the target region of a gene of interest may contain 1, optionally 2, or 3 mismatches where the guide sequence comprises about 24 nucleotides. In certain embodiments, the guide sequence contains no mismatches, i.e., is fully complementary, to the target sequence. The 5' terminus may comprise nucleotides that are not considered guide regions (i.e., do not function to direct a Cas9 protein to a target nucleic acid).

II. Modified guide RNA (gRNA)

[00365] Guide RNAs comprising modifications at various positions are disclosed herein. In some embodiments, a position of a gRNA that comprises a modification is modified with any one or more of the following types of modifications. The term "modified gRNA" generally refers to a gRNA having a modification to the chemical structure of one or more of the bases, the sugar, the phosphodiester linkage or backbone portions, including nucleotide phosphates, all as detailed and exemplified herein.

[00366] In some embodiments, the guide region of the gRNA comprises at least one modified nucleotide.

[00367] In some embodiments, the guide region of the gRNA comprises at least two modified nucleotides, optionally at least four modified nucleotides, wherein each modification, independently, optionally comprises a modified nucleotide selected from 2'-O-methyl (2'-OMe) modified nucleotide, 2'-O-(2-methoxyethyl) (2'-O-moe) modified nucleotide, a 2'-fluoro (2'-F) modified nucleotide, a phosphorothioate (PS) linkage between nucleotides, an inverted abasic modified nucleotide, or combinations thereof.

[00368] In some embodiments, the guide region of the gRNA comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 modified nucleotides. In some embodiments, the guide region of the gRNA comprises 1, 2, or 3 modified nucleotides. In some embodiments, the guide region of the gRNA comprises 4, 5, 6, 7, 8, 9, 10, 11, or 12 modified nucleotides. In some embodiments, the guide region of the gRNA comprises 6, 7, 8, 9, 10, 11, or 12 modified nucleotides.

[00369] In some embodiments, the gRNA comprises a 5' end modification. In some embodiments, the gRNA further comprises a 3' end modification.

[00370] In some embodiments, the guide region does not comprise a modified nucleotide 3' of the first three nucleotides of the guide region.

[00371] In some embodiments, the guide region does not comprise a modified nucleotide.

[00372] In some embodiments, wherein the gRNA comprises a 3' end modification. In some embodiments, the gRNA comprises a modification in the upper stem region of the repeat/anti-repeat region. In some embodiments, the gRNA comprises a modification in the hairpin 1 region. In some embodiments, the gRNA comprises a modification in the hairpin 2 region. In some embodiments, the gRNA comprises a 3' end modification, and comprising a modification in the upper stem region of the repeat/anti-repeat region. In some embodiments, the gRNA comprises a 3' end modification, and a modification in the hairpin 1 region. In some embodiments, the gRNA comprises a 3' end modification, and a modification in the hairpin 2 region. In some embodiments, the gRNA comprises a 5' end modification, and comprising a modification in the upper stem region of the repeat/anti-repeat region. In some embodiments, the gRNA comprises a 5' end modification, and a modification in the hairpin 1 region. In some embodiments, the gRNA comprises a 5' end modification, and a modification in the hairpin 2 region. In some embodiments, the gRNA comprises a 5' end modification, a modification in the upper stem region of the repeat/anti-repeat region, and a 3' end modification. In some embodiments, the gRNA comprises a 5' end modification, a modification in the hairpin 1 region, and a 3' end modification. In some embodiments, the gRNA comprises a 5' end modification, a modification in the hairpin 1 region, a modification in the hairpin 2 region, and a 3' end modification. In some embodiments, the gRNA comprises a 5' end modification, a modification in the repeat/anti-repeat region, a modification in the hairpin 1 region, a modification in the hairpin 2 region, and a 3' end modification.

[00373] In some embodiments, the gRNA does not comprise a modification at position 76. In some embodiments, the gRNA does not comprise a PS modification at position 76, i.e., a PS modification between nucleotides 76 and 77.

[00374] In some embodiments, the gRNA comprises one or more, i.e., 1, 2, 3, or 4 modifications at positions 106-109. In some embodiments, the gRNA comprises modifications at positions 106-109. In some embodiments, the modification comprises a 2'-O-methyl (2'-O-Me) modified nucleotide.

[00375] In some embodiments, the gRNA comprises a 2'-O-methyl (2'-O-Me) modified nucleotide. In some embodiments, the gRNA comprises a 2'-O-(2-methoxyethyl) (2'-O-moe) modified nucleotide. In some embodiments, the gRNA comprises a 2'-fluoro (2'-

F) modified nucleotide. In some embodiments, the gRNA comprises a phosphorothioate (PS) bond between nucleotides.

[00376] In some embodiments, the gRNA comprises a 5' end modification, a 3' end modification, or 5' and 3' end modification, such as a protective end modification. In some embodiments, the 5' end modification comprises a phosphorothioate (PS) bond between nucleotides. In some embodiments, the 5' end modification comprises a 2'-O-methyl (2'-O-Me), 2'-O-(2-methoxyethyl) (2'-O-moe), or 2'-fluoro (2'-F) modified nucleotide. In some embodiments, the 5' end modification comprises at least one phosphorothioate (PS) bond and one or more of a 2'-O-methyl (2'-O-Me), 2'-O-(2-methoxyethyl) (2'-O-moe), or 2'-fluoro (2'-F) modified nucleotide. The end modification may comprise a phosphorothioate (PS), 2'-O-methyl (2'-O-Me), 2'-O-(2-methoxyethyl) (2'-O-moe), or 2'-fluoro (2'-F) modification. Equivalent end modifications are also encompassed by embodiments described herein. In some embodiments, the gRNA comprises an end modification in combination with a modification of one or more regions of the gRNA.

[00377] Exemplary patterns of modifications are shown in Tables 1-2. In certain embodiments, exemplary modifications include patterns of modifications shown in Tables 1-2 in which 3' tails, when present, are deleted. Additional exemplary patterns are discussed below.

Types of chemical modifications described herein

2'-O-methyl modifications

[00378] Modified sugars are believed to control the puckering of nucleotide sugar rings, a physical property that influences oligonucleotide binding affinity for complementary strands, duplex formation, and interaction with nucleases. Substitutions on sugar rings can therefore alter the conformation and puckering of these sugars. For example, 2'-O-methyl (2'-OMe) modifications can increase binding affinity and nuclease stability of oligonucleotides, though as shown in the Examples, the effect of any modification at a given position in an oligonucleotide needs to be empirically determined.

[00379] The terms "mA," "mC," "mU," or "mG" may be used to denote a nucleotide that has been modified with 2'-OMe.

[00380] A ribonucleotide and a modified 2'-O-methyl ribonucleotide can be depicted as follows:



RNA



2'-O-Me

2'-O-(2-methoxyethyl) modifications

[00381] In some embodiments, the modification may be 2'-O-(2-methoxyethyl) (2'-O-moe). A modified 2'-O-moe ribonucleotide can be depicted as follows:



MOE

[00382] The terms "moeA," "moeC," "moeU," or "moeG" may be used to denote a nucleotide that has been modified with 2'-O-moe.

2'-fluoro modifications

[00383] Another chemical modification that has been shown to influence nucleotide sugar rings is halogen substitution. For example, 2'-fluoro (2'-F) substitution on nucleotide sugar rings can increase oligonucleotide binding affinity and nuclease stability.

[00384] In this application, the terms "fA," "fC," "fU," or "fG" may be used to denote a nucleotide that has been substituted with 2'-F.

[00385] A ribonucleotide without and with a 2'-F substitution can be depicted as follows:



RNA
Natural composition of RNA

2'F-RNA
2'F substitution

Phosphorothioate modifications

[00386] A phosphorothioate (PS) linkage or bond refers to a bond where a sulfur is substituted for one nonbridging phosphate oxygen in a phosphodiester linkage, for example between nucleotides. When phosphorothioates are used to generate oligonucleotides, the modified oligonucleotides may also be referred to as S-oligos.

[00387] A "*" may be used to depict a PS modification. In this application, the terms A*, C*, U*, or G* may be used to denote a nucleotide that is linked to the next (e.g., 3') nucleotide with a PS bond. Throughout this application, PS modifications are grouped with the nucleotide whose 3' carbon is bonded to the phosphorothioate; thus, indicating that a PS modification is at position 1 means that the phosphorothioate is bonded to the 3' carbon of nucleotide 1 and the 5' carbon of nucleotide 2.

[00388] In this application, the terms "mA*," "mC*," "mU*," or "mG*" may be used to denote a nucleotide that has been substituted with 2'-OMe and that is linked to the next (e.g., 3') nucleotide with a PS linkage, which may sometimes be referred to as a "PS bond." Similarly, the terms "fA*," "fC*," "fU*," or "fG*" may be used to denote a nucleotide that has been substituted with 2'-F and that is linked to the next (e.g., 3') nucleotide with a PS linkage. Equivalents of a PS linkage or bond are encompassed by embodiments described herein.

[00389] The diagram below shows the substitution of S- for a nonbridging phosphate oxygen, generating a PS linkage in lieu of a phosphodiester linkage:



Natural phosphodiester linkage of RNA

Modified phosphorothioate (PS) bond

Inverted abasic modifications

[00390] Abasic nucleotides refer to those which lack nitrogenous bases. The figure below depicts an oligonucleotide with an abasic (in this case, shown as apurinic; an abasic site could also be an apyrimidinic site, wherein the description of the abasic site is typically in reference to Watson-Crick base pairing—e.g., an apurinic site refers to a site that lacks a nitrogenous base and would typically base pair with a pyrimidinic site) site that lacks a base, wherein the base may be substituted by another moiety at the 1' position of the furan ring (e.g., a hydroxyl group, as shown below, to form a ribose or deoxyribose site, as shown below, or a hydrogen):



[00391] Inverted bases refer to those with linkages that are inverted from the normal 5' to 3' linkage (i.e., either a 5' to 5' linkage or a 3' to 3' linkage). For example:



Normal oligonucleotide linkage



5'-inverted oligonucleotide linkage



3'-inverted linkage with H-substituted 3'inverted abasic site

[00392] An abasic nucleotide can be attached with an inverted linkage. For example, an abasic nucleotide may be attached to the terminal 5' nucleotide via a 5' to 5' linkage, or an abasic nucleotide may be attached to the terminal 3' nucleotide via a 3' to 3' linkage. An inverted abasic nucleotide at either the terminal 5' or 3' nucleotide may also be called an inverted abasic end cap. In this application, the terms "invd" indicates an inverted abasic nucleotide linkage.

Deoxyribonucleotides

[00393] A deoxyribonucleotide (in which the sugar comprises a 2'-deoxy position) is considered a modification in the context of a gRNA, in that the nucleotide is modified relative to standard RNA by the substitution of a proton for a hydroxyl at the 2' position. Unless otherwise indicated, a deoxyribonucleotide modification at a position that is U in an unmodified RNA can also comprise replacement of the U nucleobase with a T.

Bicyclic ribose analog

[00394] Exemplary bicyclic ribose analogs include locked nucleic acid (LNA), ENA, bridged nucleic acid (BNA), or another LNA-like modifications. In some instances, a bicyclic ribose analog has 2' and 4' positions connected through a linker. The linker can be of the formula -X-$(CH_2)_n$- where n is 1 or 2; X is O, NR, or S; and R is H or C_{1-3} alkyl, e.g., methyl. Examples of bicyclic ribose analogs include LNAs comprising a 2′-O-CH_2-4′ bicyclic structure (oxy-LNA) (see WO 98/39352 and WO 99/14226); 2′-NH-CH_2-4′ or 2′-N(CH_3)-CH_2-4′ (amino-LNAs) (Singh et al., *J. Org. Chem.* 63:10035-10039 (1998); Singh et al., *J. Org. Chem.* 63:6078-6079 (1998)); and 2′-S-CH_2-4′ (thio-LNA) (Singh et al., *J. Org. Chem.* 63:6078-6079 (1998); Kumar et al., *Biorg. Med. Chem. Lett.* 8:2219-2222 (1998)).

ENA

[00395] An ENA modification refers to a nucleotide comprising a 2′-*O*,4′-*C*-ethylene modification. An exemplary structure of an ENA nucleotide is shown below, in which wavy lines indicate connections to the adjacent nucleotides (or terminal positions as the case may be, with the understanding that if the 3’ terminal nucleotide is an ENA nucleotide, the 3’ position may comprise a hydroxyl rather than phosphate). For further discussion of ENA nucleotides, *see, e.g.*, Koizumi et al., *Nucleic Acids Res.* 31: 3267–3273 (2003).



UNA

[00396] A UNA or unlocked nucleic acid modification refers to a nucleotide comprising a 2′,3′-seco-RNA modification, in which the 2’ and 3’ carbons are not bonded directly to each other. An exemplary structure of a UNA nucleotide is shown below, in which wavy lines indicate connections to the adjacent phosphates or modifications replacing phosphates (or terminal positions as the case may be). For further discussion of UNA nucleotides, *see, e.g.*, Snead et al., *Molecular Therapy* 2: e103, doi:10.1038/mtna.2013.36 (2013).



Base modifications

[00397] A base modification is any modification that alters the structure of a nucleobase or its bond to the backbone, including isomerization (as in pseudouridine). In some embodiments, a base modification includes inosine. In some embodiments, a modification comprises a base modification that reduces RNA endonuclease activity, e.g., by interfering with recognition of a cleavage site by an RNase or by stabilizing an RNA

structure (e.g., secondary structure) that decreases accessibility of a cleavage site to an RNase. Exemplary base modifications that can stabilize RNA structures are pseudouridine and 5-methylcytosine. *See* Peacock et al., *J Org Chem.* 76: 7295–7300 (2011). In some embodiments, a base modification can increase or decrease the melting temperature (Tm) of a nucleic acid, e.g., by increasing the hydrogen bonding in a Watson-Crick base pair, forming non-canonical base pair, or creating a mismatched base pair.

[00398] The above modifications and their equivalents are included within the scope of the embodiments described herein.

3' end modifications

[00399] In some embodiments, the terminal (i.e., last) 1, 2, 3, or 4, optionally 5, 6, or 7 nucleotides in the 3' end are modified. Throughout, this modification may be referred to as a "3' end modification". In some embodiments, the terminal (i.e., last) 1, 2, 3, or 4, optionally 5, 6, or 7 nucleotides in the 3' end comprise more than one modification. In some embodiments, at least one of the terminal (i.e., last) 1, 2, 3, or 4, optionally 5, 6, or 7 nucleotides in the 3' end are modified. In some embodiments, at least two of the terminal (i.e., last) 1, 2, 3, or 4, optionally 5, 6, or 7 nucleotides in the 3' end are modified. In some embodiments, at least three of the terminal (i.e., last) 1, 2, 3, or 4, optionally 5, 6, or 7 nucleotides in the 3' end are modified. In some embodiments, the modification comprises a PS linkage. In some embodiments, the modification to the 3' end is a 3' protective end modification. In some embodiments, the 3' end modification comprises a 3' protective end modification.

[00400] In some embodiments, the 3' end modification comprises a modified nucleotide selected from 2'-O-methyl (2'-O-Me) modified nucleotide, 2'-O-(2-methoxyethyl) (2'-O-moe) modified nucleotide, a 2'-fluoro (2'-F) modified nucleotide, a phosphorothioate (PS) linkage between nucleotides, or an inverted abasic modified nucleotide, optionally wherein the gRNA comprises at least two 3' end modifications independently selected from a 2'-O-methyl (2'-OMe) modified nucleotide, 2'-O-(2-methoxyethyl) (2'-O-moe) modified nucleotide, a 2'-fluoro (2'-F) modified nucleotide, a phosphorothioate (PS) linkage between nucleotides, and an inverted abasic modified nucleotide.

[00401] In some embodiments, the 3' end modification comprises or further comprises a 2'-O-methyl (2'-O-Me) modified nucleotide.

[00402] In some embodiments, the 3' end modification comprises or further comprises a 2'-fluoro (2'-F) modified nucleotide.

[00403] In some embodiments, the 3' end modification comprises or further comprises a phosphorothioate (PS) linkage between nucleotides.

[00404] In some embodiments, the 3' end modification comprises or further comprises an inverted abasic modified nucleotide.

[00405] In some embodiments, the 3' end modification comprises or further comprises a 2'-O-methyl (2'-O-Me) modified nucleotide and a phosphorothioate (PS) linkage between nucleotides.

[00406] In some embodiments, the 3' end modification comprises or further comprises a modification of any one or more of the last 1, 2, 3, or 4, optionally 5, 6, or 7 nucleotides. In some embodiments, the 3' end modification comprises or further comprises one modified nucleotide. In some embodiments, the 3' end modification comprises or further comprises two modified nucleotides. In some embodiments, the 3' end modification comprises or further comprises three modified nucleotides. In some embodiments, the 3' end modification comprises or further comprises four modified nucleotides. In some embodiments, the 3' end modification comprises or further comprises five modified nucleotides. In some embodiments, the 3' end modification comprises or further comprises six modified nucleotides. In some embodiments, the 3' end modification comprises or further comprises seven modified nucleotides.

[00407] In some embodiments, the 3' end modification comprises or further comprises a modification of 1-7 or 14 nucleotides.

[00408] In some embodiments, the 3' end modification comprises or further comprises modifications of 1, 2, 3, or 4, optionally 5, 6, or 7 nucleotides at the 3' end of the gRNA.

[00409] In some embodiments, the 3' end modification comprises or further comprises modifications of about 1-3, 1-4, or 1-5 nucleotides at the 3' end of the gRNA.

[00410] In some embodiments, the 3' end modification comprises or further comprises any one or more of the following: a phosphorothioate (PS) linkage between nucleotides, a 2'-O-Me modified nucleotide, a 2'-O-moe modified nucleotide, a 2'-F modified nucleotide, an inverted abasic modified nucleotide, and a combination thereof.

[00411] In some embodiments, the 3' end modification comprises or further comprises 1, 2, 3, or 4, optionally 5, 6, or 7 PS linkages between nucleotides.

[00412] In some embodiments, the 3' end modification comprises or further comprises at least one 2'-O-Me, 2'-O-moe, inverted abasic, or 2'-F modified nucleotide.

In some embodiments, the 3' end modification comprises or further comprises one PS linkage, wherein the linkage is between the last and second to last nucleotide. In some

embodiments, the 3' end modification comprises or further comprises two PS linkages between the last three nucleotides. In some embodiments, the 3' end modification comprises or further comprises four PS linkages between the last four nucleotides.

[00413] In some embodiments, the 3' end modification comprises or further comprises PS linkages between any one or more of the last four nucleotides. In some embodiments, the 3' end modification comprises or further comprises PS linkages between any one or more of the last three nucleotides. In some embodiments, the 3' end modification comprises or further comprises PS linkages between any one or more of the last 2, 3, or 4, optionally 5, 6, or 7 nucleotides.

[00414] In some embodiments, the 3' end modification comprises or further comprises a modification of one or more of the last 1-4, optionally 1-7 nucleotides, wherein the modification is a PS linkage, inverted abasic nucleotide, 2'-OMe, 2'-O-moe, 2'-F, or combinations thereof.

[00415] In some embodiments, the 3' end modification comprises or further comprises a modification to the last nucleotide with 2'-OMe, 2'-O-moe, 2'-F, or combinations thereof, and an optionally one or two PS linkages to the next nucleotide or the first nucleotide of the 3' end.

[00416] In some embodiments, the 3' end modification comprises or further comprises a modification to the last or second to last nucleotide with 2'-OMe, 2'-O-moe, 2'-F, or combinations thereof, and optionally one or more PS linkages.

[00417] In some embodiments, the 3' end modification comprises or further comprises a modification to the last, second to last, or third to last nucleotides with 2'-OMe, 2'-O-moe, 2'-F, or combinations thereof, and optionally one or more PS linkages.

[00418] In some embodiments, the 3' end modification comprises or further comprises a modification to the last, second to last, third to last, or fourth to last nucleotides with 2'-OMe, 2'-O-moe, 2'-F, or combinations thereof, and optionally one or more PS linkages.

[00419] In some embodiments, the 3' end modification comprises or further comprises a modification to the last, second to last, third to last, fourth to last, or fifth to last nucleotides with 2'-OMe, 2'-O-moe, 2'-F, or combinations thereof, and optionally one or more PS linkages.

[00420] In some embodiments, the gRNA comprising a 3' end modification comprises or further comprises a 3' tail, wherein the 3' tail comprises a modification of any one or more of the nucleotides present in the 3' tail. In some embodiments, the 3' tail is fully modified. In some embodiments, the 3' tail comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1-2, 1-3, 1-4, 1-5, 1-6, 1-

7, 1-8, 1-9, or 1-10 nucleotides, optionally where any one or more of these nucleotides are modified. In some embodiments, the 3' tail comprises 1-4 nucleotides, optionally 1-2 nucleotides.

[00421] In some embodiments, a gRNA is provided comprising a 3' end modification, wherein the 3' end modification comprises the 3' end modification as shown in any one of SEQ ID NOs: In some embodiments, a gRNA is provided comprising a 5' end modification, wherein the 5' end modification comprises a 5' end modification as shown in any one of SEQ ID NOs: 4-9 and 301-494. In some embodiments, a gRNA is provided comprising a 3' protective end modification.

[00422] In some embodiments, the gRNA comprises a 5' end modification and a 3' end modification.

5' end modifications

[00423] In some embodiments, the 5' end is modified, for example, the first 1, 2, 3, or 4, optionally 5, 6, or 7 nucleotides of the gRNA are modified. Throughout, this modification may be referred to as a "5' end modification". In some embodiments, the first 1, 2, 3, or 4, optionally 5, 6, or 7 nucleotides of the 5' end comprise more than one modification. In some embodiments, at least one of the terminal (i.e., first) 1, 2, 3, or 4, optionally 5, 6, or 7 nucleotides at the 5' end are modified. In some embodiments, at least two of the terminal 1, 2, 3, or 4, optionally 5, 6, or 7 nucleotides at the 5' end are modified. In some embodiments, at least three of the terminal 1, 2, 3, or 4, optionally 5, 6, or 7 nucleotides at the 5' end are modified. In some embodiments, the 5' end modification is a 5' protective end modification.

[00424] In some embodiments, both the 5' and 3' ends of the gRNA are modified. In some embodiments, only the 5' end of the gRNA is modified. In some embodiments, only the 3' end of the conserved region of a gRNA is modified.

[00425] In some embodiments, the gRNA comprises modifications at 1, 2, 3, or 4, optionally 5, 6, or 7 of the first 4 nucleotides, optionally the first 7 nucleotides at a 5' terminus region of the gRNA. In some embodiments, the gRNA comprises modifications at 1, 2, 3, or 4, optionally 5, 6, or 7 of the 4 terminal nucleotides, optionally 7 terminal nucleotides at a 3' end. In some embodiments, 1, 2, 3, or 4 of the first 4 nucleotides at the 5' end, or 1, 2, 3, or 4 of the terminal 4 nucleotides at the 3' end are modified. In some embodiments, 2, 3, or 4 of the first 4 nucleotides at the 5' end are linked with phosphorothioate (PS) bonds.

[00426] In some embodiments, the modification to the 5' terminus or 3' terminus comprises a 2'-O-methyl (2'-O-Me) or 2'-O-(2-methoxyethyl) (2'-O-moe) modification. In some embodiments, the modification comprises a 2'-fluoro (2'-F) modification to a nucleotide. In some embodiments, the modification comprises a phosphorothioate (PS) linkage between nucleotides. In some embodiments, the modification comprises an inverted abasic nucleotide. In some embodiments, the modification comprises a protective end modification. In some embodiments, the modification comprises a more than one modification selected from protective end modification, 2'-O-Me, 2'-O-moe, 2'-fluoro (2'-F), a phosphorothioate (PS) linkage between nucleotides, and an inverted abasic nucleotide. In some embodiments, an equivalent modification is encompassed.

[00427] In some embodiments, the gRNA comprises one or more phosphorothioate (PS) linkages between the first one, two, three, four, five, six, or seven nucleotides at the 5' terminus. In some embodiments, the gRNA comprises one or more PS linkages between the last one, two, three, or four, optionally five, six, or seven nucleotides at the 3' terminus. In some embodiments, the gRNA comprises one or more PS linkages between both the last one, two, three, or four, optionally five, six, or seven nucleotides at the 3' terminus and the first one, two, three, or four, optionally five, six, or seven nucleotides from the 5' end of the 5' terminus. In some embodiments, in addition to PS linkages, the 5' and 3' terminal nucleotides may comprise 2'-O-Me, 2'-O-moe, or 2'-F modified nucleotides.

[00428] In some embodiments, the gRNA comprises a 5' end modification, e.g., wherein the first nucleotide of the guide region is modified. In some embodiments, the gRNA comprises a 5' end modification, wherein the first nucleotide of the guide region comprises a 5' protective end modification.

[00429] In some embodiments, the 5' end modification comprises a modified nucleotide selected from a 2'-O-methyl (2'-O-Me) modified nucleotide, 2'-O-(2-methoxyethyl) (2'-O-moe) modified nucleotide, a 2'-fluoro (2'-F) modified nucleotide, a phosphorothioate (PS) linkage between nucleotides, an inverted abasic modified nucleotide, optionally wherein the gRNA comprises at least two 5' end modifications independently selected from a 2'-O-methyl (2'-OMe) modified nucleotide, 2'-O-(2-methoxyethyl) (2'-O-moe) modified nucleotide, a 2'-fluoro (2'-F) modified nucleotide, a phosphorothioate (PS) linkage between nucleotides, and an inverted abasic modified nucleotide.

[00430] In some embodiments, the 5' end modification comprises or further comprises a 2'-O-methyl (2'-O-Me) modified nucleotide.

[00431] In some embodiments, the 5' end modification comprises or further comprises a 2'-fluoro (2'-F) modified nucleotide.

[00432] In some embodiments, the 5' end modification comprises or further comprises a phosphorothioate (PS) linkage between nucleotides.

[00433] In some embodiments, the 5' end modification comprises or further comprises an inverted abasic modified nucleotide.

[00434] In some embodiments, the 5' end modification comprises or further comprises a 2'-O-methyl (2'-O-Me) modified nucleotide and a phosphorothioate (PS) linkage between nucleotides.

[00435] In some embodiments, the 5' end modification comprises or further comprises a modification of any one or more of nucleotides 1-4, optionally 1-7 of the guide region of a gRNA. In some embodiments, the 5' end modification comprises or further comprises one modified nucleotide. In some embodiments, the 5' end modification comprises or further comprises two modified nucleotides. In some embodiments, the 5' end modification comprises or further comprises three modified nucleotides. In some embodiments, the 5' end modification comprises or further comprises four modified nucleotides. In some embodiments, the 5' end modification comprises or further comprises five modified nucleotides. In some embodiments, the 5' end modification comprises or further comprises six modified nucleotides. In some embodiments, the 5' end modification comprises or further comprises seven modified nucleotides.

[00436] In some embodiments, the 5' end modification comprises or further comprises a modification of 1-7, 1- 5, 1-4, 1 -3, or 1- 2 nucleotides.

[00437] In some embodiments, the 5' end modification comprises or further comprises modifications of 1, 2, 3, or 4, optionally 5, 6, or 7 nucleotides from the 5' end. In some embodiments, the 5' end modification comprises or further comprises modifications of about 1-3, 1-4, 1-5, 1-6, or 1-7 nucleotides from the 5' end.

[00438] In some embodiments, the 5' end modification comprises or further comprises modifications at the first nucleotide at the 5' end of the gRNA. In some embodiments, the 5' end modification comprises or further comprises modifications at the first and second nucleotide from the 5' end of the gRNA. In some embodiments, the 5' end modification comprises or further comprises modifications at the first, second, and third nucleotide from the 5' end of the gRNA. In some embodiments, the 5' end modification comprises or further comprises modifications at the first, second, third, and fourth nucleotide from the 5' end of the gRNA. In some embodiments, the 5' end modification comprises or further comprises

modifications at the first, second, third, fourth, and fifth nucleotide from the 5' end of the gRNA. In some embodiments, the 5' end modification comprises or further comprises modifications at the first, second, third, fourth, fifth, and sixth nucleotide from the 5' end of the gRNA. In some embodiments, the 5' end modification comprises or further comprises modifications at the first, second, third, fourth, fifth, sixth, and seventh nucleotide from the 5' end of the gRNA.

[00439] In some embodiments, the 5' end modification comprises or further comprises a phosphorothioate (PS) linkage between nucleotides, or a 2'-O-Me modified nucleotide, or a 2'-O-moe modified nucleotide, or a 2'-F modified nucleotide, or an inverted abasic modified nucleotide, or combinations thereof.

[00440] In some embodiments, the 5' end modification comprises or further comprises 1, 2, 3, 4, 5, 6, or 7 PS linkages between nucleotides. In some embodiments, the 5' end modification comprises or further comprises about 1-2, 1-3, 1-4, 1-5, 1-6, or 1-7 PS linkages between nucleotides.

[00441] In some embodiments, the 5' end modification comprises or further comprises at least one PS linkage, wherein if there is one PS linkage, the linkage is between nucleotides 1 and 2 of the guide region.

[00442] In some embodiments, the 5' end modification comprises or further comprises at least two PS linkages, and the linkages are between nucleotides 1 and 2, and 2 and 3 of the guide region.

[00443] In some embodiments, the 5' end modification comprises or further comprises PS linkages between any one or more of nucleotides 1 and 2, 2 and 3, and 3 and 4 of the guide region.

[00444] In some embodiments, the 5' end modification comprises or further comprises PS linkages between any one or more of nucleotides 1 and 2, 2 and 3, 3 and 4, and 4 and 5 of the guide region.

[00445] In some embodiments, the 5' end modification comprises or further comprises PS linkages between any one or more of nucleotides 1 and 2, 2 and 3, 3 and 4, 4 and 5, and 5 and 6 of the guide region.

[00446] In some embodiments, the 5' end modification comprises or further comprises PS linkages between any one or more of nucleotides 1 and 2, 2 and 3, 3 and 4, 4 and 5, 5 and 6, and 7 and 8 of the guide region.

[00447] In some embodiments, the 5' end modification comprises or further comprises a modification of one or more of nucleotides 1-7 of the guide region, wherein the

modification is a PS linkage, inverted abasic nucleotide, 2'-O-Me, 2'-O-moe, 2'-F, or combinations thereof.

[00448] In some embodiments, the 5' end modification comprises or further comprises a modification to the first nucleotide of the guide region with 2'-O-Me, 2'-O-moe, 2'-F, or combinations thereof, and an optional PS linkage to the next nucleotide;

[00449] In some embodiments, the 5' end modification comprises or further comprises a modification to the first or second nucleotide of the guide region with 2'-O-Me, 2'-O-moe, 2'-F, or combinations thereof, and optionally one or more PS linkages between the first and second nucleotide or between the second and third nucleotide.

[00450] In some embodiments, the 5' end modification comprises or further comprises a modification to the first, second, or third nucleotides of the variable region with 2'-O-Me, 2'-O-moe, 2'-F, or combinations thereof, and optionally one or more PS linkages between the first and second nucleotide, between the second and third nucleotide, or between the third and the fourth nucleotide.

[00451] In some embodiments, the 5' end modification comprises or further comprises a modification to the first, second, third, or fourth nucleotides of the variable region with 2'-O-Me, 2'-O-moe, 2'-F, or combinations thereof, and optionally one or more PS linkages between the first and second nucleotide, between the second and third nucleotide, between the third and the fourth nucleotide, or between the fourth and the fifth nucleotide.

[00452] In some embodiments, the 5' end modification comprises or further comprises a modification to the first, second, third, fourth, or fifth nucleotides of the variable region with 2'-O-Me, 2'-O-moe, 2'-F, or combinations thereof, and optionally one or more PS linkages between the first and second nucleotide, between the second and third nucleotide, between the third and the fourth nucleotide, between the fourth and the fifth nucleotide, or between the fifth and the sixth nucleotide.

[00453] In some embodiments, a gRNA is provided comprising a 5' end modification, wherein the 5' end modification comprises a 5' end modification as shown in any one of SEQ ID NOs: 4-9 and 301-494, 931-946.

[00454] In some embodiments, the sgRNA comprises a 5' end modification comprising a 5' protective end modification. In some embodiments, a gRNA is provided comprising a 5' end modification, wherein the 5' end modification comprises 2'-OMe modified nucleotides at nucleotides 1, 2, and 3 of the guide region.

[00455] In some embodiments, a gRNA is provided comprising a 5' end modification, wherein the 5' end modification comprises 2'-OMe modified nucleotides at nucleotides 1, 2,

and 3 of the guide region and PS linkages between nucleotides 1 and 2, 2 and 3, and 3 and 4 of the guide region.

[00456] In some embodiments, a gRNA is provided comprising a 5' end modification, wherein the 5' end modification comprises 2'-OMe modified nucleotides at nucleotides 1, 2, 3, 4, and 5 of the guide region.

[00457] In some embodiments, a gRNA is provided comprising a 5' end modification, wherein the 5' end modification comprises 2'-OMe modified nucleotides at nucleotides 1, 2, 3, 4, and 5 of the guide region and PS linkages between nucleotides 1 and 2, 2 and 3, and 3 and 4of the guide region.

[00458] In some embodiments, a gRNA is provided comprising a 5' end modification and a 3' end modification. In some embodiments, the gRNA comprises modified nucleotides at the 5' and 3' terminus, and modified nucleotides in one or more other regions described in Table 3.

[00459] In some embodiments, the sgRNA comprises modified nucleotides that are not at the 5' or 3' ends. Exemplary patterns of modifications are described below and in Table 1.

Repeat/anti-repeat modifications

[00460] In some embodiments, a gRNA is provided comprising a repeat/anti-repeat region modification, wherein the repeat/anti-repeat region modification comprises a modification to any one or more of nucleotides 25-76 in the upper stem region.

[00461] In some embodiments, a gRNA is provided comprising a repeat/anti-repeat region modification, wherein the upper stem modification comprises a modification of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotides in the repeat/anti-repeat region.

[00462] In some embodiments, a gRNA is provided comprising an upper stem modification, wherein the upper stem modification comprises a modification of about 1-18, 1-16, 1-15, 5-18, 5-15, 8-18, 8-15, 10-18, 10-15, or 12-15 nucleotides in the repeat/anti-repeat region.

[00463] In some embodiments, a gRNA is provided comprising a repeat/anti-repeat modification, wherein the repeat/anti-repeat modification comprises a 2'-OMe modified nucleotide. In some embodiments, a gRNA is provided comprising a repeat/anti-repeat modification, wherein the repeat/anti-repeat modification comprises a 2'-O-moe modified nucleotide. In some embodiments, a gRNA is provided comprising a repeat/anti-repeat

modification, wherein the repeat/anti-repeat modification comprises a 2'-F modified nucleotide.

[00464] In some embodiments, a gRNA is provided comprising a repeat/anti-repeat modification, wherein the repeat/anti-repeat modification comprises a 2'-OMe modified nucleotide, a 2'-O-moe modified nucleotide, a 2'-F modified nucleotide, or combinations thereof.

[00465] In some embodiments, the sgRNA comprises a repeat/anti-repeat modification as shown in any one of the sequences in Table 1 or 2. In some embodiments, the gRNA does not comprise a modification at position 76 in the repeat/anti-repeat region. In some embodiments, the gRNA does not comprise a PS modification at position 76.

[00466] In some embodiments, such a repeat/anti-repeat modification is combined with a 5' protective end modification, e.g. as shown for the corresponding sequence in Table 1 or 2. In some embodiments, such a repeat/anti-repeat modification is combined with a 3' protective end modification, e.g. as shown for the corresponding sequence in Table 1 or 2. In some embodiments, such a repeat/anti-repeat modification is combined with 5' and 3' end modifications as shown for the corresponding sequence in Table 1 or 2.

[00467] In some embodiments, the gRNA comprises a 5' end modification and a repeat/anti-repeat modification. In some embodiments, the gRNA comprises a 3' end modification and a repeat/anti-repeat modification. In some embodiments, the gRNA comprises a 5' end modification, a 3' end modification and a repeat/anti-repeat modification.

Hairpin modifications

[00468] In some embodiments, the gRNA comprises a modification in the hairpin region (e.g., hairpin 1 region or hairpin 2 region). In some embodiments, the hairpin region modification comprises at least one modified nucleotide selected from a 2'-O-methyl (2'-OMe) modified nucleotide, a 2'-fluoro (2'-F) modified nucleotide, or combinations thereof.

[00469] In some embodiments, the hairpin region modification is in the hairpin 1 region. In some embodiments, the hairpin region modification is in the hairpin 2 region. In some embodiments, modifications are within the hairpin 1 and hairpin 2 regions, optionally wherein a nucleotide between hairpin 1 and 2 is also modified.

[00470] In some embodiments, the hairpin modification comprises or further comprises a 2'-O-methyl (2'-OMe) modified nucleotide.

[00471] In some embodiments, the hairpin modification comprises or further comprises a 2'-fluoro (2'-F) modified nucleotide.

[00472] In some embodiments, the hairpin region modification comprises at least one modified nucleotide selected from a 2'H modified nucleotide (DNA), PS modified nucleotide, a 2'-O-methyl (2'-O-Me) modified nucleotide, a 2'-fluoro (2'-F) modified nucleotide, or combinations thereof.

[00473] In some embodiments, the gRNA comprises one or more, i.e., 1, 2, 3, or 4 modifications at positions 106-109 in the hairpin 2 region. In some embodiments, the gRNA comprises modifications at positions 106-109. In some embodiments, the modification comprises a 2'-O-methyl (2'-O-Me) modified nucleotide.

[00474] In some embodiments, the gRNA comprises a 3' end modification, and a modification in the hairpin region. In some embodiments, the 3' end modification is within the hairpin region, i.e., in hairpin 2.

[00475] In some embodiments, the gRNA comprises a 5' end modification, and a modification in the hairpin region.

[00476] In some embodiments, the gRNA comprises a repeat/anti-repeat modification, and a modification in the hairpin region.

[00477] In some embodiments, the gRNA comprises a hairpin modification as shown in any one of the sequences in Table 1 or 2. In some embodiments, such a hairpin modification is combined with a 5' end modification as shown for the corresponding sequence in Table 1 or 2. In some embodiments, such a hairpin modification is combined with a 3' end modification as shown for the corresponding sequence in Table 1 or 2. In some embodiments, such a hairpin modification is combined with 5' and 3' end modifications as shown for the corresponding sequence in Table 1 or 2.

[00478] In some embodiments, the gRNA comprises a 3' end modification, a modification in the hairpin region, a repeat/anti-repeat modification, and a 5' end modification.

EXEMPLARY GUIDE RNAS

[00479] In some embodiments, a gRNA comprising a 5' end modification and one or more modifications in one or more of: the repeat/anti-repeat region; the hairpin 1 region; and the hairpin 2 region is provided, wherein the one or more modification is at least 99, 98, 97, 96, 95, 94, 93, 92, 91, 90, 85, 80, 75, or 70% identity to the modification pattern shown in the reference sequence identifier in Tables 1-2.

[00480] In some embodiments, the gRNAs described herein comprise any of the sequences shown in Tables 1-2. In some embodiments, the gRNAs described herein consist

of any of the sequences shown in Tables 1-2. In some embodiments, the gRNAs described herein consist of any of the sequences shown in Tables 1-2 with any 3' tail sequences removed. Further, gRNAs are encompassed that comprise the modifications of any of the sequences shown in Table 1 or 2, and identified therein by SEQ ID NO. That is, the nucleotides may be the same or different, but the modification pattern shown may be the same or similar to a modification pattern of a guide sequence of Tables 1-2. A modification pattern includes the relative position and identity of modifications of the gRNA.

[00481] In some embodiments, the modification pattern contains at least 50%, 55%, 60%, 70%, 75%, preferably at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of the modifications of any one of the sequences shown in the sequence column of Tables 1-2, or over one or more regions of the sequence. In some embodiments, the modification pattern is at least 50%, 55%, 60%, 70%, 75%, preferably at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the modification pattern of any one of the sequences shown in the sequence column of Tables 1-2. In some embodiments, the modification pattern is at least 50%, 55%, 60%, 70%, 75%, preferably at least 80%, 85%, 90%, or 95% identical to the patterns in Tables 1-2 over one or more (e.g., 1, 2, 3, 4, or 5) regions of the sequence shown in Table 3.

[00482] For example, in some embodiments, a gRNA is encompassed wherein the modification pattern is least 50%, 55%, 60%, 70%, 75%, preferably at least 80%, 85%, 90%, or 95% identical to the modification pattern of a sequence over the guide sequence. In some embodiments, a gRNA is encompassed wherein the modification pattern is least 50%, 55%, 60%, 70%, 75%, preferably at least 80%, 85%, 90%, or 95% identical over the repeat/anti-repeat region. In some embodiments, a gRNA is encompassed wherein the modification pattern is least 50%, 55%, 60%, 70%, 75%, preferably at least 80%, 85%, 90%, or 95%identical over the hairpin 1 region. In some embodiments, a gRNA is encompassed wherein the modification pattern is least 50%, 55%, 60%, 70%, 75%, 80%, preferably at least 85%, 90%, 95%, 96%, 97%, 98%, and 99% identical over the hairpin 2 region. In some embodiments, a gRNA is encompassed wherein the modification pattern is least 50%, 55%, 60%, 70%, 80%, or 90%, identical over the 3' tail. In some embodiments, the modification pattern differs from the modification pattern of a sequence of Tables 1-2, or a region as set forth in Table 3, of such a sequence, at 0, 1, 2, 3, 4, 5, or 6 nucleotides. In some embodiments, the gRNA comprises modifications that differ from the modifications of a sequence of Tables 1-2, at 0, 1, 2, 3, 4, 5, or 6 nucleotides. In some embodiments, the gRNA

comprises modifications that differ from modifications of a region set forth in Table 3 of a sequence of Tables 1-2, at 0, 1, 2, 3, 4, 5, or 6 nucleotides.

[00483] In some embodiments, a gRNA is provided comprising any one of the sequences described in SEQ ID NOs: 1-19, 21-42, 301-494, 931-946, 951, and 952. In some embodiments, a gRNA is provided consisting of any one of the sequences described in SEQ ID NOs: 1-19, 21-42, 301-494, 931-946, 951, and 952. In some embodiments, a gRNA is provided compromising any one of the sequences described in SEQ ID NOs: 1-19, 21-42, 301-494, 931-946, 951, and 952 including the modifications shown in Tables 1-2. In some embodiments, a gRNA is provided consisting of any one of the sequences described in SEQ ID NOs: 1-19, 21-42, 301-494, 931-946, 951, and 952 including the modifications shown in Tables 1-2. In some embodiments, a gRNA is provided comprising or consisting of any one of the sequences described in SEQ ID NOs: 1-19, 21-42, 301-494, 931-946, 951, and 952 including the modifications shown in Tables 1-2, wherein the 3' tail, when present, is deleted.

[00484] In some embodiments, a gRNA is provided comprising any one of the sequences of SEQ ID NOs: 6 or 9 wherein the gRNA further comprises a guide sequence that is complementary to a target sequence, and directs a Cas9 to its target for cleavage. In some embodiments, a gRNA is provided comprising nucleic acids having at least 99, 98, 97, 96, 95, 94, 93, 92, 91, 90, 85, 80, 75, or 70% identity to the nucleic acids of any one of SEQ ID NOs: 6 or 9, wherein the modification pattern is identical to the modification pattern shown in the reference sequence identifier in Tables 1-2.

[00485] FIGS. 25, 37, and 38 show exemplary sgRNAs in possible secondary structures.

[00486] In some embodiments a single guide RNA (sgRNA) comprises:

a guide sequence comprising:

2'-O-Me modified nucleotides at the first four nucleotides 1-4;

PS linkages between nucleotides 1-2, 2-3, and 3-4; and

2'-O-Me modified nucleotides at nucleotides 5, 8, 9, 11, 13,18, and 22 of the guide sequence;

a shortened repeat/anti-repeat region, wherein nucleotides 38-48 and 53-63 are deleted relative to SEQ ID NO: 500, comprising:

2'-O-Me modified nucleotides at nucleotides 25, 29, 30, 31, 32, 37, 49-52, 64, 65, 69, 70, and 73;

a PS linkage between nucleotides 76-77 between the shortened repeat/anti-repeat region and the shortened hairpin 1 region;

a shortened hairpin 1 region, wherein nucleotides 86 and 91 are deleted relative to SEQ ID NO: 500, comprising:

2'-O-Me modified nucleotides at nucleotides 80, 81, 83, 84, 85, 87-90, 92-94, and 99;

2'-O-Me modified nucleotide at nucleotide 101 between the shortened hairpin 1 region and the shortened hairpin 2 region;

a shortened hairpin 2 region, wherein nucleotides 112-120 and 127-134 are deleted relative to SEQ ID NO: 500, comprising:

2'-O-Me modified nucleotides at nucleotides 104, 110, 111, 122-125, 142, and 143,

PS linkages between nucleotides 141-142 and 142-143,

wherein one or both nucleotides 144-145 are optionally deleted relative to SEQ ID NO: 500.

[00487] In some embodiments a single guide RNA (sgRNA) is provided, comprising:

a guide region comprising:

2'-O-Me modified nucleotides at the first four nucleotides 1-4;

PS linkages between nucleotides 1-2, 2-3, and 3-4; and

2'-O-Me modified nucleotides at nucleotides 5, 8, 9, 11, 13, 18, and 22 of the guide region;

a shortened repeat/anti-repeat region, wherein nucleotides 38-48 and 53-63 are deleted relative to SEQ ID NO: 500, comprising:

2'-O-Me modified nucleotides at nucleotides 25, 29, 30, 31, 32, 37, 49-52, 64, 65, 69, 70, and 73;

a PS linkage between nucleotides 76-77 between the shortened repeat/anti-repeat region and the shortened hairpin 1 region;

a shortened hairpin 1 region, wherein nucleotides 86 and 91 are deleted relative to SEQ ID NO: 500, comprising:

2'-O-Me modified nucleotides at nucleotides 80, 81, 83, 84, 85, 87-90, 92-94, and 99;

2'-O-Me modified nucleotide at nucleotide 101 between the shortened hairpin 1 region and the shortened hairpin 2 region;

a shortened hairpin 2 region, wherein nucleotides 112-120 and 127-134 are deleted relative to SEQ ID NO: 500, comprising:

2'-O-Me modified nucleotides at nucleotides 104, 110, 111, 122-125, 142, and 143;

PS linkage between nucleotides 141-142 and 142-143,

wherein one or both nucleotides 144-145 are optionally deleted relative to SEQ ID NO: 500.

[00488] In some embodiments a single guide RNA (sgRNA) is provided, comprising:

a guide region comprising:

2'-O-Me modified nucleotides at the first four nucleotides 1-4;

PS linkages between nucleotides 1-2, 2-3, and 3-4; and

2'-O-Me modified nucleotides at nucleotides 5, 8, 9, 11, 13,18, and 22 of the guide region;

a shortened repeat/anti-repeat region, wherein nucleotides 38-47 and 54-63 are deleted relative to SEQ ID NO: 500, comprising:

2'-O-Me modified nucleotides at nucleotides 25, 29, 30, 31, 32, 37, 48, 49-52, 64, 65, 69, 70, and 73;

a PS linkage between nucleotides 76-77 between the shortened repeat/anti-repeat region and the shortened hairpin 1 region;

a shortened hairpin 1 region, wherein nucleotides 86 and 91 are deleted relative to SEQ ID NO: 500, comprising:

2'-O-Me modified nucleotides at nucleotides 80, 81, 83, 84, 85, 87-90, 92-94, and 99;

2'-O-Me modified nucleotide at nucleotide 101 between the shortened hairpin 1 region and the shortened hairpin 2 region;

a shortened hairpin 2 region, wherein nucleotides 112-120 and 127-134 are deleted relative to SEQ ID NO: 500, comprising:

2'-O-Me modified nucleotides at nucleotides 104, 110, 111, 122-125, 142, and 143;

PS linkage between nucleotides 141-142 and 142-143;

wherein one or both nucleotides 144-145 are optionally deleted relative to SEQ ID NO: 500.

[00489] In some embodiments a single guide RNA (sgRNA) comprises:

a guide region comprising:

2'-O-Me modified nucleotides at the first two nucleotides 1-2;

PS linkages between nucleotides 1-2; and

2'-O-Me modified nucleotides at nucleotides 10 and 13 of the guide region;

a shortened repeat/anti-repeat region comprising:

nucleotides 38-48 and 53-63 are deleted relative to SEQ ID NO: 500;

2'-O-Me modified nucleotides at nucleotides 25, 29, 30, 31, 32, 37, 49-52, 64, 65, 69, 70, 73;

a PS linkage between nucleotides 76-77 between the shortened repeat/anti-repeat region and the shortened hairpin 1 region;

a shortened hairpin 1 region comprising:

nucleotides 86 and 91 are deleted relative to SEQ ID NO: 500;

2'-O-Me modified nucleotides at nucleotides 80, 81, 83, 84, 85, 87-90, 92-94, 99;

2'-O-Me modified nucleotide at nucleotide 101 between the shortened hairpin 1 region and the shortened hairpin 2 region;

a shortened hairpin 2 region comprising:

nucleotides 112-120 and 127-134 are deleted relative to SEQ ID NO: 500;

2'-O-Me modified nucleotides at nucleotides 102-105, 110, 111, 122-125, 135, 136, 138, 139, 141-143,

Three PS linkages between nucleotides 140-141, 141-142 and 142-143,

wherein the sgRNA does not comprise a 3' tail.

[00490] In some embodiments a single guide RNA (sgRNA) comprises:

a guide sequence comprising:

2'-O-Me modified nucleotides at the first four nucleotides 1-4;

PS linkages between nucleotides 1-2, 2-3, and 3-4; and

2'-O-Me modified nucleotides at nucleotides 5, 8, 9, 11, 13,18, and 22 of the guide sequence;

a shortened repeat/anti-repeat region, wherein nucleotides 38-48 and 53-63 are deleted relative to SEQ ID NO: 500, comprising:

2'-O-Me modified nucleotides at nucleotides 25, 29, 30, 31, 32, 37, 49-52, 64, 65, 69, 70, and 73;

a PS linkage between nucleotides 76-77 between the shortened repeat/anti-repeat region and the shortened hairpin 1 region;

a shortened hairpin 1 region, wherein nucleotides 86 and 91 are deleted relative to SEQ ID NO: 500, comprising:

2'-O-Me modified nucleotides at nucleotides 80, 81, 83, 84, 85, 87-90, 92-94, and 99;

2'-O-Me modified nucleotide at nucleotide 101 between the shortened hairpin 1 region and the shortened hairpin 2 region;

a shortened hairpin 2 region, wherein nucleotides 112-120 and 127-135 are deleted relative to SEQ ID NO: 500, comprising:

2'-O-Me modified nucleotides at nucleotides 104, 110, 111, 122-125, 142, and 143,

PS linkages between nucleotides 141-142 and 142-143,

wherein one or both nucleotides 144-145 are optionally deleted relative to SEQ ID NO: 500.

[00491] In some embodiments a single guide RNA (sgRNA) is provided, comprising:

a guide region comprising:

2'-O-Me modified nucleotides at the first four nucleotides 1-4;

PS linkages between nucleotides 1-2, 2-3, and 3-4; and

2'-O-Me modified nucleotides at nucleotides 5, 8, 9, 11, 13, 18, and 22 of the guide region;

a shortened repeat/anti-repeat region, wherein nucleotides 38-48 and 53-63 are deleted relative to SEQ ID NO: 500, comprising:

2'-O-Me modified nucleotides at nucleotides 25, 29, 30, 31, 32, 37, 49-52, 64, 65, 69, 70, and 73;

a PS linkage between nucleotides 76-77 between the shortened repeat/anti-repeat region and the shortened hairpin 1 region;

a shortened hairpin 1 region, wherein nucleotides 86 and 91 are deleted relative to SEQ ID NO: 500, comprising:

2'-O-Me modified nucleotides at nucleotides 80, 81, 83, 84, 85, 87-90, 92-94, and 99;

2'-O-Me modified nucleotide at nucleotide 101 between the shortened hairpin 1 region and the shortened hairpin 2 region;

a shortened hairpin 2 region, wherein nucleotides 112-120 and 127-135 are deleted relative to SEQ ID NO: 500, comprising:

2'-O-Me modified nucleotides at nucleotides 104, 110, 111, 122-125, 142, and 143;

PS linkage between nucleotides 141-142 and 142-143,

wherein one or both nucleotides 144-145 are optionally deleted relative to SEQ ID NO: 500.

[00492] In some embodiments a single guide RNA (sgRNA) is provided, comprising:

a guide region comprising:

2'-O-Me modified nucleotides at the first four nucleotides 1-4;

PS linkages between nucleotides 1-2, 2-3, and 3-4; and

2'-O-Me modified nucleotides at nucleotides 5, 8, 9, 11, 13,18, and 22 of the guide region;

a shortened repeat/anti-repeat region, wherein nucleotides 38-47 and 54-63 are deleted relative to SEQ ID NO: 500, comprising:

2'-O-Me modified nucleotides at nucleotides 25, 29, 30, 31, 32, 37, 48, 49-52, 64, 65, 69, 70, and 73;

a PS linkage between nucleotides 76-77 between the shortened repeat/anti-repeat region and the shortened hairpin 1 region;

a shortened hairpin 1 region, wherein nucleotides 86 and 91 are deleted relative to SEQ ID NO: 500, comprising:

2'-O-Me modified nucleotides at nucleotides 80, 81, 83, 84, 85, 87-90, 92-94, and 99;

2'-O-Me modified nucleotide at nucleotide 101 between the shortened hairpin 1 region and the shortened hairpin 2 region;

a shortened hairpin 2 region, wherein nucleotides 112-120 and 127-135 are deleted relative to SEQ ID NO: 500, comprising:

2'-O-Me modified nucleotides at nucleotides 104, 110, 111, 122-125, 142, and 143;

PS linkage between nucleotides 141-142 and 142-143;

wherein one or both nucleotides 144-145 are optionally deleted relative to SEQ ID NO: 500.

[00493] In some embodiments a single guide RNA (sgRNA) comprises:

a guide region comprising:

2'-O-Me modified nucleotides at the first two nucleotides 1-2;

PS linkages between nucleotides 1-2; and

2'-O-Me modified nucleotides at nucleotides 10 and 13 of the guide region;

a shortened repeat/anti-repeat region comprising:

nucleotides 38-48 and 53-63 are deleted relative to SEQ ID NO: 500;

2'-O-Me modified nucleotides at nucleotides 25, 29, 30, 31, 32, 37, 49-52, 64, 65, 69, 70, 73;

a PS linkage between nucleotides 76-77 between the shortened repeat/anti-repeat region and the shortened hairpin 1 region;

a shortened hairpin 1 region comprising:

nucleotides 86 and 91 are deleted relative to SEQ ID NO: 500;

2'-O-Me modified nucleotides at nucleotides 80, 81, 83, 84, 85, 87-90, 92-94, 99;

2'-O-Me modified nucleotide at nucleotide 101 between the shortened hairpin 1 region and the shortened hairpin 2 region;

a shortened hairpin 2 region comprising:

nucleotides 112-120 and 127-135 are deleted relative to SEQ ID NO: 500;

2'-O-Me modified nucleotides at nucleotides 102-105, 110, 111, 122-125, 135, 136, 138, 139, 141-143,

Three PS linkages between nucleotides 140-141, 141-142 and 142-143,

wherein the sgRNA does not comprise a 3' tail.

[00494] In some embodiments a single guide RNA (sgRNA) comprises:

a guide sequence comprising:

2'-O-Me modified nucleotides at the first four nucleotides 1-4;

PS linkages between nucleotides 1-2, 2-3, and 3-4; and

2'-O-Me modified nucleotides at nucleotides 5, 8, 9, 11, 13,18, and 22 of the guide sequence;

a shortened repeat/anti-repeat region, wherein nucleotides 38, 41-48 and 53-60, and 63 are deleted relative to SEQ ID NO: 500, comprising:

2'-O-Me modified nucleotides at nucleotides 25, 29, 30, 31, 32, 37, 39-40, 49-52, 61-62, 64, 65, 69, 70, and 73;

a PS linkage between nucleotides 76-77 between the shortened repeat/anti-repeat region and the shortened hairpin 1 region;

a shortened hairpin 1 region, wherein nucleotides 86 and 91 are deleted relative to SEQ ID NO: 500, comprising:

2'-O-Me modified nucleotides at nucleotides 80, 81, 83, 84, 85, 87-90, 92-94, and 99;

2'-O-Me modified nucleotide at nucleotide 101 between the shortened hairpin 1 region and the shortened hairpin 2 region;

a shortened hairpin 2 region, wherein nucleotides 112-120 and 127-135 are deleted relative to SEQ ID NO: 500, comprising:

2'-O-Me modified nucleotides at nucleotides 104, 110, 111, 122-125, 142, and 143,

PS linkages between nucleotides 141-142 and 142-143,

wherein one or both nucleotides 144-145 are optionally deleted relative to SEQ ID NO: 500.

[00495] In some embodiments a single guide RNA (sgRNA) comprises:

a guide sequence comprising:

2'-O-Me modified nucleotides at the first four nucleotides 1-4;

PS linkages between nucleotides 1-2, 2-3, and 3-4; and

2'-O-Me modified nucleotides at nucleotides 5, 8, 9, 11, 13,18, and 22 of the guide sequence;

a shortened repeat/anti-repeat region, wherein nucleotides 38-48 and 53-63 are deleted relative to SEQ ID NO: 500, comprising:

2'-O-Me modified nucleotides at nucleotides 25, 29, 30, 31, 32, 37, 49-52, 64, 65, 69, 70, and 73;

a shortened hairpin 1 region, wherein nucleotides 86 and 91 are deleted relative to SEQ ID NO: 500, comprising:

2'-O-Me modified nucleotides at nucleotides 80, 81, 83, 84, 85, 87-90, 92-94, and 99;

2'-O-Me modified nucleotide at nucleotide 101 between the shortened hairpin 1 region and the shortened hairpin 2 region;

a shortened hairpin 2 region, wherein nucleotides 112-120 and 127-135 are deleted relative to SEQ ID NO: 500, comprising:

2'-O-Me modified nucleotides at nucleotides 104, 110, 111, 122-125, 142, and 143,

PS linkages between nucleotides 141-142 and 142-143,

wherein one or both nucleotides 144-145 are optionally deleted relative to SEQ ID NO: 500.

[00496] In some embodiments a single guide RNA (sgRNA) comprises:

a guide sequence comprising:

2'-O-Me modified nucleotides at the first four nucleotides 1-4;

PS linkages between nucleotides 1-2, 2-3, and 3-4; and

2'-O-Me modified nucleotides at nucleotides 5, 8, 9, 11, 13,18, and 22 of the guide sequence;

a shortened repeat/anti-repeat region, wherein nucleotides 38-48 and 53-63 are deleted relative to SEQ ID NO: 500, comprising:

2'-O-Me modified nucleotides at nucleotides 25, 29, 30, 31, 32, 37, 49-52, 64, 65, 69, 70, and 73;

a PS linkage between nucleotides 76-77 between the shortened repeat/anti-repeat region and the shortened hairpin 1 region;

a shortened hairpin 1 region, wherein nucleotides 86 and 91 are deleted relative to SEQ ID NO: 500, comprising:

2'-O-Me modified nucleotides at nucleotides 80, 81, 83, 84, 85, 87-90, 92-94, and 99;

2'-O-Me modified nucleotide at nucleotide 101 between the shortened hairpin 1 region and the shortened hairpin 2 region;

a shortened hairpin 2 region, wherein nucleotides 112-120 and 127-135 are deleted relative to SEQ ID NO: 500, comprising:

2'-O-Me modified nucleotides at nucleotides 104, 106-109,110, 111, 122-125, 142, and 143,

PS linkages between nucleotides 141-142 and 142-143,

wherein one or both nucleotides 144-145 are optionally deleted relative to SEQ ID NO: 500.

[00497] In some embodiments a single guide RNA (sgRNA) comprises:

a guide sequence comprising:

2'-O-Me modified nucleotides at the first four nucleotides 1-4;

PS linkages between nucleotides 1-2, 2-3, and 3-4; and

2'-O-Me modified nucleotides at nucleotides 5, 8, 9, 11, 13,18, and 22 of the guide sequence;

a shortened repeat/anti-repeat region, wherein nucleotides 38-48 and 53-63 are deleted relative to SEQ ID NO: 500, comprising:

2'-O-Me modified nucleotides at nucleotides 25, 29, 30, 31, 32, 37, 49-52, 64, 65, 69, 70, and 73;

a shortened hairpin 1 region, wherein nucleotides 86 and 91 are deleted relative to SEQ ID NO: 500, comprising:

2'-O-Me modified nucleotides at nucleotides 80, 81, 83, 84, 85, 87-90, 92-94, and 99;

2'-O-Me modified nucleotide at nucleotide 101 between the shortened hairpin 1 region and the shortened hairpin 2 region;

a shortened hairpin 2 region, wherein nucleotides 112-120 and 127-135 are deleted relative to SEQ ID NO: 500, comprising:

2'-O-Me modified nucleotides at nucleotides 104, 106-109, 110, 111, 122-125, 142, and 143,

PS linkages between nucleotides 141-142 and 142-143,

wherein one or both nucleotides 144-145 are optionally deleted relative to SEQ ID NO: 500.

[00498] In some embodiments a single guide RNA (sgRNA) comprises:

a guide sequence comprising:

2'-O-Me modified nucleotides at the first four nucleotides 1-4;

PS linkages between nucleotides 1-2, 2-3, and 3-4; and

2'-O-Me modified nucleotides at nucleotides 5, 8, 9, 11, 13,18, and 22 of the guide sequence;

a shortened repeat/anti-repeat region, wherein nucleotides 38, 41-48 and 53-60, and 63 are deleted relative to SEQ ID NO: 500, comprising:

2'-O-Me modified nucleotides at nucleotides 25, 29, 30, 31, 32, 37, 39-40, 49-52, 61-62, 64, 65, 69, 70, and 73;

a shortened hairpin 1 region, wherein nucleotides 86 and 91 are deleted relative to SEQ ID NO: 500, comprising:

2'-O-Me modified nucleotides at nucleotides 80, 81, 83, 84, 85, 87-90, 92-94, and 99;

2'-O-Me modified nucleotide at nucleotide 101 between the shortened hairpin 1 region and the shortened hairpin 2 region;

a shortened hairpin 2 region, wherein nucleotides 112-120 and 127-135 are deleted relative to SEQ ID NO: 500, comprising:

2'-O-Me modified nucleotides at nucleotides 104, 110, 111, 122-125, 142, and 143,

PS linkages between nucleotides 141-142 and 142-143,

wherein one or both nucleotides 144-145 are optionally deleted relative to SEQ ID NO: 500.

[00499] In some embodiments a single guide RNA (sgRNA) comprises:

a guide sequence comprising:

2'-O-Me modified nucleotides at the first four nucleotides 1-4;

PS linkages between nucleotides 1-2, 2-3, and 3-4; and

2'-O-Me modified nucleotides at nucleotides 5, 8, 9, 11, 13,18, and 22 of the guide sequence;

a shortened repeat/anti-repeat region, wherein nucleotides 38, 41-48 and 53-60, and 63 are deleted relative to SEQ ID NO: 500, comprising:

2'-O-Me modified nucleotides at nucleotides 25, 29, 30, 31, 32, 37, 39-40, 49-52, 61-62, 64, 65, 69, 70, and 73;

a PS linkage between nucleotides 76-77 between the shortened repeat/anti-repeat region and the shortened hairpin 1 region;

a shortened hairpin 1 region, wherein nucleotides 86 and 91 are deleted relative to SEQ ID NO: 500, comprising:

2'-O-Me modified nucleotides at nucleotides 80, 81, 83, 84, 85, 87-90, 92-94, and 99;

2'-O-Me modified nucleotide at nucleotide 101 between the shortened hairpin 1 region and the shortened hairpin 2 region;

a shortened hairpin 2 region, wherein nucleotides 112-120 and 127-135 are deleted relative to SEQ ID NO: 500, comprising:

2'-O-Me modified nucleotides at nucleotides 104, 106-109, 110, 111, 122-125, 142, and 143,

PS linkages between nucleotides 141-142 and 142-143,

wherein one or both nucleotides 144-145 are optionally deleted relative to SEQ ID NO: 500.

[00500] In some embodiments a single guide RNA (sgRNA) comprises:

a guide sequence comprising:

2'-O-Me modified nucleotides at the first four nucleotides 1-4;

PS linkages between nucleotides 1-2, 2-3, and 3-4; and

2'-O-Me modified nucleotides at nucleotides 5, 8, 9, 11, 13,18, and 22 of the guide sequence;

a shortened repeat/anti-repeat region, wherein nucleotides 38, 41-48 and 53-60, and 63 are deleted relative to SEQ ID NO: 500, comprising:

2'-O-Me modified nucleotides at nucleotides 25, 29, 30, 31, 32, 37, 39-40, 49-52, 61-62, 64, 65, 69, 70, and 73;

a shortened hairpin 1 region, wherein nucleotides 86 and 91 are deleted relative to SEQ ID NO: 500, comprising:

2'-O-Me modified nucleotides at nucleotides 80, 81, 83, 84, 85, 87-90, 92-94, and 99;

2'-O-Me modified nucleotide at nucleotide 101 between the shortened hairpin 1 region and the shortened hairpin 2 region;

a shortened hairpin 2 region, wherein nucleotides 112-120 and 127-135 are deleted relative to SEQ ID NO: 500, comprising:

2'-O-Me modified nucleotides at nucleotides 104, 106-109, 110, 111, 122-125, 142, and 143,

PS linkages between nucleotides 141-142 and 142-143,

wherein one or both nucleotides 144-145 are optionally deleted relative to SEQ ID NO: 500.

COMPOSITIONS AND KITS

[00501] Compositions comprising any of the gRNAs described herein and a carrier, excipient, diluent, or the like are encompassed. In some instances, the excipient or diluent is inert. In some instances, the excipient or diluent is not inert. In certain embodiments, the carrier, excipient, or diluent is non-pyrogenic. In certain embodiments, the carrier, excipient, or diluent is sterile. In some embodiments, a pharmaceutical formulation is provided comprising any of the gRNAs described herein and a pharmaceutically acceptable carrier, excipient, diluent, or the like. In some embodiments, the pharmaceutical formulation further comprises an LNP. In some embodiments, the pharmaceutical formulation further comprises a Cas9 protein or an mRNA encoding a Cas9 protein. In some embodiments, the pharmaceutical formulation comprises any one or more of the gRNAs, an LNP, and a Cas protein or mRNA encoding a Cas protein. In some embodiments, the gRNA is an sgRNA. In some embodiments, the Cas protein is a monomeric Cas protein, e.g., a Cas9 protein. In some embodiments, the Cas protein is an Nme Cas protein. In some embodiments, the Cas protein includes multiple subunits.

[00502] Also provided are kits comprising one or more gRNAs, compositions, or pharmaceutical formulations described herein. In some embodiments, a kit further comprises one or more of a solvent, solution, buffer, each separate from the composition or pharmaceutical formulation, instructions, or desiccant.

Compositions comprising an RNA-guided DNA Binding Agent or mRNA encoding RNA-guided DNA Binding Agent

[00503] In some embodiments, compositions or pharmaceutical formulations are provided comprising at least one gRNA, preferably a sgRNA, described herein and an RNA-guided DNA binding agent or a nucleic acid (e.g., an mRNA) encoding an RNA-guided DNA binding agent. In some embodiments, the RNA-guided DNA binding agent is a Cas protein. In some embodiments, the gRNA together with a Cas protein or nucleic acid (e.g., mRNA)

encoding Cas protein is called a Cas RNP. In some embodiments, the RNA-guided DNA binding agent is one that functions with the gRNA to direct an RNA-guided DNA binding agent to a target nucleic acid sequence. In some embodiments, the RNA-guided DNA binding agent is a Cas protein from the Type-II CRISPR/Cas system. In some embodiments, the Cas protein is Cas9. In some embodiments, the Cas9 protein is a wild type Cas9. In some embodiments, the Cas9 protein is derived from the *Neisseria meningitidis* Cas9 (NmeCas9). In some embodiments, compositions are provided comprising at least one gRNA and a nuclease or an mRNA encoding an NmeCas9. In some embodiments, compositions are provided comprising at least one gRNA and a nuclease or an mRNA encoding an NmeCas9. In some embodiments, the Cas induces a double strand break in target DNA. Equivalents of NmeCas9 and its homologs and variants, other Cas proteins disclosed herein are encompassed by the embodiments described herein.

[00504] RNA-guided DNA binding agents, including Cas9, encompass modified and variants thereof. Modified versions having one catalytic domain, either RuvC or HNH, that is inactive are termed "nickases." Nickases cut only one strand on the target DNA, thus creating a single-strand break. A single-strand break may also be known as a "nick." In some embodiments, the compositions and methods comprise nickases. In some embodiments, the compositions and methods comprise a nickase RNA-guided DNA binding agent, such as a nickase Cas, e.g., a nickase Cas9, that induces a nick rather than a double strand break in the target DNA.

[00505] In some embodiments, the nuclease, e.g., the RNA-guided DNA binding agent, may be modified to contain only one functional nuclease domain. For example, the RNA-guided DNA binding agent may be modified such that one of the nuclease domains is mutated or fully or partially deleted to reduce its nucleic acid cleavage activity. In some embodiments, a nickase Cas is used having a RuvC domain with reduced activity. In some embodiments, a nickase Cas is used having an inactive RuvC domain. In some embodiments, a nickase Cas is used having an HNH domain with reduced activity. In some embodiments, a nickase Cas is used having an inactive HNH domain.

[00506] In some embodiments, a conserved amino acid within an RNA-guided DNA binding agent nuclease domain is substituted to reduce or alter nuclease activity. In some embodiments, a Cas protein may comprise an amino acid substitution in the RuvC or RuvC-like nuclease domain. Exemplary amino acid substitutions in the RuvC or RuvC-like nuclease domain include H588A (based on the *N. meningitidis* Cas9 protein). In some embodiments, the Cas protein may comprise an amino acid substitution in the HNH or HNH-like nuclease

domain. Exemplary amino acid substitutions in the HNH or HNH-like nuclease domain include D16A (based on the NmeCas9 protein).

[00507] In some embodiments, the RNP complex described herein comprises a nickase or an mRNA encoding a nickase and a pair of gRNAs (one or both of which may be sgRNAs) that are complementary to the sense and antisense strands of the target sequence, respectively. In this embodiment, the gRNAs (e.g., sgRNAs) direct the nickase to a target sequence and introduce a double stranded break (DSB) by generating a nick on opposite strands of the target sequence (i.e., double nicking). In some embodiments, use of double nicking may improve specificity and reduce off-target effects. In some embodiments, a nickase RNA-guided DNA binding agent is used together with two separate gRNAs (e.g., sgRNAs) that are selected to be in close proximity to produce a double nick in the target DNA.

[00508] In some embodiments, chimeric Cas proteins are used, where one domain or region of the protein is replaced by a portion of a different protein. In some embodiments, a Cas nuclease domain may be replaced with a domain from a different nuclease such as Fok1. In some embodiments, a Cas protein may be a modified nuclease.

[00509] In some embodiments, the nuclease, e.g., the RNA-guided DNA binding agent, may be modified to induce a point mutation or base change, e.g., a deamination.

[00510] In some embodiments, the Cas protein comprises a fusion protein comprising a Cas nuclease (e.g., Cas9), which is a nickase or is catalytically inactive, linked to a heterologous functional domain. In some embodiments, the Cas protein comprises a fusion protein comprising a catalytically inactive Cas nuclease (e.g., Cas9) linked to a heterologous functional domain (see, e.g., WO2014152432). In some embodiments, the catalytically inactive Cas9 is a catalytically inactive *N. meningitidis* Cas9. In some embodiments, the catalytically inactive Cas comprises mutations that inactivate the Cas. In some embodiments, the heterologous functional domain is a domain that modifies gene expression, histones, or DNA. In some embodiments, the heterologous functional domain is a transcriptional activation domain or a transcriptional repressor domain. In some embodiments, the nuclease is a catalytically inactive Cas nuclease, such as dCas9.

[00511] In some embodiments, the heterologous functional domain is a deaminase, such as a cytidine deaminase or an adenine deaminase. In certain embodiments, the heterologous functional domain is a C to T base converter (cytidine deaminase), such as an apolipoprotein B mRNA editing enzyme (APOBEC) deaminase. A heterologous functional

domain such as a deaminase may be part of a fusion protein with a Cas nuclease having nickase activity or a Cas nuclease that is catalytically inactive.

[00512] In some embodiments, the target sequence may be adjacent to a PAM. In some embodiments, the PAM may be adjacent to or within 1, 2, 3, or 4, nucleotides of the 3' end of the target sequence. The length and the sequence of the PAM may depend on the Cas protein used. For example, the PAM may be selected from a consensus or a particular PAM sequence for a specific Nme Cas9 protein or Nme Cas9 ortholog (Edraki et al., 2019). In some embodiments, the Nme Cas9 PAM may comprise 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides in length. Non-limiting exemplary PAM sequences include NCC, N4GAYW, N4GYTT, N4GTCT, NNNNCC(a), NNNNCAAA (wherein N is defined as any nucleotide, W is defined as either A or T, and R is defined as either A or G; and (a) is a preferred, but not required, A after the second C)). In some embodiments, the PAM sequence may be NCC.

[00513] In some embodiments, the heterologous functional domain may facilitate transport of the RNA-guided DNA-binding agent into the nucleus of a cell. For example, the heterologous functional domain may be a nuclear localization signal (NLS). In some embodiments, the RNA-guided DNA-binding agent may be fused with 1-10 NLS(s). In some embodiments, the RNA-guided DNA-binding agent may be fused with 1-5 NLS(s). In some embodiments, the RNA-guided DNA-binding agent may be fused with one NLS. Where one NLS is used, the NLS is preferably fused at the N-terminus of the RNA-guided DNA-binding agent sequence. It may also be inserted within the RNA-guided DNA binding agent sequence. In other embodiments, the RNA-guided DNA-binding agent may be fused with more than one NLS. In some embodiments, the RNA-guided DNA-binding agent may be fused with 2, 3, 4, or 5 NLSs. In some embodiments, the RNA-guided DNA-binding agent may be fused with two NLSs. In some embodiments, the NLSs may be fused to the N-terminus of the RNA-guided DNA binding agent sequence. In some embodiments, the NLSs may be fused to only the N-terminus of the RNA-guided DNA binding agent sequence. In some embodiments, the RNA-guided DNA binding agent may have no NLS inserted within the RNA-guided DNA-binding agent sequence. In certain embodiments, may have no NLS C-terminal to the RNA-guided DNA-binding agent sequence.

[00514] In some embodiments, the RNA-guided DNA-binding agent may be fused with two NLSs. In certain circumstances, the two NLSs may be the same (e.g., two SV40 NLSs) or different. In some embodiments, the RNA-guided DNA-binding agent is fused to two NLS sequences (e.g., SV40) at the amino terminus. In some embodiments, the RNA-guided DNA-binding agent may be fused with two NLSs, one at the N-terminus and one at the C-terminus.

In some embodiments, the RNA-guided DNA-binding agent may be fused with 3 NLSs. In some embodiments, the RNA-guided DNA-binding agent is not fused with an NLS at the C-terminus. In some embodiments, the RNA-guided DNA-binding agent does not include an NLS inserted within the RNA-guided DNA-binding agent sequence. NLS may be fused at the C-terminus of the RNA-guided DNA-binding agent. One or more linkers are optionally included at the fusion site.

[00515] In some embodiments, the NLS may be a monopartite sequence, such as, *e.g.*, the SV40 NLS, PKKKRKV (SEQ ID NO: 669) or PKKKRRV (SEQ ID NO: 670). In some embodiments, the NLS may be a bipartite sequence, such as the NLS of nucleoplasmin, KRPAATKKAGQAKKKK (SEQ ID NO: 682). In some embodiments, the NLS sequence may comprise LAAKRSRTT (SEQ ID NO: 671), QAAKRSRTT (SEQ ID NO: 672), PAPAKRERTT (SEQ ID NO: 673), QAAKRPRTT (SEQ ID NO: 674), RAAKRPRTT (SEQ ID NO: 675), AAAKRSWSMAA (SEQ ID NO: 676), AAAKRVWSMAF (SEQ ID NO: 677), AAAKRSWSMAF (SEQ ID NO: 678), AAAKRKYFAA (SEQ ID NO: 679), RAAKRKAFAA (SEQ ID NO: 680), or RAAKRKYFAV (SEQ ID NO: 681). The NLS may be a snurportin-1 importin-β (IBB domain, e.g. an SPN1-impβ sequence. See Huber et al., 2002, J. Cell Bio., 156, 467-479. In a specific embodiment, a single PKKKRKV (SEQ ID NO: 669). In some embodiments, the first and second NLS are independently selected from an SV40 NLS, a nucleoplasmin NLS, a bipartite NLS, a c-myc like NLS, and an NLS comprising the sequence KTRAD. In certain embodiments, the first and second NLSs may be the same (*e.g.*, two SV40 NLSs). In certain embodiments, the first and second NLSs may be different.

[00516] In some embodiments, the first NLS is a SV40NLS and the second NLS is a nucleoplasmin NLS.

[00517] In some embodiments, the SV40 NLS comprises a sequence of SEQ ID NO: 683 or 684. In some embodiments, the nucleoplasmin NLS comprises a sequence of SEQ ID NO: 682. In some embodiments, the bipartite NLS comprises a sequence of SEQ ID NO: 685. In some embodiments, the c-myc like NLS comprises a sequence of SEQ ID NO: 686.

[00518] In some embodiments, the RNA-guided DNA binding agent comprises an amino acid sequence with at least 90%, 93%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 100% identity to any one of SEQ ID NOs: 600-603, 605, 607-620, or 707-712 (as shown in Table 4A).

[00519] In some embodiments, a polynucleotide encoding the RNA-guided DNA binding agent comprises a nucleotide sequence with at least 90%, 93%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 100% identity to any one of SEQ ID NOs: 621-623, 626-643, 645, 647-668, 701-706, and 713-718 (NmeCas9 mRNA and ORFs as shown in Table 4A).

[00520] In some embodiments, the mRNA encoding the RNA-guided DNA binding agent comprises an open reading frame (ORF) comprising a sequence with at least 90%, 93%, 95%, 96%, 97%, 98%, or 99%, or with 100% identity to any one of SEQ ID NOs: 621-623,626-639, and 713-718 as shown in Table 4A.

METHODS OF USE

[00521] In some embodiments, any one or more of the gRNAs (e.g., sgRNAs,), compositions, or pharmaceutical formulations described herein is for use in preparing a medicament for treating or preventing a disease or disorder in a subject.

[00522] In some embodiments, the invention comprises a method of treating or preventing a disease or disorder in subject comprising administering any one or more of the gRNAs (e.g., sgRNAs), compositions, or pharmaceutical formulations described herein.

[00523] In some embodiments, the invention comprises a method or use of modifying a target DNA comprising, administering or delivering any one or more of the gRNAs (e.g., sgRNAs), compositions, or pharmaceutical formulations described herein.

[00524] In some embodiments, the invention comprises a method or use for modulation of a target gene comprising, administering or delivering any one or more of the gRNAs (e.g., sgRNAs), compositions, or pharmaceutical formulations described herein. In some embodiments, the modulation is editing of the target gene. In some embodiments, the modulation is a change in expression of the protein encoded by the target gene.

[00525] As used herein, a "gene editing" or "genetic modification" is a change at the DNA level, e.g., induced by a gRNA/Cas complex. A gene editing or genetic modification may comprise an insertion, deletion, or substitution (base substitution, e.g., C-to-T, or point mutation), typically within a defined sequence or genomic locus. A genetic modification changes the nucleic acid sequence of the DNA. A genetic modification may be at a single nucleotide position. A genetic modification may be at multiple nucleotides, e.g., 2, 3, 4, 5 or more nucleotides, typically in close proximity to each other, e.g., contiguous nucleotides.

[00526] In some embodiments, the method or use results in gene editing. In some embodiments, the method or use results in a double-stranded break within the target gene. In some embodiments, the method or use results in formation of indel mutations during non-homologous end joining of the DSB. In some embodiments, the method or use results in an insertion or deletion of nucleotides in a target gene. In some embodiments, the insertion or deletion of nucleotides in a target gene leads to a frameshift mutation or premature stop codon that results in a non-functional protein. In some embodiments, the insertion or deletion

of nucleotides in a target gene leads to a knockdown or elimination of target gene expression. In some embodiments, the method or use comprises homology directed repair of a DSB. In some embodiments, the method or use further comprises delivering to the cell a template, wherein at least a part of the template incorporates into a target DNA at or near a double strand break site induced by the nuclease. In some embodiments, the method or use results in a single strand break within the target gene. In some embodiments, the method or use results in a base change, e.g., by deamination, within the target gene. The gene editing typically occurs within or adjacent to the portion of the target gene with which the spacer sequence forms a duplex.

[00527] In some embodiments, the method or use results in gene modulation. In some embodiments, the gene modulation is an increase or decrease in gene expression, a change in methylation state of DNA, or modification of a histone subunit. In some embodiments, the method or use results in increased or decreased expression of the protein encoded by the target gene.

[00528] The efficacy of gRNAs can be tested *in vitro* and *in vivo*. In some embodiments, the invention comprises one or more of the gRNAs, compositions, or pharmaceutical formulations described herein, wherein the gRNA results in gene modulation when provided to a cell together with a Cas nuclease, e.g., Cas9 or mRNA encoding Cas9. In some embodiments, the efficacy of gRNA can be measured *in vitro* or *in vivo*.

[00529] In some embodiments, the activity of a Cas RNP comprising a gRNA is compared to the activity of a Cas RNP comprising an unmodified sgRNA or a reference sgRNA lacking modifications present in the sgRNA, such as one or more internal linkers, or shortened regions. In some embodiments, the sgRNA do not include an internal linker.

[00530] In some embodiments, the efficiency of a gRNA in increasing or decreasing target protein expression is determined by measuring the amount of target protein.

[00531] In some embodiments, the efficiency of editing with specific gRNAs is determined by the editing present at the target location in the genome following delivery of a Cas nuclease and the gRNA. In some embodiments, the efficiency of editing with specific gRNAs is measured by next-generation sequencing (NGS). In some embodiments, the editing percentage of the target region of interest is determined. In some embodiments, the total number of sequence reads with sequence alterations, e.g., insertions or deletions (indels), or base changes with no insertion or deletion, of nucleotides into the target region of interest over the total number of sequence reads is measured following delivery of a gRNA and a Cas nuclease.

[00532] In some embodiments, the efficiency of editing with specific gRNAs is measured by the presence of sequence alterations, e.g., insertions or deletions, or base substitution, or point mutation of nucleotides introduced by successful gene editing. In some embodiments, activity of a Cas nuclease and gRNAs is tested in biochemical assays. In some embodiments, activity of a Cas nuclease and gRNAs is tested in a cell-free cleavage assay. In some embodiments, activity of a Cas nuclease and gRNAs is tested in Neuro2A cells. In some embodiments, activity of a Cas nuclease and gRNAs is tested in primary cells, e.g., primary hepatocytes.

[00533] In some embodiments, the activity of modified gRNAs is measured after *in vivo* dosing of LNPs comprising modified gRNAs and Cas protein or mRNA encoding Cas protein.

[00534] In some embodiments, *in vivo* efficacy of a gRNA or composition provided herein is determined by editing efficacy measured in DNA extracted from tissue (e.g., liver tissue) after administration of gRNA and a Cas nuclease.

[00535] In some embodiments, activation of the subject's immune response is measured by serum concentrations of cytokine(s) following *in vivo* dosing of sgRNA together with Cas nuclease mRNA or protein (e.g., formulated in an LNP). In some embodiments, the cytokine is interferon-alpha (IFN-alpha), interleukin 6 (IL-6), monocyte chemotactic protein 1 (MCP-1), or tumor necrosis factor alpha (TNF-alpha).

[00536] In some embodiments, administration of Cas RNP or Cas nuclease mRNA together with the modified gRNA (e.g., sgRNA) produces lower serum concentration(s) of immune cytokines compared to administration of unmodified sgRNA. In some embodiments, the invention comprises methods comprising administering any one of the gRNAs disclosed herein to a subject, wherein the gRNA elicits a lower concentration of immune cytokines in the subject's serum as compared to a control gRNA that is not similarly modified.

DELIVERY OF GUIDE RNA

[00537] In some embodiments, the gRNA compositions, compositions, or pharmaceutical formulations disclosed herein, alone or encoded on one or more vectors, are formulated in or administered via a lipid nanoparticle; see e.g., WO2017/173054, the contents of which are hereby incorporated by reference in their entirety.

Lipids; formulation; delivery

[00538] Disclosed herein are various embodiments using lipid nucleic acid assembly compositions comprising nucleic acids(s), or composition(s) described herein. In some embodiments, the lipid nucleic acid assembly composition comprises a gRNA described herein, e.g., a gRNA comprising a guide region and a conserved region, the conserved region comprising one or more of: (a) a shortened repeat/anti-repeat region, wherein the shortened repeat/anti-repeat region lacks 2-24 nucleotides, wherein (i) one or more of nucleotides 37-48 and 53-64 is deleted and optionally one or more of nucleotides 37-64 is substituted relative to SEQ ID NO: 500; and (ii) nucleotide 36 is linked to nucleotide 65 by at least 2 nucleotides; or (b) a shortened hairpin 1 region, wherein the shortened hairpin 1 lacks 2-10, optionally 2-8 nucleotides, wherein (i) one or more of nucleotides 82-86 and 91-95 is deleted and optionally one or more of positions 82-96 is substituted relative to SEQ ID NO: 500; and (ii) nucleotide 81 is linked to nucleotide 96 by at least 4 nucleotides; or (c) a shortened hairpin 2 region, wherein the shortened hairpin 2 lacks 2-18, optionally 2-16 nucleotides, wherein (i) one or more of nucleotides 113-121 and 126-134 is deleted and optionally one or more of nucleotides 113-134 is substituted relative to SEQ ID NO: 500; and (ii) nucleotide 112 is linked to nucleotide 135 by at least 4 nucleotides; wherein one or both nucleotides 144-145 are optionally deleted relative to SEQ ID NO: 500; wherein at least 10 nucleotides are modified nucleotides.

[00539] As used herein, a "lipid nucleic acid assembly composition" refers to lipid-based delivery compositions, including lipid nanoparticles (LNPs) and lipoplexes. LNP refers to lipid nanoparticles <100nM. LNPs are formed by precise mixing a lipid component (*e.g.*, in ethanol) with an aqueous nucleic acid component and LNPs are uniform in size. Lipoplexes are particles formed by bulk mixing the lipid and nucleic acid components and are between about 100nm and 1 micron in size. In certain embodiments the lipid nucleic acid assemblies are LNPs. As used herein, a "lipid nucleic acid assembly" comprises a plurality of (*i.e.*, more than one) lipid molecules physically associated with each other by intermolecular forces. A lipid nucleic acid assembly may comprise a bioavailable lipid having a pKa value of <7.5 or <7. The lipid nucleic acid assemblies are formed by mixing an aqueous nucleic acid-containing solution with an organic solvent-based lipid solution, *e.g.*, 100% ethanol. Suitable solutions or solvents include or may contain: water, PBS, Tris buffer, NaCl, citrate buffer, ethanol, chloroform, diethyl ether, cyclohexane, tetrahydrofuran, methanol, isopropanol. A pharmaceutically acceptable buffer may optionally be comprised in a pharmaceutical formulation comprising the lipid nucleic acid

assemblies, *e.g.*, for an *ex vivo* therapy. In some embodiments, the aqueous solution comprises a gRNA described herein. In some embodiments, the aqueous solution further comprises an mRNA encoding an RNA-guided DNA binding agent, such as Cas9.

[00540] As used herein, lipid nanoparticle (LNP) refers to a particle that comprises a plurality of (i.e., more than one) lipid molecules physically associated with each other by intermolecular forces. The LNPs may be, e.g., microspheres (including unilamellar and multilamellar vesicles, e.g., "liposomes"—lamellar phase lipid bilayers that, in some embodiments, are substantially spherical—and, in more particular embodiments, can comprise an aqueous core, e.g., comprising a substantial portion of RNA molecules), a dispersed phase in an emulsion, micelles, or an internal phase in a suspension. Emulsions, micelles, and suspensions may be suitable compositions for local and/or topical delivery. See also, e.g., WO2017173054A1, the contents of which are hereby incorporated by reference in their entirety. Any LNP known to those of skill in the art to be capable of delivering nucleotides to subjects may be utilized with the guide RNAs and the nucleic acid encoding an RNA-guided nickase and the nucleic acid encoding a cytidine deaminase described herein.

[00541] In some embodiments, the aqueous solution comprises a gRNA described herein and optionally further comprises an mRNA encoding an RNA-guided DNA binding agent, such as Cas9. A pharmaceutical formulation comprising the lipid nucleic acid assembly composition may optionally comprise a pharmaceutically acceptable buffer.

[00542] In some embodiments, the lipid nucleic acid assembly compositions include an "amine lipid" (sometimes herein or elsewhere described as an "ionizable lipid" or a "biodegradable lipid"), together with an optional "helper lipid", a "neutral lipid", and a stealth lipid such as a PEG lipid. In some embodiments, the amine lipids or ionizable lipids are cationic depending on the pH.

Amine Lipids

[00543] In some embodiments, lipid nucleic acid assembly compositions comprise an "amine lipid", which is, for example an ionizable lipid such as Lipid A or its equivalents, including acetal analogs of Lipid A.

[00544] In some embodiments, the amine lipid is Lipid A, which is (9Z,12Z)-3-((4,4-bis(octyloxy)butanoyl)oxy)-2-((((3-(diethylamino)propoxy)carbonyl)oxy)methyl)propyl octadeca-9,12-dienoate, also called 3-((4,4-bis(octyloxy)butanoyl)oxy)-2-((((3-(diethylamino)propoxy)carbonyl)oxy)methyl)propyl (9Z,12Z)-octadeca-9,12-dienoate. Lipid A can be depicted as:



[00545] Lipid A may be synthesized according to WO2015/095340 (*e.g.*, pp. 84-86). In some embodiments, the amine lipid is an equivalent to Lipid A.

[00546] In some embodiments, an amine lipid is an analog of Lipid A. In some embodiments, a Lipid A analog is an acetal analog of Lipid A. In particular lipid nucleic acid assembly compositions, the acetal analog is a C4-C12 acetal analog. In some embodiments, the acetal analog is a C5-C12 acetal analog. In additional embodiments, the acetal analog is a C5-C10 acetal analog. In further embodiments, the acetal analog is chosen from a C4, C5, C6, C7, C9, C10, C11, and C12 acetal analog.

[00547] Amine lipids and other "biodegradable lipids" suitable for use in the lipid nucleic acid assemblies described herein are biodegradable *in vivo* or *ex vivo*. The amine lipids have low toxicity (*e.g.*, are tolerated in animal models without adverse effect in amounts of greater than or equal to 10 mg/kg). In some embodiments, lipid nucleic acid assemblies comprising an amine lipid include those where at least 75% of the amine lipid is cleared from the plasma or the engineered cell within 8, 10, 12, 24, or 48 hours, or 3, 4, 5, 6, 7, or 10 days. In some embodiments, lipid nucleic acid assemblies comprising an amine lipid include those where at least 50% of the nucleic acid, *e.g.*, mRNA or gRNA, is cleared from the plasma within 8, 10, 12, 24, or 48 hours, or 3, 4, 5, 6, 7, or 10 days. In some embodiments, lipid nucleic acid assemblies comprising an amine lipid include those where at least 50% of the lipid nucleic acid assembly is cleared from the plasma within 8, 10, 12, 24, or 48 hours, or 3, 4, 5, 6, 7, or 10 days, for example by measuring a lipid (*e.g.*, an amine lipid), nucleic acid, *e.g.*, RNA/mRNA, or other component. In some embodiments, lipid-encapsulated versus free lipid, RNA, or nucleic acid component of the lipid nucleic acid assembly is measured.

[00548] Biodegradable lipids include, for example the biodegradable lipids of WO/2020/219876, WO/2020/118041, WO/2020/072605, WO/2019/067992, WO/2017/173054, WO2015/095340, and WO2014/136086, and LNPs include LNP compositions described therein, the lipids and compositions of which are hereby incorporated by reference.

[00549] Lipid clearance may be measured as described in literature. *See* Maier, M.A., *et al.* Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery

of RNAi Therapeutics. *Mol. Ther.* 2013, 21(8), 1570-78 ("*Maier*"). For example, in *Maier*, LNP-siRNA systems containing luciferases-targeting siRNA were administered to six- to eight-week-old male C57Bl/6 mice at 0.3 mg/kg by intravenous bolus injection *via* the lateral tail vein. Blood, liver, and spleen samples were collected at 0.083, 0.25, 0.5, 1, 2, 4, 8, 24, 48, 96, and 168 hours post-dose. Mice were perfused with saline before tissue collection and blood samples were processed to obtain plasma. All samples were processed and analyzed by LC-MS. Further, *Maier* describes a procedure for assessing toxicity after administration of LNP-siRNA formulations. For example, a luciferase-targeting siRNA was administered at 0, 1, 3, 5, and 10 mg/kg (5 animals/group) via single intravenous bolus injection at a dose volume of 5 mL/kg to male Sprague-Dawley rats. After 24 hours, about 1 mL of blood was obtained from the jugular vein of conscious animals and the serum was isolated. At 72 hours post-dose, all animals were euthanized for necropsy. Assessments of clinical signs, body weight, serum chemistry, organ weights and histopathology were performed. Although *Maier* describes methods for assessing siRNA-LNP formulations, these methods may be applied to assess clearance, pharmacokinetics, and toxicity of administration of lipid nucleic acid assembly compositions of the present disclosure.

[00550] Ionizable and bioavailable lipids for LNP delivery of nucleic acids known in the art are suitable. Lipids may be ionizable depending upon the pH of the medium they are in. For example, in a slightly acidic medium, the lipid, such as an amine lipid, may be protonated and thus bear a positive charge. Conversely, in a slightly basic medium, such as, for example, blood where pH is approximately 7.35, the lipid, such as an amine lipid, may not be protonated and thus bear no charge.

[00551] The ability of a lipid to bear a charge is related to its intrinsic pKa. In some embodiments, the amine lipids of the present disclosure may each, independently, have a pKa in the range of from about 5.1 to about 7.4. In some embodiments, the bioavailable lipids of the present disclosure may each, independently, have a pKa in the range of from about 5.1 to about 7.4, such as from about 5.5 to about 6.6, from about 5.6 to about 6.4, from about 5.8 to about 6.2, or from about 5.8 to about 6.5. For example, the amine lipids of the present disclosure may each, independently, have a pKa in the range of from about 5.8 to about 6.5. Lipids with a pKa ranging from about 5.1 to about 7.4 are effective for delivery of cargo *in vivo*, *e.g.* to the liver. Further, it has been found that lipids with a pKa ranging from about 5.3 to about 6.4 are effective for delivery *in vivo*, *e.g.* to tumors. *See*, *e.g.*, WO2014/136086.

Additional Lipids

[00552] "Neutral lipids" suitable for use in a lipid nucleic acid assembly composition of the disclosure include, for example, a variety of neutral, uncharged or zwitterionic lipids. Examples of neutral phospholipids suitable for use in the present disclosure include, but are not limited to, 5-heptadecylbenzene-1,3-diol (resorcinol), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), pohsphocholine (DOPC), dimyristoylphosphatidylcholine (DMPC), phosphatidylcholine (PLPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DAPC), phosphatidylethanolamine (PE), egg phosphatidylcholine (EPC), dilauryloylphosphatidylcholine (DLPC), dimyristoylphosphatidylcholine (DMPC), 1-myristoyl-2-palmitoyl phosphatidylcholine (MPPC), 1-palmitoyl-2-myristoyl phosphatidylcholine (PMPC), 1-palmitoyl-2-stearoyl phosphatidylcholine (PSPC), 1,2-diarachidoyl-sn-glycero-3-phosphocholine (DBPC), 1-stearoyl-2-palmitoyl phosphatidylcholine (SPPC), 1,2-dieicosenoyl-sn-glycero-3-phosphocholine (DEPC), palmitoyloleoyl phosphatidylcholine (POPC), lysophosphatidyl choline, dioleoyl phosphatidylethanolamine (DOPE), dilinoleoylphosphatidylcholine distearoylphosphatidylethanolamine (DSPE), dimyristoyl phosphatidylethanolamine (DMPE), dipalmitoyl phosphatidylethanolamine (DPPE), palmitoyloleoyl phosphatidylethanolamine (POPE), lysophosphatidylethanolamine and combinations thereof. In one embodiment, the neutral phospholipid may be selected from the group consisting of distearoylphosphatidylcholine (DSPC) and dimyristoyl phosphatidyl ethanolamine (DMPE). In another embodiment, the neutral phospholipid may be distearoylphosphatidylcholine (DSPC).

[00553] "Helper lipids" include steroids, sterols, and alkyl resorcinols. Helper lipids suitable for use in the present disclosure include, but are not limited to, cholesterol, 5-heptadecylresorcinol, and cholesterol hemisuccinate. In one embodiment, the helper lipid may be cholesterol. In one embodiment, the helper lipid may be cholesterol hemisuccinate.

[00554] "Stealth lipids" are lipids that alter the length of time the nanoparticles can exist *in vivo* (*e.g.*, in the blood). Stealth lipids may assist in the formulation process by, for example, reducing particle aggregation and controlling particle size. Stealth lipids used herein may modulate pharmacokinetic properties of the lipid nucleic acid assembly or aid in stability of the nanoparticle *ex vivo*. Stealth lipids suitable for use in a lipid nucleic acid assembly composition of the disclosure include, but are not limited to, stealth lipids having a hydrophilic head group linked to a lipid moiety. Stealth lipids suitable for use in a lipid nucleic acid

assembly composition of the present disclosure and information about the biochemistry of such lipids can be found in Romberg *et al.*, Pharmaceutical Research, Vol. 25, No. 1, 2008, pg. 55-71 and Hoekstra *et al.*, Biochimica et Biophysica Acta 1660 (2004) 41-52. Additional suitable PEG lipids are disclosed, *e.g.*, in WO 2006/007712.

[00555] In one embodiment, the hydrophilic head group of stealth lipid comprises a polymer moiety selected from polymers based on PEG. Stealth lipids may comprise a lipid moiety. In some embodiments, the stealth lipid is a PEG lipid.

[00556] In one embodiment, a stealth lipid comprises a polymer moiety selected from polymers based on PEG (sometimes referred to as poly(ethylene oxide)), poly(oxazoline), poly(vinyl alcohol), poly(glycerol), poly(N-vinylpyrrolidone), polyaminoacids and poly[N-(2-hydroxypropyl)methacrylamide].

[00557] In one embodiment, the PEG lipid comprises a polymer moiety based on PEG (sometimes referred to as poly(ethylene oxide)).

[00558] The PEG lipid further comprises a lipid moiety. In some embodiments, the lipid moiety may be derived from diacylglycerol or diacylglycamide, including those comprising a dialkylglycerol or dialkylglycamide group having alkyl chain length independently comprising from about C4 to about C40 saturated or unsaturated carbon atoms, wherein the chain may comprise one or more functional groups such as, for example, an amide or ester. In some embodiments, the alkyl chain length comprises about C10 to C20. The dialkylglycerol or dialkylglycamide group can further comprise one or more substituted alkyl groups. The chain lengths may be symmetrical or asymmetrical.

[00559] Unless otherwise indicated, the term "PEG" as used herein means any polyethylene glycol or other polyalkylene ether polymer. In one embodiment, PEG is an optionally substituted linear or branched polymer of ethylene glycol or ethylene oxide. In one embodiment, PEG is unsubstituted. In one embodiment, the PEG is substituted, *e.g.*, by one or more alkyl, alkoxy, acyl, hydroxy, or aryl groups. In one embodiment, the term includes PEG copolymers such as PEG-polyurethane or PEG-polypropylene (see, *e.g.*, J. Milton Harris, Poly(ethylene glycol) chemistry: biotechnical and biomedical applications (1992)); in another embodiment, the term does not include PEG copolymers. In one embodiment, the PEG has a molecular weight of from about 130 to about 50,000, in a sub-embodiment, about 150 to about 30,000, in a sub-embodiment, about 150 to about 20,000, in a sub-embodiment about 150 to about 15,000, in a sub-embodiment, about 150 to about 10,000, in a sub-embodiment, about 150 to about 6,000, in a sub-embodiment, about 150 to about 5,000, in a sub-embodiment, about 150 to about 4,000, in a sub-embodiment, about 150 to about 3,000, in a sub-

embodiment, about 300 to about 3,000, in a sub-embodiment, about 1,000 to about 3,000, and in a sub-embodiment, about 1,500 to about 2,500.

[00560] In some embodiments, the PEG (*e.g.*, conjugated to a lipid moiety or lipid, such as a stealth lipid), is a "PEG-2K," also termed "PEG 2000," which has an average molecular weight of about 2,000 Daltons. PEG-2K is represented herein by the following formula (I), wherein n is 45, meaning that the number averaged degree of polymerization comprises about 45 subunits  (I). However, other PEG embodiments known in the art may be used, including, *e.g.*, those where the number-averaged degree of polymerization comprises about 23 subunits (n=23), and/or 68 subunits (n=68). In some embodiments, n may range from about 30 to about 60. In some embodiments, n may range from about 35 to about 55. In some embodiments, n may range from about 40 to about 50. In some embodiments, n may range from about 42 to about 48. In some embodiments, n may be 45. In some embodiments, R may be selected from H, substituted alkyl, and unsubstituted alkyl. In some embodiments, R may be unsubstituted alkyl. In some embodiments, R may be methyl.

[00561] In any of the embodiments described herein, the PEG lipid may be selected from PEG-dilauroylglycerol, PEG-dimyristoylglycerol (e.g., 1,2-dimyristoyl-rac-glycero-3-methylpolyoxyethylene glycol 2000 (PEG2k-DMG) or PEG-DMG (catalog # GM-020 from NOF, Tokyo, Japan), PEG-dipalmitoylglycerol, PEG-distearoylglycerol (PEG-DSPE) (catalog # DSPE-020CN, NOF, Tokyo, Japan), PEG-dilaurylglycamide, PEG-dimyristylglycamide, PEG-dipalmitoylglycamide, and PEG-distearoylglycamide, PEG-cholesterol (1-[8'-(Cholest-5-en-3[beta]-oxy)carboxamido-3',6'-dioxaoctanyl]carbamoyl-[omega]-methyl-poly(ethylene glycol), PEG-DMB (3,4-ditetradecoxylbenzyl-[omega]-methyl-poly(ethylene glycol)ether), 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG2k-DMG) (cat. #880150P from Avanti Polar Lipids, Alabaster, Alabama, USA), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG2k-DSPE) (cat. #880120C from Avanti Polar Lipids, Alabaster, Alabama, USA), 1,2-distearoyl-sn-glycerol, methoxypolyethylene glycol (PEG2k-DSG; GS-020, NOF Tokyo, Japan), poly(ethylene glycol)-2000-dimethacrylate (PEG2k-DMA), and 1,2-distearyloxypropyl-3-amine-N-[methoxy(polyethylene glycol)-2000] (PEG2k-DSA). In one embodiment, the PEG lipid may be 1,2-dimyristoyl-rac-glycero-3-methylpolyoxyethylene glycol 2000 (PEG2k-DMG). In one embodiment, the PEG lipid may be PEG2k-DMG. In one embodiment, the PEG lipid may be PEG2k-DMG. In some embodiments, the PEG lipid may

be PEG2k-DSG. In one embodiment, the PEG lipid may be PEG2k-DSPE. In one embodiment, the PEG lipid may be PEG2k-DMA. In one embodiment, the PEG lipid may be PEG2k-C-DMA. In one embodiment, the PEG lipid may be compound S027, disclosed in WO2016/010840 (paragraphs [00240] to [00244]). In one embodiment, the PEG lipid may be PEG2k-DSA. In one embodiment, the PEG lipid may be PEG2k-C11. In some embodiments, the PEG lipid may be PEG2k-C14. In some embodiments, the PEG lipid may be PEG2k-C16. In some embodiments, the PEG lipid may be PEG2k-C18.

[00562] In preferred embodiments, the PEG lipid includes a glycerol group. In preferred embodiments, the PEG lipid includes a dimyristoylglycerol (DMG) group. In preferred embodiments, the PEG lipid comprises PEG-2k. In preferred embodiments, the PEG lipid is a PEG-DMG. In preferred embodiments, the PEG lipid is a PEG-2k-DMG. In preferred embodiments, the PEG lipid is 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol2000. In preferred embodiments, the PEG-2k-DMG is 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000.

LNP delivery of gRNA

[00563] Lipid nanoparticles (LNPs) are a well-known means for delivery of nucleotide and protein cargo, and may be used for delivery of the gRNAs (e.g., sgRNAs), compositions, or pharmaceutical formulations disclosed herein. In some embodiments, the LNPs deliver nucleic acid, protein, or nucleic acid together with protein. As used herein, lipid nanoparticle (LNP) refers to a particle that comprises a plurality of (i.e., more than one) lipid molecules physically associated with each other by intermolecular forces. The LNPs may be, e.g., microspheres (including unilamellar and multilamellar vesicles, e.g., “liposomes”—lamellar phase lipid bilayers that, in some embodiments, are substantially spherical and, in more particular embodiments, can comprise an aqueous core, e.g., comprising a substantial portion of RNA molecules), a dispersed phase in an emulsion, micelles, or an internal phase in a suspension (see, e.g., WO2017173054, the contents of which are hereby incorporated by reference in their entirety). Any LNP known to those of skill in the art to be capable of delivering nucleotides to subjects may be utilized.

[00564] In some embodiments, the invention comprises a method for delivering any one of the gRNAs disclosed herein to a subject, wherein the gRNA is associated with an LNP. In some embodiments, the gRNA/LNP is also associated with a Cas nuclease or a polynucleotide (e.g., mRNA or DNA) encoding a Cas nuclease.

[00565] In some embodiments, the invention comprises a composition comprising any one of the gRNAs disclosed and an LNP. In some embodiments, the composition further comprises a Cas9 or a polynucleotide (e.g., mRNA or DNA) encoding Cas9.

[00566] In some embodiments, provided herein is a method for delivering any of the guide RNAs described herein to a cell or a population of cells or a subject, including to a cell or population of cells in a subject *in vivo*, wherein any one or more of the components is associated with an LNP. In some embodiments, the method further comprises an RNA-guided DNA-binding agent (e.g., Cas9 or a polynucleotide (e.g., mRNA or DNA) encoding Cas9).

[00567] In some embodiments, provided herein is a composition comprising any of the guide RNAs described herein or donor construct disclosed herein, alone or in combination, with an LNP. In some embodiments, the composition further comprises an RNA-guided DNA-binding agent (e.g., Cas9 or a polynucleotide (e.g., mRNA or DNA) encoding Cas9).

[00568] In some embodiments, the LNPs comprise cationic lipids. In some embodiments, the LNPs comprise (9Z,12Z)-3-((4,4-bis(octyloxy)butanoyl)oxy)-2-((((3-(diethylamino)propoxy)carbonyl)oxy)methyl)propyl octadeca-9,12-dienoate, also called 3-((4,4-bis(octyloxy)butanoyl)oxy)-2-((((3-(diethylamino)propoxy)carbonyl)oxy)methyl)propyl (9Z,12Z)-octadeca-9,12-dienoate). In some embodiments, the LNPs comprise molar ratios of a cationic lipid amine to RNA phosphate (N:P) of about 4.5. In some embodiments, the LNPs comprise is nonyl 8-((7,7-bis(octyloxy)heptyl)(2-hydroxyethyl)amino)octanoate. In some embodiments, the LNPs comprise molar ratios of a cationic lipid amine to RNA phosphate (N:P) of about 4.5-6.5. In some embodiments, the LNPs comprise molar ratios of a cationic lipid amine to RNA phosphate (N:P) of about 4.5. In some embodiments, the LNPs comprise molar ratios of a cationic lipid amine to RNA phosphate (N:P) of about 6.0.

[00569] In some embodiments, LNPs associated with the gRNAs disclosed herein are for use in preparing a medicament for treating a disease or disorder.

[00570] Electroporation is a well-known means for delivery of cargo, and any electroporation methodology may be used for delivery of any one of the gRNAs disclosed herein. In some embodiments, electroporation may be used to deliver any one of the gRNAs disclosed herein and Cas9 or a polynucleotide (e.g., mRNA or DNA) encoding Cas9.

[00571] In some embodiments, the invention comprises a method for delivering any one of the gRNAs disclosed herein to an *ex vivo* cell, wherein the gRNA is associated with an LNP or not associated with an LNP. In some embodiments, the gRNA/LNP or gRNA is also

associated with a Cas9 or a polynucleotide (e.g., mRNA or DNA) encoding Cas9. (See, e.g., PCT/US2021/029446, incorporated herein by reference)

[00572] In some embodiments, the vector comprises one or more nucleotide sequence(s) encoding an mRNA encoding an RNA-guided DNA nuclease, which can be a Cas nuclease, such as NmeCas9. In some embodiments, the vector comprises an mRNA encoding an RNA-guided DNA nuclease, which can be a Cas protein, such as Cas9. In one embodiment, the Cas9 is NmeCas9.

[00573] In some embodiments, the components can be introduced as naked nucleic acid, as nucleic acid complexed with an agent such as a liposome or poloxamer, or they can be delivered by viral vectors (e.g., adenovirus, AAV, herpesvirus, retrovirus, lentivirus). Methods and compositions for non-viral delivery of nucleic acids include electroporation, lipofection, microinjection, biolistics, virosomes, liposomes, immunoliposomes, LNPs, polycation or lipid:nucleic acid conjugates, naked nucleic acid (e.g., naked DNA/RNA), artificial virions, and agent-enhanced uptake of DNA. Sonoporation using, e.g., the Sonitron 2000 system (Rich-Mar) can also be used for delivery of nucleic acids.

[00574] In some embodiments, LNPs associated with the gRNAs disclosed herein are for use in preparing a medicament for treating a disease or disorder.

***

[00575] This description and exemplary embodiments should not be taken as limiting. For the purposes of this specification and appended claims, unless otherwise indicated, all numbers expressing quantities, percentages, or proportions, and other numerical values used in the specification and claims, are to be understood as being modified in all instances by the term “about,” to the extent they are not already so modified.

Table 4A Table of Sequences

SEQ ID No.	Description	Sequence
600	Amino acid sequence for Nme2Cas9 encoded by mRNA A	MTGAAFKPNPINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRAR RLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVANNAHA LQTGDFRTPAELALNKFEKESGHIRNQRGDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQK MLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYG KDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFSLFKTDEDITGRLKDRVQPEILEALLKHISFDKFVQI SLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETARE VGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLVRLNEKGYVEIDHALPFS RTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKECNLNDTRYVNRFLC QFVADHILLTGKGKRRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETG KVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGAHKDTLRS AKRFVKHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLEAYGGNAKQAFDPKDNPFYKKGGQLVKAVRVEKTQES GVLLNKKNAYTIADNGDMVRVDVFCKVDKKGKNQYFIVPIYAWQVAENILPDIDCKGYRIDDSYTFCFSLHKYDLIAFQKDEKSK VEFAYYINCDSSNGRFYLAWHDKGSKEQQFRISTQNLVLIQKYQVNELGKEIRPCRLKKRPPVRSGKRTADGSEFESPKKKRKVE
601	Amino acid sequence for Nme2Cas9 encoded by mRNA B	MTGAAFKPNPINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRAR RLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVANNAHA LQTGDFRTPAELALNKFEKESGHIRNQRGDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQK MLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYG KDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFSLFKTDEDITGRLKDRVQPEILEALLKHISFDKFVQI SLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETARE VGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLVRLNEKGYVEIDHALPFS RTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKECNLNDTRYVNRFLC QFVADHILLTGKGKRRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETG KVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGAHKDTLRS AKRFVKHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLEAYGGNAKQAFDPKDNPFYKKGGQLVKAVRVEKTQES GVLLNKKNAYTIADNGDMVRVDVFCKVDKKGKNQYFIVPIYAWQVAENILPDIDCKGYRIDDSYTFCFSLHKYDLIAFQKDEKSK VEFAYYINCDSSNGRFYLAWHDKGSKEQQFRISTQNLVLIQKYQVNELGKEIRPCRLKKRPPVRSGKRTADGSEFESPKKKRKVE
602	Amino acid sequence for Nme2Cas9 encoded by mRNA C	MTGAAFKPNPINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRAR RLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVANNAHA LQTGDFRTPAELALNKFEKESGHIRNQRGDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQK MLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYG KDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFSLFKTDEDITGRLKDRVQPEILEALLKHISFDKFVQI SLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETARE VGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLVRLNEKGYVEIDHALPFS RTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKECNLNDTRYVNRFLC QFVADHILLTGKGKRRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETG

		KVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGAHKDTLRS AKRFVKHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLEAYGGNAKQAFDPKDNPFYKKGGQLVKAVRVEKTQES GVLLNKKNAYTIADNGDMVRVDVFCKVDKKGKNQYFIVPIYAWQVAENILPDIDCKGYRIDDSYTFCFSLHKYDLIAFQKDEKSK VEFAYYINCDSSNGRFYLAWHDKGSKEQQFRISTQNLVLIQKYQVNELGKEIRPCRLKKRPPVRSGKRTADGSEFESPKKKRKVE
603	Amino acid sequence for Nme2Cas9 encoded by mRNA D	MTGAAFKPNPINYILGLDIGIASVGWAMVEIDEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRAR RLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVANNAHA LQTGDFRTPAELALNKFEKESGHIRNQRGDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQK MLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYG KDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFSLFKTDEDITGRLKDRVQPEILEALLKHISFDKFVQI SLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETARE VGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLVRLNEKGYVEIDHALPFS RTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKECNLNDTRYVNRFLC QFVADHILLTGKGKRRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETG KVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGAHKDTLRS AKRFVKHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLEAYGGNAKQAFDPKDNPFYKKGGQLVKAVRVEKTQES GVLLNKKNAYTIADNGDMVRVDVFCKVDKKGKNQYFIVPIYAWQVAENILPDIDCKGYRIDDSYTFCFSLHKYDLIAFQKDEKSK VEFAYYINCDSSNGRFYLAWHDKGSKEQQFRISTQNLVLIQKYQVNELGKEIRPCRLKKRPPVRSGKRTADGSEFESPKKKRKVE
604	Amino acid sequence for SpyCas9 base editor encoded by mRNA E	MEASPASGPRHLMDPHIFTSNFNNGIGRHKTYLCYEVERLDNGTSVKMDQHRGFLHNQAKNLLCGFYGRHAELRFLDLVPSLQLD PAQIYRVTWFISWSPCFSWGCAGEVRAFLQENTHVRLRIFAARIYDYDPLYKEALQMLRDAGAQVSIMTYDEFKHCWDTFVDHQG CPFQPWDGLDEHSQALSGRLRAILQNQGNSGSETPGTSESATPESDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRH SIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEV AYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAI LSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNL SDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILE KMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMT RKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDL LFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERL KTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLH EHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQL QNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKL ITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVR EINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRP LIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVV AKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSK YVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLT NLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDGGGSPKKKRKV
605	Amino acid sequence for	MAAFKPNSINYILGLDIGIASVGWAMVEIDEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRTRRL LKREGVLQAANFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVAGNAHALQ TGDFRTPAELALNKFEKESGHIRNQRSDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKML

	Nme1Cas9 encoded by mRNA F	GHCTFEPAEPKAAKNTYTAERFTWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKD NAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSPELQDEIGTAFSLFKTDEDITGRLKDRIQPEILEALLKHISFDKFVQISL KALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETARevG KSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLGRLNEKGYVEIDHALPFSRT WDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKERNLNDTRYVNRFLCQF VADRMRLTGKGKKRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGEV LHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTLEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGQGHMETVKSA KRLDEGVSVLRVPLTQLKLKDLEKMVNRERERPKLYEALKARLEAHKDDPAKAFAEPFYKYDKAGNRTQQVKAVRVEQVQKTGVWV RNHNGIADNATMVRVDVFEKGDKYYLVPIYSWQVAKGILPDRAVVQGKDEEDWQLIDDSFNFKFSLHPNDLVEVITKKARMFGYF ASCHRGTGNINIRIHDLDHKIGKNGILEGIGVKTALSFQKYQIDELGKEIRPCRLKKRPPVRSGKRTADGSEFESPKKKRKVE
606	Amino acid sequence for UGI encoded by mRNA G	MTNLSDIIEKETGKQLVIQESILMLPEEVEEVIGNKPESDILVHTAYDESTDENVMLLTSDAPEYKPWALVIQDSNGENKIKMLS GGSKRTADGSEFESPKKKRKVE
607	Amino acid sequence for Nme2Cas9 encoded by mRNA H	MAAFKPNPINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRARRL LKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVANNAHALQ TGDFRTPAELALNKFEKESGHIRNQRGDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKML GHCTFEPAEPKAAKNTYTAERFTWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKD NAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFSLFKTDEDITGRLKDRVQPEILEALLKHISFDKFVQISL KALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETARevG KSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLVRLNEKGYVEIDHALPFSRT WDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKECNLNDTRYVNRFLCQF VADHILLTGKGKRRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGKV LHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGAHKDTLRSAK RFVKHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLEAYGGNAKQAFDPKDNPFYKKGGQLVKAVRVEKTQESGV LLNKKNAYTIADNGDMVRVDVFCKVDKSGGGSPKKKRKVSGGSGKNQYFTVPIYAWQVAENILPDIDCKGYRIDDSYTFCFSLHK YDLIAFQKDEKSKVEFAYYINCDSSNGRFYLAWHDKGSKEQQFRISTQNLVLIQKYQVNELGKEIRPCRLKKRPPVR
608	Amino acid sequence for Nme2Cas9 encoded by mRNA I	MVPKKKRKVAAFKPNPINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAH RLLRARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGV ANNAHALQTGDFRTPAELALNKFEKESGHIRNQRGDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALS GDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFF KGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFSLFKTDEDITGRLKDRVQPEILEALLKHISF DKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIH IETARevGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLVRLNEKGYVEID HALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKECNLNDTRY VNRFLCQFVADHILLTGKGKRRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKT IDKETGKVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGAH KDTLRSAKRFVKHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLEAYGGNAKQAFDPKDNPFYKKGGQLVKAVRV EKTQESGVLLNKKNAYTIADNGDMVRVDVFCKVDKKGKNQYFIVPIYAWQVAENILPDIDCKGYRIDDSYTFCFSLHKYDLIAFQ

		KDEKSKVEFAYYINCDSSNGRFYLAWHDKGSKEQQFRISTQNLVLIQKYQVNELGKEIRPCRLKKRPPVRYPYDVPDYAAAPAAK KKKLD
609	Amino acid sequence for Nme2Cas9 encoded by mRNA J	MAAFKPNPINYILGLDIGIASVGWAMVEIDEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRARRL LKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVANNAHALQ TGDFRTPAELALNKFEKESGHIRNQRGDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKML GHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKD NAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFSLFKTDEDITGRLKDRVQPEILEALLKHISFDKFVQISL KALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETARE VGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFTVGEPKSKDILKLRLYEQQHGKCLYSGKEINLVRLNEKGYVEIDHA LPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKECNLNDTRY VNRFLCQFVADHILLTGKGKRRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDG KTIDKETGKVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRK MSGAHKDTLRSAKRFVKHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLEAYGGNAKQAFDPKDNPFYSRAPN RKMSGAHKDTLRSAKRFVKHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLEAYGGNAKQAFDPKDNPFY
610	Amino acid sequence for Nme2Cas9 encoded by mRNA K	MAAFKPNPINYILGLDIGIASVGWAMVEIDEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRARRL LKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVANNAHALQ TGDFRTPAELALNKFEKESGHIRNQRGDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKML GHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKD NAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFSLFKTDEDITGRLKDRVQPEILEALLKHISFDKFVQISL KALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETAREVG KSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFTVGEPKSKDILKLRLYEQQHGKCLYSGKEINLVRLNEKGYVEIDHALPFSRT WDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKECNLNDTRYVNRFLCQF VADHILLTGKGKRRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGKV LHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGAHKDTLRSAK RFVKHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLEAYGGNAKQAFDPKDNPFYSRAPNRKMSGAHKDTLRSAK RFVKHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLEAYGGNAKQAFDPKDNPFY
611	Amino acid sequence for Nme2Cas9 encoded by mRNA L	MDGSGGGSPKKKRKVGGSGGGGAAFKPNPINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLA RSVRRLTRRRAHRLLRARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGET ADKELGALLKGVANNAHALQTGDFRTPAELALNKFEKESGHIRNQRGDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGI ETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQA RKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFSLFKTDEDITGRLKDRVQP EILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVING VVRRYGSPARIHIETARFVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFTVGEPKSKDILKLRLYEQQHGKCLYSGKEINL VRLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDED GFKECNLNDTRYVNRFLCQFVADHILLTGKGKRRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFV RYKEMNAFDGKTIDKETGKVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYVTPLFV SRAPNRKMSGAHKDTLRSAKRFVKHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLEAYGGNAKQAFDPKDNPFY

		KKGGQLVKAVRVEKTQESGVLLNKKNAYTIADNGDMVRVDVFCKVDKKGKNQYFIVPIYAWQVAENILPDIDCKGYRIDDSYTFC
		FSLHKYDLIAFQKDEKSKVEFAYYINCDSSNGRFYLAWHDKGSKEQQFRISTQNLVLIQKYQVNELGKEIRPCRLKKRPPVR
612	Amino acid sequence for Nme2Cas9 with HiBiT tag encoded by mRNA M	MDGSGGGSPKKKRKVGGSGGGAAFKPNPINYILGLDIGIASVGWAMVEIDEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLA
		RSVRRLTRRRAHRLLRARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGET
		ADKELGALLKGVANNAHALQTGDFRTPAELALNKFEKESGHIRNQRGDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGI
		ETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQA
		RKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFSLFKTDEDITGRLKDRVQP
		EILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVING
		VVRRYGSPARIHIETARREVGKSKFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINL
		VRLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDED
		GFKECNLNDTRYVNRFLCQFVADHILLTGKGKRRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFV
		RYKEMNAFDGKTIDKETGKVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYVTPLFV
		SRAPNRKMSGAHKDTLRSAKRFVKHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLEAYGGNAKQAFDPKDNPFY
		KKGGQLVKAVRVEKTQESGVLLNKKNAYTIADNGDMVRVDVFCKVDKKGKNQYFIVPIYAWQVAENILPDIDCKGYRIDDSYTFC
		FSLHKYDLIAFQKDEKSKVEFAYYINCDSSNGRFYLAWHDKGSKEQQFRISTQNLVLIQKYQVNELGKEIRPCRLKKRPPVRSGK
		ATPESVSGWRLFKKIS
613	Amino acid sequence for Nme2Cas9 encoded by mRNA N	MDGSGGGSPKKKRKVGGSGGGAAFKPNPINYILGLDIGIASVGWAMVEIDEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLA
		RSVRRLTRRRAHRLLRARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGET
		ADKELGALLKGVANNAHALQTGDFRTPAELALNKFEKESGHIRNQRGDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGI
		ETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQA
		RKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFSLFKTDEDITGRLKDRVQP
		EILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVING
		VVRRYGSPARIHIETARREVGKSKFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINL
		VRLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDED
		GFKECNLNDTRYVNRFLCQFVADHILLTGKGKRRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFV
		RYKEMNAFDGKTIDKETGKVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYVTPLFV
		SRAPNRKMSGAHKDTLRSAKRFVKHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLEAYGGNAKQAFDPKDNPFY
		KKGGQLVKAVRVEKTQESGVLLNKKNAYTIADNGDMVRVDVFCKVDKKGKNQYFIVPIYAWQVAENILPDIDCKGYRIDDSYTFC
		FSLHKYDLIAFQKDEKSKVEFAYYINCDSSNGRFYLAWHDKGSKEQQFRISTQNLVLIQKYQVNELGKEIRPCRLKKRPPVRSGK
		RTADGSGGGSPAAKKKKLD
614	Amino acid sequence for Nme2Cas9 encoded by mRNA O	MDGSGGGSPKKKRKVEDKRPAATKKAGQAKKKKGGSGGGAAFKPNPINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGVRVFE
		RAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLL
		HLIKHRGYLSQRKNEGETADKELGALLKGVANNAHALQTGDFRTPAELALNKFEKESGHIRNQRGDYSHTFSRKDLQAELILLFE
		KQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTER
		ATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFS
		LFKTDEDITGRLKDRVQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEI
		RNPVVLRALSQARKVINGVVRRYGSPARIHIETAREVGKSKFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLR
		LYEQQHGKCLYSGKEINLVRLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETS
		RFPRSKKQRILLQKFDEDGFKECNLNDTRYVNRFLCQFVADHILLTGKGKRRVFASNGQITNLLRGFWGLRKVRAENDRHHALDA

		VVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGKVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAE KLSSRPEAVHEYVTPLFVSRAPNRKMSGAHKDTLRSAKRFVKHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLE AYGGNAKQAFDPKDNPFYKKGGQLVKAVRVEKTQESGVLLNKKNAYTIADNGDMVRVDVFCKVDKKGKNQYFIVPIYAWQVAENI LPDIDCKGYRIDDSYTFCFSLHKYDLIAFQKDEKSKVEFAYYINCDSSNGRFYLAWHDKGSKEQQFRISTQNLVLIQKYQVNELG KEIRPCRLKKRPPVR
615	Amino acid sequence for Nme2Cas9 with HiBiT tag encoded by mRNA P	MDGSGGGSPKKKRKVEDKRPAATKKAGQAKKKKGGSGGGAAFKPNPINYILGLDIGIASVGWAMVEIDEENPIRLIDLGVRVFE RAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLL HLIKHRGYLSQRKNEGETADKELGALLKGVANNAHALQTGDFRTPAELALNKFEKESGHIRNQRGDYSHTFSRKDLQAELILLFE KQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTER ATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFS LFKTDEDITGRLKDRVQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEI RNPVVLRALSQARKVINGVVRRYGSPARIHIETAREVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLR LYEQQHGKCLYSGKEINLVRLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETS RFPRSKKQRILLQKFDEDGFKECNLNDTRYVNRFLCQFVADHILLTGKGKRRVFASNGQITNLLRGFWGLRKVRAENDRHHALDA VVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGKVLHQKTHFPQPWEFTAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAE KLSSRPEAVHEYVTPLFVSRAPNRKMSGAHKDTLRSAKRFVKHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLE AYGGNAKQAFDPKDNPFYKKGGQLVKAVRVEKTQESGVLLNKKNAYTIADNGDMVRVDVFCKVDKKGKNQYFIVPIYAWQVAENI LPDIDCKGYRIDDSYTFCFSLHKYDLIAFQKDEKSKVEFAYYINCDSSNGRFYLAWHDKGSKEQQFRISTQNLVLIQKYQVNELG KEIRPCRLKKRPPVRSESATPESVSGWRLFKKIS
616	Amino acid sequence for Nme2Cas9 encoded by mRNA Q	MDGSGGGSEDKRPAATKKAGQAKKKKGGSGGGAAFKPNPINYILGLDIGIASVGWAMVEIDEENPIRLIDLGVRVFERAEVPKT GDSLAMARRLARSVRRLTRRRAHRLLRARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRG YLSQRKNEGETADKELGALLKGVANNAHALQTGDFRTPAELALNKFEKESGHIRNQRGDYSHTFSRKDLQAELILLFEKQKEFGN PHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEP YRKSKLTYAQARKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFSLFKTDED ITGRLKDRVQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLR ALSQARKVINGVVRRYGSPARIHIETARFVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHG KCLYSGKEINLVRLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKK QRILLQKFDEDGFKECNLNDTRYVNRFLCQFVADHILLTGKGKRRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACST VAMQQKITRFVRYKEMNAFDGKTIDKETGKVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPE AVHEYVTPLFVSRAPNRKMSGAHKDTLRSAKRFVKHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLEAYGGNAK QAFDPKDNPFYKKGGQLVKAVRVEKTQESGVLLNKKNAYTIADNGDMVRVDVFCKVDKKGKNQYFIVPIYAWQVAENILPDIDCK GYRIDDSYTFCFSLHKYDLIAFQKDEKSKVEFAYYINCDSSNGRFYLAWHDKGSKEQQFRISTQNLVLIQKYQVNELGKEIRPCR LKKRPPVR
617	Amino acid sequence for Nme2Cas9 base editor encoded by mRNA R	MDGSGGGSPKKKRKVEDKRPAATKKAGQAKKKKGGSGGGEASPASGPRHLMDPHIFTSNFNNGIGRHKTYLCYEVERLDNGTSVK MDQHRGFLHNQAKNLLCGFYGRHAELRFLDLVPSLQLDPAQIYRVTWFISWSPCFSWGCAGEVRAFLQENTHVRLRIFAARIYDY DPLYKEALQMLRDAGAQVSIMTYDEFKHCWDTFVDHQGCPFQPWDGLDEHSQALSGRLRAILQNQGNSGSETPGTSESATPESAA FKPNPINYILGLAIGIASVGWAMVEIDEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRARRLLKR EGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVANNAHALQTGD FRTPAELAINKFEKESGHIRNQRGDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHC

		TFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKDNAE
		ASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFSLFKTDEDITGRLKDRVQPEILEALLKHISFDKFVQISLKAL
		RRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETAREVGKSF
		KDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLVRLNEKGYVEIDHALPFSRTWDD
		SFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKECNLNDTRYVNRFLCQFVAD
		HILLTGKGKRRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGKVLHQ
		KTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGAHKDTLRSAKRFV
		KHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLEAYGGNAKQAFDPKDNPFYKKGGQLVKAVRVEKTQESGVLLN
		KKNAYTIADNGDMVRVDVFCKVDKKGKNQYFIVPIYAWQVAENILPDIDCKGYRIDDSYTFCFSLHKYDLIAFQKDEKSKVEFAY
		YINCDSSNGRFYLAWHDKGSKEQQFRISTQNLVLIQKYQVNELGKEIRPCRLKKRPPVRSGKRTADGSEFESPKKKRKVE
618	Amino acid sequence for Nme2Cas9 base editor encoded by mRNA S	MDGSGGGSPKKKRKVEDKRPAATKKAGQAKKKKGGSGGGEASPASGPRHLMDPHIFTSNFNNGIGRHKTYLCYEVERLDNGTSVK
		MDQHRGFLHNQAKNLLCGFYGRHAELRFLDLVPSLQLDPAQIYRVTWFISWSPCFSWGCAGEVRAFLQENTHVRLRIFAARIYDY
		DPLYKEALQMLRDAGAQVSIMTYDEFKHCWDTFVDHQGCPFQPWDGLDEHSQALSGRLRAILQNQGNSGSETPGTSESATPESAA
		FKPNPINYILGLAIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRARRLLKR
		EGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVANNAHALQTGD
		FRTPAELALNKFEKESGHIRNQRGDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHC
		TFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKDNAE
		ASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFSLFKTDEDITGRLKDRVQPEILEALLKHISFDKFVQISLKAL
		RRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETARFVGKSF
		KDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLVRLNEKGYVEIDHALPFSRTWDD
		SFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKECNLNDTRYVNRFLCQFVAD
		HILLTGKGKRRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGKVLHQ
		KTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGAHKDTLRSAKRFV
		KHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLEAYGGNAKQAFDPKDNPFYKKGGQLVKAVRVEKTQESGVLLN
		KKNAYTIADNGDMVRVDVFCKVDKKGKNQYFIVPIYAWQVAENILPDIDCKGYRIDDSYTFCFSLHKYDLIAFQKDEKSKVEFAY
		YINCDSSNGRFYLAWHDKGSKEQQFRISTQNLVLIQKYQVNELGKEIRPCRLKKRPPVR
619	Amino acid sequence for Nme2Cas9 base editor encoded by mRNA T	MEASPASGPRHLMDPHIFTSNFNNGIGRHKTYLCYEVERLDNGTSVKMDQHRGFLHNQAKNLLCGFYGRHAELRFLDLVPSLQLD
		PAQIYRVTWFISWSPCFSWGCAGEVRAFLQENTHVRLRIFAARIYDYDPLYKEALQMLRDAGAQVSIMTYDEFKHCWDTFVDHQG
		CPFQPWDGLDEHSQALSGRLRAILQNQGNSGSETPGTSESATPESAAFKPNPINYILGLAIGIASVGWAMVEIDEEENPIRLIDL
		GVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLE
		WSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVANNAHALQTGDFRTPAELALNKFEKESGHIRNQRGDYSHTFSRKDLQAE
		LILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERP
		LTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDE
		IGTAFSLFKTDEDITGRLKDRVQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPP
		IPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETARFVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSK
		DILKLRLYEQQHGKCLYSGKEINLVRLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFK
		ARVETSRFPRSKKQRILLQKFDEDGFKECNLNDTRYVNRFLCQFVADHILLTGKGKRRVFASNGQITNLLRGFWGLRKVRAENDR
		HHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGKVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKL
		RTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGAHKDTLRSAKRFVKHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEA

		LKARLEAYGGNAKQAFDPKDNPFYKKGGQLVKAVRVEKTQESGVLLNKKNAYTIADNGDMVRVDVFCKVDKKGKNQYFIVPIYAW QVAENILPDIDCKGYRIDDSYTFCFSLHKYDLIAFQKDEKSKVEFAYYINCDSSNGRFYLAWHDKGSKEQQFRISTQNLVLIQKY QVNELGKEIRPCRLKKRPPVRSGKRTADGSEFESPKKKRKVE
620	Amino acid sequence for Nme2Cas9 encoded by mRNA U	MKLGSIEFIKVNKGSGSGSGAPESATESGGTSTESEGSAGSAGSTSTESEGTSTESEGSAGTSTESEGSAGTSESA TESGGTSTESEGSSSTGAAFKPNPINYILGLDIGIASVGWAMVEIDEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVR RLTRRRAHRLLRARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKE LGALLKGVANNAHALQTGDFRTPAELALNKFEKESGHIRNQRGDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLL MTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLL GLEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFSLFKTDEDITGRLKDRVQPEILE ALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRR YGSPARIHIETARFVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLVRLN EKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKE CNLNDTRYVNRFLCQFVADHILLTGKGKRRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKE MNAFDGKTIDKETGKVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAP NRKMSGAHKDTLRSAKRFVKHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLEAYGGNAKQAFDPKDNPFYKKGG QLVKAVRVEKTQESGVLLNKKNAYTIADNGDMVRVDVFCKVDKKGKNQYFIVPIYAWQVAENILPDIDCKGYRIDDSYTFCFSLH KYDLIAFQKDEKSKVEFAYYINCDSSNGRFYLAWHDKGSKEQQFRISTQNLVLIQKYQVNELGKEIRPCRLKKRPPVRSGKRTAD GSEFESPKKKRKVE
621	mRNA B encoding Nme2Cas9	GGGAAGCUCAGAAUAAACGCUCAACUUUGGCCGGAUCUGCCACCAUGACCGGUGCCGCCUUCAAGCCCAACCCAUCACAU CCUGGGCCUGGACAUCGGCAUCGCCUCCGUGGGCUGGGCCAUGGUGGAGAUCGACGAGGAGGAGAACCCCAUCCGGCUGAUCGAC CUGGGCGUGCGGGUGUUCGAGCGGGCCGAGGUGCCCAAGACCGGCGACUCCCUGGCCCUGGCCCGGUCCCGGUCCGUGC GGCGGCUGACCCGGCGGCGGCCCACCGGCUGCUGCGGCCCGGCGGCUGCUGAAGCGGGAGGGCGUGCUGCAGGCCGCCGACUU CGACGAGAACGGCCUGAUCAAGUCCCUGCCCAACACCCCCUGGCAGCUGCGGCCGCCGCCCUGGACCCGAAGCUGACCCCCUG GAGUGGUCCGCCGUGCUGCACCUGAUCAAGCACCGGGGCUACCUGUCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGG AGCUGGGCGCCCUGCUGAAGGGCGUGGCCAACAACGCCCACGCCCUGCAGACCGGCGACUCCCCGCCGAGCUGGCCCU GAACAAGUUCGAGAAGGAGUCCGGCCACAUCCGGAACCAGCGGGGCGACUACUCCCACACCUUCUCCCGGAAGGACCUGCAGGCC GAGCUGAUCCUGCUGUUCGAGAAGCAGAAGGAGUUCGGCAACCCCCACGUGUCCGGCGGCCUGAAGGAGGGCAUCGAGACCCUGC UGAUGACCCAGCGGCCCGCCCUGUCCGGCGACGCCGUGCAGAAGAUGCUGGGCCACUGCACCUUCGAGCCCGCCGAGCCCAAGGC CGCCAAGAACACCUACACCGCCGAGCGGUUCAUCUGGCUGACCAAGCUGAACAACCUGCGGAUCCUGGAGGCAGGGCUCCGAGCGG CCCCUGACCGACACCGAGCGGGCCACCCUGAUGGACGAGCCCUACCGGAAGUCCAAGCUGACCUACGCCCAGGCCCAGGACCCGGAAGCUGC UGGGCCUGGAGGACACCGCCUUCUUCAAGGGCCUGCGGUACGGCAAGGACACAACGCCGAGGCCUCCACCCUGAUGGAGAUGAAGGC CUACCACGCCAUCUCCCGGGCCCUGGAGAAGGAGGCCUGAAGGACACAAGAAGUCCCCCCUGAACCUGUCCUCCGAGCUGCAGGAC GAGAUCGGCACCGCCUUCUCCCUGUUCAAGACCGACGAGGACAUCACCGGCCGGCUGAAGGACCGGGUGCAGCCCGAGAUCCUGG AGGCCCUGCUGAAGCACAUCUCCUUCGACAAGUUCGUGCAGAUCUCCCUGAAGGCCCUGCGGCGGAUCGUGCCCCUGAUGGAGCA GGGCAAGCGGUACGACGAGGCCUGCGCCGAGAUCUACGGCGACCACUACGGCAAGAAGAACACCGAGGAGAAGAUCUACCUGCCC CCCAUCCCCGCCGACGAGAUCCGGAACCCCGUGGUGCUGCGGGCCCUGUCCCAGGCCCGGAAGGUGAUCAACGGCGUGGUGCGGC GGUACGGCUCCCCCGCCCGGAUCCACAUCGAGACCGCCCGGGAGGUGGGCAAGUCCUUCAAGGACCGGAAGGAGAUCGAGAAGCG GCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCCAAGUUCCGGGAGUACUUCCCCCAACUUCGUGGGCGAGCCCAAGUCC AAGGACAUCCUGAAGCUGCGGCUGUACGAGCAGCACGGCAAGUGCCUGUACUCCGGCAAGGAGAUCAACCUGGUGCGGCUGA

		ACGAGAAGGGCUACGUGGAGAUCGACCACGCCCUGCCCUUCUCCCGGACCUGGGACGACUCCUUCAACAACAAGGUGCUGGUGCU GGGCUCCGAGAACCAGAACAAGGGCAACCAGACCCCCUACGAGUACUUCAACGGCAAGGACAACUCCCGGGAGUGGCAGGAGUUC AAGGCCCGGGUGGAGACCUCCCGGUUCCCCCGGUCCAAGAAGCAGCGGAUCCUGCUGCAGAAGUUCGACGAGGACGGCUUCAAGG AGUGCAACCUGAACGACACCCGGUACGUGAACCGCUUCCUGUGCCAGUUCGUGGCCGACCACAUCCUGCUGACCGGCAAGGGCAA GCGGCGGGUGUUCGCCUCCAACGGCCAGAUCACCAACCUGCUGCGGGGCUUCUGGGGCCUGCGGAAGGUGCGGGCCGAGAACGAC CGGCACCACGCCCUGGACGCCGUGGUGGUGGCCUGCUCCACCGUGGCCAUGCAGCAGAAGAUCACCCGGUUCGUGCGGUACAAGG AGAUGAACGCCUUCGACGGCAAGACCAUCGACAAGGAGACCGGCAAGGUGCUGCACCAGAAGACCCACUUCCCCCAGCCCUGGGA GUUCUUCGCCCAGGAGGUGAUGAUCCGGGUGUUCGGCAAGCCCGACGGCAAGCCCGAGUUCGAGGAGGCCGACACCCCCGAGAAG CUGCGGACCCUGCUGGCCGAGAAGCUGUCCUCCCGGCCCGAGGCCGUGCACGAGUACGUGACCCCCCUGUUCGUGUCCCGGGCCC CCAACCGGAAGAUGUCCGGCGCCCACAAGGACACCCUGCGGUCCGCCAAGCGGUUCGUGAAGCACAACGAGAAGAUCUCCGUGAA GCGGGUGUGGCUGACCGAGAUCAAGCUGGCCGACCUGGAGAACAUGGUGAACUACAAGAACGGCCGGGAGAUCGAGCUGUACGAG GCCCUGAAGGCCCGGCUGGAGGCCUACGGCGGCAACGCCAAGCAGGCCUUCGACCCCAAGGACAACCCCUUCUACAAGAAGGGCG GCCAGCUGGUGAAGGCCGUGCGGGUGGAGAAGACCCAGGAGUCCGGCGUGCUGCUGAACAAGAAGAACGCCUACACCAUCGCCGA CAACGGCGACAUGGUGCGGGUGGACGUGUUCUGCAAGGUGGACAAGAAGGGCAAGAACCAGUACUUCAUCGUGCCCAUCUACGCC UGGCAGGUGGCCGAGAACAUCCUGCCCGACAUCGACUGCAAGGGCUACCGGAUCGACGACUCCUACACCUUCUGCUUCUCCCUGC ACAAGUACGACCUGAUCGCCUUCCAGAAGGACGAGAAGUCCAAGGUGGAGUUCGCCUACUACAUCAACUGCGACUCCUCCAACGG CCGGUUCUACCUGGCCUGGCACGACAAGGGCUCCAAGGAGCAGCAGUUCCGGAUCUCCACCCAGAACCUGGUGCUGAUCCAGAAG UACCAGGUGAACGAGCUGGGCAAGGAGAUCCGGCCCUGCCGGCUGAAGAAGCGGCCCCCCGUGCGGUCCGGAAAGCGGACCGCCG ACGGCUCCGAGUUCGAGUCCCCCAAGAAGAAGCGGAAGGUGGAGUAGCUAGCACCAGCCUCAAGAACACCCGAAUGGAGUCUCUA AGCUACAUAAUACCAACUUACACUUUACAAAAUGUUGUCCCCCAAAAUGUAGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUU UCUUCACAUUCUCUCGAGAAAAAAAAAAAAAUGGAAAAAAAAAAAAACGGAAAAAAAAAAAAAGGUAAAAAAAAAAAAAUAUAAAAAAA AAAAACAUAAAAAAAAAAAAACGAAAAAAAAAAAAACGUAAAAAAAAAAAAACUCAAAAAAAAAAAAGAUAAAAAAAAAAAAACCUAAA AAAAAAAAAUGUAAAAAAAAAAAAAUCUAG
622	mRNA C encoding Nme2Cas9	GGGAAGCUCAGAAUAAACGCUCAACUUUGGCCGGAUCUGCCACCAUGACCGGUGCCGCCUUCAAGCCCAACCCCAUCAACUACAU CCUGGGCCUGGACAUCGGCAUCGCCUCCGUGGGCUGGGCCAUGGUGGAGAUCGACGAGGAGGAGAACCCCAUCCGGCUGAUCGAC CUGGGCGUGCGGGUGUUCGAGCGGGCCGAGGUGCCCAAGACCGGCGACUCCCUGGCCAUGGCCCGGCGGCUGGCCCGGUCCGUGC GGCGGCUGACCCGGCGGCGGGCCCACCGGCUGCUGCGGGCCCGGCGGCUGCUGAAGCGGGAGGGCGUGCUGCAGGCCGCCGACUU CGACGAGAACGGCCUGAUCAAGUCCCUGCCCAACACCCCCUGGCAGCUGCGGGCCGCCGCCCUGGACCGGAAGCUGACCCCCCUG GAGUGGUCCGCCGUGCUGCUGCACCUGAUCAAGCACCGGGGCUACCUGUCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGG AGCUGGGCGCCCUGCUGAAGGGCGUGGCCAACAACGCCCACGCCCUGCAGACCGGCGACUUCCGGACCCCCGCCGAGCUGGCCCU GAACAAGUUCGAGAAGGAGUCCGGCCACAUCCGGAACCAGCGGGGCGACUACUCCCACACCUUCUCCCGGAAGGACCUGCAGGCC GAGCUGAUCCUGCUGUUCGAGAAGCAGAAGGAGUUCGGCAACCCCCACGUGUCCGGCGGCCUGAAGGAGGGCAUCGAGACCCUGC UGAUGACCCAGCGGCCCGCCCUGUCCGGCGACGCCGUGCAGAAGAUGCUGGGCCACUGCACCUUCGAGCCCGCCGAGCCCAAGGC CGCCAAGAACACCUACACCGCCGAGCGGUUCAUCUGGCUGACCAAGCUGAACAACCUGCGGAUCCUGGAGCAGGGCUCCGAGCGG CCCCUGACCGACACCGAGCGGGCCACCCUGAUGGACGAGCCCUACCGGAAGUCCAAGCUGACCUACGCCCAGGCCCGGAAGCUGC UGGGCCUGGAGGACACCGCCUUCUUCAAGGGCCUGCGGUACGGCAAGGACAACGCCGAGGCCUCCACCCUGAUGGAGAUGAAGGC CUACCACGCCAUCUCCCGGGCCCUGGAGAAGGAGGGCCUGAAGGACAAGAAGUCCCCCCUGAACCUGUCCUCCGAGCUGCAGGAC GAGAUCGGCACCGCCUUCUCCCUGUUCAAGACCGACGAGGACAUCACCGGCCGGCUGAAGGACCGGGUGCAGCCCGAGAUCCUGG AGGCCCUGCUGAAGCACAUCUCCUUCGACAAGUUCGUGCAGAUCUCCCUGAAGGCCCUGCGGCGGAUCGUGCCCCUGAUGGAGCA

		GGGCAAGCGGUACGACGAGGCCUGCGCCGAGAUCUACGGCGACCACUACGGCAAGAAGGAACACCGAGGAGAAGAUCUACCUGCCC
		CCCAUCCCCGCCGACGAGAUCCGGAACCCCGUGGUGCUGCGGGCCCUGUCCCAGGCCCGGAAGGUGAUCAACGGCGUGGUGCGGC
		GGUACGGCUCCCCCCGCCCGGAUCCACAUCGAGACCGCCCGGGAGGUGGGCAAGUCCUUCAAGGACCGGAAGGAGAUCGAGAAGCG
		GCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGUUCCGGGAGUACUUCCCCAACUUCGUGGGCGAGCCCAAGUCC
		AAGGACAUCCUGAAGCUGCGGCUGUACGAGCAGCACGGCAAGUGCCUGUACUCCGGCAAGGAGAUCAACCUGGUGCGGCUGA
		ACGAGAAGGGCUACGUGGAGAUCGACCACGCCCUGCCCUUCUCCCGGACCUGGGACGACUCCUUCAACAACAAGGUGCUGGUGCU
		GGGCUCCGAGAACCAGAACAAGGGCAACCAGACCCCCUACGAGUACUUCAACGGCAAGGACAACUCCCGGGAGUGGCAGGAGUUC
		AAGGCCCGGGUGGAGACCUCCCGGUUCCCCAAGAAGCAGCGGAUCCUGCUGCAGAAGUUCGACGAGGACGGCUUCAAGG
		AGUGCAACCUGAACGACACCCGGUACGUGAACCGCUUCCUGUGCCAGUUCGUGGCCGACCACAUCCUGCUGACCGGCAAGGGCAA
		GCGGCGGGUGUUCGCCUCCAACGGCCAGAUCACCAACCUGCUGCGGGGCUUCUGGGGCCUGCGGAAGGUGCGGGCCGAGAACGAC
		CGGCACCACGCCCUGGACGCCGUGGUGGCCUGCUCCACCGUGGCCAUGCAGAAGAUCACCCGGUUCGUGCGGUACAAGGAG
		AGAUGAACGCCUUCGACGGCAAGACCAUCGACAAGGAGACCGGCAAGGUGCUGCACCAGAAGACCCACUUCCCCCAGCCCUGGGA
		GUUCUUCGCCCAGGAGGUGAUGAUCCGGUUCGGCAAGCCCGACGGCAAGCCCGAGUUCGAGGAGGCCGACACCCCCGAGAAG
		CUGCGGACCCUGCUGGCCGAGAAGCUGUCCCUCCCGGCCCGAGGCCGUGCACGAGUACGUGACCCCCCUGUUCGUGUCCCGGGCCC
		CCAACCGGAAGAUGUCCGGCGCCCACAAGGACACCCUGCGGUCCGCCAAGCGGUUCGUGAAGCACAACGAGAAGAUCUCCGUGAA
		GCGGUGUGGCUGACCGAGAUCAAGCUGGCCGACCUGGAGAACUACGGUGAACUACAAGAACGGCCGGGAGAUCGAGCUGUACGAG
		GCCCUGAAGGCCCGGCUGGAGGCCUACGGCGGCAACGCCAAGCAGGCCUUCGACCCCAAGGACAACCCCUUCUACAAGAAGGGCG
		GCCAGCUGGUGAAGGCCGUGCGGGUGGAGAAGACCCAGGAGUCCGGCGUGCUGCUGAACAAGAAGGCCUACACCAUCGCCGA
		CAACGGCGACAUGGUGCGGUGGACGUGUUCUGCAAGGUGGACAAGAAGGGCAAGAACCAGUACUUCGUGCCCAUCUACGCC
		UGGCAGGUGGCCGAGAACAUCCUGCCCGACAUCGACUGCAAGGGCUACCGGAUCGACGACUCCUACACCUUCUGCUUCUCCCUGC
		ACAAGUACGACCUGAUCGCCUUCCAGAAGGACGAGAAGUCCAAGGUGGAGUUCGCCUACUACAUCAACUGCGACUCCUCCUCCAACGG
		CCGGUUCUACCUGGCCUGGCACGACAAGGGCUCCAAGGAGCAGGCAGUUCCGGAUCUCCACCCAGAACCUGGUGCUGAUCCAGAAG
		UACCAGGUGAACGAGCUGGGCAAGGAGAUCCGGCCCUGCGGCUGAAGAAGCGGCCCCCCGUGCGGUCCGGAAAGCGGACCGCCG
		ACGGCUCCGAGUUCGAGUCCCCCAAGAAGCGGAAGGUGGAGUAGCUAGCACCAGCCUCAAGAACACCCGAAUGGAGUCUCUA
		AGCUACAUAAUACCAACUUACACUUUACAAAUGUUGUCCCCCAAAAUGUAGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUU
		UCUUCACAUUCUCUCGAGAAAAAAAAAAAAUGGAAAAAAAAAAAAACGGAAAAAAAAAAAAAGGUAAAAAAAAAAAAAUAAAAAA
		AAAAACAUAAAAAAAAAAAAAACGAAAAAAAAAAAAAAACUCAAAAAAAAAAAAAAAGAUAAAAAAAAAAAAAACCUAAA
		AAAAAAAAAUGUAAAAAAAAAAAAGGGAAAAAAAAAAAAAACGCAAAAAAAAAAAAAAACACAAAAAAAAAAAAAUGCAAAAAAAAAAU
		CGAAAAAAAAAAAAAUCUAAAAAAAAAAAAAAACGAAAAAAAAAAAAAAACCCAAAAAAAAAAAAAAAGACAAAAAAAAAAAAAAAUAGAAAAAAAAAA
		AAAGUUAAAAAAA
623	mRNA D encoding Nme2Cas9	GGGAAGCUCAGAAUAAACGCUCAACUUUGGCCGGAUCUGCCACCAUGACCGGUGCCGCCUUCAAGCCCAACCCCAUCAACUACAU
		CCUGGGCCUGGACAUCGGCAUCGCCUCCGUGGGCUGGGCCAUGGUGGAGAUCGACGAGGAGGAACCCCAUCCGGCUGAUCGAC
		CUGGGCGUGCGGGUGUUCGAGCGGGCCGAGGUGCCCAAGACCGGCGACUCCCUGGCCAUGGCCCGGCGGCUGGCCCGGUCCGUGC
		GGCGGCUGACCCGGCGGCGGCCCACCGGCUGCUGCGGGCCCGGCGGCUGCUGAAGCGGGAGGGCGUGCUGCAGGCCGCCGACUU
		CGACGAGAACGGCCUGAUCAAGUCCCUGCCCAACACCCCCUGGCAGCUGCGGGCCGCCGCCCUGGACCGGAAGCUGACCCCCCUG
		GAGUGGUCCGCCGUGCUGCACCUGAUCAAGCACCGGGGCUACCUGUCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGG
		AGCUGGGCGCCCUGCUGAAGGGCGUGGCCAACGCCCACGCCCUGCAGACCGGCGACUUCCGGACCCCCGCCGAGCUGGCCCU
		GAACAAGUUCGAGAAGGAGUCCGGCCACAUCCGGAACCAGCGGGGCGACUACUCCCACACCUUCUCCCGGAAGGACCUGCAGGCC
		GAGCUGAUCCUGCUGUUCGAGAAGCAGAAGGAGUUCGGCAACCCCCACGUGUCCGGCGCCUGAAGGAGGGCAUCGAGACCCUGC

		UGAUGACCCAGCGGCCCGCCCUGUCCGGCGACGCCGUGCAGAAGAUGCUGGGCCACUGCACCUUCGAGCCCGCCGAGCCCAAGGC CGCCAAGAACACCUACACCGCCGAGCGGUUCAUCUGGCUGACCAAGCUGAACAACCUGCGGAUCCUGGAGCAGGGCUCCGAGCGG CCCCUGACCGACACCGAGCGGGCCACCCUGAUGGACGAGCCCUACCGGAAGUCCAAGCUGACCUACGCCCAGGCCCGGAAGCUGC UGGGCCUGGAGGACACCGCCUUCUUCAAGGGCCUGCGGUACGGCAAGGACAACGCCGAGGCCUCCACCCUGAUGGAGAUGAAGGC CUACCACGCCAUCUCCCGGGCCCUGGAGAAGGAGGGCCUGAAGGACAAGAAGUCCCCCCUGAACCUGUCCUCCGAGCUGCAGGAC GAGAUCGGCACCGCCUUCUCCCUGUUCAAGACCGACGAGGACAUCACCGGCCGGCUGAAGGACCGGGUGCAGCCCGAGAUCCUGG AGGCCCUGCUGAAGCACAUCUCCUUCGACAAGUUCGUGCAGAUCUCCCUGAAGGCCCUGCGGCGGAUCGUGCCCCUGAUGGAGCA GGGCAAGCGGUACGACGAGGCCUGCGCCGAGAUCUACGGCGACCACUACGGCAAGAAGAACACCGAGGAGAAGAUCUACCUGCCC CCCAUCCCCGCCGACGAGAUCCGGAACCCCGUGGUGCUGCGGGCCCUGUCCCAGGCCCGGAAGGUGAUCAACGGCGUGGUGCGGC GGUACGGCUCCCCCGCCCGGAUCCACAUCGAGACCGCCCGGGAGGUGGGCAAGUCCUUCAAGGACCGGAAGGAGAUCGAGAAGCG GCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGUUCCGGGAGUACUUCCCCAACUUCGUGGGCGAGCCCAAGUCC AAGGACAUCCUGAAGCUGCGGCUGUACGAGCAGCAGCACGGCAAGUGCCUGUACUCCGGCAAGGAGAUCAACCUGGUGCGGCUGA ACGAGAAGGGCUACGUGGAGAUCGACCACGCCCUGCCCUUCUCCCGGACCUGGGACGACUCCUUCAACAACAAGGUGCUGGUGCU GGGCUCCGAGAACCAGAACAAGGGCAACCAGACCCCCUACGAGUACUUCAACGGCAAGGACAACUCCCGGGAGUGGCAGGAGUUC AAGGCCCGGGUGGAGACCUCCCGGUUCCCCCGGUCCAAGAAGCAGCGGAUCCUGCUGCAGAAGUUCGACGAGGACGGCUUCAAGG AGUGCAACCUGAACGACACCCGGUACGUGAACCGCUUCCUGUGCCAGUUCGUGGCCGACCACAUCCUGCUGACCGGCAAGGGCAA GCGGCGGGUGUUCGCCUCCAACGGCCAGAUCACCAACCUGCUGCGGGGCUUCUGGGGCCUGCGGAAGGUGCGGGCCGAGAACGAC CGGCACCACGCCCUGGACGCCGUGGUGGUGGCCUGCUCCACCGUGGCCAUGCAGCAGAAGAUCACCCGGUUCGUGCGGUACAAGG AGAUGAACGCCUUCGACGGCAAGACCAUCGACAAGGAGACCGGCAAGGUGCUGCACCAGAAGACCCACUUCCCCCAGCCCUGGGA GUUCUUCGCCCAGGAGGUGAUGAUCCGGGUGUUCGGCAAGCCCGACGGCAAGCCCGAGUUCGAGGAGGCCGACACCCCCGAGAAG CUGCGGACCCUGCUGGCCGAGAAGCUGUCCUCCCGGCCCGAGGCCGUGCACGAGUACGUGACCCCCCUGUUCGUGUCCCGGGCCC CCAACCGGAAGAUGUCCGGCGCCCACAAGGACACCCUGCGGUCCGCCAAGCGGUUCGUGAAGCACAACGAGAAGAUCUCCGUGAA GCGGGUGUGGCUGACCGAGAUCAAGCUGGCCGACCUGGAGAACAUGGUGAACUACAAGAACGGCCGGGAGAUCGAGCUGUACGAG GCCCUGAAGGCCCGGCUGGAGGCCUACGGCGGCAACGCCAAGCAGGCCUUCGACCCCAAGGACAACCCCUUCUACAAGAAGGGCG GCCAGCUGGUGAAGGCCGUGCGGGUGGAGAAGACCCAGGAGUCCGGCGUGCUGCUGAACAAGAAGAACGCCUACACCAUCGCCGA CAACGGCGACAUGGUGCGGGUGGACGUGUUCUGCAAGGUGGACAAGAAGGGCAAGAACCAGUACUUCAUCGUGCCCAUCUACGCC UGGCAGGUGGCCGAGAACAUCCUGCCCGACAUCGACUGCAAGGGCUACCGGAUCGACGACUCCUACACCUUCUGCUUCUCCCUGC ACAAGUACGACCUGAUCGCCUUCCAGAAGGACGAGAAGUCCAAGGUGGAGUUCGCCUACUACAUCAACUGCGACUCCUCCAACGG CCGGUUCUACCUGGCCUGGCACGACAAGGGCUCCAAGGAGCAGCAGUUCCGGAUCUCCACCCAGAACCUGGUGCUGAUCCAGAAG UACCAGGUGAACGAGCUGGGCAAGGAGAUCCGGCCCUGCCGGCUGAAGAAGCGGCCCCCCGUGCGGUCCGGAAAGCGGACCGCCG ACGGCUCCGAGUUCGAGUCCCCCAAGAAGAAGCGGAAGGUGGAGUAGCUAGCACCAGCCUCAAGAACACCCGAAUGGAGUCUCUA AGCUACAUAAUACCAACUUACACUUUACAAAAUGUUGUCCCCCAAAAUGUAGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUU UCUUCACAUUCUCUCGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAUCUAG
624	mRNA E encoding SpyCas9 base editor	GGGAAGCUCAGAAUAAACGCUCAACUUUGGCCGGAUCUGCCACCAUGGAGGCCUCCCCCGCCUCCGGCCCCCGGCACCUGAUGGA CCCCCACAUCUUCACCUCCAACUUCAACAACGGCAUCGGCCGGCACAAGACCUACCUGUGCUACGAGGUGGAGCGGCUGGACAAC GGCACCUCCGUGAAGAUGGACCAGCACCGGGGCUUCCUGCACAACCAGGCCAAGAACCUGCUGUGCGGCUUCUACGGCCGGCACG CCGAGCUGCGGUUCCUGGACCUGGUGCCCUCCCUGCAGCUGGACCCCGCCCAGAUCUACCGGGUGACCUGGUUCAUCUCCUGGUC CCCCUGCUUCUCCUGGGGCUGCGCCGGCGAGGUGCGGGCCUUCCUGCAGGAGAACACCCACGUGCGGCUGCGGAUCUUCGCCGCC

CGGAUCUACGACUACGACCCCCUGUACAAGGAGGCCCUGCAGAUGCUGCGGGACGCCGGCGCCCAGGUGUCCAUCAUGACCUACG		
ACGAGUUCAAGCACUGCUGGGACACCUUCGUGGACCACCAGGGCUGCCCCUUCCAGCCCUGGGACGGCCUGGACGAGCACUCCCA		
GGCCCUGUCCGGCCGGCUGCGGCCAUCCUGCAGAACCAGGGCAACUCCGGCUCCGAGACCCCCGGCACCUCCGAGUCCGCCACC		
CCCGAGUCCGACAAGAAGUACUCCAUCGGCCUGGCCAUCGGCACCAACUCCGUGGGCUGGGCCGUGAUCACCGACGAGUACAAGG		
UGCCCUCCAAGAAGUUCAAGGUGCUGGGCAACACCGACCGGCACUCCAUCAAGAAGAACCUGAUCGGCGCCCUGCUGUUCGACUC		
CGGCGAGACCGCCGAGGCCACCCGGCUGAAGCGGACCGCCCGGCGGCGGUACACCCGGCGGAAGAACCGGAUCUGCUACCUGCAG		
GAGAUCUUCUCCAACGAGAUGGCCAAGGUGGACGACUCCUUCUUCCACCGGCUGGAGGAGUCCUUCCUGGUGGAGGAGGACAAGA		
AGCACGAGCGGCACCCCAUCUUCGGCAACAUCGUGGACGAGGUGGCCUACCACGAGAAGUACCCCACCAUCUACCACCUGCGGAA		
GAAGCUGGUGGACUCCACCGACAAGGCCGACCUGCGGCUGAUCUACCUGGCCCUGGCCCACAUGAUCAAGUUCCGGGGCCACUUC		
CUGAUCGAGGGCGACCUGAACCCCGACAACUCCGACGUGGACAAGCUGUUCAUCCAGCUGGUGCAGACCUACAACCAGCUGUUCG		
AGGAGAACCCCAUCAACGCCUCCGGCGUGGACGCCAAGGCCAUCCUGUCCGCCCGGCUGUCCAAGUCCCGGCGCCUGGAGAACCU		
GAUCGCCCAGCUGCCCGGCGAGAAGAAGAACGGCCUGUUCGGCAACCUGAUCGCCCUGUCCCUGGGCCUGACCCCCAACUUCAAG		
UCCAACUUCGACCUGGCCGAGGACGCCAAGCUGCAGCUGUCCAAGGACACCUACGACGACGACCUGGACAACCUGCUGGCCCAGA		
UCGGCGACCAGUACGCCGACCUGUUCCUGGCCGCCAAGAACCUGUCCGACGCCAUCCUGCUGUCCGACAUCCUGCGGGUGAACAC		
CGAGAUCACCAAGGCCCCCCUGUCCGCCUCCAUGAUCAAGCGGUACGACGAGCACCACCAGGACCUGACCCUGAAGGCCCUG		
GUGCGGCAGCUGCCCGAGAAGUACAAGGAGAUCUUCUUCGACCAGUCCAAGAACGGCUACGCCGGCUACAUCGACGGCGGCG		
CCUCCCAGGAGGAGUUCUACAAGUUCAUCAAGCCCAUCCUGGAGAAGAUGGACGGCACCGAGGAGCUGCUGGUGAAGCUGAACCG		
GGAGGACCUGCUGCGGAAGCAGCGGACCUUCGACAACGGCUCCAUCCCCCACCAGAUCCACCUGGGCGAGCUGCACGCCAUCCUG		
CGGCGGCAGGAGGACUUCUACCCCUUCCUGAAGGACAACCGGGAGAAGAUCGAGAAGAUCCUGACCUUCCGGAUCCCCUACUACG		
UGGGCCCCCUGGCCCGGGGCAACUCCCGGUUCGCCUGGAUGACCCGGAAGUCCGAGGAGACCAUCACCCCCUGGAACUUCGAGGA		
GGUGGUGGACAAGGGCGCCUCCGCCCAGUCCUUCAUCGAGCGGAUGACCAACUUCGACAAGAACCUGCCCAACGAGAAGGUGCUG		
CCCAAGCACUCCCUGCUGUACGAGUACUUCACCGUGUACAACGAGCUGACCAAGGUGAAGUACGUGACCGAGGGCAUGCGGAAGC		
CCGCCUUCCUGUCCGGCGAGCAGAAGAAGGCCAUCGUGGACCUGCUGUUCAAGACCAACCGGAAGGUGACCGUGAAGCAGCUGAA		
GGAGGACUACUUCAAGAAGAUCGAGUGCUUCGACUCCGUGGAGAUCUCCGGCGUGGAGGACCGGUUCAACGCCUCCCUGGGCACC		
UACCACGACCUGCUGAAGAUCAUCAAGGACAAGGACUUCCUGGACAACGAGGAGAACGAGGACAUCCUGGAGGACAUCGUGCUGA		
CCCUGACCCUGUUCGAGGACCGGGAGAUGAUCGAGGAGCGGCUGAAGACCUACGCCCACCUGUUCGACGACAAGGUGAUGAAGCA		
GCUGAAGCGGCGGCGGUACACCGGCUGGGGCCGGCUGUCCCGGAAGCUGAUCAACGGCAUCCGGGACAAGCAGUCCGGCAAGACC		
AUCCUGGACUUCCUGAAGUCCGACGGCUUCGCCAACCGGAACUUCCAUGCAGCUGAUCCACGACUCCCUGACCUUCAAGGAGG		
ACAUCCAGAAGGCCCAGGUGUCCGGCCAGGGCGACUCCCUGCACGAGCACAUCGCCAACCUGGCCGGCUCCCCCGCCAUCAAGAA		
GGGCAUCCUGCAGACCGUGAAGGUGGUGGACGAGCUGGUGAAGGUGAUGGGCCGGCACAAGCCCGAGAACAUCGUGAUCGAGAUG		
GCCCGGGAGAACCAGACCACCCAGAAGGGCCAGAAGAACUCCCGGGAGCGGAUGAAGCGGAUCGAGGAGGGCAUCAAGGAGCUGG		
GCUCCCAGAUCCUGAAGGAGCACCCCGUGGAGAACACCCAGCUGCAGAACGAGAAGCUGUACCUGUACUACCUGCAGAACGGCCG		
GGACAUGUACGUGGACCAGGAGCUGGACAUCAACCGGCUGUCCGACUACGACGUGGACCACAUCGUGCCCCAGUCCUUCCUGAAG		
GACGACUCCAUCGACAACAAGGUGCUGACCCGGUCCGACAAGAACCGGGGCAAGUCCGACAACGUGCCCUCCGAGGAGGUGGUGA		
AGAAGAUGAAGAACUACUGGCGGCAGCUGCUGAACGCCAAGCUGAUCACCCAGCGGAAGUUCGACAACCUGACCAAGGCCGAGCG		
GGGCGGCCUGUCCGAGCUGGACAAGGCCGGCUUCAUCAAGCGGCAGCUGGUGGAGACCCGCAGAUCACCAAGCACGUGGCCCAG		
AUCCUGGACUCCCGGAUGAACACCAAGUACGACGAGAACGACAAGCUGAUCCGGGAGGUGAAGGUGAUCACCCUGAAGUCCAAGC		
UGGUGUCCGACUUCCGGAAGGACUUCCAGUUCUACAAGGUGCGGGAGAUCAACAACUACCACCACGCCCACGACGCCUACCUGAA		
CGCCGUGGUGGGCACCGCCCUGAUCAAGAAGUACCCCAAGCUGGAGUUCGUGUACGGCGACUACAAGGUGUACGACGUG		

		CGGAAGAUGAUCGCCAAGUCCGAGCAGGAGAUCGGCAAGGCCACCGCCAAGUACUUCUUCUACUCCAACAUCAUGAACUUCUUCA AGACCGAGAUCACCCUGGCCAACGGCGAGAUCCGGAAGCGGCCCCUGAUCGAGACCAACGGCGAGACCGGCGAGAUCGUGUGGGA CAAGGGCCGGGACUUCGCCACCGUGCGGAAGGUGCUGUCCAUGCCCCAGGUGAACAUCGUGAAGAAGACCGAGGUGCAGACCGGC GGCUUCUCCAAGGAGUCCAUCCUGCCCAAGCGGAACUCCGACAAGCUGAUCGCCCGGAAGAAGGACUGGGACCCCAAGAAGUACG GCGGCUUCGACUCCCCCACCGUGGCCUACUCCGUGCUGGUGGUGGCCAAGGUGGAGAAGGGCAAGUCCAAGAAGCUGAAGUCCGU GAAGGAGCUGCUGGGCAUCACCAUCAUGGAGCGGUCCUCCUUCGAGAAGAACCCCAUCGACUUCCUGGAGGCCAAGGGCUACAAG GAGGUGAAGAAGGACCUGAUCAUCAAGCUGCCCAAGUACUCCCUGUUCGAGCUGGAGAACGGCCGGAAGCGGAUGCUGGCCUCCG CCGGCGAGCUGCAGAAGGGCAACGAGCUGGCCCUGCCCUCCAAGUACGUGAACUUCCUGUACCUGGCCUCCCACUACGAGAAGCU GAAGGGCUCCCCCGAGGACAACGAGCAGAAGCAGCUGUUCGUGGAGCAGCACAAGCACUACCUGGACGAGAUCAUCGAGCAGAUC UCCGAGUUCUCCAAGCGGGUGAUCCUGGCCGACGCCAACCUGGACAAGGUGCUGUCCGCCUACAACAAGCACCGGGACAAGCCCA UCCGGGAGCAGGCCGAGAACAUCAUCCACCUGUUCACCCUGACCAACCUGGGCGCCCCCGCCGCCUUCAAGUACUUCGACACCAC CAUCGACCGGAAGCGGUACACCUCCACCAAGGAGGUGCUGGACGCCACCCUGAUCCACCAGUCCAUCACCGGCCUGUACGAGACC CGGAUCGACCUGUCCCAGCUGGGCGGCGACGGCGGCGGCUCCCCCAAGAAGAAGCGGAAGGUGUGACUAGCACCAGCCUCAAGAA CACCCGAAUGGAGUCUCUAAGCUACAUAAUACCAACUUACACUUUACAAAAUGUUGUCCCCCAAAAUGUAGCCAUUCGUAUCUGC UCCUAAUAAAAAGAAAGUUUCUUCACAUUCUCUCGAGAAAAAAAAAAAAAUGGAAAAAAAAAAAAACGGAAAAAAAAAAAAAGGUAAA AAAAAAAAAUAUAAAAAAAAAAAAACAUAAAAAAAAAAAAACGAAAAAAAAAAAAACGUAAAAAAAAAAAAACUCAAAAAAAAAAAAAGA UAAAAAAAAAAAAACCUAAAAAAAAAAAAAUGUAAAAAAAAAAAAAGGGAAAAAAAAAAAAACGCAAAAAAAAAAAAACACAAAAAAAAA AAAUGCAAAAAAAAAAAAAUCGAAAAAAAAAAAAAUCUAAAAAAAAAAAAACGAAAAAAAAAAAAACCCAAAAAAAAAAAAAGACAAAAA AAAAAAAUAGAAAAAAAAAAAAAGUUAAAAAAAAAAAAACUGAAAAAAAAAAAAAUUUAAAAAAAAAAAAAUCUAG
625	mRNA G encoding UGI	GGGAAGCUCAGAAUAAACGCUCAACUUUGGCCGGAUCUGCCACCAUGACCAACCUGUCCGACAUCAUCGAGAAGGAGACCGGCAA GCAGCUGGUGAUCCAGGAGUCCAUCCUGAUGCUGCCCGAGGAGGUGGAGGAGGUGAUCGGCAACAAGCCCGAGUCCGACAUCCUG GUGCACACCGCCUACGACGAGUCCACCGACGAGAACGUGAUGCUGCUGACCUCCGACGCCCCCGAGUACAAGCCCUGGGCCCUGG UGAUCCAGGACUCCAACGGCGAGAACAAGAUCAAGAUGCUGUCCGGCGGCUCCAAGCGGACCGCCGACGGCUCCGAGUUCGAGUC CCCCAAGAAGAAGCGGAAGGUGGAGUGAUAGCUAGCACCAGCCUCAAGAACACCCGAAUGGAGUCUCUAAGCUACAUAAUACCAA CUUACACUUUACAAAAUGUUGUCCCCCAAAAUGUAGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUCUCG AGAAAAAAAAAAAAAUGGAAAAAAAAAAAAACGGAAAAAAAAAAAAAGGUAAAAAAAAAAAAAUAUAAAAAAAAAAAAACAUAAAAAAAAA AAAACGAAAAAAAAAAAAACGUAAAAAAAAAAAAACUCAAAAAAAAAAAAAGAUAAAAAAAAAAAAACCUAAAAAAAAAAAAAUGUAAAA AAAAAAAAGGGAAAAAAAAAAAAACGCAAAAAAAAAAAAACACAAAAAAAAAAAAAUGCAAAAAAAAAAAAAUCGAAAAAAAAAAAAAUC UAAAAAAAAAAAAACGAAAAAAAAAAAAACCCAAAAAAAAAAAAAGACAAAAAAAAAAAAAUAGAAAAAAAAAAAAAGUUAAAAAAAAAAA AACUGAAAAAAAAAAAAAUUUAAAAAAAAAAAAAUCUAG
626	mRNA H encoding Nme2Cas9	GGGaagctcagaataaacgctcaactttggccggatctgccacCATGGCCGCCTTCAAGCCCAACCCCATCAACTACATCCTGGG CCTGGACATCGGCATCGCCTCCGTGGGCTGGGCCATGGTGGAGATCGACGAGGAGGAGAACCCCATCCGGCTGATCGACCTGGGC GTGCGGGTGTTCGAGCGGGCCGAGGTGCCCAAGACCGGCGACTCCCTGGCCATGGCCCGGCGGCTGGCCCGGTCCGTGCGGCGGC TGACCCGGCGGCGGGCCCACCGGCTGCTGCGGGCCCGGCGGCTGCTGAAGCGGGAGGGCGTGCTGCAGGCCGCCGACTTCGACGA GAACGGCCTGATCAAGTCCCTGCCCAACACCCCCTGGCAGCTGCGGGCCGCCGCCCTGGACCGGAAGCTGACCCCCCTGGAGTGG TCCGCCGTGCTGCTGCACCTGATCAAGCACCGGGGCTACCTGTCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCTGG GCGCCCTGCTGAAGGGCGTGGCCAACAACGCCCACGCCCTGCAGACCGGCGACTTCCGGACCCCCGCCGAGCTGGCCCTGAACAA GTTCGAGAAGGAGTCCGGCCACATCCGGAACCAGCGGGGCGACTACTCCCACACCTTCTCCCGGAAGGACCTGCAGGCCGAGCTG ATCCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGTGTCCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGA

		CCCAGCGGCCCGCCCTGTCCGGCGACGCCGTGCAGAAGATGCTGGGCCACTGCACCTTCGAGCCCGCCGAGCCCAAGGCCGCCAA
		GAACACCTACACCGCCGAGCGGTTCATCTGGCTGACCAAGCTGAACAACCTGCGGATCCTGGAGCAGGGCTCCGAGCGGCCCCTG
		ACCGACACCGAGCGGCCACCCTGATGGACGAGCCCTACCGGAAGTCCAAGCTGACCTACGCCCAGGCCCGGAAGCTGCTGGGCC
		TGGAGGACACCGCCTTCTTCAAGGGCCTGCGGTACGGCAAGGACAACGCCGAGGCCTCCACCCTGATGGAGATGAAGGCCTACCA
		CGCCATCTCCCGGGCCCTGGAGAAGGAGGGCCTGAAGGACAAGAAGTCCCCCCTGAACCTGTCCTCCGAGCTGCAGGACGAGATC
		GGCACCGCCTTCTCCCTGTTCAAGACCGACGAGGACATCACCGGCCGGCTGAAGGACCGGGTGCAGCCCGAGATCCTGGAGGCCC
		TGCTGAAGCACATCTCCTTCGACAAGTTCGTGCAGATCTCCCTGAAGGCCCTGCGGCGGATCGTGCCCCTGATGGAGCAGGGCAA
		GCGGTACGACGAGGCCTGCGCCGAGATCTACGGCGACCACTACGGCAAGAAGAACACCGAGGAGAAGATCTACCTGCCCCCCATC
		CCCGCCGACGAGATCCGGAACCCCGTGGTGCTGCGGGCCCTGTCCCAGGCCCGGAAGGTGATCAACGGCGTGGTGCGGCGGTACG
		GCTCCCCCGCCCGGATCCACATCGAGACCGCCCGGGAGGTGGGCAAGTCCTTCAAGGACCGGAAGGAGATCGAGAAGCGGCAGGA
		GGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGTTCCGGGAGTACTTCCCCAACTTCGTGGGCGAGCCCAAGTCCAAGGAC
		ATCCTGAAGCTGCGGCTGTACGAGCAGCAGCACGGCAAGTGCCTGTACTCCGGCAAGGAGATCAACCTGGTGCGGCTGAACGAGA
		AGGGCTACGTGGAGATCGACCACGCCTCCCTGCCCTTCTCCCGGACCTGGGACGACTCCTTCAACAACAAGGTGCTGGTGCTGGGCTC
		CGAGAACCAGAACAAGGGCAACCAGACCCCCTACGAGTACTTCAACGGCAAGGACAACTCCCGGGAGTGGCAGGAGTTCAAGGCC
		CGGGTGGAGACCTCCCGGTTCCCCCGGTCCAAGAAGCAGCGGATCCTGCTGCAGAAGTTCGACGAGGACGGCTTCAAGGAGTGCA
		ACCTGAACGACACCCGGTACGTGAACCGGTTCCTGTGCCAGTTCGTGGCCGACCACATCCTGCTGACCGGCAAGGGCAAGCGGCG
		GGTGTTCGCCTCCAACGGCCAGATCACCAACCTGCTGCGGGGCTTCTGGGGCCTGCGGAAGGTGCGGGCCGAGAACGACCGGCAC
		CACGCCCTGGACGCCGTGGTGGTGGCCTGCTCCACCGTGGCCATGCAGCAGAAGATCACCCGGTTCGTGCGGTACAAGGAGATGA
		ACGCCTTCGACGGCAAGACCATCGACAAGGAGACCGGCAAGGTGCTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTT
		CGCCCAGGAGGTGATGATCCGGGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACACCCCCGAGAAGCTGCGG
		ACCCTGCTGGCCGAGAAGCTGTCCTCCCGGCCCGAGGCCGTGCACGAGTACGTGACCCCCCTGTTCGTGTCCCGGGCCCCCAACC
		GGAAGATGTCCGGCGCCCACAAGGACACCCTGCGGTCCGCCAAGCGGTTCGTGAAGCACAACGAGAAGATCTCCGTGAAGCGGGT
		GTGGCTGACCGAGATCAAGCTGGCCGACCTGGAGAACATGGTGAACTACAAGAACGGCCGGGAGATCGAGCTGTACGAGGCCCTG
		AAGGCCCGGCTGGAGGCCTACGGCGGCAACGCCAAGCAGGCCTTCGACCCCAAGGACAACCCCTTCTACAAGAAGGGCGGCCAGC
		TGGTGAAGGCCGTGCGGGTGGAGAAGACCCAGGAGTCCGGCGTGCTGCTGAACAAGAAGAACGCCTACACCATCGCCGACAACGG
		CGACATGGTGCGGGTGGACGTGTTCTGCAAGGTGGACAAGTCCGGCGGCGGCTCCCCCAAGAAGCGGAAGGTGTCCGGCGGC
		TCCGGCAAGAACCAGTACTTCATCGTGCCCATCTACGCCTGGCAGGTGGCCGAGAACATCCTGCCCGACATCGACTGCAAGGGCT
		ACCGGATCGACGACTCCTACACCTTCTGCTTCTCCCTGCACAAGTACGACCTGATCGCCTTCCAGAAGGACGAGAAGTCCAAGGT
		GGAGTTCGCCTACTACATCAACTGCGACTCCTCCAACGGCCGGTTCTACCTGGCCTGGCACGACAAGGGCTCCAAGGAGCAGCAG
		TTCCGGATCTCCACCCAGAACCTGGTGCTGATCCAGAAGTACCAGGTGAACGAGCTGGGCAAGGAGATCCGGCCCTGCCGGCTGA
		AGAAGCGGCCCCCCGTGCGGTAGCTAGCaccagcctcaagaacacccgaatggagtctcttaagctacataataccaacttacact
		ttacaaaatgttgtccccaaaatgtagccattcgtatctgctccctaataaaaagaaagttttcttcacatttctCTCGAGAAAAAA
		AAAAAATGGAAAAAAAAAAAAAAGGTAAAAAAAAAAAAAAATATAAAAAAAAAAAAAACATAAAAAAAAAAAAAACGAA
		AAAAAAAAAAGTAAAAAAAAAAAAACTCAAAAAAAAAAAAAAGATAAAAAAAAAAAAAACCTAAAAAAAAAAAAAATGTAAAAAAAAAAAAAA
		GGGAAAAAAAAAAAAACGCAAAAAAAAAAAAACACAAAAAAAAAAAAAAATGCAAAAAAAAAAAAAAATCGAAAAAAAAAAAAAAATCTAAAAAAA
		AAAACGAAAAAAAAAAAAAAACCCAAAAAAAAAAAAAAAGACAAAAAAAAAAAAAAATAGAAAAAAAAAAAAAAGTTAAAAAAAAAAAAACTGAAA
		AAAAAAAATTTAAAAAAAAAAAAAT
627	mRNA I encoding Nme2Cas9	GGGaagctcagaataaacgctcaactttggccggatctgccacCATGGTGCCCAAGAAGAAGCGGAAGGTGGCCGCCTTCAAGCC
		CAACCCCATCAACTACATCCTGGGCCTGGACATCGGCATCGGCATCGCCTCCGTGGGCTGGGCCATGGTGGAGATCGACGAGGAGGAGAAC

CCCATCCGGCTGATCGACCTGGGCGTGCGGGTGTTCGAGCGGGCCGAGGTGCCCAAGACCGGCGACTCCCTGGCCATGGCCCGGC
GGCTGGCCCGGTCCGTGCGGCGGCTGACCCGGCGGCGGCCCACCGGCTGCTGCGGGCCCGGCGGCTGCTGAAGCGGGAGGGCGT
GCTGCAGGCCGCCGACTTCGACGAGAACGGCCTGATCAAGTCCCTGCCCAACACCCCCTGGCAGCTGCGGGCCGCCGCCCTGGAC
CGGAAGCTGACCCCCCCTGGAGTGGTCCGCCGTGCTGCTGCACCTGATCAAGCACCGGGGCTACCTGTCCCAGCGGAAGAACGAGG
GCGAGACCGCCGACAAGGAGCTGGGCGGCCCTGCTGAAGGGCGTGGCCAACAACGCCCACGCCCTGCAGACCGGCGACTTCCGGAC
CCCCGCCGAGCTGGCCCTGAACAAGTTCGAGAAGGAGTCCGGCCACATCCGGAACCAGCGCGGGCGACTACTCCCACACCTTCTCC
CGGAAGGACCTGCAGGCCGAGCTGATCCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCCACGTGTCCGGCGGCCTGAAGG
AGGGCATCGAGACCCTGCTGATGACCCAGCGGCCCGCCCTGTCCGGCGACGCCGTGCAGAAGATGCTGGGCCACTGCACCTTCGA
GCCCGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGCGGTTCATCTGGCTGACCAAGCTGAACAACCTGCGGATCCTG
GAGCAGGGCTCCGAGCGGCCCCTGACCGACACCGAGCGGGCCACCCTGATGGACGAGCCCTACCGGAAGTCCAAGCTGACCTACG
CCCAGGCCCGGAAGCTGCTGGGCCTGGAGGACACCGCCTTCTTCAAGGGCCTGCGGTACGGCAAGGACAACGCCGAGGCCTCCAC
CCTGATGGAGATGAAGGCCTACCACGCCATCTCCCGGGCCCTGGAGAAGGAGGCCTGAAGGACAAGAAGTCCCCCCTGAACCTG
TCCTCCGAGCTGCAGGACGAGATCGGCACCGCCTTCTCCCTGTTCAAGACCGACGAGGACATCACCGGCCGGCTGAAGGACCGGG
TGCAGCCCGAGATCCTGGAGGCCCTGCTGAAGCACATCTCCTTCGACAAGTTCGTGCAGATCTCCCTGAAGGCCCTGCGGCGGAT
CGTGCCCCTGATGGAGCAGGGCAAGCGGTACGACGAGGCCTGCGCCGAGATCTACGGCGACCACTACGGCAAGAAGAACACCGAG
GAGAAGATCTACCTGCCCCCCATCCCCGCCGACGAGATCCGGAACCCCGTGGTGCTGCGGGCCCTGTCCCAGGCCCGGAAGGTGA
TCAACGGCGTGGTGCGGCCGGTACGGCTCCCCCGCCCGGATCCACATCGAGACCGCCCGGGAGGTGGGCAAGTCCTTCAAGGACCG
GAAGGAGATCGAGAAGCGGCAGGAGAGGAAGGACCGGGAGAAGGCCGCCGCCAAGTTCCGGGAGTACTTCCCCCAACTTC
GTGGGCGAGCCCAAGTCCAAGGACATCCTGAAGCTGCGGCTGTACGAGCAGCAGCACGGCAAGTGCCTGTACTCCGGCAAGGAGA
TCAACCTGGTGCGGCTGAACGAGAAGGGCTACGTGGAGATCGACCACGCCCTGCCCTTCTCCCGGACCTGGGACGACTCCTTCAA
CAACAAGGTGCTGGTGCTGGGCTCCGAGAACCAGAACAAGGGCAACCAGACCCCCTACGAGTACTTCAACGGCAAGGACAACTCC
CGGGAGTGGCAGGAGTTCAAGGCCCGGGTGGAGACCTCCCCGGTTCCCCCGGTCCAAGAAGCAGCGGATCCTGCTGCAGAAGTTCG
ACGAGGACGGCTTCAAGGAGTGCAACCTGAACGACACCCGGTACGTGAACCGGTTCCTGTGCGTGGCCGACCACATCCT
GCTGACCGGCAAGGGCAAGCGGCGGGTGTTCGCCTCCAACGGCCAGATCACCAACCTGCTGCGGGGCTTCTGGGGCCTGCGGAAG
GTGCGGGCCGAGAACGACCGGCACCACGCCCTGGACGCCGTGGTGGTGGCCTGCTCCACCGTGGCCATGCAGCAGAAGATCACCC
GGTTCGTGCGGTACAAGGAGATGAACGCCTTCGACGGCAAGACCATCGACAAGGAGACCGGCAAGGTGCTGCACCAGAAGACCCA
CTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCCGGGTGTTCGGCAAGCCCGAGTTCGAGGAG
GCCGACACCCCCGAGAAGCTGCGGACCCTGCTGGCCGAGAAGCTGTCCTCCCGGCCCGAGGCCGTGCACGAGTACGTGACCCCCC
TGTTCGTGTCCCGGGCCCCCAACCGGAAGATGTCCGGCGCCCACAAGGACACCCTGCGGTCCGCCAAGCGGTTCGTGAAGCACAA
CGAGAAGATCTCCGTGAAGCGGGTGTGGCTGACCGAGATCAAGCTGGAGAACATGGTGAACTACAAGAACGGCCGG
GAGATCGAGCTGTACGAGGCCCTGAAGGCCCTGGAGGCCTACGGCGGCAACGCCAAGCAGGCCTTCGACCCCAAGGACAACC
CCTTCTACAAGAAGGGCGGCCAGCTGGTGAAGGCCGTGCGGGTGGAGAAGACCCAGGAGTCCGGCGTGCTGCTGAACAAGAAGAA
CGCCTACACCATCGCCGACAACGGCGACATGGTGCGGGTGGACGTGTTCTGCAAGGTGGACAAGAAGGGCAAGAACCAGTACTTC
ATCGTGCCCATCTACGCCTGGCAGGTGGCCGAGAACATCCTGCCCGACATCGACTGCAAGGGCTACCGGATCGACGACTCCTACA
CCTTCTGCTTCTCCCTGCACAAGTACGACCTGATCGCCTTCCAGAAGGACGAGAAGTCCAAGGTGGAGTTCGCCTACTACATCAA
CTGCGACTCCTCCAACGGCCGGTTCTACCTGGCCTGGCACGACAAGGGCTCCAAGGAGCAGCAGTTCCGGATCTCCACCCAGAAC
CTGGTGCTGATCCAGAAGTACCAGGTGAACGAGCTGGGCAAGGAGATCCGGCCCTGCCGGCTGAAGAAGCGGCCCCCCGTGCGGT
ACCCCTACGACGTGCCCGACTACGCCGCCCTGCGCCCCCGCCGCCAAGAAGAAGCTGGACTAGCTAGCaccagcctcaagaacacc
cgaatggagtctctaagctacataataccaacttacacttacaaaatgttgtccccaaaatgtagccattcgtatctgctcct

		aataaaaagaaagtttcttcacattctCTCGAGAAAAAAAAAAAAATGGAAAAAAAAAAAAACGGAAAAAAAAAAAAAGGTAAAAAAA AAAAATATAAAAAAAAAAAAACATAAAAAAAAAAAAACGAAAAAAAAAAAAACGTAAAAAAAAAAAAACTCAAAAAAAAAAAAAGATAAA AAAAAAAAACCTAAAAAAAAAAAAATGTAAAAAAAAAAAAAGGGAAAAAAAAAAAAACGCAAAAAAAAAAAAACACAAAAAAAAAAAAAT GCAAAAAAAAAAAAATCGAAAAAAAAAAAAATCTAAAAAAAAAAAAACGAAAAAAAAAAAAACCCAAAAAAAAAAAAAGACAAAAAAAAA AAATAGAAAAAAAAAAAAAGTTAAAAAAAAAAAAACTGAAAAAAAAAAAAATTTAAAAAAAAAAAAAT
628	mRNA J encoding Nme2Cas9	GGGAAGCUCAGAAUAAACGCUCAACUUUGGCCGGAUCUGCCACCAUGGUGCCCAAGAAGAAGCGGAAGGUGGAGGACAAGCGGCC CGCCGCCACCAAGAAGGCCGGCCAGGCCAAGAAGAAGAAGAUGGCCGCCUUCAAGCCCAACCCCAUCAACUACAUCCUGGGCCUG GACAUCGGCAUCGCCUCCGUGGGCUGGGCCAUGGUGGAGAUCGACGAGGAGGAGAACCCCAUCCGGCUGAUCGACCUGGGCGUGC GGGUGUUCGAGCGGGCCGAGGUGCCCAAGACCGGCGACUCCCUGGCCAUGGCCCGGCGGCUGGCCCGGUCCGUGCGGCGGCUGAC CCGGCGGCGGGCCCACCGGCUGCUGCGGGCCCGGCGGCUGCUGAAGCGGGAGGGCGUGCUGCAGGCCGCCGACUUCGACGAGAAC GGCCUGAUCAAGUCCCUGCCCAACACCCCCUGGCAGCUGCGGGCCGCCGCCCUGGACCGGAAGCUGACCCCCCUGGAGUGGUCCG CCGUGCUGCUGCACCUGAUCAAGCACCGGGGCUACCUGUCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCUGGGCGC CCUGCUGAAGGGCGUGGCCAACAACGCCCACGCCCUGCAGACCGGCGACUUCCGGACCCCCGCCGAGCUGGCCCUGAACAAGUUC GAGAAGGAGUCCGGCCACAUCCGGAACCAGCGGGGCGACUACUCCCACACCUUCUCCCGGAAGGACCUGCAGGCCGAGCUGAUCC UGCUGUUCGAGAAGCAGAAGGAGUUCGGCAACCCCCACGUGUCCGGCGGCCUGAAGGAGGGCAUCGAGACCCUGCUGAUGACCCA GCGGCCCGCCCUGUCCGGCGACGCCGUGCAGAAGAUGCUGGGCCACUGCACCUUCGAGCCCGCCGAGCCCAAGGCCGCCAAGAAC ACCUACACCGCCGAGCGGUUCAUCUGGCUGACCAAGCUGAACAACCUGCGGAUCCUGGAGCAGGGCUCCGAGCGGCCCCUGACCG ACACCGAGCGGGCCACCCUGAUGGACGAGCCCUACCGGAAGUCCAAGCUGACCUACGCCCAGGCCCGGAAGCUGCUGGGCCUGGA GGACACCGCCUUCUUCAAGGGCCUGCGGUACGGCAAGGACAACGCCGAGGCCUCCACCCUGAUGGAGAUGAAGGCCUACCACGCC AUCUCCCGGGCCCUGGAGAAGGAGGGCCUGAAGGACAAGAAGUCCCCCCUGAACCUGUCCUCCGAGCUGCAGGACGAGAUCGGCA CCGCCUUCUCCCUGUUCAAGACCGACGAGGACAUCACCGGCCGGCUGAAGGACCGGGUGCAGCCCGAGAUCCUGGAGGCCCUGCU GAAGCACAUCUCCUUCGACAAGUUCGUGCAGAUCUCCCUGAAGGCCCUGCGGCGGAUCGUGCCCCUGAUGGAGCAGGGCAAGCGG UACGACGAGGCCUGCGCCGAGAUCUACGGCGACCACUACGGCAAGAAGAACACCGAGGAGAAGAUCUACCUGCCCCCCAUCCCCG CCGACGAGAUCCGGAACCCCGUGGUGCUGCGGGCCCUGUCCCAGGCCCGGAAGGUGAUCAACGGCGUGGUGCGGCGGUACGGCUC CCCCGCCCGGAUCCACAUCGAGACCGCCCGGGAGGUGGGCAAGUCCUUCAAGGACCGGAAGGAGAUCGAGAAGCGGCAGGAGGAG AACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGUUCCGGGAGUACUUCCCCAACUUCGUGGGCGAGCCCAAGUCCAAGGACAUCC UGAAGCUGCGGCUGUACGAGCAGCAGCACGGCAAGUGCCUGUACUCCGGCAAGGAGAUCAACCUGGUGCGGCUGAACGAGAAGGG CUACGUGGAGAUCGACCACGCCCUGCCCUUCUCCCGGACCUGGGACGACUCCUUCAACAACAAGGUGCUGGUGCUGGGCUCCGAG AACCAGAACAAGGGCAACCAGACCCCCUACGAGUACUUCAACGGCAAGGACAACUCCCGGGAGUGGCAGGAGUUCAAGGCCCGGG UGGAGACCUCCCGGUUCCCCCGGUCCAAGAAGCAGCGGAUCCUGCUGCAGAAGUUCGACGAGGACGGCUUCAAGGAGUGCAACCU GAACGACACCCGGUACGUGAACCGGUUCCUGUGCCAGUUCGUGGCCGACCACAUCCUGCUGACCGGCAAGGGCAAGCGGCGGGUG UUCGCCUCCAACGGCCAGAUCACCAACCUGCUGCGGGGCUUCUGGGGCCUGCGGAAGGUGCGGGCCGAGAACGACCGGCACCACG CCCUGGACGCCGUGGUGGUGGCCUGCUCCACCGUGGCCAUGCAGCAGAAGAUCACCCGGUUCGUGCGGUACAAGGAGAUGAACGC CUUCGACGGCAAGACCAUCGACAAGGAGACCGGCAAGGUGCUGCACCAGAAGACCCACUUCCCCCAGCCCUGGGAGUUCUUCGCC CAGGAGGUGAUGAUCCGGGUGUUCGGCAAGCCCGACGGCAAGCCCGAGUUCGAGGAGGCCGACACCCCCGAGAAGCUGCGGACCC UGCUGGCCGAGAAGCUGUCCUCCCGGCCCGAGGCCGUGCACGAGUACGUGACCCCCCUGUUCGUGUCCCGGGCCCCCAACCGGAA GAUGUCCGGCGCCCACAAGGACACCCUGCGGUCCGCCAAGCGGUUCGUGAAGCACAACGAGAAGAUCUCCGUGAAGCGGGUGUGG CUGACCGAGAUCAAGCUGGCCGACCUGGAGAACAUGGUGAACUACAAGAACGGCCGGGAGAUCGAGCUGUACGAGGCCCUGAAGG CCCGGCUGGAGGCCUACGGCGGCAACGCCAAGCAGGCCUUCGACCCCAAGGACAACCCCUUCUACAAGAAGGGCGGCCAGCUGGU

		GAAGGCCGUGCGGGUGGAGAAGACCCAGGAGUCCGGCGUGCUGCUGAACAAGAAGAACGCCUACACCAUCGCCGACAACGGCGAC AUGGUGCGGGUGGACGUGUUCUGCAAGGUGGACAAGAAGGGCAAGAACCAGUACUUCAUCGUGCCCAUCUACGCCUGGCAGGUGG CCGAGAACAUCCUGCCCGACAUCGACUGCAAGGGCUACCGGAUCGACGACUCCUACACCUUCUGCUUCUCCCUGCACAAGUACGA CCUGAUCGCCUUCCAGAAGGACGAGAAGUCCAAGGUGGAGUUCGCCUACUACAUCAACUGCGACUCCUCCAACGGCCGGUUCUAC CUGGCCUGGCACGACAAGGGCUCCAAGGAGCAGCAGUUCCGGAUCUCCACCCAGAACCUGGUGCUGAUCCAGAAGUACCAGGUGA ACGAGCUGGGCAAGGAGAUCCGGCCCUGCCGGCUGAAGAAGCGGCCCCCGUGCGGGAGGACAAGCGGCCCGCCGCCACCAAGAA GGCCGGCCAGGCCAAGAAGAAGAAGUACCCCUACGACGUGCCCGACUACGCCGGCUACCCCUACGACGUGCCCGACUACGCCGGC UCCUACCCCUACGACGUGCCCGACUACGCCGCCGCCCCCGCCGCCAAGAAGAAGAAGCUGGACUAGCUAGCACCAGCCUCAAGAA CACCCGAAUGGAGUCUCUAAGCUACAUAAUACCAACUUACACUUUACAAAAUGUUGUCCCCCAAAAUGUAGCCAUUCGUAUCUGC UCCUAAUAAAAAGAAAGUUUCUUCACAUUCUCUCGAGAAAAAAAAAAAAAUGGAAAAAAAAAAAAAACGGAAAAAAAAAAAAAGGUAAA AAAAAAAAAUAUAAAAAAAAAAAAACAUAAAAAAAAAAAAACGAAAAAAAAAAAAACGUAAAAAAAAAAAAACUCAAAAAAAAAAAAAGA UAAAAAAAAAAAAACCUAAAAAAAAAAAAAUGUAAAAAAAAAAAAAGGGAAAAAAAAAAAAACGCAAAAAAAAAAAAACACAAAAAAAAA AAAUGCAAAAAAAAAAAAAUCGAAAAAAAAAAAAAUCUAAAAAAAAAAAAACGAAAAAAAAAAAAACCCAAAAAAAAAAAAAGACAAAAA AAAAAAAUAGAAAAAAAAAAAAAGUUAAAAAAAAAAAAACUGAAAAAAAAAAAAAUUUAAAAAAAAAAAAAUCUAG
629	mRNA K encoding Nme2Cas9	GGGaagctcagaataaacgctcaactttggccggatctgccacCatggccgccttcaagcccaaccccatcaactacatcctggg cctggacatcggcatcgcctccgtgggctgggccatggtggagatcgacgaggaggagaaccccatccggctgatcgacctgggc gtgcgggtgttcgagcgggccgaggtgcccaagaccggcgactccctggccatggcccggcggctggcccggtccgtgcggcggc tgacccggcggcgggcccaccggctgctgcgggcccggcggctgctgaagcgggagggcgtgctgcaggccgccgacttcgacga gaacggcctgatcaagtccctgcccaacacccccctggcagctgcgggccgccgccctggaccggaagctgacccccctggagtgg tccgccgtgctgctgcacctgatcaagcaccggggctacctgtcccagcggaagaacgagggcgagaccgccgacaaggagctgg gcgccctgctgaagggcgtggccaacaacgcccacgccctgcagaccggcgacttccggacccccgccgagctggccctgaacaa gttcgagaaggagtccggccacatccggaaccagcggggcgactactcccacaccttctcccggaaggacctgcaggccgagctg atcctgctgttcgagaagcagaaggagttcggcaacccccacgtgtccggcggcctgaaggagggcatcgagaccctgctgatga cccagcggcccgccctgtccggcgacgccgtgcagaagatgctgggccactgcaccttcgagcccgccgagcccaaggccgccaa gaacacctacaccgccgagcggttcatctggctgaccaagctgaacaacctgcggatcctggagcagggctccgagcggcccctg accgacaccgagcgggccaccctgatggacgagccctaccggaagtccaagctgacctacgcccaggcccggaagctgctgggcc tggaggacaccgccttcttcaagggcctgcggtacggcaaggacaacgccgaggcctccaccctgatggagatgaaggcctacca cgccatctcccgggccctggagaaggagggcctgaaggacaagaagtcccccctgaacctgtcctccgagctgcaggacgagatc ggcaccgccttctccctgttcaagaccgacgaggacatcaccggccggctgaaggaccgggtgcagcccgagatcctggaggccc tgctgaagcacatctccttcgacaagttcgtgcagatctccctgaaggccctgcggcggatcgtgcccctgatggagcagggcaa gcggtacgacgaggcctgcgccgagatctacggcgaccactacggcaagaagaacaccgaggagaagatctacctgccccccatc cccgccgacgagatccggaaccccgtggtgctgcgggccctgtcccaggcccggaaggtgatcaacggcgtggtgcggcggtacg gctcccccgcccggatccacatcgagaccgcccgggaggtgggcaagtccttcaaggaccggaaggagatcgagaagcggcagga ggagaaccggaaggaccgggagaaggccgccgccaagttccgggagtacttccccaacttcgtgggcgagcccaagtccaaggac atcctgaagctgcggctgtacgagcagcagcacggcaagtgcctgtactccggcaaggagatcaacctggtgcggctgaacgaga agggctacgtggagatcgaccacgccctgcccttctcccggacctgggacgactccttcaacaacaaggtgctggtgctgggctc cgagaaccagaacaagggcaaccagacccccctacgagtacttcaacggcaaggacaactcccgggagtggcaggagttcaaggcc cgggtggagacctcccggttcccccggtccaagaagcagcggatcctgctgcagaagttcgacgaggacggcttcaaggagtgca acctgaacgacacccggtacgtgaaccggttcctgtgccagttcgtggccgaccacatcctgctgaccggcaagggcaagcggcg

		ggtgttcgcctccaacggccagatcaccaacctgctgcggggcttctggggcctgcggaaggtgcgggccgagaacgaccggcac cacgccctggacgccgtggtggtggcctgctccaccgtggccatgcagcagaagatcacccggttcgtgcggtacaaggagatga acgccttcgacggcaagaccatcgacaaggagaccggcaaggtgctgcaccagaagacccacttcccccagccctgggagttctt cgcccaggaggtgatgatccgggtgttcggcaagcccgacggcaagcccgagttcgaggaggccgacacccccgagaagctgcgg accctgctggccgagaagctgtcctcccggcccgaggccgtgcacgagtacgtgacccccctgttcgtgtcccgggcccccaacc ggaagatgtccggcgcccacaaggacaccctgcggtccgccaagcggttcgtgaagcacaacgagaagatctccgtgaagcgggt gtggctgaccgagatcaagctggccgacctggagaacatggtgaactacaagaacggccgggagatcgagctgtacgaggccctg aaggcccggctggaggcctacggcggcaacgccaagcaggccttcgaccccaaggacaaccccttctacaagaagggcggccagc tggtgaaggccgtgcgggtggagaagacccaggagtccggcgtgctgctgaacaagaagaacgcctacaccatcgccgacaacgg cgacatggtgcgggtggacgtgttctgcaaggtggacaagaagggcaagaaccagtacttcatcgtgcccatctacgcctggcag gtggccgagaacatcctgcccgacatcgactgcaagggctaccggatcgacgactcctacaccttctgcttctccctgcacaagt acgacctgatcgccttccagaaggacgagaagtccaaggtggagttcgcctactacatcaactgcgactcctccaacggccggtt ctacctggcctggcacgacaagggctccaaggagcagcagttccggatctccacccagaacctggtgctgatccagaagtaccag gtgaacgagctgggcaaggagatccggccctgccggctgaagaagcggcccccgtgcggTCCGGAAAGCGGACCGCCGACGGCT CCGGAGGAGGAAGCCCCAAGAAGAAGCGGAAGGTGtagctagcaccagcctcaagaacacccgaatggagtctctaagctacata ataccaacttacactttacaaaatgttgtcccccaaaatgtagccattcgtatctgctcctaataaaaagaaagtttcttcacat tctctcgagAAAAAAAAAAAATGGAAAAAAAAAAAACGGAAAAAAAAAAAAGGTAAAAAAAAAAAATATAAAAAAAAAAAACATA AAAAAAAAAAACGAAAAAAAAAAAACGTAAAAAAAAAAACTCAAAAAAAAAAAGATAAAAAAAAAAAACCTAAAAAAAAAAAATG TAAAAAAAAAAAAGGGAAAAAAAAAAAACGCAAAAAAAAAAAACACAAAAAAAAAAAATGCAAAAAAAAAAAATCGAAAAAAAAA AAATCTAAAAAAAAAAAACGAAAAAAAAAAAACCCAAAAAAAAAAAAGACAAAAAAAAAAAATAGAAAAAAAAAAAGTTAAAAAA AAAAAACTGAAAAAAAAAAAATTTAAAAAAAAAAAAT
630	mRNA L encoding Nme2Cas9	GGGaagctcagaataaacgctcaactttggccggatctgccacCatgGACGGCTCCGGCGGCGGCTCCCCCAAGAAGAAGCGGAA GGTGGGCGGCTCCGGCGGCGGCgccgccttcaagcccaaccccatcaactacatcctgggcctggacatcggcatcgcctccgtg ggctgggccatggtggagatcgacgaggaggagaaccccatccggctgatcgacctgggcgtgcgggtgttcgagcgggccgagg tgcccaagaccggcgactccctggccatggcccggcggctggcccggtccgtgcggcggctgacccggcggcgggcccaccggct gctgcgggcccggcggctgctgaagcgggagggcgtgctgcaggccgccgacttcgacgagaacggcctgatcaagtccctgccc aacacccccctggcagctgcgggccgccgccctggaccggaagctgacccccctggagtggtccgccgtgctgctgcacctgatca agcaccggggctacctgtcccagcggaagaacgagggcgagaccgccgacaaggagctgggcgccctgctgaagggcgtggccaa caacgcccacgccctgcagaccggcgacttccggacccccgccgagctggccctgaacaagttcgagaaggagtccggccacatc cggaaccagcggggcgactactcccacaccttctcccggaaggacctgcaggccgagctgatcctgctgttcgagaagcagaagg agttcggcaaccccccacgtgtccggcggcctgaaggagggcatcgagaccctgctgatgacccagcggcccgccctgtccggcga cgccgtgcagaagatgctgggccactgcaccttcgagcccgccgagcccaaggccgccaagaacacctacaccgccgagcggttc atctggctgaccaagctgaacaacctgcggatcctggagcagggctccgagcggcccctgaccgacaccgagcgggccaccctga tggacgagccctaccggaagtccaagctgacctacgcccaggcccggaagctgctgggcctggaggacaccgccttcttcaaggg cctgcggtacggcaaggacaacgccgaggcctccaccctgatggagatgaaggcctaccacgccatctcccgggccctggagaag gagggcctgaaggacaagaagtccccccctgaacctgtcctccgagctgcaggacgagatcggcaccgccttctccctgttcaaga ccgacgaggacatcaccggccggctgaaggaccgggtgcagcccgagatcctggaggccctgctgaagcacatctccttcgacaa gttcgtgcagatctccctgaaggccctgcggcggatcgtgcccctgatggagcagggcaagcggtacgacgaggcctgcgccgag atctacggcgaccactacggcaagaagaacaccgaggagaagatctacctgccccccatccccgccgacgagatccggaaccccg

		tggtgctgcgggccctgtcccaggcccggaaggtgatcaacggcgtggtgcggcggtacggctcccccgcccggatccacatcga gaccgcccgggaggtgggcaagtccttcaaggaccggaaggagatcgagaagcggcaggaggagaaccggaaggaccgggagaag gccgccgccaagttccgggagtacttccccaacttcgtgggcgagcccaagtccaaggacatcctgaagctgcggctgtacgagc agcagcacggcaagtgcctgtactccggcaaggagatcaacctggtgcggctgaacgagaagggctacgtggagatcgaccacgc cctgcccttctcccggacctgggacgactccttcaacaacaaggtgctggtgctgggctccgagaaccagaacaagggcaaccag acccccctacgagtacttcaacggcaaggacaactcccgggagtggcaggagttcaaggcccgggtggagacctcccggttcccc ggtccaagaagcagcggatcctgctgcagaagttcgacgaggacggcttcaaggagtgcaacctgaacgacacccggtacgtgaa ccggttcctgtgccagttcgtggccgaccacatcctgctgaccggcaagggcaagcggcgggtgttcgcctccaacggccagatc accaacctgctgcggggcttctggggcctgcggaaggtgcgggccgagaacgaccggcaccacgccctggacgccgtggtggtgg cctgctccaccgtggccatgcagcagaagatcacccggttcgtgcggtacaaggagatgaacgccttcgacggcaagaccatcga caaggagaccggcaaggtgctgcaccagaagacccacttcccccagccctgggagttcttcgcccaggaggtgatgatccgggtg ttcggcaagcccgacggcaagcccgagttcgaggaggccgacacccccgagaagctgcggaccctgctggccgagaagctgtcct cccggcccgaggccgtgcacgagtacgtgacccccctgttcgtgtcccgggcccccaaccggaagatgtccggcgcccacaagga caccctgcggtccgccaagcggttcgtgaagcacaacgagaagatctccgtgaagcgggtgtggctgaccgagatcaagctggcc gacctggagaacatggtgaactacaagaacggccgggagatcgagctgtacgaggccctgaaggcccggctggaggcctacggcg gcaacgccaagcaggccttcgaccccaaggacaaccccttctacaagaagggcggccagctggtgaaggccgtgcgggtggagaa gacccaggagtccggcgtgctgctgaacaagaagaacgcctacaccatcgccgacaacggcgacatggtgcgggtggacgtgttc tgcaaggtggacaagaagggcaagaaccagtacttcatcgtgcccatctacgcctggcaggtggccgagaacatcctgcccgaca tcgactgcaagggctaccggatcgacgactcctacaccttctgcttctccctgcacaagtacgacctgatcgccttccagaagga cgagaagtccaaggtggagttcgcctactacatcaactgcgactcctccaacggccggttctacctggcctggcacgacaagggc tccaaggagcagcagttccggatctccacccagaacctggtgctgatccagaagtaccaggtgaacgagctgggcaaggagatcc ggccctgccggctgaagaagcggcccccgtgcggtagctagcaccagcctcaagaacacccgaatggagtctctaagctacata ataccaacttacactttacaaaatgttgtcccccaaaatgtagccattcgtatctgctcctaataaaaagaaagtttcttcacat tctctcgagAAAAAAAAAAAATGGAAAAAAAAAAAACGGAAAAAAAAAAAAGGTAAAAAAAAAAAATATAAAAAAAAAAAACATA AAAAAAAAAAACGAAAAAAAAAAAACGTAAAAAAAAAAAACTCAAAAAAAAAAAGATAAAAAAAAAAAACCTAAAAAAAAAAAAT GTAAAAAAAAAAAAGGGAAAAAAAAAAAACGCAAAAAAAAAAAACACAAAAAAAAAAAAATGCAAAAAAAAAAAAATCGAAAAAAAAA AAAATCTAAAAAAAAAAAACGAAAAAAAAAAAACCCAAAAAAAAAAAAGACAAAAAAAAAAAATAGAAAAAAAAAAAGTTAAAAA AAAAAAACTGAAAAAAAAAAAAATTTAAAAAAAAAAAAT
631	mRNA M encoding Nme2Cas9 with HiBiT tag	GGGAAGCUCAGAAUAAACGCUCAACUUUGGCCGGAUCUGCCACCAUGGACGGCUCCGGCGGCGGCUCCCCCAAGAAGAAGCGGAA GGUGGGCGGCUCCGGCGGCGGCGCCGCCUUCAAGCCCAACCCCAUCAACUACAUCCUGGGCCUGGACAUCGGCAUCGCCUCCGUG GGCUGGGCCAUGGUGGAGAUCGACGAGGAGGAGAACCCCAUCCGGCUGAUCGACCUGGGCGUGCGGGUGUUCGAGCGGGCCGAGG UGCCCAAGACCGGCGACUCCCUGGCCAUGGCCCGGCGGCUGGCCCGGUCCGUGCGGCGGCUGACCCGGCGGCGGGCCCACCGGCU GCUGCGGGCCCGGCGGCUGCUGAAGCGGGAGGGCGUGCUGCAGGCCGCCGACUUCGACGAGAACGGCCUGAUCAAGUCCCUGCCC AACACCCCCUGGCAGCUGCGGGCCGCCGCCCUGGACCGGAAGCUGACCCCCCUGGAGUGGUCCGCCGUGCUGCUGCACCUGAUCA AGCACCGGGGCUACCUGUCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCUGGGCGCCCUGCUGAAGGGCGUGGCCAA CAACGCCCACGCCCUGCAGACCGGCGACUUCCGGACCCCCGCCGAGCUGGCCCUGAACAAGUUCGAGAAGGAGUCCGGCCACAUC CGGAACCAGCGGGGCGACUACUCCCACACCUUCUCCCGGAAGGACCUGCAGGCCGAGCUGAUCCUGCUGUUCGAGAAGCAGAAGG AGUUCGGCAACCCCCACGUGUCCGGCGGCCUGAAGGAGGGCAUCGAGACCCUGCUGAUGACCCAGCGGCCCGCCCUGUCCGGCGA CGCCGUGCAGAAGAUGCUGGGCCACUGCACCUUCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCUACACCGCCGAGCGGUUC

AUCUGGCUGACCAAGCUGAACAACCUGCGGAUCCUGGAGCAGGGCUCCGAGCGGCCCCUGACCGACACCGAGCGGGCCACCCUGA UGGACGAGCCCUACCGGAAGUCCAAGCUGACCUACGCCCAGGCCCGGAAGCUGCUGGGCCUGGAGGACACCGCCUUCUUCAAGGG CCUGCGGUACGGCAAGGACAACGCCGAGGCCUCCACCCUGAUGGAGAUGAAGGCCUACCACGCCAUCUCCCGGGCCCUGGAGAAG GAGGGCCUGAAGGACAAGAAGUCCCCCCCUGAACCUGUCCUCCGAGCUGCAGGACGAGAUCGGCACCGCCUUCUCCCUGUUCAAGA CCGACGAGGACAUCACCGGCCGGCUGAAGGACCGGGUGCAGCCCGAGAUCCUGGAGGCCCUGCUGAAGCACAUCUCCUUCGACAA GUUCGUGCAGAUCUCCCUGAAGGCCCUGCGGCGGAUCGUGCCCCUGAUGGAGCAGGGCAAGCGGUACGACGAGGCCUGCGCCGAG AUCUACGGCGACCACUACGGCAAGAAGAACACCGAGGAGAAGAUCUACCUGCCCCCCAUCCCCGCCGACGAGAUCCGGAACCCCG UGGUGCUGCGGCCCUGUCCCAGGCCCGGAAGGUGAUCAACGGCGUGGUGCGGCUCCCCCGCCCGGAUCCACAUCGA GACCGCCCGGGAGGUGGGCAAGUCCUUCAAGGACCGGAAGGAGAUCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAG GCCGCCGCCAAGUUCCGGGAGUACUUCCCCAACUUCGUGGGCGAGCCCAAGUCCAAGGACAUCCUGAAGCUGCGGCUGUACGAGC AGCAGCACGGCAAGUGCCUGUACUCCGGCAAGGAGAUCAACCUGGUGCGGCUGAACGAGAAGGGCUACGUGGAGAUCGACCACGC CCUGCCCUUCUCCCGGACCUGGGACGACUCCUUCAACAACAAGGUGCUGGUGCUCCGAGAACCAGAACAAGGGCAACCAG ACCCCCUACGAGUACUUCAACGGCAAGGACAACUCCCGGGAGUGGCAGGAGUUCAAGGCCCGGGUGGAGACCUCCCGGUUCCCCC GGUCCAAGAAGCAGCGGAUCCUGCUGCAGAAGUUCGACGAGGACGGCUUCAAGGAGUGCAACCUGAACGACACCCGGUACGUGAA CCGGUUCCUGUGCCAGUUCGUGGCCGACCACAUCCUGCUGACCGGCAAGGGCGACGGCGGUGUUCGCCUCCCAACGGCCAGAUC ACCAACCUGCUGCGGGGCUUCUGGGGCCUGCGGAAGGUGCGGGCCGAGAACGACCGCCACCACGCCCUGGACGGCCGUGGUGG CCUGCUCCACCGUGGCCAUGCAGCAGAAGAUCACCCGGUUCGUGCGGUACAAGGAGAUGAACGCCUUCGACGGCAAGACCAUCGA CAAGGAGACCGGCAAGGUGCUGCACCAGAAGACCCACAUUCCCCCAGCCCUGGAGUUCUUCGCCCAGGAGGUGAUGAUCCGGGUG UUCGGCCAAGCCCGACGGCAAGCCCGAGUUCGAGGAGGCCGACACCCCCGAGAAGCUGCGGACCCUGGCCGAGAAGCUGUCCU CCCGGCCCGAGGCCGUGCACGAGUACGUGACCCCCCUGUUCGUGUCCCGGGCCCCCAACCGGAAGAUGUCCGGCGCCCACAAGGA CACCCUGCGGUCCGCCAAGCGGUUCGUGAAGCACAACGAGAUGAUCUCCGUGAAGCGGGUGUGGCUGACCGAGAUCAAGCUGGCC GACCUGGAGAACAUGGUGAACUACAAGAACGGCGCCGGGAGAUCGAGCUGUACGAAGGCCCUGAAGGCCCUGAAGAAGCUGUCC GCAACGCCAAGCAGGCCUUCGACCCCAAGGACAACCCCUUCUACAAGAAGGGCGGCCAGCUGGUGAAGGCCGUGCGGUGGAGAA GACCCAGGAGUCCGGCGUGCUGCUGAACAAGAAGACGCCUACACCAUCGCCGACAACGGCGACAUGGUGCGGGUGGACGUGUUC UGCAAGGUGGACAAGAAGGGCAAGAACCAGUACUUCAUCGUGCCCAUCUACGCCUGGCAGGUGGCCGAGAACAUCCUGCCCGACA UCGACUGCAAGGGCUACCGGAUCGACGACUCCUACACCUUCUGCUUCUCCCUGCACAAGUACGACCUGAUCGCCUUCCAGAAGGA CGAGAAGUCCAAGGUGGAGUUCGCCUACUACAUCAACAUCUGCGACUCCUCCAACGGCCGUUCUACCUGGCCUGGCACGACAAGGGC UCCAAGGAGCAGCAGUUCCGGAUCUCCACCCAGAACCUGGUGCUGAUCCAGAAGUACCAGGUGAACGAGCUGGGCAAGGAGAUCCC GGCCCUGCCGGCUGAAGAAGCGGCCCCCGUGCGGUCCGAGUCCGCCACCCCCGAGUCCGUGUCCGGCUGGCGGCUGUUCAAGAA GAUCUCCUAGCUAGCACCAGCCUCAAGAACACCCGAAUGGAGUCUCUAAGCUACAUAAUACCAACUUUACACUUUACAAAAUGUUG UCCCCCAAAAUGUAGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUCUCGAGAAAAAAAAAAAUGGAAAA AAAAAAAAAGGAAAAAAAAAAAGGUAAAAAAAAAAAAUAUAAAAAAAAAAAAAACAUAAAAAAAAAAAAAACGAAAAAAAAAAAACGU AAAAAAAAAAACUCAAAAAAAAAAAAAGAUAAAAAAAAAAAAACCUAAAAAAAAAAAAAUGUAAAAAAAAAAAAAGGAAAAAAAAAA AACGCAAAAAAAAAAAAACACAAAAAAAAAAAAAUGCAAAAAAAAAAAAAUCGAAAAAAAAAAAAAUCUAAAAAAAAAAAACGAAAAAA AAAAACCCAAAAAAAAAAAAAGACAAAAAAAAAAAAAAUAGAAAAAAAAAAAAAGUUAAAAAAAAAAAAACUGAAAAAAAAAAAAUUUA AAAAAAAAAAUCUAG	632	mRNA N encoding Nme2Cas9
GGGAAGCUCAGAAUAAACGCUCAACUUUGGCCGGAUCUGCCACCAUGGACGGCUCCGGCGGCGGCUCCCCCCAAGAAGAAGCGGAA GGUGGGCGGCUCCGGCGGCGGCCGCCUUCAAGCCCAACCCCAUCACUACAUCCUGGGCCUGGACAUCGGCAUCGCCUCCGUG GGCUGGGCCAUGGUGGAGAUCGACGAGGAGGAGAACCCCAUCCGGCUGAUCGACCUGGGCGUGCGGUUCGAGGCGGGCCGAGG		

UGCCCAAGACCGGCGACUCCCUGGCCAUGGCCCGGCUGGCCCGGUCCGUGCGGCUGACCCGGCGGCGCGGCCCACCGGCU		
GCUGCGGCCCGGCGGCUGCUGAAGCGGGAGGGCGUGCUGCAGGCCGCCGACUUCGACGAGAACGGCCUGAUCAAGUCCCUGCCC		
AACACCCCCUGGCAGCUGCGGCCGCCGCCCUGGACCGGAAGCUGACCCCCCUGGAGUGGUCCGCCGUGCUGCUGCACCUGAUCA		
AGCACCGGGGCUACCUGUCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCUGGGCGCCCUGCUGAAGGGCGUGGCCAA		
CAACGCCCACGCCCUGCAGACCGGCGACUUCCGGACCCCCGCCGAGCUGGCCCUGAACAAGUUCGAGAAGGAGUCCGGCCACAUC		
CGGAACCAGCGGGGGCGACUACUCCCACACCUUCUCCCGGAAGGACCUGCAGGCCGAGCUGAUCCUGCUGUUCGAGAAGCAGAAGG		
AGUUCGGCAACCCCCACGUGUCCGGCGGCCUGAAGGAGGGCAUCGAGACCCUGCUGAUGACCCAGCGGCCCGCCCUGUCCGGCGA		
CGCCGUGCAGAAGAUGCUGGGCCACUGCACCUUCGAGCCCGAGCCCAAGGCCGCCAAGAACACCUACACCGCCGAGCGGUUC		
AUCUGGCUGACCAAGCUGAACAACCUGCGGAUCCUGGAGCAGGGCUCCGAGCGGCCCCUGACCGACACCGAGCGGGCCACCCUGA		
UGGACGAGCCCUACCGGAAGUCCAAGCUGACCUACGCCCAGGCCCGGAAGCUGCUGGGCCUGGAGGACACCGCCUUCUUCAAGGG		
CCUGCGGUACGGCAAGGACAACGCCGAGGCCUCCACCCUGAUGGAGAUGAAGGCCUACCACGCCAUCUCCCGGGCCCUGGAGAAG		
GAGGGCCUGAAGGACAAGAAGUCCCCCCUGAACCUGUCCUCCGAGCUGCAGGACGAGAUCGGCACCGCCUUCUCCCUGUUCAAGA		
CCGACGAGGACAUCACCGGCCGGCUGAAGGACCGGGUGCAGCCCGAGAUCCUGGAGGCCCUGCUGAAGCACAUCUCCUUCGACAA		
GUUCGUGCAGAUCUCCCUGAAGGCCCUGCGGCGAUCGUGCCCCUGAUGGAGCAGGGCAAGCGGUACGACGAGGCCUGCGCCGAG		
AUCUACGGCGACCACUACGGCAAGAAGAACACCGAGGAGAUCUACCUGCCCCCCAUCCCCGCCGACGAGAUCCGGAACCCCG		
UGGUGCUGCGGCCCUGUCCCAGGCCCGGAAGGUGAUCAACGGCGUGGUGCGGCGGUACGGCUCCCCCGCCCGGAUCCACAUCGA		
GACCGCCCGGGAGGUGGGCAAGUCCUUCAAGGACCGGAAGAGGAUCGAGAAGCGGCAGGAGGAGAACCGGGAAGGACCGGAGAAG		
GCCGCCGCCAAGUUCCGGGAGUACUUCCCCAACUUCGUGGGCGAGCCCAAGUCCAAGGACAUCCUGAAGCUGCGGCUGUACGAGC		
AGCAGCACGGCAAGUGCCUGUACUCCGGCAAGGAGAUCAACCUGGUGCGCGGCUGAACGAGAAGGGCUACGUGGAGAUCGACCAC		
CCUGCCCUUCUCCCGGACCUGGGACGACUCCUUCAACAACAAGGUGCUGGUGCUGGGCUCCCGAGAACCAGAACGGCAACCAG		
ACCCCCUACGAGUACUUCAACGGCCAAGGACAACUCCCGGGAGUGGCAGGAGUUCAAGGCCCGGGUGGAGACCUCCCGGUUCCCCC		
GGUCCAAGAAGCAGCGGAUCCUGCUGCAGAAGUUCGACGAGGACGGCUUCAAGGAGUGCAACCUGAACGACACCCGGUACGUGAA		
CCGGUUCCUGUGCCAGUUCGUGGCCGACCACAUCCUGCUGACCGGCGAGGGCAAGCGGCGGGUGUUCGCCUCCCAACGGCCAGAUC		
ACCAACCUGCUGCGGGCUUCUGGGGCCUGCGGAAGGUGCGGGCCGAGAACGACCGCCACCAGCGCCGUGGUGGUGG		
CCUGCUCCACCGUGGCCAUGCAGCAGAAGAUCACCCGGUUCGUGCGGUACAAGGAGAUGAACGCCUUCGACGGCAAGACCAUCGA		
CAAGGAGACCGGCAAGGUGCUGCACCAGAAGACCCACUUCCCCCAGCCCUGGGAGUUCUUCGCCCAGGAGGUGAUGAUCCGGGUG		
UUCGGCAAGCCCGACGGCAAGCCCGAGUUCGAGGAGGCCGACACCCCCGAGAAGCUGCGGACCCUGCUGGCCGAGAAGCUGUCCU		
CCCGGCCCGAGGCCGUGCACGAGUACGUGACCCCCCUGUUCGUGUCCCGGGCCCCCAACCGGAAGAUGUCCGGCGCCCACAAGGA		
CACCCUGCGGUCCGCCAAGCGGUUCGUGAAGCACAACGAGAAGAUCUCCGUGAAGCGGGUGUGGCUGACCGAGAUCAAGCUGGCC		
GACCUGGAGAACAUGGUGAACUACAAGAACGGCCGGGAGAUCGAGCUGUACGAGGCCCUGAAGGCCCUGGAGGCCUACGGCG		
GCAACGCCAAGCAGGCCUUCGACCCCAAGGACAACCCCUUCUACAAGAAGGGCGGCCAGCUGGUGAAGGCCGUGCGGGUGGAGAA		
GACCCAGGAGUCCGGCGUGCUGCUGAACAAGAAGAACGCCUACACCAUCGCCGACAACGGCGACAUGGUGCGGUGGACGUGUUC		
UGCAAGGUGGACAAGAAGGGCAAGAACCAGUACUUCAUCGUGCCCAUCUACGCCUGGCAGGUGGCCGAGAACAUCCUGCCCGACA		
UCGACUGCAAGGGCUACCGGAUCGACGACUCCUACACCUUCUGCUUCUCCCUGCACAAGUACGACCUGAUCGCCUUCCAGAAGGA		
CGAGAAGUCCAAGGUGGAGUUCGCCUUCUACAUCAACUGCGACUCCUCCACGGCCGGUUCUACCUGGCCUGGCACGACAAGGGC		
UCCAAGGAGCAGCAGUUCCGGAUCUCCACACCCAGAACCUGGUGCUGAUCCAGAAGUACCAGGUGAACGAGCUGGGCAAGGAGAUCC		
GGCCCUGCCGGCUGAAGAAGCGGCCCCCCGUGCGGUCCGGAAAGCGGACCGCCGACGGCUCCGGAGGAGGAAGCCCCGCGCCAA		
GAAGAAGAAGCUGGACUAGCUAGCACCAGCCUCAAGAACACCCGAAUGGAGUCUCUAAGCUACAUAAUACCAACUUACACUUUAC		
AAAAUGUUGUCCCCCAAAAUGUAGCCAUUCGUAUCUGCUCCUAAUAAAAAAGAAAGUUUCUUCACAUUCUCUCCGAGAAAAAAAAAAA		

		AAUGGAAAAAAAAAAAAAACGGAAAAAAAAAAAAAAAGGUAAAAAAAAAAAAAAAUAUAAAAAAAAAAAAAAACAUAAAAAAAAAAAAAACGAAAAAA
		AAAAAACGUAAAAAAAAAAAAAAAACUCAAAAAAAAAAAAAAAGAUAAAAAAAAAAAAAAAACCUAAAAAAAAAAAAAAAUGUAAAAAAAAAAAAAGGAA
		AAAAAAAAAACGCAAAAAAAAAAAAAACACAAAAAAAAAAAAAAUGCAAAAAAAAAAAAAAAUCGAAAAAAAAAAAAAAAUCUAAAAAAAAAAAAAAA
		CGAAAAAAAAAAAACCCAAAAAAAAAAAAAAAGACAAAAAAAAAAAAAAAUAGAAAAAAAAAAAAAAAGUUAAAAAAAAAAAAAACUGAAAAAAAAAA
		AAAUUUAAAAAAAAAAAAAAUCUAG
633	mRNA O encoding Nme2Cas9	GGGAAGCUCAGAAUAAACGCUCAACUUUGGCCGGAUCUGCCACCAUGGACGGCUCCGGCGGCGGCUCCCCCAAGAAGAAGCGGAA
		GGUGGAGGACAAGCGGCCCGCCGCCACCAAGAAGGCCGGCCAGGCCAAGAAGAAGGGCGGCUCCGGCGGCGGCGCCGCCUUC
		AAGCCCAACCCCAUCAACUACAUCCUGGGCCUGGACAUCGGCAUCGCCUCCGUGGGCUGGGCCAUGGUGGAGAUCGACGAGGAGG
		AGAACCCCAUCCGGCUGAUCGACCUGGGUGUUCGAGCGGGCCGAGGUGCCCAAGACCGGCGACUCCCUGGCCAUGGCC
		CCGGCGGCUGGCCCGGUCCGUGCGGCGGCUGACCCGGCUGCUGCGGGCCCGGCGGCUGCUGAAGCGGGAG
		GGCGUGCUGCAGGCCGCCGACUUCGACGAGAACGGCCUGAUCAAGUCCCUGCCCAACACCCCCUGGCAGCUGCGGGCCGCCGCCC
		UGGACCGGAAGCUGACCCCCCUGGAGUGGUCCGCCGUGCUGCACCUGAUCAAGCACCGGGGCUACCUGUCCCAGCGGAAGAA
		CGAGGGCGAGACCGCCGACAAGGAGCUGGGCGCCCUGCUGAAGGGCGUGGCCAACACGCCCACGCCCUGCAGACCGGCGACUUC
		CGGACCCCCGCCGAGCUGGCCCUGAACAAGUUCGAGAAGGAGUCCGGCCACAUCCGGAACCAGCGGGGCGACUACUCCCACACCU
		UCUCCCGGAAGGACCUGCAGGCCGAGCUGAUCCUGCUGUUCGAGAAGGAGUUCGGCAACCCCCACGUGUCCGGCGGCCU
		GAAGGAGGGCAUCGAGACCCUGCUGAUGACCCAGCGGCCCGCCCUGUCCGGCGACGCCGUGCAGAAGAUGCUGGGCCACUGCACC
		UUCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCUACACCGCCGAGCGGUUCAUCUGGCUGACCAAGCUGAACAACCUGCGGA
		UCCUGGAGCAGGGCUCCGAGCGGCCCCUGACCGACACCGAGCGGGCCACCCUGAUGGACGAGCCCUACCGGAAGUCCACAAGCUGAC
		CUACGCCCAGGCCCGGAAGCUGCUGGGCGUGGAGGACACCGCCUUCUUCAAGGGCCUGCGGUACGGCAAGGACAACGCCGAGGCC
		UCCACCCUGAUGGAGAUGAAGGCCUACCACGCCAUCUCCCGGGCCCUGGAGAAGGAGGGCCUGAAGGACAAGAAGUCCCCCCUGA
		ACCUGUCCUCCGAGCUGCAGGACGAGAUCGGCACCGCCUUCUCCCUGUUCAAGACCGACGAGGACAUCACCGGCCGGCUGAAGGA
		CCGGGUGCAGCCCGAGAUCCUGGAGGCCCUGCUGAAGCACAUCUCCUUCGACAAGUUCGUGCAGAUCUCCCUGAAGGCCCUGCGG
		CGGAUCGUGCCCCUGAUGGAGCAGGGCAAGCGGUACGACGAGCUGCUGCGCCGAGAUCUACGGCGACCACUACGGCAAGAAGAACA
		CCGAGGAGAAGAUCUACCUGCCCCCCAUCCCCGCCGACGAGAUCCGGAACCCCGUGGUGCUGCGGCGGCCCUGUCCCAGGCCCGGAA
		GGUGAUCAACGGCGUGGUGCGGCGGUACGGCUCCCCCGCCGAUCCCACAUCGAGACCGCCGCGGAGGUGGGCAAGUCCUUCAAG
		GACCGGAAGGAGAUCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGUUCCGGGAGUACUUCCCCA
		ACUUCGUGGGCGAGCCCAAGUCCAAGGACAUCCUGAAGCUGCGGCUGUACGAGCAGCACGGCAAGUGCCUGUACUCCGGCAA
		GGAGAUCAACCUGGUGCGGCUGAACGAGAAGGGCUACGUGGAGAUCGACCACCGCCUGCCCUUCUCCCGGACCUGGGACGACUCC
		UUCAACAACAAGGUGCUGGUGCUGGGCUCCGAGAACCAGAACAAGGGCAACCAGACCCCCUACGAGUACUUCAACGGCAAGGACA
		ACUCCCGGGAGUGGCAGGAGUUCAAGGCCCGGGUGGAGACCUCCCCGGUCCCCCGGUCCAAGAAGCAGCGGAUCCUGCUGCAGAA
		GUUCGACGAGGACGGCUUCAAGGAGUGCAACCUGAACGACACCCGGUACGUGAACCGGUUCCUGUGCCAGUUCGUGGCCGACCAC
		AUCCUGCUGACCGGCAAGGGCAAGCGGCGGGUGUUCGCCUCCAACGGCCAGAUCACCAACCUGCUGCGGGGCUUCUGGGGCCUGC
		GGAAGGUGCGGGCCGAGAACGACCGGCACCACGCCCUGGACGCCGUGGUGGUGGCCUGCUCCACCGUGGCCAUGCAGCAGAAGAU
		CACCCGGUUCGUGCGGUACAAGGAGAUGAACGCCUUCGACGGCAAGACCAUCGACAAGGAGACCGGCGAGGUGCUGCACCAGAAG
		ACCCACUUCCCCCAGCCCUGGGAGUUCUUCGCCCAGGAGGUGAUGCUCGGUGUUCCGGCCAAGCCCGACGGCAAGGCCCGAGUUCG
		AGGAGGCCGACACCCCCGAGAAGCUGCGGACCCUGCUGGCCGAGAAGCUGUCCUCCCGGCCCGAGGCCGUGCACGAGUACGUGAC
		CCCCCUGUUCGUGUCCCGGGCCCCCAACCGGAAGAUGUCCGGCGCCCACAAGGACACCCUGGAGAUCCAGCUGGUCCGGUUCGUGAAG
		CACAACGAGAAGAUCUCCGUGAAGCGGGUGUGGCUGACCGAGAUCAAGCUGGCCGACCUGGAGAAACAUGGUGAACUACAAGAACG
		GCCGGGAGAUCGAGCUGUACGAGGCCCUGAAGGCCCGGCUGGAGGCCUACGGCGGCAACGCCAAGCAGGCCUUCGACCCCAAGGA

		CAACCCCUUCUACAAGAAGGGCGGCCAGCUGGUGAAGGCCGUGCGGGUGGAGAAGACCCAGGAGUCCGGCGUGCUGCUGAACAAG
		AAGAACGCCUACACCAUCGCCGACAACGGCGACAUGGUGCGGGUGGACGUGUUCUGCAAGGUGGACAAGAAGGGCAAGAACCAGU
		ACUUCAUCGUGCCCAUCUACGCCUGGCAGGUGGCCGAGAACAUCCUGCCCGACAUCGACUGCAAGGGCUACCGGAUCGACGACUC
		CUACACCUUCUGCUUCUCCCCUGCACAAGUACGACCUGAUCGCCUUCCAGAAGGACGAGAAGUCCAAGGUGGAGUUCGCCUACUAC
		AUCAACUGCGACUCCUCCAACGGCCGGUUCUACCUGGCCUGGCACGACAAGGGCUCCAAGGAGCAGCAGUUCCGGAUCUCCACCC
		AGAACCUGGUGCUGAUCCAGAAGUACGAGCUGGAACGAGGAGAUCCGGCCCUGCCGGCUGAAGAAGCGGCCCCCCGU
		GCGGUAGCUAGCACCAGCCUCCAAGAACACCCGAAUGGAGUCUCUAAGCUACAUAAUACCAACUUUACACUUUACAAAAUGUUGUCC
		CCCAAAAUGUAGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUCUCGAGAAAAAAAAAAAAAUGGAAAAAAA
		AAAAACGGAAAAAAAAAAAAAAAGGUAAAAAAAAAAAAAUAAAAAAAAAAAAAAACAUAAAAAAAAAAAAAAAACGAAAAAAAAAAAAAACGUAAA
		AAAAAAAAACUCAAAAAAAAAAAAAAAGAUAAAAAAAAAAAAAAACCUAAAAAAAAAAAAAAAAUGUAAAAAAAAAAAAAAAGGGAAAAAAAAAAAAAACG
		CAAAAAAAAAAAACACAAAAAAAAAAAAAAAUGCAAAAAAAAAAAAAAAAUCGAAAAAAAAAAAAAAAAUCUAAAAAAAAAAAAAAAAACGAAAAAAAAAAAA
		AACCCAAAAAAAAAAAAAGACAAAAAAAAAAAAAAUAGAAAAAAAAAAAAAAAAGUUAAAAAAAAAAAAAAACUGAAAAAAAAAAAAAAAUUUAAAAAA
		AAAAAAUCUAG
	634	mRNA P encoding Nme2Cas9 with HiBiT tag
		GGGAAGCUCAGAAUAAACGCUCAACUUUGGCCGGAUCUGCCACCAUGGACGGCUCCGGCGGCGGCUCCCCCAAGAAGAAGCGGAA
		GGUGGAGGACAAGCGGCCCCGCCGCCACCAGAAGGCCGGCCAGGCCAAGAAGAAGGGCGGCUCCGGCGGCGGCGCCGCCUUC
		AAGCCCAACCCCAUCAACUACAUCCUGGGCCUGGACAUCGGCAUCGCCUCCGUGGGCUGGGCCAUGGUGGAGAUCGACGAGGAGG
		AGAACCCCAUCCGGCUGAUCGACCUGGGCGUGCGGGUGUUCGAGCGGGCCGAGGUGCCCAAGACCGGCGACUCCCUGGCCAUGGC
		CCGGCGGCUGGCCCGGUCCGUGCGGCGCUGACCCGGCGGGCCCACCGGCUGCUGCGGCGCCGGCUGCUGAAGCGGGAG
		GGCGUGCUGCAGGCCGCCGACUUCGACGAGAACGGCCUGAUCAAGUCCCUGCCCAACACCCCCUGGCAGCUGCGGCCGCCGCCC
		UGGACCGGAAGCUGACCCCCCUGGAGUGGUCCGCCGUGCUGCUGCACCUGAUCAAGCACCGGGGCUACCUGUCCCAGCGGAAGAA
		CGAGGGCGAGACCGCCGACAAGGAGCUGGGCGCCCUGCUGAAGGGCGUGGCCAACACGCCCACGCCCUGCAGACCGGCGACUUC
		CGGACCCCCGCCGAGCUGGCCCUGAACACAAGUUCGAGAAGGAGUCCGGCCACACUCCGGAACCAGCGGGCGACUACUCCCACACCU
		UCUCCCGGAAGGACCUGCAGGCCGAGCUGAUCCUGCUGUUCGAGAAGGAGUUCGGCAACCCCCACGUGUCCGGCGGCCU
		GAAGGAGGGCAUCGAGACCCUGCUGAUGACCCAGCGGCCCGCCCUGUCCGGCGACGCCGUGCAGAAGAUGCUGGGCCACCUGCACC
		UUCGAGCCCGCCGAGGCCCAAGGCCGCCAAGAACACCUACACCGCCGAGCGGUUCAUCUGGCUGACCAAGCUGAACAACCUGCGGA
		UCCUGGAGCAGGGCUCCGAGCGGCCCCUGACCGACACCGAGCGGGCCACCCUGAUGGACGAGCCCUACCGGAAGUCCAAGCUGAC
		CUACGCCCAGGCCCGGAAGCUGCUGGGCCUGGAGGACACCGCCUUCUUCAAGGGCCUGCGGUACGGCAAGGACAACGCCGAGGCC
		UCCACCCUGAUGGAGAUGAAGGCCUACCACGCCAUCUCCCGGGCCCUGGAGAAGGAGGGCCUGAAGGACAAGAAGUCCCCCCUGA
		ACCUGUCCUCCGAGCUGCAGGACGAGAUCGGCACCGCCUUCUCCCUGUUCAAGACCGACGAGGACAUCACCGGCCGGCUGAAGGA
		CCGGGUGCAGCCCGAGAUCCUGGAGGCCCUGCUGAAGCACAUCUCCUUCGACAAGUUCGUGCAGAUCUCCCUGAAGGCCCUGCGG
		CGGAUCGUGCCCCUGAUGGAGCAGGGCAAGCGGUACGACGAGGCCUGCGCCGAGAUCUACGGCGACCACUACGGCAAGAAGAACA
		CCGAGGAGAAGAUCUACCUGCCCCCCAUCCCCGCCGACGAGAUCCGGAACCCCGUGGUGCUGCGGGCCCUGUCCCAGGCCCGGAA
		GGUGAUCAACGGCGUGGUGCGGCGGUACGGCUCCCCCGCCCGGAUCCACAUCGAGUUCGUGCAGAUCUCCCUGAAGGCCCUUCAAG
		GACCGGAAGGAGAUCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGUUCCGGGAGUACUUCCCCA
		ACUUCGUGGGCGAGCCCAAGUCCAAGGACAUCCUGAAGCUGCGGCUGUACGAGCAGCACGGCAAGUGCCUGUACUCCGGCAA
		GGAGAUCACCUGGUGCGGCUGAACGAGAAGGGCUACGUGGAGAUCGACCACGCCUGCCCUUCUCCCGGACCUGGGACGACUCCC
		UUCAACAACAAGGUGCUGGUGCUGGGCUCCGAGAACCAGAACAAGGGCAACCAGACCCCCUACGAGUACUUCAACGGCAAGGACA
		ACUCCCGGGAGUGGCAGGAGUUCAAGGCCCGGGUGGAGACCUCCCGGUUCCCCCGGUCCAAGAAGCAGCGGAUCCUGCUGCAGAA
		GUUCGACGAGGACGGCUUCAAGGAGUGCAACCUGGAACGACACCCGGUACGUGAACCGGUUCCUGUGCCAGUUCGUGGCCGACCAC

		AUCCUGCUGACCGGCAAGGGCAAGCGGCGGGUGUUCGCCUCCAACGGCCAGAUCACCAACCUGCUGCGGGGCUUCUGGGGCCUGCGGAAGGUGCGGGCCGAGAACGACCGGCACCACGCCCUGGACGCCGUGGUGGUGGCCUGCUCCACCGUGGCCAUGCAGCAGAAGAUCACCCGGUUCGUGCGGUACAAGGAGAUGAACGCCUUCGACGGCAAGACCAUCGACAAGGAGACCGGCAAGGUGCUGCACCAGAAGACCCACUUCCCCCAGCCCUGGGAGUUCUUCGCCCAGGAGGUGAUGAUCCGGGUGUUCGGCAAGCCCGACGGCAAGCCCGAGUUCGAGGAGGCCGACACCCCCGAGAAGCUGCGGACCCUGCUGGCCGAGAAGCUGUCCUCCCGGCCCGAGGCCGUGCACGAGUACGUGACCCCCCUGUUCGUGUCCCGGGCCCCCAACCGGAAGAUGUCCGGCGCCCACAAGGACACCCUGCGGUCCGCCAAGCGGUUCGUGAAGCACAACGAGAAGAUCUCCGUGAAGCGGGUGUGGCUGACCGAGAUCAAGCUGGCCGACCUGGAGAACAUGGUGAACUACAAGAACGGCCGGGAGAUCGAGCUGUACGAGGCCCUGAAGGCCCGGCUGGAGGCCUACGGCGGCAACGCCAAGCAGGCCUUCGACCCCAAGGACAACCCCUUCUACAAGAAGGGCGGCCAGCUGGUGAAGGCCGUGCGGGUGGAGAAGACCCAGGAGUCCGGCGUGCUGCUGAACAAGAAGAACGCCUACACCAUCGCCGACAACGGCGACAUGGUGCGGGUGGACGUGUUCUGCAAGGUGGACAAGAAGGGCAAGAACCAGUACUUCAUCGUGCCCAUCUACGCCUGGCAGGUGGCCGAGAACAUCCUGCCCGACAUCGACUGCAAGGGCUACCGGAUCGACGACUCCUACACCUUCUGCUUCUCCCUGCACAAGUACGACCUGAUCGCCUUCCAGAAGGACGAGAAGUCCAAGGUGGAGUUCGCCUACUACAUCAACUGCGACUCCUCCAACGGCCGGUUCUACCUGGCCUGGCACGACAAGGGCUCCAAGGAGCAGCAGUUCCGGAUCUCCACCCAGAACCUGGUGCUGAUCCAGAAGUACCAGGUGAACGAGCUGGGCAAGGAGAUCCGGCCCUGCCGGCUGAAGAAGCGGCCCCCGUGCGGUCCGAGUCCGCCACCCCCGAGUCCGUGUCCGGCUGGCGGCUGUUCAAGAAGAUCUCCUAGCUAGCACCAGCCUCAAGAACACCCGAAUGGAGUCUCUAAGCUACAUAAUACCAACUUACACUUUACAAAAUGUUGUCCCCCAAAAUGUAGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUCUCGAGAAAAAAAAAAAAUGGAAAAAAAAAAAAACGGAAAAAAAAAAAAGGUAAAAAAAAAAAAUAUAAAAAAAAAAAACAUAAAAAAAAAAAACGAAAAAAAAAAAACGUAAAAAAAAAAAACUCAAAAAAAAAAAAGAUAAAAAAAAAAAACCUAAAAAAAAAAAAUGUAAAAAAAAAAAAGGGAAAAAAAAAAAACGCAAAAAAAAAAAACACAAAAAAAAAAAAUGCAAAAAAAAAAAAUCGAAAAAAAAAAAAUCUAAAAAAAAAAAACGAAAAAAAAAAAACCCAAAAAAAAAAAAGACAAAAAAAAAAAAUAGAAAAAAAAAAAAGUUAAAAAAAAAAAACUGAAAAAAAAAAAAUUUAAAAAAAAAAAAUCUAG
635	mRNA Q encoding Nme2Cas9	GGGAAGCUCAGAAUAAACGCUCAACUUUGGCCGGAUCUGCCACCAUGGACGGCUCCGGCGGCGGCUCCCCCAAGAAGAAGCGGAAGGUGGGCGGCUCCGGCGGCGGCGCCGCCUUCAAGCCCAACCCCAUCAACUACAUCCUGGGCCUGGACAUCGGCAUCGCCUCCGUGGGCUGGGCCAUGGUGGAGAUCGACGAGGAGGAGAACCCCAUCCGGCUGAUCGACCUGGGCGUGCGGGUGUUCGAGCGGGCCGAGGUGCCCAAGACCGGCGACUCCCUGGCCAUGGCCCGGCGGCUGGCCCGGUCCGUGCGGCGGCUGACCCGGCGGCGGGCCCACCGGCUGCUGCGGGCCCGGCGGCUGCUGAAGCGGGAGGGCGUGCUGCAGGCCGCCGACUUCGACGAGAACGGCCUGAUCAAGUCCCUGCCCAACACCCCCUGGCAGCUGCGGGCCGCCGCCCUGGACCGGAAGCUGACCCCCCUGGAGUGGUCCGCCGUGCUGCUGCACCUGAUCAAGCACCGGGGCUACCUGUCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCUGGGCGCCCUGCUGAAGGGCGUGGCCAACAACGCCCACGCCCUGCAGACCGGCGACUUCCGGACCCCCGCCGAGCUGGCCCUGAACAAGUUCGAGAAGGAGUCCGGCCACAUCCGGAACCAGCGGGGCGACUACUCCCACACCUUCUCCCGGAAGGACCUGCAGGCCGAGCUGAUCCUGCUGUUCGAGAAGCAGAAGGAGUUCGGCAACCCCCACGUGUCCGGCGGCCUGAAGGAGGGCAUCGAGACCCUGCUGAUGACCCAGCGGCCCGCCCUGUCCGGCGACGCCGUGCAGAAGAUGCUGGGCCACUGCACCUUCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCUACACCGCCGAGCGGUUCAUCUGGCUGACCAAGCUGAACAACCUGCGGAUCCUGGAGCAGGGCUCCGAGCGGCCCCUGACCGACACCGAGCGGGCCACCCUGAUGGACGAGCCCUACCGGAAGUCCAAGCUGACCUACGCCCAGGCCCGGAAGCUGCUGGGCCUGGAGGACACCGCCUUCUUCAAGGGCCUGCGGUACGGCAAGGACAACGCCGAGGCCUCCACCCUGAUGGAGAUGAAGGCCUACCACGCCAUCUCCCGGGCCCUGGAGAAGGAGGGCCUGAAGGACAAGAAGUCCCCCCUGAACCUGUCCUCCGAGCUGCAGGACGAGAUCGGCACCGCCUUCUCCCUGUUCAAGACCGACGAGGACAUCACCGGCCGGCUGAAGGACCGGGUGCAGCCCGAGAUCCUGGAGGCCCUGCUGAAGCACAUCUCCUUCGACAAGUUCGUGCAGAUCUCCCUGAAGGCCCUGCGGCGGAUCGUGCCCCUGAUGGAGCAGGGCAAGCGGUACGACGAGGCCUGCGCCGAGAUCUACGGCGACCACUACGGCAAGAAGAACACCGAGGAGAAGAUCUACCUGCCCCCCAUCCCCGCCGACGAGAUCCGGAACCCCG

	636	mRNA R encoding Nme2Cas9 base editor

UGGUGCUGCGGCCCUGUCCCAGGCCCGGAAGGUGAUCAACGGCGUGGUGCGGCGGUACGGCUCCCCCGCCCGGAUCCACAUCGA
GACCGCCCGGGAGGUGGGCAAGUCCUUCAAGGACCGGAAGGAGAUCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAG
GCCGCCGCCAAGUUCCGGGAGUACUUCCCCAACUUCGUGGGCGAGCCCAAGUCCAAGGACAUCCUGAAGCUGCGGCUGUACGAGC
AGCAGCACGGCAAGUGCCUGUACUCCGGCAAGGAGAUCAACCUGGUGCGGCUGAACGAGAAGGGCUACGUGGAGAUCGACCACGC
CCUGCCCUUCUCCCGGACCUGGGACGACUCCUUCAACAACAAGGUGCUGGUGCUGGGCUCCGAGAACCAGAACAAGGGCAACCAG
ACCCCCUACGAGUACUUCAACGGCAAGGACAACUCCCGGGAGUGGCAGGAGUUCAAGGCCCGGGUGGAGACCUCCCGGUUCCCCC
GGUCCAAGAAGCAGCGGAUCCUGCUGCAGAAGUUCGACGAGGACGGCUUCAAGGAGUGCAACCUGAACGACACCCGGUACGUGAA
CCGGUUCCUGUGCCAGUUCGUGGCCGACCACAUCCUGCUGACCGGCAAGGGCAAGCGGCGGGUGUUCGCCUCCAACGGCCAGAUC
ACCAACCUGCUGCGGGGCUUCUGGGGCCUGCGGAAGGUGCGGCCGAGAACGACCGGCACCACGCCCUGGACGCCGUGGUGGUGG
CCUGCUCCACCGUGGCCAUGCAGCAGAAGAUCACCCGGUUCGUGCGGUACAAGGAGAUGAACGCCUUCGACGGCAAGACCAUCGA
CAAGGAGACCGGCAAGGUGCUGCACCAGAAGACCCACUUCCCCCAGCCCUGGGAGUUCUUCGCCCAGGAGGUGAUGAUCCGGGUG
UUCGGCCAAGCCCGACGGCCAAGCCCGAGUUCGAGGAGGCCGACACCCCCGAGAAGCUGCGGACCCUGGCCGAGAAGCUGUCCU
CCCGGCCCGAGGCCGUGCACGAGUACGUGACCCCCCUGUUCGUGUCCCGGGCCCCCAACCGGAAGAUGUCCGGCGCCCACAAGGA
CACCCUGCGGUCCGCCAAGCGGUUCGUGAAGCACAACGAGAUGAUCUCCGUGAAGCGGGUGUGGCUGACCGAGAUCAAGCUGGCC
GACCUGGAGAACAUGGUGAACUACAAGAACGGCCGGGAGAUCGAGCUGUACGAGGCCCUGGAGGCCUACGGCGCGCAGUACCCC
GCAACGCCAAGGCAGGCCUUCGACCCCAAGGACAACCCCUUCUACACAAGAAGGGCGGCCAGCUGGUGAAGGCCGUGCGGGUGGAGAA
GACCCAGGAGUCCGGCGUGCUGAACAAGAAGAACGCCUACACCAUCGCCGACAACGGCGACAUGGUGCGGGUGGACGUGUUC
UGCAAGGUGGACAAGAAGGGCAAGAACCAGUACUUCAUCGUGCCCAUCUACGCCUGGCCAGGUGGCCGAGAACAUCCUGCCCGACA
UCGACUGCAAGGGCUACCGGAUCGACGACUCCUACACCUUCUGCUUCUCCCUGCACAAGUACGACCUGAUCGCCUUCCAGAAGGA
CGAGAAGUCCAAGGUGGAGUUCGCCUACAUCAACUGCGACUCCUCCAACGGCCGGUUCUACCUGGCCUGGCACGACAAGGGC
UCCAAGGAGCAGCAGUUCCGGAUCUCCACCCAGAACCUGGUGCUGAUCCAGAAGUACCAGGUGAACGAGCUGGGCAAGGAGAUCCC
GGCCUGCCGGCUGAAGAAGCGGCCCCCCGUGCGGUAGCUAGCACCAGCCUCAAGAACACCCGAAUGGAGUCUCUAAGCUACAUA
AUACCAACUUACACUUUACAAAAUGUUGUCCCCCAAAAUGUAGCCAUUCGUAUCUGCUCCCUAAUAAAAAGAAAGUUUCUUCACAU
UCUCUCGAGAAAAAAAAAAAUGGAAAAAAAAAAAAAAAAAGGUAAAAAAAAAAAAAAUAUAAAAAAAAAAAAACAUA
AAAAAAAAAAACGAAAAAAAAAAAAAAAACGUAAAAAAAAAAAAAAACUCAAAAAAAAAAAAAAGAUAAAAAAAAAAAAACCUAAAAAAAAAAAAAU
GUAAAAAAAAAAAAGGGAAAAAAAAAAAAAAACGCAAAAAAAAAAAAAAACACAAAAAAAAAAAAAAUGCAAAAAAAAAAAAAAUCGAAAAAAAAA
AAAAUCUAAAAAAAAAAAAAACGAAAAAAAAAAAAAAACCCAAAAAAAAAAAAAAAGACAAAAAAAAAAAAAAUAGAAAAAAAAAAAAAGUUAAAAA
AAAAAAACUGAAAAAAAAAAAAUUAAAAAAAAAAAAAAUCUAG

mRNA R encoding Nme2Cas9 base editor	GGGaagctcagaataaacgctcaactttggccggatctgccaccATGGACGGCTCCGGCGCGGCTCCCCCAAGAAGAAGCGGAA
	GGTGGAGGACAAGCGGCCCGCCGCCACCAAGAAGGCCGGCCAGGCCAAGAAGAAGGGCGGCTCCGGCGGCGGCGAGGCCTCC
	CCCGCCTCCGGCCCCCCGGCACCTGATGGACCCCCCACATCTTCACCTCCAACTTCAACAACGGCATCGGCCGGCACAAGACCTACC
	TGTGCTACGAGGTGGAGCGGCTGGACAACGGCACCTCCGTGAAGATGGACCAGCACCGGGGCTTCCTGCACAACCAGGCCAAGAA
	CCTGCTGTGCGGCTTCTACGGCCGGCACGCCGAGCTGCGGTTCCTGGACCTGGTGCCCTCCTGCAGCTGGACCCCGCCCAGATC
	TACCGGGTGACCTGGTTCATCTCCTGGTCCCCCTGCTTCTCCTGGGGCTGCGCCGGCGAGGTGCGGGCCTTCCTGCAGGAGAACA
	CCCACGTGCGGCTGCGGATCTTCGCCGCCCGGATCTACGACTACGACCCCCTGTACAAGGAGGCCCTGCAGATGCTGCGGGACGC
	CGGCGCCCAGGTGTCCATCATGACCTACGACGAGTTCAAGCACTGCTGGGACACCTTCGTGGACCACCAGGGCTGCCCCTTCCAG
	CCCTGGGACGGCCTGGACGAGCACTCCCAGGCCCTGTCCGGCCGGCTGCGGGCCATCCTGCAGAACCAGGGCAACTCCGGCTCCG
	AGACCCCCGGCACCTCCGAGTCCGCCACCCCCGAGTCCGGCAGCGTTCAAACCAAATcccatcaactacatcctgggcctggccat
	cggcatcgcctccgtgggctgggccatggtggagatcgacgaggaggagaaccccatccggctgatcgacctgggcgtgcgggtg

ttcgagcgggccgaggtgcccaagaccggcgcactcccctggccatggcccggcggctgcccggtccgtgcggcggctgacccggc		
ggcgggcccaccggctgctgcgggcccggcggctgctgaaagcgggagggcgtgctgcaggccgccgacttcgacgagaacggcct		
gatcaagtccctgcccaacacccccctgggcagctgcgggccgccgccctggaccggaagctgacccccctggagtggtccgccgtg		
ctgctgcacctgatcaagcaccgggggctacctgtcccagcggaagaacgagggcgagaccgccgacacaaggagctgggcgccctgc		
tgaagggcgtggccaacaacgcccacgccctgcagaccggcgacttccggacccccgccgagctggccctgaacaagttcgagaaa		
ggagtccggccacatccggaaccagcgggcgactactcccacacctttcccggaaggacctgcaggccgagctgatcctgctg		
ttcgagaagcagaaggagttcggcaacccccacgtgtccgcggcctgaaggagggcatcgagaccctgctgatgaccccagcggc		
ccgccctgtccggcgacgccgtgcagaagatgctgggccactgcacctcgagcccgccgagcccaaggccgccaagaacaccta		
caccgccgagcggttcatctggctgaccaagctgaacaacctgcggatcctggagcagggctccgagcggccccctgaccgcacacc		
gagcgggccacccctgatggacgagccctaccggaagtccaagctgacctacgcccaggcccgggaagctgctgggcctggaggaca		
ccgcctcttcaagggcctgcggtacggcaaggacaacgccgaggcctccacacctgatggagatgaaggcctaccacgccatctc		
ccgggccctggagaagagggcctgaaggacaagaagtccccctgaacctgtcctccgagctgcaggacgagatcggcaccgcc		
ttctccctgttcaagaccgacgaggacatcaccggccggctgaaggaccgggtgcagcccgagatcctggaggccctgctgaagc		
acatcctccttcgacaagttcgtgcagatctccctgaaggccctgcggcggatcgtgccccctgatggagcagggcaagcggtacga		
cgaggcctgcgccgagatctacggcgaccactacggcaagaagaacaccgaggagaagatctacctgccccccatcccccgccgac		
gagatccggaacccccgtggtgctgcgggccctgtcccaggcccggaaggtgatcaacgtggtgcggcggtacggctccccccg		
cccggatccacatcgagaccgcccgcgggaggtgggcaagtccttcaaggaccggaaggagatcgagaaggcggcaggaggagaaccg		
gaaggaccgggagaaggccgccgccgccaagttcccgggagtacttcccccaacttcgtgggcgagcccaagtccaaggacatcctgaag		
ctgcggctgtacgagcagcagcacggcaatgtgcctgtactccgccaaggagatcaacctggtgcggctgaacgagaaagggctacg		
tggagatcgaccacgccgccctgccttctcccggacctgggacgcactcctcaacaacaaggtgctggtgctgggctccgagaacca		
gaacaagggcaaccagacccccctacgagtacttcaacggcaaggacaactcccgggagtggcagggagttcaagggcccgggtggag		
acctcccggttcccccgtccaagaagcagcgggatcctgctgcagaagttcgacgagggacggcttcaaggagtgcaacctgaacg		
acacccggtacgtgaaccgcttcctgtgccagttcgtggccgaccacatcctgctgaccggcaagggcaagcggcgggtgttcgc		
ctccaacggccagatcaccaacctgctgcgggcttctgggcctgcggaaggtgcgggccgagaaccgacccggcaccacgccctg		
gacgccgtggtggtggcctgctccaccgtggccatgcagcagaagatcaccgcggttcgtgcggtacaaggagatgaacgcctcg		
acggcaagaccatcgacaaggagaccggcaaggtgctgcacccagaagacccactttccccccagccctgggagttcttcgcccagga		
ggtgatgatccgggtgttcggcaagccccgacggcaagccccgagttcgaggaggccgacaccccgagaagctgcggaccctgctg		
gccgagaagctgtcctccccggccgaggccgtgcacgagtacgtgaccccccgttcgtgtcccgggcccccaaccggaagatgt		
ccggcgcccacaaggacaccctgcggtccgccaagcggttcgtgaagcacaacgagaagatctccgtgaagcgggtgtggctgac		
cgagatcaagctggccgacctggagaacatggtgaactacaagaacggccgggagatcgagctgtacgaggccctgaaggcccgg		
ctggaggcctacggcggccaagccaggccttcgacccccaaggacaacccctctacaagaagggcggccagctggtgaagg		
ccgtgcgggtggagaagacccaggagtccggcgtgctgctgaacaagaagaacgcctacaccatcgccgacaacggcgacatggt		
gcgggtggacgtgttctgcaaggtggacaagaagggcaagaaccagtacttcatcgtgcccatctacgcctggcaggtggccgag		
aacatcctgcccgacatcgactgcaagggctaccggatcgacgactcctacacacctctgctcttcctgcacaagtacgacctga		
tcgccttccagaaggacgagaagtccaaggtggagttcgcctactacatcaactgcgactcctccaacggccggttctacctggc		
ctggcacgacaagggctccaaggagcagcagtccggatctccacccagaacctggtgctgatccagaagtaccaggtgaacgag		
ctgggcaaggagatccggccctgccggctgaagaagcggccccccgtgcggtccggaaagcggaccgccgacggctccgagttccg		
agtcccccaagaagaagcggaaggtggagtagTGActagcaccagcctcaagaacacccgaatggagtctctaagctacataata		
ccaacttacacttacaaaatgttgtcccccaaaatgtagccattcgtatctgctcctaataaaaagaaagtttcttcacattct		

		cTCGAGAAAAAAAAAAAAATGGAAAAAAAAAAAACGGAAAAAAAAAAAAGGTAAAAAAAAAAAATATAAAAAAAAAAACATAAAAAA AAAAAACGAAAAAAAAAAAACGTAAAAAAAAAAAACTCAAAAAAAAAAAGATAAAAAAAAAAAACCTAAAAAAAAAAAATGTAAA AAAAAAAAAGGAAAAAAAAAAAACGCAAAAAAAAAAAACACAAAAAAAAAAAATGCAAAAAAAAAAAATCGAAAAAAAAAAAATC TAAAAAAAAAAAACGAAAAAAAAAAAACCCAAAAAAAAAAAAGACAAAAAAAAAAAATAGAAAAAAAAAAAGTTAAAAAAAAAAA ACTGAAAAAAAAAAAATTTAAAAAAAAAAAAT
637	mRNA S encoding Nme2Cas9 base editor	GGGAAGCUCAGAAUAAACGCUCAACUUUGGCCGGAUCUGCCACCAUGGACGGCUCCGGCGGCGGCUCCCCCAAGAAGAAGCGGAA GGUGGAGGACAAGCGGCCCGCCGCCACCAAGAAGGCCGGCCAGGCCAAGAAGAAGAAGGGCGGCUCCGGCGGCGGCGAGGCCUCC CCCGCCUCCGGCCCCCGGCACCUGAUGGACCCCCACAUCUUCACCUCCAACUUCAACAACGGCAUCGGCCGGCACAAGACCUACC UGUGCUACGAGGUGGAGCGGCUGGACAACGGCACCUCCGUGAAGAUGGACCAGCACCGGGGCUUCCUGCACAACCAGGCCAAGAA CCUGCUGUGCGGCUUCUACGGCCGGCACGCCGAGCUGCGGUUCCUGGACCUGGUGCCCUCCCUGCAGCUGGACCCCGCCCAGAUC UACCGGGUGACCUGGUUCAUCUCCUGGUCCCCCUGCUUCUCCUGGGGCUGCGCCGGCGAGGUGCGGGCCUUCCUGCAGGAGAACA CCCACGUGCGGCUGCGGAUCUUCGCCGCCCGGAUCUACGACUACGACCCCCUGUACAAGGAGGCCCUGCAGAUGCUGCGGGACGC CGGCGCCCAGGUGUCCAUCAUGACCUACGACGAGUUCAAGCACUGCUGGGACACCUUCGUGGACCACCAGGGCUGCCCCUUCCAG CCCUGGGACGGCCUGGACGAGCACUCCCAGGCCCUGUCCGGCCGGCUGCGGGCCAUCCUGCAGAACCAGGGCAACUCCGGCUCCG AGACCCCCGGCACCUCCGAGUCCGCCACCCCCGAGUCCGCAGCGUUCAAACCAAAUCCCAUCAACUACAUCCUGGGCCUGGCCAU CGGCAUCGCCUCCGUGGGCUGGGCCAUGGUGGAGAUCGACGAGGAGGAGAACCCCAUCCGGCUGAUCGACCUGGGCGUGCGGGUG UUCGAGCGGGCCGAGGUGCCCAAGACCGGCGACUCCCUGGCCAUGGCCCGGCGGCUGGCCCGGUCCGUGCGGCGGCUGACCCGGC GGCGGGCCCACCGGCUGCUGCGGGCCCGGCGGCUGCUGAAGCGGGAGGGCGUGCUGCAGGCCGCCGACUUCGACGAGAACGGCCU GAUCAAGUCCCUGCCCAACACCCCCUGGCAGCUGCGGGCCGCCGCCCUGGACCGGAAGCUGACCCCCCUGGAGUGGUCCGCCGUG CUGCUGCACCUGAUCAAGCACCGGGGCUACCUGUCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCUGGGCGCCCUGC UGAAGGGCGUGGCCAACAACGCCCACGCCCUGCAGACCGGCGACUUCCGGACCCCCGCCGAGCUGGCCCUGAACAAGUUCGAGAA GGAGUCCGGCCACAUCCGGAACCAGCGGGGCGACUACUCCCACACCUUCUCCCGGAAGGACCUGCAGGCCGAGCUGAUCCUGCUG UUCGAGAAGCAGAAGGAGUUCGGCAACCCCCACGUGUCCGGCGGCCUGAAGGAGGGCAUCGAGACCCUGCUGAUGACCCAGCGGC CCGCCCUGUCCGGCGACGCCGUGCAGAAGAUGCUGGGCCACUGCACCUUCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCUA CACCGCCGAGCGGUUCAUCUGGCUGACCAAGCUGAACAACCUGCGGAUCCUGGAGCAGGGCUCCGAGCGGCCCCUGACCGACACC GAGCGGGCCACCCUGAUGGACGAGCCCUACCGGAAGUCCAAGCUGACCUACGCCCAGGCCCGGAAGCUGCUGGGCCUGGAGGACA CCGCCUUCUUCAAGGGCCUGCGGUACGGCAAGGACAACGCCGAGGCCUCCACCCUGAUGGAGAUGAAGGCCUACCACGCCAUCUC CCGGGCCCUGGAGAAGGAGGGCCUGAAGGACAAGAAGUCCCCCCUGAACCUGUCCUCCGAGCUGCAGGACGAGAUCGGCACCGCC UUCUCCCUGUUCAAGACCGACGAGGACAUCACCGGCCGGCUGAAGGACCGGGUGCAGCCCGAGAUCCUGGAGGCCCUGCUGAAGC ACAUCUCCUUCGACAAGUUCGUGCAGAUCUCCCUGAAGGCCCUGCGGCGGAUCGUGCCCCUGAUGGAGCAGGGCAAGCGGUACGA CGAGGCCUGCGCCGAGAUCUACGGCGACCACUACGGCAAGAAGAACACCGAGGAGAAGAUCUACCUGCCCCCCAUCCCCGCCGAC GAGAUCCGGAACCCCGUGGUGCUGCGGGCCCUGUCCCAGGCCCGGAAGGUGAUCAACGGCGUGGUGCGGCGGUACGGCUCCCCCG CCCGGAUCCACAUCGAGACCGCCCGGGAGGUGGGCAAGUCCUUCAAGGACCGGAAGGAGAUCGAGAAGCGGCAGGAGGAGAACCG GAAGGACCGGGAGAAGGCCGCCGCCAAGUUCCGGGAGUACUUCCCCAACUUCGUGGGCGAGCCCAAGUCCAAGGACAUCCUGAAG CUGCGGCUGUACGAGCAGCAGCACGGCAAGUGCCUGUACUCCGGCAAGGAGAUCAACCUGGUGCGGCUGAACGAGAAGGGCUACG UGGAGAUCGACCACGCCCUGCCCUUCUCCCGGACCUGGGACGACUCCUUCAACAACAAGGUGCUGGUGCUGGGCUCCGAGAACCA GAACAAGGGCAACCAGACCCCCUACGAGUACUUCAACGGCAAGGACAACUCCCGGGAGUGGCAGGAGUUCAAGGCCCGGGUGGAG ACCUCCCGGUUCCCCCGGUCCAAGAAGCAGCGGAUCCUGCUGCAGAAGUUCGACGAGGACGGCUUCAAGGAGUGCAACCUGAACG ACACCCGGUACGUGAACCGCUUCCUGUGCCAGUUCGUGGCCGACCACAUCCUGCUGACCGGCAAGGGCAAGCGGCGGGUGUUCGC

		CUCCAACGGCCAGAUCACCAACCUGCUGCGGGGCUUCUGGGGCCUGCGGAAGGUGCGGGCCGAGAACGACCGGCACCACGCCCUG
		GACGCCGUGGUGGUGGCCUGCUCCACCGUGGCCAUGCAGCAGAAGAUCACCCGGUUCGUGCGGUACAAGGAGAUGAACGCCUUCG
		ACGGCAAGACCAUCGACAAGGAGACCGGCAAGGUGCUGCACCAGAAGACCCACUUCCCCCAGCCCUGGGAGUUCUUCGCCCAGGA
		GGUGAUGAUCCGGGUGUUCGGCAAGCCCGACGGCAAGCCCCGAGUUCGAGGAGGCCGACACCCCCGAGAAGCUGCGGACCCUGCUG
		GCCGAGAAGCUGUCCUCCCCGGCCCGAGGCCGUGCACGAGUACGUGACCCCCCUGUUCGUGUCCCGGGCCCCCAACCGGAAGAUGU
		CCGGCGCCCACAAGGACACCCUGCGGUCCGCCAAGCGGUUCGUGAAGCACAACGAGAAGAUCUCCGUGAAGCGGGUGUGGCUGAC
		CGAGAUCAAGCUGGCCGACCUGGAGAACAUGGUGAACUACAAGAACGGCCGGGAGAUCGAGCUGUACGAGGCCCUGAAGGCCCGG
		CUGGAGGCCUACGGCGGCAACGCCAAGCAGGCCUUCGACCCCAAGGACAACCCCUUCUACAAGAAGGGCGGCCAGCUGGUGAAGG
		CCGUGCGGGUGGAGAAGACCCAGGAGUCCGGCGUGCUGAACAAGAAGCGCCCCACCGUGAAGCAGGUGGCCGAG
		GCGGGUGGACGUGUUCUGCAAGGUGGACAAGAAGGGCAAGAACCAGUACUUCAUCGUGCCCCAUCUACGCCUGGCAGGUGGGCCGAG
		AACAUCCUGCCCGACAUCGACUGCAAGGGCUACCGGAUCGACGACUCCUACACCUUCUGCUUCUCCCUGCACAAGUACGACCUGA
		UCGCCUUCCAGAAGGACGAGAAGUCCAAGGUGGAGUUUCGCCUACUACAUCAACUGCGACUCCUCCAACGGCCGGUUCUACCUGGC
		CUGGCACGACAAGGGCUCCAAGGAGCAGCAGUUCCGGAUCUCCACCCAGAACCUGGUGCUGAUCCAGAAGUACCAGGUGAACGAG
		CUGGGCAAGGAGAUCCGGCCCUGCCGGCUGCGAAGAAGCGGCCCCCGUGCGGUAGUGACUAGCACCAGCCUCAAGAACACCCGAAU
		GGAGUCUCUAAGCUACAUAAUACCAACUUACACUUUACACAAAUGUUGUCCCCCAAAUGUAGCCAUUCGUAUCUGCUCCUAAUAA
		AAGAAAGUUUCUUCACAUUCUCUCGAGAAAAAAAAAAAAAUGGAAAAAAAAAAAAAACGGAAAAAAAAAAAAAAGGUAAAAAAAAAAU
		AUAAAAAAAAAACAUAAAAAAAAAAAAACGAAAAAAAAAAAAAAACGUAAAAAAAAAAAAAAACUCAAAAAAAAAAAAAGAUAAAAAAAAAAA
		ACCUAAAAAAAAAAAAUGUAAAAAAAAAAAAAGGGAAAAAAAAAAAAAACGCAAAAAAAAAAAAAACACAAAAAAAAAAAAAUGCAAAAAAA
		AAAAUCGAAAAAAAAAAAAAUCUAAAAAAAAAAAAAACGAAAAAAAAAAAAAACCCAAAAAAAAAAAAAAGACAAAAAAAAAAAAAUAGAAA
		AAAAAAAGUUAAAAAAAAAAAAAACUGAAAAAAAAAAAAAUUUAAAAAAAAAAAAAAAUCUAG
638	mRNA T encoding Nme2Cas9 base editor	GGGaagctcagaataaacgctcaacttttggccggatctgccaccATGGAGGCCTCCCCCGCCTCCGGCCCCCGGCACCTGATGGA
		CCCCCACATCTTCACCTCCAACTTCAACAACGGCATCGGCCGGCACAAGACCTACCTGTGCTACGAGGTGGAGCGGCTGGACAAC
		GGCACCTCCGTGAAGATGGACCAGCACCGGGGCTTCCTGCACAACCAGGCCAAGAACCTGCTGTGCGGCTTCTACGGCCGGCACG
		CCGAGCTGCGGTTCCTGGACCTGGTGCCCTCCCTGCAGCTGGACCCCGCCCAGATCTACCGGGTGACCTGGTTCATCTCCTGGTC
		CCCCTGCTTCTCCTGGGGCTGCGCCGGCGAGGTGCGGGCCTTCCTGCAGGAGAACACCCACGTGCGGCTGCGGATCTTCGCCGCC
		CGGATCTACGACTACGACCCCCTGTACAAGGAGGCCCTGCAGATGCTGCGGGACGCCGGCGCCCAGGTGTCCATCATGACCTACG
		ACGAGTTCAAGCACTGCTGGGACACCTTCGTGGACCACCAGGGCTGCCCCTTCCAGCCCTGGGACGGCCTGGACGAGCACTCCCA
		GGCCCTGTCCGGCCGGCTGCGGGCCATCCTGCAGAACCAGGGCAACTCCGGCTCCGAGACCCCCGGCACCTCCGAGTCCGCCACC
		CCCGAGTCCGCAGCGTTCAAACCAAATcccatcaactacatcctgggcctggccatcgcctccgtgggctgggccatgg
		tggagatcgacgaggaggagaaccccatccggctgatcgacctgggcgtgcgggtgttcgagcgggccgaggtgcccaagaccgg
		cgactccctggccatggcccggcggctggcccggtccgtgacccggcggcgggcccaccggctgctgcgggcccgg
		cggctgctgaagcgggagggcgtgctgcaggccgccgacttcgacgagaacggcctgatcaagtccctgcccaacaccccctggc
		agctgcgggccgccgcctggaccggaagctgaccccccctggagtggtccgccgtgctgctgcacctgatcaagcaccgggggcta
		cctgtcccagcggaagaacgagggcgagaccgccgacaaggagctgggcgccctgctgaagggcgtggccaacaacgcccaccgcc
		ctgcagaccggcgacttccggaccccccgccgagctggccctgaacaagttcgagaagggagtccggccacatccggaaccagcgggg
		gcgactacccacacctttcccggaaggacctgcaggccgagctgatcctgctgttcgagaagcagaaggagttcggcaacccc
		ccacgtgtccggcggcctgaaggagggcatcgagaccctgctgatgacccagcggcccgccctgtccggcgacgccgtgcagaag
		atgctgggccactgcacctcgagcccgccgcccaaggcgcccaagaacacctacaccgccgagcgggccacccctgatggacgagccccta
		agctgaacaacctgcggatcctggagcagggctccgagcggccctgaccgacaccgagcgggccacccctgatggacgagccccta

	639	mRNA U encoding Nme2Cas9

ccggaagtccaagctgacctacgcccaggcccggaagctgctggcctggaggacaccgccttcttcaagggcctgcggtacggc
aaggacaacgccgaggcctccaccctgatggagatgaaggcctaccacgccatctcccgggccctggagaaggagggcctgaagg
acaagaagtcccccctgaacctgtcctccgagctgcaggacgagatcggcaccgcctttccctgttcaagaccgacgaggacat
caccggccggctgaaggaccgggtgcagcccgagatcctggaggccctgctgaagcacatcttccttcgacaagttcgtgcagatc
tccctgaaggccctgcgcggatcgtgccctgatggagcagggcaagcggtacgacgaggccttgcgccgaggatctacggcgacc
actacggcaagaagaacaccgaggagaagatctacctgccccccatccccgccgacgagatccggaacccgtggtgctgcgggc
cctgtcccaggccgcggaaggtgatcaacggcgtggtgcggcggctcccccgcccgggatccacatcgaagaccgccgcgggag
gtgggcaagtccttcaaggaccggaagaagcggcaggaggagaaccgggaagaaggccgccgccaaagt
tccgggagtactttccccaacttcgtgggcgagcccaagtccaaggacatcctgaagctgcggctgtacgagcagcagcacggcaa
gtgcctgtactccggcaaggagatcaacctggtgcggctgaacgagaagggctacgtggagatcgacccacgccctgccttctcc
cggacctgggacgactccttcaacaacaaggtgctggtgcgccgagaaccagaagggcaaccagacccccctacgagt
acttcaacggcaaggacaactcccgggagtggcaggagttcaagggcccggttcccccggtccaagaagca
gcggatcctgctgcagaagttcgacgaggacggcttcaaggagtgcaacctgaacgacacccggtacgttcctgtgc
cagttcgtggccgaccacatcctgctgaccggcaagggcgcgggtgttcgcctcccaacgggccagatcaccaacctgctgc
gggcttctgggggcctgcgggaggtgcgggccgagaacgaccgccacccgcctggatggtgcctgctccaccgt
ggccatgcagcagaagatcacccggttcgtgcggtacaaggagatgaacgccttcgacggcaagaccatcgacaaggagaccggc
aaggtgctgcaccagaagacccactcccccagccctgggagttcttcgcccaggaggtgatgatccgggtgttcggcaagcccg
acggcaagccccgagttcgaggaggccgacaccccgagaagctgcggccgagaagctgtcctcccgggcccgaggc
cgtgcacgagtacgtgaccccctgttcgtgtcccgggccccccaaccggaagatgtccggccgcccacaaggacaccctgcggtcc
gccaagcggttcgtgaagcacaacgagaagatctccgtgaagcgggtgtggctgaccgagatcaagctggccgacctggagaaca
tggtgaactacaagaacggccgggagatcgagctgtacgaggccctgaaggccctggagggcctacgcggcaaacgccaagca
ggccttcgacccccaaggacaacccccttctacaagaagggcggccagctggtgaaggccgtgcgggtggagaagacccaggagtcc
ggcgtgctgctgaacaagaagaacgcctacaccatcgccgacaacggcgacatggtgcgggtggacgtgttctgcaaggtggaca
agaagggcaagaaccagtacttcatcgtgcccatctacgcctggcaggtggccgagaacatcctgcccgacatcgactgcaaggg
ctaccggatcgacgactcctacaccttctgcttctcccctgcacaagtacgacctgatcgcctccagaaggacgagaagtccaag
gtggagttcgcctactacatcaactgcgactcctcccaacggccgttctacctggcctggcacgacaagggctccaaggagcagc
agttccggatctccacccagaacctggtgctgatccagaagtaccagctgaacgagctgggcaaggagatccggcccttgccggct
gaagaagcggcccccccgtgcggtccggaaagcggaccgccgactccgagttcgagtcccccaagaagaagcggaagtggtgag
tagTGActagcaccagcctcaagaacaccgaatggagtctctaagctacatataaccaactttacacttacaaaatgttgtccc
ccaaaatgtagccattcgtatctgctcctaataaaagaaagttttcttcacattctcTCGAGAAAAAAAAAAAAAAAAGGAAAAAAA
AAAACGGAAAAAAAAAAAAAGGTAAAAAAAAAAATATAAAAAAAAAACATAAAAAAAAAAAAAAACGAAAAAAAAAAAAAACGTAAAAAA
AAAAAACTCAAAAAAAAAAAAAGATAAAAAAAAAAACCTAAAAAAAAAAAAAAATGTAAAAAAAAAAAAAAGGGAAAAAAAAAAAACGCAAA
AAAAAAAACACAAAAAAAAAAAAATGCAAAAAAAAAAAATCGAAAAAAAAAAAAATCTAAAAAAAAAAAAAACGAAAAAAAAAAAACC
CAAAAAAAAAAAAGACAAAAAAAAAAAATAGAAAAAAAAAAAAAGTTAAAAAAAAAAAAAACTGAAAAAAAAAAAAAATTTAAAAAAAAAAA
AAT

GGGaagctcagaataaacgctcaactttggccggatctgccacCATGaagCTGggcTCCatcGAGttcATCaagGTGaacAAGgg
cTCCggcTCCggcTCCGGCgccCCCgagTCCgccACCgagTCCggcGGCaccTCCaccGAGtccGAGggctCCGccGGCaccTCC
accGAGtccGAGggctccGCCggcTCCgccGGCtccaccTCCaccGAGgagGGCaccTCCaccGAGtccGAGggctccGCCggcA
CCtccACCgagtccgagGGCtccGCCggcACCtccGAGtccgcccACCgagTCCggcGGCaccTCCaccGAGtccGAGggctCCtc


cTCCaccggtgccgccttcaagcccaaccccatcaactacatcctgggcctggacatcggcatcgcctccgtgggctgggccatg
gtggagatcgacgaggaggagaacccccatccggctgatcgacctgggcgtgcgggttctgagcgggccgaggtgcccaagaccg
gcgactccctggccatggcccggcgcggctccgtgcggcggctgaccccggcgggcccaccggctgctgcgggcccg
gcggctgctgaagcgggagggcgtgctgcaggccgccgacttcgacgagaacggcctgatcaagtccctgcccaacacccctgg
cagctgcgggccgccgccctggaccggaagctgaccccctgggagtggtccgccgtgctgctgcacctgatcaagcaccgggct
acctgtcccagcggaagaacgagggcgagaccgccgacaaggagctgggcgccctgctgaagggcgtggccaacaacgcccacgc
cctgcagaccggcgacttccggaccccgccgagctggccctgaacaagttcgagaaggagtccggccacatccggaaccagcgg
ggcgactacccccacacctttcccggaaggacctgcaggccgagctgatcctgctgttcgagaagcagaaggagttcggcaaacc
cccacgtgtccggcggcctgaaggagggcatcgagaccctgctgatgaccacgagcgcccgccctgtccggcgacgccgtgcagaa
gatgctgggccactgcacctttcgagccccgccgagccccaaggccgccaagaacacctacaccgccgagcggttcatctggctgacc
aagctgaacaacctgcggatcctggagcagggctccgagcggccccctgaccgacaccgagcgggccacccgatggacgagccct
accggaagtccaagctgacctacgcccaggccccggaagctgctgggcctggagaccgccctgcgccgagatcctacggcgtacgg
caaggacaacgccgaggcctccacacctgatggagatgaaggcctaccacgccatctcccgggccctggagaaggagggcctgaag
gacaagaagtccccccctgaacctgtcctccgagctgcaggacgagatcggcacccgcctttcctccctgttcaagaccgacgaggaca
tcaccggccggctgaaggacccgggtgcagccgagatcctggagggccctgctgaagcacatctccttcgacaagttcgtgcagat
ctccctgaaggccctgcggcggatcgtgccctgatggagcagggcaagcggtacgacgaggccctgcgccgagatctacgggcgac
cactacggcaagaagaacaccgaggagaagatctacctgccccccatcccgccgacgagatccggaacccctggtgctgcgggg
ccctgtcccaggccccggaaggtgatcaacggcgtggtgcggcggtacggctccccccgcccgatccacatcgagaccgcccgggga
ggtgggcaagtccttcaaggaccggaaggagatcgagaagcggcgcaggaggagaaccggaagaggccgccgcccaag
ttccgggagtacttcccccaacttcgtgggcgagccccaagtccaaggacatcctgaagctgcggctgtacgagcagcagcacggca
agtgcctgtactccggcaaggagatcaacctggtgcggctgaacgagaagggctacgtggagatcgaccacgccctgccctgctctc
ccggacctgggacgactccttcaacaacaaggtgctggtgctgggctccgagaaccagaacaagggcaaccagacccccctacgag
tacttcaacggcaaggacaactcccgggagtggcaggagttcaaggcccgggtggagacctcccggttcccccggtccaagaagc
agcggatcctgctgcagaagttcgacgaggacggcttcaaggagtgcaacctgaacgacacccggtacgtgaaccgcttcctgtg
ccagttcgtggccgaccacatcctgctgaccggcaagggcgcgggtgttcgcctccaacggccagatcaccaacctgctg
cgggcttctgggggcctgcggaaggtgcgggccgagaacgaccggcacccacgcctggacgccgtggtggtggctgcctccaccg
tggccatgcagcagaagatcacccggttcgtgcggctacaaggagatgaacgcctttcgaccgaggcaaggagaccgg
caaggtgctgcaccagaagacccacttccccagccctgggagttcttcgcccaggaggtgatgatccgggtgttcggcaagccc
gacggcaagcccgagttcgaggaggccgacaccccgagaagctgcggaccctgctggccgagaagtgtcctcccggcccgagg
ccgtgcacgagtacgtgaccccccctgttcgtgtcccgggcccccaaccggaagatgtccggcgccccacaaggacacctgcggtc
cgccaagcggttcgtgaagcacaacgagaagatctccgtgaagcgggtgtggctgaccgagatcaaggctggccgacctggagaac
atggtgaactacaagaacggccgggagatcgagctgtacgaggccctgaaggcccggctggaggcctacggcggcaacgccaagc
aggccttcgaccccaaggacaacccccttctacaagaagggcggccagctggtgaaggccgtgcgggtggagaagacccaggagtc
cggcgtgctgctgaacaagaagaacgcctacaccatcgccgacaacggcgacatggtgcgggtggacgtgttctgcaaggtggac
aagaagggcaagaaccagtacttcatcgtgccccatctacgctggcaggtggccgagaacatcctgccgacatcgactgcaagg
gctaccggatcgacgactcctacaccttctgctctccctgcacaagtacgacctgatcgcctttccagaaggacgagaagtccaa
ggtggagttcgcctactacatcaactgcgactcctccaacggccggttctacctggcctggcacgacaagggctccaaggagcag
cagttccggatctccacccagaacctggtgctgatccagaagtaccaggtgaacgagctgggcaaggagatccggccctgccggc
tgaagaagcggcccccccgtgcggtccggaaagcggaccgccgcacggctccgagttcgagtcccccaagaagaagcggaaggtgga

		gtgactagcaccagcctcaagaacacccgaatggagtcttctaagctacataataccaacttacacttacaaaatgttgtccccc aaaatgtagccattcgtatctgctccctaataaaaagaaagttttcttcacattctcTCGAGAAAAAAAAAAAAAAAAATGGAAAAAAAAAA AACGGAAAAAAAAAAAAAGGTAAAAAAAAAAAAAATATTAAAAAAAAAAAAAAAACATAAAAAAAAAAAAAAAACGAAAAAAAAAAAAA AAAAACTCAAAAAAAAAAAAAAGATAAAAAAAAAAAAAACCTAAAAAAAAAAAAAAATGTAAAAAAAAAAAAAAGGGAAA
640	Open reading frame for Nme2Cas9 encoded by mRNA A	atgaccggtgccgccttcaagcccaacccatcaacatacatcctgggcctggacatcggcatcgcctcccgtgggccatgg tggagatcgacgaggaggagaacccatccggctgatcgacctgggcgtgcgggtgttcgaggcgggccgaggtgcccaagaccgg cgactccctggccatggcccggcggctggcccggtccgtgcggcgctgaccgcggcccaccgggctgctgcgggcccgg cggctgctgaagcgggagggcgtgctgcaggccgccgacttcgacgagaacggccctgatcaagtccctgcccaacacccctggc agctgcgggccgccgcccctggaccggaagctgaccccctggagtggtccgccgtgctgctgcacctgatcaagcaccgggcta cctgtcccagcggaagaacgagggcgagaccgccgacaaggagctgggcgccctgctgaagggcgtggccaacaacgcccacgcc ctgcagaccggcgacttccggaccccccgccgagctggccctgaacaagttcgagaagaggagtccgagcacatccgaacaccagcggg gcgactacccacacctttcccggaaggacctgcgagccgagctgatcctgctgttcgagaagcagaaggagttcggcaaccc ccacgtgtccggcggcctgaaggagggcatcgagaccctgctgatgacccagcggccgccctgtccggcgacgccgtgcagaag atgctgggccactgcacctccgagccccgagccccaaggccgcccaagaacacctacaccgccgagcggttcatctggctgacca agctgaacacacctgcggatcctggagcagggctccgagcggccccctgaccgacaccgagcgggccacccctgatggacgagccccta ccggaagtccaagctgacctacgcccagggcccggaagctgctgggcctggaggacaccgcctcttcttcaaggcctgcggtacggc aaggacaacgccgaggcctccacccctgatggagatgaaggcctaccacgccatctcccgggccctggagaaggagggcctgaagg acaagaagtcccccctgaacctgtcctccgagctgcaggacgagatcggcaccgcctttctccctgttcaagaccgacgaggacat caccggccggctgaaggaccgggtgcagcccgagatcctggaggccctgctgaagcacatctccttcgacaagttcgtgatc tccctgaaggccctgcggcggatcgtgccccctgatggagcagggcaagcggtacgacgagggcctgcgcgagatctacgggacc actacggcaagaagaacaccgaggagaagatctacctgcgccccccatcccccgccgacgagatccgggaacccgtggtgctgcgggc cctgtcccaggcccggaaggtgatcaacggcgtggtgcggcggtacgtcctccccgcccgatccacatcgagaccgcccgggag gtgggcaagtccttcaaggaccggaaggagatcgagaagaagcggcaggaggagaaccgggagaaggccgccgccaagt tccgggagtacttcccccaacttcgtgggcgagcccaagtccaaggacatcctgaagctgcggctgtacgagcagcagcacgcaa gtgcctgtacctccggcaaggagatcaacctggtgcggctgaacgagaagggctacgtggagatcgaccacgcccgcctttctcc cggacctgggacgactccttcaacaacaaggtgctggtgctgggctccgagaacaagggcaacccagacccccctacgagt actttcaacggcaaggacaactcccgggagtggcaggagttcaaggcccgggtggagacctccccggttccccggtccaagaagca gcggatcctgctgcagaagttcgacgaggacggcttccaagggagtgcaacctgaacgacacccggtacgtgaaccgcttcctgtgc cagttcgtggccgaccacatcctgctgacccggcaagggcaagcggcgggtgttcgcctccaacgggccagatcaccaacctgctgc ggggcttctgggggcctgcggaaggtgcgggccgagaacgaccggcaccacgcccgtggagcgccgtgtggtggcctgctccaccgt ggccatgcagcagaagatcacccggttcgtgcggtacaaggagatgaacgcctttcgacggcaagaccatcgacaaggagacgggc aaggtgctgcaccagaagacccacttcccccagccctgggagttcttcgcccaggaggtgatgatccgggtgttcggcaagcccg acggcaagcccgagttcgaggaggccgacacccccgagaaagctgcggaccctgctggccgagaagctgtcctcccgggcccgaggc cgtgcacgagtacgtgaccccccgttcgtgtcccgggccccccaaccgggaagatgtccgggcgcccacaaggacaccctgcggtcc gccaagcggttcgtgaagcacaacgagaagatctccgtgaagcgggtgtggctgaccgagatcaagctggccgacctggagaaca tggtgaactacaagaacggccgggagatcgagctgtacgaggccctgaaggccctggaggcctacggcggcaacgccaagca ggccttcgaccccaaggacaaccccttctacaagaagggcggccagctggtgaaggccgtgcgggtggagaagacccagaggtcc ggcgtgctgctgaacaagaagaacgcctacaccatcgccgacaacggcgacatggtgcggggtggacgtgttctgcaaggtggaca agaagggcaagaaccagtacttcatcgtgccccatctagcctggcaggtggccgagaacatcctgcccgacatcgactgcaaggg

		ctaccggatcgacgactcctacacctttctgcttctccctgcacaagtacgacctgatcgccttccagaaggacgagaagtccaag
		gtggagttcgcctactacatcaactgcgactcctccaacggccggttctacctggcctggcacgacacaaggctccaaggagcagc
		agttccggatctccacccagaacctggtgctgatccagaagtaccaggtgaacgagctgggcaaggagatccgccctgccggct
		gaagaagcggccccccgtgcggtccggaaagcggaccgccgactccgagttcgagtcccccaagaagaagcggaaggtggag
		tag
641	Open reading frame for Nme2Cas9 encoded by mRNA B	atgaccggtgccgccttcaagcccaacccatcaactacatcctgggcctggacatcggcatcgcctcccgtgggccatgg
		tggagatcgacgaggaggagaacccatccggctgatcgacctgggcgtgcgggttcgagcgggccgaggtgcccaagaccgg
		cgactccctggccatggccccggcggctgccgtgcggcggctgaccccggcggcccaccgggctgctgcgggcccgg
		cggctgctgaagcgggagggcgtgctgcaggccgccgacttcgacgagaacggcctgatcaagtccctgcccaacacccctggc
		agctgcgggccgccgccctggaccggaagctgaccccctggagtggtccgccgtgctgctgcacctgatcaagcaccgggcta
		cctgtcccagcggaagaacgagggcgagaccgccgacaagggagctgggcgccctgctgaagggcgtggccaacaacgcccacgcc
		ctgcagaccggcgacttccgggaccccgccgagctggccctgaacaagttccgagaagggagtccgggccacatccggaacccagcggg
		gcgactacttcccacacctttctcccgggaaggacctgcaggccgagctgatcctgctgttcgagaagcagaaggagttcggcaaccc
		ccacgtgtccggcggcctgaaggagggcatcgagaccctgctgatgacccagcggcccgccctgtccggcgacgccgtgcagaag
		atgctgggccactgcaccttcgagcccgccgccaaggcccgccaagaacacctacaccgccgagcggttcatctggctgacca
		agctgaacaacctgcggatcctggagcagggctccgagcggccccctgaccgacaccgagcgggccacccctgatggacgagccccta
		ccggaagtccaagctgacctacgcccaggcccggaagctgctgggcctggaggacaccgccttcttcaagggcctgcggtacggc
		aaggacaacgccgaggcctcccaccctgatggagatgaaggcctaccacgccatctcccgggccctggagaaggagggcctgaagg
		acaagaagtcccccctgaacctgtcctccgagctgcaggacgagatcggcaccgcctttctccctgttcaagaccgacgaggacat
		caccggccggctgaaggaccgggtgcagcccgagatcctggagggccctgctgaagcacatctccttcgacaagttcgtgcagatc
		tccctgaaggccctgcggcggatcgtgccctgatggagcagggcaagcggtacgacgagggcctgcgccgagatctacgggcgacc
		actacggcaagaagaacaccgaggagaagatctacctgccccccatccccgccgacgagatccgggaacccctggtgctgcgggc
		cctgtcccaggcccggaaggtgatcaacggcgtggtgcggcggtacgtcctccccgcccgatccacatcgagaccgcccgggag
		gtgggcaagtccttcaaggaccggaagaggagatcgagaagcggcaggaggagaaccggaaggaccgggagaaggccgccgccaagt
		tccgggagtacttcccccaacttcgtgggcgagcccaagtccaaggacatcctgaagctgcggctgtacgagcagcagcacggcaa
		gtgcctgtactccggcaaggagatcaacctggtgcggctgaacgagaagggctacgtggagatcgaccacgccctgccctttctcc
		cggacctgggacgactccttcaacaacaaggtgctggtgctgggctccgagaacaagaacgggcaacccagacccctacgagt
		acttcaacggcaaggacaactccgggagtggcaggagttcaaggcccgggtggagacctcccggttcccccggtccaagaagca
		gcggatcctgctgcagaagttcgacgaggacggcttcaaggagtgcaacctgaacgacacccggtacgtgaaccgcttcctgtgc
		cagttcgtggccgaccacatcctgctgaccggcaagggcaagcggcgggtgttcgcctccaacgggccagatcaccaacctgctgc
		ggggcttctgggcctgcgaaggtgcgggccgagaacgaccggcaccacgccctggacgccgtggtggtggcctgctccaccgt
		ggccatgcagcagaagatcacccggttcgtgcggtacaaggagatgaacgccttcgacggcaagaccatcgacaaggagaccggc
		aaggtgctgcaccagaagacccacttcccccagcctgggagttcttcgcccaggaggtgatgatccgggtgttcggcaagcccg
		acggcaagcccgagttcgaggaggccgacacccccgagaagctgcggaccctgctggccgagaagctgtcctcccgggcccgaggc
		cgtgcacgagtacgtgaccccctgttcgtgtcccgggccccccaaccggaagatgtccggcgcccacaaggacaccctgcggtcc
		gccaagcggttcgtgaagcacaacgagaagatctccgtgaagcgggtgtggctgaccgagatcaagctggccgacctggagaaca
		tggtgaactacaagaacggccgggagatcgagctgtacgaggccctgaaggccctgcggctggaggcctacggcggcaacgccaagca
		ggcctcgaccccaaggacaaccccttctacaagaagggcggccagctggtgaaggccgtgcgggtggagaagacccagggagtcc
		ggcgtgctgctgaacaagaagaacgcctacaccatcgccgacaacggcgacatggtgcgggtggacgtgttctgcaaggtggaca

		agaagggcaagaaccagtacttcatcgtgcccatctacgcctggcaggtggccgagaacatcctgcccgacatcgactgcaaggg ctaccggatcgacgactcctacaccttctgcttctccctgcacaagtacgacctgatcgcctttccagaaggacgagaagtccaag gtggagttcgcctactacatcaactgcgactcctccaacgggccggttctacctggcctggcacgacaagggctccaaggagcagc agttccggatctccacccagaacctggtgctgatccagaagtaccaggtgaacgagctgggcaaggagatccgcctgccggct gaagaagcggccccccgtgcggtccggaaagcggaccgccgacggctccgagttcgagtcccccaagaagaagcggaaggtggag tag
642	Open reading frame for Nme2Cas9 encoded by mRNA C	atgaccggtgccgccttcaagcccaacccatcaactacatcctgggcctggacatcggcatcgcctccgtgggctgggccatgg tggagatcgacgaggaggagaacccatccggctgatcgacctgggcgtgcgggtgttcgagcgggccgaggtgcccaagaccgg cgactccctggccatggcccgcggctggccccggtccgtgcggcggctgaccacggctgctgcgtgcgggcccgg cggctgctgaagcgggagggcgtgctgcaggccgccgacttcgacgagaacggcctgatcaagtccctgcccaacacccctggc agctgcgggccgccgcctggaccggaagctgaccccctggagtggtccgccgtgctgctgcacctgatcaagcaccgggcta cctgtcccagcggaagaacgagggcgagaccgccgcacaaggagctgggcgccctgctgaaggcgtggccaacaacgcccaccgcc ctgcagaccggcgacttccgggaccccgccgagctggccctgaacaagttcgagaagggagtccgggccacatccggaacccagcggg gcgactacccccacacctttcccgggaaggacctgcaggccgagctgatcctgctgttcgagaagcagaaggagttcggcaaccc ccacgtgtccggcggcctgaaggagggcatcgagaccctgctgatgaccccagcggccccgccctgtccggcgacgccgtgcagaag atgctgggccactgcaccttcgagcccgccgccaaggccgccaagaacacctacaccgccgagcggttcatctggctgacca agctgaacacctgcggatcctggagcagggctccgagcggccccctgaccgacaccgagcgggccacccctgatggacgagccccta ccggaagtccaagctgacctacgcccagggccccggaagctgctgggccctgcgtgaaggacaccgccttcttcaaggcctgcggtacggc aaggacaacgccgaggcctccaccctgatggagatgaaggcctaccacgccatctcccgggccctggagaaggagggcctgaagg acaagaagtcccccctgaacctgtcctccgagctgcaggacgagatcggcgcaccgcctttctccctgttcaagaccgacgaggacat caccggccggctgaaggaccgggtgcagcccgagatcctggaggccctgctgaagcacatctccttcgacaagttcgtgcagatc tccctgaaggccctgcgcggatcgtgccccctgatggagcagggcaagcggtacgacgagctgcgcgccgagatctacggcgacc actacggcaagaagaacaccgaggagaagatctaccgtgcccccatccccgccgacgagatccgggaacccgtggtgctgcgggc cctgtcccaggccccggaaggtgatcaacggcgtggtgcggcggtacggctcccccgccgacatccgagaccgcccgggag gtgggcaagtccttcaaggaccggaaggagatcgagaagcggcaggaggaagaaccggaagggaccgggagaaggccgccgccaagt tccgggagtacttcccccaacttcgtgggcgagcccaagtccaaggacatcctgaagctgcggctgtacgagcagcacggcaa gtgcctgtactccggcaaggagatcaacctggtgcggctgaacgagaagggctacgtggagatcgaccacgccctgccctttctcc cggacctgggacgactccttcaacaacaaggtgctggtgctgggctccgagaaccaagaacaagggcaaccagacccccctacgagt acttcaacggcaaggacaactcccgggagtggcaggagttcaagggcccgggtggagacctcccggttccccggtccaagaagca gcggatcctgctgcagaagttcgacgaggacggcttcaaggagtgcaacctgaacgacaccccggtacgtgaaccgcttcctgtgc cagttcgtggccgaccacatcctgctgaccggcaagggcaagcggcgggtgttcgcctccaacggccagatcaccaacctgctgc ggggcttctggggcctgcggaaggtgcgggccgagaacgaccggcaccacgcctggacgccgtggtggtggcctgctccaccgt ggccatgcagcagaagatcacccggttcgtgcggtacaaggagatgaacgccttcgacggcaagaccatcgacaaggagaccggc aaggtgctgcaccagaagacccacttccccagcctgggagttctctcgcccaggaggtgatgatccgggtgttcggcaagcccg acggcaagcccgagttcgaggaggccgacacccccgagaagctgcggaccctgctggccgagaagctgtcctcccgggccgaggc cgtgcacgagtacgtgaccccccgttcgtgtcccgggccccccaaccgggaagatgtccgggcgcccacaaggacaccctgcggtcc gccaagcggttcgtgaagcacaacgagaagatctccgtgaagcgggtgtggctgaccgagatcaagctggccgacctggagaaca tggtgaactacaagaacggccgggagatcgagctgtacgaggccctgaaggccctggaggctacgcggcggcaacgccaagca ggccttcgaccccaaggacaacccctttctacaagaagggcggccagctggtgaagggccgtgcgggtggagaagacccaggagtcc

		ggcgtgctgctgaacaagaagaacgcctacaccatcgccgacaacggcgacatggtgcgggtggacgtgttctgcaaggtggaca agaagggcaagaaccagtacttcatcgtgcccatctacgcctggcaggtggccgagaacatcctgcccgacatcgactgcaagggg ctaccggatcgacgactcctacaccttctgcttctccctgcacaagtacgacctgatcgccttccagaaggacgagaagtccaag gtggagttcgcctactacatcaactgcgactcctccaacggccggttctacctggcctggcacgacaagggctccaaggagcagc agttccggatctccacccagaacctggtgctgatccagaagtaccaggtgaacgagctgggcaaggagatccgcgccctgccggct gaagaagcggccccccgtgcggtccggaaagcggaccgccgacggctccgagttcgagtccccccaagaagaagcggaaggtggag tag
643	Open reading frame for Nme2Cas9 encoded by mRNA D	atgaccggtgccgccttcaagcccaacccatcaactacatcctgggcctggacatcggcatcgcctcccgtgggctgggccatgg tggagatcgacgaggaggagaacccatccggctgatcgacctgggcgtgcgggtgttcgagcgggccgaggtgcccaagaccgg cgactccctggccatggcccgcggctggcccggctgcggcgggcccaccggctgctgcgggcccgg cggctgctgaagcgggagggcgtgctgcaggccgccgacttcgacgagaacggcctgatcaagtccctgcccaacaccccctggc agctgcgggccgccgcctggaccggaagctgaccccctggagtggtccgccgtgctgctgcatcctgatcaagcaccgggcta cctgtcccagcggaagaacgagggcgagaccgccgacaaggagctgggcgccctgctgaaggcgtggccaacaacgcccacgcc ctgcagaccggcgacttccgggaccccgccgagctggccctgaacaagttccgagaaggagtccggccacatccggaacccagcggg gcgactacttcccacacctttctcccggaaggaccgagctgatcctgctgttcgagaaagcagaaggagttcggcgacgaccc ccacgtgtccggcggcctgaaggagggcatcgagaccctgctgatgacccagcggccccgccctgtccggcgacgccgtgcagaag atgctgggccactgcaccttcgagcccgccgccgaggccaagaacacctacaccgccgagcggttcatctggctgacca agctgaacaacctgcggatcctggagcagggctccgagcggccccctgaccgacaccgagcgggccaccctgatggacgagccccta ccggaagtccaagctgacctacgcccagggcccggaagctgctgggcctggaggacaccgccttcttcaaggggcctgcggtacggc aaggacaacgccgaggcctccacccctgatggagatgaaggcctaccacgccatctcccgggccctggagaaggagggcctgaagg acaagaagtcccccctgaacctgtcctccgagctgcaggacgagatcggcaccgcctttctccctgttcaagaccgacgaggacat caccggccggctgaaggaccgggtgcagcccgagatcctggaggccctgctgaagcacatctccttcgacaagttcgtgcagatc tccctgaaggccctgcggcggatcgtgccctgatggagcagggcaagcggtacgacgagggcctgcgccgagatctacgggcgacc actacggcaagaagaacaccgaggagaagatctacctgcgcccccatccccgccgacgagatccgggaacccgtggtgctgcgggc cctgtcccaggccccggaaggtgatcaacggcgtggtgcggcggtacgtcctccccgcccgcgatccacatcgaggaccgcccgggag gtgggcaagtccttcaaggaccggaagaggagatcgagaagcggcaggaggagaaccggaaggaccgggagaaggccgccgccgcaagt tccgggagtacttccccaacttcgtgggcgagcccaagtccaaggacatcctgaagctgcggctgtacgagcagcagcacggcaa gtgcctgtactccggcaaggagatcaacctggtgcggctgaacgagaagggctacgtggagatcgaccacgccctgccctttctcc cggacctgggacgactccttcaacaacaaggtgctggtgctgggctccgagaaccagaacaagggcaaccagacccccctacgagt acttcaacggcaaggacaactcccgggagtggcaggagttcaaggcccgggtggagacctcccggttcccccggtccaagaagca gcggatcctgctgcagaagttcgacgaggacggcttcaaggagtgcaacctgaacgacacccggtacgtgaaccgcttcctgtgc cagttcgtggccgaccacatcctgctgaccggcaagggcaagcggcgggtgttcgcctccaacgggccagatcaccaacctgctgc ggggcttctgggcctgcgaaggtgcgggccgagaacgaccggcaccacgccctggacgccgtggtggtggcctgctccaccgt ggccatgcagcagaagatcacccggttcgtgcggtacaaggagatgaacgccttcgacggcaagaccatcgacaaggagaccggc aaggtgctgcaccagaagacccactcccccagccctgggagttctctcgcccaggaggtgatgatccgggtgttcggcaagcccg acggcaagcccgagttcgaggaggccgacaccccccgagaagctgcggaccctgctggccgagaagctgtcctcccgggcccgaggc cgtgcacgagtacgtgaccccccgttcgtgtcccgggccccccaaccggaagatgtccggcgcccacaaggacaccctgcggtcc gccaagcggttcgtgaagcacaacgagaagatctccgtgaagcgggtgtggctgaccgagatcaagctggccgacctggagaaca tggtgaactacaagaacggccgggagatcgagctgtacgaggccctgaaggccctggaggctacgcggcggcaacgccaagca

		ggccttcgacccaaggacaacaccccttctacaagaagggcggccagctggtgaaggccgtgcgggtggagaagacccaggagtcc ggcgtgctgctgaacaagaagaacgcctacaccatcgccgacaacggcgacatggtgcgggtggacgtgttctgcaaggtggaca agaagggcaagaaccagtacttcatcgtgcccatctacgcctggcaggtggccgagaacatcctgcccgacatcgactgcaaggg ctaccggatcgacgactcctacaccttctgcttctccctgcacaagtacgacctgatcgccttccagaaggacgagaagtccaag gtggagttcgcctactacatcaactgcgactcctccaacgccggttctacctggcctggcacgacaaggctccaaggagagcagc agttccggatctccacccagaacctggtgctgatccagaagtaccaggtgaacgagctgggcaaggagatccgccctgccggct gaagaagcggccccccgtgcggtccggaaagcggaccgccgactccgagttcgagtcccccaagaagaagcggaaggtggag tag
644	Open reading frame for SpyCas9 base editor encoded by mRNA E	ATGgaggcctccccgcctccggccccggcacctgatggaccccacatcttcacctccAACTTCAACAAGgcATCggccggC ACAAGaccTACCTGTGCTACgaggtggagcggCTGGACAACggcacctccgtgAAGATGGACCAGCACgcggggcTTCCTGCACAA CCAGgccAAGAACCTGCTGTGCggcTTCTACggccggCACgccgagCTGcggTTCCTGGACCTGgtgccctccCTGCAGCTGGAC cccgccCAGATCTACcgggtgaccTGGTTCATCtccTGGtcccccTGCTTCtccTGGggcTGCgccggcgaggtgcgggccTTCC TGCAGgagAACaccCACgtgcggCTGcggATCTTCgccgcccgggATCTACGACTACGACcccCTGTACAAGgaggccCTGCAGAT GCTGcggGACgccggcgcccCAGgtgtccATCATGaccTACGACgagTTCAAGCACTGCTGGGACaccTTCgtgGACCACCAGggc TGCcccTTCCAGccctTGGGACGggcCTGGACgagCACtcccCAGgccCTGtccggccggCTGcgggccATCCTGCAGAACCAGggcA ACtccggctccgagacccccggcacctccgccacccccgagtccgacaagaagtactccatcgggcctggCcatcggcac caactccgtgggctgggccgtgatcaccgacgagtacaaggtgccctccaagaagttcaaggtgctgggcaacaccgacccggcac tccatcaagaagaacctgatcgggcgccctgctgttcgactccggcgagaccgccgaagccacccggctgaagcggaccgcccggc ggcggtacacccggcggaagaaccggatctgctacctgcaggagatcttctccaacgagatggccaaggtggacgactccttctt ccaccggctggaggagtccttcctggtggaggaggacaagaagcacgagcgccacccccatcttcggcaacatcgtggacgaggtg gcctaccacgagaagtacccccacatctaccacctgcggaagaagctggtggactccaccgacaaggccgacctgcggctgatct acctggccctggcccacatgatcaagttccgggccacttcctgatcgagggcgacctgaacccggacaactccgacgtggacaaa gctgttcatccagctggtgcagacctacaacgagctgttcgaggagaacccccatcaacgcctccggcgtggacgccaaggccatc ctgtccgcccggctgtccaagtcccggcggctggagaacctgatcgcccagctgcccggcgagaagaacggcctgttcggca acctgatcgccctgtccctgggcctgacccccaacttcaagtccaacttcgacctggccgaggacgccaagctgcagctgtccaa ggacacctacgacgacgacctggacaacctgctggcccagatcggcgaccagtacgccgacctgtttcctggccgccaagaacctg tccgacgccatcctgctgtccgacatcctgcgggtgaacaccgagatcaccaaggcccccctgtccgcctccatgatcaagcggt acgacgagcaccaccaggacctgaccctgctgaaggccctggtgcggcagctgcccgagaagtacaaggagatcttcttcga ccagtccaagaacggctacgccggctacatcgacgggggcgcctcccaggaggagttctacaagttcatcaagcccatcctggag aagatggacggcaccgaggagctgctggtgaagctgaaccgggaggaggacctgctgcggaagcagcggacctttcgacaacggctcca tccccaccagatccacctgggcgagctgcacgccatcctgcggcggcaggaggacttctaccccttcctgaaggacaaccgggaa gaagatcgagaagatcctgaccttccggatcccctactacgtgggcccctggccgcgggcaactcccggttcgcctggatgacc cggaagtccgaggagaccatcaccccctggaacttcgaggaggtggtggacaagggcgcctccgccagtcctttcatcgagcgga tgaccaacttcgacaagaacctgcccaacgagaaggtgctgcccaagcactccctgctgtacgagtacttcaccgtgtacaacga gctgaccaaggtgaaatacgtgaccgagggcatgcggaagccgcctttcctgtccggcgagcagaaggaagccatcgtggacctg ctgttcaagaccaaccggaaggtgaccgtgaagcagctgaaggaggactacttcaagaagatcgagtgcttcgactccgtggaga tctccggcgtggaggaccggttcaacgcctccctgggcacctaccacgacctgctgaagatcatcaaggacaaggacttcctgga caacgaggagaacgaggacatcctggaggacatcgtgctgaccctgacccttgttcgaggaccgggagatgatcgaggagcggctg aagacctacgcccacctgttcgacgacaaggtgatgaagcagctgaagcggcggtacaccggctgggggccggctgtcccgga

		agctgatcaacgtcgcatccgggacaagcagtccggcaagaccatcctggacttcctgaagtccgacggcttcgccaaccggaactt
		catgcagctgatccacgacgactccctgaccttcaaggaggacatccagaaggcccaggtgtccggccagggcgactccctgcac
		gagcacatcgccaacctggccggctcccccgccatcaagaagggcatcctgcagaccgtgaaggtggtggacgagctggtgaagg
		tgatgggccggcacaagcccgagaacatcgtgatcgagatggcccgggagaaccagaccacccagaaggccagaagaactcccg
		ggagcggatgaagcggatcgaggagggcatcaaggagctgggctcccagatcctgaaggagcacccccgtggagaacacccagctg
		cagaacgagaagctgtacctgtactacctgcagaacgggcgggacatgtacgtggaccaggagctggacatcaaccggctgtccg
		actacgacgtggaccacatcgtgccccagtcctttcctgaaggacgactccatcgacaacaaggtgctgacccggtcccgacaagaa
		ccggggcaagtccgacaacgtgccctccgaggaggtggtgaagaagatgaagaactactggcggcagctgctgaacgccaagctg
		atcacccagcggaagttcgacaacctgaccaaggccgagcgggggcggcctgtccgagctggacaagaggccggcttcatcaagcggc
		agctggtggagacccggcagatcacaagcacgtggcccagatcctggactcccggatgaacaccaagtacgacgagaacgacaa
		gctgatccgggaggtgaaggtgatcaccctgaagtccaagctggtgtccgacttccggaaggacttccagttctacaaggtgcgg
		gagatcaacaactaccacgcccacgacgcctacctgaacgccgtggtgggcaccgccctgatcaagaagtaccccaagctgg
		agtccgagttcgtgtacggcgactacaaggtgtacgacgtgcggaagatgatcgccaagtccgagcaggagatcggcaaggccac
		cgccaagtacttcttctactcccaacatcatgaacttcttcaagaccgagatcaccctggccaacggcgagatccgcaagcggccc
		ctgatcgagaccaacggcgagaccggcgagatcgtgtgggacaagggccgggacttcgccaccgtgcgcaaggtgctgtccatgc
		cccaggtgaacatcgtgaagaagaccgaggtgcagacccggcggcttctccaagggagtccatcctgccccaagcggaactccgacaa
		gctgatcgcccgcaagaagggactgggacccccaagaagtacggcggcttcgactcccccaccgtggctactcccgtggctgtg
		gccaaggtggagaagggcaagtcccaagaagctgaagtccgtgaaggagctgctgggcatcaccatcatggagcggtcctccttcg
		agaagaacccccatcgacttcctggaggccaagggctacaaggaggtgaagaaggacctgatcatcaagctgcccaagtactccct
		gttcgagctggagaacggccgcaagcgcatgctggcctccgccggcgagctgcagaagggcaacgagctgccctgccctccaag
		tacgtgaactttcttgtacctggcctcccactacgagaagctgaagggctccccccgaggacaacgagcagaagcagctgtttcgtgg
		agcagcacaagcactacctggacgagatcatcgagcagatctccgagttcttccaagcgggtgatcctggccgacgccaacctgga
		caaggtgctgtccgcctacaacaagcaccgggacaaagcccatccgggagcaggccgagaacatcatccacctgttcaccctgacc
		aacctgggcgccccccgccgccttcaagtacttcgacaccacccatcgaccggaagcgtacacctccacaaggaggtgctggacg
		ccacctgatccaccagtccatcaccggcctgtacgagacccggatcgacctgtcccagctgggcggcgacggcggcggctcccc
		caagaagaagcggaaggtgTgA
645	Open reading frame for Nme1Cas9 encoded by mRNA F	ATGGCAGCATTCAAGCCGAACTCGATCAACTACATCCTGGGACTGGACATCGGAATCGCATCGGTCGGATGGGCAATGGTCGAAA
		TCGACGAAGAAGAAAACCCGATCAGACTGATCGACCTGGGAGTCAGAGTCTTCGAAAGAGCAGAAGTCCCGAAGACAGGAGACTC
		GCTGGCAATGGCAAGAAGACTGGCAAGATCGGTCAGAAGACTGACAAGAAGAAGAGCACACAGACTGCTGAGAACAAGAAGACTG
		CTGAAGAGAGAAGGAGTCCTGCAGGCAGCAAACTTCGACGAAAACGGACTGATCAAGTCGCTGCCGAACACACACCGTGGCAGCTGA
		GAGCAGCAGCACTGGACAGAAAGCTGACACCGCTGGAATGGTCGGCAGTCCTGCTGCACCTGATCAAGCACAGAGGATACCTGTC
		GCAGAGAAAGAACGAAGGAGAAACAGCAGACAAGGAACTGGGAGCACTGCTGAAGGGAGTCGCAGGAAACGCACACGCACTGCAG
		ACAGGAGACTTCAGAACACCGGCAGAACTGGCACTGAACAAGTTCGAAAAGGAATCGGGACACATCAGAAACCAGAGATCGGACT
		ACTCGCACACATTCTCGAGAAAGGACCTGCAGGCAGAACTGATCCTGCTGTTCGAAAGCAGAAGGAATTCGGAAACCCGCACGT
		CTCGGGAGGACTGAAGGAGGAATCGAAACACTGCTGATGACACAGAGACCGGCACTGTCGGGAGACGCAGTCCAGAAGATGCTG
		GGACACTGCACATTCGAACCGGCAGAACCGAAGGCAGCAAAGAACACATACACAGCAGAAAGATTCATCTGGCTGACAAAGCTGA
		ACAACCTGAGAATCCTGGAACAGGGATCGGAAAGACCGCTGACAGACACAGAAAGAGCAACACTGATGGACGAACCGTACAGAAA
		GTCGAAGCTGACATACGCACAGGCAAGAAAGCTGCTGGGACTGGAAGACACAGCATTCTTCAAGGGACTGAGATACGGAAAGGAC
		AACGCAGAAGCATCGACACTGATGGAAATGAAGGCATACCACGCCAATCTCGAGAGCACTGGAAAAGGAAGGACTGAAGGACAAGA

		AGTCGCCGCTGAACCTGTCGCCGGAACTGCAGGACGAAATCGGAACAGCATTCTCGCTGTTCAAGACAGACGAAGACATCACAGG
		AAGACTGAAGGACAGAATCCAGCCGGAAATCCTGGAAGCACTGCTGAAGCACATCTCGTTCGACAAGTTCGTCCAGATCTCGCTG
		AAGGCACTGAGAAGAATCGTCCCGCTGATGGAACAGGGAAAGAGATACGACGAAGCATGCGCAGAAATCTACGGAGACCACTACG
		GAAAGAAGAACACAGAAGAAAAGATCTACCTGCCGCCGATCCCGGCAGACGAAATCAGAAACCCGGTCGTCCTGAGAGCACTGTC
		GCAGGCAAGAAAGGTCATCAACGGAGTCGTCAGAAGATACGGATCGCCGGCAAGAATCCACATCGAAACAGCAAGAGAAGTCGGA
		AAGTCGTTCAAGGACAGAAAGGAAATCGAAAAGAGACAGGAAGAAAACAGAAAGGACAGAGAAAAGGCAGCAGCAAAGTTCAGAG
		AATACTTCCCGAACTTCGTCGGAGAACCGAAGTCGAAGGACATCCTGAAGCTGAGACTGTACGAACAGCAGCACGGAAAGTGCCT
		GTACTCGGGAAAGGAAATCAACCTGGGAAGACTGAACGAAAAGGGATACGTCGAAATCGACCACGCACTGCCGTTCTCGAGAACA
		TGGGACGACTCGTTCAACAACAAGGTCCTGGTCCTGGGATCGGAAAACCAGAACAAGGGAAACCAGACACCGTACGAATACTTCA
		ACGGAAAGGACAACTCGAGAGAATGGCAGGAATTCAAGGCAAGAGTCGAAACATCGAGATTCCCGAGATCGAAGAAGCAGAGAAT
		CCTGCTGCAGAAGTTCGACGAAGACGGATTCAAGGAAAGAAACCTGAACGACACAAGATACGTCAACAGATTCCTGTGCCAGTTC
		GTCGCAGACAGAATGAGACTGACAGGAAAGGGAAAGAAGAGTCTTCGCATCGAACGGACAGATCACAAACCTGCTGAGAGGAT
		TCTGGGGACTGAGAAAGGTCAGAGCAGAAAACGACACAGACACCACGCACTGGACGCAGTCGTCGTCGCATGCTCGACAGTCGCAAT
		GCAGCAGAAGATCACAAGATTCGTCAGATACAAGGAAATGAACGCATTCGACGGAAAGACAATCGACAAGGAAACAGGAGAAGTC
		CTGCACCAGAAGACACACTTCCCGCAGCCGTGGGAATTCTTCGCACAGGAAGTCATGATCAGAGTCTTCGGAAAGCCGGACGGAA
		AGCCGGAATTCGAAGAAGCAGACACACTGGAAAAGCTGAGAACACTGCTGGCAGAAAAGCTGTCGTCGAGACCGGAAGCAGTCCA
		CGAATACGTCACACCGCTGTTCGTCTCGAGAGCACCGAACAGAAAGATGTCGGGACAGGGACACATGGAAACAGTCAAGTCGGCA
		AAGAGACTGGACGAAGGAGTCTCGGTCCTGAGAGTCCCGCTGACACAGCTGAAGCTGAAGGACCTGGAAAAGATGGTCAACAGAG
		AAAGAGAACCGAAGCTGTACGAAGCACTGAAGGCAAGACTGGAAGCACACAAGGACGACCCGGCAAAGGCATTCGCAGAACCGTT
		CTACAAGTACGACAAGGCAGGAAACAGAACACAGGCAGGTCAAGGCAGTCAGAGTCGAACAGGTCCAGAAGACAGGAGTCTGGGTC
		AGAAACCACAACGGAATCGCAGACAACGCAACAATGGTCAGATAGACGTCTTCGAAAGGGAGACAAGTACTACCTGGTCCCGA
		TCTACTCGTGGCAGGTCGCAAAGGGAATCCTGCCGGACAGAGCAGTCGTCCAGGGAAAGGACGAAGAAGACTGGCAGCTGATCGA
		CGACTCGTTCAACTTCAAGTTCTCGCTGCACCCGAACGACCTGGTCGAAGTCATCACAAAGAAGGCAAGAATGTTCGGATACTTC
		GCATCGTGCCACAGAGGAACAGGAAACATCAACATCAGAATCCACGACCTGGACCACAAGATCGGAAAGAACGGAATCCTGGAAG
		GAATCGGAGTCAAGACACACTGTCGTTCCAGAAGTACCAGATCGACGAACTGGGAAAGGAAATCAGACCGTGCAGACTGAAGAA
		GAGACCGCCGGTCAGATCCGGAAAGAGAACAGCAGACGGATTCGAATTCGCCGAAGAAGAAGAGGTGGAGTGGATGATAG
646	Open reading frame for UGI encoded by mRNA G	ATGACCAACCTGTCCGACATCATCGAGAAGGAGACCGGCAAGCAGCTGGTGATCCAGGAGTCCATCTCCATGCTGCCCGAGGAGG
		TGGAGGAGGTGATCGGCAACAAGCCCGAGTCCGACATCCTGGTGCACACCGCCTACGACGAGTCCACCGACGAGAACGTGATGCT
		GCTGACCTCCGACGCCCCCGAGTACAAGCCCTGGGCCCTGGTGATCCAGGACTCCAACGGCGAGAACAAGATCAAGATGCTGTCC
		GGCGGCTCCAAGCGGACCGCCGACGGCTCCGAGTTCGAGTCCCCCAAGAAGAAGCGGAAGGTGGAGTGGATAG
647	Open reading frame for Nme2Cas9 encoded by mRNA H	ATGGCCGCCTTCAAGCCCAACCCCATCAACTACATCCTGGGCCTGGACATCGGCATCGCCTCCGTGGGCTGGGCCATGGTGGAGA
		TCGACGAGGAGGAGAACCCCATCCGGCTGATCGACCTGGGCGTGCGGGTGTTCGAGCGGGCCGAGGTGCCCAAGACCGGCGACTC
		CCTGGCCATGGCCCGGCGGCTGGCCCGGTCCGTGCGGCGGCTGACCCGGCGCGGCGGGCCCACCGGCTGCTGCGGGCCCGGCGGCTG
		CTGAAGCGGGAGGGCGTGCTGCAGGCCGCCGACTTCGACGAGAACGGCCTGATCAAGTCCCTGCCCAACACCCCCTGGCAGCTGC
		GGGCCGCCGCCCTGGACCGGAAGCTGACCCCCCTGGAGTGGTCCGCCGTGCTGCTGATCAAGCACCGGGGCTACCTGTC
		CCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCTGGGCGCCCTGCTGAAGGGCGTGGCCAACACGCCCCACGCCCTGCAG
		ACCGGCGACTTCCGGACCCCCGCCGAGCTGGCCCTGAACAAGTTCGAGAAGGAGTCCGGCCACATCCGGAACCAGCGGGGCGACT
		ACTCCCACACCTTCTCCCGGAAGGACCTGCAGGCCGAGCTGATCCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGT
		GTCCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGACCCAGCGGCCCGCCCTGTCCGGCGACGCCGTGCAGAAGATGCTG

		GGCCACTGCACCTTCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGCGGTTCATCTGGCTGACCAAGCTGA
		ACAACCTGCGGATCCTGGAGCAGGGCTCCGAGCGGCCCCTGACCGACACCGAGCGGGCCACCCTGATGGACGAGCCCTACCGGAA
		GTCCAAGCTGACCTACGCCCAGGCCCGGAAGCTGCTGGGCCTGGAGGACACCGCCTTCTTCAAGGGCCTGCGGTACGGCAAGGAC
		AACGCCGAGGCCTCCACCCTGATGGAGATGAAGGCCTACCACGCCATCTCCCGGGCCCTGGAGAAGGAGGCCTGAAGGACAAGA
		AGTCCCCCCTGAACCTGTCCTCCGAGCTGCAGGACGAGATCGGCACCGCCTTCTCCCTGTTCAAGACCGACGAGGACATCACCGG
		CCGGCTGAAGGACCGGGTGCAGCCCGAGATCCTGGAGGCCCTGCTGAAGCACATCTCCTTCGACAAGTTCGTGCAGATCTCCCTG
		AAGGCCCTGCGGCGGATCGTGCCCCTGATGGAGCAGGGCAAGCGGTACGACGAGGCCTGCGCCGAGATCTACGGCGACCACACTACG
		GCAAGAAGAACACCGAGGAGAAGATCTACCTGCCCCCCATCCCCGCCGACGAGATCCGGAACCCCGTGGTGCTGCGGGCCCTGTC
		CCAGGCCCGGAAGGTGATCAACGGCGTGGTGCGGCGGTACGGCTCCCCCGCCCGGATCCACATCGAGACCGCCCGGGAGGTGGGC
		AAGTCCTTCAAGGACCGGAAGGAGATCGAGAAGCGGCAGGAGGAGAACCGGGAAGGACCGGCGCCGCCAAGTTCCGGG
		AGTACTTCCCCAACTTCGTGGGCGAGCCCAAGGACATCCTGAAGCTGCGGCTGTACGAGCAGCACGGCAAGTGCCT
		GTACTCCGGCAAGGAGATCAACCTGGTGCGCTGAACGAGAAGGGCTACGTGGAGATCGACCACGCCCTGCCCTTCTCCCGGACC
		TGGGACGACTCCTTCAACAACAAGGTGCTGGTGCTGGGCTCCGAGAACCAGAACAAGGGCAACCAGACCCCCTACGAGTACTTCA
		ACGGCAAGGACAACTCCCGGGAGTGGCAGGAGTTCAAGGCCCGGGTGGAGACCTCCCGGTTCCCCCGGTCCAAGAAGCAGCGGAT
		CCTGCTGCAGAAGTTCGACGAGGACGGCTTCAAGGAGTGCAACCTGAACGACACCCGGTACGTGAACCGGTTCCTGTGCCAGTTC
		GTGGCCGACCACATCCTGCTGACCGGCAAGGGCAAGCGGCGGGTGTTCGCCTCCAACGGCCAGATCACCAACCTGCTGCGGGGCT
		TCTGGGGCCTGCGGAAGGTGCGGGCCGAGAACGACCGGCACCACGCCCTGGACGCCGTGGTGGTGGCCTGCTCCACCGTGGCCAT
		GCAGCAGAAGATCACCCGGTTCGTGCGGTACAAGGAGATGAACGCCTTCGACGGCAAGACCATCGACAAGGAGACCGGCAAGGTG
		CTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCCGGGTGTTCGGCAAGCCCGACGGCA
		AGCCCGAGTTCGAGGAGGCCGACACCCCCGAGAAGCTGCGGACCCTGCTGGCCGAGAAGCTGTCCTCCCGGCCCGAGGCCGTGCA
		CGAGTACGTGACCCCCCTGTTCGTGTCCCGGGCCCCCAACCGGAAGATGTCCGGCGCCCACAAGGACACCCTGCGGTCCGCCAAG
		CGGTTCGTGAAGCACAACGAGAAGATCTCCGTGAAGCGGGTGTGGCTGACCGAGATCAAGCTGGCCGACCTGGAGAACATGGTGA
		ACTACAAGAACGGCCGGGAGATCGAGCTGTACGAGGCCCTGAAGGCCCGGCTGGAGGCCTACGGCGGCAACGCCAAGCAGGCCTT
		CGACCCCAAGGACAACCCCTTCTACAAGAAGGGCGGCCAGCTGGTGAAGGCCGTGCGGGTGGAGAAGACCCAGGAGTCCGGCGTG
		CTGCTGAACAAGAAGAACGCCTACACCATCGCCGACAACGGCGACATGGTGCGGGTGGACGTGTTCTGCAAGGTGGACAAGTCCG
		GCGGCGGCTCCCCCAAGAAGAAGCGGAAGGTGTCCGGCGCTCCGGCAAGAACCAGTACTTCATCGTGCCCATCTACGCCTGGCA
		GGTGGCCGAGAACATCCTGCCCGACATCGACTGCAAGGGCTACCGGATCGACGACTCCTACACCTTCTGCTTCTCCCTGCACAAG
		TACGACCTGATCGCCTTCCAGAAGGACGAGAAGTCCAAGGTGGAGTTCGCCTACTACATCAACTGCGACTCCTCCACCAACGGCCGGT
		TCTACCTGGCCTGGCACGACAAGGGCTCCAAGGAGCAGCAGTTCCGGATCTCCACCCAGAACCTGGTGCTGATCCAGAAGTACCA
		GGTGAACGAGCTGGGCAAGGAGATCCGGCCCTGCCGGCTGAAGAAGCGGCCCCCCGTGCGGTAG
648	Open reading frame for Nme2Cas9 encoded by mRNA I	ATGGTGCCCAAGAAGAAGCGGAAGGTGGCCGCCTTCAAGCCCAACCCCATCAACTACATCCTGGGCCTGGACATCGGCATCGCCT
		CCGTGGGCTGGGCCATGGTGGAGATCGACGAGGAGGAGAACCCCATCCGGCTGATCGACCTGGGCGTGCGGGTGTTCGAGCGGGC
		CGAGGTGCCCAAGACCGGCGACTCCCTGGCCATGGCCCGGCGGCTGGCCCGGTCCGTGCGGCGGCTGACCCGGCGGCGGGCCCAC
		CGGCTGCTGCGGGCCCGGCGGCTGCTGAAGCGGGAGGGCGTGCTGCAGGCCGCCGACTTCGACGAGAACGGCCTGATCAAGTCCC
		TGCCCAACACCCCCTGGCAGCTGCGGGCCGCCGCCCTGGACCGGAAGCTGACCCCCCTGGAGTGGTCCGCCGTGCTGCTGCACCT
		GATCAAGCACCGGGGCTACCTGTCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCTGGGCGCCCTGCTGAAGGGCGTG
		GCCAACGCCCACGCCCTGCAGACCGGCGACTTCCGGACCCCCGCCGAGCTGGCCCTGAACAAGTTCGAGAAGGAGTCCGGCCC
		ACATCCGGAACCAGCGGGGCGACTACTCCCACACCTTCTCCCGGAAGGACCTGCAGGCCGAGCTGATCCTGCTGTTCGAGAAGCA
		GAAGGAGTTCGGCAACCCCCACGTGTCCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGACCCAGCGGCCCGCCCTGTCC

		GGCGACGCCGTGCAGAAGATGCTGGGCCACCTGCACCTTCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGC
		GGTTCATCTGGCTGACCAAGCTGAACAACCTGCGGATCCTGGAGCAGGGCTCCGAGCGGCCCCTGACCGACACCGAGCGGGCCAC
		CCTGATGGACGAGCCCTACCGGAAGTCCAAGCTGACCTACGCCCAGGCCCGGAAGCTGCTGGGCCTGGAGGACACCGCCTTCTTC
		AAGGGCCTGCGGTACGGCAAGGACAACGCCGAGGCCTCCACCCTGATGGAGATGAAGGCCTACCACGCCATCTCCCGGGCCCTGG
		AGAAGGAGGGCCTGAAGGACAAGAAGTCCCCCCTGAACCTGTCCTCCGAGCTGCAGGACGAGATCGGCACCGCCTTCTCCCTGTT
		CAAGACCGACGAGGACATCACCGGCCGGCTGAAGGACCGGGTGCAGCCCGAGATCCTGGAGGCCCTGCTGAAGCTGCGGCTGTA
		GACAAGTTCGTGCAGATCTCCCTGAAGGCCCTGCGGCGGATCGTGCCCCTGATGGAGCAGGGCAAGCGGTACGACGAGGCCTGCG
		CCGAGATCTACGGCGACCACTACGGCAAGAAGAACACCGAGGAGAAGATCTACCTGCCCCCCATCCCCGCCGACGAGATCCGGAA
		CCCCGTGGTGCTGCGGGCCCTGTCCCAGGCCCGGAAGGTGATCAACGGCGTGGTGCGGCGGTACGGCTCCCCCGCCCGGATCCAC
		ATCGAGACCGCCCGGGAGGTGGGCAAGTCCTTCAAGGACCGGAAGGAGATCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGG
		AGAAGGCCGCCGCCAAGTTCCGGGAGTACTTCCCCAACTTCGTGGGCGAGCCCAAGTCCAAGGACATCCTGAAGCTGCGGCTGTA
		CGAGCAGCACGGCAAGTGCCTGTACTCCGGCAAGGAGATCAACCTGGTGCGGCTGAACGAGAAGGGCTACGTGGAGATCGAC
		CACGCCCTGCCCTTCTCCCGGACCTGGGACGACTCCTTCAACAACAAGGTGCTGGTGCTGGGCTCCGAGAACCAGAACAAGGGCA
		ACCAGACCCCCTACGAGTACTTCAACGGCAAGGACAACTCCCGGGAGTGGCAGGAGTTCAAGGCCCGGGTGGAGACCTCCCGGTT
		CCCCCGGTCCAAGAAGCAGCGGATCCTGCTGCAGAAGTTCGACGAGGACGGCTTCAAGGAGATGTACGCCTTCGACGGCAAGACC
		GTGAACCGGTTCCTGTGCCAGTTCGTGGCCGACCACATCCTGCTGACCGGCAAGGGCAAGCGGCGGTGTTCGCCTCCAACGGCC
		AGATCACCAACCTGCTGCGGGGCTTCTGGGGCCTGCGGAAGGTGCGGGCCGAGAACGACCGGCACCCAGCCCTGGACGCCGTGGT
		GGTGGCCTGCTCCACCGTGGCCATGCAGCAGAAGATCACCCGGTTCGTGCGGTACAAGGAGATGAACGCCTTCGACGGCAAGACC
		ATCGACAAGGAGACCGGCAAGGTGCTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCC
		GGGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACACCCCCGAGAAGCTGCGGCCGAGAAGCT
		GTCCTCCCGGCCCGAGGCCGTGCACGAGTACGTGACCCCCCTGTTCGTGTCCGGGCCCCCAACCGGAAGATGTCCGGCGCCCAC
		AAGGACACCCTGCGGTCCGCCAAGCGGTTCGTGAAGCACAACGAGAAGATCTCCGTGAAGCGGGTGTGGCTGACCGAGATCAAGC
		TGGCCGACCTGGAGAACATGGTGAACTACAAGAACGGCCGGGAGATCGAGCTGTACGAGGCCCTGAAGGCCCTGGAGGCCTA
		CGGCGGCAACGCCAAGCAGGCCTTCGACCCCAAGGACAACCCCTTCTACAAGAAGGGCGGCCAGCTGGTGAAGGCCGTGCGGGTG
		GAGAAGACCCAGGAGTCCGGCGTGCTGCTGAACAAGAACGCCTACACCATCGCCGACAACGGCGACATGGTGCGGGTGGACG
		TGTTCTGCAAGGTGGACAAGAAGGGCAAGAACCAGTACTTCATCGTGCCCATCTACGCCTGGCAGGTGGCCGAGAACATCCTGCC
		CGACATCGACTGCAAGGGCTACCGGATCGACGACTCCTACACCTTCTGCTTCTCCCTGCACAAGTACGACCTGATCGCCTTCCAG
		AAGGACGAGAAGTCCAAGGTGGAGTTCGCCTACTACATCAACTGCGACTCCTCCAACGGCCGGTTCTACCTGGCCTGGCACGACA
		AGGGCTCCAAGGAGCAGCAGTTCCGGATCTCCACCCAGAACCTGGTGCTGATCCAGAAGTACCAGGTGAACGAGCTGGGCAAGGA
		GATCCGGCCCTGCCGGCTGAAGAAGCGGCCCCCCGTGCGGTACCCCTACGACGTGCCCGACTACGCCGCCCCGCCCAAG
		AAGAAGAAGCTGGACTAG
649	Open reading frame for Nme2Cas9 encoded by mRNA J	ATGGCCGCCTTCAAGCCCAACCCCATCAACTACATCCTGGGCCTGGACATCGGCATCGCCTCCGTGGGCTGGGCCATGGTGGAGA
		TCGACGAGGAGGAGAACCCCATCCGGCTGATCGACCTGGGCGTGCGGGTGTTCGAGCGGGCCGAGGTGCCCAAGACCGGCGACTC
		CCTGGCCATGGCCCGGCGGCTGGCCCGGTCCGTGCGGCGGCTGACCCGGCGGCGGGCCCACCGGCTGCTGCGGGCCCGGCGGCTG
		CTGAAGCGGGAGGGCGTGCTGCAGGCCGCCGACTTCGACGAGAACGGCCTGATCAAGTCCCTGCCCAACACCCCCTGGCAGCTGC
		GGGCCGCCGCCCTGGACCGGAAGCTGACCCCCCTGGAGTGGTCCGCCGTGCTGCTGATCAAGCACCGGGGCTACCTGTC
		CCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCTGGGCGCCCTGCTGAAGGGCGTGGCCAACACGCCCCACGCCCTGCAG
		ACCGGCGACTTCCGGACCCCCGCCGAGCTGGCCCTGAACAAGTTCGAGAAGGAGTCCGGCCACATCCGGAACCAGCGGGGCGACT
		ACTCCCACACCTTCTCCCGGAAGGACCTGCAGGCCGAGCTGATCCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGT

		GTCCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGACCCAGCGGCCCGCCCTGTCCGGCGACGCCGTGCAGAAGATGCTG
		GGCCACTGCACCTTCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGCGGTTCATCTGGCTGACCAAGCTGA
		ACAACCTGCGGATCCTGGAGCAGGGCTCCGAGCGGCCCCTGACCGACACCGAGCGGGCCACCCTGATGGACGAGCCCTACCGGAA
		GTCCAAGCTGACCTACGCCCAGGCCCGGAAGCTGCTGGGCCTGGAGGACACCGCCTTCTTCAAGGGCCTGCGGTACGGCAAGGAC
		AACGCCGAGGCCTCCACCCTGATGGAGATGAAGGCCTACCACGCCATCTCCCGGGCCCTGGAGAAGGAGGGCCTGAAGGACAAGA
		AGTCCCCCCTGAACCTGTCCTCCGAGCTGCAGGACGAGATCGGCACCGCCTTCTCCCTGTTCAAGACCGACGAGGACATCACCGG
		CCGGCTGAAGGACCGGGTGCAGCCCGAGATCCTGGAGGCCCTGCTGAAGCACATCTCCTTCGACAAGTTCGTGCAGATCTCCCTG
		AAGGCCCTGCGGCGGATCGTGCCCCTGATGGAGCAGGGCAAGCGGTACGACGAGGCCTGCGCCGAGATCTACGGCGACCACACTA
		GCAAGAAGAACACCGAGGAGAAGATCTACCTGCCCCCCATCCCCGCCGACGAGATCCGGAACCCCGTGGTGCTGCGGGCCCTGTC
		CCAGGCCCGGAAGGTGATCAACGGCGTGGTGCGGCGGTACGGCTCCCCCGCCCGGATCCACATCGAGACCGCCCGGGAGGTGGGC
		AAGTCCTTCAAGGACCGGAAGGAGATCGAGAAGCGGCAGGAGGAGAACCGGGAGAAGGCCGCCGCCAAGTTCCGGG
		AGTACTTCCCCAACTTCGTGGGCGAGCCCAAGTCCAAGGACATCCTGAAGCTGCGGCTGTACGAGCAGCACGGCAAGTGCCT
		GTACTCCGGCAAGGAGATCAACCTGGTGCGGCTGAACGAGAAGGGCTACGTGGAGATCGACCACGCCTGCCCTTCTCCCGGACC
		TGGGACGACTCCTTCAACAACAAGGTGCTGGTGCTGGGCTCCGAGAACCAGAACAAGGGCAACCAGACCCCCTACGAGTACTTCA
		ACGGCAAGGACAACTCCCGGGAGTGGCAGGAGTTCAAGGCCCGGGTGGAGACCTCCCCCGGTTCCCCCGGTCCAAGAAGCAGCGGAT
		CCTGCTGCAGAAGTTCGACGAGGACGGCTTCAAGGAGTGCAACCTGAACGACACCCGGTACGTGAACCGGTTCCTGTGCCAGTTC
		GTGGCCGACCACATCCTGCTGACCGGCAAGGGCAAGCGGCGGGTGTTCGCCTCCAACGGCCAGATCACCAACCTGCTGCGGGGCT
		TCTGGGGCCTGCGGAAGGTGCGGGCCGAGAACGACCGGCACCACGCCCTGGACGCCGTGGTGGTGGCCTGCTCCACCGTGGCCAT
		GCAGCAGAAGATCACCCGGTTCGTGCGGTACAAGGAGATGAACGCCTTCGACGGCAAGACCATCGACGAGACCGGCAAGGTG
		CTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCCGGGTGTTCGGCAAGCCCGACGGCA
		AGCCCGAGTTCGAGGAGGCCGACACCCCCGAGAAGCTGCGGACCCTGCTGGCCGAGAAGCTGTCCTCCCGGCCCGAGGCCGTGCA
		CGAGTACGTGACCCCCCTGTTCGTGTCCGGGCCCCCAACCGGAAGATGTCCGGCGCCCACAAGGACACCCTGCGGTCCGCCAAG
		CGGTTCGTGAAGCACAACGAGAAGATCTCCGTGAAGCGGGTGTGGCTGACCGAGATCAAGCTGGCCGACCTGGAGAACATGGTGA
		ACTACAAGAACGGCCGGGAGATCGAGCTGTACGAGGCCCTGAAGGCCCGGCTGGAGGCCTACGGCGGCAACGCCAAGCAGGCCTT
		CGACCCCAAGGACAACCCCTTCTACAAGAAGGGCGGCCAGCTGGTGAAGGCCGTGCGGGTGGAGAAGACCCAGGAGTCCGGCGTG
		CTGCTGAACAAGAAGAACGCCTACACCATCGCCGACAACGGCGACATGGTGCGGGTGGACGTGTTCTGCAAGGTGGACAAGAAGG
		GCAAGAACCAGTACTTCATCGTGCCCATCTACGCCTGGCAGGTGGCCGAGAACATCCTGCCCGACATCGACTGCAAGGGCTACCG
		GATCGACGACTCCTACACCTTCTGCTTCTCCCTGCACAAGTACGACCTGATCGCCTTCCAGAAGGACGAGAAGTCCAAGGTGGAG
		TTCGCCTACTACATCAACTGCGACTCCTCCAACGGCCGGTTCTACCTGGCCTGGCACGACAAGGGCTCCAAGGAGCAGCAGTTCC
		GGATCTCCACCCAGAACCTGGTGCTGATCCAGAAGTACCAGGTGAACGAGCTGGGCAAGGAGATCCGGCCCTGCCGGCTGAAGAA
		GCGGCCCCCCGTGCGG
650	Open reading frame for Nme2Cas9 encoded by mRNA K	atggccgccttcaagcccaaccccatcaactacatcctgggcctggacatcggcatcgcctccgtgggctgggccatggtggaga tcgacgaggaggagaaccccatccggctgatcgacctgggcgtgcgggtgttcgagcgggccgaggtgcccaagagaccggcgactc cctggccatggcccggcggctggcccggtccgtgcggcggctgaccggcgcgggcccaccggctgctgcgggcccggcggctg ctgaagcgggaggcgctgctgcaggccgccgacttcgacgagaacggcctgatcaagtccctgcccaacaccccctggcagctgc gggccgccgccctggaccggaagctgaccccctgggagtggtccgccgtgctgctgcacctgatcaagcaccgggggctacctgtc ccagcggaagaacgagggcgagaccgccgacaaggagctgggcgccctgctgaagggcgtggccaacaacgcccacgccctgcag accggcgacttccggaccccccgccgagctggccctgaacaagttcgagaaggagtccggccacatccgagaaccagcgggcgact actcccacacctctcccggaaggacctgcaggccgagctgatcctgctgttcgagaagcagaaggagttcggcaacccccacgt

		gtccggcggcctgaaggagggcatcgagaccctgctgatgacccagcggcccgccctgtccggcgacgccgtgcagaagatgctg
		ggccactgcacctttcgagcccgccgagcccaaggccgccaagaacacctacaccgccgagcggttcatctggctgaccaagctga
		acaacctgcggatcctggagcagggctccgagcggcccctgaccgacaccgagcgggccacccctgatggacgagccctaccggaa
		gtccaagctgacctacgcccaggcccggaagctgctgggcctggaggacaccgccttcttcaaggggcctgcggtacggcaaggac
		aacgccgaggcctccaccctgatggagatgaaggcctaccacgccatctcccgggccctggagaaggagggcctgaaggacaaga
		agtccccctgaacctgtcctccgagctgcaggacgagatcggcaccgccttctccctgttcaagaccgacgaggacatcaccgg
		ccggctgaaggaccgggtgcagcccgagatcctggaggccctgctgaagcacatcctccttcgacaagttcgtgcagatctccctg
		aaggccctgcggcggatcgtgccccctgatggagcagggctacgcgaggcctgcgccgagatctacgtgcccttctcccggacc
		gcaagaagaacaccgaggagaagatctacctgccccccatccccgccgacgagatccggaacccctggtgctgcgggccctgtc
		ccaggcccggaaggtgatcaacggcgtggtgcggcggtacggctccccccgcccccggatccacatcgagaccgcccgggaggtgggc
		aagtccttcaaggaccggaagaggatcgagaagcggcagaggagaaccgggagaaggaccgggagaaggccgccgcccaagttccggg
		agtactccccaacttcgtgggcgagcccaagtccaaggacatcctgaagctgcggctgtacgagcagcacgcagcgacgtgcct
		gtactccggcaaggagatcaacctggtgcggctgaacgagaagggctacgtggagatcgaccacgcccttcctcccggacc
		tgggacgactccttcaacaacaaggtgctggtgctgggctccgagaaccagaacaagggcaacccagaccccctacgagtacttca
		acggcaaggacaactccccgggagtggcaggagttcaagggcccggtggagacctcccccggttcccccggtccaagaagcagcggat
		cctgctgcagaagttcgacgaggacggcttccaaggagtgcaacctgaacgacacccggtacgtgaaccggttcctgtgccagttc
		gtggccgaccacatcctgctgaccggcaagggcgagcgggtgttcgcctccaacggccagatcaccaacctgctgcgggggct
		tctgggcctgcggaaggtgcgggccgagaacgaccggcaccacgccctggacgccgtggtggtggcctgctccaccgtggccat
		gcagcagaagatcacccggttcgtgcggtacaaggagatgaacgccttcgacggcaagaccatcgacaaggagaccgggcaaggtg
		ctgcaccagaagacccactttccccagcccttgggagttcttcgcccaggagggtgatgatccgggtgttcggcaagcccgacggca
		agcccgagttcgaggaggccgacacccccgagaagctgcggaccctgctggccgagaagctgtcctcccggcccgagggccgtgca
		cgagtacgtgaccccccctgttcgtgtcccgggcccccaaccggaagatgtccgggcgcccacaaggacaccctgcggtccgccaag
		cggttcgtgaagcacaacgagaagaagatctccgtgaagcgggtgtggctgaccgagatcaagctggccgacctggagaacatggtga
		actacaagaacggccgggagatcgagctgtacgaggccctgaaggccccggctggaggcctacgcggcaacgccaagcaggcctt
		cgacccaaggacaaccccttctacaagaagggcggccagctggtgaaggccgtgcgggtggagaagacccaggagtccggcgtg
		ctgctgaacaagaagaacgcctacaccatcgccgacaacggcgacatggtgcgggtggacgtgttctgcaaggtggacaagaagg
		gcaagaaccagtacttcatcgtgccccatctacgcctggcaggtggccgagaacatcctgccgacatcgactgcaagggctaccg
		gatcgacgactcctacaccttctgcttctccctgcacaagtacgacctgatcgccttccagaaggacgagaagtccaagtggag
		ttcgcctactacatcaactgcgactcctccaacggccggttctacctggcctggcacgacaagggctccaaggagcagcagttcc
		ggatctccacccagaacctggtgctgatccagaagtaccaggtgaacgagctgggcaaggagatccggccctgccggctgaagaa
		gcggccccccgtgcgg
651	Open reading frame for Nme2Cas9 encoded by mRNA L	atgGACGGCTCCGGCGGCGGCTCCCCCAAGAAGAAGCGGAAGGTGGGCGGCTCCGGCGGCGGCgccgcctcaagcccaacccca
		tcaactacatcctgggcctggacatcggcatcgcctccgtgggctgggccatggtggagatcgacgaggaggagaacccccatccg
		gctgatcgacctgggcgtgcgggtgttcgagcgggccgaggtgcccaagagaccggcgactccctggccggcggctggccc
		cggtccgtgcggcggctgacccggcggcgggcccaccggctgctgcgggccgcggctgctgaagcgggagggcgtgctgcagg
		ccgccgacttcgacgagaacggcctgatcaagtccctgcccaacaccccctggcagctgcgggccgccgccctggaccggaagct
		gaccccctggagtggtccgccgtgctgctgcacctgatcaagcaccgggggctacctgtcccagcggaagaacgagggcgagacc
		gccgacaaggagctgggcgccctgctgaagggcgtggccaacaacgcccacgccctgcagaccggcgactccgggaccccccgccg
		agctggccctgaacaagttcgagaaggagtccggccacatccggaaccagcgggcgactactcccacacctctcccggaagga

	652	Open reading frame for Nme2Cas9 with HiBiT tag encoded by mRNA

cctgcaggccgagctgatcctgctgttcgagaagcagaaggagttcggcaaccccccacgtgtccggcggcctgaaggagggcatc
gagaccctgctgatgacccagcggcccgccctgtccggcgacgccgtgcagaagatgctgggccaccttcgagcccgccg
agcccaaggccgccaagaacacctacaccgccgagcggttcatctggctgaccaagctgaacaacctgcggatcctggagcaggg
ctccgagcggccccctgaccgacaccgagcggcacccttcgatggacgagaagtccaagctgtacctacgcccaggcc
cggaagctgctgggcctggaggacaccgcctcttcaagggcctgcggtacggcaaggacaacgccgaggcctcccacccctgatgg
agatgaaggcctaccacgccatcccccggcccctggagaaggagggcctgaaggacaagaagtcccccctgaacctgtcctccga
gctgcaggacgagatcggcaccgccttctccctgttcaagaccgacgaggacatcaccggccggctgaaggaccgggtgcagccc
gagatcctggaggccctgctgaagcacatcctccttcgacaagttcgtgcagatctcccctgaagggccctgcggcggatcgtgcccc
tgatggagcagggcaagcggtacgacgaggccgtgcgccgagatctacggcgaccactacggcaagaagaacaccgaggagaagat
ctacctgccccccatcccccgccgacgagatccggaaccccgtggtgctgcgggccctgtcccaggcccggaaggtgatcaacggc
gtggtgcggcggtacggctccccgcccgatccacatcgagaccgcccgggaggtgggcaagtccttcaaggaccggaaggaga
tcgagaagcggcaggaggagaacccgggagaaggccgccgccaagttccgggagtactttccccaacttcgtgggcga
gcccaagtccaaggacatcctgaagctgcggctgtacgagcagcacggcaagtgcctgtactccggcaaggagatcaacctg
gtgcggctgaacgagaagggctacgtggagatcgaccacgccctgccctgcccttctcccggacctgggacgactccttcaacaacaagg
tgctggtgctgggctccgagaacaagggcaacccagaccccctacgagtacttcaacggcaaggacaactcccgggagtg
gcaggagttcaaggccgggtggagacctcccggttccccccggtccaagaagcagcggatcctgctgcagaagttcgacgaggac
ggcttcaaggagtgcaacctgaacgacaccggtacgtgaaccggttcctgtgccagttcgtggccgaccacatcctgctgaccg
gcaagggcaagcggcgggtgttcgcctccaacgggccagatcaccaacctgctgcgggcttctgggcctgcggaaggtgcgggc
cgagaacgaccggcaccacgccctggacgccgtggtggtggctccctgctccaccgtggccatgcagaagatcacccggttcgtg
cggtacaaggagatgaacgccttcgacgcaagaccatcgacaaggagaccgtgctgcaccagaagacccactttccccc
agccctgggagttcttcgcccaggaggtgatgatccgggtgttcggcaagcccgacgcggcaagccccgagttcgaggaggccgacac
cccgagaagctgcggaccctgctggccgagaagctgtcctcccggcccgaggccgtgcacgagtacgtgaccccctgttcgtg
tcccgggccccaaccggaagatgtccggcgcccacaaggacaccctgcggtccgccaagcggttcgtgaagcacaacgagaaga
tctccgtgaagcgggtgtggctgaccgagatcaagctggccgacctggagaacatgttgaactacaagaacggccgggagatcga
gctgtacgagcgccctgaagggccccggctgaagcctacgggcaacgccaagcaggccttcgacccaaggacaacccctttctac
aagaagggcggccagctggtgaaggccgtgcgggtggagaagacccaggagtccggcgtgctgctgaacaagaagaacgcctaca
ccatcgccgacaacggcgacatggtgcgggtggacgtgttctgcaaggtggacaagaagggcaagaacctacgtgccc
catctacgcctggcaggtggccgagaacatcctgcccgacatcgactgcaagggctaccgagcgactccctacacctttctgc
ttctccctgcacaagtacgacctgatcgccttccagaaggacgagaagtccaagtggagttcgcctactacatcaactgcgact
cctccaacggccggttctacctggcctggcacgacaagggctccaaggagcagcagttcccggatctcccaccgagaacctggtgct
gatccagaagtaccaggtgaacgagctgggcaaggagatccggccctgccggctgaagaagcgggccccccgtgcggtag

ATGGACGGCTCCGGCGGCGGCTCCCCCAAGAAGAAGCGGAAGGTGGGCGGCTCCGGCGGCGGCGCCGCCTTCAAGCCCAACCCA
TCAACTACATCCTGGGCCTGGACATCGGCATCGCCTCCGTGGGCTGGGCCATGGTGGAGATCGACGAGGAGGAGAACCCCATCCG
GCTGATCGACCTGGGCGTGCGGGTGTTCGAGCGGGCCGAGGTGCCCAAGACCGGCGACTCCCTGGCCATGGCCCGGCGGCTGGCC
CGGTCCGTGCGGCGGCTGACCCGGCGGCGGCCCACCGGCTGCTGCGGGCCCGGCGGCTGCTGAAGCGGGAGGGCGTGCTGCAGG
CCGCCGACTTCGACGAGAACGGCCTGATCAAGTCCCTGCCCAACACCCCCTGGCAGCTGCGGGCCGCCGCCCTGGACCGGAAGCT
GACCCCCCTGGAGTGGTCCGCCGTGCTGCTGCACCTGATCAAGCACCGGGGCTACCTGTCCCAGCGGAAGAACGAGGGCGAGACC
GCCGACAAGGAGCTGGGCGCCCTGCTGAAGGGCGTGGCCAACGCCCACGCCCTGCAGACCGGCGACTTCCGGACCCCCGCCG
AGCTGGCCCTGAACAAGTTCGAGAAGGAGTCCGGCCACATCCGGAACCAGCGGGGCGACTACTCCCACACCTTCTCCCGGAAGGA

		CCTGCAGGCCGAGCTGATCCTGCTGTTCGAGAAGCAGAAGGAGTTCGGCAACCCCCACGTGTCCGGCGGCCTGAAGGAGGGCATC
		GAGACCCTGCTGATGACCCAGCGGCCCGCCCTGTCCGGCGACGCCGTGCAGAAGATGCTGGGCCACTGCACCTTCGAGCCCGCCG
		AGCCCAAGGCCGCCAAGAACACCTACACCGCCGAGCGGTTCATCTGGCTGACCAAGCTGAACAACCTGCGGATCCTGGAGCAGGG
		CTCCGAGCGGCCCCTGACCGACACCGAGCGGGCCACCCTGATGGACGAGCCCTACCGGAAGTCCAAGCTGACCTACGCCCAGGCC
		CGGAAGCTGCTGGGCCTGGAGGACACCGCCTTCTTCAAGGGCCTGCGGTACGGCAAGGACAACGCCGAGGCCTCCACCCTGATGG
		AGATGAAGGCCTACCACGCCATCTCCCGGGCCCTGGAGAAGGAGGGCCTGAAGGACAAGAAGTCCCCCCTGAACCTGTCCTCCGA
		GCTGCAGGACGAGATCGGCACCGCCTTCTCCCTGTTCAAGACCGACGAGGACATCACCGGCCGGCTGAAGGACCGGGTGCAGCCC
		GAGATCCTGGAGGCCCTGCTGAAGCACATCTCCTTCGACAAGTTCGTGCAGATCTCCCTGAAGGCCCTGCGGCGGATCGTGCCCC
		TGATGGAGCAGGGCAAGCGGTACGACGAGGCCTGCGCCCGAGATCTACGGCGACCACTACGGCAAGAAGAACACCGAGGAGAAGAT
		CTACCTGCCCCCCATCCCGCCGACGAGATCCGGAACCCCGTGGTGCTGCGGGCCCTGTCCCAGGCCCGGAAGGTGATCAACGGC
		GTGGTGCGGCGGTACGGCTCCCCCGCCCGGATCCACATCGAGACCGCCGCCGGGAGGTGGGCAAGTCCTTCAAGGACCGGAAGGAGA
		TCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGTTCCGGGAGTACTTCCCCAACTTCGTGGGCGA
		GCCCAAGTCCAAGGACATCCTGAAGCTGCGGCTGTACGAGCAGCACGGCAAGTGCCTGTACTCCGGCAAGGAGATCAACCTG
		GTGCGGCTGAACGAGAAGGGCTACGTGGAGATCGACCACGCCCTGCCCTTCTCCCGGACCTGGGACGACTCCTTCAACAACAAGG
		TGCTGGTGCTGGGCTCCGAGAACCAGAACAAGGGCAACCAGACCCCCTACGAGTACTTCAACGGCAAGGACAACTCCCGGGAGTG
		GCAGGAGTTCAAGGCCCGGGTGGAGACCTCCCGGTTCCCCAAGAAGCAGCGGATCCTGCTGCAGAAGTTCGACGAGGAC
		GGCTTCAAGGAGTGCAACCTGAACGACACCCGGTACGTGAACCGGTTCCTGTGCCAGTTCGTGGCCGACCACATCCTGCTGACCG
		GCAAGGGCAAGCGGCGGGTGTTCGCCTCCAACGGCCAGATCACCAACCTGCTGCGGGGCTTCTGGGCCTGCGGAAGGTGCGGGC
		CGAGAACGACCGGCACCACGCCCTGGACGCCGTGGTGGTGGCCTGCTCCACCGTGGCCATGCAGCAGAAGATCACCCGGTTCGTG
		CGGTACAAGGAGATGAACGCCTTCGACGGCAAGACCATCGACAAGGAGACCGTGCACCAGAAGACCCACTTCCCCC
		AGCCCTGGGAGTTCTTCGCCCAGGAGGTGATGATCCGGGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACAC
		CCCCGAGAAGCTGCGGACCCTGCTGGCCGAGAAGCTGTCCTCCCGGCCCGAGGCCGTGCACGAGTACGTGACCCCCCTGTTCGTG
		TCCCGGGCCCCCAACCGGAAGATGTCCGGCGCCCACAAGGACACCCTGCGGTCCGCCAAGCGGTTCGTGAAGCACAACGAGAAGA
		TCTCCGTGAAGCGGGTGTGGCTGACCGAGATCAAGCTGGCCGACCTGGAGAACATGGTGAACTACAAGAACGGCCGGGAGATCGA
		GCTGTACGAGGCCCTGAAGGCCCGGCTGGAGGCCTACGGCGGCAACGCCAAGCAGGCCTTCGACCCCAAGGACAACCCCTTCTAC
		AAGAAGGGCGGCCAGCTGGTGAAGGCCGTGCGGGTGGAGAAGACCCAGGAGTCCGGCGTGCTGCTGAACAAGAAGAACGCCTACA
		CCATCGCCGACAACGGCGACATGGTGCGGGTGGACGTGTTCTGCAAGGTGGACAAGAAGGGCAAGAACCAGTACTTCATCGTGCCC
		CATCTACGCCTGGCAGGTGGCCGAGAACATCCTGCCCGACATCGACTGCAAGGGCTACCGGATCGACGACTCCTACACCTTCTGC
		TTCTCCCTGCACAAGTACGACCTGATCGCCTTCCAGAAGGACGAGAAGTCCAAGGTGGAGTTCGCCTACTACATCAACTGCGACT
		CCTCCAACGGCCGGTTCTACCTGGCCTGGCACGACAAGGGCTCCAAGGAGCAGCAGTTCCGGATCTCCACCCAGAACCTGGTGCT
		GATCCAGAAGTACCAGGTGAACGAGCTGGGCAAGGAGATCCGGCCCTGCCGGCTGAAGAAGCGGCCCCCCGTGCGGTCCGAGTCC
		GCCACCCCCGAGTCCGTGTCCGGCTGGCGGCTGTTCAAGAAGATCTCCTAG
653	Open reading frame for Nme2Cas9 encoded by mRNA N	atgGACGGCTCCGGCGGCGGCTCCCCCAAGAAGAAGCGGAAGGTGGGCGGCTCCGGCGGCGGCgccgcctcaagcccaacccca tcaactacatcctgggcctggacatcggcatcgcctccgtgggctgggccatggtggagatcgacgaggaggagaacccccatccg gctgatcgacctgggcgtgcgggtgttcgagcgggccgaggtgcccaagaccggcgactccctggccatggcccggcgctggcc cggtccgtgcggcggctgacccggcgcggcccaccgctgctgcgggccgcggctgctgaagcgggagggcgtgctgcagg ccgccgacttcgacgagaacggcctgatcaagtccctgcccaacacccctggcagctgcgggccgccctggaccggaagct gaccccctggagtggtccgccgtgctgcacctgatcaagcaccgggctacctgtcccagcggaagaacgagggcgagacc gccgacaaggagctgggcgccctgctgaagggcgtggccaacaacgcccacgccctgcagaccggcgactccgggaccccgccg

	654	Open reading frame for Nme2Cas9 encoded by mRNA O

agctggccctgaacaagttcgagaaggagtccggccacatccggaaccagcggggcgactactcccacacctttcccggaagga
cctgcaggccgagctgatcctgctgttcgagaagcagaaggagttcggcaacccccacgtgtccggcggcctgaaggagggcatc
gagaccctgctgatgaccacgcggcccgcctgtccggcgacgccgtgcagaagatgctgggccacctgcaccttcgagcccgccg
agcccaaggccgccaagaacacctacaccgcgagcggttcatctggctgaccaagctgcggatcctggagcaggg
ctccgagcggccccctgaccgacaccgagcgggccacccctacggaagtccaagctgtgacctacgcccaggcc
cggaagctgctgggcctggaggacaccgccttcttcaagggcctgcggtacggcaaggacaacgccgaggcctccacccctgatgg
agatgaaggcctaccacgccatctcccgggccctggagaaggagggcctgaagacaagaagtcccccctgaacctgtcctccga
gctgcaggacgagatcggcaccgccttctccctgttcaagaccgacgaggacatcaccgggccggctgaaggaccgggtgcagccc
gagatcctggaggccctgctgaagcacatcctccttcgacaagttcgtgcagatctcccgtgaaggccctgcgcggatcgtgcccc
tgatggagcagggcaagcggtacgacgaggcctgcgccgagatctacggcgaccactacggcaagaagaacaccgaggagaagat
ctacctgcccccccatcccccgccgacgagatccggaaccccgtggtgctgcgggccctgtcccaggccgccgaagggtgatcaacggc
gtggtgcgcggtacggctccccgcccgatccacatcgagaccgcccgggaggtgggcaagtccttcaaggaccgaaggaga
tcgaagaagcggcagaggaggagaaccgggaagaaggccgccgccaagttcccgaactttcgtgggcga
gcccaagtccaaggacatcctgaagctgcggctgtacgagcagcacggcaagtgcctgtactccggcaaggagatcaacctg
gtgcggctgaacgagaagggctacgtggagatcgaccacgccctgccttctcccggacctgggacgactcctcaacaacaagg
tgctggtgctgggctccgagaaccagaacaagggcaacccagaccccctacgagtacttcaacgggcaaggacaactcccgggagtg
gcaggagttcaagggcccgggtggagacctccccggttccccgtccaagaagcagcggatcctgctgcagaagttcgacgaggac
ggcttcaaggagtgcaacctgaacgacaccggtacgtgaaccgttcctgtgccagttcgtggccgaccacatcctgctgaccg
gcaagggcaagcggcgggtgttcgcctccaacggccagatcaccaacctgctgcgggcttctgggcctgcggaaggtgcgggc
cgagaacgaccggcaccacgccctggacgccgtggtggtggctgctccaccgtggccatgcagcagaagatcacccggttcgtg
cggtacaaggagatgaacgccttcgacgggcaagaccatcgacaaggagaccgtgctgcaccagaagacccactttcccccc
agccctgggagttcttcgcccaggaggtgatgatccgggtgttcggcaagcccgacgtgcaggaggccgacac
cccgagaagctgcggaccctgctggccgagaagctgtcctcccggcccgaggccgtgcacgagtacgtgaccccctgttcgtg
tcccgggcccccaaccggaagatgtccggcgcccacaaggacaccctgcggttccgtcaagccaacgagaaaga
tctccgtgaagcgggtgtggctgaccgagatcaagctggccgacctggagaacatggtgaactacaagaacggccgggagatcga
gctgtacgaggccctgaaggccccggctggaggcctacgccgccaagccaggccttcgacccccaaggacaacccctctac
aagaagggcggccagctggtgaaggccgtgcgggtggagaagacccaggagtccggcgtgctgctgaacaagaagaacgcctaca
ccatcgccgacaacggcgacatggtgcgggtggacgtgttctgcaaggtggacaagaagggcaagaaccagtacttcatcgtgcc
catctacgcctggcaggtggccgagaaacatcctgcccgacatcgactgcaagggctaccggatcgacgacttcctacacctttctgc
ttctccctgcacaagtacgacctgatcgccttccagaaggacgagaagtccaaggtggagttcgcctactacaaactgcgact
cctccaacggccggttctacctggcctggcacgacaagggctccaaggagcagcagttcccggatctccacccagaacctggtgct
gatccagaagtaccaggtgaacgagctgggcaaggagatccggccctgccggctgaagaagcgggccccccgtgcggTCCGGAAAG
CGGACCGCCGACGGCTCCGGAGGAGGAAGCCCCGCCGCCAAGAAGAAGAAGCTGGACtag

atgGACGGCTCCGGCGGCGGCTCCCCCAAGAAGAAGCGGAAGGTGGAGGACAAGCGGCCCGCCGCCACCAAGAAGGCCGGCCAGG
CCAAGAAGAAGAAGGGCGGCTCCGGCGGCGGCgccgcctttcaagcccaacccccatcaactacatcctgggcctggacatcggcat
cgcctccgtgggctgggccatggtggagatcgacgaggaggagaaccccatccggctgatcgacctgggcgtgcgggtgttcgag
cgggccgaggtgcccaagaccggcgactccctggccatggcccgggcggctgctgcaggccgccgactTcgacgagaacggcctgatcaa
gtcctgcccaacaccccctggcagctgcgggccgccctggaccggaagctgacccccctggagtggtccgccgtgctgctg

Open reading frame for Nme2Cas9 encoded by mRNA O

	655	Open reading frame for Nme2Cas9 with HiBiT tag

cacctgatcaagcaccgggctacctgtcccagcggaagaacgagggcgagaccgccgacaaggagctgggcgccctgctgaagg
gcgtggccaacaacgcccacgcccgcctgcagaccggcgacttccggacccccgccgagctggccctgaacaagttcgagaaggagctc
cggccacatccggaaccagcgggcgactacctcccacacctttcccggaaggacctgcaggccgagctgatcctgctgttcgag
aagcagaaggagttcggcaaccccacgtgtccggcggcctgaaggagggcatcgagacccctgctgatgaccagcggccgcccc
tgtccggcgacgccgtgcagaagatgctgggccactgcacttcgagcccgccgagcccaaggccgccaagaacacctacaccgc
cgagcggttcatctggctgaccaagctgaacaacctgcggatcctggagcagggctccgagcggccctgaccgacaccgagcgg
gccaccctgatggacgagccctaccgggaagtccaagctgacctacgcccagggcccgcggaagctgctgggcctggaggacaccgcct
tcttcaagggcctgcggtacgtgcaggacaagcgccgaggcctcccacccctgatggagatgaaggcctaccacgccatctcccgggc
cctggagaaggagggcctgaaggacaagaagtcccccctgaacctgtcctccgagctgcaggacgagatcggcaccgccttctcc
ctgttcaagaccgacgaggacatcaccggccggctgaaggaccgggtgcagcccgagatcctggaggccctgctgaagcacatct
ccttcgacaagttcgtgcagatctcccctgaaggccctgcgcggatcgtgccccctgatggagcagggcaagcggtacgacgaggc
ctgcgccgagatctacggcgaccactacggcaagaagaacaccgaggagaagatctacctgccccccatcccccgccgacgagatc
cggaacccctgtggtgctgcgggcccctgtcccaggccccgaaggtgatcaacggcgtggtgcgccggctcccccgccccgga
tccacatcgagaccgcccgggaggtgggcaagtccttcaaggaccggaaggagatcgagaagcggcaggaggagaaccggaaggga
ccgggagaaggccgccgcccaagttcccgggagtacttcccccaacttcgtgggcgagcccaagtccaaggacatcctgaagctgcgg
ctgtacgagcagcacgccgacgtgcctgtactccggcaaggagatcaacctggtgcggctgaacgagaaggctacgtggaga
tcgaccacgccctgccttctcccggacctgggacgactccttcaacaacaaggtgctggtgctgggctccgagaaccagaacaa
gggcaaccagacccccctacgagtacttcaacggcaaggacaactcccgggagtggcaggagttcaaggcccggtggagacctcc
cggttcccccggtccaagaagcagcggatcctgctgcagaagttcgacgagggacggcttcaaggagtgcaacctgaacgacaccc
ggtacgtgaaccggttcctgtgccagttcgtggccgaccacatcctgctgacccgcaagggcaagcgcggcgtgttcgcctccaa
cggccagatcaccaacctgctgcgggggcttctgggcctgcggaaggtgcgggccgagaacgaccgcgccaccacgccctggacgcc
gtggtggtggcctgctccaccgtggccatgcagcagaagatcaccccggttcgtgcggtacaaggagatgaacgccttcgacggca
agaccatcgacaagggagaccggcaaggtgctgcaccagaagacccactcccccagcccctgggagttcttcgcccaggaggtgat
gatccgggtgttcggcaagcccgacgcgagttcgaggaggccgacaccccgagaagctgcgtgaccctgctggccgag
aagctgtcctcccggccgaggccgtgcacgagtacgtgaccccctgttcgtgtcccgggcccccaaccgggaagatgtccggcg
cccacaaggacaccctgcggtccgccaagcggttcgtgaaggcacacaacgagaagatctccgtgaagcgggtgtggctgaccgagat
caagctggccgacctggagaacatggtgaactacaagaacggccgggagatcgagctgtacgagggcccggctggag
gcctacggcggcaacgccaagcaggccttcgacccccaaggacaacccccttctacaagaagggcggccagctggtgaaggccgtgc
gggtggagaagacccaggagtccggcgtgctgctgaacaagaagaacgcctacaccatcgccgacaacggcgacatggtgcgggt
ggacgtgttctgcaaggtggacaacaagaggggcaagaaccagtacttcatcgtgccccatctacgcctggcaggtggccgagaacatc
ctgcccgacatcgactgcaagggctaccggatcgacgactcctacacctgcttctccctgcacaagtacgacctgatcgcct
tccagaaggacgagaagtccaaggtggagttcgcctactacatcaactgcgactcctccaacggccggttctacctggcctggca
cgacaagggctccaaggagcagcagttccggatctccacccagaacctggtgctgatccagaagtaccaggtgaacgagctgggc
aaggagatccggccctgccggctgaagaagcggccccccgtgcggtag

atgGACGGCTCCGGCGGCGGCTCCCCCAAGAAGAAGCGGAAGGTGGAGGACAAGCGGCCCGCCGCCACCACCAAGAAGGCCGGCCAGG
CCAAGAAGAAGAAGGGCGGCTCCGGCGGCGGCGCCGCCTTCAAGCCCAACCCCATCAACTACATCCTGGGCCTGGACATCGGCATT
CGCCTCCGTGGGCTGGGCCATGGTGGAGATCGACGAGGAGGAGAACCCCATCCGGCTGATCGACCTGGGCGTGCGGGTGTTCGAG
CGGGCCGAGGTGCCCAAGACCGGCGACTCCCTGGCCATGGCCCGGCGGCTGGCCCGGTCCGTGCGGCGGCTGACCCGGCGGCGGG
CCCACCGGCTGCTGCGGGCCCGGCGGCTGCTGAAGCGGGAGGGCGTGCTGCAGGCCGCCGACTTCGACGAGAACGGCCTGATCAA

	encoded by mRNA P	GTCCCTGCCCAACACCCCCTGGCAGCTGCGGGCCGCCGCCCTGGACCGGAAGCTGACCCCCCTGGAGTGGTCCGCCGTGCTGCTG
		CACCTGATCAAGCACCGGGGCTACCTGTCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCTGGGCGCCCTGCTGAAGG
		GCGTGGCCAACAACGCCCACGCCCTGCAGACCGGCGACTTCCGGACCCCCGCCGAGCTGGCCCTGAACAAGTTCGAGAAGGAGTC
		CGGCCACATCCGGAACCAGCGGGGCGACTACTCCCACACCTTCTCCCGGAAGGACCTGCAGGCCGAGCTGATCCTGCTGTTCGAG
		AAGCAGAAGGAGTTCGGCAACCCCCACGTGTCCGGCGGCCTGAAGGAGGGCATCGAGACCCTGCTGATGACCCAGCGGCCCGCCC
		TGTCCGGCGACGCCGTGCAGAAGATGCTGGGCCACTGCACCTTCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCTACACCGC
		CGAGCGGTTCATCTGGCTGACCAAGCTGAACAACCTGCGGATCCTGGAGCAGGGCTCCGAGCGGCCCCTGACCGACACCGAGCGG
		GCCACCCTGATGGACGAGCCCTACCGGAAGTCCAAGCTGACCTACGCCCAGGCCCGGAAGCTGCTGGGCCTGGAGGACACCGCCT
		TCTTCAAGGGCCTGCGGTACGGCAAGGACAACGCCGAGGCCTCCACCCTGATGGAGATGAAGGCCTACCACGCCATCTCCCGGGC
		CCTGGAGAAGGAGGGCCTGAAGGACAAGAAGTCCCCCCTGAACCTGTCCTCCGAGCTGCAGGACGAGATCGGCACCGCCTTCTCC
		CTGTTCAAGACCGACGAGGACATCACCGGCCGGCTGAAGGACCGGGTGCAGCCCGAGATCCTGGAGGCCCTGCTGAAGCACATCT
		CCTTCGACAAGTTCGTGCAGATCTCCCTGAAGGCCCTGCGGCGATCGTGCCCCTGATGGAGCAGGGCAAGCGGTACGACGAGGGC
		CTGCGCCGAGATCTACGGCGACCACTACGGCAAGAAGAACACCGAGGAGAAGATCTACCTGCCCCCCATCCCCGCCGACGAGATC
		CGGAACCCCGTGGTGCTGCGGGCCCTGTCCCAGGCCCGGAAGGTGATCAACGGCGTGGTGCGGCGGTACGGCTCCCCCGCCCGGA
		TCCACATCGAGACCGCCCGGGAGGTGGGCAAGTCCTTCAAGGACCGGAAGGAGATCGAGAAGCGGCAGGAGGAGAACCGGAAGGA
		CCGGGAGAAGGCCGCCGCCCAAGTTCCGGGAGTACTTCCCCAACTTCGTGGGCGAGCCCAAGTCCAAGGACATCCTGAAGCTGCGG
		CTGTACGAGCAGCAGCACGGCAAGTGCCTGTACTCCGGCAAGGAGATCAACCTGGTGCGGCTGAACGAGAAGGGCTACGTGGAGA
		TCGACCACGCCCTGCCCTTCTCCCGGACCTGGGACGACTCCTTCAACAACAAGGTGCTGGTGCTGGGCTCCGAGAACCAGAACAA
		GGGCAACCAGACCCCCTACGAGTACTTCAACGGCAAGGACAACTCCCGGGAGTGGCAGGAGTTCAAGGCCCGGGTGGAGACCTCC
		CGGTTCCCCCGGTCCAAGAAGCAGCGGATCCTGCTGCAGAAGTTCGACGAGGACGGCTTCAAGGAGTGCAACCTGAACGACACCC
		GGTACGTGAACCGGTTCCTGTGCCAGTTCGTGGCCGACCACATCCTGCTGACCGGCAAGGGCAAGCGGCGGGTGTTCGCCTCCAA
		CGGCCAGATCACCAACCTGCTGCGGGGCTTCTGGGCCTGCGGCCGAGAACGACCGGCACCACGCCCTGGACGCCC
		GTGGTGGTGGCCTGCTCCACCGTGGCCATGCAGCAGAAGATCACCCGGTTCGTGCGGTACAAGGAGATGAACGCCTTCGACGGCA
		AGACCATCGACAAGGAGACCGGCAAGGTGCTGCACCAGAAGACCCACTTCCCCCAGCCCTGGGAGTTCTTCGCCCAGGAGGTGAT
		GATCCGGGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGGCCGACACCCCCGAGAAGCTGCGGACCCTGCTGGCCGAG
		AAGCTGTCCTCCCGGCCCGAGGCCGTGCACGAGTACGTGACCCCCCTGTTCGTGTCCCGGGCCCCCAACCGGAAGATGTCCGGCG
		CCCACAAGGACACCCTGCGGTCCGCCAAGCGGTTCGTGAAGCACAACGAGAAGATCTCCGTGAAGCGGGTGTGGCTGACCGAGAT
		CAAGCTGGCCGACCTGGAGAACATGGTGAACTACAAGAACGGCCGGGAGATCGAGCTGTACGAGGCCCTGAAGGCCCGGCTGGAG
		GCCTACGGCGGCAACGCCAAGCAGGCCTTCGACCCCAAGGACAACCCCTTCTACAAGAAGGGCGGCCAGCTGGTGAAGGCCGTGC
		GGGTGGAGAAGACCCAGGAGTCCGGCGTGCTGCTGAACAAGAAGAACGCCTACACCATCGCCGACAACGGCGACATGGTGCGGGT
		GGACGTGTTCTGCAAGGTGGACAAGAAGGGCAAGAACCAGTACTTCATCGTGCCCATCTACGCCTGGCAGGTGGCCGAGAACATC
		CTGCCCGACATCGACTGCAAGGGCTACCGGATCGACGACTCCTACACCTTCTGCTTCTCCCTGCACAAGTACGACCTGATCGCCT
		TCCAGAAGGACGAGAAGTCCAAGGTGGAGTTCGCCTACTACATCAACTGCGACTCCTCCAACGGCCGGTTCTACCTGGCCTGGCA
		CGACAAGGGCTCCAAGGAGCAGCAGTTCCGGATCTCCACCCAGAACCTGGTGCTGATCCAGAAGTACCAGGTGAACGAGCTGGGC
		AAGGAGATCCGGCCCTGCCGGCTGAAGAAGCGGCCCCCCGTGCGGTCCGAGTCCGCCACCCCCGAGTCCGTGTCCGGCTGGCGGC
		TGTTCAAGAAGATCTCCTAG
656	Open reading frame for	atgGACGGCTCCGGCGGCGGCTCCGAGGACAAGCGGCCCGCCGCCACCAAGAAGGCCGGCCAGGCCAAGAAGAAGGGCGGCT
		CCGGCGGCGGCgccgccttcaagcccaaccccatccggctgatcgacctgggcgtgcgggtgttcgagcgggccgaggtgcccaagacc
		ggtggagatcgacgaggaggagaaccccatccggctgatcgacctgggcgtgcgggtgttcgagcgggccgaggtgcccaagacc

	Nme2Cas9 encoded by mRNA Q	ggcgactccctggccatggccccggcggctggcccggtccgtgcggcggctgaccccggcggcgggcccaccggctgctgcgggccc ggcggctgctgaagcgggagggcgtgctgcaggccgccgacttcgacgagaacggcctgatcaagtccctgcccaacacccctg gcagctgcgggccgccgcccctggaccggaagctgaccccccctggagtggtccgccgtgctgctgcacctgatcaagcaccgggc tacctgtcccagcggaagaacgagggcgagaccgccgacaaggagctgggcgccctgctgaagggcgtggccaacaacgcccacg ccctgcagaccgggcgacttccggacccccgccgagctggccctgaacaagttccgagaaggagtccggccacatccggaacccagcg gggcgactacctcccacacctctcccggaaggacctgcagccgagctgatcctgctgttcgagaagcagaaggagttcggcaac ccccacgtgtccggcggcctgaaggagggcatcgagacccctgctgatgacccagcggcccgccctgtccggcgacgccgtgcaga agatgctgggccacctgcacctccgagccccgccgcccaaggccgcccaagaacacctacaccgccgagcggttcatctggctgac caagctgaacaacctgcggatcctggagcagggctccgagcggccccctgaccgacaccgagcgggccacccctgatggacgagccc taccggaagtccaagctgacctacgcccagggcccggaagctgctgggcctggaggacaccgcctttctcaagggcctgcggtacg gcaaggacaacgccgaggcctccacccctgatggagatgaaggcctaccacgccctgtccgagatcgagcaggtgctgaagaagg ggacaagaagtcccccctgaacctgtcctccgagctgcaggacgagatcggcgcaccgccttctcccctgttcaagaccgacgaggac atcaccggccggctgaaggaccgggtgcagcccgagatcctgggaggccctgctgaagcacatcctccttcgacaagttcgtgcaga tctccctgaaggccctgcggcggatcgtgccccctgatggagcagggcaagcggtacgacgaggcctgcgccgagatctacggcga ccactacggcaagaagaacaccgaggagatctacctgccccccatccccgccgacgagatccggaacccctgggtgctgcgg gccctgtcccaggccccggaaggtgatcaacggcgtggtgcggcggtacggctccccccgcccccggatccacatcgagaccgcccgggg aggtgggcaagtccttcaaggaccggaaggagatcgagaagcggcaggaggagaacccggaaggaagggccgccgccaa gttccgggagtacttccccaactttcgtgggcgagcccaagtccaaggacatcctgaagctgcggctgtacgagcagcagcacggc aagtgcctgtactccggcaaggagatcaacctggtgcggctgaacgagaagggctacgtggagatcgaccacgccctgcccttct ccggacctgggacgactccttcaacaacaaggtgctggtgctgggctccgagaaccagaacaagggcaaccagacccccctacga gtacttcaacggcaaggacaactcccgggagtggcaggagttcaagggcccgggtggagacctcccgttccccggctccaagaag cagcggatcctgctgcagaaggttcgacgaggacgcttcaaggagtgcaacctgaacgacacccggtacgtgaaccggttcctgt gccagttcgtggccgaccacatcctgctgaccgacgaagcggcgggtgttcgcctccaacgggccagatcaccaacctgct gcgggcttctgggggcctgcgaaggtgcgggccgagaacgaccgccacccgccctggacgccgtggtggtggcctgctccacc gtggccatgcagcagaagatcacccggttcgtgcggtacaaggagatgaacgccttcgacggcaagaccatcgacaaggagaccg gcaaggtgctgcaccagaagacccactttcccccagccctgggagttcttcgcccaggaggtgatgatccgggtgttcggcaagcc cgacggcaagcccgagttcgaggagggccgacacccccgagaagctgcggaccctgctggccgagaaagctgtcctcccggcccgag gccgtgcacgagtacgtgaccccccgttcgtgtcccgggccccaaccgggaagatgtccggcgccacaaggacacccctgcggt ccgccaagcggttcgtgaagcacaacgagaagatctccgtgaagcgggtgtggctgaccgagatcaagctggccgacctggagaa catggtgaactacaagaacggccgggagatcgagctgtacgaggccctgaaggccctggaggcctacgtgcggcaacgccaag caggccttcgaccccaaggacaacccccttctacaagaagggcggccagctggtgaaggccgtgcgggtggagaagacccaggagt ccggcgtgctgctgaacaagaagaacgcctacaccatcgccgacaacggcgacatggtgcgggtggacgtgttctgcaaggtgga caagaagggcaagaaccagtacttcatcgtgcccatctacgcctggcaggtggccgagaacatcctgcccgacatcgactgcaag ggctaccggatcgacgcactcctacacacctttctgctttcccctgcacaagtacgacctgatcgccttccagaaggacgagaagtcca aggtggagttcgcctactacatcaactgcgactcctccaacggccggttctacctggcctggcacgacacaaggctccaaggagca gcagttccggatctccacccagaacctggtgctgatccagaagtaccaggtgaacgagctgggcaaggagatccggccctgccgg ctgaagaagcggccccccgtgcggtag
657	Open reading frame for	ATGGACGGCTCCGGCGGCGGCTCCCCCAAGAAGAAGCGGAAGGTGGAGGACAAGCGGCCCGCCGCCACCAAGAAGGCCGGCCAGG CCAAGAAGAAGAAGGGCGGCTCCGGCGGCGGCGAGGCCTCCCCCGCCTCCGGCCCCCGGCACCTGATGGACCCCCCACATCTTCAC

Nme2Cas9 base editor encoded by mRNA R	CTCCAACTTCAACAACGGCATCGGCCGGCACAAGACCTACCTGTGCTACGAGGTGGAGCGGCTGGACAACGGCACCTCCGTGAAG
	ATGGACCAGCACCGGGGCTTCCTGCACAACCAGGCCAAGAACCTGCTGTGCGGCCGGCACGCCGAGCTGCGGTTCC
	TGGACCTGGTGCCCTCCCTGCAGCTGGACCCCGCCCAGATCTACCGGGTGACCTGGTTCATCTCCTGGTCCCCCTGCTTCTCCTG
	GGGCTGCGCCGGCGAGGTGCGGCCTTCCTGCAGGAGAACACCCACGTGCGGCTGCGGATCTTCGCCGCCCGGATCTACGACTAC
	GACCCCCTGTACAAGGAGGCCCTGCAGATGCTGCGGGACGCCGGCGCCCAGGTGTCCATCATGACCTACGACGAGTTCAAGCACT
	GCTGGGACACCTTCGTGGACCACCAGGGCTGCCCCTTCCAGCCCTGGGACGGCCTGGACGAGCACTCCCAGGCCCTGTCCGGCCG
	GCTGCGGGCCATCCTGCAGAACCAGGGCAACTCCGGCTCCGAGACCCCCGGCACCTCCGAGTCCGCCACCCCCGAGTCCGCAGCG
	TTCAAACCAAATcccatcaactacatcctgggccatcggcatcgcctccgtgggctgggccatggtggagatcgacgagg
	aggagaacccatccggctgatcgacctgggcgtgcgggtgttcgagcgggccgaggtgcccaagaccggcgactccctggccat
	ggcccggcggctggccccggtccgtgcggcggctgaccgtgctgcgggcccggcggctgctgaagcgg
	gagggcgtgctgcaggccgccgacttcgacagagaacggcctgatcaagtccctgcccaacaccccctggcagctgcgggccgccg
	ccctggaccggaagctgaccccctggagtggtccgccgtgctgctgcacctgatcaagcaccgggctacctgtcccagcggaa
	gaacgagggcgagaccgcccgacaaggagctgggcgccctgctgaagggcgtggccaacaacgcccacgccctgcagaccggcgac
	ttccggaccccccgccgagctggccctgaacaagttcgagaaggagtccggccacatccgggaaccagcgggcgactactcccaca
	ccttctcccggaagggacctgcaggccgagctgatcctgctgttcgagaaggcagaaggagttcggcgacccccacgtgttcggcgg
	cctgaaggagggcatcgagaccctgctgatgacccagcggcccgccctgtccggcgacgccgtgcagaagatgctgggccactgc
	acttcgagcccgccgccgagcccaaggccgccaagaacacctacaccgccgagcggttcatctggctgaccaagctgaaacaacctgc
	ggatcctggagcagggctccgagcggccccctgaccgacaccgagcgggccacccctgatggcgagcgaagtccaagct
	gacctacgccccaggccccggaagctgctgggccttggaggacaccgccttcttcaagggccctgcggtacggcaaggacaacgccgag
	gcctccaccctgatggagatgaaggcctaccacgccatctcccgggccctggagaaggagggcctgaaggacaagaagtccccc
	tgaacctgtcctccgagctgcaggacgagatcggccaccgccttctccctgttcaagaccgacgagggcatcaccggccggctgaa
	ggaccgggtgcagccccgagatcctggagggccctgctgaagcacatctccttcgacaagttcgtgcagatctccctgaaggccctg
	cggcggatcgtgccccctgatggagcagggcaagcggtacgacgagggcctgcgccgagatctacgggcgaccactacggcaaagaaga
	acaccgaggagaagatctacctgcccccatcccccgccgacgagatccggaaccccgtggtgctgcgggccctgtcccaggcccg
	gaaggtgatcaacgggcgtggtgcggcggtacggctccccgcccgagatccacatcgagaccgcccgggagtgggcaagtcctttc
	aaggaccggaaggagatcgagaagcggcaggaggagaaccggaaggagaccgggagaaggcccgccgccaagttccgggagtactttcc
	ccaacttcgtgggcgagcccaagtccaaggacatcctgaagctgcggctgtacgagcagcacggcaagtgcctgtactccgg
	caaggagatcaacctggtgcggctgaacgagaagggctacgtggagatcgacaccacgcccttctcccggacctgggacgac
	tccttcaacaacaaggtgctggtgctgggctccgagaaccagaacaagggcaacccagacccccctacgagtacttcaacgcggcaagg
	acaacttcccgggagtggcaggagttcaaggcccgggtggagacctcccggttcccccggttccaagaagcagcggatcctgctgca
	gaagttcgacgaggacggcttcaaggagtgcaacctgaacgacacccggtacgtgaacgcttccttcgtgccagttcgtggccgac
	cacatcctgctgaccggcaagggcaagcggcgggtgttcgcctccaacggccagatcaccaacctgctgcgggggcttctgggccc
	tgcggaaggtgcgggccgagaacgaccggcaccacgcccttggacgccgtggtggtggcctgctccaccgtggccatgcagcagaa
	gatcacccggttcgtgcggtacaaggagatgaacgccttcgacggcaagaccatcgacaaggagaccgtgctgcaccagaa
	aagacccactttcccccagccctgggagttctttcgcccaggaggtgatccgggtgttcggcaagcccgacggcaagccgagt
	tcgaggaggccgacaccccgagaagctgcggaccctgctggccgagaagctgtcctcccggcccgaggccgtgcacgagtacgt
	gaccccctgttcgtgtcccgggcccccaaccggaagatgtccggcgcccacaaggacaccctgcggtccgccaagcggttcgtg
	aagcacaacgagaagatctccgtgaagcgggtgtggctgaccgagatcaagctggccgacctggagaagaacatggtgaactacaaga
	acggccgggagatcgagctgtacgaggccctgaaggccctggaggccctacgccggcaacgccaaggccctcgacccccaa

		ggacaaccccttctacaagaaggcggccagctggtgaaggccgtgcgggtggagaagacccaggagtccggcgtgctgctgaac
		aagaagaacgcctacaccatcgccgacaacggcgacatggtgcgggtggacgtgttctgcaaggtggacaagaagggcaagaacc
		agtacttcatcgtgccatctacgcctggcaggtggccgagaacatcctgcccgacatcgactgcaagggctaccggatcgacga
		ctcctacaccttctgcttctccctgcacaagtacgacctgatcgcctccagaaggacgagaagtccaaggtggagttcgcctac
		tacatcaactgcgactcctccaacgggccggttctacctggcctggcacgacaagggctccaaggagcagcagttccggatctcca
		cccagaacctggtgctgatccagaagtaccaggtgaacgagctgggcaaggagatccgcctgccggctgaagaagcggcccccc
		cgtgcggtccggaaagcggaccgccgacggctccgagttcgagtcccccaagaagaagcggaaggtggagtag
658	Open reading frame for Nme2Cas9 base editor encoded by mRNA R	ATGGACGGCTCCGGCGGCGGCTCCCCCAAGAAGAAGCGGAAGGTGGAGGACAAGCGGCCGCCACCAAGAAGGCCGGCCAGG
		CCAAGAAGAAGAAGGGCGGCTCCGGCGGCGAGGCCTCCCCCGCCTCCGGCCCCCGGCACCTGATGGACCCCCCACATCTTCAC
		CTCCAACTTCAACAACGGCATCGGCCGGCACAAGACCTACCTGTGCTACGAGGTGGAGCGGCTGGACAACGGCACCTCCGTGAAG
		ATGGACCAGCACCGGGGCTTCCTGCACAACCAGGCCAAGAACCTGCTGTGCGGCTCTACGGCCGGCACGCCGAGCTGCGGTTCC
		TGGACCTGGTGCCCTCCCTGCAGCTGGACCCCGCCCAGATCTACCGGGTGACCTGGTTCATCTCCTGGTCCCCCTGCTTCTCCTG
		GGGCTGCGCCGGCGAGGTGCGGGCCTTCCTGCAGGAGAACACCCACGTGCGGCTGCGGATCTTCGCCGCCCGGATCTACGACTAC
		GACCCCCTGTACAAGGAGGCCCTGCAGATGCTGCGGGACGCCGGCGCCCAGGTGTCCATCATGACCTACGACGAGTTCAAGCACT
		GCTGGGACACCTTCGTGGACCACCAGGGCTGCCCCTTCCAGCCCTGGACGGCCTGGACGAGCACTCCCAGGCCCTGTCCGGCCG
		GCTGCGGGCCATCCTGCAGAACCAGGGCAACTCCGGCTCCGAGACCCCCGGCACCTCCGAGTCCGCCACCCCCGAGTCCGCAGCG
		TTCAAACCAAATcccatcaactacatcctgggcctggccatcggcatcgcctccgtgggctgggccatggtggagatcgacgagg
		aggagaacccatccggctgatcgacctgggcgtgcgggtgttcgagcgggccgaggtgcccaagaccggcgactccctggccat
		ggcccggcggctggccgtgcggcggctgaccgggcgcggccccaccggctgctgcgctgctgaagcgg
		gagggcgtgctgcagggccgccgacttcgacgagaacggcctgatcaagtccctgcccaacaccccctggcagctgcgggccgccg
		ccctggaccggaagctgaccccctggagtggtccgccgtgctgctgcacctgatcaagcaccgggggctacctgtcccagcggaa
		gaacgagggcgagaccgccgacaaggagctgggcgccctgctgaagggcgtggccaacaacgccccacgccctgcagaccggcgac
		ttccggacccccgccgagctggccctgaacaagttcgagaaggagtccggccacatccggaaccagcgggcgactactcccaca
		ccttctcccggaagggacctgcaggccgagctgatcctgctgttcgagaagcagaaggagttcggcaaccccacgtgtccggcgg
		cctgaaggagggcatcgagaccctgctgatgacccagcggccgccctgtccggcgacgccgtgcagaagatgctgggccactgc
		acttcgagccgccgccgagcccaaggccgccaagaacacctacaccgccgagcggttcatctggctgaccaagctgaacaacctgc
		ggatcctggagcagggctccgagcggccctgaccgacaccgagcgggccacccctgatggacgcctaccggaagtccaagct
		gacctacgcccaggccgggaagctgctgggcctggaggacaccgcctcttcaagggcctgcggtacggcaaggacaacgccgag
		gcctccaccctgatggagatgaaggcctaccacgccatctcccgggccctggagaaggagggcctgaaggacaagaagtccccc
		tgaacctgtcctccgagctgcaggacgagatcggcaccgcctttcccttcaagaccgacgaggacatcaccggccggctgaa
		ggaccgggtgcagcccgagatcctggaggccctgctgaagcacatctccttcgacaagttcgtgcagatctccctgaaggccctg
		cgcggatcgtgcccctgatggagcagggcaagcggtacgacgaggccgtgcgccgagatctacggcgaccactacggcaagaaga
		acaccgaggagaagatctacctgccccccatcccgccgacgagatccggaacccgtggtgctgcgggccctgtcccaggcccg
		gaaggtgatcaacggcgtggtgcggcggtacggctccccgcccgatccacatcgagaccgcccgggaggtgggcaagtccttc
		aaggaccggaaggagatcgagaagcggcaggaggagaaccggaaggaccgggagaaggccgccgccaagttccgggagtacttcc
		ccaacttcgtgggcgagcccaagtccaaggacatcctgaagctgcggctgtacgagcagcacggcaagtgcctgtactccgg
		caaggagatcaacctggtgcggctgaacgagaagggctacgtggagatcgaccaccacgccctgccctttctcccggacctgggacgac
		tccttcaacaacaaggtgctggtgctgggctccgagaaccagaacaagggcaaccagacccccctacgagtacttcaacggcaagg
		acaactcccgggagtggcaggagttcaaggccgggtggagacctcccggttcccccggtccaagaagcagcggatcctgctgca

		gaagttcgacgaggacggcttcaaggagtgcaacctgaacgacacccggtacgtgaaccgcttcctgtgccagttcgtggccgac
		cacatcctgctgaccggcaagggcaagcggcgggtgttcgcctccaacggccagatcaccaacctgctgcggggcttctgggccc
		tgcggaaggtgcgggccgagaacgaccggcaccaccgcccctggacgccgtggtggtcctgctccaccgtggccatgcagcagaa
		gatcacccggttcgtgcggtacaaggagatgaacgccttcgacggcaagaccatcgacaaggagaccggcaagggtgctgcaccag
		aagacccactcccccagccctgggagttcttcgcccaggaggtgatgatccgggtgttcggcaagcccgacgcaagcccgagt
		tcgaggaggccgacaccccgagaagctgcggaccctgctggccgagaagctgtcctcccggcccgaggccgtgcacgagtacgt
		gaccccctgttcgtgtcccgggccccccaaccggaagatgtccggcgcccacaaggacaccctgcggtccgccaagcggttcgtg
		aagcacaacgagaagatctccgtgaagcgggtgtggctgaccgagatcaagctggccgacctggagaacatggtgaactacaaga
		acggccgggagatcgagctgtacgaggccctgaaggccctggaggcctacgcggcaacgccaagcaggcctcgacccccaa
		ggacaacccccttctacaagaagggcggccagctggtgaaggccgtgcgggtggagaagacccaggagtccggcgtgctgaac
		aagaagaacgcctacaccatcgccgacaacggcgacatggtgcgggtggacgtgttctgcaaggtggacaagaagggcaagaacc
		agtacttcatcgtgccccatctacgcctggcaggtggccgagaacatcctgccgacatcgactgcaagggctaccggatcgacga
		ctcctacaccttctgcttctccctgcacaagtacgacctgatcgcctccagaaggacgagaagtccaaggtggagttcgcctac
		tacatcaactgcgactcctccaacggccggttctacctggcctggcacgacaaggagcagcagttccggatctcca
		cccagaacctggtgctgatccagaagtaccaggtgaacgagctgggcaaggagatccggccctgccggctgaagaagcggcccccc
		cgtgcggtag
659	Open reading frame for Nme2Cas9 base editor encoded by mRNA S	ATGGAGGCCTCCCCCGCCTCCGGCCCCCGGCACCTGATGGACCCCCACATCTTCACCTCCAACTTCAACAACGGCATCGGCCGGC
		ACAAGACCTACCTGTGCTACGAGGTGGAGCGGCTGGACAACGGCACCTCCGTGAAGATGGACCAGCACCGGGGCTTCCTGCACAA
		CCAGGCCAAGAACCTGCTGTGCGGCTTCTACGGCCGGCACGCCGAGCTGCGGTTCCTGGACCTGGTGCCCTCCCTGCAGCTGGAC
		CCCGCCCAGATCTACCGGGTGACCTGGTTCATCTCCTGGTCCCCCTGCTTCTCCTGGGGCTGCGCCGGCGAGGTGCGGCCTTCC
		TGCAGGAGAACACCCACGTGCGGCTGCGGATCTTCGCCGCCCGGATCTACGACTACGACCCCCTGTACAAGGAGGCCCTGCAGAT
		GCTGCGGGACGCCGGCGCCCAGGTGTCCATCATGACCTACGACGAGTTCAAGCACTGCTGGGACCACCTTCGTGGACCACCAGGGC
		TGCCCCTTCCAGCCCTGGGACGGCCTGGACGAGCACTCCCAGGCCCTGTCCGGCCGGCTGCGGGCCATCCTGCAGAACCAGGGCA
		ACTCCGGCTCCGAGACCCCCGGCACCTCCGAGTCCGCCACCCCCGAGTCCGCAGCGTTCAAACCAAATcccatcaactacatcct
		gggcctggccatcggcatcgccctccgtgggctgggccatggtggagatcgacgaggaggagaacccccatccggctgatcgacctg
		ggcgtgcgggtgttcgagcgggccgaggtgcccaagaccggcgcgactccctggccatggccccggccgggctccgctccgtgcggc
		ggctgaccccggcggcgggccccaccggctgctgcgggcccggcggctgctgaagcgggaggcgtgctgcaggccgccgacttcga
		cgagaacggcctgatcaagtccctgcccaacaccccctggcagctgcgggccgccgccctggaccggaagctgaccccccctggag
		tggtccgccgtgctgctgcacctgatcaagcaccgggggctacctgtcccagcggaagaacgagggcgagaccgccgacaaggagc
		tgggcgccctgctgaagggcgtggccaacaacgccccacgccctgcagaccggcgcactccgaccccgccgcgagctggccctgaa
		caagttcgagaaggagtccggccacatccggaaccagcggggcgactactcccacacctttcccggaaggacctgcaggccgag
		ctgatcctgctgttcgagaagcagaaggagttcggcaacccccacgtgtccggcggcctgaaggagggcatcgagaccctgctga
		tgacccagcggcccgcctgtccggcgacgccgtgcagaagatgctgggccactgcacctgcgagcccgccgagcccaagggccgc
		caagaacacctacaccgccgagcggttcatctggctgaccaagctgaacaacctgcgcgagaccggcgagctcgagcggccc
		ctgaccgacaccgagcgggccacccctgatggacgagccctacgccgaagtccaagctgacctacgccaggcccggaagctgctgg
		gcctggaggacaccgcctcttcaagggcctgcggtacggcaaggacaacgccgaggcctccacccctgatggagatgaaggccta
		ccacgccatctcccgggccctggagaaggagggcctgaaggacaagaagtccccctgaacctgtcctccgagctgcaggacgag
		atcggcaccgcctcttccctgttcaagaccgacgaggacatcaccggccggctgaaggaccgggtgcagcccgagatcctggagg
		ccctgctgaagcacatcctccttcgacaagttcgtgcagatctccctgaaggccctgcgggcggatcgtgccctgatggagcaggg

caagcggtacgacgaggcctgcgccgagatctacggcgaccactacggcaagaagaacaccgaggagaagatctacctgccccccc atccccgccgacgagatccggaacccctggtgctgcgggccctgtcccaggccccggaaggtgatcaacggcgtggtgcggcggt acggctccccccgccccggatccacatcgagaccgcccgggaggtgggcaagtccttcaaggaccggaaggagatcgagaagcggca ggaggagaaccggaaggaccgggagaagcgccgccgccaagttcccgggagtactttcccccaacttcgtgggcgagcccaagtccaag gacatcctgaagctgcggctgtacgagcagcagcacggcaagtgcctgtactccggcaaggagatcaacctggtgcggctgaacg agaaggctacgtggagatcgaccacgccgccctgcctttctcccggacctgggacgactcctcaacaacaaggtgctggtgctggg ctccgagaaccagaacaagggcaaccagacccccctacgagtacttcaacgggcaaggacaactcccgggagtggcaggagttcaag gcccggtggagacctcccggttcccccggtccaagaagcagcggatcctgctgcagaagttcgacgaggacgccgacacccccgagaagct gcaacctgaacgacacccggtacgtgaaccgcttcctgtgccagttcgtggccgaccatcctgctgaccggcaagggcaagcg gcgggtgttcgcctccaacgggccagatcaccaacctgctgcgggcttctgggcctgcggaagtgcgggccgagaacgaccgg caccacgccctggacgccgtggtggtgcctgctccaccgtggccatgcagcagaagatcacccggttcgtgctgcggtacaaggaga tgaacgcctccgacgccaagacccatcgagtactttcaacgggcaaggacaactcccgggagtggcaggagttcaag cttcgcccaggaggtgatgatccgggtgttcggcaagcccgacggcaagccccgagttcgaggaggccgacacccccgagaagctg cggaccctgctggccgagaagctgtcctcccggcccgaggccgtgcacgagtacgtgaccccctgttcgtgtcccgggcccccca accggaagatgtccggcgcccacaaggacaccctgcggtccgccaagcggttcgtgaagcacaacgagaagatctccgtgaagcg ggtgtggctgaccgagatcaagctggccgacctggagaacatggtgtgaactacaagaacggccgggagatcgagctgtacgaggcc ctgaaggcccggctggagggcctacgggcgcaacgccaagcaggccttcgacccccaaggacaacccctttctacaagaagggcggcc agctggtgaaggccgtgcgggtggagaagacccaggagtccggcgtgctgctgaacaagaagaacgcctacaccatcgccgacaa cggcgacatggtgcgggtggacgtgttctgcaaggtggacaagaaggccaagaaccagtacttcatcgtgcccatctacgcctgg caggtggccgagaacatcctgcccgacatcgactgcaagggctaccggatcgacgactcctctacacctttctgctttctcccctgcaca agtacgacctgatcgccttccagaaggacgagaagtccaagggtggagttcgcctactacatcaactgcgactcctcccaacggccg gttctacctggcctgggcacgacaagggctccaaggagcagcagttccggatctccacccagaacctggtgctgatccagaagtac caggtgaacgagctgggcaaggagatccggccctgccggctgaagaagcggccccccgtgcggtccggaaagcggaccgccgacg gctccgagttcgagtccccaagaagaagcggaaggtggagtag	ATGaagCTGggcTCCatcGAGttcATCaagGTGaacAAGggcTCCggcTCCggcTCCGGCgccCCCgagTCCgccACCgagTCCg gcGGCaccTCCaccGAGtccGAGgcTCCgccGGCaccTCCaccGAGtccGAGgctccGCCggcTCCgccGGCtccaccTCCac cGAGgagGGCaccTCCaccGAGtccGAGggctccGCCggcACCtccACCgagtccgagGGCtccGCCggcACCtccGAGtccgcc ACCgagTCCggcGGCaccTCCaccGAGtccGAGggcTCCtccTCCaccggtgccgccttcaagcccaacccccatcaactacatcc tgggcctggacatcggcatcgcctccgtgggctgggccatggtggagatcgacgaggaggagaacccccatccggctgatcgacct gggcgtgcgggtgttcgagcgggccgaggtgcccaagaccggcgacctccctggccatggccccggctgggcccggtccgtgcgg cggctgaccccggcggcgggcccaccggctgctgcgggccccggcggctgctgaagcgggagggcgtgctgcaggccgccgacttccg acgagaacggcctgatcaagtccctgcccaacaccccctggcagctgcgggccgccgcctggaccggaagctgaccccccctgga gtggtccgccgtgctgctgcacctgatcaagcaccgggggctacctgtcccagcggaagaacgagggcgagaccgccgacaaggag ctgggcgccctgctgaagggcgtggccaacaacgccccacgccctgcagaccggcgacttccggaccccgccgagctggccctga acaagttcgagaaggagatccggccacatccggaaccagcgggcgactactcccacacctttcccggaaggacctgcaggccga gctgatcctgctgttcgagaagcagaaggagttcggcaacccccacgtgtccggcggcctgaaggagggcatcgagacgcctgctg atgacccagcggcccgccctgtccggcgacgccgtgcagaagatgctgggccactgcacttcgagccgccgagcccaaggccg ccaagaacacctacaccgccgagcgggccacccctgatggacgagctccctaccggaagtccaagctgacctacgcccaggcccgggaagctgctg	660 Open reading frame for Nme2Cas9 encoded by mRNA U

		ggcctggaggacaccgccttcttcaagggcctgcggtacggcaaggacaacgccgaggcctccaccctgatggagatgaaggcct accacgccatctcccgggcccctggagaaggagggcctgaaggacaagaagtcccccctgaacctgtcctccgagctgcaggacga gatcggcaccgcctttctcccctgttcaagaccgacgaggacatcaccggccgctgaaggaccgggtgcagcccgagatcctggag gccctgctgaagcacatctccttcgacaagttcgtgcagatctccctgaaggccctgcggcggatcgtgccctgatggagcagg gcaagcggtacgacgaggcctgcgccgagatctacggcgaccactacggcaagaagaacaccgaggagaagatctacctgccccc catccccgccgacgagatccggaacccctggtgctgcgggccctgtcccaggccgtgaaggtgatcaacggcgtggtgcggcgg tacggctccccgccgatccacatcgagaccgccccgggaggtgggcaagtccttcaaggaccggaaggagatcgagaagcggc aggaggagaaccggaaggaccgggagaaggccgccgccaagttccgggagtactcccccaacttcgtgggcgagcccaagtccaa ggacatcctgaagctgcggctgtacgagcagcacgcggcaagtgcctgtactccggcaaggagatcaacctggtgcggctgaac gagaagggctacgtggagatcgaccacgccctgccctttctcccggacctgggacgactcccttcaacaacaaggtgctggtgctgg gctccgagaacccagaacaagggcaacccagacccccctacgagtacttcaacgcggcaaggacaactcccgggagtggcaggagttcaa ggcccgggtggagacctcccggttcccccgtccaagaagcagcggatcctgctgcagaagttcgacgaggacggcttcaaggag tgcaacctgaacgacacccggtacgtgaaccgcttcctgtgccagttcgtggccgaccacatcctgctgaccggcaagggcaagc ggcgggtgttcgcctccaacggccagatcaccaacctgctgcgggcttctgggcctgcggaaggtgcgggccgagaacgaccg gcaccacgccctggacgccgtggtggtgcctgctccaccgtggccatgcagcagaagatcacccggttcgtgcggtacaaggag atgaacgccttcgacggcaagaccatcgacaaggagaccgtgcaccagaagacccactttccccagcccctgggagt tcttcgcccaggaggtgatgtacccgggtgttcggcaagcccgacgcaagcccgagttcgaggaggccgacacccccgagaagct gcggaccctgctggccgagaagctgtcctcccggcccgaggccgtgcacgagtacgtgaccccccctgttcgtgtcccgggcccccc aaccggaagatgtccggcgcccacaaggacaccctgcgtccgccaagcggttcgtgaagcacaacgagaagatctccgtgaagc gggtgtggctgaccgagatcaagctggccgacctggagaacatggtgaactacaagaacggccgggagatcgagctgtacgaggc cctgaaggccccggctgaggcctacggcggcaacgccaaggcaggcctccgacccccaaggacaacccctcttctacaagaagggcggc cagctggtgaaggccgtgcgggtggagaagacccaggagtccggcgtgctgctgaacaagaagaacgcctacaccatcgccgaca acggcgacatggtgcgggtggacgtgttctgcaaggtggacaagaagggcaagaaccagtacttcatcgtgccctatctacgcctg gcaggtggccgagaacatcctgcccgacatcgactgcaagggctaccggatcgacgactcctacacctttctgcttctcccctgcac aagtacgacctgatcgcctttccagaaggacgagaagtccaaggtggagttcgcctactacatcaactgcgactcctcccaacggcc ggttctacctggcctggcacgacaagggctccaaggagcagcagttccggatctcccacccagaacctggtgctgatccagaagta ccaggtgaacgagctgggcaaggagatccggccctgcggctgaagaagcgggccccccgtgcggtccggaaagcggaccgccgac ggctccgagttcgagtccccccaagaagaagcggaaggtggagtga	
661	ORF encoding Sp. Cas9	ATGGACAAGAAGTACAGCATCGGACTGGACATCGGAACAAACAGCGTCGGATGGGCAGTCATCACAGACGAATACAAGGTCCCGA GCAAGAAGTTCAAGGTCCTGGGAAACACAGACGACACAGCATCAAGAAGAACCTGATCGGAGCACTGCTGTTCGACAGCGGAGA AACAGCAGAAGCAACAAGACTGAAGAGAACAGCAAGAAGATACACAAGAAGAAAGAACAGAATCTGCTACCTGCAGGAAATC TTCAGCAACGAAATGGCAAAGGTCGACGACAGCTTCTTCCACAGACTGGAAGAAAGCTTCCTGGTCGAAGAAGACAAGAAGCACG AAAGACACCCGATCTTCGGAAACATCGTCGACGAAGTCGCATACCACGAAAAGTACCCGACAATCTACCACCTGAGAAAGAAGCT GGTCGACAGCACAGACAAGGCAGACCTGAGACTGATCTACCTGGCACTGGCACACATGATCAAGTTCAGAGGACACTTCCTGATC GAAGGAGACCTGAACCCGGACAACAGCGACGTCGACAAGCTGTTCATCCAGCTGGTCCAGACATACAACCAGCTGTTCGAAGAAA ACCCGATCAACGCAAGCGGAGTCGACGCAAAGGCAATCCTGAGCGCAAGACTGAGCAAGAGCAGAAGACTGGAAAACCTGATCGC ACAGCTGCCGGGAGAAAAGAAGAACGGACTGTTCGGAAACCTGATCGCACTGAGCCTGGGACTGACACCGAACTTCAAGAGCAAC TTCGACCTGGCAGAAGACGCAAAGCTGCAGCTGAGCAAGGACACATACGACGACGACCTGGACAACCTGCTGGCACAGATCGGAG ACCAGTACGCAGACCTGTTCCTGGCAGCAAAGAACCTGAGCGACGCAATCCTGCTGAGCGACATCCTGAGAGTCAACACAGAAAT

CACAAAGGCACCGCTGAGCGCAAGCATGATCAAGAGATACGACGAACACCACCAGGACCTGACACTGCTGAAGGCACTGGTCAGA		
CAGCAGCTGCCGGAAAAGTACAAGGAAATCTTCTTCGACCAGAGCAAGAACGGATACGCCAGGATACATCGACGGAGGAGCAAGCC		
AGGAAGAATTCTACAAGTTCATCAAGCCGATCCTGGAAAAGATGGACGGAACAGAAGAACTGCTGGTCAAGCTGAACAGAGAAGA		
CCTGCTGAGAAAGCAGAGAACATTCGACAACGGAAGCATCCCGCACCAGATCCACCTGGGAGAACTGCACGCAATCCTGAGAAGA		
CAGGAAGACTTCTACCCGTTCCTGAAGGACAACAGAGAAAAAGATCGAAAAGATCCTGACATTCAGAATCCCGTACTACGTCGGAC		
CGCTGGCAAGAGGAAACAGCAGATTCGCATGGATGACAAGAAAGAGCGAAGAAACAATCACACCGTGGAACTTCGAAGAAGTCGT		
CGACAAGGGAGCAAGCGCACAGAGCTTCATCGAAAGAATGACAAACTTCGACAAGAACCTGCCGAACGAAAAGGTCCTGCCGAAG		
CACAGCCTGCTGTACGAATACTTCACAGTCTACAACGAACTGACAAAGGTCAAGTACGTCACAGAAGGAATGAGAAAGCCGGCAT		
TCCTGAGCGGAGAACAGAAGAAGGCAATCGTCGACCTGCTGTTCAAGACAAACAGAAAGGTCACAGTCAAGCAGCTGAAGGAAGA		
CTACTTCAAGAAGATCGAATGCTTCGACAGCGTCGAAATCAGCGGAGTCGAAGACAGATTCAACGCAAGCCTGGGAACATACCAC		
GACCTGCTGAAGATCATCAAGGACAAGGACTTCCTGGACAACGAAGAAAACGAAGACATCCTGGAAGACATCGTCCTGACACTGA		
CACTGTTCGAAGACAGAGAAATGATCGAAGAAAGACTGAAGACATACGCACACCTGTTCGACGACAAGGTCATGAAGCAGCTGAA		
GAGAAGAGATACACAGGATGGGGAAGACTGAGCAGAAAGCTGATCAACGGAATCAGAGACAAGCAGACAAGTCTGGACAATCCTG		
GACTTCCTGAAGAGCGACGGATTCGCAAACAGAACTTCATGCAGCTGATCCACGACGACAGCCTGACATTCAAGGAAGACATCC		
AGAAGGCACAGGTCAGCGGACAGGGACACGCCTGCACGAACACATCGCAACCTGGCAGGAAGCCCGGCAATCAAGAAGGGAAT		
CCTGCAGACAGTCAAGGTCGTCGACGAACTGGTCAAGGTCATGGGACACAAGCCGGAAACATCGTCATCGAAATGGCAAGA		
GAAACCAGACAACACAGAAGGGACAGAAGAACAGCAGAGAAAGAATGAAGAGAATCGAAGAAGGAATCAAGGAACTGGGAAGCC		
AGATCCTGAAGGAACACCCGGTCGAAAACACACAGCTGCAGAACGAAAAGCTGTACCTGTACTACCTGCAGAACGGAAGAGACAT		
GTACGTCGACCAGGAACTGGACATCAACAGACTGAGCGACTACGACGTCGACCACATCGTCCCCCAGAGCTTCCTGAAGGACGAC		
AGCATCGACAACAAGGTCCTGACAAGAAGCGACAAGAACAGAGGAAAGAGCGACAACGTCCCGAGCGAAGAAGTCGTCAAGAAGA		
TGAAGAACTACTGGAGACAGCTGCTGAACGCAAAGCTGATCACACAGAGAAAGTTCGACAACCTGACAAAGGCAGAGAGAGGAGG		
ACTGAGCGAACTGGACAAGGCAGGATTCATCAAGAGACAGCTGGTCGAAACAAGACAGATCACACAAAGCACGTCGCACAGATCCTG		
GACAGCAGAATGAACACAAAGTACGACGAAAACGACAAGCTGATCAGAGAAGTCAAGGTCATCACACTGAAGAGCAAGCTGGTCA		
GCGACTTCAGAAAGGACTTCCAGTTCTACAAGGTCAGAGAAATCAACAACTACCACGCACACGACGCATACCTGAACGCAGT		
CGTCGGAACAGCACTGATCAAGAAGTACCCGAAGCTGGAAAGCGAATTCGTCTACGGAGACTACAAGGTCTACGACGTCAGAAAG		
ATGATCGCAAAGAGCGAACAGGAAATCGGAAAGGCAACAAGCAAAGTACTTCTTCTACAGCAACATCATGAACTTCTTCAAGACAG		
AAATCACACTGGCAAACGGAGAAATCAGAAAGAGACCGCTGATCGAAACAAACGGAGAAACAGGAGAAATCGTCTGGGACAAGGG		
AAGAGACTTCGCAACAGTCAGAAAGGTCCTGAGCATGCCGCAGGTCAACATCGTCAAGAAGACAGAAGTCCAGACAGGAGGATTC		
AGCAAGGAAAGCATCCTGCCGAAGAGAAACAGCGACAAGCTGATCGCCAAGAAAGACTGGGACCCGAAGAAGTACGGAGGATT		
TCGACAGCCCGACAGTCGCATACAGCGTCCTGGTCGTCGCAAAGGTCGAAAAGGGAAAGAGCAAGAAGCTGAAGAGCGTCAAGGA		
ACTGCTGGGAATCACAATCATGGAAAGAAGCAGCTTCGAAAAGAACCCGATCGACTTCCTGGAAGCAAAGGGATACAAGGAAGTC		
AAGAAGGACCTGATCATCAAGCTGCCGAAGTACAGCCTGTTCGAACTGGAAAACGGAAGAAAGAGAATGCTGGCAAGCGCAGGAG		
AACTGCAGAAGGGAAACGAACTGGCACTGCCGAGCAAGTACGTCAACTTCCTGTACCTGGCAAGCCACTACGAAAAGCTGAAGGG		
AAGCCCGGAAGACAACGAACAGAAGCAGCTGTTCGTCGAACAGCACAAGCACTACCTGGACGAAATCATCGAACAGATCAGCGAA		
TTCAGCAAGAGAGTCATCCTGGCAGACGCAAACCTGGACAAGGTCCTGAGCGCATACAACAAGCACAGAGACAAGCCGATCAGAG		
AACAGGCAGAAAACATCATCCACCTGTTCACACTGACAAACCTGGGAGCACCGGCAGCATTCAAGTACTTCGACACAACAATCGA		
CAGAAAGAGATACACAAGCACAAAGGAAGTCCTGGACGCAACACTGATCCACCAGAGCATCACAGGACTGTACGAAACAAGAATC		
GACCTGAGCCAGCTGGGAGGAGACGGAGGAGGAAGCCCGAAGAAGAGAAGGTCTAG		

662	ORF encoding Sp. Cas9	ATGGACAAGAAGTACTCCATCGGCCTGGACATCGGCACCAACTCCGTGGGCTGGGCCGTGATCACCGACGAGTACAAGGTGCCCT
		CCAAGAAGTTCAAGGTGCTGGGCAACACCGACCGGCACTCCATCAAGAAGAACCTGATCGGCGCCCTGCTGTTCGACTCCGGCGA
		GACCGCCGAGGCCACCCGGCTGAAGCGGACCGCCCGGCGGCGGTACACCCGGCGCGGAAGAACCGGATCTGCTACCTGCAGGAGATC
		TTCTCCAACGAGATGGCCAAGGTGGACGACTCCTTCTTCCACCGGCTGGAGGAGTCCTTCCTGGTGGAGGAGGACAAGAAGCACG
		AGCGGCACCCCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTACCCCACCATCTACCACCTGCGGAAGAAGCT
		GGTGGACTCCACCGACAAGGCCGACCTGCGGCTGATCTACCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGATC
		GAGGGCGACCTGAACCCCGACAACTCCGACGTGGACAAGCTGTTCATCCAGCTGGTGCAGACCTACAACCAGCTGTTCGAGGAGA
		ACCCCATCAACGCCTCCGGCGTGGACGCCAAGGCCATCCTGTCCGCCCGGCTGTCCAAGTCCCGGCGCCTGGAGAACCTGATCGC
		CCAGCTGCCCGGCGAGAAGAAGAACGGCCTGTTCGGCAACCTGATCGCCCTGTCCCTGGGCCTGACCCCCAACTTCAAGTCCAAC
		TTCGACCTGGCCGAGGACGCCAAGCTGCAGCTGTCCAAGGACACCTACGACGACCTGGACAACCTGCTGGCCCAGATCGGCG
		ACCAGTACGCCGACCTGTTCCTGGCCGCCAAGAACCTGTCCGACGCCATCCTGCTGTCCGACATCCTGCGGGTGAACACCGAGAT
		CACCAAGGCCCCCCTGTCCGCCTCCATGATCAAGCGGTACGACGAGCACCACCAGGACCTGACCCTGCTGAAGGCCCTGGTGCGG
		CAGCAGCTGCCCGAGAAGTACAAGGAGATCTTCTTCGACCAGTCCAAGAACGGCTACGCCGGCTACATCGACGGCGGCGCCTCCC
		AGGAGGAGTTCTACAAGTTCATCAAGCCCATCCTGGAGAAGATGGACGGCACCGAGGAGCTGCTGGTGAAGCTGAACCGGGAGGA
		CCTGCTGCGGAAGCAGCGGACCTTCGACAACGGCTCCATCCCCCACCAGATCCACCTGGGCGAGCTGCACGCCATCCTGCGGCGG
		CAGGAGGACTTCTACCCCTTCCTGAAGGACAACCGGGAGAAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACTACGTGGGCC
		CCCTGGCCCGGGGCAACTCCCGGTTCGCCTGGATGACCGGAAGTCCGAGGAGACCATCACCCCCTGGAACTTCGAGGAGGTGGT
		GGACAAGGGCGCCTCCGCCCAGTCCTTCATCGAGCGGATGACCAACTTCGACAAGAACCTGCCCAACGAGAAGGTGCTGCCCAAG
		CACTCCCTGCTGTACGAGTACTTCACCGTGTACAACGAGCTGACCAAGGTGAAGTACGTGACCGAGGGCATGCGGAAGCCCGCCT
		TCCTGTCCGGCGAGCAGAAGAAGGCCATCGTGGACCTGCTGTTCAAGACCAACCGGAAGGTGACCGTGAAGCAGCTGAAGGAGGA
		CTACTTCAAGAAGATCGAGTGCTTCGACTCCGTGGAGATCTCCGGCGTGGAGGACCGGTTCAACGCCTCCCTGGGCACCTACCAC
		GACCTGCTGAAGATCATCAAGGACAAGGACTTCCTGGACAACGAGGAGAACGAGGACATCCTGGAGGACATCGTGCTGACCCTGA
		CCCTGTTCGAGGACCGGGAGATGATCGAGGAGCGGCTGAAGACCTACGCCCACCTGTTCGACGACAAGGTGATGAAGCAGCTGAA
		GCGGCGGCGGTACACCGGCTGGGGCCGGCTGTCCCGGAAGCTGATCAACGGCATCCGGGACAAGCAGTCCGGCAAGACCATCCTG
		GACTTCCTGAAGTCCGACGGCTTCGCCAACCGGAACTTCATGCAGCTGATCCACGACGACTCCCTGACCTTCAAGGAGGACATCC
		AGAAGGCCCAGGTGTCCGGCCAGGGCGACTCCCTGCACGAGCACATCGCCAACCTGGCCGGCTCCCCCGCCATCAAGAAGGGCAT
		CCTGCAGACCGTGAAGGTGGTGGACGAGCTGGTGAAGGTGATGGGCCGGCACAAGCCCGAGAACATCGTGATCGAGATGGCCCGG
		GAGAACCAGACCACCCAGAAGGGCCAGAAGAACTCCCGGGAGCGGATGAAGCGGATCGAGGAGGGCATCAAGGAGCTGGGCTCCC
		AGATCCTGAAGGAGCACCCCGTGGAGAACACCCAGCTGCAGAACGAGAAGCTGTACCTGTACTACCTGCAGAACGGCCGGGACAT
		GTACGTGGACCAGGAGCTGGACATCAACCGGCTGTCCGACTACGACGTGGACCACATCGTGCCCCAGTCCTTCCTGAAGGACGAC
		TCCATCGACAACAAGGTGCTGACCCGGTCCGACAAGAACCGGGGCAAGTCCGACAACGTGCCCTCCGAGGAGGTGGTGAAGAAGA
		TGAAGAACTACTGGCGGCAGCTGCTGAACGCCAAGCTGATCACCCAGCGGAAGTTCGACAACCTGACCAAGGCCGAGCGGGGCGG
		CCTGTCCGAGCTGGACAAGGCCGGCTTCATCAAGCGGCAGCTGGTGGAGACCCGGCAGATCACCAAGCACGTGGCCCAGATCCTG
		GACTCCCGGATGAACACCAAGTACGACGAGAACGACAAGCTGATCCGGGAGGTGAAGGTGATCACCCTGAAGTCCAAGCTGGTGT
		CCGACTTCCGGAAGGACTTCCAGTTCTACAAGGTGCGGGAGATCAACAACTACCACCACGCCCACGACGCCTACCTGAACGCCGT
		GGTGGGCACCGCCCTGATCAAGAAGTACCCCAAGCTGGAGTCCGAGTTCGTGTACGGCGACTACAAGGTGTACGACGTGCGGAAG
		ATGATCGCCAAGTCCGAGCAGGAGATCGGCAAGGCCACCGCCAAGTACTTCTTCTACTCCAACATCATGAACTTCTTCAAGACCG
		AGATCACCCTGGCCAACGGCGAGATCCGGAAGCGGCCCCTGATCGAGACCAACGGCGAGACCGGCGAGATCGTGTGGGACAAGGG
		CCGGGACTTCGCCACCGTGCGGAAGGTGCTGTCCATGCCCCAGGTGAACATCGTGAAGAAGACCGAGGTGCAGACCGGCGGCTTC

		TCCAAGGAGTCCATCCTGCCCAAGCGGAACTCCGACAAGCTGATCGCCCGGAAGAAGGACTGGGACCCCAAGAAGTACGGCGGCT
		TCGACTCCCCCACCGTGGCCTACTCCGTGCTGGTGGTGGCCAAGGTGGAGAAGGGCAAGTCCAAGAAGCTGAAGTCCGTGAAGGA
		GCTGCTGGGCATCACCATCATGGAGCGGTCCTCCTTCGAGAAGAACCCCATCGACTTCCTGGAGGCCAAGGGCTACAAGGAGGTG
		AAGAAGGACCTGATCATCAAGCTGCCCAAGTACTCCCTGTTCGAGCTGGAGAACGGCCGGAAGCGGATGCTGGCCTCCGCCGGCG
		AGCTGCAGAAGGGCAACGAGCTGGCCCTGCCCTCCAAGTACGTGAACTTCCTGTACCTGGCCTCCCACTACGAGAAGCTGAAGGG
		CTCCCCCGAGGACAACGAGCAGAAGCAGCTGTTCGTGGAGCAGCACAAGCACTACCTGGACGAGATCATCGAGCAGATCTCCGAG
		TTCTCCAAGCGGGTGATCCTGGCCGACGCCAACCTGGACAAGGTGCTGTCCGCCTACAACAAGCACCGGGACAAGCCCATCCGGG
		AGCAGGCCGAGAACATCATCCACCTGTTCACCCTGACCAACCTGGGCGCCCCCGCCGCCTTCAAGTACTTCGACACCACCATCGA
		CCGGAAGCGGTACACCTCCACCAAGGAGGTGCTGGACGCCACCCTGATCCACCAGTCCATCACCGGCCTGTACGAGACCCGGATC
		GACCTGTCCCAGCTGGGCGGCGACGGCGGCGCTCCCCCAAGAAGAAGCGGAAGGTGTGA
663	ORF encoding Sp. Cas9	AUGGACAAGAAGUACAGCAUCGGCCUGGACAUCGGCACGAACAGCGUUGGCUGGGCUGUGAUCACGGACGAGUACAAGGUUCCCU
		CAAGAAGUUCAAGGUGCUGGGCAACACCGACCGGCACAGCAUCAAGAAGAAUCUCAUCGGUGCACUGCUGUUCGACAGCGGUGA
		GACGGCCGAAGCCACGCGGCUGAAGCGGACCGCCGCGCCGGCGGUACACGCGGCGGAAGAACCGGAUCUGCUACCUGCAGGAGAUC
		UUCAGCAACGAGAUGGCCAAGGUGGACGACAGCUUCUUCCACCGGCUGGAGGAGAGCUUCCUGGUGGAGGAGGACAAGAAGCACG
		AGCGGCACCCCAUCUUCGGCAACAUCGUGGACGAAGUCGCCUACCACGAGAAGUACCCCACCAUCUACCACCUGCGGAAGAAGCU
		GGUGGACUCGACUGACAAGGCCGACCUGCGGCUGAUCUACCUGGCCCUCGCCCACAUGAUAAAGUUCCGGGGCCACUUCCUGAUC
		GAGGGCGACCUGAACCCUGACAACAGCGACGUGGACAAGCUGUUCAUCCAGCUGGUGCAGACCUACAACCAGCUGUUCGAGGAGA
		ACCCCAUCAACGCCAGCGGCGUGGACGCCAAGGCCAUCCUCAGCGCCCGCCUCAGCAAGAGCCGGCGCCUGGAGAACUCAUCGCC
		CCAGCUUCCAGGUGAGAAGAAUGGGCUGUUCGGCAACUCAUCGCACUCAGCCUGGGCCUGACUCCCAACUUCAAGAGCAAC
		UUCGACCUGGCCGAGGACGCCAAGCUGCAGCUCAGCAAGGACACCUACGACGACGACCUGGACAACUCCUGGCCCAGAUCGGCG
		ACCAGUACGCCGACCUGUUCCUGGCUGCCAAGAACUCAGCGACGCCAUCCUGCUCAGCGACAUCCUGCGGGUGAACACAGAGAU
		CACGAAGGCCCCCUCAGCGCCAGCAUGAUAAAGCGGUACGACGAGCACCACCAGGACCUGACGCUGAAGGCACUGGUGCGG
		CAGCAGCUUCCAGAGAAGUACAAGGAGAUCUUCUUCGACCAGAGCAAGAAUGGGUACGCCGGUUACAUCGACGGUGGUGCCAGCC
		AGGAGGAGUUCUACAAGUUCAUCAAGCCCAUCCUGGAGAAGAUGGACGGCACAGAGGAGCUGCUGGUGAAGCUGAACAGGGAGGA
		CCUGCUGCGGAAGCAGCGGACGUUCGACAACGGGAGCAUCCCCCACCAGAUCCACCUGGGUGAGCUGCACGCCAUCCUGCGGCGG
		CAGGAGGACUUCUACCCCUUCCUGAAGGACAACAGGGAGAAGAUCGAGAAGAUCCUGACGUUCCGGAUCCCCUACUACGUUGGCCC
		CCCUGGCCCGCGGCAACAGCCGGUUCGCCUGGAUGACGCGAGGAGCGAGGAGACGAUCACUCCCUGGAACUUCGAGGAAGUCGU
		GGACAAGGGUGCCAGCGCCCAGAGCUUCAUCGAGCGGAUGACGAACUUCGACAAGAAUCUUCCAAACGAGAAGGUGCUUCCAAAG
		CACAGCCUGCUGUACGAGUACUUCACGGUGUACAACGAGCUGACGAAGGUGAAGUACGUGACAGAGGGCAUGCGGAAGCCCGCCU
		UCCUCAGCGGUGAGCAGAAGAAGGCCAUCGUGGACCUGCUGUUCAAGACGAACCGGAAGGUGACGGUGAAGCAGCUGAAGGAGGA
		CUACUUCAAGAAGAUCGAGUGCUUCGACAGCGUGGAGAUCAGCGGCGUGGAGGACCGGUUCAACGCCAGCCUGGGCACCUACCAC
		GACCUGCUGAAGAUCAUCAAGGACAAGGACUUCCUGGACAACGAGGAGAACGAGGACAUCCUGGAGGACAUCGUGCUGACGCUGA
		CGCUGUUCGAGGACAGGGAGAUGAUAGAGGAGCGGCUGAAGACCUACGCCCACCUGUUCGACGACAAGGUGAUGAAGCAGCUGAA
		GCGGCGGCGGUACACGGGCUGGGGCCGGCUCAGCCGGAAGCUGAUCAAUGGGAUCCGAGACAAGCAGAGCGGCAAGACGAUCCUG
		GACUUCCUGAAGAGCGACGGCUUCGCCAACCGGAACUUCAUGCAGCUGAUCCACGACGACAGCCUGACCUUCAAGGAGGACAUCC
		AGAAGGCCCAGGUCAGCGGCCAGGGCGACAGCCUGCACGAGCACAUCGCCAACUCUCCGCCGGGAGCCCCGCCAUCAAGAAGGGAU
		CCUGCAGACGGUGAAGGUGGUGGACGAGCUGGUGAAGGUGAUGGGCCGGCACAAGCCAGAGAACAUCGUGAUCGAGAUGGCCAGG
		GAGAACCAGACGACUCAAAGGGGCAGAAGAACAGCAGGGAGCGGAUGAAGCGGAUCGAGGAGGGCAUCAAGGAGCUGGGCAGCC
		AGAUCCUGAAGGAGCACCCCGUGGAGAACACUCAACUGCAGAACGAGAAGCUGUACCUGUACUACCUGCAGAAUGGGCGAGACAU

		GUACGUGGACCAGGAGCUGGACAUCAACCGGCUCAGCGACUACGACGUGGACCACAUCGUUCCCCAGAGCUUCCUGAAGGACGAC
		AGCAUCGACAACAAGGUGCUGACGCGGAGCGACAAGAACCGGGGCAAGAGCGACAACGUUCCCUCAGAGGAAGUCGUGAAGAAGA
		UGAAGAACUACUGGCGGCAGCUGCUGAACGCCAAGCUGAUCACUCAACGGAAGUUCGACAAUCUCACGAAGGCCGAGCGGGGUGG
		CCUCAGCGAGCUGGACAAGGCCGGGUUCAUCAAGCGGCAGCUGGUGGAGACGCGGCAGAUCACGAAGCACGUGGCCCAGAUCCUG
		GACAGCCGGAUGAACACGAAGUACGACGAGAACGACAAGCUGAUCAGGGAAGUCAAGGUGAUCACGCUGAAGAGCAAGCUGGUCA
		GCGACUUCCGGAAGGACUUCCAGUUCUACAAGGUGAGGGAGAUCAACAACUACCACGCCCACGACGCCUACCUGAACGCUGU
		GGUUGGCACGGCACUGAUCAAGAAGUACCCCAAGCUGGAGAGCGAGUUCGUGUACGGCGACUACAAGGUGUACGACGUGCGGAAG
		AUGAUAGCCAAGAGCGAGCAGGAGAUCGGCAAGGCCACGGCCAAGUACUUCUUCUACAGCAACAUCAUGAACUUCUUCAAGACAG
		AGAUCACGCUGGCCAAUGGUGAGAUCCGGAAGCGGCCCCUGAUCGAGACGAAUGGUGAGACGGGUGAGAUCGUGUGGGACAAGGG
		GCGAGACUUCGCCACGGUGCGGAAGGUGCUCAGCAUGCCCCAGGUGAACAUCGUGAAGAAGACAGAAGUCCAGACGGGUGGCUUC
		AGCAAGGAGAGCAUCCUUCCAAAGCGGAACAGCGACAAGCUGAUCGCCCGCAAGAAGGACUGGGACCCCAAGAAGUACGGUGGCU
		UCGACAGCCCCACCGUGGCCUACAGCGUGCUGGUGGUGGCCAAGGUGGAGAAGGGGAAGAGCAAGAAGCUGAAGAGCGUGAAGGA
		GCUGCUGGGCAUCACGAUCAUGGAGCGGAGCAGCUUCGAGAAGAACCCCAUCGACUUCCUGGAAGCCAAGGGGUACAAGGAAGUC
		AAGAAGGACCUGAUCAUCAAGCUUCCAAAGUACAGCCUGUUCGAGCUGGAGAAUGGGCGGAAGCGGAUGCUGGCCAGCGCCGGUG
		AGCUGCAGAAGGGGAACGAGCUGGCACUUCCCUCAAAGUACGUGAACUUCCUGUACCUGGCCAGCCACUACGAGAAGCUGAAGGG
		GAGCCCAGAGGACAACGAGCAGAAGCAGCUGUUCGUGGAGCAGCACAAGCACUACCUGGACGAGAUCAUCGAGCAGAUCAGCGAG
		UUCAGCAAGCGGGUGAUCCUGGCCGACGCCAAUCUCGACAAGGUGCUCAGCGCCUACAACAAGCACCGAGACAAGCCCAUCAGGG
		AGCAGGCCGAGAACAUCAUCCACCUGUUCACGCUGACGAAUCUCGGUGCCCCCGCUGCCUUCAAGUACUUCGACACGACGAUCGA
		CCGGAAGCGGUACACGUCGACUAAGGAAGUCCUGGACGCCACGCUGAUCCACCAGAGCAUCACGGGCCUGUACGAGACGCGGAUC
		GACCUCAGCCAGCUGGGUGGCGACGGUGGUGGCAGCCCCAAGAAGAAGCGGAAGGUGUAG
664	ORF encoding Sp. Cas9	AUGGACAAGAAGUACAGCAUCGGCCUCGACAUCGGCACCAACAGCGUCGGCUGGGCCGUCAUCACCGACGAGUACAAGGUCCCCA
		GCAAGAAGUUCAAGGUCCUGGGCAACACCGACCGCCACAGCAUCAAGAAGAACCUCAUCGGCGCCCUCCUCUUCGACAGCGGCGA
		GACCGCCGAGGCCACCCGCCUCAAGCGCACCGCCCGCCGCUACACCCGCCGCAAGAACCGCAUCUGCUACCUCCAGGAGAUC
		UUCAGCAACGAGAUGGCCAAGGUCGACGACAGCUUCUUCCACCGCCUCGAGGAGAGCUUCCUCGUCGAGGAGGACAAGAAGCACG
		AGCGCCACCCCAUCUUCGGCAACAUCGUCGACGAGGUCGCCUACCACGAGAAGUACCCCACCAUCUACCACCUCCGCAAGAAGCU
		CGUCGACAGCACCGACAAGGCCGACCUCCGCCUCAUCUACCUCGCCCUCGCCCACAUGAUCAAGUUCCGCGGCCACUUCCUCAUC
		GAGGGCGACCUCAACCCGGACAACAGCGACGUCGACAAGCUCUUCAUCCAGCUCGUCCAGACCUACAACCAGCUCUUCGAGGAGA
		ACCCCAUCAACGCCAGCGGCGUCGACGCCAAGGCCAUCCUCAGCGCCCGCCUCAGCAAGAGCCGCCUCGAGAACCUCAUCGC
		CCAGCUCCCCGGCGAGAAGAAGAACGGCCUCUUCGGCAACCUCAUCGCCCUCAGCCUCGGCCUCACCCCCAACUUCAAGAGCAAC
		UUCGACCUCGCCGAGGACGCCAAGCUCCAGCUCAGCAAGGACACCUACGACGACGACCUCGACAACCUCCUCGCCCAGAUCGGCG
		ACCAGUACGCCGACCUCUUCCUCGCCGCCAAGAACCUCAGCGACGCCAUCCUCCUCUCCGACAUCCUGAGAGUCAACACCGAGAU
		CACCAAGGCCCCCCUCAGCGCCAGCAUGAUCAAGCGCUACGACGAGCACCACCAGGACCUCACCCUCCUCAAGGCCCUCGUCCGC
		CAGCAGCUCCCCGAGAAGUACAAGGAGAUCUUCUUCGACCAGAGCAAGAACGGCUACGCCGGCUACAUCGACGGCGGCGCCAGCC
		AGGAGGAGUUCUACAAGUUCAUCAAGCCCAUCCUCGAGAAGAUGGACGGCACCGAGGAGCUCCUCGUCAAGCUCAACCGCGAGGA
		CCUCCUCCGCAAGCAGCGCACCUUCGACAACGGCAGCAUCCCCCACCAGAUCCACCUCGGCGAGCUCCACGCCAUCCUCCGCCGC
		CAGGAGGACUUCUACCCCUUCCUCAAGGACAACCGCGAGAAGAUCGAGAAGAUCCUCACCUUCCGCAUCCCCUACUACGUCGGCCC
		CCUCGCCCGCGGCAACAGCCGCUUCGCCUGGAUGACCCGCAAGAGCGAGGAGACCAUCACCCCCUGGAACUUCGAGGAGGUCGU
		CGACAAGGGCGCCAGCGCCCAGAGCUUCAUCGAGCGCAUGACCAACUUCGACAAGAACCUCCCCAACGAGAAGGUCCUCCCCAAG
		CACAGCCUCCUCUACGAGUACUUCACCGUCUACAACGAGCUCACCAAGGUCAAGUACGUCACCGAGGGCAUGCGCAAGCCCGCCU

		UCCUCAGCGGCGAGCAGAAGAAGGCCAUCGUCGACCUCCUCUUCAAGACCAACCGCAAGGUCACCGUCAAGCAGCUCAAGGAGGA
		CUACUUCAAGAAGAUCGAGUGCUUCGACAGCGUCGAGAUCAGCGGCGUCGAGGACCGCUUCAACGCCAGCCUCGGCACCUACCAC
		GACCUCCUCAAGAUCAUCAAGGACAAGGACUUCCUCGACAACGAGGAGAACGAGGACAUCCUCGAGGACAUCGUCCUCACCCUCA
		CCCUCUUCGAGGACCGCGAGAUGAUCGAGGAGCGCCUCAAGACCUACGCCCACCUCUUCGACGACAAGGUCAUGAAGCAGCUCAA
		GCGCCGCCGCUACACCGGCUGGGGCCGCCUCAGCCGCAAGCUCAUCAACGGCAUCCGCGACAAGCAGAGCGGCAAGACCAUCCUC
		GACUUCCUCAAGAGCGACGGCUUCGCCAACCGCAACUUCAUGCAGCUCAUCCACGACGACAGCCUCACCUUCAAGGAGGACAUCC
		AGAAGGCCCAGGUCAGCGGCCAGGGCGACACAGCCUCCACGAGCACAUCGCCAACCUCGCCGGCAGCCCCGCCAUCAAGAAGGGCAU
		CCUCCAGACCGUCAAGGUCGUCGACGAGCUCGUCAAGGUCAUGGGCCGCCACAAGCCCGAGAACAUCGUCAUCGAGAUGGCCCGC
		GAGAACCAGACCACCCAGAAGGGCCAGAAGAACAGCCGCGAGCGCAUGAAGCGCAUCGAGGAGGGCAUCAAGGAGCUCGGCAGCC
		AGAUCCUCAAGGAGCACCCCGUCGAGAACACCCAGCUCCAGAACGAGAAGCUCUACCUCUACUACCUCCAGAACGGCCGCGACAU
		GUACGUCGACCAGGAGCUCGACAUCAACCGCCUCAGCGACUACGACGUCGACCACAUCGUCCCCCAGAGCUUCCUCAAGGACGAC
		AGCAUCGACAACAAGGUCCUCACCCGCAGCGACAAGAACCGCGGCAAGAGCGACAACGUCCCCAGCGAGGAGGUCGUCAAGAAGA
		UGAAGAACUACUGGCGCCAGCUCCUCAACGCCAAGCUCAUCACCCAGCGCAAGUUCGACAACCUCACCAAGGCCGAGCGCGGCGG
		CCUCAGCGAGCUCGACAAGGCCGGCUUCAUCAAGCGCCAGCUCGUCGAGACCCGCCAGAUCACCAAGCACGUCGCCCAGAUCCUC
		GACAGCCGCAUGAACACCAAGUACGACGAGAACGACAAGCUCAUCCGCGAGGUCAAGGUCACCCUCAAGAGCAAGCUCGUCA
		GCGACUUCCGCAAGGACUUCCAGUUCUACAAGGUCCGCGAGAUCAACAACUACCACGCCCACGACGCCUACCUCAACGCCGU
		CGUCGGCACCGCCCUCAUCAAGAAGUACCCCAAGCUCGAGAGCGAGUUCGUCUACGGCGACUACAAGGUCUACGACGUCCGCAAG
		AUGAUCGCCAAGAGCGAGCAGGAGAUCGGCAAGGCCACCGCCAAGUACUUCUUCUACAGCAACAUCAUGAACUUCUUCAAGACCG
		AGAUCACCCUCGCCAACGGCGAGAUCCGCAAGCGCCCCCUCAUCGAGACCAACGGCGAGACCGGCGAGAUCGUCUGGGACAAGGG
		CCGCGACUUCGCCACCGUCCGCAAGGUCCUCAGCAUGCCCCAGGUCAACAUCGUCAAGAAGACCGAGGUCCAGACCGGCGGCUUC
		AGCAAGGAGAGCAUCCUCCCCAAGCGCAACAGCGACAAGCUCAUCGCCCGCAAGAAGGACUGGGACCCCAAGAAGUACGGCGGCU
		UCGACAGCCCCACCGUCGCCUACAGCGUCCUCGUCGUCGCCAAGGUCGAGAAGGGCAAGAGCAAGAAGCUCAAGAGCGUCAAGGA
		GCUCCUCGGCAUCACCAUCAUGGAGCGCAGCUUCGAGAAGAACCCCAUCGACUUCCUCGAGGCCAAGGGCUACAAGGAGGUC
		AAGAAGGACCUCAUCAUCAAGCUCCCCAAGUACAGCCUCUUCGAGCUCGAGAACGGCCGCAAGCGCAUGCUCGCCAGCGCCGGCG
		AGCUCCAGAAGGGCAACGAGCUCGCCCUCCCCAGCAAGUACGUCAACUUCCUCUACCUCGCCAGCCACUACGAGAAGCUCAAGGG
		CAGCCCCGAGGACAAGGAGCAGAAGCAGCUCUUCGUCGAGCACAAGCACUACCUCGACGAGAUCAUCGAGCAGAUCAGCGAG
		UUCAGCAAGCGCGUCAUCCUCGCCGACGCCAACCUCGACAAGGUCCUCAGCGCCUACAACAAGCACCGCGACAAGCCCAUCCGCG
		AGCAGGCCGAGAACAUCAUCCACCUCUUCACCCUCACCAACCUCGGCGCCCCCGCCGCCUUCAAGUACUUCGACACCACCAUCGA
		CCGCAAGCGCUACACCAGCACCAAGGAGGUCCUCGACGCCACCCUCAUCCACCAGAGCAUCACCGGCCUCUACGAGACCCGCAUC
		GACCUCAGCCAGCUCGGCGACGGCGGCGCAGCCCCAAGAAGAAGCGCAAGGUCUAG
665	ORF encoding Sp. Cas9	ATGGACAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACAGCGTGGGCTGGGCCGTGATCACCGACGAGTACAAGGTGCCCA
		GCAAGAAGTTCAAGGTGCTGGGCAACACCGACCGGCACAGCATCAAGAAGAACCTGATCGGCGCCCTGCTGTTCGACAGCGGCGA
		GACCGCCGAGGCCACCCGGCTGAAGCGGACCGCCCGGCGGCGGTACACCCGGCGGAAGAACCGGATCTGCTACCTGCAGGAGATC
		TTCAGCAACGAGATGGCCAAGGTGGACGACAGCTTCTTCCACCGGCTGGAGGAGAGCTTCCTGGTGGAGGAGGACAAGAAGCACG
		AGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTACCCCACCATCTACCACCTGCGGAAGAAGCT
		GGTGGACAGCACCGACAAGGCCGACCTGCGGCTGATCTACCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGATC
		GAGGGCGACCTGAACCCCGACAACAGCGACGTGGACAAGCTGTTCATCCAGCTGGTGCAGACCTACAACCAGCTGTTCGAGGAGA
		ACCCCATCAACGCCAGCGGCGTGGACGCCAAGGCCATCCTGAGCGCCCGGCTGAGCAAGAGCCGGCGGCTGGAGAACCTGATCGC
		CCAGCTGCCCGGCGAGAAGAAGAACGGCCTGTTCGGCAACCTGATCGCCCTGAGCCTGGGCCTGACCCCCAACTTCAAGAGCAAC


TTCGACCTGGCCGAGGACGCCAAGCTGCAGCTGAGCAAGGACACCTACGACGACGACCTGGACAACCTGCTGGCCCAGATCGGCG
ACCAGTACGCCGACCTGTTCCTGGCCGCCAAGAACCTGAGCGACGCCATCCTGCTGAGCGACATCCTGCGGGTGAACACCGAGAT
CACCAAGGCCCCCCTGAGCGCCAGCATGATCAAGCGGTACGACGAGCACCACCAGGACCTGACCCTGAAGGCCCTGGTGCGG
CAGCAGCTGCCCGAGAAGTACAAGGAGATCTTCTTCGACCAGAGCAAGAACGGCTACGCCGGCTACATCGACGGCGGCGCCAGCC
AGGAGGAGTTCTACAAGTTCATCAAGCCCATCCTGGAGAAGATGGACGGCACCGAGGAGCTGCTGGTGAAGCTGAACCGGGAGGA
CCTGCTGCGGAAGCAGCGGACCTTCGACAACGGCAGCATCCCCCACCAGATCCACCTGGGCGAGCTGCACGCCATCCTGCGGCGG
CAGGAGGACTTCTACCCCTTCCTGAAGGACAACCGGGAGAAGATCGAGAAGATCCTGACCTTCCGGATCCCCTACTACGTGGGCC
CCCTGGCCCGGGGCAACAGCCGGTTCGCCTGGATGACCCGGAAGAGCGAGGAGACCATCACCCCCTGGAACTTCGAGGAGGTGGT
GGACAAGGGCGCCAGCGCCCAGAGCTTCATCGAGCGGATGACCAACTTCGACAAGAACCTGCCCAACGAGAAGGTGCTGCCCAAG
CACAGCCTGCTGTACGAGTACTTCACCGTGTACAACGAGCTGACCAAGGTGAAGTACGTGACCGAGGGCATGCGGAAGCCCGCCT
TCCTGAGCGGCGAGCAGAAGAAGGCCATCGTGGACCTGCTGTTCAAGACCAACCGGAAGGTGACCGTGAAGCAGCTGAAGGAGGA
CTACTTCAAGAAGATCGAGTGCTTCGACAGCGTGGAGATCAGCGGCGTGGAGGACCGGTTCAACGCCAGCCTGGGCACCTACCAC
GACCTGCTGAAGATCATCAAGGACAAGGACTTCCTGGACAACGAGGAGAACGAGGACATCCTGGAGGACATCGTGCTGACCCTGA
CCCTGTTCGAGGACCGGGAGATGATCGAGGAGCGGCTGAAGACCTACGCCCACCTGTTCGACGACAAGGTGATGAAGCAGCTGAA
GCGGCGGCGGTACACCGGCTGGGCCGGCTGAGCCGGAAGCTGATCAACGGCATCCGGGACAAGCAGAGCGGCAAGACCATCCTG
GACTTCCTGAAGAGCGACGGCTTCGCCAACCGGAACTTCATGCAGCTGATCCACGACGACAGCCTGACCTTCAAGGAGGACATCC
AGAAGGCCCAGGTGAGCGGCGAGGGCGACAGCCTGCACGAGCACATCGCCAACCTGGCCGGCAGCCCCGCCATCAAGAAGGGCAT
CCTGCAGACCGTGAAGGTGGTGGACGAGCTGGTGAAGGTGATGGGCCGGCACAAGCCCGAGAACATCGTGATCGAGATGGCCCGG
GAGAACCAGACCACCCAGAAGGGCCAGAAGAACAGCCGGGAGCGGATGAAGCGGATCGAGGAGGGCATCAAGGAGCTGGGCAGCC
AGATCCTGAAGGAGCACCCCGTGGAGAACACCCAGCTGCAGAACGAGAAGCTGTACCTGTACTACCTGCAGAACGGCCGGGACAT
GTACGTGGACCAGGAGCTGGACATCAACCGGCTGAGCGACTACGACGTGGACCACATCGTGCCCCAGAGCTTCCTGAAGGACGAC
AGCATCGACAACAAGGTGCTGACCCGGAGCGACAAGAACCGGGGCAAGAGCGACAACGTGCCCAGCGAGGAGGTGGTGAAGAAGA
TGAAGAACTACTGGCGGCAGCTGCTGAACGCCAAGCTGATCACCCAGCGGAAGTTCGACAACCTGACCAAGGCCGAGCGGGGCGG
CCTGAGCGAGCTGGACAAGGCCGGCTTCATCAAGCGGCAGCTGGTGGAGACCCGGCAGATCACCAAGCACGTGGCCCAGATCCTG
GACAGCCGGATGAACACCAAGTACGACGAGAACGACAAGCTGATCCGGGAGGTGAAGGTGACCGTGATCACCCTGAAGAGCAAGCTG
GCGACTTCCGGAAGGACTTCCAGTTCTACAAGGTGCGGGAGATCAACAACTACCACCACGCCCACGACGCCTACCTGAACGCCGT
GGTGGGCACCGCCCTGATCAAGAAGTACCCCAAGCTGGAGAGCGAGTTCGTGTACGGCGACTACAAGGTGTACGACGTGCGGAAG
ATGATCGCCAAGAGCGAGCAGGAGATCGGCAAGGCCACCGCCAAGTACTTCTTCTACAGCAACATCATGAACTTCTTCAAGACCG
AGATCACCCTGGCCAACGGCGAGATCCGGAAGCGGCCCCTGATCGAGACCAACGGCGAGACCGGCGAGATCGTGTGGGACAAGGG
CCGGGACTTCGCCACCGTGCGGAAGGTGCTGAGCATGCCCCAGGTGAACATCGTGAAGAAGACCGAGGTGCAGACGGGCGGCTTC
AGCAAGGAGAGCATCCTGCCCAAGCGGAACAGCGACAAGCTGATCGCCCGGAAGAAGGACTGGGACCCCAAGAAGTACGGCGGCT
TCGACAGCCCCACCGTGGCCTACAGCGTGCTGGTGGTGGCCAAGGTGGAGAAGGGCAAGAGCAAGAAGCTGAAGAGCGTGAAGGA
GCTGCTGGGCATCACCATCATGGAGCGGAGCAGCTTCGAGAAGAACCCCATCGACTTCCTGGAGGCCAAGGGCTACAAGGAGGTG
AAGAAGGACCTGATCATCAAGCTGCCCAAGTACAGCCTGTTCGAGCTGGAGAACGGCCGGAAGCGGATGCTGGCCAGCGCCGGCG
AGCTGCAGAAGGGCAACGAGCTGGCCCTGCCCAGCAAGTACGTGAACTTCCTGTACCTGGCCAGCCACTACGAGAAGCTGAAGGG
CAGCCCCGAGGACAACGAGCAGAAGCAGCTGTTCGTGGAGCAGCACAAGCACTACCTGGACGAGATCATCGAGCAGATCAGCGAG
TTCAGCAAGCGGGTGATCCTGGCCGACGCCAACCTGGACAAGGTGCTGAGCGCCTACAACAAGCACCGGGACAAGCCCATCCGGG
AGCAGGCCGAGAACATCATCCACCTGTTCACCCTGACCAACCTGGGCGCCCCCGCCTTCAAGTACTTCGACACCACCATCGA

		CCGGAAGCGGTACACCAGCACCAAGGAGGTGCTGGACGCCACCCTGATCCACCAGAGCATCACCGGCCTGTACGAGACCCGGATC
		GACCTGAGCCAGCTGGGCGGCGACGGCGGCGCAGCCCCAAGAAGAAGCGGAAGGTGTGA
666	amino acid sequence for Sp. Cas9	MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEI
		FSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLI
		EGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSN
		FDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVR
		QQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRR
		QEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPK
		HSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYH
		DLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTIL
		DFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMAR
		ENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDD
		SIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQIL
		DSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRK
		MIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGF
		SKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEV
		KKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISE
		FSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRI
		DLSQLGGDGGGSPKKKRKV
667	Open reading frame for Cas9 with HiBiT tag	AUGGACAAGAAGUACUCCAUCGGCCUGGACAUCGGCACCAACUCCGUGGGCUGGGCCGUGAUCACCGACGAGUACAAGGUGCCCU
		CCAAGAAGUUCAAGGUGCUGGGCAACACCGACCGGCACUCCAUCAAGAAGAACCUGAUCGGCGCCCUGCUGUUCGACUCCGGCGA
		GACCGCCGAGGCCACCCGGCUGAAGCGGACCGCCCGGCGGUACACCCGGCGGAAGAACCGGAUCUGCUACCUGCAGGAGAUC
		UUCUCCAACGAGAUGGCCAAGGUGGACGACUCCUUCUUCCACCGGCUGGAGGAGUCCUUCCUGGUGGAGGACAAGAAGCACG
		AGCGGCACCCCAUCUUCGGCAACAUCGUGGACGAGGUGGCCUACCACGAGAAGUACCCCACCAUCUACCACCUGCGGAAGAAGCU
		GGUGGACUCCACCGACAAGGCCGACCUGCGGCUGAUCUACCUGGCCCUGGCCCACAUGAUCAAGUUCCGGGGCCACUUCCUGAUC
		GAGGGCGACCUGAACCCCGACAACUCCGACGUGGACAAGCUGUUCAUCCAGCUGGUGCAGACCUACAACCAGCUGUUCGAGGAGA
		ACCCCAUCAACGCCUCCGGCGUGGACGCCAAGGCCAUCCUGUCCGCCCGGCUGUCCAAGUCCCGGCGGCUGGAGAACCUGAUCGC
		CCAGCUGCCCGGCGAGAAGAAGAACGGCCUGUUCGGCAACCUGAUCGCCCUGUCCCUGGGCCUGACCCCCAACUUCAAGUCCAAC
		UUCGACCUGGCCGAGGACGCCAAGCUGCAGCUGUCCAAGGACACCUACGACGACGACCUGGACAACCUGCUGGCCCAGAUCGGCG
		ACCAGUACGCCGACCUGUUCCUGGCCGCCAAGAACCUGUCCGACGCCAUCCUGCUGUCCGACAUCCUGCGGGUGAACACCGAGAU
		CACCAAGGCCCCCCUGUCCGCCUCCAUGAUCAAGCGGUACGACGAGCACCACCAGGACCUGACCCUGAAGGCCCUGGUGCGG
		CAGCAGCUGCCCGAGAAGUACAAGGAGAUCUUCUUCGACCAGUCCAAGAACGGCUACGCCGGCUACAUCGACGGCGGCGCCUCCC
		AGGAGGAGUUCUACAAGUUCAUCAAGCCCAUCCUGGAGAAGAUGGACGGCACCGAGGAGCUGCUGGUGAAGCUGAACCGGGAGGA
		CCUGCUGCGGAAGCAGCGGACCUUCGACAACGGCUCCAUCCCCCACCAGAUCCACCUGGGCGAGCUGCACGCCAUCCUGCGGCGG
		CAGGAGGACUUCUACCCCUUCCUGAAGGACAACCGGGAGAAGAUCGAGAAGAUCCUGACCUUCCGGAUCCCCUACUACGUGGGCCC
		CCCUGGCCCGGGGCAACUCCCGGUUCGCCUGGAUGACCGGAAGUCCGAGGAGACCAUCACCCCCUGGAACUUCGAGGAGGUGGU
		GGACAAGGGCGCCUCCGCCCAGUCCUUCAUCGAGCGGAUGACCAACUUCGACAAGAACCUGCCCAACGAGAAGGUGCUGCCCAAG
		CACUCCCUGCUGUACGAGUACUUCACCGUGUACAACGAGCUGACCAAGGUGAAGUACGUGACCGAGGGCAUGCGGAAGCCCGCCU
		UCCUGUCCGGCGAGCAGAAGAAGGCCAUCGUGGACCUGCUGUUCAAGACCAACCGGAAGGUGACCGUGAAGCAGCUGAAGGAGGA

		CUACUUCAAGAAGAUCGAGUGCUUCGACUCCGUGGAGAUCUCCGGCGUGGAGGACCGGUUCAACGCCUCCCUGGGCACCUACCAC
		GACCUGCUGAAGAUCAUCAAGGACAAGGACUUCCUGGACAACGAGGAGAACGAGGACAUCCUGGAGGACAUCGUGCUGACCCUGA
		CCCUGUUCGAGGACCGGGAGAUGAUCGAGGAGCGGCUGAAGACCUACGCCCACCUGUUCGACGACAAGGUGAUGAAGCAGCUGAA
		GCGGCGGCGGUACACCGGCUGGGGCCGGCUGUCCCGGAAGCUGAUCAACGGCAUCCGGGACAAGCAGUCCGGCAAGACCAUCCUG
		GACUUCCUGAAGUCCGACGGCUUCGCCAACCGGAACUUCAUGCAGCUGAUCCACGACGACUCCCUGACCUUCAAGGAGGACAUCC
		AGAAGGCCCAGGUGUCCGGCCAGGGCGACUCCCUGCACGAGCACAUCGCCAACCUGGCCGGCUCCCCCGCCAUCAAGAAGGGCAU
		CCUGCAGACCGUGAAGGUGGUGGACGAGCUGGUGAAGGUGAUGGGCCGGCACAAGCCCGAGAACAUCGUGAUCGAGAUGGCCCGG
		GAGAACCAGACCACCCAGAAGGGCCAGAAGAACUCCCGGGAGCGGAUGAAGCGGAUCGAGGAGGGCAUCAAGGAGCUGGGCUCCC
		AGAUCCUGAAGGAGCACCCCGUGGAGAACACCCAGCUGCAGAACGAGAAGCUGUACCUGUACUACCUGCAGAACGGCCGGGACAU
		GUACGUGGACCAGGAGCUGGACAUCAACCGGCUGUCCGACUACGACGUGGACCACAUCGUGCCCCAGUCCUUCCUGAAGGACGAC
		UCCAUCGACAACAAGGUGCUGACCCGGUCCGACAAGAACCGGGGCAAGUCCGACAACGUGCCCUCCGAGGAGGUGGUGAAGAAGA
		UGAAGAACUACUGGCGGCAGCUGCUGAACGCCAAGCUGAUCACCCAGCGGAAGUUCGACAACCUGACCAAGGCCGAGCGGGGCGG
		CCUGUCCGAGCUGGACAAGGCCGGCUUCAUCAAGCGGCAGCUGGUGGAGACCCGGCAGAUCACCAAGCACGUGGCCCAGAUCCUG
		GACUCCCGGAUGAACACCAAGUACGACGAGAACGACAAGCUGAUCCGGGAGGUGAAGGUGAUCACCCUGAAGUCCAAGCUGGUGU
		CCGACUUCCGGAAGGACUUCCAGUUCUACAAGGUGCGGGAGAUCAACAACUACCACGCCCACGACGCCUACCUGAACGCCGUU
		GGUGGGCACCGCCCUGAUCAAGAAGUACCCCAAGCUGGAGUCCGAGUUCGUGUACGGCGACUACAAGGUGUACGACGUGCGGAAG
		AUGAUCGCCAAGUCCGAGCAGGAGAUCGGCAAGGCCACCGCCAAGUACUUCUUCUACUCCAACAUCAUGAACUUCUUCAAGACCG
		AGAUCACCCUGGCCAACGGCGAGAUCCGGAAGCGGCCCCUGAUCGAGACCAACGGCGAGACCGGCGAGAUCGUGUGGGACAAGGG
		CCGGGACUUCGCCACCGUGCGGAAGGUGCUGUCCAUGCCCCAGGUGAACAUCGUGAAGAAGACCGAGGUGCAGACCGGCGGCUUC
		UCCAAGGAGUCCAUCCUGCCCAAGCGGAACUCCGACAAGCUGAUCGCCCGGAAGAAGGACUGGGACCCCAAGAAGUACGGCGGCU
		UCGACUCCCCCACCGUGGCCUACUCCGUGCUGGUGGUGGCCAAGGUGGAGAAGGGCAAGUCCAAGAAGCUGAAGUCCGUGAAGGA
		GCUGCUGGGCAUCACCAUCAUGGAGCGGUCCUCCUUCGAGAAGAACCCCAUCGACUUCCUGGAGGCCAAGGGCUACAAGGAGGUG
		AAGAAGGACCUGAUCAUCAAGCUGCCCAAGUACUCCCUGUUCGAGCUGGAGAACGGCCGGAAGCGGAUGCUGGCCUCCGCCGGCG
		AGCUGCAGAAGGGCAACGAGCUGGCCCUGCCCUCCAAGUACGUGAACUUCCUGUACCUGGCCUCCCACUACGAGAAGCUGAAGGG
		CUCCCCCGAGGACAACGAGCAGAAGCAGCUGUUCGUGGAGCAGCACAAGCACUACCUGGACGAGAUCAUCGAGCAGAUCUCCGAG
		UUCUCCAAGCGGGUGAUCCUGGCCGACGCCAACCUGGACAAGGUGCUGUCCGCCUACAACAAGCACCGGGACAAGCCCAUCCGGG
		AGCAGGCCGAGAACAUCAUCCACCUGUUCACCCUGACCAACCUGGGCGCCCCCGCCGCCUUCAAGUACUUCGACACCACCAUCGA
		CCGGAAGCGGUACACCUCCACCAAGGAGGUGCUGGACGCCACCCUGAUCCACCAGUCCAUCACCGGCCUGUACGAGACCCGGAUC
		GACCUGUCCCAGCUGGGCGGCGACGGCGGCGCUCCCCCCAAGAAGAAGCGGAAGGUGUCCGAGUCCGCCACCCCCGAGUCCGUGU
		CCGGCUGGCGGCUGUUCAAGAAGAUCUCCUGA
668	Amino acid sequence for Cas9 with HiBiT tag	MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRYTRRKNRICYLQEI
		FSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLI
		EGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSN
		FDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVR
		QQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRR
		QEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPK
		HSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYH
		DLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTIL
		DFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMAR

		ENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDD SIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQIL DSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRK MIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGF SKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEV KKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISE FSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRI DLSQLGGDGGGSPKKKRKVSESATPESVSGWRLFKKIS
669	SV40 NLS	PKKKRKV
670	Alternate SV40 NLS	PKKKRRV
671	Exemplary NLS 1	LAAKRSRTT
672	Exemplary NLS 2	QAAKRSRTT
673	Exemplary NLS 3	PAPAKRERTT
674	Exemplary NLS 4	QAAKRPRTT
675	Exemplary NLS 5	RAAKRPRTT
676	Exemplary NLS 6	AAAKRSWSMAA
677	Exemplary NLS 7	AAAKRVWSMAF
678	Exemplary NLS 8	AAAKRSWSMAF
679	Exemplary NLS 9	AAAKRKYFAA
680	Exemplary NLS 10	RAAKRKAFAA
681	Exemplary NLS 11	RAAKRKYFAV
682	Nucleoplasmin NLS	KRPAATKKAGQAKKKK
683	Alternative SV40 NLS	PKKKRKVE
684	Alternative SV40 NLS	KKKRKVE
685	bipartite NLS	KRTADGSEFESPKKKRKVE
686	c-myc like NLS	PAAKKKKLD
687-700	Not used	

701	Exemplary sequence encoding Nme2Cas9 (mRNA AA)	GGGAAGCUCAGAAUAAACGCUCAACUUUGGCCGGAUCUGCCACCAUGGACGGCUCCGGCGGCGGCUCCCCCAAGAAGAAGCGGAA
		GGUGGAGGACAAGCGGCCCGCCGCCACCAGAAGGCCGGCCAGGCCAAGAAGAAGGGCGGCUCCGGCGGCGGCGCCGCCUUC
		AAGCCCAACCCCAUCAACUACAUCCUGGGCCUGGACAUCGGCAUCGCCUCCGUGGGCUGGGCCAUGGUGGAGAUCGACGAGGAGG
		AGAACCCCAUCCGGCUGAUCGACCUGGGCGUGCGGGUGUUCGAGCGGGCCGAGGUGCCCAAGACCGGCGACUCCCUGGCCAUGGC
		CCGGCGGCUGGCCCGGUCCGUGCGGCGGCUGACCCGGCGGCGGGCCCACCGGCUGCUGCGGCCCGGCGGCUGCUGAAGCGGGAG
		GGCGUGCUGCAGGCCGCCGACUUCGACGAGAACGGCCUGAUCAAGUCCCUGCCCAACACCCCCUGGCAGCUGCGGGCCGCCGCCC
		UGGACCGGAAGCUGACCCCCCUGGAGUGGUCCGCCGUGCUGCUGCACCUGAUCAAGCACCGGGGCUACCUGUCCCAGCGGAAGAA
		CGAGGGCGAGACCGCCGACAAGGAGCUGGGCGCCCUGCUGAAGGGCGUGGCCAACACGCCCACGCCUGCAGACCGGCGACUUC
		CGGACCCCCGCCGAGCUGGCCCUGAACAAGUUCGAGAAGGAGUCCGGCCACAUCCGGAACCAGCGGGGCGACUACUCCCACACCU
		UCUCCCGGAAGGACCUGCAGGCCGAGCUGAUCCUGCUGUUCGAGAAGCAGAAGGAGUUCGGCAACCCCCACGUGUCCGGCGGCCU
		GAAGGAGGGCAUCGAGACCCUGCUGAUGACCCAGCGGCCCGCCCUGUCCGGCGACGCCGUGCAGAAGAUGCUGGGCCACUGCACC
		UUCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCUACACCGCCGAGCGGUUCAUCUGGCUGACCAAGCUGAACAACCUGCGGA
		UCCUGGAGCAGGGCUCCGAGCGGCCCCUGACCGACACCGAGCGGGCCACCCUGAUGGACGAGCCCUACCGGAAGUCCAAGCUGAC
		CUACGCCCAGGCCCGGAAGCUGCUGGGCCUGGAGGACACCGCCUUCUUCAAGGGCCUGCGGUACGGCAAGGACAACGCCGAGGCC
		UCCACCCUGAUGGAGAUGAAGGCCUACCACGCCAUCUCCCGGGCCCUGAAGGAGGGCCUGAAGGACAAGAAGAACA
		ACCUGUCCUCCGAGCUGCAGGACGAGAUCGGCACCGCCUUCUCCCUGUUCAAGACCGACGAGGACAUCACCGGCCGGCUGAAGGA
		CCGGGUGCAGCCCGAGAUCCUGGAGGCCCUGCUGAAGCACAUCUCCUUCGACAAGUUCGUGCAGAUCUCCCUGAAGGCCCUGCGG
		CGGAUCGUGCCCCUGAUGGAGCAGGGCAAGCGGUACGACGAGCUGCGCCGAGAUCUACGGCGACCACGCAAGAAGAACA
		CCGAGGAGAAGAUCUACCUGCCCCCCAUCCCCGCCGACGAGAUCCCGGAACCCCGUGGUGCUGCGGGCCCUGUCCCAGGCCCGGAA
		GGUGAUCAACGGCGUGGUGCGGCGGUACGGCUCCCCCGCCCGGAUCCACAUCGAGACCGCCGCCGGAGAGGUGGGCAAGUCCUUCAAG
		GACCGGAAGGAGAUCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGCCGCCGCCGCCAAGUUCCGGGAGUACUUCCCCA
		ACUUCGUGGGCGAGCCCAAGUCCAAGGACAUCCUGAAGCUGCGGCUGUACGAGCAGCACGGCAAGUGCCUGUACUCCGGCAA
		GGAGAUCAACCUGGUGCGGCUGAACGAGAAGGGCUACGUGGAGAUCGACCACGCCUGCCCUUCUCCCGGACCUGGGACGACUCCC
		UUCAACAACAAGGUGCUGGUGCUGGGCUCCCGAGAACCAGAACAAGGGCAACCAGACCCCCUACGAGUACUUCAACGGCAAGGACA
		ACUCCCGGGAGUGGCAGGAGUUCAAGGCCCGGGUGGAGACCUCCCCGGUCCCAAGAAGCAGCGGAUCCUGCUGCAGAA
		GUUCGACGAGGACGGCUUCAAGGAGUGCAACCUGAACGACACCCGGUACGUGAACCGGUUCCUGUGCCAGUUCGUGGCCGACCAC
		AUCCUGCUGACCGGCAAGGGCGGCGGUGUUCGCCUCCAACGGCCAGAUCACCAACCUGCUGCGGGGCUUCUGGGGCCUGC
		GGAAGGUGCGGCCGAGAACGACCGGCACCACGCCCUGGACGCCGUGGUGGUGGCCUGCUCCACCGUGGCCAUGCAGCAGAAGAU
		CACCCGGUUCGUGCGGUACAAGGAGAUGAACGCCUUCGACGGCAAGACCAUCGACAAGGAGACCGGCAAGGUGCUGCACCAGAAG
		ACCCACUUCCCCCAGCCCUGGGAGUUCUUCGCCCAGGAGGUGAUGAUCCGGGUGUUCGGCAAGCCCGACGGCAAGCCCGAGUUCG
		AGGAGGCCGACACCCCCGAGAAGCUGCGGACCCUGCUGGCCGAGAAGCUGUCCUCCCGGCCCGAGGCCGUGCACGAGUACGUGAC
		CCCCCUGUUCGUGUCCCGGGCCCCCAACCGGAAGAUGUCCGGCGCCCACAAGGACACCCUGCGGUCCGCCAAGCGGUUCGUGAAG
		CACAACGAGAAGAUCUCCGUGAAGCGGGUGUGGCUGACCGAGAUCAAGCUGGCCGACGUGGAGAAACAUGGUGAACUACAAGAACG
		GCCGGGAGAUCGAGCUGUACGAGGCCCUGAAGGCCCGGCUGGAGGCCUACGGCAACGCCAAGCAGGCCUUCGACCCCAAGGA
		CAACCCCUUCUACAAGAAGGGCGGCCAGCUGGUGAAGGCCGUGCGGGUGGAGAAGACCCAGGAGUCCGGCGUGCUGCUGAACAAG
		AAGAACGCCUACACCAUCGCCGACAACGGCGACAUGGUGCGGGUGGACGUGUUCUGCAAGGUGGACAAGAAGGGCAAGAACCAGU
		ACUUCAUCGUGCCCAUCUACGCCUGGCAGGUGGCCGAGAACAUCCUGCCCGACAUCGACUGCAAGGGCUACCGGAUCGACGACUC
		CUACACCUUCUGCUUCUCCCUGCACAAGUACGACCUGAUCGCCUUCCAGAAGGACGAGAAGUCCAAGGUGGAGUUCGCCUACUAC
		AUCAACUGCGACUCCUCCCAACGGCCGGUUCUACCUGGCCUGGCACGACAAGGGCUCCAAGGAGCAGCAGUUCCGGAUCUCCCACCC

		AGAACCUGGUGCUGAUCCAGAAGUACCAGGUGAACGAGCUGGGCAAGGAGAUCCGGCCUGCCGGCUGAAGAAGCGGCCCCCCGU
		GCGGUAGCUAGCACCAGCCUCAAGAACACCCGAAUGGAGUCUCUAAGCUACACAUAAUACCAACUUACACUUUACAAAAUGUUGUCC
		CCCAAAAUGUAGCCAUUCGUAUCUGCUCCUAUAAAAAAGAAAGUUUCUUCACAUUCUCAAAAAAAAAAAAAAAAAAAAAAAAAAAA
		AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
		AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
		AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
702	Exemplary sequence encoding Nme1Cas9 (mRNA AB)	GGGUCCCGCAGUCGGCGUCCAGCGGCUCUGCUUGUUCGUGUGUGUCGUUGCAGGCCUUAUUCGGAUCCGCCACCAUGGCAGCA
		UUCAAGCCGAACUCGAUCAACUACAUCCUGGGACUGGACAUCGGAAUCGCAUCGGUCGGAUGGGCAAUGGUCGAAAUCGACGAAG
		AAGAAAACCCGAUCAGACUGAUCGACCUGGGAGUCAGAGUCUUCGAAAGAGCAGAAGUCCCGAAGACAGGAGACUCGCUGGCAAU
		GGCAAGAAGACUGGCAAGAUCGGUCAGAAGACUGACAAGAAGAGCACACAGACUGCUGAGAACAAGAAGACUGCUGAAGAGA
		GAAGGAGUCCUGCAGGCAGCAAACUUCGACGAAAACGGACUGAUCAAGUCGCUGCCGAACACACCGUGGCAGCUGAGAGCAGCAG
		CACUGGACAGAAAGCUGACACCGCUGGAAUGGUCGGCAGUCCUGCUGCACCUGAUCAAGCACAGAGGAUACCUGUCGCAGAAA
		GAACGAAGGAGAAACAGCAGACAAGGAAGCACUGGGAGCACUGCUGAAAGGGAGUCGCAGAAACGCACACGCACACUGCAGACAGGAGAC
		UUCAGAACACCGGCAGAACUGGCACUGAACAAGUUCGAAAAGGAAUCGGGACACAUCAGAAACCAGAGAUCGGACUACUCGCACA
		CAUUCUCGAGAAAGGACCUGCAGGCAGAACUGAUCCUGCUGUUCGAAAAGCAGAAGGAAUUCGGAAACCCGCACGUCUCGGAGG
		ACUGAAGGAAGGAAUCGAAACACUGCUGAUGACACAGACCGGCACUGUCGGGAGACGCAGUCCAGAAGAUGCUGGGACACUGC
		ACAUUCGAACCGGCAGAACCGAAGGGCAGCAAAGAACACAUACACAGCAGAAAGAUUCAUCUGGCUGACAAAGCUGAACAACCUGA
		GAAUCCUGGAACAGGGAUCGGAAAGACCGCUGACAGACACAGAAAGAGCAACACUGAUGGACGAACCGUACAGAAAGUCGAAGCU
		GACAUACGCACAGGCAAGAAGCUGCUGGGACUGGAAGACACAGCAUUCUUCAAGGGACUGAGAUACGGAAAGGACAACGCAGAA
		GCAUCGACACUGAUGGAAAUGAAGGCAUACCACGCAAUCUCGAGAGCACUGGAAAAGGAAGGACUGAAGGACAAGAAGUCGCCGC
		UGAACCUGUCGCCGGAACUGCAGGACGAAAUCGGAACAGCAUUCUCGCUGUUCAAGACAGACGAAGACAUCACAGGAAGACUGAA
		GGACAGAAUCCAGCCGGAAAUCCUGGAAGCACUGCUGAAGCACAUCUCGUUCGACAAGUUCGUCCAGAUCUCGCUGAAGGCACUG
		AGAAGAAUCGUCCCGCUGAUGGAACAGGGAAAGAGAUACGACGAAGCAUGCGCAGAAAUCUACGGAGACCACUACGGAAAGAAGA
		ACACAGAAGAAAAGAUCUACCUGCCGCCGAUCCCGGCAGACGAAAUCAGAAACCCGGUCGUCCUGAGAGCACUGUCGCAGGCAAG
		AAAGGUCAUCAACGGAGUCGUCAGAAGAUACGGAUCGCCGGCAAGAAUCCACAUCGAAACAGCAAGAGAAGUCGGAAAGUCGUUC
		AAGGACAGAAAGGAAAUCGAAAAGAGACAGGAAGAAAACAGAAAGGACAGAGAAAAGGCAGCAGCAAAGUUCAGAGAAUACUUCC
		CGAACUUCGUCGGAGAACCGAAGUCGAAGGACAUCCUGAAGCUGUACGAGCACGCAGCACGGAAAGUGCCUGUACUCUCGGG
		AAAGGAAAUCAACCUGGGAAGACUGAACGAAAAGGGAUACGUCGAAAUCGACCACACGCACUGCCGUUCUCGAGAACAUGGGACGAC
		UCGUUCAACAACAAGGUCCUGGUCCUGGGAUCGGAAAACCAGAACAAGGGAAACCAGACACCGUACGAAUACUUCAACGGAAAGG
		ACAACUCGAGAGAAUGGCAGGAAUUCAAGGCAAGAGUCGAAACAUCGAGAUUCCCGAGAUCGAAGAAGCAGAGAAGUCCUGCA
		GAAGUUCGACGAAGACGGAUUCAAGGAAAGAACCUGAACACACAAGAUACGUCAACAGAUUCCUGUGCCAGUUCGUCGCAGAC
		AGAAUGAGACUGACAGGAAAGGGAAAGAGAGUCUUCGCAUCGAACGGACAGAUCACAAACCUGCUGAGAGGAUUCUGGGGAC
		UGAGAAAGGUCAGAGCAGAAACGACAGACACCACGCACUGGACGCAGUCGUCGCAUGCUCGACAGUCGCAAUGCAGCAGAA
		GAUCACAAGAUUCGUCAGAUACAAGGAAAUGAACGCAUUCGACGGAAAGACAAUCGACAAGGAAACAGGAGAAGUCCUGCACCAG
		AAGACACACUUCCCGCAGCCGUGGGAAUUCUUCGCACAGGAAGUCAUGAUCAGAGUCUUCGGAAAGCCGGACGGAAAGCCGGAAU
		UCGAAGAAGCAGACACACUGGAAAAGCUGAGAACACUGCUGGCAGAAAAGCUGUCGUCGAGGACCGGAAGCAGUCCACGAAUACGU
		CACACCGCUGUUCGUCUCGAGAGCACCGAACACAGAAAGAUGUCGGGACAGGGACACAUGGAAACAGUCAAGUCGGCAAAGAGACUG
		GACGAAGGAGUCUCGGUCCUGAGAGUCCCGCUGACACAGCUGAAGCUGAAGGAGGACCUGGAAAAGAUGGUCAACAGAGAAAGAGAAC
		CGAAGCUGUACGAAGCACUGAAGGCAAGACUGGAAGCACACAAGGACGACCCGGCAAAGGCAUUCGCAGAACCGUUCUACAAGUA

		CGACAAGGCAGGAAACAGAACACAGCAGGUCAAGGCAGUCAGAGUCGAACAGGUCCAGAAGACAGGAGUCUGGGUCAGAAACCAC AACGGAAUCGCAGACAACGCAACAAUGGUCAGAGUAGACGUCUUCGAAAAGGGAGACAAGUACUACCUGGUCCCGAUCUACUCGU GGCAGGUCGCAAAGGGAAUCCUGCCGGACAGAGCAGUCGUCCAGGGAAAGGACGAAGAAGACUGGCAGCUGAUCGACGACUCGUU CAACUUCAAGUUCUCGCUGCACCCGAACGACCUGGUCGAAGUCAUCACAAAGAAGGCAAGAAUGUUCGGAUACUUCGCAUCGUGC CACAGAGGAACAGGAAACAUCAACAUCAGAAUCCACGACCUGGACCACAAGAUCGGAAAGAACGGAAUCCUGGAAGGAAUCGGAG UCAAGACAGCACUGUCGUUCCAGAAGUACCAGAUCGACGAACUGGGAAAGGAAAUCAGACCGUGCAGACUGAAGAAGAGACCGCC GGUCAGAUCCGGAAAGAGAACAGCAGACGGAUCGGAAUUCGAAUCGCCGAAGAAGAAGAGAAAGGUCGAAUGAUAGCUAGCCAUC ACAUUUAAAAGCAUCUCAGCCUACCAUGAGAAUAAGAGAAAGAAAAUGAAGAUCAAUAGCUUAUUCAUCUCUUUUUCUUUUUCGU UGGUGUAAAGCCAACACCCUGUCUAAAAAACAUAAAUUUCUUUAAUCAUUUUGCCUCUUUUCUCUGUGCUUCAAUUAAUAAAAAA UGGAAAGAACCUCGAGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAUCUAG
703	Exemplary sequence encoding Nme2Cas9 with HiBiT tag (mRNA V)	GGGAAGCUCAGAAUAAACGCUCAACUUUGGCCGGAUCUGCCACCAUGGACGGCUCCGGCGGCGGCUCCCCCAAGAAGAAGCGGAA GGUGGAGGACAAGCGGCCCGCCGCCACCAAGAAGGCCGGCCAGGCCAAGAAGAAGAAGGGCGGCUCCGGCGGCGGCGCCGCCUUC AAGCCCAACCCCAUCAACUACAUCCUGGGCCUGGACAUCGGCAUCGCCUCCGUGGGCUGGGCCAUGGUGGAGAUCGACGAGGAG AGAACCCCAUCCGGCUGAUCGACCUGGGCGUGCGGGUGUUCGAGCGGGCCGAGGUGCCCAAGACCGGCGACUCCCUGGCCAUGGC CCGGCGGCUGGCCCGGUCCGUGCGGCGGCUGACCCGGCGGCGGGCCCACCGGCUGCUGCGGGCCCGGCGGCUGCUGAAGCGGGAG GGCGUGCUGCAGGCCGCCGACUUCGACGAGAACGGCCUGAUCAAGUCCCUGCCCAACACCCCCUGGCAGCUGCGGGCCGCCGCCC UGGACCGGAAGCUGACCCCCCUGGAGUGGUCCGCCGUGCUGCUGCACCUGAUCAAGCACCGGGGCUACCUGUCCCAGCGGAAGAA CGAGGGCGAGACCGCCGACAAGGAGCUGGGCGCCCUGCUGAAGGGCGUGGCCAACAACGCCCACGCCCUGCAGACCGGCGACUUC CGGACCCCCGCCGAGCUGGCCCUGAACAAGUUCGAGAAGGAGUCCGGCCACAUCCGGAACCAGCGGGGCGACUACUCCCACACCU UCUCCCGGAAGGACCUGCAGGCCGAGCUGAUCCUGCUGUUCGAGAAGCAGAAGGAGUUCGGCAACCCCCACGUGUCCGGCGGCCU GAAGGAGGGCAUCGAGACCCUGCUGAUGACCCAGCGGCCCGCCCUGUCCGGCGACGCCGUGCAGAAGAUGCUGGGCCACUGCACC UUCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCUACACCGCCGAGCGGUUCAUCUGGCUGACCAAGCUGAACAACCUGCGGA UCCUGGAGCAGGGCUCCGAGCGGCCCCUGACCGACACCGAGCGGGCCACCCUGAUGGACGAGCCCUACCGGAAGUCCAAGCUGAC CUACGCCCAGGCCCGGAAGCUGCUGGGCCUGGAGGACACCGCCUUCUUCAAGGGCCUGCGGUACGGCAAGGACAACGCCGAGGCC UCCACCCUGAUGGAGAUGAAGGCCUACCACGCCAUCUCCCGGGCCCUGGAGAAGGAGGGCCUGAAGGACAAGAAGUCCCCCCUGA ACCUGUCCUCCGAGCUGCAGGACGAGAUCGGCACCGCCUUCUCCCUGUUCAAGACCGACGAGGACAUCACCGGCCGGCUGAAGGA CCGGGUGCAGCCCGAGAUCCUGGAGGCCCUGCUGAAGCACAUCUCCUUCGACAAGUUCGUGCAGAUCUCCCUGAAGGCCCUGCGG CGGAUCGUGCCCCUGAUGGAGCAGGGCAAGCGGUACGACGAGGCCUGCGCCGAGAUCUACGGCGACCACUACGGCAAGAAGAACA CCGAGGAGAAGAUCUACCUGCCCCCCAUCCCCGCCGACGAGAUCCGGAACCCCGUGGUGCUGCGGGCCCUGUCCCAGGCCCGGAA GGUGAUCAACGGCGUGGUGCGGCGGUACGGCUCCCCCGCCCGGAUCCACAUCGAGACCGCCCGGGAGGUGGGCAAGUCCUUCAAG GACCGGAAGGAGAUCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGUUCCGGGAGUACUUCCCCA ACUUCGUGGGCGAGCCCAAGUCCAAGGACAUCCUGAAGCUGCGGCUGUACGAGCAGCAGCACGGCAAGUGCCUGUACUCCGGCAA GGAGAUCAACCUGGUGCGGCUGAACGAGAAGGGCUACGUGGAGAUCGACCACGCCCUGCCCUUCUCCCGGACCUGGGACGACUCC UUCAACAACAAGGUGCUGGUGCUGGGCUCCGAGAACCAGAACAAGGGCAACCAGACCCCCUACGAGUACUUCAACGGCAAGGACA ACUCCCGGGAGUGGCAGGAGUUCAAGGCCCGGGUGGAGACCUCCCGGUUCCCCCGGUCCAAGAAGCAGCGGAUCCUGCUGCAGAA GUUCGACGAGGACGGCUUCAAGGAGUGCAACCUGAACGACACCCGGUACGUGAACCGGUUCCUGUGCCAGUUCGUGGCCGACCAC AUCCUGCUGACCGGCAAGGGCAAGCGGCGGGUGUUCGCCUCCAACGGCCAGAUCACCAACCUGCUGCGGGGCUUCUGGGGCCUGC GGAAGGUGCGGGCCGAGAACGACCGGCACCACGCCCUGGACGCCGUGGUGGUGGCCUGCUCCACCGUGGCCAUGCAGCAGAAGAU

		CACCCGGUUCGUGCGGUACAAGGAGAUGAACGCCUUCGACGGCAAGACCAUCGACAAGGAGACCGGCAAGGUGCUGCACCAGAAG
		ACCCACUUCCCCCAGCCCUGGGAGUUCUUCGCCCAGGAGGUGAUGAUCCGGGUGUUCGGCAAGCCCGACGGCAAGCCCGAGUUCG
		AGGAGGCCGACACCCCCGAGAAGCUGCGGACCCUGCUGGCCGAGAAGCUGUCCUCCCGGCCCGAGGCCGUGCACGAGUACGUGAC
		CCCCCUGUUCGUGUCCCGGGCCCCCAACCGGAAGAUGUCCGGCGCCCACAAGGACACCCCUGCGGUCCGCCAAGCGGUUCGUGAAG
		CACAACGAGAAGAUCUCCGUGAAGCGGGUGUGGCUGACCGAGAUCAAGCUGGCCGACCUGGAGAACAUGGUGAACUACAAGAACG
		GCCGGGAGAUCGAGCUGUACGAGGCCCUGAAGGCCCGGCUGGAGGCCUACGGCAACGCCAAGGACAGGCCUUCGACCCCAAGGA
		CAACCCCUUCUACAAGAAGGGCGGCCAGUGGUGAAGGCCGUGCGGGUGGAGAAGACCCAGGAGUCCGGCGUGCUGAACAAG
		AAGAACGCCUACACCAUCGCCGACAAGGACACUGGUGUCUGCAAGGUGGACAAGAAGGGCAAGAACCAGU
		ACUUCAUCGUGCCCAUCUACGCCUGGCAGGUGGCCGAGAACAUCCUGCCCGACAUCGACUGCAAGGGCUACCGGAUCGACUC
		CUACACCUUCUGCUUCUCCCUGCACAAGUACGACCUGAUCGCCUUCCAGAAGGACGAGAAGUCCCAAGGUGGAGUUCGCCUACUAC
		AUCAACUGCGACUCCUCCCAACGGCCGGUUCUACCUGGCCUGGCACGACAAGGGCUCCCAAGGAGCAGCAGUUCCGGCGUGCUGAACAAG
		AGAACCUGGUGCUGAUCCAGAAGUACCAGGUGAACGAGCUGGGCAAGGAGAUCCGGCCCUGCCGGCUGAAGAAGCGGCCCCCCGU
		GCGGUCCGAGUCCGCCACCCCCGAGUCCGUGUCCGGCUGGCGGCUGUUCAAGAAGAUCUCCCUAGCUACCAGCCUCAAGAACA
		CCCGAAUGGAGUCUCUAAGCUACAUAAUACCAACUUUACACUUUACAAAAUGUUGUCCCCCAAAAUGUAGCCAUUCGUAUCUGCUC
		CUAAUAAAAAGAAAGUUUCUUCACAUUCUAAAAAAAAAAAAAUGGAAAAAAAAAAAAAAACGGAAAAAAAAAAAAAAAGGUAAAAAAAAAAA
		AUAUAAAAAAAAAAACAUAAAAAAAAAAAAAAACGUAAAAAAAAAAAAAAAACUCAAAAAAAAAAAAAAGAUAAAAAAAA
		AAAAACCUAAAAAAAAAAAAAAUGUAAAAAAAAAAAAAAAGGGAAAAAAAAAAAAAAAACGCAAAAAAAAAAAAAAACACAAAAAAAAAAAAAAUGCAA
		AAAAAAAAAAAUCGAAAAAAAAAAAAAAAUCUAAAAAAAAAAAAAAAACGAAAAAAAAAAAAAAAACCCAAAAAAAAAAAAAAAGACAAAAAAAAAAAU
		AGAAAAAAAAAAAAAGUUAAAAAAAAAAAAAAACUGAAAAAAAAAAAAAAAUUUAAAAAAAAAAAAAAUCUCGA
704	Exemplary sequence encoding NmelCas9 with HiBiT tag (mRNA X)	GGGAAGCUCAGAAUAAAACGCUCAACUUUGGCCGGAUCUGCCACCAUGGACGGCUCCGGCGGCGGCUCCCCCCAAGAAGAAGCGGAA
		GGUGGAGGACAAGCGGCCCGCCGCCACCAAGAAGGCCGGCCAGGCCAAGAAGAAGGGCGGCUCCGGCGGCGGCGGCAGCAUUC
		AAGCCAAACUCAAUCAAUUACAUCCUGGGACUGGACAUCGGCAUCGCAUCCGUCGGUGGGCUAUGGUCGAAAUCGACGAGGAGG
		AGAACCCCAUCCGCCUGAUCGAUCUGGGCGUGCGCGUGUUUGAGAGGGCAGAGGUGCCUAAGACCGGCGACAGCCUGGCCAUGGC
		ACGGAGACUGGCACGCUCCGUGAGGCGCCUGACCCGGAGAAGGGCCCACAGACUGCUGAGGACACGCCGGCUGCUGAAGAGGGAG
		GGCGUGCUGCAGGCCGCCAACUUCGAUGAGAAUGGCCUGAUCAAGUCCCUGCCCAAUACCCCUUGGCAGCUGAGGGCAGCCGCCC
		UGGACCGCAAGCUGACACCUCUGGAGUGGUCCGCCGUGCUGCUGCACCUGAUCAAGCACCGGGGCUACCUGUCUCAGAGAAAGAA
		CGAGGGCGAGACAGCCGAUAAGGAGCUGGGCGCCCUGCUGAAGGGAGUGGCAGGAAAUGCCACACGCCCUGCAGACCGGCGACUUU
		CGCACACCAGCCGAGCUGGCCCUGAACAAGUUCGAGAAGGAGAGCGGCCACAUCCGCAAUCAGCGGUCUGACUAUAGCCACACCU
		UCUCCCGGAAGGAUCUGCAGGCCGAGCUGAUCCUGCUGUUUGAGAAGCAGAAGGAGUUCGGCAACCCACACGUGUCUGGCGGCCU
		GAAGGAGGGCAUCGAGACACUGCUGAUGACACAGCGGCCCGGCCCGAGCGGCGACGCAGUGCAGAAGAUGCUGGGACACUGCACC
		UUUGAGCCAGCCGAGCCCAAGGCCGCCAAGAAUACCUACACAGCCGAGCGGUUCAUCUGGCUGACAAAGCUGAACAAUCUGAGGA
		UCCUGGAGCAGGGAAGCGAGCGCCCACUGACCGACACAGAGAGGGCCACCCUGAUGGAUGAGCCCUACCGCAAGUCCAAGCUGAC
		AUAUGCACAGGCAAGGAAGCUGCUGGGCCUGGAGGACACCGCCUUCUUUAAGGGCCUGAGAUACGGCAAGGAUAACGCCGAGGCC
		UCUACACUGAUGGAGAUGAAGGCCUAUCACGCCAUCAGCAGGGCCCUGGAGAAGGAGGCCUGAAGGACAAGAAGUCCCCCACUGA
		AUCUGUCUCCCGAGCUGCAGGAUGAGAUCGGCACCGCCUUUAGCCUGUUCAAGACCGACGAGGAUAUCACAGGCAGACUGAAGGA
		CAGGAUCCAGCCAGAGAUCCUGGAGGCCCUGCUGAAGCACAUCAGCUUUGAUAAGUUCGUGCAGAUCAGCCUGAAGGCCCUGCGG
		AGGAUCGUGCCACUGAUGGAGCAGGGCAAGAGGUACGACGAGGCCUGCGCCGAAAUCUACGGCGAUCACUAUGGCAAGAAGAACA
		CAGAGGAGAAAAUCUACCUGCCCCUAUCCCCGCCGAUGAGAUCAGGAACCCUGUGGUGCUGCGCGCCCUGUCUCAGGCAAGAAA
		AGUGAUCAACGGAGUGGUGCGCCGGUACGGCAGCCCCGCCAGAAUCCACAUCGAGACAGCCAGGGAAGUGGGCAAGUCCUUUAAG

	705	Exemplary sequence encoding Nme1Cas9 with HiBiT tag (mRNA Y)

GACAGAAAGGAGAUCGAGAAGAGGCAGGAGGAGAACAGAAAGGAUAGGGAGAAGGCCGCCGCCAAGUUCAGAGAGUACUUUCCUA
AUUUCGUGGGCGAGCCAAAGUCCAAGGAUAUCCUGAAGCUGAGGCUGUACGAGCAGCACAGCCGGCAAGUGUCUGUAUUCUGGCAA
GGAGAUCAACCUGGGCCGCCUGAAUGAGAAGGGCUAUGUGGAGAUCGACCACGCCCUGCCUUUUUCUCGGACCUGGGACGAUAGC
UUCAACAAUAAGGUGCUGGUGCUGGGCUCUGAGAACCAGAAUAAGGGCAACCAGACACCCUACGAGUAUUUCAACGGCAAGGACA
AUAGCCGCGAGUGGCAGGAGUUUAAGGCAAGGGUGGAGACAAGCAGGUUCCCUCGGUCCAAGAAGCAGAGAAUCCUGCUGCAGAA
GUUUGACGAGGAUGGCUUCAAGGAGAGGAACCUGAAUGACACCCGCUACGUGAAUCGGUUUCUGUGCCAGUUCGUGGCCGAUAGA
AUGAGGCUGACCGGCAAGGGCAAGAAGAGAGUGUUUGCCUCCAACGGCCAGAUCACAAAUCUGCUGAGGGGCUUCUGGGGCCUGA
GAAAGGUGAGGGCAGAGAACGACAGGCACCACGCACUGGAUGCAGUGGUGGUGGCAUGUUCUACCGUGGCCAUGCAGCAGAAGAU
CACACGCUUUGUGCGGUAUAAGGAGAUGAAUGCCUUCGACGGCAAGACCAUCGAUAAGGAGACAGGCGAGGUGCUGCACCAGAAG
ACACACUUUCCUCAGCCAUGGGAGUUUCUUUGCCCAGGAAGUGAUGAUCCGGGUGUUUGGCAAGCCUGACGGCAAGCCAGAGUUCG
AGGAGGCCGAUACCCUGGAGAAGCUGAAACACUGCUGGCAGAAGAAGCUGAGCUCCAGGCCCGAGGCCAGUGCACGAGUACGUGAC
CCCACUGUUCGUGUCUAGAGCCCCCAACAGGAAGAUGAGAGCGGCCAGGGCCACAUGGAGACAGUGAAGUCCGCCAAGAGACUGGAC
GAGGGCGUGUCUGUGCUGAGGGUGCCUCUGACACAGCUGAAGCUGGAGAAGAUGGUGAAUCGCGAGCUGGAGCCAA
AGCUGUAUGAGGCCCUGAAGGCAAGGCUGGAGGCACACAAGGACGAUCCUGCCAAGGCCUUUGCCGAGCCAUUCUACAAGUAUGA
UAAGGCCGGCAACAGAACCCAGCAGGUGAAGGCCGUGAGAGGUGGAGCAGGUGCAGAAGACAGGCGUGUGGGUGCGCAACCACAAU
GGCAUCGCCGACAAUGCUACCAUGGUGCGGUGGACGUGUUUGAGAAGGGCGAUAAGUACUAUCUGGUGCCCAUCUACAGCUGGC
AGGUGGCCAAGGGCAUCCUGCCUGAUAGAGCCGUGGUGCAGGGCAAGGACGAGGAGGAUUGGCAGCUGAUCGACGAUUCCUUCAA
CUUUAAGUUCUCUCUGCACCCCAAUGACCUGGUGGAAGUGAUCACCAAGAAGGCCAGGAUGUUUGGCUACUUCGCCUCCUGCCAC
CGCGGCACAGGCAACAUCAAUAUCCGGAUCCACGACCUGGAUCACAAGAUCGGCAAGAACGGCAUCCUGGAGGGCAUCGGCGUGA
AGACAGCCUGAGCUUCCAGAAGUAUCAGAUCGACGAGCUGGGCAAGGAGAUCAGACCUUGUAGGCUGAAGAAGCGCCCACCGU
GCGGUCCGAGUCCGCCACCCCGAGUCCGUGUCCGGCUGGCGGCUGUUCAAGAAGAUCUCCCUAGCUACCAGCCUCAAGAACA
CCCGAAUGGAGUCUCUAAGCUACAUAAUACCAACUUACACUUUACAAAAUGUUGUCCCCCAAAAUGUAGCCAUUCGUAUCUGCUC
CUAAUAAAAGAAAGUUUCUUCACAUUCUAAAAAAAAAAAAAUGGAAAAAAAAAAAAAAAAAGGUAAAAAAAAAAAA
AUAUAAAAAAAAAAACAUAAAAAAAAAAAAAACGAAAAAAAAAAAAAAAACUCAAAAAAAAAAAAAAGAUAAAAAAA
AAAAACCUAAAAAAAAAAAAAAUGUAAAAAAAAAAAAAAGGGAAAAAAAAAAAAAAACGCAAAAAAAAAAAAAACACAAAAAAAAAAAAAUGCAA
AAAAAAAAAAAUCGAAAAAAAAAAAAAUCUAAAAAAAAAAAAAACGAAAAAAAAAAAAAAACCCAAAAAAAAAAAAAGACAAAAAAAAAAAAU
AGAAAAAAAAAAAGUUAAAAAAAAAAAAAACUGAAAAAAAAAAAAAAUUUAAAAAAAAAAAAUCUCGA

GGGAAGCUCAGAAUAAACGCUCAACUUUGGCCGGAUCUGCCACCAUGGACGGCUCCGGCGGCGGCUCCCCCAAGAAGAAGCGGAA	
GGUGGAGGACAAGCGGCCCGCCACCAAGAAGGCCGGCCAGGCCAAGAAGAAGGGCGGCUCCGGCGGCGGCGCCGCCUUC	
AAGCCCAACUCCAUCAACUACAUCCUGGGCCUGGACAUCGGCAUCGCCUCCGUGGGCUGGGCCAUGGUGGAGAUCGACGAGGAGG	
AGAACCCCAUCCGGCUGAUCGACCUGGGGUGUUCGAGCGGGCCGAGGUGCCCAAGACCGGCGACUCCCUGGCCAUGGC	
CCGGCGGCUGGCCCGGUCCGUGCGGCUGACCCGGCGGGGCCCACCGGCUGCUGCGGACCCGGCGGCUGCUGAAGCGGGAG	
GGCGUGCUGCAGGCCGCCAACUUCGACGAGAACGGCCUGAUCAAGCUGCCCUGCCCAACACACCCCUGGCAGCUGCGGGCCGCGCCC	
UGGACCGGAAGCUGACCCCCCUGGAGUGGUCCGCCGUGCUGCUGCACCUGAUCAAGGCACCGGGGCUACCUGUCCCAGCGGAAGAA	
CGAGGGCGAGACCGCCGACAAGGAGCUGGGCGCCCUGCUGAAGGGCGUGGCCGGCAACGCCCACGCCCUGCAGACCGGCGACUUC	
CGGACCCCCGCCGAGCUGGCCCUGAACAAGUUCGAGAAGGAGUCCGGCCACCAUCCGGAACCAGCGGUCCGACUACUCCCACACCU	
UCUCCCGGAAGGACCUGCAGGCCGAGCUGAUCCUGCUGUUCGAGAAGCAGAAGGAGUUCGGCAACCCCCACGUGUCCGGCGGCCU	
GAAGGAGGGCAUCGAGACCCUGCUGAUGACCCAGCGCCCCGCCCCGUCCGGCGACGCCGUGCAGAAGAUGCUGGGCCACUGCACC	
UUCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCUACACCGCCGAGCGGUUCAUCUGGCUGACCAAGCUGAACCUGCGGA	

		UCCUGGAGCAGGGCUCCGAGCGGCCCCUGACCGACACCGAGCGGGCCACCCUGAUGGACGAGCCCUACCGGAAGUCCAAGCUGAC CUACGCCCAGGCCCGGAAGCUGCUGGGCCUGGAGGACACCGCCUUCUUCAAGGGCCUGCGGUACGGCAAGGACAACGCCGAGGCC UCCACCCUGAUGGAGAUGAAGGCCUACCACGCCAUCUCCCGGGCCCUGGAGAAGGAGGGCCUGAAGGACAAGAAGUCCCCCCUGA ACCUGUCCCCCGAGCUGCAGGACGAGAUCGGCACCGCCUUCUCCCUGUUCAAGACCGACGAGGACAUCACCGGCCGGCUGAAGGA CCGGAUCCAGCCCGAGAUCCUGGAGGCCCUGCUGAAGCACAUCUCCUUCGACAAGUUCGUGCAGAUCUCCCUGAAGGCCCUGCGG CGGAUCGUGCCCCUGAUGGAGCAGGGCAAGCGGUACGACGAGGCCUGCGCCGAGAUCUACGGCGACCACUACGGCAAGAAGAACA CCGAGGAGAAGAUCUACCUGCCCCCCAUCCCCGCCGACGAGAUCCGGAACCCCGUGGUGCUGCGGGCCCUGUCCCAGGCCCGGAA GGUGAUCAACGGCGUGGUGCGGCGGUACGGCUCCCCCGCCCGGAUCCACAUCGAGACCGCCCGGGAGGUGGGCAAGUCCUUCAAG GACCGGAAGGAGAUCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCGGGAGAAGGCCGCCGCCAAGUUCCGGGAGUACUUCCCCA ACUUCGUGGGCGAGCCCAAGUCCAAGGACAUCCUGAAGCUGCGGCUGUACGAGCAGCAGCACGGCAAGUGCCUGUACUCCGGCAA GGAGAUCAACCUGGGCCGGCUGAACGAGAAGGGCUACGUGGAGAUCGACCACGCCCUGCCCUUCUCCCGGACCUGGGACGACUCC UUCAACAACAAGGUGCUGGUGCUGGGCUCCGAGAACCAGAACAAGGGCAACCAGACCCCCUACGAGUACUUCAACGGCAAGGACA ACUCCCGGGAGUGGCAGGAGUUCAAGGCCCGGGUGGAGACCUCCCGGUUCCCCCGGUCCAAGAAGCAGCGGAUCCUGCUGCAGAA GUUCGACGAGGACGGCUUCAAGGAGCGGAACCUGAACGACACCCGGUACGUGAACCGGUUCCUGUGCCAGUUCGUGGCCGACCGG AUGCGGCUGACCGGCAAGGGCAAGAAGCGGGUGUUCGCCUCCAACGGCCAGAUCACCAACCUGCUGCGGGGCUUCUGGGGCCUGC GGAAGGUGCGGGCCGAGAACGACCGGCACCACGCCCUGGACGCCGUGGUGGUGGCCUGCUCCACCGUGGCCAUGCAGCAGAAGAU CACCCGGUUCGUGCGGUACAAGGAGAUGAACGCCUUCGACGGCAAGACCAUCGACAAGGAGACCGGCGAGGUGCUGCACCAGAAG ACCCACUUCCCCCAGCCCUGGGAGUUCUUCGCCCAGGAGGUGAUGAUCCGGGUGUUCGGCAAGCCCGACGGCAAGCCCGAGUUCG AGGAGGCCGACACCCUGGAGAAGCUGCGGACCCUGCUGGCCGAGAAGCUGUCCUCCCGGCCCGAGGCCGUGCACGAGUACGUGAC CCCCCUGUUCGUGUCCCGGGCCCCCAACCGGAAGAUGUCCGGCCAGGGCCACAUGGAGACCGUGAAGUCCGCCAAGCGGCUGGAC GAGGGCGUGUCCGUGCUGCGGGUGCCCCUGACCCAGCUGAAGCUGAAGGACCUGGAGAAGAUGGUGAACCGGGAGCGGGAGCCCA AGCUGUACGAGGCCCUGAAGGCCCGGCUGGAGGCCCACAAGGACGACCCCGCCAAGGCCUUCGCCGAGCCCUUCUACAAGUACGA CAAGGCCGGCAACCGGACCCAGCAGGUGAAGGCCGUGCGGGUGGAGCAGGUGCAGAAGACCGGCGUGUGGGUGCGGAACCACAAC GGCAUCGCCGACAACGCCACCAUGGUGCGGGUGGACGUGUUCGAGAAGGGCGACAAGUACUACCUGGUGCCCAUCUACUCCUGGC AGGUGGCCAAGGGCAUCCUGCCCGACCGGGCCGUGGUGCAGGGCAAGGACGAGGAGGACUGGCAGCUGAUCGACGACUCCUUCAA CUUCAAGUUCUCCCUGCACCCCAACGACCUGGUGGAGGUGAUCACCAAGAAGGCCCGGAUGUUCGGCUACUUCGCCUCCUGCCAC CGGGGCACCGGCAACAUCAACAUCCGGAUCCACGACCUGGACCACAAGAUCGGCAAGAACGGCAUCCUGGAGGGCAUCGGCGUGA AGACCGCCCUGUCCUUCCAGAAGUACCAGAUCGACGAGCUGGGCAAGGAGAUCCGGCCCUGCCGGCUGAAGAAGCGGCCCCCCGU GCGGUCCGAGUCCGCCACCCCCGAGUCCGUGUCCGGCUGGCGGCUGUUCAAGAAGAUCUCCUAGCUAGCACCAGCCUCAAGAACA CCCGAAUGGAGUCUCUAAGCUACAUAAUACCAACUUACACUUUACAAAAUGUUGUCCCCCAAAAUGUAGCCAUUCGUAUCUGCUC CUAAUAAAAAGAAAGUUUCUUCACAUUCUAAAAAAAAAAAAUGGAAAAAAAAAAAACGGAAAAAAAAAAAAGGUAAAAAAAAAAA AUAUAAAAAAAAAAAACAUAAAAAAAAAAAACGAAAAAAAAAAAACGUAAAAAAAAAAAACUCAAAAAAAAAAAAGAUAAAAAAA AAAAACCUAAAAAAAAAAAAAUGUAAAAAAAAAAAAGGGAAAAAAAAAAAACGCAAAAAAAAAAAACACAAAAAAAAAAAAUGCAA AAAAAAAAAAUCGAAAAAAAAAAAAUCUAAAAAAAAAAAACGAAAAAAAAAAAACCCAAAAAAAAAAAAGACAAAAAAAAAAAAU AGAAAAAAAAAAAAGUUAAAAAAAAAAAACUGAAAAAAAAAAAAUUUAAAAAAAAAAAAUCUCGA
706	Exemplary sequence encoding	GGGAAGCUCAGAAUAAACGCUCAACUUUGGCCGGAUCUGCCACCAUGGACGGCUCCGGCGGCGGCUCCCCCAAGAAGAAGCGGAA GGUGGAGGACAAGCGGCCCGCCGCCACCAAGAAGGCCGGCCAGGCCAAGAAGAAGAAGGGCGGCUCCGGCGGCGCCGCCUUCAAG CCCAACCCCAUCAACUACAUCCUGGGCCUGGACAUCGGCAUCGCCUCCGUGGGCUGGGCCAUGGUGGAGAUCGACGAGGAGGAGA ACCCCAUCCGGCUGAUCGACCUGGGCGUGCGGGUGUUCGAGCGGGCCGAGGUGCCCAAGACCGGCGACUCCCUGGCCAUGGCCCG

Nme3Cas9 with HiBiT tag (mRNA 2)	GCGGCUGGCCCGGUCCGUGCGGCGGCUGACCCGGCGGGCCCACCGGCUGCUGCGGGCCCGGCGGCUGCUGAAGCGGGAGGGC
	GUGCUGCAGGCCGCCGACUUCGACGAGAACGGCCUGAUCAAGUCCCUGCCCAACACCCCCUGGCAGCUGCGGGCCGCCGCCCUGG
	ACCGGAAGCUGACCCCCCCUGGAGUGGUCCGCCGUGCUGCACCUGAUCAAGCACCGGGGCUACCUGUCCCAGCGGAAGAACGA
	GGGCGAGACCGCCGACAAGGAGCUGGGGCGCCCUGCUGAAGGGCGUGGCCGACAACGCCCACGCCCUGCAGACCGGCGACUUCCGG
	ACCCCCGCCGAGCUGGCCCUGAACAAGUUCGAGAAGGAGUGCGGCCACACUCCGGAACCAGCGGGGCGACUACUCCCACACCUUCU
	CCCGGAAGGACCUGCAGGCCGAGCUGAACCUGCUGUUCGAGAAGCAGAAGGAGUUCGGCAACCCCCACGUGUCCGGCGGCCUGAA
	GGAGGGCAUCGAGACCCUGCUGAUGACCCAGCGGCCCGCCCUGUCCGGCGACGCCGUGCAGAAGAUGCUGGGCCACUGCACCUUC
	GAGCCCGCCGAGCCCAAGAACACCUACACCGCCGAGCGGUUCAUCUGGCUGACCAAGCUGAACACAACCUGCGGAUCC
	UGGAGCAGGGCUCCGAGCGGCCCCUGACCGACACCGAGCGGGCCACCCUGAUGGACGAGCCCUACCGGAAGUCCAAGUCUGACCUA
	CGCCCAGGCCCGGAAGCUGCUGUCCCUGGAGGACACCGCCUUCUUCAAGGGCCUGCGGUACGGCAAGGACAACGCCGAGGCCUCC
	ACCCUGAUGGAGAUGAAGGCCUACCACACCAUCUCCCGGGCCCUGGAGAAGGAGGCCUGAAGGACAAGAAGUCCCCCCUGAACC
	UGUCCCCCGAGCUGCAGGACGAGAUCGGCACCGCCUUCUCCCUGUUCAAGACCGACGAGGACAUCACCGGCCGGCUGAAGGACCG
	GAUCCAGCCCGAGAUCCUGGAGGCCCUGCUGAAGCACAUCUCCUUCGACAAGUUCGUGCAGAUCUCCCUGAAGGCCCUGCGGCGG
	AUCGUGCCCCUGAUGGAGCAGGGCAAGCGGUACGACGAGGCCUGCGCCGAGAUCUACGGCGACCACUACGGCAAGAAGAACACCG
	AGGAGAAGAUCUACCUGCCCCCCAUCCCCGCCGACGAGAUCCGGAACCCCGUGGUGCUGCGGGCCCUGUCCCAGGGCCCGGAAGGU
	GAUCAACGGCGUGGUGCGGCGGUACGGCUCCCCCGCCCCGAUCCACACUCGAGACCGCCCGGGAGGUGGGCCAAGUCCUUCAAGGAC
	CGGAAGGAGAUCGAGAAGCGGGCAGGAGGAAGGACCGGGAGAAGGCCGCCGCCCAAGUUCCGGGAGUACUUCCCCCAACU
	UCGUGGGCGAGCCCAAGUCCAAGGACAUCCUGAAGCUGCGGCUGUACGAGCAGCACGGCAAGUGCCUGUACUCCCGGCAAGGA
	GAUCAACCUGGGCCGGCUGAACGAGAAGGGCUACGUGGAGAUCGACCACGCCUUCCUGCCCUUCUCCCGGACCUGGGACGACUCCUUC
	AACAACAAGGUGCUGGUGCUGGGCUCCGAGAACCAGAACAAGGGCAACCAGACCCCCUACGAGUACUUCAACGGCAAGGACAACU
	CCCGGGAGUGGCAGGAGUUCAAGGCCCGGGUGGAGACCUCCCCGGUUCCCCCGGUCCAAGAAGCAGCGGAUCCUGCUGCAGAAGUU
	CGACGAGGACGGCUUCAAGGAGCGCAACCUGAACGACACCCGGUACGUGAACCGGUUCCUGUGCCAGUUCGUGGCCGACCGGAUG
	CGGCUGACCGGCAAGGGCAAGAAGCGGUGUUCGCCUCCAACGGCCAGAUCACCAACCUGCUGCGGGGCUUCUUGGGGCCUGCGGA
	AGGUGCGGGCCGAGAACGACCGGCACCACGCCCUGGACGCCGUGGUGGUGGCCUGCUCCACCGUGGCCAUGCAGCAGAAGAUCAC
	CCGGUUCGUGCGGUACAAGGAGAUGAACGCCUUCGACGGCAAGACCAUCGACAAGGAGACCGGCGAGGUGCUGCACCAGAAGACC
	CACUUCCCCCAGCCCUGGGAGUUCUUCGCCCAGGAGGUGAUGAUCCGGGUGUUCGGCAAGCCCGACGGCCAAGCCCGAGUUCGAGG
	AGGCCGACACCCCCGAGAAGCUGCGGACCCUGCUGGCCGAGAAGCUGUCCUCCCGGCCCGAGGCCGUGCACGAGUACGUGACCCCC
	CCUGUUCGUGUCCCGGCCCCCAACCGGAAGAUGUCCGGCCAGGGCCACAUGGAGACCGUGAAGUCCGCCAAGCGGCUGGACGAG
	GGCGUGUCCGUGCUGCGGUGCCCCUGACCCAGCUGAAGCUGAAGGACCUGGAGAAGAUGGUGAACCGGGAGCGGGAGCCCAAGC
	UGUACGAGGCCCUGAAGGCCCGGCUGGAGGCCCACAAGGACGACCCCGCCAAGGCCUUCGCCGAGCCCUUCUACAAGUACGACAA
	GGCCGGCAACCGGACCCAGGUGAAGGCCGUGCGGUGGAGCAGGUGCAGAAGACCGGCGUGUGGGUGCGGAACCACACAACGGC
	AUCGCCGACAACGCCACCAUGGUGCGGGUGGACGUGUUCGAGAAGGGCGACAAGUACUACCUGGUGCCCAUCUACUCCUGGCAGG
	UGGCCAAGGGCAUCCUGCCCGACCGGGCCGUGGUGGCCUACGCCGACGAGGAGGACUGGACCGUGAUCGACGAGUCCUUCCGGUU
	CAAGUUCGUGCUGUACUCCAACGACCUGAUCAAGGUGCAGCUGAAGAAGGACUCCUUCCUGGGCUACUUCGUCGGCCUGGACCGG
	GCCACCGGCGCCAUCUCCCUGCGGGAGCACGACCUGGAGAAGUCCAAGGGCAAGGACGGCAUGCACCGGAUCGGCGUGAAGACCG
	CCCUGUCCUUCCAGAAGUACCAGAUCGACGAGAUGGGCAAGGAGUCCGGCCCUGCCGGCUGAAGAAGCGGCCCCCCGUGCGGUC
	CGAGUCCGCCACCCCCGAGUCCGUGUCCGGCUGGCGGCUGUUCAAGAAGAUCUCCUAGCUAGCACCAGCCUCAAGAACACCCGAA
	UGGAGUCUCUAAGCUACAUAAUACCAACUUACACUUUACAAAAUGUUGUCCCCCAAAAUGUAGCCAUUCGUAUCUGCUCCUAAUA
	AAAGAAAGUUUCUUCACAUUCCUCGAGAAAAAAAAAAAAAUGGAAAAAAAAAAAAAAACGGAAAAAAAAAAAAAAAGGUAAAAAAAAAAA

		AUAUAAAAAAAAAAAACAUAAAAAAAAAAAAACGAAAAAAAAAAAAAACGUAAAAAAAAAAAAACUCAAAAAAAAAAAAGAUAAAAAAA
		AAAAACCUAAAAAAAAAAAAAAAAUGUAAAAAAAAAAAAGGGAAAAAAAAAAAAACGCAAAAAAAAAAAAACACAAAAAAAAAAAUGCAA
		AAAAAAAAAAUCGAAAAAAAAAAAAAUCUAAAAAAAAAAAAACGAAAAAAAAAAAAACCCAAAAAAAAAAAAAGACAAAAAAAAAAAU
		AGAAAAAAAAAAAAGUUAAAAAAAAAAAAACUGAAAAAAAAAAAAAUUAAAAAAAAAAAAUCUAG
707	Exemplary amino acid sequence for Nme2Cas9 (mRNA AA amino acid)	MDGSGGGSPKKKRKVEDKRPAATKKAGQAKKKKGGSGGGAAFKPNPINYILGLDIGIASVGWAMVEIDEENPIRLIDLGVRVFE RAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLL HLIKHRGYLSQRKNEGETADKELGALLKGVANNAHALQTGDFRTPAELALNKFEKESGHIRNQRGDYSHTFSRKDLQAELILLFE KQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTER ATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFS LFKTDEDITGRLKDRVQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEI RNPVVLRALSQARKVINGVVRRYGSPARIHIETARDVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLR LYEQQHGKCLYSGKEINLVRLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETS RFPRSKKQRILLQKFDEDGFKECNLNDTRYVNRFLCQFVADHILLTGKGKRRVFASNGQITNLLRGFWGLRKVRAENDRHHALDA VVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGKVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAE KLSSRPEAVHEYVTPLFVSRAPNRKMSGAHKDTLRSAKRFVKHNEKISVKPVWLTEIKLADLENMVNYKNGREIELYEALKARLE AYGGNAKQAFDPKDNPFYKKGGQLVKAVRVEKTQESGVLLNKKNAYTIADNGDMVRVDVFCKVDKKGKNQYFIVPIYAWQVAENI LPDIDCKGYRIDDSYTFCFSLHKYDLIAFQKDEKSKVEFAYYINCDSSNGRFYLAWHDKGSKEQQFRISTQNLVLIQKYQVNELG KEIRPCRLKKRPPVR*
708	Exemplary amino acid sequence for Nme1Cas9 (mRNA BB amino acid)	MAAFKPNSINYILGLDIGIASVGWAMVEIDEENPIRLIDLGVRVFERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRTRRL LKREGVLQAANFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVAGNAHALQ TGDFRTPAELALNKFEKESGHIRNQRSDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKML GHCTFEPAEPKAAKNTYTAERFTWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFTKGLRYGKD NAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSPELQDEIGTAFSLFKTDEDITGRLKDRIQPEILEALLKHISFDKFVQISL KALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRRYGSPARIHIETARDVG KSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLGRLNEKGYVEIDHALPFSRT WDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKERNLNDTRYVNRFLCQF VADRMRLTGKGKKRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGEV LHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTLEKLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGQGHMETVKSA KRLDEGVSVLRVPLTQLKLKDLEKMVNREREPKLYEALKARLEAHKDDPAKAFAEPFYKYDKAGNRTQQVKAVRVEQVQKTGVWV RNHNGIADNATMVRVDVFEKGDKYYLVPIYSWQVAKGILPDRAVVQGKDEEDWQLIDDSFNFKFSLHPNDLVEVITKKARMFGYF ASCHRGTGNINIRIHDLDHKIGKNGILEGIGVKTALSFQKYQIDELGKEIRPCRLKKRPPVRSGKRTADGSEFESPKKKRKVE*
709	Exemplary amino acid sequence for Nme2Cas9 with HiBiT tag (mRNA V amino acid)	MDGSGGGSPKKKRKVEDKRPAATKKAGQAKKKKGGSGGGAAFKPNPINYILGLDIGIASVGWAMVEIDEENPIRLIDLGVRVFE RAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRAREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLL HLIKHRGYLSQRKNEGETADKELGALLKGVANNAHALQTGDFRTPAELALNKFEKESGHIRNQRGDYSHTFSRKDLQAELILLFE KQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTER ATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFS LFKTDEDITGRLKDRVQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEI RNPVVLRALSQARKVINGVVRRYGSPARIHIETARDVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLR LYEQQHGKCLYSGKEINLVRLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETS

		RFPRSKKQRILLQKFDEDGFKECNLNDTRYVNRFLCQFVADHILLTGKGKRRVFASNGQITNLLRGFWGLRKVRAENDRHHALDA
		VVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGKVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAE
		KLSSRPEAVHEYVTPLFVSRAPNRKMSGAHKDTLRSAKRFVKHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLE
		AYGGNAKQAFDPKDNPFYKKGGQLVKAVRVEKTQESGVLLNKKNAYTIADNGDMVRVDVFCKVDKKGKNQYFIVPIYAWQVAENI
		LPDIDCKGYRIDDSYTFCFSLHKYDLIAFQKDEKSKVEFAYYINCDSSNGRFYLAWHDKGSKEQQFRISTQNLVLIQKYQVNELG
		KEIRPCRLKKRPPVRSESATPESVSGWRLFKKIS*
710	Exemplary amino acid sequence for Nme1Cas9 with HiBiT tag (mRNA X amino acid)	MDGSGGGSPKKKRKVEDKRPAATKKAGQAKKKKGGSGGGAAFKPNSINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGVRVFE
		RAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRTRRLLKREGVLQAANFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLL
		HLIKHRGYLSQRKNEGETADKELGALLKGVAGNAHALQTGDFRTPAELALNKFEKESGHIRNQRSDYSHTFSRKDLQAELILLFE
		KQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTER
		ATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSPELQDEIGTAFS
		LFKTDEDITGRLKDRIQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEI
		RNPVVLRALSQARKVINGVVRRYGSPARIHIETARDVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLR
		LYEQQHGKCLYSGKEINLGRLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETS
		RFPRSKKQRILLQKFDEDGFKERNLNDTRYVNRFLCQFVADRMRLTGKGKKRVFASNGQITNLLRGFWGLRKVRAENDRHHALDA
		VVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGEVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTLEKLRTLLAE
		KLSSRPEAVHEYVTPLFVSRAPNRKMSGQGHMETVKSAKRLDEGVSVLRVPLTQLKLKDLEKMVNRERERPKLYEALKARLEAHKD
		DPAKAFAEPFYKYDKAGNRTQQVKAVRVEQVQKTGVWVRNHNGIADNATMVRVDVFEKGDKYYLVPIYSWQVAKGILPDRAVVQG
		KDEEDWQLIDDSFNFKFSLHPNDLVEVITKKARMFGYFASCHRGTGNINIRIHDLDHKIGKNGILEGIGVKTALSFQKYQIDELG
		KEIRPCRLKKRPPVRSESATPESVSGWRLFKKIS*
711	Exemplary amino acid sequence for Nme1Cas9 with HiBiT tag (mRNA Y amino acid)	MDGSGGGSPKKKRKVEDKRPAATKKAGQAKKKKGGSGGGAAFKPNSINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGVRVFE
		RAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRTRRLLKREGVLQAANFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLL
		HLIKHRGYLSQRKNEGETADKELGALLKGVAGNAHALQTGDFRTPAELALNKFEKESGHIRNQRSDYSHTFSRKDLQAELILLFE
		KQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTER
		ATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSPELQDEIGTAFS
		LFKTDEDITGRLKDRIQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEI
		RNPVVLRALSQARKVINGVVRRYGSPARIHIETARDVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLR
		LYEQQHGKCLYSGKEINLGRLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETS
		RFPRSKKQRILLQKFDEDGFKERNLNDTRYVNRFLCQFVADRMRLTGKGKKRVFASNGQITNLLRGFWGLRKVRAENDRHHALDA
		VVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGEVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTLEKLRTLLAE
		KLSSRPEAVHEYVTPLFVSRAPNRKMSGQGHMETVKSAKRLDEGVSVLRVPLTQLKLKDLEKMVNRERERPKLYEALKARLEAHKD
		DPAKAFAEPFYKYDKAGNRTQQVKAVRVEQVQKTGVWVRNHNGIADNATMVRVDVFEKGDKYYLVPIYSWQVAKGILPDRAVVQG
		KDEEDWQLIDDSFNFKFSLHPNDLVEVITKKARMFGYFASCHRGTGNINIRIHDLDHKIGKNGILEGIGVKTALSFQKYQIDELG
		KEIRPCRLKKRPPVRSESATPESVSGWRLFKKIS*
712	Exemplary amino acid sequence for Nme3Cas9 with HiBiT tag	MDGSGGGSPKKKRKVEDKRPAATKKAGQAKKKKGGSGGAAFKPNPINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGVRVFER
		AEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRKREGVLQAADFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLH
		LIKHRGYLSQRKNEGETADKELGALLKGVADNAHALQTGDFRTPAELALNKFEKECGHIRNQRGDYSHTFSRKDLQAELNLLFEK
		QKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGSERPLTDTERA
		TLMDEPYRKSKLTYAQARKLLSLEDTAFFKGLRYGKDNAEASTLMEMKAYHTISRALEKEGLKDKKSPLNLSPELQDEIGTAFSL

	(mRNA Z amino acid)	FKTDEDITGRLKDRIQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIR NPVVLRALSQARKVINGVVRRYGSPARIHIETARE VGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRL YEQQHGKCLYSGKEINLGRLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSR FPRSKKQRILLQKFDEDGFKERNLNDTRYVNRFLCQFVADRMRLTGKGKKRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAV VVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGEVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEK LSSRPEAVHEYVTPLFVSRAPNRKMSGQGHMETVKSAKRLDEGVSVLRVPLTQLKLKDLEKMVNRERE PKLYEALKARLEAHKDD PAKAFAEPFYKYDKAGNRTQQVKAVRVEQVQKTGVWVRNHNGIADNATMVRVDVFEKGDKYYLVPIYSWQVAKGILPDRAVVAYA DEEDWTVIDESFRFKFVLYSNDLIKVQLKKDSFLGYFSGLDRATGAISLREHDLEKSKGKDGMHRIGVKTALSFQKYQIDEMGKE IRPCRLKKRPPVRSESATPESVSGWRLFKKIS*
713	Exemplary open reading frame for Nme2Cas9 (mRNA AA ORF)	augGACGGCUCCGGCGGCGGCUCCCCCAAGAAGAAGCGGAAGGUGGAGGACAAGCGGCCCGCCGCCACCAAGAAGGCCGGCCAGG CCAAGAAGAAGGGCGGCUCCGGCGGCGGCgccgccuucaagccccaaccccaucaacuaccuggccuggacaucggcau cgccucccgugggcuggcgaggagaacgcgaggagaacccccauccggcugaucgaccugggcgugcgcgggcuguucgag cgggccgaggugcccaagaccggcgacuccccuggcccaugggcccgguccgugcggcgcugaccccggcgcgcgggg cccaccggcugcugcgggcccggcgcugcugaagcgggaggcgugcugcaggcccgccgacuucgacgagaacggcccugaucaa guccccugcccaacacccccuggcagcugcgggcgccgcccgcuggaccgaagcugaccccccuggagugguccgccgugcugcug caccugaucaagcaccgggguacuccugucccagcggaagaacgagggcgagacccgccgacaaggagagcuggcgcccugcugaagg gcguggccaacaacgcccacgccccugcagaccggcgacuucccgccgagcuggcccugaacaaguucgagaagaaggaguc cggccacaucccggaaccagcgggcgcgcugcuacgcccgcgaccgcgagaagcgcaucgagcugaucccugcuguucgag aagcagaaaggaguucggcaacccccacgugucccggcggccugaaggagggcgcaucgagacccugcugaugacccagcggccgccgccc uguccggcgacgccgugcagaagaugcugggccacugcacuucgagcccgccgccgagcccaaggccgccgcaagaacaccuacaccgc cgagcgguucaucuggcugaccaagcugaaacaaccugcggaucccuggagcagggucccgagcggcccccugaccgacaccgagcgg gccacccugauggacgagcccuaccggaaguccaagcugaccuacgcccaggcccgaagcugcuggggcccuggaggacaccgccu ucuucaagggccugcgguacggcaaggacaacgccgaggccucccaccccugauggagaugaaggccuacccaccgcccaucucccgggc ccuggagaaggagggccugaaggacaagaaguccccccugaaccuguccucccgagcugcaggacgagaucgggcaccgccguccucc cuguucaagaccgacgaggacaucaccggccgcuugaaggaccgggugcagcccgagaucccuggaggcccugcugaagcacaucu ccuucgacaaguucgugcagaucucccugaaggccucggcgcggaucgugccccugauggagcagggcaagcgguacgacgaggc cugcgccgagaucuacggcgaccacuacggcaagaagaacaccgaggagaagaucuaccugcccccccaucccccgccgacgagauc cggaaccccguggugcugcgggcccuguccaggcccggaaggugaucaacggcguggugcggcgguacggcucccccccgcccgga uccacaucgagaccgcccgggaggugggcaaguccuucaaggaccggaagagaucgagaagcggcaggaggaggagaaccggaagga ccgggagaaggccgccgccaaguucccgggaguacuucccccaacuucguggcgagcccaaguccaagaacacgaucccugaagcgg cuguacgagcagcagcacggcaaguggcccuguacucccggcaaggagaucaacaccuggugcggcgaacgagaaggcuacguggaga ucgaccacgcccugcccuucucccggaccuggacgacucccuucaacaacaaggugcuggugcuccgagaaccagaacaaa gggcaaccagacccccuacgaguacuucaacggcaaggacaacucccgggaguggcaggaguucaaggcccgggugaagaccucc cgguucccccggucaagaagcagcggaucccugcugcagaaguucgacgaggacggcuucaaggagugcaaccugaacgacaccc gguacgugaaccgguucccuguggccagucgugccgaccacauccugcugcaaggcgacgcggcgggugucgccucccaa cggccagaucaccaaccugcugcgggggcuucuggggccugcggaaggugcgggccgagaacgaccgccacccgcccuggacgccc gugguggugccugcucccaccgugccaugcagcagaagaucacccgguucgugcggcuacaaggagaugaacgccuucgacggca agaccaucgacaaggagaccggcaaggugcugcaccagaagacccacuucccccccugggaguucuucgcccaggaggugau gauccgggguucgugcaagccccgacggcaagcccgaguucgaggagggccgacacccccgagaagcugcgggccgaccugcgag

		aagcuguccucccggccgaggccgugcacgaguacgugacccccccuguucgugucccgggcccccaaccggaagauguccggcg
		cccacaaggacacccugccgguccgccaagcgguucgugaagcacaacgagaagcaucccgugaagcgggugguggcugaccgagau
		caagcuggccgaccuggagaacauggugaacuacaagaacggccgggagaucgagcuguacgaggcccugaaggcccggcuggag
		gccuacggcggcaacgccaagcaggccuucgacccccaaggacaacccccuucuacaagaagggcggccagcuggugaaggccgugc
		ggguggagaagacccaggaguccggcgugcugcugaacaagaagacgccuacacaccaucgccgacaacgggcgacaugugcgggu
		ggacguguucugcaaggugacaagaaggcaagaaccaguacuucaucgugcccaucuacgccuggcaggugcgaagaacauc
		cugcccgacaucgacugcaagggcuaccgaucgacgacuccuacaccaccuucugcuucuccccugcacaaguacgaccugaucgccu
		uccagaaggacgagaaguccaaggugguguucgccuacuacaucaacugcgacuccuccaacggccgguucuaccuggccuggca
		cgacaagggcuccaaggagcagcaguucccggaucuccacccagaaccuggugcugaucccagaaguaccaggugaacgagcugggc
		aaggagauccggccccugccggcugaagaagcggcccccgugcgguag
714	Exemplary open reading frame for Nme1Cas9 (mRNA AB ORF)	AUGGCAGCAUUCAAGCCGAACUCGAUCAACUACAUCCUGGGACUGGACAUCGGAAUCGCAUCGGUCGGAUGGGCAAUGGUCGAAA
		UCGACGAAGAAAACCCGAUCAGACUGAUCGACCUGGGAGUCAGAGUCUUCGAAAGAGCAGAAGUCCCGAAGACAGGAGACUC
		GCUGGCAAUGGCAAGAAGACUGGUCAAGAUCGGUCAGAAGACUGACAAGAAGAGCACACAGACUGCUGAGAACAAGAAGACUG
		CUGAAGAGAAGGAGUCCUGCAGGCAGCAAACUUCGACGAAAACGGACUGAUCAAGUCGCUGCCGAACACACCGUGGCAGCUGA
		GAGCAGCGCACUGGACAGAAAGCUGACACCGCUGGAAUGGUCGGCAGUCCUGCUGCACCUGAUCAAGCACAGAGGAUACCUGUC
		GCAGAGAAAGAACGAAGGAGAAACAGCAGACAAGGAACUGGGAGCACUGCUGAAGGGAGUCGCAGGAAACGCACACGCACUGCAG
		ACAGGAGACUUCAGAACACCGGCAGAACUGGCACUGAACAAGUUCGAAAAGGAAUCGGGACACAUCAGAAACCAGAGAUCGGACU
		ACUCGCACACAUUCUCGAGAAAGGACCUGCAGGCAGAACUGAUCCUGCUGUUCGAAAAGCAGAAGGAAUUCGGAAACCCGCACGU
		CUCGGGAGGACUGAAGGAGGAAUCGAAACACUGCUGAUGACACAGAGACCGGCACUGUCGGGAGACGCAGUCCAGAAGAUGCUG
		GGACACUGCACAUUCGAACCGGCAGAACCGAAAGGCAGCAAAGAACACAUACACAGCAGAAAAGAUUCAUCUGGCUGACAAAGCUGA
		ACAACCUGAGAAAUCCUGGAACAGGGAUCGGAAAGACCGCUGACAGACACAGAAAGAGCAACACUGAUGGACGAACCGUACAGAAA
		GUCGAAGCUGACAUACGCCACAGGCAAGAAAGCUGCUGGGACUGGAAGACACAGCAUUCUUCAAGGGACUGAGAUACGGAAAGGAC
		AACGCAGAAGCAUCGACACUGAUGGAAAUGAAGGCAUACCACGCAAUCUCGAGAGCACUGGAAAAGGAGGACUGAAGGACAAGA
		AGUCGCCGCUGAACCUGUCGCCGGAACUGCAGGACGAAAUCGGAACAGCAUUCUCGCUGUUCAAGACAGACGAAGACAUCACAGG
		AAGACUGAAGGACAGAAUCCAGCCGGAAAUCCUGGAAGCACUGCUGAAGCACAUCUCGUUCGACAAGUUCGUCCAGAUCUCGCUG
		AAGGCACUGAGAAGAAUCGUCCCGCUGAUGGAACAGGGAAAGAGAUACGACGAAGCAUGCGCAGAAAUCUACGGAGACCACACUACG
		GAAAGAAGAACACAGAAGAAAAGAUCUACCUGCCGCCGAUCCCGGCAGACGAAAUCAGAAACCCGGUCGUCCUGAGAGCACUGUC
		GCAGGCAAGAAAGGUCAUCAACGGAGUCGUCAGAAGAUACGGAUCGCCGGCAAGAAUCCACAUCGAAACAGCAAGAGAAGUCGGA
		AAGUCGUUCAAGGACAGAAAGGAAAUCGAAAAGAGACAGGAAGAAAACAGAAAGGACAGAGAAAAGGCAGCAGCAAAGUUCAGAG
		AAUACUUCCCGAACUUCGUCGGAGAACCGAAGUCGAAGGACAUCCUGAAGCUGAUCGAACAGCAGCACGGAAAGUGCCU
		GUACUCGGAAAGGAAAUCACCUGGGAAGACUGAACGAAAAGGGAUACGUCGAAAUCGACCACGCACUGCCGUUCUCGAGAACA
		UGGGACGACUCGUUCAACACAAGGUCCUGGGAUCGGAAAACCAGAACAAGGGAAACCAGACACCGUACGAAUACUUCA
		ACGGAAAGGACAACUCGAGAGAAUGGCAGGAAUUCAAGGCAAGAGUCGAAACAUCGAGAUUCCCGAGAUCGAAGAAGCAGAGAAU
		CCUGCUGCAGAAGUUCGACGAAGACGGAUUCAAGGAAAGAAACCUGAACGACACAAGAUACGUCAACAGAUUCCUGUGCCAGUUC
		GUCGCAGACAGAAUGAGACUGACAGGAAAGGGAAAGAGAGUCUUCGCAUCGAACGGACAGAUCACAAACCUGCUGAGAGGAU
		UCUGGGGACUGAGAAAGGUCAGAGCAGAAAACGACAGACACCACGCACUGGACGCAGUCGUCGUCGCAUGCUCGACAGUCGCAAU
		GCAGCAGAAGACAAGAUUCGUCAGAUACAAGGAAAUGAACGCAUUCGACGGAAAGACAAUCGACAAGGAAACAGGAGAAGUC
		CUGCACCAGAAGACACACUUCCCGCAGCCGUGGGAAUUCUUCGCACAGGAAGUCAUGAUCAGAGUCUUCGGAAAGCCGGACGAA
		AGCCGGAAUUCGAAGAAGCAGACACACUGGAAAGCUGAGAACACUGCUGGCAGAAAGCUGUCGUCGAGAAGCCGGAAGCAGUCCA

		CGAAUACGUCACACCGCUGUUCGUCUCGAGAGCACCGAACAGAAAGAUGUCGGGACAGGGACACAUGGAAACAGUCAAGUCGGCA
		AAGAGACUGGACGAAGGAGAGUCUCGGUCCUGAGAGUCCCGCUGACACAGCUGAAGCUGAAGGACCUGGAAAAGAUGGUCAACACAGAG
		AAAGAGAACCGAAGCUGUUACGAAGCACUGAAGGCAAGACUGGAAGCACACACAAGGACGACCCGGCAAAGGCAUUCGCAGAACCGUU
		CUACAAGUACGACAAGGCAGGAAACAGAACACAGCAGGUCAAGGCAGUCAGAGUCGAACAGGUCCAGAAGACAGGAGUCUGGGUC
		AGAAACCACACAACGGAAUCGCAGACAACAAUGGUCAGAGUAGACGUCUUCGAAAAGGGAGACAAGUACUACCUGGUCCCGA
		UCUACUCGUGGCAGGUCGCAAAGGGAAUCCUGCCGGACAGAGCAGUCGUCCAGGGAAAGGACGAAGAAGACUGGCAGCUGAUCGA
		CGACUCGUUCAACUUCAAGUUCUCGCUGCACCCGAACGACCUGGUCGAAGUCAUCACAAAGAAGGCAAGAAUGUUCGGAUACUUC
		GCAUCGUGCCACAGAGGAAACAGGAAACAUCAACAUCAGAAUCCACGACCUGGACCACAAGAUCGGAAAGAACGGAAUCCUGGAAG
		GAAUCGGAGUCAAGACAGCACUGUCGUUCCAGAAGUACCAGACGACGAACUGGGAAAGGAAAUCAGACCGUGCAGACUGAAGAA
		GAGACCGCCGGUCAGAUCCGGAAAGAGAACAGCAGACGGAUCGGAAUUCGAAUCGCCGAAGAAGAAGAGAAGGUCGAAUGA
715	Exemplary open reading frame for Nme2Cas9 with HiBiT tag (mRNA V ORF)	augGACGGCUCCGGCGGCGGCUCCCCCAAGAAGAAGCGGAAGGUGGAGGACAAGCGGCCCGCCACCAAGAAGGCCGGCCAGG
		CCAAGAAGAAGAGGCGGCUCCGGCGGCGCCGCCUUCAAGCCCAACCCCAUCACUACAUCCUGGGCCUGGACAUCGGCAU
		CGCCUCCGUGGGCUGGGCCAUGGUGAGAUCGACGAGGAGGAGAACCCCAUCCGGCUGAUCGACCUGGGCGUGCGGGUGUUCGAG
		CGGGCCGAGGUGCCCAAGACCGGCGACUCCCUGGCCAUGGCCCGGCUGGCCCGGUCCGUGCGGCGGCUGACCCGGCGGCGGG
		CCCACCGGCUGCUGGCGGCCCGGCGGCUGCUGAAGCGGGAGGGCGUGCUGCAGGCCGCCGACUUCGACGAGAACGGCCUGAUCAA
		GUCCCUGCCCAACACCCCCUGGCAGCUGCGGGCCGCCGCGGACCGGAAGCUGACCCCCCUGGAGUGGUCCGCCGUGCUGCUG
		CACCUGAUCAAGCACCGGGGCUACCUGUCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCUGGGCGCCCUGCUGAAGG
		GCGUGGCCAACAACGCCCACGCCCUGCAGACCGGCGACUUCCGGACCCCCGCCGAGCUGGCCCUGAACAAGUUCGAGAAGGAGUC
		CGGCCACAUCCGGAACCAGCGGGGCGACUACUCCCACACCUUCUCCCGGAAGGACCUGCAGGCCGAGCUGAUCCUGCUGUUCGAG
		AAGCAGAAGGAGUUCGGCAACCCCCACGUGUCCGGCGGCCUGAAGGAGGGCAUCGAGACCCUGCUGAUGACCCAGCGGCCCGCCC
		UGUCCGGCGACGCCGUGCAGAAGAUGCUGGGCCACUGCACCUUCGAGCCCGCCGAGCCCAAGGCCGCCAAGAACACCUACACCGC
		CGAGCGGUUCAUCUGGCUGACCAAGCUGAACACAACCUGCGGAUCCUGGAGCAGGGCUCCGAGCGGCCCCUGACCGACACCGAGCGG
		GCCACCCUGAUGGACGAGCCCUACCGGAAGUCCAAGCUGACCUACGCCCAGGCCCGGAAGCUGCUGGGCCUGGAGGACACCGCCU
		UCUUCAAGGGCCUGCGGUACGGCAAGGACACAAGAAGUCCCCCCUGAUGGAGAUGAAGGCCUACCACGCCAUCUCCCGGGC
		CCUGGAGAAGGAGGGCCUGAAGGACACAAGAAGUCCCCCCUGAACCUGUCCUCCGAGCUGCAGGACGAGAUCGGCACCGCCUUCUCCC
		CUGUUCAAGACCGACGAGGACAUCACACCGGCCGGCUGAAGGACCGGGUGCACAGCCCGAGAUCCUGGAGGCCCUGCUGAAGCACAUCU
		CCUUCGACAAGUUCGUGCAGAUCUCCCUGAAGGCCCUGCGCGGAUCGUGCCCCUGAUGGAGCAGGGCAAGGCGGUACGACGAGGC
		CUGCGCCGAGAUCUACGGCGACCACUACGGCAAGAAGAACACCGAGGAGAAGAUCUACCUGCCCCCCAUCCCCGCCGACGAGAUC
		CGGAACCCCGUGGUGCUGCGGGCCCUGUCCCAGGCCCGGAAGGUGAUCAACGGCGUGGUGCGGCGGUACGGCUCCCCCGCCCGGA
		UCCACAUCGAGACCGCCCGGGAGGUGGGCAAGUCCUUCAAGGACCGGAAGGAGAUCGAGAAGCGGCAGGAGAAGCACCGGAAGGA
		CCGGGAGAAGGCCGCCGCCAAGUUCCGGGAGUACUUCCCCAACUUCGUGGGCGAGCCCAAGUCCAAGGACAUCCUGAAGCUGCGG
		CUGUACGAGCAGCAGCACGGCAAGUGCCUGUACUCCGGCAAGGAGAUCAACCUGGUGCGGCUGAACGAGAAGGGCUACGUGGAGA
		UCGACCACGCCCUGCCCUUCUCCCGGACCUGGGACGACUCCUUCAACAACAAGGUGCUGGUGCUGGGCUCCGAGAACCAGAACAAA
		GGGCAACCAGACCCCCUACGAGUACUUCAACGGCAAGGACAACUCCCGGGAGUGGCAGGAGUUCAAGGCCCGGGUGGAGACCUCC
		CGGUUCCCCCGGUCCAAGAAGCAGCGGAUCCUGCUGCAGAAGUUCGACGAGGACGGCUUCAAGGAGUGCUACCUGAACGACACCC
		GGUACGUGGAACCGGUUCCUGUGCCAGUUCGUGGCCGACCACAUCCUGCUGACCGGCAAGGGCAAGCGGCGGGUGUUCGCCUCCAA
		CGGCCAGAUCACCAACCUGCUGCGGGGCUUCUGGGCCUGCGGAAGGUGCGGGCCGAGAACGACCGCCACGCCCUGGACGCCC
		GUGGUGGUGGCCUGCUCCACCGUGGCCAUGCAGCAGAAGAUCACCCGGUUCGUGCGGUACAAGGAGAUGAACGCCUUCGACGGCA
		AGACCAUCGACAAGGAGACCGGCAAGUGCUGCACCAGAAGACCCACUUCCCCCAGCCCUGGGAGUUCUUCGCCCAGGAGGUGAU

		GAUCCGGGUGUUCGGCAAGCCCGACGGCAAGCCCGAGUUCGAGGAGGCCGACACCCCCGAGAAGCUGCGGACCCUGCUGGCCGAG
		AAGCUGUCCCUCCCGGCCCGAGGCCGUGCACGAGUACGUGACCCCCCUGUUCGUGUCCCGGGCCCCCAACCGGAAGAUGUCCGGCG
		CCCACAAGGACACCCUGCGGUCCGCCAAGCGGUUCGUGAAGCACACGAGAAGAUCUCCGUGAAGCGGGUGUGGCUGACCGAGAU
		CAAGCUGGCCGACCUGGAGAACAUGGUGAACUACAAGAACGGCCGGGAGAUCGAGCUGUACGAGGCCCUGAAGGCCCGGCUGGAG
		GCCUACGGCGGCAACGCCAAGGCAGGCCUUCGACCCCAAGGACAACCCCUUCUACAAGAAGGGCGGCCAGCUGGUGAAGGCCGUGC
		GGGUGGAGAAGACCCAGGAGUCCGGCGUGCUGAACAAGAAGAACGCCUACACCAUCGCCGACAACGGCGACAUGGUGCGGGU
		GGACGUGUUCUGCAAGGUGGACAAGAAGGGCAAGAACCAGUACUUCAUCGUGCCCAUCUACGCCUGGGCAGGUGGCCGAGAACAUC
		CUGCCCGACAUCGACUGCAAGGGCUACCGGAUCGACUCCUACACCUUCUGCUUCUCCCUGCACAAGUACGACCUGAUCGCCU
		UCCAGAAGGACGAGAAGUCCAAGGUGGAGUUCGCCUACUACAUCAUCAAGCUGCGACUCCUCCAACGGCCGGUUCUACCUGGCCUGGCA
		CGACAAGGGCUCCAAGGAGCAGCAGUUCCGGAUCUCCACCCAGAACCUGGUGCUGAUCCAGAAGUACCAGGUGAACGAGCUGGGC
		AAGGAGAUCCGGCCCUGCCGGCUGAAGAAGCGGCCCCCCGUGCGGUCCGAGUCCGCCACCCCCGAGUCCGUGUCCGGCUGGCGGC
		UGUUCAAGAAGAUCUCCUAG
716	Exemplary open reading frame for Nme1Cas9 with HiBiT tag (mRNA X ORF)	augGACGGCUCCGGCGGCGGCUCCCCCCAAGAAGAAGCGGAAGGUGGAGGACAAGCGGCCCGCCGCCACCAAGAAGGCCGGCCAGG
		CCAAGAAGAAGAAGGGCGGCUCCGGCGGCGCAGCAUUCAAGCCAAACUCAAUCAAUUACAUCCUGGGACUGGACAUCGGCAU
		CGCAUCCGUCGGGUGGGCUAUGGUCGAAAUCGACGAGGAGGAGAACCCCAUCCGCCUGAUCGAGUCUGGGCGUGCGCGUGUUUGAG
		AGGGCAGAGGUGCCUAAGACCGGCGCACAGCCUGGCCAUGGCACGGAGACUGGCACGCUCCGUGAGGCGCCUGACCCGGAGAAGGG
		CCCACAGACUGCUGAGGACACGCCGGCUGCUGAAGAGGGAGGGCGUGCUGCAGGCCGCCAACUUCGAUGAGAAUGGCCUGAUCAA
		GUCCCUGCCCAAUACCCCUUGGCAGCUGAGGGCAGCCGCCUGGACCGCAAGCUGACACCUCUGGAGUGGUCCGCCGUGCUGCUG
		CACCUGAUCAAGCACCGGGGCUACCUGUCUCAGAGAAAGAACGAGGGCGAGACAGCCGAUAAGGAGCUGGGCGCCCUGCUGAAGG
		GAGUGGCAGGAAAUGCACACGCCCUGCAGACCGGCGACUUUCGCACACCAGCCGAGCUGGCCCUGAACAAGUUCGAGAAGGAGAG
		CGGCCACAUCCGCAAUCAGCGGUCUGACUAUAGCCACACCUUCUCCCGGAAGGAUCUGCAGGCCGAGCUGAUCCUGCUGUUUGAG
		AAGCAGAAGGAGUUCGGCAACCCACACGUGUCUGGCGGCCUGAAGGAGGGCAUCGAGACACUGCUGAUGACACAGCGGCCCGCCC
		UGAGCGGCGACGCAGUGCAGAAGAUGCUGGGACACUGCACCUUUGAGCCAGCCGAGCCCAAGGCCCGCCAAGAAUACCUACACAGC
		CGAGCGGUUCAUCUGGCUGACAAAGCUGAACAAUCUGAGGAUCCUGGAGCAGGGAAGCGAGCGCGCCCACUGACCGACACAGAGAGG
		GCCACCCUGAUGGAUGAGCCCUACCGCAAGUCCAAGCUGACAUAUGCACAGGCAAGGAAGCUGCUGGGCCUGGAGGACACCGCCU
		UCUUUAAGGGCCUGAGAUACGGCAAGGAUAACGCCGAGGCCUCUACACUGAUGGAGAUGAAGGCCUAUCACGCCAUCAGCAGGGC
		CCUGGAGAAGGAGGGCCUGAAGGACAAGAAGUCCCCACUGAAUCUGUCUCCCGAGCUGCAGGAUGAGAUCGGCACCGCCUUUAGC
		CUGUUCAAGACCGACGAGGAUAUCACAGGCAGACUGAAGGACAGGAUCCAGCCAGAGAUCCUGGAGGCCCUGCUGAAGCACAUCA
		GCUUUGAUAAGUUCGUGCAGAUCAGCCUGAAGGCCCUGCGGAGGAUCGUGCCACUGAUGGAGCAGGGCAAGACGCUGGCAGAUGC
		CUGCGCCGAAAUCUACGGCGAUCACUAUGGCAAGAAGAACACAGAGGAGAAAAUCUACCUGCCCCCUAUCCCCGCCGAUGAGAUC
		AGGAACCCUGUGGUGCUGCGCGCCCUGUCUCAGGCAAGAAAAGUGAUCAACGGAGUGGUGCGCCGGUACGGCAGCCCCGCCAGAA
		UCCACAUCGAGACAGCCAGGGAAGUGGGCAAGUCCUUUAAGGACAGAAAGGAGAUCGAGAAGAGGCAGGAGGAGAACAGAAAGGA
		UAGGGAGAAGGCCGCCGCCAAGUUCAGAGAGUACUUUCCUAAUUUCGUGGGCGAGCCAAAGUCCAAGGAUAUCCUGAAGCUGAGG
		CUGUACGAGCAGCACGCCGGCAAGUGUCUGUAUUCUGGCAAGGAGAUCAACCUGGGCCGCCUGAAUGAGAAGGGCUAUGUGGAGA
		UCGACCACGCCCUGCCUUUUUCUCGGACCUGGGACGAUAGCUUCAACAAUAAGGUGCUGGUGCUGGGCUCUGAGAACCAGAAUAA
		GGGCAACCAGACACCCUACGAGUAUUUCAACGGCAAGGACAAUAGCCGCGAGUGGCAGGAGUUUAAGGCAAGGGUGGAGACAAGC
		AGGUUCCCUCGGUCCAAGAAGCAGAGAAUCCUGCUGCAGAAGUUUGACGAGGAUGGCUUCAAGGAGAGGAACCUGAAUGACACCC
		GCUACGUGAAUCGGUUUCUGUGCCAGUUCGUGGCCGAUAGAAUGAGGCUGACCGGCAAGGGCAAGAAGAGGUGUUUGCCUCCAA
		CGGCCAGAUCACAAAUCUGCUGAGGGGCUUCUGGGGCCUGAGAAAGGUGAGGGCAGAGAACGACAGGCACCACGCACUGGAUGCA

		GUGGUGGUGGCAUGUUCUACCGUGGCCAUGCAGCAGAAGAUCACACGCUUUGUGCGGUAUAAGGAGAUGAAUGCCUUCGACGGCA
		AGACCAUCGAUAAGGAGACAGGCGAGGUGCUGCACCAGAAGACACACUUUCCUCAGCCAUGGGAGUUCUUUGCCCAGGAAGUGAU
		GAUCCGGGUGUUUUGGCAAGCCUGACGGCAAGCCAGAGUUCGAGGAGGCCGAUACCCUGGAGAAGCUGAGAAGCACUGCUGGCAGAG
		AAGCUGAGCUCCCAGGCCCGAGGCCAGUGCACGAGUACGUGACCCCACUGUUCGUCUAGAGCCCCCAACAGGAAGAUGAGCGGCC
		AGGGCCACAUGGAGACAGUGAAGUCCGCCAAGAGACUGGACGAGGGCGUGUCUGUGCUGAGGGUGCCUCUGACACAGCUGAAGCU
		GAAGGAUCUGGAGAAGAUGGUGAAUCGCGAGCGGGAGCCAAAGCUGUAUGAGGCCCUGAAGGCAAGGCUGGAGGCCACACAAGGAC
		GAUCCUGCCAAGGCCUUUGCCGAGCCAUUCUACAAGUAUGAUAAGGCCGGCAACAGAACCCAGCAGGUGAAGGCCGUGAGGGUGG
		AGCAGGUGCAGAAGACAGGCGUGUGGGUGCGCAACCACAAUGGCAUCGCCGACAAUGCUACCAUGGUGCGGGUGGACGUGUUUGA
		GAAGGGCGAUAAGUACUAUCUGGUGCCCAUCUACAGCUGGCAGGUGGCCAAGGGCAUCCUGCCUGAUAGAGCCGUGGUGCAGGGC
		AAGGACGAGGAGGAUUGGCAGCUGAUCGACGAUUCCUUCAACUUUAAGUUCUCUGCACCCCCAAUGACCUGGUGGAAGUGAUCA
		CCAAGAAGGCCAGGAUGUUUGGCUACUUCGCCUCCUGCCACCGGCACAGGCAACAUCAAUAUCCGGAUCCACGACCUGGAUCA
		CAAGAUCGGCAAGAACGGCAUCCUGGAGGGCAUCGGCGUGAAGACAGCCCUGAGCUUCCAGAAGUAUCAGAUCGACGAGCUGGGC
		AAGGAGAUCAGACCUUGUAGGCUGAAGAAGCGCCCACCCGUGCGGUCCGAGUCCGCCACCCCCGAGUCCGUGUCCGGCUGGCGGC
		UGUUCAAGAAGAUCUCCUAG
717	Exemplary amino acid open reading frame for Nme1Cas9 with HiBiT tag (mRNA Y ORF)	augGACGGCUCCGGCGGCGGCUCCCCCCAAGAAGAAGCGGAAGGUGGAGGACAAGCGGCCCGCCGCCACCAAGAAGGCCGGCCAGG
		CCAAGAAGAAGAAGGGCGGCUCCGGCGGCGGCGCCUUCAAGCCCAACUCCAUCAACUACAUCCUGGGCCUGGACAUCGGCAU
		CGCCUCCGUGGGCUGGGCCAUGGUGGAGAUCGACGAGGAGGAGAACCCCAUCCGGCUGAUCGACCUGGGCGUGCGGCUGUUCGAG
		CGGGCCGAGGUGCCCAAGACCGGCGACUCCCUGGCCAUGGCCCGGCUGGUCCGUGCGGCGGCUGACCCGGCGGCGGG
		CCCACCGGCUGCUGCGGACCCGGCGGCUGCUGAAGCGGGAGGGCGUGCUGCAGGCCGCCAACUUCGACGAGAACGGCCUGAUCAA
		GUCCCUGCCCAACACCCCCUGGCAGCUGCGGGCCGCCGCCUGGACCGGAAGCUGACCCCCCUGGAGUGGUCCGCCGUGCUGCUG
		CACCUGAUCAAGCACCGGGGCUACCUGUCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCUGGGCGCCCUGCUGAAGG
		GCGUGGCCGGCAACACGCCCACGCCCUGCAGACCGGCGACUUCCGGACCCCCGCCGAGCUGGCCCUGAACAAGUUCGAGAAGGAGUC
		CGGCCACAUCCGGAACCAGCGGUCCGACUACUCCCACACCUUCUCCCGGAAGGACCUGCAGGCCGAGCUGAUCCUGCUGUUCGAG
		AAGCAGAAGGAGUUCGGCAACCCCCACGUGUCCGGCGGCCUGAAGGAGGGCAUCGAGACCCUGCUGAUGGACCCAGCGGCCGCCC
		UGUCCGGCGACGCCGUGCAGAAGAUGCUGGGCCACUGCACCUUCGAGCCCGCCAAGGCCCGCCUACACCGC
		CGAGCGGUUCAUCUGGCUGACCAAGCUGAACACCCUGCGGAUCCUGGAGCAGGGCUCCGAGCGGCCCCUGACCGACACCGAGCGG
		GCCACCCUGAUGGACGAGCCCUACCGGAAGUCCAAGCUGACCUACGCCCAGGCCCGGAAGCUGCUGGGCCUGGAGGACACCGCCU
		UCUUCAAGGGCCUGCGGUACGGCAAGGACACAACGCCGAGGCCUCCCACCCUGAUGGAGAUGAAGGCCUACCACGCCAUCUCCCGGGC
		CCUGGAGAAGGAGGGCCUGAAGGACAAGAAGUCCCCCCUGAACCUGUCCCCCGAGCUGCAGGACGAGAUCGGCACCGCCUUCUCC
		CUGUUCAAGACCGACGAGGACAUCACCGGCCGGCUGAAGGACCGGAUCCAGCCCGAGAUCCUGGAGGGCCCUGCUGAAGCACAUCU
		CCUUCGACAAGUUCGUGCAGAUCUCCCUGAAGGCCCUGCGGCGGAUCGUGCCCCUGAUGGAGCAGGGCAAGCGGUACGACGAGGC
		CUGCGCCGAGAUCUACGGCGACCACUACGGCAAGAAGAACACCGAGGAGAAGAUCUACCUGCCCCCCAUCCCCGCCGACGAGAUC
		CGGAACCCCGUGGUGCUGCGGCCCUGUCCCAGGCCCGGAAGGUGAUCAACGGCGUGGUGCGGCGGUACGGCUCCCCCGCCCGGA
		UCCACAUCGAGACCGCCCGGGAGGUGGGCAAGUCCUUCAAGGACCGGAAGGAGAUCGAGAAGCGGCAGGAGGAGAACCGGAAGGA
		CCGGGAGAAGGCCGCCGCCAAGUUCCGGGAGUACUUCCCCAACUUCGUGGGCGAGCCCAAGUCCAAGGACAUCCUGAAGCUGCGG
		CUGUACGAGCAGCAGCACGGCAAGUGCCUGUACUCCGGCAAGGAGAUCAACCUGGGCCGGCUGAACGAGAAGGGCUACGUGGAGA
		UCGACCACGCCCUGCCCUUCUCCCGGACCUGGGACGACUCCUUCAACAACAAGGUGCUGGUGCUGGGCUCCGAGAACCAGAACAA
		GGGCAACCAGACCCCCUACGAGUACUUCAACGGCAAGGACAACUCCCGGGAGUGGCAGGAGUUCAAGGCCCGGGUGGAGACCUCC
		CGGUUCCCCCGGUCCAAGAAGCAGCGGAUCCUGCUGCAGAAGUUCGACGAGGACGGCUUCAAGGAGCGGCAGCUGAACGACACCC

		GGUACGUGAACCGGUUCCUGUGCCAGUUCGUGGCCGACCGGAUGCGGCUGACCGGCAAGGGCAAGAAGCGGGUGUUCGCCUCCAA
		CGGCCAGAUCACCAACCUGCUGCGGGGCUUCUUGGGCCUGCGGAAGGUGCGGCCGAGAACGACCGGCACCACGCCCUGGACGCC
		GUGGUGGUGGCCUGCUCCACCGUGGCCAUGCAGCAGAAGAUCACCCGGUUCGUGGCGGUACAAGGAGAUGAACGCCUUCGACGGCA
		AGACCAUCGACAAGGAGACCGGCGAGGUGCUGCACCAGAAGACCCACUUCCCCCAGCCCUGGGAGUUCUUCGCCCAGGAGGUGAU
		GAUCCGGGUGUUCGGCAAGCCCGACGGCAAGCCCGAGUUCGAGGAGGCCGACACCCUGGAGAAGCUGCGGACCCUGCUGGCCGAG
		AAGCUGUCCUCCCGGCCCGAGGCCGUGCACGAGUACGUGACCCCCCUGUUCGUGGGCCCCCCAACCGGAAGAUGUCCGGCC
		AGGGCCACAUGGAGACCGUGAAGUCCGCCAAGCGGCUGGACGAGGGCGUGUCCGUGCUGCGGGUGCCCCUGACCCAGCUGAAGCU
		GAAGGACCUGGAGAAGAUGGUGAACCGGGAGCGGGAGCCCAAGCUGUACGAGGCCCUGAAGGCCCGGCUGGAGGCCCACAAGGAC
		GACCCCGCCAAGGCCUUCGCCGAGCCCUUCUACAAGUACGACAAGGCCGGCAACCGGACCCAGCAGGUGAAGGCCGUGCGGGUGG
		AGCAGGUGCAGAAGACCGGCGUGUGGGUGCGGAACCACAACGGCAUCGCCGACAACGCCACCAUGGUGCGGGUGGACGUGUUCGA
		GAAGGGCGACAAGUACUACCUGGUGCCCAUCUACUCCUGGCAGGUGGCCAAGGGCAUCCUGCCCGACCGGGCCGUGGUGCAGGGC
		AAGGACGAGGAGGACUGGCAGCUGAUCGACGACUCCUUCAACUUCCUCCCUGCACCCCAACGACCUGGUGGAGGAGGUGAUCA
		CCAAGAAGGCCCGGAUGUUCGGCUACUUCGCCUCCUGCCACCGGGGCACCGGCAACAUCAACGUCCGGAUCCACGACCUGGACCA
		CAAGAUCGGCAAGAACGGCAUCCUGGAGGGCGUGAAGACCGCCUGUUCCUUCCAGAAGUACCAGAUCGACGAGUGGGC
		AAGGAGAUCCGGCCCUGCCGGCUGAAGAAGCGGCCCCCCGUGCGGUCCGAGUCCGCCACCCCCGAGUCCGUGUCCGGCUGGCGGC
		UGUUCAAGAAGAUCUCCUAG
718	Exemplary open reading frame for Nme3Cas9 with HiBiT tag (mRNA Z ORF)	augGACGGCUCCGGCGGCGGCUCCCCCCAAGAAGAAGCGGAAGGUGGAGGACAAGCGGCCCGCCGCCACCAAGAAGGCCGGCCAGG
		CCAAGAAGAAGAAGGCGGCUCCGGCGCCGCCGCUUCAAGCCCAACCCCAUCACUACAUCCUGGGCCUGGACAUCGGCAUCGCC
		CUCCGUGGGCUGGGCCAUGGUGGAGAUCGACGAGGAGGAGAACCCCAUCCGGCUGAUCGACCUGGGCGUGCGGUGUUCGAGCGG
		GCCGAGGUGCCCAAGACCGGCGACUCCCUGGCCAUGGCCCGGCGGCUGGCCCGGUCCGUGCGGCUGGCCGGCGGCGGCCC
		ACCGGCUGCUGCGGGCCCGGCGGCUGCUGAAGCGGGAGGGCGUGCUGCAGGCCGCCGACUUCGACGAGAACGGCCUGAUCAAGUC
		CCUGCCCAACACCCCCUGGCAGCUGGCGGCCGCCCUGGACCGGAAGCUGACCCCCCUGGAGUGGUCCGCCGUGCUGCUGCAC
		CUGAUCAAGCACCGGGGCUACCUGUCCCAGCGGAAGAACGAGGGCGAGACCGCCGACAAGGAGCUGGGCGCCCUGCUGAAGGGCG
		UGGCCGACAACGCCCACGCCCUGCAGACCGGCGACUUCCGGACCCCCGCCGAGCUGGCCCUGAACAAGUUCGAGAAGGAGUGCGG
		CCACAUCCGGAACCAGCGGGGCGACUACUCCCACACCUUCUCCCGGAAGGACCUGCAGGCCGAGCUGAACCUGCUGUUCGAGAAG
		CAGAAGGAGUUCGGCAACCCCCACGUGUCCGGCGCCUGAAGGAGGGCAUCGAGACCCUGCUGAUGACCCAGCGGCCCGCCUGU
		CCGGCGACGCCGUGCAGAAGAUGCUGGGCCACUGCACCUUCGAGCCCGCCGAGCCCAAGAACACCUACACCGCCGA
		GCGGUUCAUCUGGCUGACCAAGCUGAACAACCUGCGGAUCCUGGAGCAGGGCUCCGAGCGGCCCCUGACCGACACCGAGCGGCCC
		ACCCUGAUGGACGAGCCCUACCGGAAGUCCAAGCUGACCUACGCCCAGGCCCGGAAGCUGCUGUCCCUGGAGGACACCGCCUUCU
		UCAAGGGCCUGCGGUACGGCAAGGACAACGCCGAGGCCUCCACCCUGAUGGAGAUGAAGGCCUACCACCACACCAUCUCCCGGGCCCU
		GGAGAAGGAGGCCUGAAGGACAAGAAGUCCCCCCUGAACCUGUCCCCCGAGCUGCAGGACGAGAUCGGCACCGCCUUCUCCCUG
		UUCAAGACCGACGAGGACAUCACCGGCCGGCUGAAGGACCGGAUCCAGCCCGAGAUCCUGGAGGCCCUGCUGAAGCACAUCUCCU
		UCGACAAGUUCGUGCAGAUCUCCCUGAAGGCCUGCGGCGGAUCGUGCCCCUGAUGGAGCAGGGCAAGCGGUACGACGAGGCCUG
		CGCCGAGAUCUACGGCGACCACUACGGCAAGAAGAACACCGAGGAGAAGAUCUACCUGCCCCCCAUCCCCGCCGACGAGAUCCGG
		AACCCCGUGGUGCUGCGGGCCCUGUCCCAGGCCCGGAAGGUGAUCAACGGCGUGGUGCGGCGUACGGCUCCCCCGCCCGGAUCC
		ACAUCGAGACCGCCCGGGAGGUGGGCAAGUCCUUCAAGGACCGGAAGGAGAUCGAGAAGCGGCAGGAGGAGAACCGGAAGGACCG
		GGAGAAGGCCGCCGCCAAGUUCCGGGAGUACUUCCCCAACUUCGUGGGCGAGCCCAAGUCCAAGGACAUCCUGAAGCUGCGGCUG
		UACGAGCAGCAGCACGGCAAGUGCCUGUACUCCGGCAAGGAGAUCAACCUGGGCCGGCUGAACGAGAAGGGCUACGUGGAGAUCG
		ACCACGCCCUGCCCUUCUCCCGGACCUGGGACGACUCCUUCAACAACAAGGUGCUGGUGCUGGGCUCCGAGAACCAGAACAAGGG

		CAACCAGACCCCCUACGAGUACUUCAACGGCAAGGACAACUCCCGGGAGUGGCAGGAGUUCAAGGCCCGGGUGGAGACCUCCCGG UUCCCCCGGUCCAAGAAGCAGCGGAUCCUGCUGCAGAAGUUCGACGAGGACGGCUUCAAGGAGCGGAACCUGAACGACACCCGGU ACGUGAACCGGUUCCUGUGCCAGUUCGUGGCCGACCGGAUGCGGCUGACCGGCAAGGGCAAGAAGCGGGUGUUCGCCUCCAACGG CCAGAUCACCAACCUGCUGCGGGGCUUCUGGGGCCUGCGGAAGGUGCGGGCCGAGAACGACCGGCACCACGCCCUGGACGCCGUG GUGGUGGCCUGCUCCACCGUGGCCAUGCAGCAGAAGAUCACCCGGUUCGUGCGGUACAAGGAGAUGAACGCCUUCGACGGCAAGA CCAUCGACAAGGAGACCGGCGAGGUGCUGCACCAGAAGACCCACUUCCCCCAGCCCUGGGAGUUCUUCGCCCAGGAGGUGAUGAU CCGGGUGUUCGGCAAGCCCGACGGCAAGCCCGAGUUCGAGGAGGCCGACACCCCCGAGAAGCUGCGGACCCUGCUGGCCGAGAAG CUGUCCUCCCGGCCCGAGGCCGUGCACGAGUACGUGACCCCCCUGUUCGUGUCCCGGGCCCCCAACCGGAAGAUGUCCGGCCAGG GCCACAUGGAGACCGUGAAGUCCGCCAAGCGGCUGGACGAGGGCGUGUCCGUGCUGCGGGUGCCCCUGACCCAGCUGAAGCUGAA GGACCUGGAGAAGAUGGUGAACCGGGAGCGGGAGCCCAAGCUGUACGAGGCCCUGAAGGCCCGGCUGGAGGCCCACAAGGACGAC CCCGCCAAGGCCUUCGCCGAGCCCUUCUACAAGUACGACAAGGCCGGCAACCGGACCCAGCAGGUGAAGGCCGUGCGGGUGGAGC AGGUGCAGAAGACCGGCGUGUGGGUGCGGAACCACAACGGCAUCGCCGACAACGCCACCAUGGUGCGGGUGGACGUGUUCGAGAA GGGCGACAAGUACUACCUGGUGCCCAUCUACUCCUGGCAGGUGGCCAAGGGCAUCCUGCCCGACCGGGCCGUGGUGGCCUACGCC GACGAGGAGGACUGGACCGUGAUCGACGAGUCCUUCCGGUUCAAGUUCGUGCUGUACUCCAACGACCUGAUCAAGGUGCAGCUGA AGAAGGACUCCUUCCUGGGCUACUUCUCCGGCCUGGACCGGGCCACCGGCGCCAUCUCCCUGCGGGAGCACGACCUGGAGAAGUC CAAGGGCAAGGACGGCAUGCACCGGAUCGGCGUGAAGACCGCCCUGUCCUUCCAGAAGUACCAGAUCGACGAGAUGGGCAAGGAG AUCCGGCCCUGCCGGCUGAAGAAGCGGCCCCCCGUGCGGUCCGAGUCCGCCACCCCCGAGUCCGUGUCCGGCUGGCGGCUGUUCA AGAAGAUCUCCUAG

Table 4B: Additional Sequences

G000502 (unmodified)	758	ACACAAAUACCAGUCCAGCGGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU
G000502	759	mA*mC*mA*CAAAUACCAGUCCAGCGGUUUUAGAmGmCmUmAmGmAmAmAmUmAmGmCAAGUUAAAAUAAGGCUAGUCCGUUAUCAmAmCmUmUmGmAmAmAmAmAmGmUmGmGmCmAmCmCmGmAmGmUmCmGmGmUmGmCmU*mU*mU*mU
RNAWT-145	760	GGCGCTTCGCCAGCCATTCCTGCGTTGTAGCTCCCTTTCTCATTTCGGAAACGAAATGAGAACCGTTGCTACAATAAGGCCGTCTGAAAAGATGTGCCGCAACACGCTCTGCCCCTTAAAGCTTCTGCTTTAAGGGGCATCGTTTAT
RNA9-102	761	GGCGCTTCGCCAGCCATTCCTGCGTTGTAGCCTTCTGAAAAGAAGGCTACAATAAGGCCGTCTGAAAAGATGTGCCGCAACGCTCTGCTTCTGCATCGTtt
RNA7-106	762	GGCGCTTCGCCAGCCATTCCTGCGTTGTAGCTCCCTCTGAAAAGCCGTTGCTACAATAAGGCCGTCTGAAAAGATGTGCCGCAACGCTCTGCTTCTGCATCGTtt
RNA8-106	763	GGCGCTTCGCCAGCCATTCCTGCGTTGTAGCTCCCTTTCTGAAAAGAACCGTTGCTACAATAAGGCCGTCTGAAAAGATGTGCCGCAACGCTCTGCTTCTGCAtt
RNA6-110	764	GGCGCTTCGCCAGCCATTCCTGCGTTGTAGCTCCCTTTCTGAAAAGAACCGTTGCTACAATAAGGCCGTCTGAAAAGATGTGCCGCAACGCTCTGCTTCTGCATCGTtt

RNA6b-110	765	GGCGCTTCGCCAGCCATTCCTGCGTTGTAGCCTTCTCATTGAAAAATGAGAAGGCTACAATAAGGCCGTCTGAAAAGATGTGCCGCAACGCTCTGCTTCTG CATCGttt
RNA5-112	766	GGCGCTTCGCCAGCCATTCCTGCGTTGTAGCTCCCTCTGAAAAGCCGTTGCTACAATAAGGCCGTCTGAAAAGATGTGCCGCAACGCTCTGCCCCTTTTCT AAGGGGCAtt
RNA4-116	767	GGCGCTTCGCCAGCCATTCCTGCGTTGTAGCTCCCTTTCTGAAAAGAACCGTTGCTACAATAAGGCCGTCTGAAAAGATGTGCCGCAACGCTCTGCCCCTT TTCTAAGGGGCAtt
RNA3-122	768	gGGGCGCTTCGCCAGCCATTCCTGCGTTGTAGCTCCCTTTCTCAGGAAACTGAGAACCGTTGCTACAATAAGGCCGTCTGAAAAGATGTGCCGCAACGCTC TGCCCCTTTTCTAAGGGGCAT
RNA2-126	769	GGCGCTTCGCCAGCCATTCCTGCGTTGTAGCTCCCTTCTCAGGAAACTGAGAACCGTTGCTACAATAAGGCCGTCTGAAAAGATGTGCCGCAACGCTCTGC CCCTtTTCTAAGGGGCATCGtttT
RNA17-101	770	GGCGCTTCGCCAGCCATTCCTGCGttGtAGCtCCCtGAAACCGttGCtACAAtAAGGCCGtGAAAAtGtGCCGCAACGCtCtGCCtCtGGCAtCGtttT
RNA18-103	771	GGCGCTTCGCCAGCCATTCCTGCGttGtAGCtCCCtGAAACCGttGCtACAAtAAGGCCGtCGAAAGAtGtGCCGCAACGCtCtGCCtCtGGCAtCGttt T
RNA15-105	772	GGCGCTTCGCCAGCCATTCCTGCGttGtAGCtCCCtGAAACCGttGCtACAAtAAGGCCGtGAAAAtGtGCCGCAACGCtCtGCCGCtCtCtGCGGCAtCGt ttT
RNA16-105	773	GGCGCTTCGCCAGCCATTCCTGCGttGtAGCtCCCtGAAACCGttGCtACAAtAAGGCCGtCtGAAAAGAtGtGCCGCAACGCtCtGCCtCtCtGGCAtCGt ttT
RNA13-107	774	GGCGCTTCGCCAGCCATTCCTGCGttGtAGCtCCCttCGGAAACGACCGttGCtACAAtAAGGCCGtGAAAAtGtGCCGCAACGCtCtGCCttCtGGCAtC GtttT
RNA14-109	775	GGCGCTTCGCCAGCCATTCCTGCGttGtAGCtCCCtGAAACCGttGCtACAAtAAGGCCGtCtGAAAAGAtGtGCCGCAACGCtCtGCCGCttCtGCGGCA tCGtttT
RNA12-111	776	GGCGCTTCGCCAGCCATTCCTGCGttGtAGCtCCCttCGGAAACGACCGttGCtACAAtAAGGCCGtCtGAAAAGAtGtGCCGCAACGCtCtGCCttCtGG CAtCGtttT
RNA11-113	777	GGCGCTTCGCCAGCCATTCCTGCGttGtAGCtCCCttCGGAAACGACCGttGCtACAAtAAGGCCGtGAAAAtGtGCCGCAACGCtCtGCCGCttCtGCGG CAtCGtttTTT
RNA10-115	778	GGCGCTTCGCCAGCCATTCCTGCGttGtAGCtCCCttCGGAAACGACCGttGCtACAAtAAGGCCGtCtGAAAAGAtGtGCCGCAACGCtCtGCCGCttCt GCGGCAtCGtttT
R10B-111	779	GGCGCTTCGCCAGCCATTCCTGCGTTGTAGCTCCCTTGGAAACACCGTTGCTACAATAAGGCCGTTGAAAAATGTGCCGCAACGCTCTGCCCTTCTGGGCA TCGTTTTTTT
R10E-109	780	GGCGCTTCGCCAGCCATTCCTGCGTTGTAGCTCCCTTGGAAACACCGTTGCTACAATAAGGCCGTCGAAAGATGTGCCGCAACGCTCTGCCCTTCTGGGCA TCGTTTT
R10F-113	781	GGCGCTTCGCCAGCCATTCCTGCGTTGTAGCTCCCTTGGAAACACCGTTGCTACAATAAGGCCGTCTGAAAAGATGTGCCGCAACGCTCTGCCGCTTCTGC GGCATCGTTTT
R10G-113	782	GGCGCTTCGCCAGCCATTCCTGCGTTGTAGCTCCCTTCGGAAACGACCGTTGCTACAATAAGGCCGTCTGAAAAGATGTGCCGCAACGCTCTGCCGTTCTC GGCATCGTTTT
R10H-113	783	GGCGCTTCGCCAGCCATTCCTGCGTTGTAGCTCCCTTCGGAAACGACCGTTGCTACAATAAGGCCGTCTGAAAAGATGTGCCGCAACGCTCTGCCCTTCTG GGCATCGTTTT

R10I-113	784	GGCGCTTCGCCAGCCATTCCTGCGTTGTAGCTCCCTTCGGAAACGACCGTTGCTACAATAAGGCCGTTGAAAAATGTGCCGCAACGCTCTGCCGCTTCTGC GGCATCGTTTT
R10J-113	785	GGCGCTTCGCCAGCCATTCCTGCGTTGTAGCTCCCTTCGGAAACGACCGTTGCTACAATAAGGCCGTCGAAAGATGTGCCGCAACGCTCTGCCGCTTCTGC GGCATCGTTTT
R19-112	786	GGCGCTTCGCCAGCCATTCCTGCGTTGTAGCTCCCTTCGGAACGACCGTTGCTACAATAAGGCCGTCTGAAAGATGTGCCGCAACGCTCTGCCGCTCTGCG GCATCGTTTT
ES99	787	GGCGCTTCGCCAGCCATTCCTGCGTTGTAGCTCCCGAAACGTTGCTACAATAAGGCCGTCTGAAAAGATGTGCCGCAACGCTCTGCTTCTGCATCGTT
ES121	788	gGGGCGCTTCGCCAGCCATTCCTGCGTTGTAGCTCCCGAAACGTTGCTACAATAAGGCCCGTCTGAAAAGATGTGCCGCAACGCTCTGCCCCTTAAAGCTT CTGCTTTAAGGGGCATCGTTTA
ES111	789	GGCGCTTCGCCAGCCATTCCTGCGTTGTAGCTCCCGAAACGTTGCTACAATAAGGCCGTCTGAAAAGATGTGCCGCAACGCTCTGCCCCTTTCTAAGGGG CATCGTTTA
ES105	790	GGCGCTTCGCCAGCCATTCCTGCGTTGTAGCTCCCGAAACGTTGCTACAATAAGGCCGTCTGAAAAGATGTGCCGCAACGCTCTGCttCTGCATCGTTTAt ttT
	791 - 799	Not used
G023066	800	mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGmUUGmUmAmGmCUCCCmU(LL)mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC(LL)mGm AmUGUGCmCGmCAAmCGCUCUmGmCC(LL)GGCAUCG*mU*mU
G023067	801	mC*mU*mU*mCmACCmAmGGmAGmAAGCCmGUCAmCACmGUUGmUmAmGmCUCCCmU(LL)mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC(LL)mGm AmUGUGCmCGmCAAmCGCUCUmGmCC(LL)GGCAUCG*mU*mU
G023068	802	mC*mU*mU*mCmACCmAmGmAGmAAGCCmGUCAmCACmGUUGmUmAmGmCUCCCmU(LL)mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC(LL)mGm AmUGUGCmCGmCAAmCGCUCUmGmCC(LL)GGCAUCG*mU*mU
G023069	803	CUUCACCAGGAGAAGCCGUCACACmGUUGmUmAmGmCUCCCmU(LL)mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC(LL)mGmAmUGUGCmCGmCAA mCGCUCUmGmCC(LL)GGCAUCG*mU*mU
G023070	804	mC*mU*mU*CACCAGGAGAAGCCGUCACACmGUUGmUmAmGmCUCCCmU(LL)mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC(LL)mGmAmUGUGCm CGmCAAmCGCUCUmGmCC(LL)GGCAUCG*mU*mU
G023071	805	mC*mU*mU*mCACCAGGAGAAGCCGUCACACmGUUGmUmAmGmCUCCCmU(LL)mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC(LL)mGmAmUGUGC mCGmCAAmCGCUCUmGmCC(LL)GGCAUCG*mU*mU
G023072	806	mC*mU*mU*CmACCAGGAGAAGCCGUCACACmGUUGmUmAmGmCUCCCmU(LL)mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC(LL)mGmAmUGUGC mCGmCAAmCGCUCUmGmCC(LL)GGCAUCG*mU*mU
G023073	807	mC*mU*mU*CACCAmGGAGAAGCCGUCACACmGUUGmUmAmGmCUCCCmU(LL)mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC(LL)mGmAmUGUGC mCGmCAAmCGCUCUmGmCC(LL)GGCAUCG*mU*mU
G023074	808	mC*mU*mU*CACCAGGmAGAAGCCGUCACACmGUUGmUmAmGmCUCCCmU(LL)mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC(LL)mGmAmUGUGC mCGmCAAmCGCUCUmGmCC(LL)GGCAUCG*mU*mU
G023075	809	mC*mU*mU*CACCAGGAGmAAGCCGUCACACmGUUGmUmAmGmCUCCCmU(LL)mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC(LL)mGmAmUGUGC mCGmCAAmCGCUCUmGmCC(LL)GGCAUCG*mU*mU
G023076	810	mC*mU*mU*CACCAGGAGAAGCCmGUCACACmGUUGmUmAmGmCUCCCmU(LL)mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC(LL)mGmAmUGUGC mCGmCAAmCGCUCUmGmCC(LL)GGCAUCG*mU*mU

G02307 7	811	mC*mU*mU*CACCAGGAGAAGCCGUCAmCACmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmAmUGUGC mCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02307 8	812	mC*mU*mU*CmACCmAmGGmAGmAAGCCmGUCAmCACmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmA mUGUGCmCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02307 9	813	mC*mU*mU*mCACCmAmGGmAGmAAGCCmGUCAmCACmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmA mUGUGCmCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02308 0	814	mC*mU*mU*mCmACCAmGGmAGmAAGCCmGUCAmCACmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmA mUGUGCmCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02308 1	815	mC*mU*mU*mCmACCmAGGmAGmAAGCCmGUCAmCACmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmA mUGUGCmCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02308 2	816	mC*mU*mU*mCmACCmAmGGAGmAAGCCmGUCAmCACmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmA mUGUGCmCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02308 3	817	mC*mU*mU*mCmACCmAmGGmAGAAGCCmGUCAmCACmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmA mUGUGCmCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02308 4	818	mC*mU*mU*mCmACCmAmGGmAGmAAGCCGUCAmCACmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmA mUGUGCmCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02308 5	819	mC*mU*mU*mCmACCmAmGGmAGmAAGCCmGUCACACmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmA mUGUGCmCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02308 6	820	CUUCACCAAGAGAAGCCGUCACACmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmAmUGUGCmCGmCAA mCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02308 7	821	mC*mU*mU*CACCAAGAGAAGCCGUCACACmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmAmUGUGCm CGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02308 8	822	mC*mU*mU*mCACCAAGAGAAGCCGUCACACmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmAmUGUGC mCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02308 9	823	mC*mU*mU*CmACCAAGAGAAGCCGUCACACmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmAmUGUGC mCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02309 0	824	mC*mU*mU*CACCAmAGAGAAGCCGUCACACmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmAmUGUGC mCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02309 1	825	mC*mU*mU*CACCAAGmAGAAGCCGUCACACmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmAmUGUGC mCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02309 2	826	mC*mU*mU*CACCAAGAGmAAGCCGUCACACmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmAmUGUGC mCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02309 3	827	mC*mU*mU*CACCAAGAGAAGCCmGUCACACmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmAmUGUGC mCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02309 4	828	mC*mU*mU*CACCAAGAGAAGCCGUCAmCACmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmAmUGUGC mCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02309 5	829	mC*mU*mU*CmACCmAmAGmAGmAAGCCmGUCAmCACmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmA mUGUGCmCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU

G02309 6	830	mC*mU*mU*mCACCmAmAGmAGmAAGCCmGUCAmCACmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmA mUGUGCmCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02309 7	831	mC*mU*mU*mCmACCAmAGmAGmAAGCCmGUCAmCACmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmA mUGUGCmCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02309 8	832	mC*mU*mU*mCmACCmAAGmAGmAAGCCmGUCAmCACmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmA mUGUGCmCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02309 9	833	mC*mU*mU*mCmACCmAmAGAGmAAGCCmGUCAmCACmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmA mUGUGCmCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02310 0	834	mC*mU*mU*mCmACCmAmAGmAGAAGCCmGUCAmCACmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmA mUGUGCmCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02310 1	835	mC*mU*mU*mCmACCmAmAGmAGmAAGCCGUCAmCACmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmA mUGUGCmCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02310 2	836	mC*mU*mU*mCmACCmAmAGmAGmAAGCCmGUCACmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmA mUGUGCmCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02310 3	837	CCAAGUGUCUUCCAGUACGAUUUGmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmAmUGUGCmCGmCAA mCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02310 4	838	mC*mC*mA*AGUGUCUUCCAGUACGAUUUGmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmAmUGUGCm CGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02310 5	839	mC*mC*mA*mAGUGUCUUCCAGUACGAUUUGmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmAmUGUGC mCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02310 6	840	mC*mC*mA*AmGUGUCUUCCAGUACGAUUUGmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmAmUGUGC mCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02310 7	841	mC*mC*mA*AGUGUmCUUCCAGUACGAUUUGmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmAmUGUGC mCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02310 8	842	mC*mC*mA*AGUGUCUmUCCAGUACGAUUUGmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmAmUGUGC mCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02310 9	843	mC*mC*mA*AGUGUCUUCmCAGUACGAUUUGmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmAmUGUGC mCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02311 0	844	mC*mC*mA*AGUGUCUUCCAGUAmCGAUUUGmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmAmUGUGC mCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02311 1	845	mC*mC*mA*AGUGUCUUCCAGUACGAUmUUGmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmAmUGUGC mCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02311 2	846	mC*mC*mA*AmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmA mUGUGCmCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02311 3	847	mC*mC*mA*mAGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmA mUGUGCmCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02311 4	848	mC*mC*mA*mAmGUGUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmA mUGUGCmCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU

G02311 5	849	mC*mC*mA*mAmGUGmUCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmA mUGUGCmCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02311 6	850	mC*mC*mA*mAmGUGmUmCUUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmA mUGUGCmCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02311 7	851	mC*mC*mA*mAmGUGmUmCUmUCCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmA mUGUGCmCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02311 8	852	mC*mC*mA*mAmGUGmUmCUmUCmCAGUACGAUmUUGmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmA mUGUGCmCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02311 9	853	mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUUUGmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmA mUGUGCmCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02312 0	854	mC*mU*mU*CACCmAGGAGAAGCCGUCACACmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmAmUGUGC mCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02312 1	855	mC*mU*mU*CACCmAAGAGAAGCCGUCACACmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmAmUGUGC mCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
G02312 2	856	mC*mC*mA*AGUGmUCUUCCAGUACGAUUUGmGUUGmUmAmGmCUCCCmU (L1) mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC (L1) mGmAmUGUGC mCGmCAAmCGCUCUmGmCC (L1) GGCAUCG*mU*mU
TR0182 27	857	mC*mG*mA*UGAGAACCGUUGCUACAAUAAGGCCGUCUGAAAAGAUGUGCCGCAACGCUCUGCCCUUAAGCUUCUGCUUUAU*mA*mU*mU
TR0182 28	858	mC*mG*mA*UGAGAACCGUUGCUACAAUAAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCCUUAAGCUUCUGCUUUAU*mA*mU*mU
TR0182 29	859	mC*mG*mA*UGAGAACCGUUGCUACAAUAAGGCCGUGAAAAUGUGCCGCAACGCUCUGCCCUUAAGCUUCUGCUUUAU*mA*mU*mU
TR0182 30	860	mC*mG*mA*UGAGAACCGUUGCUACAAUAAGGCCGGAAAUGUGCCGCAACGCUCUGCCCUUAAGCUUCUGCUUUAU*mA*mU*mU
TR0182 31	861	mC*mG*mA*UGAGAACCGUUGCUACAAUAAGGCCGAAAGUGCCGCAACGCUCUGCCCUUAAGCUUCUGCUUUAU*mA*mU*mU
TR0182 32	862	mC*mG*mA*UGAGAACCGUUGCUACAAUAAGGCCGUCUGAAAAGAUGUGCCGCAACGCUCUGCCCUUAAGUUCUCUUUAU*mA*mU*mU
TR0182 33	863	mC*mG*mA*UGAGAACCGUUGCUACAAUAAGGCCGUCUGAAAAGAUGUGCCGCAACGCUCUGCCCUUAAUUCUUUUAAGUUU*mA*mU*mU
TR0182 34	864	mC*mG*mA*UGAGAACCGUUGCUACAAUAAGGCCGUCUGAAAAGAUGUGCCGCAACGCUCUGCCCUUAUUCUUAAGUUU*mA*mU*mU
TR0182 35	865	mC*mG*mA*UGAGAACCGUUGCUACAAUAAGGCCGUCUGAAAAGAUGUGCCGCAACGCUCUGCCCUUUUCUAAGUUU*mA*mU*mU
TR0182 36	866	mC*mG*mA*UGAGAACCGUUGCUACAAUAAGGCCGUCUGAAAAGAUGUGCCGCAACGCUCUGCCCUUUCUAGUUU*mA*mU*mU
TR0182 37	867	mC*mG*mA*UGAGAACCGUUGCUACAAUAAGGCCGUCUGAAAAGAUGUGCCGCAACGCUCUGCCCUUCUGGUUU*mA*mU*mU

TR0182 38	868	mC*mG*mA*UGAGAACCGUUGCUACAAUAAGGCCGUCUGAAAAGAUGUGCCGCAACGCUCUGCCUUCUGGCAUCGUUU*mA*mU*mU
TR0182 39	869	mC*mG*mA*UGAGAACCGUUGCUACAAUAAGGCCGUCUGAAAAGAUGUGCCGCAACGCUCUGCUUCUGCAUCGUUU*mA*mU*mU
TR0182 40	870	mC*mG*mA*UGAGAACCGUUGCUACAAUAAGGCCGUCUGAAAAGAUGUGCCGCAACGCUCUGUUCUCAUCGUUU*mA*mU*mU
TR0182 41	871	mC*mG*mA*UGAGAACCGUUGCUACAAUAAGGCCGUGAAAAUGUGCCGCAACGCUCUGCCUUCUGGCAUCGUUU*mA*mU*mU
TR0182 42	872	mC*mG*mA*UGAGAACCGUUGCUACAAUAAGGCCGUCUGAAAAGAUGUGCCGCAACGCUCUGCCCCUUAAGCUUCUGCUUAAGGGCAUCG*mU*mU*mU
CR0186 48	873	mA*mC*mU*mCmACUmCmAmCmCCmACmCmAmGACAmCAmCmGUUmGmUmAmGmCmUCCCmU*mU*mU*mC*mC*mA*mU*mC*mG
CR0186 56	874	mG*mU*mG*mUmGUCmCmCmUmCUmCCmCCmAmCCCGmUCmCmGUUmGmUmAmGmCmUCCCmU*mU*mU*mC*U*mC*mA*mU*mC*mG
CR0184 73	875	mG*mU*mG*UGUCCCUCUCCCCACCCGUCCGUUGUGUAGCUCCCCUUUCUCA*mU*mC*mG
CR0184 74	876	mG*mU*mG*UGUCCCUCUCCCCACCCGUCCCmGUUGmUmAmGmCmUCCCCmUmUmUmCmUmCmA*mU*mC*mG
CR0184 75	877	mG*mU*mG*mUmGmUCCCmUmCmUmCmCCCmAmCCCCGmUCCGUUGUAGCUCCCCUUUCUCA*mU*mC*mG
CR0184 76	878	mG*mU*mG*mUmGmUCCCmUmCmUmCmCCCmAmCCCCGmUCCmGUUGmUmAmGmCmUCCCmUmUmUmCmUmCmA*mU*mC*mG
TR0184 77	879	mC*mG*mA*UGAGAACCGUUGCUACAAUAAGGCCGUCUmGmAmAmAmAAGAUGUGCCGCAACGCUCUGCCCUUAAGCmUmUmCmUGCUUAAGGGCAUCGUU*mU*mA*mU
TR0184 78	880	mC*mG*mA*UGAGAACCGUUGCUACAAUAAGGCCGUCUmGmAmAmAAGAUGUGCCGCAACGCUCUGCCCUUAAGCmGmAmAmAGCUUAAGGGCAUCGUU*mU*mA*mU
TR0184 79	881	mCmGmAUGAGAACCGUUGCUACAAUAAGGCCGUCUmGmAmAmAAGAUGUGCCGCAACGCUCUGCCCUUAAGCmUmUmCmUGCUUAAGGGCAUCGUUmUmAmU
TR0184 80	882	mC*mG*mA*UGAGAAAGGUUGCUACAAUAAGGCCGUCUmGmAmAmAAGAUGUGCCGCAACGCUCUGCCCUUAAGCmUmUmCmUGCUUAAGGGCAUCGUU*mU*mA*mU
TR0184 81	883	mC*mG*mA*UGAGAACCGUUGCUACAAUAAGGCCGUCUmGmAmAmAAGAUGUGCCGCAACGCUCUGCCCUUAAGCmUmUmCmUGCUUAAGGGCAUCGU*U*mU*mU
TR0184 82	884	mC*mG*mA*UGAGAACCGUUGCUACAAUAAGGCCGUCUmGmAmAmAAGAUGUGCCGCAACGCUCUGCCCUUAAGCmUmUmCmUGCUUAAGGGCAUCGU*mU*mU*mU
TR0184 83	885	mC*mG*mA*UGAGAACCGUUGCUACAAUAAGGCCGUCUmGmAmAmAAGAUGUGCCGCAACGCUCUGCCCUUAAGCmUmUmCmUGCUUAAGGGCAUCG*mU*mU*mU
TR0184 84	886	mC*mG*mA*mUmGmAmGmAmAmCmCGUUGmCUACAAmUAAGmGmCmCmGmUmCmUmGmAmAmAmGmAmAmUGUmGmCmCGCAmAmCmGmCmUmCmUmGmCmCCmUmUmAmAmGmCmUmUmCmUmGmCmUmUmAmAGmGmGCAUCGmUmU*mU*mA*mU

TR0184 85	887	mC*mG*mA*mUmGmAmGmAmAmGGUUGmCUACAAmUAAGmGmCmCmGmUmCmUmGmAmAmAmGmAmUGUmGmCmCGCAmAmCmGmCmUmCmUmGmCm CCmUmUmAmAmGmCmCmUmUmCmUmGmCmUmUmAmAGmGmGCAUCGmUmU*mU*mA*mU
TR0184 86	888	mC*mG*mA*mUmGmAmGmAmAmCmCGUUGmCUACAAmUAAGmGmCmCmGmUmCmUmGmAmAmAmGmAmUGUmGmCmCGCAmAmCmGmCmUmCmUmGmCm CCmUmUmAmAmGmCmCmUmUmCmUmGmCmUmUmAmAGmGmGCAUCG*mU*mU*mU
TR0184 87	889	mC*mG*mA*mUmGmAmGmAmAmCmCGUUGmCUACAAmUAAGmGmCmCmGmUmCmUmGmAmAmAmGmAmUGUmGmCmCGCAmAmCmGmCmUmCmUmGmCmCCmU mUmCmUmGmGCAUCGmUmU*mU*mA*mU
TR0184 88	890	mC*mG*mA*mUmGmAmGmAmAmCmCGUUGmCUACAAmUAAGmGmCmCmGmUmCmUmGmAmAmAmGmAmUGUmGmCmCGCAmAmCmGmCmUmCmUmGmCmCCmU mUmCmUmGmGCAUCG*mU*mU
TR0184 89	891	mC*mG*mA*mUmGmAmGmAmAmCmCGUUGmCUACAAmUAAGGCCGUCUmGmAmAmAGAUGUGCCGCAACGCUCUGCCCUUAAGCmUmUmCmUGCUUAAGG GCAUCGUU*mU*mA*mU
TR0184 90	892	mC*mG*mA*mUGAGAACCGUUGCUACAAUAAGmGmCmCmGmUmCmUmGmAmAmAmGmAmUGUmGmCmCGCAACGCUCUGCCCUUAAGCmUmUmCmUGCUU AAGGGCAUCGUU*mU*mA*mU
TR0184 91	893	mC*mG*mA*mUGAGAACCGUUGCUACAAUAAGGCCGUCUmGmAmAmAGAUGUGCCGCAmAmCmGmCmUmCmUmGmAmAmGmCmUmUmCmUmG mCmUmUmAmAGmGmGCAUCGmUmU*mU*mA*mU
TR0184 92	894	mC*mG*mA*mUmGmAmGmAmAmCmCGUUGmCUACAAmUAAGmGmCmCmGmUmCmUmGmAmAmAmGmAmUGUmGmCmCGCAACGCUCUGCCCUUAAGCmU mUmCmUGCUUAAGGGCAUCGUU*mU*mA*mU
TR0184 93	895	mC*mG*mA*mUmGmAmGmAmAmCmCGUUGmCUACAAmUAAGGCCGUCUmGmAmAmAGAUGUGCCGCAmAmCmGmCmUmCmUmGmAmAmGmC mUmUmCmUmGmCmCmUmUmAmAGmGmGCAUCGmUmU*mU*mA*mU
TR0184 94	896	mC*mG*mA*UGAGAACCGUUGCUACAAUAAGmGmCmCmGmUmCmUmGmAmAmAmGmAmUGUmGmCmCGCAmAmCmGmCmUmCmUmGmAmA mGmCmUmUmCmUmGmCmUmUmAmAGmGmGCAUCGmUmU*mU*mA*mU
TR0184 95	897	mC*mG*mA*mUmGmAmGmAmAmCmCGUUGmCUACAAmUAAGGCCGUCUmGmAmAmAGAUGUGCCGCAACGCUCUGCCCUUAAGCmUmUmCmUGCUUAA GGGCAUCGUU*mU*mA*mU
TR0184 96	898	mC*mG*mA*UGAGAACCGUUGCUACAAUAmAGmGmCmCmGmUmCmUmGmAmAmAmGmAmUGmUmGmCmCmGmCAACGCUCUGCCCUUAAGCmUmUmCmU GCUUAAGGGCAUCGUU*mU*mA*mU
TR0184 97	899	mC*mG*mA*UGAGAACCGUUGCUACAAUAAGGCCGUCUmGmAmAmAGAUGUGCCGCmAmAmCmGmCmUmCmUmGmAmAmGmCmUmUmCmUmU mGmCmUmUmAmAGmGmGCmAmUmCmGmUmU*mU*mA*mU
TR0184 98	900	mC*mG*mA*mUmGmAmGmAmAmCmCGUUGmCUACAAmUAAmAGmGmCmCmGmUmCmUmGmAmAmAmGmAmUGmUmGmCmCGmCAACGCUCUGCCCUUA AGCmUmUmCmUGCUUAAGGGCAUCGUU*mU*mA*mU
TR0184 99	901	mC*mG*mA*mUmGmAmGmAmAmCmCGUUGmCUACAAmUAAGGCCGUCUmGmAmAmAGAUGUGCCGCmAmAmCmGmCmUmCmUmGmAmAmGmCmUmUmAmA mGmCmUmUmCmUmGmCmUmUmAmAGmGmGCmAmUmCmGmUmU*mU*mA*mU
TR0185 00	902	mC*mG*mA*UGAGAACCGUUGCUACAAUAmAGmGmCmCmGmUmCmUmGmAmAmAmGmAmUGmUmGmCmCmGmCmAmAmCmGmCmUmCmUmGmCmCmUm UmAmAmGmCmUmUmCmUmGmCmUmUmAmAGmGmGCmAmUmCmGmUmU*mU*mA*mU
G02749 2	903	mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmUUGmGUUGmUmAmGmCUCCCUmUmUmCmGmAmAmAmGmAmCmCGUUmGmCUAmCAAU*AAGmGmCCm GmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU
G02749 3	904	mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCUmUmUmCmGmAmAmAmGmAmCmCGUUmGmCUAmCAAU*AAGmGmCCm GmUmGmAmAmAmAmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU
G02749 4	905	mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCUmUmUmCmGmAmAmAmGmAmCmCGUUmGmCUAmCAAU*AAGmGmCCm GmGmAmAmAmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU

G02749 5	906	mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmUmCmGmAmAmAmGmAmCmCGUUmGmCUAmCAAU*AAGmGmCCm GmAmAmAGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU
G02749 6	907	mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmAmAmAG UGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU
G02410 3	908	mC*mA*mA*mGmUCUmGmUCmUCUAUmUCACmCGAmGUUGmUmAmGmCUCCCmU(LL)mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC(LL)mGm AmUGUGCmCGmCAAmCGCUCUmGmCC(LL)GGCAUCG*mU*mU
G02410 4	909	mG*mG*mU*mGmAAUAmAmGmCAmGACAGmACUUmGUCmGUUGmUmAmGmCUCCCmU(LL)mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC(LL)mGm AmUGUGCmCGmCAAmCGCUCUmGmCC(LL)GGCAUCG*mU*mU
G02410 8	910	mG*mA*mU*mUmAAAAmCmCCmGGmCCACUmUUCAmGGAmGUUGmUmAmGmCUCCCmU(LL)mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC(LL)mGm AmUGUGCmCGmCAAmCGCUCUmGmCC(LL)GGCAUCG*mU*mU
G02410 9	911	mC*mA*mG*mUmGACmAmAGmUCmUGUCUmGCCUmAUUmGUUGmUmAmGmCUCCCmU(LL)mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC(LL)mGm AmUGUGCmCGmCAAmCGCUCUmGmCC(LL)GGCAUCG*mU*mU
G02411 0	912	mG*mU*mU*mGmAAGmGmCGmUUmUGCACmAUGCmAAAmGUUGmUmAmGmCUCCCmU(LL)mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC(LL)mGm AmUGUGCmCGmCAAmCGCUCUmGmCC(LL)GGCAUCG*mU*mU
G02411 1	913	mU*mC*mC*mUmGUGmAmUGmUCmAAGCUmGGUCmGAGmGUUGmUmAmGmCUCCCmU(LL)mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC(LL)mGm AmUGUGCmCGmCAAmCGCUCUmGmCC(LL)GGCAUCG*mU*mU
G02411 2	914	mC*mA*mG*mGmUUUUmUmGAmAAmGUUUAmGGUUmCGUmGUUGmUmAmGmCUCCCmU(LL)mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC(LL)mGm AmUGUGCmCGmCAAmCGCUCUmGmCC(LL)GGCAUCG*mU*mU
G02411 3	915	mA*mU*mC*mAmGAAmUmCCmUUmACUUUmGUGAmCACmGUUGmUmAmGmCUCCCmU(LL)mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC(LL)mGm AmUGUGCmCGmCAAmCGCUCUmGmCC(LL)GGCAUCG*mU*mU
G02411 4	916	mG*mA*mA*mGmUCCmAmUAmGAmCCUCAmUGUCmUAGmGUUGmUmAmGmCUCCCmU(LL)mCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmC(LL)mGm AmUGUGCmCGmCAAmCGCUCUmGmCC(LL)GGCAUCG*mU*mU
G02884 4	917	mU*mG*mU*mCmUGCmCmUAmUUmCACCGmAUUUmUGAmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGm AmAmAmGmAmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU
G02884 5	918	mU*mG*mC*mCmUAUmUmCAmCCmGAUUUmUGAmUCUmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGm AmAmAmGmAmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU
G02884 6	919	mC*mG*mA*mUmUUUUmGmAUmUCmUCAAAmCAAAmUGUmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGm AmAmAmGmAmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU
G02884 7	920	mG*mU*mA*mAmGGAmUmUCmUGmAUGUGmUAUAmUCAmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGm AmAmAmGmAmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU
G02884 8	921	mA*mG*mA*mGmCAAmCmAGmUGmCUGUGmGCCUmGGAmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGm AmAmAmGmAmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU
G02884 9	922	mU*mG*mG*mAmGCAmAmCAmAAmUCUGAmCUUUmGCAmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGm AmAmAmGmAmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU
G02885 0	923	mA*mU*mG*mCmUGUmUmGUmUGmAAGGCmGUUUmGCAmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGm AmAmAmGmAmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU
G02885 1	924	mU*mU*mU*mUmGAAmAmGUmUUmAGGUUmCGUAmUCUmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGm AmAmAmGmAmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU

G028852	925	mU*mU*mA*mCmUUUmGmUGmACmACAUUmUGUUmUGAmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmGmAmUGUGCmCmGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU
G028853	926	mG*mA*mU*mUmAAAmCmCCmGGmCCACUmUUCAmGGAmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmGmAmUGUGCmCmGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU
G021469	927	mA*mU*mA*mUmCCAmGmAAmCCmCUGACmCCUGmCCGmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmGmAmUGUGCmCmGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU
G024739	928	mA*mG*mG*mAmCCAmGmCCmUCmAGACAmCAAAmUACmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmGmAmUGUGCmCmGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU
G024741	929	mC*mU*mG*mCmCUCmGmGAmCGmGCAUCmUAGAmACUmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmGmAmUGUGCmCmGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU
G024743	930	mA*mG*mG*mCmAGAmGmGAmGGmAGCAGmACGAmUGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmGmAmUGUGCmCmGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU
G029377	931	mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAUA AGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCmGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU
G029378	932	mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCmAmA UAAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCmGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU
G029379	933	mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAmAU AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCmGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU
G029380	934	mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCmAmA U*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCmGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU
G029381	935	mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAdT AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCmGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU
G029382	936	mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU* AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCmGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU
G029383	937	mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU* AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCmGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUCG*mU*mU
G029384	938	mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU* AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCmGmCAAmCmGmCmUmUmCmUGGCAUCG*mU*mU
G029385	939	mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU* AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCmGmCAAmCmGmCmUmUmCmUGGCAUCG*mU*mU
G029386	940	mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU* AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCmGmCAAmCmGmCmUmUmCmUGGCAUCG*mU*mU
G029387	941	mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU* AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCmGmCmAmAmCmGmCmUmUmCmUGGCAUCG*mU*mU

G02938 8	942	mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU* AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCAUmCmG*mU*mU
G02938 9	943	mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU* AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCGCUCUmGmCCmUmUmCmUGGCmAmUmCmG*mU*mU
G02939 0	944	mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU* AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCmAmAmCmGmCmUmCmUmGmCmCmUmUmCmUGGCmAmUmCmG*mU*mU
G02939 1	945	mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU* AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCmAmAmCmGmCmUmCmUmGmCmCmUmUmCmUGGCAUmCmG*mU*mU
G02939 2	946	mC*mC*mA*mAmGUGmUmCUmUCmCAGUAmCGAUmUUGmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU* AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGmCAAmCmGmCmUmCmUmGmCCmUmUmCmUGGCAUmCmG*mU*mU
G02473 9	947	AGGACCAGCCUCAGACACAAAUACGUUGUAGCUCCCUGAAACCGUUGCUACAAUAAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCUUCUGGCAUCGUU
G02474 1	948	CUGCCUCGGACGGCAUCUAGAACUGUUGUAGCUCCCUGAAACCGUUGCUACAAUAAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCUUCUGGCAUCGUU
G02474 3	949	AGGCAGAGGAGGAGCAGACGAUGAGUUGUAGCUCCCUGAAACCGUUGCUACAAUAAGGCCGUCGAAAGAUGUGCCGCAACGCUCUGCCUUCUGGCAUCGUU

[00576] It is understood that if a DNA sequence (comprising Ts) is referenced herein with respect to an RNA, then Ts should be replaced with Us (which may be modified or unmodified depending on the context), and vice versa.

[00577] Nucleotide modifications are indicated in Table 4 as follows: m: 2'-OMe; *: PS linkage; f: 2'-fluoro; (invd): inverted abasic; moe: 2'-moe; e: ENA; d: deoxyribonucleotide (also note that T is always a deoxyribonucleotide); x: UNA. In the sgRNA modified sequences, in certain embodiments, each A, C, G, U, and N is independently a ribose sugar (2'-OH). In certain embodiments, each A, C, G, U, and N is a ribose sugar (2'-OH). Thus, for example, mA represents 2'-O-methyl adenosine; xA represents a UNA nucleotide with an adenine nucleobase; eA represents an ENA nucleotide with an adenine nucleobase; and dA represents an adenosine deoxyribonucleotide. As used herein, (L1) refers to an internal linker having a bridging length of about 15-21 atoms.

[00578] sgRNA designations are sometimes provided with one or more leading zeroes immediately following the G. This does not affect the meaning of the designation. Thus, for example, G000282, G0282, G00282, and G282 refer to the same sgRNA. Similarly, crRNA and or trRNA designations are sometimes provided with one or more leading zeroes immediately following the CR or TR, respectively, which does not

affect the meaning of the designation. Thus, for example, CR000100, CR00100, CR0100, and CR100 refer to the same crRNA, and TR000200, TR00200, TR0200, and TR200 refer to the same trRNA.

EXAMPLES

[00579] The following examples are provided to illustrate certain disclosed embodiments and are not to be construed as limiting the scope of this disclosure in any way.

Example 1. Materials and Methods

In vitro transcription ("IVT") of nuclease mRNA

[00580] Capped and polyadenylated mRNA containing N1-methyl pseudo-U was generated by *in vitro* transcription using routine methods. For example, a plasmid DNA containing a T7 promoter, a sequence for transcription, and a polyadenylation region was linearized with XbaI per manufacturer's protocol. The XbaI was inactivated by heating. The linearized plasmid was purified from enzyme and buffer salts. The IVT reaction to generate modified mRNA was performed by incubating at 37°C: 50 ng/μL linearized plasmid; 2-5 mM each of GTP, ATP, CTP, and N1-methyl pseudo-UTP (Trilink); 10-25 mM ARCA (Trilink); 5 U/μL T7 RNA polymerase; 1 U/μL Murine RNase inhibitor (NEB); 0.004 U/μL Inorganic E. coli pyrophosphatase (NEB); and 1x reaction buffer. TURBO DNase (Thermo Fisher) was added to a final concentration of 0.01 U/μL, and the reaction was incubated at 37°C to remove the DNA template.

[00581] The mRNA was purified using a MegaClear Transcription Clean-up kit (Thermo Fisher) or a RNeasy Maxi kit (Qiagen) per the manufacturers' protocols. Alternatively, the mRNA was purified through a precipitation protocol, which in some cases was followed by HPLC-based purification. Briefly, after the DNase digestion, mRNA was purified using LiCl precipitation, ammonium acetate precipitation, and sodium acetate precipitation. For HPLC purified mRNA, after the LiCl precipitation and reconstitution, the mRNA was purified by RP-IP HPLC (see, e.g., Kariko, et al. Nucleic Acids Research, 2011, Vol. 39, No. 21 el42). The fractions chosen for pooling were combined and desalted by sodium acetate/ethanol precipitation as described above. In a further alternative method, mRNA was purified with a LiCl precipitation method followed by further purification by tangential flow filtration. RNA concentrations were determined by measuring the light absorbance at 260 nm (Nanodrop), and transcripts were analyzed by capillary electrophoresis by Bioanalyzer (Agilent).

[00582] *Streptococcus pyogenes* ("Spy") Cas9 mRNA was generated from plasmid DNA encoding an open reading frame according to SEQ ID Nos: 661-665 (see sequences in

Table 4A). When the sequences cited in this paragraph are referred to below with respect to RNAs, it is understood that Ts should be replaced with Us (which can be modified nucleosides as described above). Messenger RNAs used in the Examples include a 5' cap and a 3' polyadenylation sequence e.g., up to 100 nts and are identified in Table 4A. Guide RNAs are chemically synthesized by methods known in the art.

[00583] Guide RNA was chemically synthesized by commercial vendors or using standard *in vitro* synthesis techniques with modified nucleotides.

Hepatocyte cell preparation

[00584] Primary mouse hepatocytes (PMH), primary rat hepatocytes (PRH), primary human hepatocytes (PHH), and primary cynomolgus hepatocytes (PCH) were prepared as follows. PMH (Gibco, MCM837, unless otherwise specified), PRH (Gibco, Rs977, unless otherwise specified), PCH (In Vitro ADMET Laboratories, 10136011, unless otherwise specified), PHH (Gibco, Hu8284, unless otherwise specified) were thawed and resuspended in 50 mL Cryopreserved Hepatocyte Recovery Media (CHRM) (Invitrogen, CM7000) followed by centrifugation. Cells were resuspended in hepatocyte medium with plating supplements: Williams' E Medium Plating Supplements with FBS content (Gibco, Cat. A13450). Cells were pelleted by centrifugation, resuspended in media and plated at a density of 20,000 cells/well for PMH, and 30,000 for PHH on Bio-coat collagen I coated 96-well plates (Corning # 354407). Plated cells were allowed to settle and adhere for 4-6 hours in a tissue culture incubator at 37°C and 5% CO_2 atmosphere. After incubation cells were checked for monolayer formation and were washed once and plated with 100 µL hepatocyte maintenance medium: Williams' E Medium (Gibco, Cat. A12176-01) plus supplement pack (Gibco, Cat. CM3000).

HEK cell preparation

[00585] HEK-293 cells (ATCC, CRL-1573, unless otherwise specified) were thawed and resuspended in serum-free Dulbecco's Modified Eagle Medium (Corning #10-013-CV) with 10% FBS content (Gibco #A31605-02) and 1% Penicillin-Streptomycin (Gibco #15070063). Cells were counted and plated in Dulbecco's Modified Eagle Medium (Corning #10-013-CV) with 10% FBS content (Gibco #A31605-02) on 96-well tissue culture plate (Falcon, #353072). Plated cells were allowed to settle and adhere for 18 hours in a tissue culture incubator at 37°C and 5% CO_2 atmosphere.

Preparation of LNP formulation containing sgRNA and Cas9 mRNA

[00586] In general, the lipid nanoparticle components were dissolved in 100% ethanol at various molar ratios. The RNA cargos (e.g., Cas9 mRNA and sgRNA) were dissolved in 25 mM citrate, 100 mM NaCl, pH 5.0, resulting in a concentration of RNA cargo of approximately 0.45 mg/mL. The LNPs used contained ionizable lipid ((9Z,12Z)-3-((4,4-bis(octyloxy)butanoyl)oxy)-2-((((3-(diethylamino)propoxy)carbonyl)oxy)methyl)propyl octadeca-9,12-dienoate, also called 3-((4,4-bis(octyloxy)butanoyl)oxy)-2-((((3-(diethylamino)propoxy)carbonyl)oxy)methyl)propyl (9Z,12Z)-octadeca-9,12-dienoate), also called herein Lipid A, cholesterol, distearoylphosphatidylcholine (DSPC), and 1,2-dimyristoyl-rac-glycero-3-methylpolyoxyethylene glycol 2000 (PEG2k-DMG) in a molar ratio of 50% Lipid A, 38% cholesterol, 9% DSPC, and 3% PEG2k-DMG. The LNPs were formulated with a lipid amine to RNA phosphate (N:P) molar ratio of about 6. The LNPs used comprise a single RNA species such as Cas9 mRNA or a sgRNA. LNP are similarly prepared with a mixture of Cas9 mRNA and a guide RNA.

[00587] The LNPs were prepared using a cross-flow technique utilizing impinging jet mixing of the lipid in ethanol with two volumes of RNA solution and one volume of water. First, the lipid in ethanol was mixed through a mixing cross with the two volumes of RNA solution. Then, a fourth stream of water was mixed with the outlet stream of the cross through an inline tee (*See* WO2016010840 FIG. 2). The LNPs were held for 1 hour at room temperature, and further diluted with water (approximately 1:1 v/v). Diluted LNPs were buffer exchanged into 50 mM Tris, 45 mM NaCl, 5% (w/v) sucrose, pH 7.5 (TSS) and concentrated as needed by methods known in the art. The resulting mixture was then filtered using a 0.2 μm sterile filter. The final LNPs were characterized to determine the encapsulation efficiency, polydispersity index, and average particle size. The final LNP was stored at 4°C or -80°C until further use.

sgRNA and Cas9 mRNA lipofection

[00588] Lipofection of Cas9 mRNA and gRNAs used pre-mixed lipid formulations. The lipofection reagent contained ionizable Lipid A, cholesterol, DSPC, and PEG2k-DMG in a molar ratio of 50% Lipid A, 38% cholesterol, 9% DSPC, and 3% PEG2k-DMG. This mixture was reconstituted in 100% ethanol then mixed with RNA (e.g., Cas9 mRNA and gRNA) at a lipid amine to RNA phosphate (N:P) molar ratio of about 6.0.

Next-generation sequencing ("NGS") and analysis for editing efficiency

[00589] Genomic DNA was extracted using a commercial kit according to the manufacturer's protocol, for example QuickExtract™ DNA Extraction Solution (Lucigen, Cat. QE09050). To quantitatively determine the efficiency of editing at the target location in the genome, deep sequencing was utilized to identify the presence of insertions and deletions introduced by gene editing. PCR primers were designed around the target site within the gene of interest (*e.g.*, TRAC) and the genomic area of interest was amplified. Primer sequence design was done as is standard in the field.

[00590] Additional PCR was performed according to the manufacturer's protocols (Illumina) to add chemistry for sequencing. The amplicons were sequenced on an Illumina MiSeq instrument. The reads were aligned to the human reference genome (e.g., hg38) after eliminating those having low quality scores. Reads that overlapped the target region of interest were re-aligned to the local genome sequence to improve the alignment. Then the number of wild type reads versus the number of reads which contain C-to-T mutations, C-to-A/G mutations, or indels was calculated. Insertions and deletions were scored in a 20 bp region centered on the predicted Cas9 cleavage site. Indel percentage is defined as the total number of sequencing reads with one or more base inserted or deleted within the 20 bp scoring region divided by the total number of sequencing reads, including wild type. C-to-T mutations or C-to-A/G mutations were scored in a 40 bp region including 10 bp upstream and 10 bp downstream of the 20 bp sgRNA target sequence. The C-to-T editing percentage is defined as the total number of sequencing reads with either one or more C-to-T mutations within the 40 bp region divided by the total number of sequencing reads, including wild type. The percentage of C-to-A/G mutations are calculated similarly.

Example 2. *In vitro* editing with truncated NmeCas9 guides in human embryonic kidney (HEK) cells

[00591] Truncated Nme-Cas9 sgRNAs targeting the SEAP gene were designed and tested to evaluate the impact of each modification on guide functionality. Modifications in guides that retained their editing efficacy were considered well-tolerated and included in future studies.

Example 2.1 Plasmid evaluation of sgRNA modification patterns

HEK Cell Preparation

[00592] HEK-Blue™ cells, a HEK reporter cell line with a SEAP reporter, from (Invivogen, Cat. hkb-il1b) were thawed and resuspended in 15 mL Growth Media (DMEM, 4.5 g/l glucose, 2 mM L-Glutamine, 10%(v/v) fetal bovine serum (FBS), 50 U/ml penicillin, 50 mg/ml streptomycin, 100 mg/ml Normocin™ followed by centrifugation. The supernatant was discarded and the pelleted cells resuspended in Growth Media. Cells were plated at a density of 10,000 cells/well on 96-well tissue culture plate (Falcon, #353072) with Test Medium: DMEM, 4.5 g/l glucose, 2 mM L-Glutamine, 10% (v/v), heat-inactivated FBS (30 min at 56 °C), 50 U/ml penicillin, 50 mg/ml, streptomycin, 100 mg/ml Normocin™). Plated cells were allowed to settle and adhere for 18 hours in a tissue culture incubator at 37°C and 5% CO_2 atmosphere.

Plasmid-based transfection

[00593] NmeCas9 sgRNA truncation variants, with identical 23-nt complementarity to the SEAP cassette of the HEK-Blue™ cells, but with different sgRNA scaffold truncations were designed and cloned using standard Gibson Assembly methods for plasmid generation. The final plasmid reaction was plated on Luria Broth (LB) plates (Teknova, L8000) supplemented with ampicillin (Teknova, L5104) and incubated in a tissue culture incubator at 37°C. Plasmid colonies were inoculated in 4 ml Luria Broth plates (Teknova, L8000) supplemented with 100 ug/mL ampicillin (Teknova, A2135) and incubated at 37°C overnight. Plasmids were purified according to manufacturer's instructions using Zyppy plasmid purification kit (Zymo Research, D4036).

[00594] After incubation, plasmid concentrations were measured using Qubit HS assay (Invitrogen, Catalog #Q32851) and diluted to 50 ng/µL. The plasmid DNA for each sgRNA and a pcDNA3.1 transfection plasmid encoding Nme1Cas9 (SEQ ID NO: 645) were diluted in Opti-MEM (Thermo Fisher, L3000015) and lipoplexed using Lipofectamine 3000 (Thermo Fisher, Catalog #51985091) according to manufacturer's instructions. Briefly, the lipofectamine-DNA mixture was incubated for 15 minutes at room temperature. After incubation, 10 µl of the mixture was added to HEK-Blue™ cells and incubated in a tissue culture incubator at 37°C and 5% CO_2 atmosphere for 72 hours. Post-transfection, cells were harvested. Genomic DNA isolation and NGS analysis was performed as described in Example 1.

[00595] Editing efficiency was determined for unmodified sgRNA designs with identical 23-nt complementarity to the SEAP loci but with different sgRNA scaffold truncations. The assays were performed in three iterative rounds of screening to identify truncations that altered editing efficiency, either alone or in combination. Cells were prepared and analyzed using the same protocols and control plasmid (RNAWT-145). Samples were included in triplicates in each assay. Mean editing results with standard deviation (SD) are shown in Table 5 and Fig. 1. The relatively low levels of editing efficiency observed may result from the SEAP sgRNAs editing both the endogenous human SEAP gene as well as the exogenous SEAP expression cassette engineered into the HEK-Blue™ cells. NGS primers were designed such that only the editing events at the exogenous SEAP locus were quantified. Nevertheless, editing at the endogenous loci is not expected to change the relative editing levels read at the exogenous SEAP locus using truncated SEAP sgRNAs.

Table 5. Mean percent editing in HEK-Blue™ cells

Experiment	Plasmid ID	Mean % Edit	SD
Round 1	RNAWT-145	6.8	0.3
	RNA9-102	0.3	0.0
	RNA7-106	5.0	0.6
	RNA8-106	0.6	0.2
	RNA6-110	4.3	0.6
	RNA6b-110	0.4	0.0
	RNA5-112	0.4	0.1
	RNA4-116	0.6	0.3
	RNA3-122	1.9	0.1
	RNA2-126	6.6	0.3
	ES-100	4.6	1.7
	ES-121	5.0	0.8
Round 2	RNAWT-145	7.5	0.8
	RNA17-101	3.7	0.5
	RNA18-103	4.4	0.4
	RNA15-105	0.1	0.0
	RNA16-105	4.2	0.2
	RNA13-107	4.1	0.4
	RNA14-109	6.4	0.5
	RNA12-111	8.3	0.8
	RNA11-113	6.9	1.0
	RNA10-115	10.2	0.6
Round 3	RNAWT-145	10.5	1.0
	R10B-111	7.6	1.2
	R10E-109	8.7	1.2
	R10F-113	5.7	0.5

Experiment	Plasmid ID	Mean % Edit	SD
	R10G-113	4.6	0.6
	R10H-113	5.4	0.8
	R10I-113	4.4	1.1
	R10J-113	3.2	0.9
	R19-112	4.7	0.9

Example 2.2. Evaluation of gRNA chemical modifications in HEK-293 cells

[00596] Guide modification patterns of select truncated sgRNA tested in the study described above were further evaluated to assess the impact of the modifications on guide editing efficiency. A stable cell line expressing Nme2 Cas9 from a lentiviral expression construct, referred to herein as HEK-Nme2, was engineered for constitutive Nme2 Cas9 expression.

HEK Cell Preparation

[00597] HEK-293 (ATCC, CRL-1573) cells were thawed in maintenance media (DMEM (Corning, #10-013-CV), 10% FBS (Gibco, #A31605-02)). Cells were then plated at a cell density of 200,000 cells per well in 6-well plates (Corning, #353046) in Dulbecco's Modified Eagle Medium (Corning #10-013-CV) with 10% FBS content (Gibco, #A31605-02). Cells were transduced in the presence of polybrene (Millipore Sigma, TR-1003) following the manufacturer's protocol with Cellecta #SVCRU617-L lentiviral vector encoding Nme2 Cas9 (SEQ ID NO: 640).

[00598] Cells were incubated for 10 days in a tissue culture incubator at 37°C and 5% CO_2 atmosphere. Cells were subsequently washed, processed on a cell sorter (Sony Biotechnologies, SH800Z) and analyzed using the FlowJo software package for GFP luminescence. Polyclonal mixtures of the selected HEK-Nme2 cells prepared with a MOI of 2 were used for subsequent studies.

[00599] Transduced HEK-Nme2 cells described above were thawed and resuspended in serum-free Dulbecco's Modified Eagle Medium (Corning #10-013-CV) with 10% FBS content (Gibco #A31605-02) and 1% Penicillin-Streptomycin (Gibco #15070063). Cells were counted and plated at a density of 20,000 cells/well in Dulbecco's Modified Eagle Medium (Corning #10-013-CV) with 10% FBS content (Gibco #A31605-02) on 96-well tissue culture plate (Falcon, #353072). Plated cells were allowed to settle and adhere for 18 hours in a tissue culture incubator at 37°C and 5% CO_2 atmosphere.

Cell transfection using MessengerMAX

[00600] Guide modification patterns consisting of 2'-O methyl (2'-OMe) and phosphorothioate (PS) modifications were tested in the context of sgRNA to evaluate the impact of the modifications on guide editing efficiency.

[00601] Truncated dual guide RNAs (dgRNA) were created by annealing modified, truncated tracrRNAs to modified crRNA targeting one of two sites on VEGFA (T25 or T47, target sites previously published in WO2019094791) in a mixture of 1 µl 100 µM crRNA, 1 µL 100 µM tracrRNA and 8 uL Duplex Buffer (Integrated DNA Technologies, #11-05-01-12). The Nme2-Cas9 tracrRNA and crRNA solution was annealed at 95°C for 3 minutes followed by an incremental temperature decrease of 0.1C/s to 20°C. Samples were kept on ice until used. Dual guide RNA with an initial concentration of 10 uM was diluted in Opti-MEM (Thermo Fisher, #51985091) for a concentration of 250 nM in 10 uL and mixed with Lipofectamine MessengerMAX (Invitrogen, catalog #LMRNA001) according to manufacturer instructions. A 20 uL aliquot of the solution was added to each tissue culture well for each concentration and incubated in a tissue culture incubator at 37°C and 5% CO_2 atmosphere for 72 hours.

[00602] Post incubation, genomic DNA was isolated and NGS analysis was performed as described above.

[00603] Editing efficiency was evaluated as described in Example 1 for the dgRNA containing the 16 truncated tracrRNAs (TR0#####) annealed to the crRNAs (CR0#####), indicated in Table 6, targeting the two genomic sites (T25, T47) in the VEGFA gene at dgRNA concentrations of 50 nM. Duplicate samples were included in the assay. Mean editing results with standard deviation (SD) are shown in Table 6 and Fig. 2.

Table 6. *In vitro* editing in HEK-Nme2 cells

Tracr ID	VEGFA Site 1 (T25-CR018648)		VEGFA Site 2 (T47-CR018656)	
	Mean % Edit	SD	Mean % Edit	SD
TR018227	7.1	0.1	26.0	2.1
TR018228	8.6	0.2	28.4	8.7
TR018229	4.9	1.1	25.7	6.3
TR018230	2.1	0.1	23.7	1.5
TR018231	1.1	0.2	23.6	5.2
TR018232	2.4	0.8	30.3	4.3
TR018233	2.2	0.6	26.8	1.6

Tracr ID	VEGFA Site 1 (T25-CR018648)		VEGFA Site 2 (T47-CR018656)	
	Mean % Edit	SD	Mean % Edit	SD
TR018234	0.0	0.0	32.6	2.4
TR018235	6.1	0.2	20.3	3.4
TR018236	8.0	0.6	30.8	3.3
TR018237	0.1	0.1	0.3	0.1
TR018238	5.5	0.0	32.6	2.3
TR018239	1.6	0.1	26.8	5.5
TR018240	1.0	0.2	9.4	2.5
TR018241	2.4	0.4	11.3	0.5
TR018242	2.4	0.4	34.3	2.2

Example 3. *In vitro* editing with chemically modified Nme2Cas9 sgRNAs

Example 3.1 Evaluation of modified sgRNA in HEK-Nme2 cells

[00604] Guide modification patterns consisting of 2'-O methyl (2'-OMe) and phosphorothioate (PS) modifications were tested in the context of sgRNA to evaluate the impact of the modifications on guide editing efficiency.

HEK Cell Preparation

[00605] HEK-Nme2 cells were prepared as described in Example 2. Cells were counted and plated at a density of 30,000 cells/well (Falcon, #353072). Cells were transfected as described in Examples 2.2. Seventy-two hours post transfection, the cells were prepared for NGS analysis as described in Example 1.

[00606] Editing efficiency was evaluated for 43 chemically modified sgRNA targeting the VEGFA gene at site T47 as described in Example 2.2. Two separate experiments were conducted with samples tested in triplicates in each assay. The results obtained in both experiments were comparable so the mean editing results with standard deviation (SD) from a single experiment are shown in Table 7 and Fig. 3. "ND" in the table represents values that could not be determined due to experimental failure.

Table 7. Mean percent editing in HEK-Nme2 cells

Guide ID	Mean % Edit	SD	Guide ID	Mean % Edit	SD	Guide ID	Mean % Edit	SD
G020031	3.9	1.0	G020046	28.1	5.1	G020060	6.3	0.5

Guide ID	Mean % Edit	SD	Guide ID	Mean % Edit	SD	Guide ID	Mean % Edit	SD
G020032	20.4	1.3	G020047	12.6	3.0	G020061	11.1	5.8
G020033	1.1	0.0	G020048	13.5	4.2	G020062	4.2	2.0
G020034	15.5	1.4	G020049	1.1	0.1	G020063	ND	ND
G020035	1.4	0.2	G020050	11.1	1.7	G020064	25.7	2.9
G020036	14.4	2.3	G020051	12.9	3.3	G020065	ND	ND
G020037	13.8	0.9	G020052	5.8	1.3	G020066	37.5	4.4
G020038	5.9	1.8	G020053	20.0	4.2	G020067	39.0	5.5
G020039	20.0	5.0	G020054	46.6	8.2	G020068	54.3	2.5
G020040	47.2	5.0	G020055	34.7	2.2	G020069	28.2	3.8
G020041	45.3	5.5	G020056	17.6	2.9	G020070	1.5	0.4
G020042	54.3	5.1	G020057	9.5	3.3	G020071	43.3	5.5
G020043	42.7	11.3	G020058	14.3	2.0	G020072	48.3	2.6
G020044	54.5	0.5	G020059	6.6	3.7	G020073	61.5	1.2
G020045	5.7	3.9						

Example 3.2 Evaluation of alternative sgRNA modification patterns in HEK-293 cells

[00607] Additional Nme2 sgRNAs with alternative modification patterns were tested in HEK-293 cells (ATCC, CRL-1573) to evaluate the impact of additional chemical modifications on guide editing efficiency. Cells were prepared and transfected as described in Example 1, delivering 100 ng Nme2 mRNA and sgRNA at a final concentration of 50 nM. Cells were plated at a density of 15,000 cells/well. Seventy-two hours post transfection, genomic DNA was isolated and analyzed via NGS as described in Example 1.

[00608] Editing efficiency was evaluated for 54 chemically modified sgRNAs targeting the VEGFA gene at site T47 as provided above. Triplicate samples were tested in each assay. Mean editing results with standard deviation (SD) are shown in Table 8 and Fig. 4.

Table 8. Mean percent editing in HEK-293 cells

Guide ID	Mean % Edit	SD	Guide ID	Mean % Edit	SD	Guide ID	Mean % Edit	SD
G020044	76.2	3.9	G020721	76.1	5.9	G020739	84.8	0.4
G020054	78.1	9.4	G020722	76.2	5.7	G020740	78.9	3.7
G020057	47.3	5.8	G020723	73.3	5.1	G020741	66.6	2.5
G020058	32.8	7.1	G020724	73.7	2.5	G020742	82.4	2.4
G020063	54.1	2.7	G020725	82.4	2.9	G020743	80.9	3.1
G020065	72.2	0.2	G020726	72.2	1.2	G020744	79.0	5.0

Guide ID	Mean % Edit	SD	Guide ID	Mean % Edit	SD	Guide ID	Mean % Edit	SD
G020070	9.3	0.3	G020727	79.3	0.8	G020745	79.7	1.9
G020073	75.5	0.6	G020728	85.3	5.3	G020746	85.5	4.3
G020711	34.7	8.6	G020729	76.9	0.5	G020747	21.9	3.4
G020712	39.9	3.3	G020730	80.6	2.4	G020748	84.2	2.0
G020713	47.2	3.6	G020731	81.4	1.8	G020749	75.7	1.2
G020714	60.7	7.7	G020732	80.7	1.0	G020750	75.2	2.5
G020715	69.0	1.9	G020733	78.7	4.6	G020751	72.0	5.4
G020716	62.2	9.5	G020734	77.3	6.3	G020752	78.4	2.7
G020717	75.9	2.2	G020735	80.6	2.8	G020753	77.3	10.2
G020718	81.3	1.4	G020736	78.5	2.7	G020754	80.7	1.1
G020719	74.3	6.4	G020737	70.4	4.6	G020755	73.6	2.0
G020720	73.0	3.4	G020738	73.7	5.6	G020756	76.5	4.0

Example 4. *In vitro* editing with selected guides in Primary Mouse Hepatocytes (PMH)

[00609] A modified sgRNA screen was conducted to evaluate the editing efficiency of 95 different sgRNAs targeting various sites within the mouse TTR gene. Based on that study, two sgRNAs (G021320 and G021256) were selected for evaluation in a dose response assay. These two test guides were compared to a mouse TTR SpyCas9 guide (G000502) with a 20 nucleotide guide sequence. The tested NmeCas9 sgRNAs targeting the mouse TTR gene include a 24 nucleotide guide sequence (as represented by N) and a guide scaffold as follows: mN*mNNNNNNNNmNNNmNNNNNNNNNNNNmGUUGmUmAmGmCUCCCmUmGm AmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAm UGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmGCmAmUC*mG*mU*mU (SEQ ID NO: 4), where A, C, G, U, and N are adenine, cytosine, guanine, uracil, and any ribonucleotide, respectively, unless otherwise indicated. An m is indicative of a 2'O-methyl modification, and an * is indicative of a phosphorothioate linkage between the nucleotides. Unmodified and modified versions of the guides are provided in Table 1-2.

[00610] Guides and Cas9 mRNA were lipofected, as described below, into primary mouse hepatocytes (PMH). PMH (In Vitro ADMET Laboratories MCM114) were prepared as described in Example 1. Lipofections were performed as described in Example 1 with a dose response of sgRNA and mRNA. Briefly, cells were incubated at 37°C, 5% CO_2 for 24 hours prior to treatment with lipoplexes. Lipoplexes were incubated in maintenance media containing 10% fetal bovine serum (FBS) at 37°C for 10 minutes. Post-incubation the lipoplexes were added to the mouse hepatocytes in an 8 point, 3-fold dose response assay starting at maximum

dose of 300 ng Cas9 mRNA and 50 nM sgRNA. Messenger RNA doses scale along with gRNA dose in each condition, although only gRNA dose is listed in Table 9. The cells were lysed 72 hours post-treatment and NGS analysis was performed as described in Example 1.

[00611] Dose response of editing efficiency to guide concentration was performed in triplicate samples. Table 9 shows mean percent editing and standard deviation (SD) at each guide concentration and a calculated EC_{50} value. Mean and standard deviation (SD) is illustrated in Fig. 5.

Table 9. Mean percent editing in primary mouse hepatocytes

Sample	EC_{50} (nM)	SgRNA (nM)	Mean % Edit	SD
SpyCas9 mRNA + G000502	22.0	50	95.7	0.3
		16.7	40.9	14.8
		5.6	6.4	3.3
		1.9	0.8	0.3
		0.6	0.2	0.08
		0.2	0.1	0
		0.1	0.1	0
		0	0.1	0
Nme2 Cas9 mRNA Q (SEQ ID NO: 635) + G021320	18.7	50	86.5	0.9
		16.7	41.8	2.1
		5.6	5.8	1.4
		1.9	1.2	0.3
		0.6	0.4	0.2
		0.2	0.1	0.1
		0.1	0.1	0
		0	0.1	0
Nme2 Cas9 mRNA Q (SEQ ID NO: 635) + G021256	20.9	50	92.3	0.5
		16.7	35.1	2
		5.6	2.6	0.5
		1.9	0.6	0.4
		0.6	0.1	0
		0.2	0.1	0
		0.1	0.1	0
		0	0.1	0

Example 5. *In vitro* editing in Primary Mouse Hepatocytes (PMH) with dilution curve

Example 5.1. Modified sgRNA evaluation using dilution series

[00612] Modified sgRNAs with various scaffold structures, all targeting a previously published site in the mouse pcsk9 gene (see WO2019094791) were designed as shown in Tables 1-2 and tested for editing efficiency using in primary mouse hepatocytes (PMH). Cells were prepared as described in Example 1 using PMH cells (In Vitro ADMET Laboratories) and plated at a density of 20,000 cells/well. Cells were transfected using MessengerMax (Invitrogen) according to the manufacturer's protocols with 1 ng/µl Nme2 Cas9 mRNA (mRNA U) and sgRNA at concentrations as indicated in Table 10. Duplicate samples were included in the assay. Cells were harvested 72 hours following transfection and analyzed by NGS as described in Example 1. Mean percent editing with standard deviation are shown in Table 10 and Fig. 6.

Table 10. Mean percent editing in PMH

Guide concentration (nM)	G017564		G017565		G017566	
	Mean % editing	SD	Mean % editing	SD	Mean % editing	SD
50.0	25.7	3.2	25.6	4.9	27.7	0.4
25.0	27.8	1.4	20.0	1.7	26.4	4.7
12.5	15.3	1.7	12.9	0.8	18.2	1.7
6.3	10.6	0.6	8.7	0.9	12.6	0.9
3.1	5.3	0.2	3.6	0.3	6.7	0.7
1.6	5.0	1.1	3.6	0.6	4.8	0.2
0.8	1.3	0.5	0.2	0.1	2.8	0.3
0.4	0.8	0.3	0.5	0.1	1.8	0.1
0.2	0.3	0.1	0.2	0.1	0.7	0.1
0.1	0.1	0.0	0.1	0.1	0.2	0.1
0.0	0.1	0.0	0.0	0.0	0.3	0.1

Example 5.2. Evaluation of mRNA poly-A tail modifications and cargo ratios

[00613] An sgRNA targeting the mouse pcsk9 gene was selected from Table 10 to evaluate guide editing efficiency resulting from particular combinations of poly-A tail modifications and sgRNA:mRNA ratios. PMH cells used were prepared, treated, and analyzed as described in Example 1 unless otherwise noted. PMH (Gibco) were plated at a density of 15,000 cells/well.

[00614] LNPs were generally prepared as described in Example 1. LNPs were prepared with the lipid composition of 50/9/38/3, expressed as the molar ratio of ionizable lipid A/cholesterol/DSPC/PEG, respectively. The LNPs were formulated with a lipid amine to RNA phosphate (N:P) molar ratio of about 6. LNPs encapsulated gRNA G017566 or one of three mRNAs encoding the same Nme2Cas9 open reading frame (ORF) but with different encoded poly-A tails, as indicated in Table 11. A preliminary experiment holding the sgRNA application constant and varying the amount of mRNA applied showed that 1:1 sgRNA:mRNA ratio by weight resulted in the highest percent editing. In the current Example, increasing doses mRNA LNP and gRNA LNP were applied to cells in 100 µl media as described in Table 11, maintaining a 1:1 sgRNA:mRNA ratio by weight. Table 11 and Fig. 7 show mean percent editing and standard deviation (SD).

Table 11. Mean percent editing in PMH

Total RNA (ng)	mRNA C SEQ ID NO: 622		mRNA B SEQ ID NO:621		mRNA D SEQ ID NO: 623	
	Mean % editing	SD	Mean % editing	SD	Mean % editing	N
333.	49.1	0.9	44.3	0.0	39.6	1
111.	37.5	3.2	43.4	0.2	30.3	1
37.	12.8	0.2	15.6	1.0	9.3	1
12.3	1.3	0.2	2.2	0.0	1.1	1
4.1	0.1	0.0	0.2	0.0	0.0	1
1.4	0.1	0.0	0.0	0.0	0.1	1
0.5	0.1	0.0	0.1	0.1	0.0	1

Example 5.3. sgRNA:mRNA ratio relative to sgRNA or pgRNA using LNPs

[00615] Studies were conducted to evaluate the editing efficiency of sgRNA designs that contain PEG linkers (pgRNA). The study compared two gRNAs targeting TTR with the same guide sequence, one of which included three PEG linkers in the constant region of the guide (pgRNA, G021846) and one of which did not (G021845) as shown in Table 12. The guides and mRNA were formulated in separate LNPs and mixed to the desired ratios for delivery to primary mouse hepatocytes (PMH) via lipid nanoparticles (LNPs).

[00616] PMH cells were prepared, treated, and analyzed as described in Example 1 unless otherwise noted. PMH cells from In Vitro ADMET Laboratories (Lot#MCM114) were plated at a density of 15,000 cells/well. Cells were treated with LNPs as described below. LNPs were generally prepared as described in Example 1. LNPs were prepared with the lipid composition

of 50/9/38/3, expressed as the molar ratio of ionizable lipid A/cholesterol/DSPC/PEG, respectively. The LNPs were formulated with a lipid amine to RNA phosphate (N:P) molar ratio of about 6. LNPs encapsulated a single RNA species, either gRNA G021845, gRNA G021846 or mRNA (mRNA M; SEQ ID NO: 631) as described in Example 1.

[00617] PMH cells were treated with varying amounts of LNPs at ratios of gRNA to mRNA of 1:4, 1:2, 1:1, 2:1, 4:1, or 8:1 by weight of RNA cargo. Duplicate samples were included in each assay. Guides were assayed in an 8 point 3-fold dose response curve starting at 1 ng/uL total RNA concentration as shown in Table 12. Mean percent editing results are shown in Table 12. Fig. 8A shows mean percent editing for sgRNA G021845 and Fig. 8B shows mean percent editing for sgRNA G021846. "ND" in the table represents values that could not be detected due to experimental failure.

Table 12. Mean percent editing in PMH

Cargo ratio (gRNA:mRNA)	LNP dose (ng/uL)	sgRNA (G021845)		pgRNA (G021846)	
		Mean % editing	SD	Mean % editing	SD
1:4	1	88.1	1.7	ND	ND
	0.3	68.7	5.7	78	0.3
	0.1	28.1	4.1	39.8	8.2
	0.03	8.7	2	5.1	0
	0.01	1.5	0.4	4	1.2
	0.004	0.6	0.5	0.2	0
	0.001	0.3	0.2	0.6	0.3
1:2	1	90.6	0	91.2	2.9
	0.3	78	2.4	85.6	1.4
	0.1	41.5	5.8	56.6	4.4
	0.03	23	5.4	17.5	0
	0.01	6.1	4.3	18.6	0.5
	0.004	0.1	0.1	3.4	1.7
	0.001	0.1	0	2.4	0.7
1:1	1	90.9	1.4	94.7	0.6
	0.3	71.8	4.2	84.7	0.9
	0.1	45.7	3.2	64.3	5.3
	0.03	27.4	1	44.8	11.5
	0.01	4.7	2.5	10.2	4.3
	0.004	0.2	0	1.7	0.7
	0.001	0.1	0	0.7	0.5
2:1	1	92.4	1.6	94.5	0.8
	0.3	80	1.3	85.7	0.2

Cargo ratio (gRNA:mRNA)	LNP dose (ng/uL)	sgRNA (G021845)		pgRNA (G021846)	
		Mean % editing	SD	Mean % editing	SD
	0.1	45.4	0	68	7.9
	0.03	47.2	3	49.3	0
	0.01	18.1	1.8	28.8	4.1
	0.004	0.8	0.7	3.8	2.4
	0.001	0.2	0.1	0.8	0.3
4:1	1	87.9	1.9	90.1	0
	0.3	80.2	2.2	84	0.1
	0.1	43.4	0	60.4	0.1
	0.03	46.2	0.5	46.1	0
	0.01	11.3	2.3	26.7	4.9
	0.004	0.4	0.2	1.5	0.4
	0.001	0.4	0.1	0.5	0.3
8:1	1	89.2	0	87.5	0
	0.3	76.7	3.9	78.6	3.1
	0.1	59.5	9.4	59.4	1.1
	0.03	36.4	7	45.3	0.5
	0.01	8.2	1.2	18.7	2.9
	0.004	0.6	0.6	2.6	0.3
	0.001	0.1	0	0.6	0.2

Example 5.4 *In vitro* editing of modified pegylated guides (pgRNAs) in PMH using LNPs

Modified pgRNA having the same targeting site in the mouse TTR gene were assayed to evaluate the editing efficiency in PMH cells.

[00618] PMH cells were prepared, treated, and analyzed as described in Example 1 unless otherwise noted. PMH cells from In Vitro ADMET Laboratories (Lot#MC148) were used and plated at a density of 15,000 cells/well. LNP formulations were prepared as described in Example 1. LNPs were prepared with the lipid composition of 50/9/38/3, expressed as the molar ratio of ionizable lipid A/cholesterol/DSPC/PEG, respectively. The LNPs were formulated with a lipid amine to RNA phosphate (N:P) molar ratio of about 6 and a gRNA indicated in Table I or mRNA

[00619] PMH in 100 µl media were treated with LNP for 30 ng total mRNA (mRNA P). by weight and LNP for gRNA in the amounts indicated in Table 13. Samples were run in duplicate. Mean editing results for PMH are shown in Table 13. and in Fig. 9.

Table 13. Mean percent editing in PMH

Guide ID	LNP sgRNA (ng/uL)	Mean % editing	SD	Guide ID	LNP sgRNA (ng/uL)	Mean % editing	SD
G021844	0.7	96.6	0.5	G023416	0.7	91.5	1.8
	0.23	95.0	0.5		0.23	84.8	0.1
	0.08	80.0	5.9		0.08	56.4	2.7
	0.03	51.9	1.9		0.03	28.2	3.6
	0.009	13.9	0.4		0.009	10.0	1.7
	0.003	4.6	0.9		0.003	3.2	0.0
	0.001	0.8	0.1		0.001	0.8	0.3
	0.0003	0.2	0.1		0.0003	0.2	0.0
	0.0001	0.1	0.0		0.0001	0.1	0.0
	0.00004	0.2	0.1		0.00004	0.1	0.0
	0.00001	0.1	0.0		0.00001	0.1	0.0
	0	0.1	0.0		0	0.1	0.0
G023413	0.7	96.4	0.4	G023417	0.7	90.5	1.8
	0.23	92.5	0.7		0.23	71.6	0.2
	0.08	73.9	0.9		0.08	30.9	6.7
	0.03	36.4	2.6		0.03	12.8	1.3
	0.009	10.3	1.5		0.009	4.8	1.5
	0.003	2.4	0.7		0.003	0.4	0.4
	0.001	0.6	0.1		0.001	0.2	0.1
	0.0003	0.3	0.0		0.0003	0.1	0.0
	0.0001	0.1	0.0		0.0001	0.1	0.1
	0.00004	0.1	0.0		0.00004	0.1	0.0
	0.00001	0.1	0.0		0.00001	0.1	0.0
	0	0.1	0.0		0	0.1	0.0
G023414	0.7	96.5	0.2	G023418	0.7	96.8	0.3
	0.23	92.7	0.4		0.23	90.8	1.7
	0.08	74.1	2.7		0.08	63.3	1.8
	0.03	45.7	1.5		0.03	27.7	2.4
	0.009	13.7	0.7		0.009	8.8	0.5
	0.003	4.3	1.3		0.003	1.9	0.6
	0.001	0.7	0.1		0.001	0.7	0.2
	0.0003	0.2	0.0		0.0003	0.2	0.1
	0.0001	0.2	0.1		0.0001	0.1	0.0
	0.00004	0.2	0.1		0.00004	0.1	0.0
	0.00001	0.1	0.0		0.00001	0.1	0.0
	0	0.1	0.0		0	0.2	0.1
G023415	0.7	96.5	0.5	G023419	0.7	96.6	0.6

Guide ID	LNP sgRNA (ng/uL)	Mean % editing	SD	Guide ID	LNP sgRNA (ng/uL)	Mean % editing	SD
	0.23	92.6	0.7		0.23	93.4	1.3
	0.08	73.1	0.2		0.08	71.1	3.3
	0.03	34.4	0.8		0.03	29.0	4.6
	0.009	14.2	0.2		0.009	9.7	4.1
	0.003	3.9	0.4		0.003	2.3	0.5
	0.001	0.5	0.2		0.001	0.4	0.0
	0.0003	0.2	0.0		0.0003	0.1	0.0
	0.0001	0.2	0.0		0.0001	0.2	0.0
	0.00004	0.1	0.0		0.00004	0.2	0.0
	0.00001	0.1	0.0		0.00001	0.1	0.0
	0	0.1	0.0		0	0.1	0.0

Example 6. Chemical modification screens

Example 6.1. Chemical modification screens in HEK-293 cells

[00620] Editing efficiency was determined for chemically modified crRNA targeting two different VEGFA target sites (TS-25, TS-47). Each dgRNA contained a combination of a crRNA and a tracRNA with chemical modifications. Chemical modifications included phosphorothioate (PS) or 2'-O' methyl (2'-OMe) modifications to bases at the 5' and 3' ends of both the crRNA and the tracrRNA (EndMod).

[00621] HEK-Nme2 cells were prepared as described in Example 2 except cells with MOI at 0.8 were used in this study. Cells were plated at a cell density of 10,000 cells per well. Cells were then transfected with dual guide RNA via the MessengerMax protocol described in Example 2.2 at a final concentration of 25 nM dgRNA. Duplicate samples were included in the assay. After 72 hours, genomic DNA (gDNA) was extracted from the cells and prepared for NGS analysis as described in Example 1. NGS analysis results were evaluated using the Graphpad Prism software (version 9). Mean percent editing is shown in Table 14 and Figs. 10A-10B.

Table 14. Mean percent editing with different combinations of crRNA and tracrRNA

TracrRNA ID	Site TS-25			Site TS-47		
	crRNA ID	Mean % Edit	SD	crRNA ID	Mean % Edit	SD
TR018617	CR017872	4.20	2.20	CR018650	3.25	0.25
TR018618	UnMod	3.05	1.05	UnMod	6.90	1.50

TracrRNA ID	Site TS-25			Site TS-47		
	crRNA ID	Mean % Edit	SD	crRNA ID	Mean % Edit	SD
TR018619		0.75	0.25		8.55	2.15
TR018620		0.10	0.00		1.95	0.05
TR018621		0.25	0.05		3.80	1.50
TR018622		0.10	0.00		1.15	0.75
TR018617		3.80	2.30		7.70	0.10
TR018618		17.30	5.00		26.70	3.60
TR018619	CR017873 EndMod	9.00	2.90	CR018651 EndMod	20.85	4.25
TR018620		3.05	0.45		13.15	3.85
TR018621		9.40	2.30		18.35	3.55
TR018622		0.50	0.20		1.20	0.40
TR018617		4.95	1.75		9.10	2.90
TR018618		18.85	4.15		27.50	5.40
TR018619	CR018473 RaMod	18.00	2.50	CR018652 RaMod	28.45	3.05
TR018620		3.15	0.25		8.60	3.60
TR018621		15.15	1.25		19.60	3.00
TR018622		0.30	0.10		1.40	0.10
TR018617		3.35	1.55		2.80	0.40
TR018618		15.60	4.80		12.35	0.85
TR018619	CR018645 RA-maxPS	12.75	1.95	CR018653 RA-maxPS	25.95	1.35
TR018620		2.30	0.50		5.75	1.45
TR018621		9.40	0.00		10.95	2.55
TR018622		0.15	0.05		0.70	0.70
TR018617		5.20	1.90		4.30	1.70
TR018618		15.75	3.85		1.70	0.10
TR018619	CR018646 maxPS	9.50	0.90	CR018654 maxPS	21.30	1.70
TR018620		2.20	0.00		6.60	2.60
TR018621		9.55	1.05		9.15	4.65
TR018622		0.15	0.05		2.55	1.15
TR018617		4.65	1.75		5.00	0.80
TR018618		12.15	4.25		26.85	2.25
TR018619	CR018647 Target-2'-OMe	8.05	1.45	CR018655 Target-2'-OMe	26.30	1.00
TR018620		4.00	0.40		9.55	0.95
TR018621		9.70	1.50		15.65	2.85
TR018622		0.10	0.00		1.25	0.25
TR018617		7.00	3.10		10.50	0.50
TR018618		23.40	8.00		21.10	1.90
TR018619	CR018648 Max-2'-OMe	11.70	4.30	CR018656 Max-2'-OMe	25.05	0.65
TR018620		3.30	0.00		13.90	0.90
TR018621		13.30	2.20		23.60	0.70
TR018622		0.20	0.00		1.25	0.45
TR018617	CR018649	1.55	0.05	CR018657	6.55	0.15
TR018618		14.60	4.10		11.65	0.65

TracrRNA ID	Site TS-25			Site TS-47		
	crRNA ID	Mean % Edit	SD	crRNA ID	Mean % Edit	SD
TR018619	Max-2'-OMe	4.35	1.25	Max-2'-OMe	29.05	2.35
TR018620		1.25	0.15		9.40	1.80
TR018621		10.85	3.55		20.45	6.65
TR018622		0.10	0.00		1.70	0.10

[00622] The additional combinations of chemically modified crRNA and tracrRNA were tested to assess editing efficiency. Editing efficiency was determined for chemically modified dgRNA targeting the previously described TS47 site within the VEGFA gene. Each dgRNA contained a combination of a crRNA and a tracrRNA with chemical modifications. HEK-Nme2 cells were obtained and prepared as described in Example 2. Cells (MOI=2) were plated at a cell density of 10,000 cells per well. Cells were then transfected with dual guide RNA via the MessengerMax protocol previously described in Example 2.2 at a final concentration of 25 nM dgRNA. Duplicate samples were included in the assay. After 72 hours, gDNA was extracted from cells, prepared for NGS analysis, and NGS results analyzed as described above and in Example 1. Mean percent editing is shown in Table 15 and Fig. 11.

Table 15. Mean percent editing with modified crRNAs and tracrRNAs

tracrRNA ID	CR018473		CR018474		CR018475		CR018476	
	Mean % Edit	SD	Mean % Edit	SD	Mean % Edit	SD	Mean % Edit	SD
TR018477	20.5	0.1	32.8	1.9	14.2	4.1	22.2	2.1
TR018478	5.8	1.3	25.6	4.0	6.1	0.2	14.2	0.3
TR018479	35.7	2.3	37.9	2.7	19.9	1.7	15.4	0.6
TR018480	37.4	0.4	29.7	0.5	20.2	1.3	1.2	0.3
TR018481	24.9	1.0	29.9	0.1	1.9	0.2	23.6	0.7
TR018482	0.3	0.1	0.5	0.1	0.9	0.3	0.8	0.1
TR018483	30.3	1.4	31.8	1.7	16.9	0.4	21.1	3.1
TR018484	16.2	1.8	18.2	1.2	17.9	1.1	23.2	3.0
TR018485	26.1	0.2	6.6	1.3	1.5	0.4	5.9	1.1
TR018486	32.0	4.8	17.9	0.8	2.8	0.1	15.7	0.3
TR018487	8.0	1.6	30.1	1.0	12.2	0.0	21.8	0.7
TR018488	36.2	0.8	25.1	1.2	21.0	1.0	31.0	0.3
TR018489	34.9	0.4	20.1	1.6	19.5	0.5	29.4	1.3
TR018490	21.9	0.3	28.5	0.3	10.2	1.6	13.8	1.4
TR018491	24.7	1.2	28.3	1.4	19.6	1.4	26.1	0.0

TR018492	13.6	1.5	18.3	0.3	12.4	3.0	18.7	1.9
TR018493	19.9	0.8	8.4	2.0	9.6	1.9	22.7	3.2
TR018494	1.1	0.9	0.4	0.2	0.3	0.2	0.3	0.1
TR018495	19.4	1.6	27.8	0.7	1.4	0.7	1.9	0.3
TR018496	38.7	0.9	35.5	1.0	13.3	1.7	32.9	1.7
TR018497	27.5	1.1	16.6	0.5	13.1	0.2	23.0	0.7
TR018498	28.0	1.2	38.1	1.0	18.6	2.9	24.9	1.7
TR018499	33.9	0.1	36.4	0.5	26.6	0.9	37.8	1.2
TR018500	0.7	0.5	0.5	0.2	3.1	0.7	4.7	1.3

Example 6.2 Evaluation of guide sequence chemical modifications in PMH

[00623] Pegylated guide RNA (pgRNA) with chemical modifications in the guide sequence were tested for editing efficacy at two distinct mouse TTR regions (Exon 1 and Exon 3) in PMH. PMH (In Vitro ADMET Laboratories) were prepared as described in Example 1. Lipofection of Nme2 Cas9 mRNA (mRNA O SEQ ID NO: 633) and gRNAs targeting two distinct loci in mouse TTR as indicated in Table 16 used pre-mixed lipid compositions as described in Example 1. Lipoplexes were used to treat cells with 100 ng/100 ul Nme2 mRNA and with gRNA at the concentrations indicated in Table 16. Cells were incubated in maintenance media + 10% FBS (Corning #35-010-CF) at 37°C for 72 hours. Post incubation, genomic DNA was isolated and NGS analysis was performed as described in Example 1.

[00624] Editing efficiency was determined for various guide modification patterns at three gRNA concentrations (3 nM, 8 nM, or 25 nM). Duplicate samples were included in the assay. Mean editing results are shown in Table 16 and Figs. 12A-12B for test guides with the N79 pgRNA design (G023066 or G023067) that are lacking a 2'-OMe at specified nucleotide position in the target-binding region of the gRNA. Table 17 and Figs. 12C-12D show mean percent editing for test guides with the End-Mod pgRNA designs (G023070 or G023104) with additional 2'-OMe modifications at the specified nucleotide position in the target-binding region of the gRNA. "ND" in the table represents values that could not be detected due to experimental failure.

Table 16. Mean percent editing for N79 pgRNAs lacking 2'-OMe modification at the specified position in the guide sequence.

Locus	Guide Sequence Modification	Guide	gRNA concentrations					
			3 nM		8 nM		25 nM	
			Mean % Edit	SD	Mean % Edit	SD	Mean % Edit	SD
Exon-1	High mod pgRNA	G023067	ND	ND	61.8	0.3	76.3	4.6
	No-Mod	G023069	5.1	0.4	13.0	0.2	33.8	0.3
	End-Mod	G023070	23.7	3.9	48.1	0.3	61.2	2.0
	POSITION 4	G023078	36.5	4.1	50.7	3.5	69.5	0.1
	POSITION 5	G023079	57.7	0.5	63.2	3.5	71.2	3.0
	POSITION 8	G023080	47.3	4.2	46.1	2.9	78.4	0.2
	POSITION 9	G023081	50.4	2.2	46.8	5.6	57.4	4.1
	POSITION 11	G023082	31.2	2.3	39.3	1.9	50.7	3.6
	POSITION 13	G023083	46.5	3.7	49.2	3.8	46.6	9.2
	POSITION 18	G023084	46.8	1.8	47.7	7	60.7	4.1
	POSITION 22	G023085	9.5	2.6	35.2	5.8	49.6	3.9
Exon-3	High mod pgRNA	G023066	38.8	4.0	79.2	4.2	88.0	1.0
	No-Mod	G023103	1.3	0.5	20	0.2	37.3	1.6
	End-Mod	G023104	20.3	4.7	50.1	4.9	62.1	5.1
	POSITION 4	G023112	56.7	3.8	64.3	3.2	77.2	2.0
	POSITION 5	G023113	41.0	8.9	68.4	1.3	81.8	1.8
	POSITION 8	G023114	56.3	2.2	76.8	14	87.5	0.5
	POSITION 9	G023115	59.5	9.0	63.6	1.9	80.8	0.9
	POSITION 11	G023116	49.4	10.3	49.5	7.1	67.8	0.2
	POSITION 13	G023117	49.0	9.4	55.1	5.7	70.3	1.2
	POSITION 18	G023118	52.9	7.3	56.6	6.0	74.4	3.4
	POSITION 22	G023119	21.7	4.1	30.5	3.3	40.8	1.2

ND = no data reported due to technical failure.

Table 17. Mean percent editing for end modified pgRNAs with an additional 2'-OMe modification at the specified position in the target-binding region of the pgRNAs.

Locus	Guide Sequence Modification	Guide	gRNA concentrations					
			3 nM		8 nM		25 nM	
			Mean % Edit	SD	Mean % Edit	SD	Mean % Edit	SD
Exon-1	High mod pgRNA	G023067	ND	ND	61.8	0.3	76.3	4.6
	No-Mod	G023069	5.1	0.4	13.0	0.2	33.8	0.3
	End-Mod	G023070	23.7	3.9	48.1	0.3	61.2	2.0
	POSITION 4	G023071	22.4	4.0	51.0	5.3	54.2	0.6
	POSITION 5	G023072	18.8	2.1	45.8	5.3	60.5	1.2
	POSITION 8	G023120	65.3	26	41.3	5.0	38.6	7.2
	POSITION 9	G023073	31.1	3.1	47.7	1.0	62.4	6.3
	POSITION 11	G023074	24.0	5.6	52.0	1.7	66.5	1.4

Locus	Guide Sequence Modification	Guide	gRNA concentrations					
			3 nM		8 nM		25 nM	
			Mean % Edit	SD	Mean % Edit	SD	Mean % Edit	SD
	POSITION 13	G023075	ND	ND	48.2	3.6	62.5	0.8
	POSITION 18	G023076	17.2	1.6	43.1	0.2	48.1	2.8
	POSITION 22	G023077	30.6	2.5	59.1	7.2	ND	ND
Exon-3	High mod pgRNA	G023066	38.8	4.0	79.2	4.2	88.0	1.0
	No-Mod	G023103	1.3	0.5	20.0	0.2	37.3	1.6
	End-Mod	G023104	20.3	4.7	50.1	4.9	62.1	5.1
	POSITION 4	G023105	7.0	1.4	52.6	6.8	51.6	2.2
	POSITION 5	G023106	22.8	4.2	ND	ND	63.8	3.4
	POSITION 8	G023122	34.6	5.4	53.2	6.5	66.9	1.9
	POSITION 9	G023107	19.3	5.1	ND	ND	ND	ND
	POSITION 11	G023108	27.1	7.5	49.6	6.8	50.5	0.7
	POSITION 13	G023109	13.6	2.8	41.6	3.4	ND	ND
	POSITION 18	G023110	25.1	8.8	46.2	3.9	54.1	1.1
	POSITION 22	G023111	22.3	6.6	56.8	1.1	61.2	3.9

ND = no data reported due to technical failure.

Example 7. Base editing with Nme2-base editor and chemically modified sgRNA in HepG2 cells

[00625] Base editor constructs comprising an APOBEC3A deaminase domain fused to Nme2Cas9 D16A nickase were tested for base conversion efficiency with various guide designs in HepG2 cells.

[00626] HepG2 cells constitutively overexpress solute carrier family 10 member 1 (SLC10A1) (HepG2-NTCP, Seeger et al. Mol Ther Nucleic Acids. 2014 Dec; 3(12): e216*)* were thawed and resuspended in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS) (Media Y) followed by centrifugation. The supernatant was discarded and the cells were resuspended in Media Y and plated at a density of 25,000 cells per well in a 96-well collagen coated plate (Corning, Cat. 354407) in 100uL of Media Y.

[00627] Nme2Cas9 base editor mRNAs were prepared by *in vitro* transcription essentially as described in Example 1 from plasmids encoding mRNA R (2XNLS N-terminal, 1xC-terminal NLS Nme2 base editor), mRNA S (2XNLS N-terminal, NLS Nme2 base editor ORF), and mRNA T (1X C-term NLS Nme2 base editor ORF). SpyCas9 mRNA and uracil glycosylase inhibitor (UGI) mRNA (SEQ ID NO: 625) were transcribed from plasmids using the same method.

[00628] Chemically modified NmeCas9 sgRNAs targeted to NTCP, with different PAM sequences, (G020927, G020928) or VEGFA (G020073) and SpyCas9 sgRNA targeted to NTCP (G020929) were synthesized using routine methods.

[00629] Guide RNA, editor mRNA, and UGI mRNA were mixed at a 1:1:1 weight ratio with premixed transfection reagent containing Lipid A, cholesterol, DSPC, and PEG2k-DMG in a 50:38:9:3 molar ratio, respectively. Reagents were combined at a lipid amine to RNA phosphate (N:P) molar ratio of about 6.0. RNA-lipid mixture was mixed approximately 1:1 with 10% FBS media and incubated for 10 minutes. Post-incubation, the cells were treated with the RNA-lipid mixture in an 8-point, 2-fold serial dilution starting at 400 ng total editor RNA per well.

[00630] At 72 hours post-treatment, cells were lysed for NGS analysis as provided in Example 1.

[00631] Dose response of editing efficiency to guide concentration was performed in triplicate. Table 18 – shows mean editing percentages calculated at each guide concentration and a calculated EC50 value. The target site in VEGFA is prone to indel formation due to high GC content. All editor mRNAs achieved the same maximum C to T editing. There were slight differences in EC50 where mRNA S outperformed mRNA R and mRNA T.

Table 18. Mean editing percentages in HepG2-NTCP cells at VEGFA locus (G020073) and Nme2 base editor.

mRNA	Nme-base editor (ng)	C-to-T %				C-to-A/G %			Indel %		
		Mean	SD	n	EC50	Mean	SD	n	Mean	SD	n
mRNA R	0	0.20	0.14	2	6.86	0.80	0.00	2	0.70	0.14	2
	6.25	36.05	1.63	2		2.30	0.28	2	14.25	0.21	2
	12.5	49.70	1.13	2		2.95	0.49	2	16.35	1.06	2
	25	57.60	0.42	2		2.75	0.07	2	17.45	0.21	2
	50	67.15	1.34	2		2.65	0.07	2	17.90	0.14	2
	100	70.50	0.99	2		2.65	0.07	2	18.80	0.28	2
	200	72.75	0.49	2		2.90	0.57	2	18.75	0.49	2
	400	72.00	0.14	2		3.10	0.14	2	20.40	0.99	2
mRNA S	0	0.50	0.00	1	3.86	1.00	0.00	1	0.60	0.00	1
	6.25	49.60	3.25	2		2.10	0.14	2	14.05	0.21	2
	12.5	57.05	0.78	2		2.50	0.42	2	16.50	0.14	2
	25	66.95	0.49	2		2.40	0.00	2	16.25	0.21	2
	50	71.45	0.35	2		2.40	0.00	2	17.25	0.07	2
	100	71.60	0.85	2		2.55	0.35	2	17.90	0.14	2
	200	73.70	0.28	2		2.65	0.07	2	19.00	0.28	2

mRNA	Nme-base editor (ng)	C-to-T %				C-to-A/G %			Indel %		
		Mean	SD	n	EC50	Mean	SD	n	Mean	SD	n
	400	73.80	0.14	2		3.05	0.35	2	18.70	0.42	2
mRNA T	0	0.55	0.49	2	4.84	1.05	0.21	2	0.55	0.07	2
	6.25	45.55	0.21	2		2.60	0.28	2	17.15	0.64	2
	12.5	56.40	1.84	2		2.80	0.00	2	19.40	0.14	2
	25	64.95	1.06	2		3.15	0.35	2	19.40	1.70	2
	50	70.70	0.28	2		3.25	0.21	2	20.00	0.71	2
	100	72.20	2.83	2		2.75	0.21	2	19.80	1.56	2
	200	70.90	0.99	2		3.15	0.35	2	19.70	0.85	2
	400	71.80	0.14	2		3.45	0.21	2	20.95	0.35	2

Example 8. Base editing with chemically modified sgRNA in PMH

[00632] Base editor constructs comprising an APOBEC3A deaminase domain fused to Nme2Cas9 nickase were tested for base conversion efficiency with various guide designs in primary mouse hepatocytes (PMH). PMH (In Vitro ADMET Laboratories, cat# MC148) were thawed and plated as described in Example 1. Nme2Cas9 base editor mRNAs mRNA R, mRNA S, and mRNA T; and uracil glycosylase inhibitor (UGI) mRNA (SEQ ID NO: 625) were prepared as described in Example 1 and paired with a series of chemically modified sgRNA targeted to mouse TTR and screened at a single dose of 128 ng of base editor mRNA. At 72 hours post-treatment, cells were lysed for NGS analysis as provided in Example 1. The mean editing of representative guides (ratio of edit types) is shown in Table 19.

Table 19. Mean editing percentages in PMH cells using modified gRNAs targeting the TTR locus and an Nme2 base editor.

mRNA	Guide	C-to-T %			C-to-A/G %			Indel %		
		Mean	SD	N	Mean	SD	N	Mean	SD	N
mRNA R	G021237	69.00	5.94	2	3.65	1.63	2	9.00	3.39	2
	G021249	47.15	2.33	2	1.20	0.14	2	1.45	1.34	2
	G021321	7.25	0.92	2	0.25	0.21	2	91.25	0.92	2
mRNA S	G021237	76.75	1.34	2	4.35	1.48	2	7.95	1.34	2
	G021249	54.05	4.17	2	1.20	0.28	2	1.60	0.42	2
	G021321	0.50	n/a	1	0.10	n/a	1	99.00	n/a	1
mRNA T	G021237	73.55	5.44	2	5.15	2.47	2	12.50	1.70	2
	G021249	53.30	5.52	2	1.05	0.21	2	2.15	1.63	2
	G021321	7.05	1.20	2	0.55	0.21	2	90.40	2.97	2

n/a = SD is not applicable when only 1 replicate is reported.

Example 9. Nme2-mRNA studies

Example 9.1 – *In vitro* editing in Primary Mouse Hepatocytes

[00633] Messenger mRNAs encoding Nme2Cas9 ORFs with different NLS placements were assayed for editing efficiency in primary mouse hepatocytes (PMH).

[00634] PMH were prepared as described in Example 1. Lipofection was performed using Lipofectamine MessengerMAX Transfection Reagent (Invitrogen LMRNA001) according to the manufacturer's protocol to transform cells with 100 nM sgRNA G020361 targeting mouse PCSK9 and with mRNA at the concentrations listed in Table 20. Triplicate samples were included in the assay. After 72 hours incubation at 37°C in Maintenance Media, cells were harvested and NGS analysis was performed as described in Example 1. Mean editing results with standard deviation (SD) are shown in Table 20 and Fig. 13.

Table 20. Mean editing percentage in at the PCSK9 locus in PMH

Construct	mRNA Concentration (ng/uL)	Mean % editing	SD
mRNA H SEQ ID NO: 626	2.00	0.07	0.05
	0.66	0.07	0.05
	0.22	0.03	0.05
	0.07	0.03	0.05
	0.03	0.03	0.05
	0.008	0.00	0.00
	0.003	0.00	0.00
	0.00	0.05	0.05
mRNA I SEQ ID NO: 627	2.00	22.53	1.59
	0.66	10.37	2.25
	0.22	0.80	0.22
	0.07	0.07	0.05
	0.03	0.07	0.05
	0.008	0.03	0.05
	0.003	0.03	0.05
	0.00	0.20	0.28
mRNA J SEQ ID NO: 628	2.00	26.30	0.86
	0.66	10.07	1.27
	0.22	0.93	0.33
	0.07	0.03	0.05
	0.03	0.03	0.05
	0.008	0.03	0.05
	0.003	0.03	0.05

Construct	mRNA Concentration (ng/uL)	Mean % editing	SD
	0.00	0.05	0.05
mRNA K SEQ ID NO: 629	2.00	14.20	1.84
	0.66	6.70	1.16
	0.22	0.53	0.17
	0.07	0.07	0.09
	0.03	0.03	0.05
	0.008	0.00	0.00
	0.003	0.00	0.00
	0.00	0.05	0.05
mRNA L SEQ ID NO: 630	2.00	23.30	0.80
	0.66	10.57	1.54
	0.22	0.70	0.42
	0.7	0.07	0.05
	0.03	0.07	0.05
	0.008	0.07	0.05
	0.003	0.03	0.05
	0.00	0.05	0.05
mRNA N SEQ ID NO: 631	2.00	22.63	2.25
	0.66	11.00	0.00
	0.22	0.97	0.19
	0.07	0.17	0.09
	0.03	0.03	0.05
	0.008	0.03	0.05
	0.003	0.00	0.00
	0.00	0.05	0.05
mRNA C SEQ ID NO: 632	2.00	19.90	0.16
	0.66	8.40	2.20
	0.22	0.70	0.22
	0.07	0.03	0.05
	0.03	0.00	0.00
	0.008	0.03	0.05
	0.003	0.00	0.00
	0.00	0.00	0.00

Example 9.2 – Dose Response of Nme2 ORF variants and guides with chemical modification variations

[00635] Messenger mRNAs encoding Nme2Cas9 ORFs with different NLS configurations were assayed for editing efficiency in primary human hepatocytes (PHH) and HEK-293 cells.

Assays were performed using gRNAs with identical guide sequences targeting VEGFA locus TS47 and gRNAs had various lengths and chemical modification patterns. PHH cells prepared as described in Example 1. HEK293 cells were thawed and plated at a density of 30,000 cells/well in 96 well plates in DMEM (Corning, 10-013-CV) with 10% FBS and incubated for 24 hours. Lipofection was performed using Lipofectamine MessengerMAX Transfection Reagent (Invitrogen LMRNA001) according to the manufacturer's protocol. A dose response 1:3 dilution series starting at a top dose of 100 nM gRNA and 1 ng/uL mRNA, was used to transform cells with gRNA at the concentrations listed in Tables LS3.1 and LS3.2. Replicate samples were included in the assay. After 72 hours incubation at 37°C, cells were harvested and NGS analysis was performed as described in Example 1. Mean editing results with standard deviation (SD) are shown in Table 21Aand Figs.14A-14C for HEK cells and Table 21B and Figs. 14D-14F for PHH.

Table 21A. Mean percent editing in HEK cells

mRNA	gRNA [nM]	G020055			G020073		
		Mean	SD	N	Mean	SD	N
mRNA C	100	76.05	5.18	4	90.50	4.15	4
	33.33	61.68	14.86	4	75.55	8.65	4
	11.11	32.93	8.59	4	63.53	11.92	4
	3.70	14.63	4.08	4	39.88	2.40	4
	1.23	5.95	1.42	4	13.00	5.36	4
	0.41	3.35	0.60	4	6.03	1.05	4
	0.14	2.05	0.50	4	3.65	0.47	4
	0.00	1.50	0.22	4	1.30	0.22	4
mRNA I	100	85.55	7.06	4	88.08	4.90	4
	33.33	65.33	17.06	4	77.13	4.78	4
	11.11	34.98	12.93	4	48.63	4.83	4
	3.70	21.25	13.09	4	22.43	6.49	4
	1.23	8.03	8.06	4	9.80	2.12	4
	0.41	2.83	1.94	4	5.55	0.94	4
	0.14	2.15	0.83	4	2.45	0.60	4
mRNA J	100	87.03	3.79	4	90.93	1.14	4
	33.33	72.25	4.18	4	72.08	3.88	4
	11.11	40.05	5.01	4	42.83	9.02	4
	3.70	11.65	5.34	4	16.63	6.64	4
	1.23	5.78	0.86	4	7.00	1.47	4
	0.41	2.60	0.42	4	4.50	2.76	4
	0.14	1.53	0.50	4	1.78	0.24	4
	0.00	1.33	0.13	4	1.53	0.25	4

Table 21B. Mean percent editing in PHH cells

mRNA	gRNA [nM]	G020055			G020073		
		Mean	SD	N	Mean	SD	N
mRNA C	100	27.70	4.29	3	31.43	3.63	3
	33.33	32.98	5.10	4	31.58	2.49	4
	11.11	25.55	2.53	4	33.58	1.06	4
	3.70	13.80	3.68	4	19.38	3.86	4
	1.23	6.20	0.68	4	12.83	3.60	4
	0.41	2.70	0.81	4	6.35	1.41	4
	0.14	2.25	0.66	4	3.18	1.05	4
	0.00	1.65	0.24	4	1.50	0.18	4
mRNA I	100	25.00	2.73	4	29.88	1.67	4
	33.33	25.73	3.69	4	26.60	4.95	4
	11.11	26.08	3.23	4	22.98	3.09	4
	3.70	14.55	3.74	4	19.03	3.55	4
	1.23	7.65	0.70	4	7.28	3.41	4
	0.41	4.18	0.97	4	4.15	0.62	4
	0.14	2.18	0.15	4	2.83	0.93	4
	0.00	1.40	0.12	4	1.35	0.17	4
mRNA J	100	27.90	1.57	4	36.38	5.06	4
	33.33	26.50	3.59	4	32.95	2.27	4
	11.11	21.23	3.98	4	29.88	3.59	4
	3.70	14.85	2.37	4	14.88	2.81	4
	1.23	6.78	2.29	4	6.43	0.74	4
	0.41	2.73	1.35	4	3.13	0.49	4
	0.14	2.63	1.69	4	2.45	0.73	4
	0.00	1.40	0.12	4	1.50	0.16	4

Example 9.3 – Dose Response of Nme2 NLS variants using LNPs in PMH

[00636] Messenger mRNAs encoding Nme2Cas9 ORFs with different NLS placements were assayed for editing efficiency in primary mouse hepatocytes (PMH). The assay tested guides targeting the mouse TTR locus and included both sgRNA and pgRNA designs.

[00637] PMH were prepared as in Example 1. LNPs were generally prepared as described in Example 1 with a single RNA species as cargo, as indicated in Table 22. LNPs were prepared with the lipid composition of 50/9/38/3, expressed as the molar ratio of ionizable Lipid A/cholesterol/DSPC/PEG, respectively. The LNPs were formulated with a lipid amine to RNA phosphate (N:P) molar ratio of about 6.

[00638] Cells were treated with 60 ng/100 µl LNP containing gRNA by RNA weight and with LNP containing mRNA as indicated in Table 22. Cells were incubated for 72 hours at 37°C in Williams' E Medium (Gibco, A1217601) with maintenance supplements and 10% fetal bovine serum. After 72 hours incubation at 37°C, cells were harvested and editing was assessed by NGS as described in Example 1. Mean percent editing data is shown in Table 22 and FIG. 15.

Table 22. Mean percent editing at the mouse TTR locus in primary mouse hepatocytes.

Sample	mRNA LNP (ng RNA)	Mean % Editing	SD	N
mRNA P (2xNLS) G021536	40.000	92.30	0.85	3
	13.330	82.67	1.61	3
	4.440	62.27	2.96	3
	1.480	32.80	4.54	3
	0.490	11.23	1.37	3
	0.160	3.40	0.71	3
	0.050	0.80	0.22	3
	0.018	0.30	0.08	3
	0.006	0.20	0.08	3
	0.002	0.13	0.05	3
	0.001	0.13	0.05	3
	0.000	0.10	0.00	3
mRNA P (2xNLS) G021844 (pgRNA)	40.000	96.17	0.12	3
	13.330	91.83	0.34	3
	4.440	75.37	6.80	3
	1.480	44.53	13.11	3
	0.490	18.30	5.77	3
	0.160	5.50	1.43	3
	0.050	1.63	0.71	3
	0.018	0.33	0.05	3
	0.006	0.17	0.05	3
	0.002	0.07	0.05	3
	0.001	0.10	0.00	3
	0.000	0.07	0.05	3
mRNA M (1xNLS) G021536	40.000	84.27	1.23	3
	13.330	66.23	5.39	3
	4.440	33.80	5.14	3
	1.480	10.17	5.51	3
	0.490	4.20	0.92	3

Sample	mRNA LNP (ng RNA)	Mean % Editing	SD	N
	0.160	1.10	0.45	3
	0.050	0.33	0.17	3
	0.018	0.23	0.09	3
	0.006	0.10	0.00	3
	0.002	0.10	0.00	3
	0.001	0.10	0.00	3
	0.000	0.07	0.05	3
mRNA M (1xNLS) G021844 (pgRNA)	40.000	88.83	0.37	3
	13.330	74.37	4.63	3
	4.440	39.00	3.72	3
	1.480	16.40	2.52	3
	0.490	4.03	0.77	3
	0.160	1.27	0.05	3
	0.050	0.23	0.05	3
	0.018	0.20	0.08	3
	0.006	0.10	0.00	3
	0.002	0.10	0.00	3
	0.001	0.10	0.00	3
	0.000	0.10	0.00	3

Example 9.4 – Dose Response of Nme2 NLS variants using LNPs in PMH

[00639] Messenger mRNAs encoding Nme2Cas9 ORFs with different NLS placements were assayed for editing efficiency in primary mouse hepatocytes (PMH).

[00640] PMH (Gibco, MC148) were prepared as described in Example 1. LNPs were generally prepared as described in Example 1 with a single RNA species as cargo. LNPs were prepared with the lipid composition of 50/9/38/3, expressed as the molar ratio of ionizable Lipid A/cholesterol/DSPC/PEG, respectively. The LNPs were formulated with a lipid amine to RNA phosphate (N:P) molar ratio of about 6.

[00641] Cells were treated with 30 ng by RNA weight /100 µl of LNP containing gRNA G021844 and with LNP containing mRNA as indicated in Table LS4. Cells were incubated for 24 hours in Williams' E Medium (Gibco, A1217601) with maintenance supplements and 10% fetal bovine serum. After 72 hours incubation, cells were harvested and editing was assessed by NGS as described in Example 1. Mean percent editing data is shown in Table 23 and FIG. 16.

Table 23. Mean editing percentage in PMH treated with LNPs.

mRNA	mRNA LNP (ng/uL)	Mean	SD	N	EC_{50} (ng/uL)
mRNA C	0.30	86.30	4.46	3	0.0082
	0.10	84.17	5.52		
	0.03	75.80	1.91		
	0.01	43.90	14.36		
	0.004	34.03	8.64		
	0.001	15.63	4.35		
	0.0004	6.17	2.41		
	0.0001	3.47	0.62		
	0.00005	2.37	0.34		
	0.00002	3.00	0.64		
	0.00001	2.60	0.57		
	0.00	2.70	0.16		
mRNA J	0.30	91.30	2.92	3	0.0053
	0.10	89.60	4.23		
	0.03	80.93	8.17		
	0.01	62.85	14.35		
	0.004	39.95	5.15		
	0.001	16.70	3.79		
	0.0004	7.73	2.98		
	0.0001	4.23	0.95		
	0.00005	2.80	0.70		
	0.00002	3.23	0.54		
	0.00001	2.67	0.48		
	0.00	3.60	0.57		
mRNA Q	0.30	90.67	4.40	3	0.0065
	0.10	86.77	5.43		
	0.03	80.27	6.65		
	0.01	56.90	5.48		
	0.004	35.45	1.35		
	0.001	12.63	3.16		
	0.0004	5.17	0.56		
	0.0001	2.73	0.17		
	0.00005	2.97	0.41		
	0.00002	2.73	0.21		
	0.00001	2.87	0.56		
	0.00	2.43	0.82		
mRNA N	0.30	93.93	2.20	3	00045
	0.10	90.97	1.77		

mRNA	mRNA LNP (ng/uL)	Mean	SD	N	EC_{50} (ng/uL)
	0.03	82.80	8.24		
	0.01	68.67	10.18		
	0.004	42.07	2.25		
	0.001	24.13	4.21		
	0.0004	10.60	0.94		
	0.0001	4.67	0.66		
	0.00005	3.30	1.84		
	0.00002	3.37	0.69		
	0.00001	2.53	0.90		
	0.00	2.33	1.48		
mRNA P	0.30	94.47	1.04	3	0.0036
	0.10	95.03	0.96		
	0.03	91.27	2.36		
	0.01	74.77	6.91		
	0.004	50.57	4.89		
	0.001	22.67	0.25		
	0.0004	8.27	0.74		
	0.0001	4.93	0.70		
	0.00005	3.37	0.74		
	0.00002	2.93	0.68		
	0.00001	2.87	0.05		
	0.00	2.87	0.45		
mRNA M	0.30	92.00	0.80	3	0.0093
	0.10	91.40	1.90		
	0.03	79.70	0.70		
	0.01	53.10	6.80		
	0.004	22.47	14.28		
	0.001	8.20	4.20		
	0.0004	4.57	1.57		
	0.0001	2.73	0.31		
	0.00005	3.07	0.21		
	0.00002	2.93	0.09		
	0.00001	2.77	0.66		
	0.00	3.47	1.09		
mRNA O	0.30	89.40	7.00	3	0.0042
	0.10	86.83	12.52		
	0.03	78.17	15.41		
	0.01	64.83	12.48		
	0.004	47.33	9.03		

mRNA	mRNA LNP (ng/uL)	Mean	SD	N	EC_{50} (ng/uL)
	0.001	20.67	7.12		
	0.0004	8.60	2.95		
	0.0001	2.47	1.33		
	0.00005	4.13	0.37		
	0.00002	2.80	0.62		
	0.00001	11.13	231.		
	0.00	6.13	2.16		

Example 10 – NmeCas9 protein expression

Example 10.1 Protein expression in primary human hepatocytes

[00642] To quantify expression of each mRNA construct, mRNA and protein expression levels were measured following LNP delivery of mRNAs encoding either SpyCas9 or NmeCas9 to primary human hepatocytes.

[00643] PHH cells were prepared as described in Example 1. LNPs were generally prepared as described in Example 1 with a single RNA species as cargo. The LNPs contained Lipid A, cholesterol, DSPC, and PEG2k-DMG in a 50:38:9:3 molar ratio, respectively. The LNPs were formulated with a lipid amine to RNA phosphate (N:P) molar ratio of about 6.

[00644] Cells were dosed with one LNP containing mRNA (mRNA only), or two LNPs containing either mRNA or gRNA. Each LNP was applied to cells at 16.7 ng total RNA cargo/100 µl. Upon treatment with LNPs, cells were incubated for 24 hours at 37°C in Williams' E Medium (Gibco, A1217601) with maintenance supplements and 10% fetal bovine serum. After 24 hours incubation, cells were harvested and expression was quantified via Nano-Glo HiBiT lytic detection system (Promega, N3030) following manufacturer's instructions. Raw luminescence was normalized to a standard curve using HiBiT Control Protein (Promega, N3010). Protein expression of different Cas9 variants, shown in Table 24 and FIG. 17, was normalized to the expression of SpyCas9 measured in corresponding hepatocytes delivered with only the SpyCas9 mRNA. Consistent with the data shown in Table 24, protein expression from these same constructs was higher for the NmeCas9 construct than for the SpyCas9 construct when detected by western blot with an anti-HiBiT antibody from PHH cell extracts or as measured by HiBiT detection in PMH, PCH, PHH, and PRH cells.

Table 24. Mean fold-expression of Cas9 variants as compared to SpyCas9 expression in

corresponding hepatocytes delivered with only the SpyCas9 mRNA, as measured by the HiBiT assay

mRNA	gRNA	Cell Type	Fold-expression	
			Mean	N
Spy Cas9 mRNA	None	PMH	1	2
		PRH	1	3
		PCH	1	3
		PHH	1	3
	G000502	PMH	0.8	2
		PRH	2.7	3
		PCH	1.8	3
		PHH	0.6	3
Nme2 Cas9 mRNA M	None	PMH	6.8	2
		PRH	19.2	3
		PCH	7.3	3
		PHH	4.3	3
	G021536	PMH	5.1	2
		PRH	11.5	3
		PCH	4.1	3
		PHH	3.0	3

Example 10.2: Protein expression in T cells

[00645] To quantify expression of each mRNA construct, protein expression levels were measured following LNP delivery of mRNAs encoding either SpyCas9 or Nme2Cas9 to T Cells.

[00646] Healthy human donor apheresis was obtained commercially (Hemacare, Cat #). T cells from two donors (W106 and W864) were isolated by negative selection using the EasySep Human T cell Isolation Kit (Stem Cell Technology, Cat. 17951) on the MultiMACS Cell24 Separator Plus instrument according to manufacturer instruction. Isolated T cells were cryopreserved in CS10 freezing media (Cryostor, Cat., 07930) for future use.

[00647] Upon thaw, T cells were cultured in complete T cell growth media composed of CTS OpTmizer Base Media (CTS OpTmizer Media (Gibco, A1048501) with 1X GlutaMAX, 10mM HEPES buffer, 1% Penicillin/Streptomycin)) supplemented with cytokines (200 IU/ml IL2, 5 ng/ml IL7 and 5 ng/ml IL15) and 2.5% human serum (Gemini, 100-512). After overnight rest at 37°C, T cells at a density of 1e6/mL were activated with T cell TransAct Reagent (1:100 dilution, Miltenyi) and incubated in a tissue culture incubator for 48 hours.

[00648] The activated T cells were treated with LNPs delivering mRNAs encoding Nme2 -mRNA or Spy mRNA with HiBiT tags. LNPs were generally prepared as in Example 1. LNPs

were formulated with a lipid amine to RNA phosphate (N:P) molar ratio of about 6. The LNPs encapsulating Nme2Cas9 mRNAs used Lipid A, cholesterol, DSPC, and PEG2k-DMG in a molar ratio of 50:38:9:3 respectively. The LNP encapsulating SpyCas9 mRNA used Lipid A, cholesterol, DSPC, and PEG2k-DMG in a 50:10:38.5:1.5 molar ratio, respectively. No guide RNA was provided in this experiment.

[00649] Immediately prior to LNP treatment of T cells, LNPs were preincubated at 37°C for 5 minutes at an LNP concentration of 13.33 ug/ml total RNA with 10 ug/mL ApoE3 (Peprotech, Cat#350-02) in complete T cell media supplemented with cytokines (200 IU/ml IL2 (Peprotech, Cat. 200-02), 5 ng/ml IL7 (Peprotech, Cat. 200-07), and 5 ng/ml IL15 (Peprotech, Cat. 200-15) and 2.5% human serum (Gemini, 100-512). After incubation, LNPs were then mixed 1:1 by volume with T cells in the complete T cell media with cytokines used for ApoE incubation. T cells were harvested for protein expression analysis at 24h, 48h, and 72h post LNP treatment. T cells were lysed by Nano-Glo® HiBiT Lytic Assay (Promega) and Cas9 protein levels quantified via Nano-Glo® Nano-Glo HiBiT Extracellular Detection System (Promega, Cat. N2420) following the manufacturer's instructions. Luminescence was measured using the Biotek Neo2 plate reader. Linear regression was plotted on GraphPad using the protein number and luminescence readouts from the standard controls, forcing the line to go through X = 0, Y = 0. Used the Y = ax + 0 equation to calculate number of proteins per lysate.

[00650] Samples were normalized to the mean of SpyCas9 at 0.83 ug/ml LNP dose. Tables 25A-25B, and Figs. 18A-18F show the relative Cas9 protein expression in activated cells when mRNA at 24, 48, and 72 hours post LNP treatment in Donor 1 or Donor 2. Cas9 was expressed in a dose dependent manner in activated T cells. Protein expression was higher from Nme2Cas9 samples in comparison to the SpyCas9 sample in activated T cells.

Table 25A. Protein expression normalized to the mean SpyCas9 0.83 ug/ml sample for donor 1

Timepoint (hours)	LNP (ug/mL)	T cell Donor 1					
		mRNA P		mRNA M		Spy Cas9	
		Mean	N	Mean	N	Mean	N
24 h	6.67	89.3	2	86.5	2	26.5	2
	3.33	67.7	2	50.3	2	11.3	2
	1.67	32.4	2	13.5	2	4.4	2
	0.83	7.3	2	2.9	2	1.0	2
	0.42	1.6	2	0.8	2	0.2	2
	0.21	0.4	2	0.3	2	0.1	2

Timepoint (hours)	LNP (ug/mL)	T cell Donor 1					
		mRNA P		mRNA M		Spy Cas9	
		Mean	N	Mean	N	Mean	N
	0.10	0.2	2	0.1	2	0.0	2
	0.00	0.0	2	0.0	2	0.0	2
48 h	6.67	657.2	2	987.0	2	165.9	2
	3.33	487.4	2	551.0	2	58.5	2
	1.67	271.0	2	165.1	2	21.4	2
	0.83	64.5	2	32.3	2	4.3	2
	0.42	11.8	2	7.8	2	1.0	2
	0.21	3.2	2	2.6	2	0.1	2
	0.10	1.1	2	0.7	2	0.1	2
	0.00	0.0	2	0.0	2	0.0	2
72 h	6.67	53.8	2	125.6	2	24.6	2
	3.33	40.8	2	75.6	2	11.6	2
	1.67	23.1	2	25.0	2	3.5	2
	0.83	5.6	2	4.0	2	1.0	2
	0.42	1.0	2	1.3	2	0.2	2
	0.21	0.2	2	0.4	2	0.0	2
	0.10	0.2	2	0.0	2	0.1	2
	0.00	0.0	2	0.0	2	0.0	2

Table 25B. Protein expression normalized to the mean SpyCas9 0.83 ug/ml sample for donor 2

Timepoint (hours)	LNP (ug/mL)	T cell Donor 2					
		mRNA P		mRNA M		SpyCas9	
		Mean	SD	Mean	SD	Mean	SD
24 h	6.67	151.5	2	134.0	2	36.2	2
	3.33	98.2	2	64.5	2	17.2	2
	1.67	37.6	2	19.4	2	4.9	2
	0.83	10.4	2	4.5	2	1.0	2
	0.42	2.4	2	1.0	2	0.2	2
	0.21	0.7	2	0.4	2	0.1	2
	0.10	0.3	2	0.2	2	0.0	2
	0.00	0.0	2	0.0	2	0.0	2
48 h	6.67	713.6	2	1067.3	2	119.0	2
	3.33	507.5	2	587.1	2	54.9	2
	1.67	229.0	2	149.2	2	15.9	2
	0.83	59.1	2	33.8	2	3.6	2
	0.42	10.5	2	8.3	2	1.0	2
	0.21	3.1	2	2.8	2	0.3	2
	0.10	1.0	2	1.9	2	0.2	2
	0.00	0.0	2	0.2	2	0.0	2
72 h	6.67	53.8	2	108.2	2	17.1	2

Timepoint (hours)	LNP (ug/mL)	T cell Donor 2					
		mRNA P		mRNA M		SpyCas9	
		Mean	SD	Mean	SD	Mean	SD
	3.33	40.7	2	60.5	2	8.3	2
	1.67	19.3	2	18.2	2	3.1	2
	0.83	4.7	2	3.8	2	1.0	2
	0.42	1.3	2	1.4	2	0.3	2
	0.21	0.4	2	0.4	2	0.1	2
	0.10	0.3	2	0.0	2	0.4	2
	0.00	0.0	2	0.1	2	0.0	2

Example 11. *In vivo* editing in mouse liver using lipid nanoparticles (LNPs)

[00651] The LNPs used in all *in vivo* studies were formulated as described in Example 1. Deviations from the protocol are noted in the respective Example. Transport and storage solution (TSS) used in LNP preparation was dosed in the experiment as a vehicle-only negative control.

***In vivo* editing in the mouse model**

[00652] Selected guide designs were tested for editing efficiency *in vivo*. CD-1 female mice, ranging 6-10 weeks of age were used in each study involving mice. Animals were weighed pre-dose. LNPs were formulated generally as described in Example 1. LNPs contained ionizable Lipid A, cholesterol, DSPC, and PEG2k-DMG in a 50:38:9:3 molar ratio, respectively. The lipid nucleic acid assemblies were formulated with a lipid amine to RNA phosphate (N:P) molar ratio of about 6.

[00653] LNPs were dosed via the lateral tail vein at a volume of 0.2 mL per animal (approximately 10 mL per kilogram body weight). Body weight was measured at twenty-four hours post-administration. About 6-7 days after LNP delivery, animals were euthanized by exsanguination under isoflurane anesthesia post-dose. Blood was collected via cardiac puncture into serum separator tubes. For studies involving *in vivo* editing, liver tissue was collected from the left medial lobe from each animal for DNA extraction and analysis.

[00654] For the *in vivo* studies, genomic DNA was extracted from tissue using a bead-based extraction kit, e.g., the Zymo Quick- DNA 96 kit (Zymo Research, Cat. #D3010) according to the manufacturer's protocol.NGS analysis was performed as described in Example 1.

Transthyretin (TTR) ELISA Analysis Used in Animal Studies

[00655] Blood was collected, and the serum was isolated as described above. The total TTR serum levels were determined using a Mouse Prealbumin (Transthyretin) ELISA Kit (Aviva Systems Biology, Cat. OKIA00111). Kit reagents and standards were prepared according to the manufacturer's protocol. Mouse serum was diluted to a final dilution of 10,000-fold with 1x assay diluent. 10,000-fold. Both standard curve dilutions (100 µL each) and diluted serum samples were added to each well of the ELISA plate pre-coated with capture antibody. The plate was incubated at room temperature for 30 minutes before washing. Enzyme-antibody conjugate (100 µL per well) was added for a 20-minute incubation. Unbound antibody conjugate was removed and the plate was washed again before the addition of the chromogenic substrate solution. The plate was incubated for 10 minutes before adding 100 µL of the stop solution, e.g., sulfuric acid (approximately 0.3 M). The plate was read on a Clariostar plate reader at an absorbance of 450 nm. Serum TTR levels were calculated by SoftMax Pro software ver. 6.4.2 or Mars software ver. 3.31 using a four-parameter logistic curve fit off the standard curve. Final serum values were adjusted for the assay dilution. Percent protein knockdown (%KD) values were determined relative to controls, which generally were animals sham-treated with vehicle (TSS) unless otherwise indicated. Percent TSS was calculated by division of each sample TTR value by the average value of the TSS group then adjusted to a percentage value.

Example 11.1. *In vivo* editing using co-formulated LNPs

[00656] The editing efficiency of the modified sgRNAs tested in Example D.2 were further evaluated in a mouse model. Guide RNA designs with identical guide sequences targeting mouse PCSK9 but with conserved regions differing lengths were tested LNPs were prepared as described in Example 1. The LNPs were prepared using ionizable lipid A, cholesterol, DSPC, and PEG2k-DMG in a 50:38:9:3 molar ratio, respectively. The LNPs were formulated with a lipid amine to RNA phosphate (N:P) molar ratio of about 6. A gRNA targeting the PCSK9 gene, as indicated in Table 26, and mRNA C were co-formulated at 1:2 gRNA to mRNA by weight in LNPs. LNPs were administered to female CD-1 mice (n=5) at a dose of 1 mg/kg of total RNA as described above. Mice were euthanized at 7 days post dosing. The editing efficiency for LNPs containing the indicated sgRNAs are shown in Table 26 and illustrated in Fig. 19.

Table 26. Mean percent editing in mouse liver.

Guide	Dose (mg/kg)	Mean % Edit	SD
Vehicle	-	0.0	0.0
G017564	1	2.5	0.9
G017565	1	2.2	1.0
G017566	1	2.2	1.2

Example 11.2. *In vivo* editing using pgRNA and mRNA LNPs

[00657] The editing efficiency of modified pgRNAs were evaluated *in vivo*. Four nucleotides in each of the loops of the repeat/anti-repeat region, hairpin 1, and hairpin 2 were substituted with Spacer-18 PEG linkers, in addition to the guide modifications specified in the previous study in Example 11.1.

[00658] LNPs were generally prepared as described in Example 1 with a single RNA species as cargo. The LNPs contained lipid A, cholesterol, DSPC, and PEG2k-DMG in a 50:38:9:3 molar ratio, respectively. The LNPs were formulated with a lipid amine to RNA phosphate (N:P) molar ratio of about 6.

[00659] LNPs containing gRNAs targeting TTR gene indicated in Table 27 were administered to female CD-1 mice (n=5) at a dose of 0.1 mg/kg or 0.3 mg/kg of total RNA as described above. LNP containing mRNA (mRNA M; SEQ ID NO: 631) and LNP containing a pgRNA (G021846 or G021844) were delivered simultaneously at a ratio of 1:2 by RNA weight, respectively. Mice were euthanized at 7 days post dose.

[00660] The editing efficiency, serum TTR knockdown, and percent TSS for the LNPs containing the indicated pgRNAs are shown in Table 27 and illustrated in Figs. 20A-20C respectively.

Table 27. Liver Editing, Serum TTR protein, and TTR protein knockdown

Guide	Dose (mg/kg)	Mean % Edit	SD	Mean serum TTR (ug/ml)	SD	Mean %TSS	SD
TSS	NA	0.1	0	733.1	131.2	100	17.9
G021846	0.1	21.9	2.8	369.5	56.2	50.4	7.7
	0.3	33.8	2.9	269.8	21.3	36.8	2.6
G021844	0.1	59.6	3.9	84.1	26.6	11.5	3.6
	0.3	71.6	1.8	24.4	9.2	3.3	1.2

[00661] A pgRNA (G021844) from the study described above was evaluated in mice with alternative mRNAs at varied dose levels. LNPs were generally prepared as described in Example 1 with a single RNA species as cargo. LNPs containing pgRNA (G21844) or mRNA (mRNA P or mRNA M) were formulated as described in Example 1. The LNPs used in were prepared with ionizable lipid A, cholesterol, DSPC, and PEG2k-DMG in a 50:38:9:3 molar ratio, respectively. The LNPs were formulated with a lipid amine to RNA phosphate (N:P) molar ratio of about 6. Both G000502 and G021844 target exon 3 of the mouse TTR gene. LNP containing pgRNA and LNP containing mRNA were dosed simultaneously based on combined RNA weight at a ratio of 2:1 guide:mRNA by RNA weight , respectively. An additional LNP was co-formulated with G000502 and SpyCas9 mRNA at a ratio of 1:2 by weight, respectively, a preferred SpyCas9 guide:mRNA ratio.

[00662] LNPs indicated in Table 28 were administered to female CD-1 mice (n=4) at a dose of 0.1 mg/kg or 0.03 mg/kg of total RNA. The editing efficiency for LNPs containing the indicated gRNAs are shown in Table 28 and illustrated in Fig. 20D-20E.

Table 28. Liver Editing and Serum TTR protein knockdown

Guide	mRNA	Dose (mg/kg)	Mean % Edit	SD	Mean serum TTR (ug/ml)	SD
TSS	TSS	NA	0.12	0.04	937.4	100.5
G000502	SpyCas9	0.1	44.50	6.9	370.7	80.1
G021844	mRNA P SEQ ID NO: 634	0.03	37.70	2.9	398.7	41.9
		0.1	65.40	2.2	92.8	27.5
	mRNA M SEQ ID NO: 631	0.03	32.02	2.1	527.4	93.6
		0.1	62.50	17.4	268.6	236.8

Example 11.3. *In vivo* editing using sgRNA and mRNA LNPs

[00663] LNPs were generally prepared as described in Example 1 with a single RNA species as cargo. The LNPs used in were prepared with Lipid A, cholesterol, DSPC, and PEG2k-DMG in a 50:38:9:3 molar ratio, respectively. The LNPs were formulated with a lipid amine to RNA phosphate (N:P) molar ratio of about 6. The sgRNAs were designed to target the pcsk9 gene (G020361) or the Rosa26 gene (G020848).

[00664] LNPs containing sgRNA or mRNA were administered to female CD-1 mice (n=5) at a dose of 1 mg/kg of total RNA. The mRNAs tested (mRNA C (SEQ ID NO:622), mRNA J (SEQ ID NO: 628), mRNA Q (SEQ ID NO: 635), mRNA N (SEQ ID NO: 632) were designed with varying numbers and arrangements of NLS. LNPs were dosed simultaneously based on

the combined weight of RNA cargo at a 1:1 ratio of gRNA:mRNA by RNA weight. Mean percent editing is shown in Table 29 and illustrated in Fig. 21.

Table 29. Mean percent editing in mouse liver.

Guide	mRNA	Dose (mg/kg)	Mean %indel	SD
TSS	TSS	NA	0.1	0.0
G020361	mRNA C	1	3.7	1.5
	mRNA J	1	2.1	0.8
	mRNA Q	1	4.5	1.8
	mRNA N	1	3.6	1.0
G020848	mRNA C	1	0.8	0.3
	mRNA J	1	0.4	0.1
	mRNA Q	1	0.7	0.2
	mRNA N	1	0.9	0.5

Example 12. *In vivo* editing with NmeCas9 and either sgRNA or pgRNA

[00665] The editing efficiency of the modified pgRNAs tested with Nme2Cas9 was tested in a mouse model. All Nme sgRNAs tested comprised the same 24nt guide sequence targeting mTTR.

[00666] LNPs were generally prepared as described in Example 1 with a single RNA species as cargo. The LNPs used in were prepared with Lipid A, cholesterol, DSPC, and PEG2k-DMG in a 50:38:9:3 molar ratio, respectively. The LNPs were formulated with a lipid amine to RNA phosphate (N:P) molar ratio of about 6. The LNPs were mixed at a ratio of 2:1 by weight of gRNA to mRNA cargo. Dose is calculated based on the combined RNA weight of gRNA and mRNA. Transport and storage solution (TSS) used in LNP preparation was dosed in the experiment as a vehicle-only negative control.

[00667] CD-1 female mice, ranging 6-10 weeks of age were used in each study involving mice (n = 5 per group, except TSS control n= 4). Formulations were administered intravenously via tail vein injection according to the doses listed in Table 30. Animals were periodically observed for adverse effects for at least 24 hours post-dose. Six days after treatment, animals were euthanized by cardiac puncture under isoflurane anesthesia; liver tissue was collected for downstream analysis. Liver punches weighing between 5 and 15 mg were collected for isolation of genomic DNA and total RNA. Genomic DNA samples were analyzed with NGS sequencing as described in Example 1. The editing efficiency for LNPs containing the indicated mRNAs and gRNAs are shown in Table 30 and illustrated in Fig. 22.

Table 30. Mean percent editing in mouse liver

mRNA	gRNA	Dose (mg/kg)	Mean % Edit	SD	N
TSS	TSS	-	0.08	0.05	4
mRNA P (2x N term NLS, HiBiT)	G021536 (101-nt Nme sgRNA)	0.03	21.68	6.87	5
		0.1	63.22	3.28	5
mRNA P (2x N term NLS, HiBiT)	G021844 (93-nt Nme pgRNA)	0.03	36.28	9.45	5
		0.1	66.44	3.55	5
mRNA O (2 x N-term NLS)	G021844 (93-nt Nme pgRNA)	0.03	40.88	14.16	5
		0.1	66.02	5.01	5

Example 13. *In vivo* base editing with Nme2Cas9 gRNA

[00668] The editing efficiency of the modified gRNAs with different mRNAs were tested with Nme base editor construct in the mouse model. This experiment was performed in parallel to Example 12 and used the same control samples. LNPs were generally prepared as described in Example 1 with a single RNA species as cargo. The LNPs used were prepared with Lipid A, cholesterol, DSPC, and PEG2k-DMG in a 50:38:9:3 molar ratio, respectively. The LNPs were formulated with a lipid amine to RNA phosphate (N:P) molar ratio of about 6. The LNPs used were formulated as described in Example 1, except that each component, guide RNA, or mRNA was formulated individually into an LNP, and the LNP were mixed prior to administration as described in Table 31. For Nme2Cas9 and Nme2Cas9 base editor samples, LNPs were mixed at a ratio of 2:1 by weight of gRNA to editor mRNA cargo. For SpyCas9 base editor samples, LNPs were mixed at a ratio of 1:2 by weight of gRNA to editor mRNA cargo. Dose, as indicated in Table 31 and Figure 14, is calculated based on the combined RNA weight of gRNA and editor mRNA. Base editor samples were treated with an additional 0.03 mpk of UGI mRNA. Transport and storage solution (TSS) used in LNP preparation was dosed in the experiment as a vehicle-only negative control.

[00669] CD-1 female mice, ranging 6-10 weeks of age were used in each study involving mice (n = 5 per group, except TSS control n= 4). Formulations were administered intravenously via tail vein injection according to the doses listed in Table 31. Animals were periodically observed for adverse effects for at least 24 hours post-dose. Six days after treatment, animals were euthanized by cardiac puncture under isoflurane anesthesia; liver tissue were collected for downstream analysis. Liver punches weighing between 5 and 15 mg

were collected for isolation of genomic DNA and total RNA. Genomic DNA was extracted using a DNA isolation kit (ZymoResearch,. D3010) and samples were analyzed with NGS sequencing as described in Example 1. The editing efficiency for LNPs containing the indicated gRNAs are shown in Table 31 and illustrated in Fig. 23.

Table 31. Mean percent editing in mouse liver.

Sample	Dose (mg/kg)	C-to-T %			C-to-A/G %			Indel %		
		Mean	SD	n	Mean	SD	n	Mean	SD	n
TSS	0	0.00	0.00	4	0.10	0.00	4	0.08	0.05	4
mRNA O + G021844 (Nme2Cas9 + pgRNA)	0.03	0.00	0.00	5	0.08	0.04	5	40.88	14.16	5
	0.1	0.00	0.00	5	0.02	0.04	5	66.02	5.01	5
mRNA S + mRNA G + G021844 (Nme2 base editor + UGI + pgRNA)	0.03	25.60	5.28	5	3.50	0.76	5	11.14	2.18	5
	0.1	46.34	1.53	5	5.74	0.33	5	13.52	0.90	5
mRNA E + mRNA G + G000502 (SpyBC22n + UGI + sgRNA)	0.03	9.28	2.82	5	0.94	0.54	5	7.34	1.61	5
	0.1	30.72	8.51	5	2.86	0.23	5	15.60	2.58	5

Example 14. Dose Response Curve for NmeCas9 gRNA in PMH with Nme2Cas9

[00670] The editing efficiency of the modified gRNAs was tested with Nme2Cas9 construct in primary mouse hepatocytes (PMH). All Nme sgRNAs tested comprised the same 24nt guide sequence targeting the mouse TTR gene (mTTR).

[00671] PMH (Gibco, Lot MC931) were thawed and resuspended in hepatocyte thawing medium with plating supplements (William's E Medium (Gibco, Cat. A12176-01)) with dexamethasone + cocktail supplement (Gibco, Cat. A15563, Lot 2019842) and Plating Supplements with FBS content (Gibco, Cat. A13450, Lot 1970698) followed by centrifugation. The supernatant was discarded, and the pelleted cells resuspended in hepatocyte plating medium plus supplement pack (Invitrogen, Cat. A1217601 and Gibco, Cat. CM3000). Cells were counted and plated on Bio-coat collagen I coated 96-well plates (Thermo Fisher, Cat. 877272) at a concentration of 15,000 cells/well. Plated cells were allowed to settle and adhere for 4-6 hours in a tissue culture incubator at 37°C and 5% CO2 atmosphere. After incubation cells were checked for monolayer formation and were washed once with hepatocyte maintenance medium (Invitrogen, Cat. A1217601 and Gibco, Cat. CM4000).

[00672] LNPs were generally prepared as described in Example 1 with a cargo of 1:2 by weight of gRNA to mRNA O. The LNPs used were prepared with a molar ratio of 50% Lipid A, 38% cholesterol, 9% DSPC, and 3% PEG2k-DMG. The LNPs were formulated with a lipid amine to RNA phosphate (N:P) molar ratio of 6. Each LNP was applied to cells using an 8 point 4-fold serial dilution starting at 300 ng of total RNA per 100 µl well (about 32.25 nM gRNA concentration per well) as shown in Table 32. Upon treatment with LNPs, cells were incubated for 24 hours at 37°C in Williams' E Medium (Gibco, A1217601) with maintenance supplements and 3% fetal bovine serum. Samples were run in triplicate. After 72 hours, cells were harvested and analyzed by NGS as described in Example 1.

[00673] The editing efficiency for LNPs containing the indicated gRNAs, and the corresponding EC50 for each, are shown in Table 32 and illustrated in Fig. 26.

Table 32. Mean percent indels at the TTR locus in primary mouse hepatocytes.

Guide	% indels	ng RNA								EC50 (ng RNA)
		300	75	18.75	4.68	1.17	0.29	0.07	0	
G021536	Mean	97.7	96.4	90.9	43.1	13.9	1.3	0.3	0.0	5.23
	SD	0.5	0.3	5.0	10.1	6.5	0.7	0.1	0.0	
G021844	Mean	96.7	96.9	93.8	60.6	27.2	4.0	0.5	0.3	2.86
	SD	0.8	0.3	1.9	7.5	13.4	2.7	0.3	0.1	
G027492	Mean	97.1	96.5	95.2	64.3	30.2	6.2	0.5	0.0	2.49
	SD	1.4	0.4	1.6	13.4	15.9	3.5	0.4	0.1	
G027493	Mean	96.5	94.9	82.7	32.4	8.6	0.9	0.0	0.0	6.95
	SD	0.1	0.6	6.4	6.2	5.5	0.8	0.1	0.0	
G027494	Mean	96.0	91.7	78.3	19.6	6.7	0.7	0.0	0.0	9.06
	SD	1.0	2.2	8.9	7.6	4.0	0.4	0.1	0.0	
G027495	Mean	96.0	94.6	83.8	22.0	11.6	1.8	0.2	0.1	8.31
	SD	0.5	1.8	6.8	9.5	7.3	1.8	0.1	0.1	
G027496	Mean	96.2	93.2	77.8	13.2	5.4	0.4	0.1	0.0	10.22
	SD	0.7	2.9	8.4	3.4	2.7	0.4	0.1	0.0	

Example 15. *In vivo* editing with NmeCas9 gRNA

[00674] The editing efficiency of the modified gRNAs was tested with Nme2Cas9 construct in mice. All Nme sgRNAs tested comprised the same 24 nt guide sequence targeting the mouse TTR gene (mTTR).

[00675] LNPs were generally prepared as described in Example 1 with a cargo of 1:2 by weight of gRNA to mRNA O. The LNPs used were prepared with a molar ratio of 50% Lipid A, 38% cholesterol, 9% DSPC, and 3% PEG2k-DMG. The LNPs were formulated with

a lipid amine to RNA phosphate (N:P) molar ratio of about 6. Dose was calculated based on the combined RNA weight of gRNA and mRNA. Transport and storage solution (TSS) used in LNP preparation was dosed in the experiment as a vehicle-only negative control.

[00676] CD-1 female mice, about 6-8 weeks old, were used in each study involving mice (n = 5 for all groups). Animals were fed regular chow with standard upkeep. Animals were weighed before dose administration. TSS and LNP formulations were administered intravenously via tail vein injection with a dosage of 0.03 mpk. Animals were periodically observed for adverse effects for at least 24 hours post-dose. Seven days after treatment, animals were euthanized by cardiac exsanguination under isoflurane anesthesia; blood for serum preparation and liver tissue were collected for downstream analysis.

[00677] Serum TTR levels shown in Table 33 and Fig. 27 were produced using Serum TTR ELISA – Prealbumin ELISA (Aviva Systems; cat#OKIA00111) according to the manufacturer's protocol. The level of serum TTR is significantly lower in all experimental groups compared to the negative control (TSS).

Table 33. Serum TTR levels (ug/ml).

Guide ID	Serum TTR (ug/ml)	SD	%TSS
TSS	704.9	98.3	100%
G021844	150.0	84.9	21%
G021536	371.1	95.6	53%
G027492	239.4	30.5	34%
G027493	423.4	170.0	60%
G027494	496.3	89.8	70%
G027495	263.6	68.9	37%
G027496	362.4	52.7	51%

[00678] Liver biopsy punches weighing between 5 and 15 mg were collected for isolation of genomic DNA. Genomic DNA was extracted using a DNA isolation kit (ZymoResearch, D3012) and samples were analyzed with NGS sequencing (n=5 for all groups) as described in Example 1. The editing efficiency for LNPs containing the indicated gRNAs are shown in Table 34 and illustrated in Fig. 28.

Table 34. Mean percent indels at the TTR locus in mouse liver samples

Guide	Mean	SD
TSS	0.12	0.22
G021844	57.1	5.7
G021536	31.5	4.9
G027492	51.3	10.4
G027493	27.0	14.0
G027494	17.6	8.6
G027495	43.2	7.2
G027496	23.5	8.6

Example 16. *In vivo* editing with NmeCas9 gRNA

[00679] The editing efficiency of the modified gRNAs was tested with Nme2Cas9 mRNA in mice. All Nme sgRNAs tested comprised the same 24nt guide sequence targeting mTTR.

[00680] LNPs were generally prepared as described in Example 1 with a cargo of 1:2 by weight of gRNA to mRNA O. The LNPs used were prepared with a molar ratio of 50% Lipid A, 38% cholesterol, 9% DSPC, and 3% PEG2k-DMG. The LNPs were formulated with a lipid amine to RNA phosphate (N:P) molar ratio of about 6. Dose was calculated based on the combined RNA weight of gRNA and mRNA. Transport and storage solution (TSS) used in LNP preparation was dosed in the experiment as a vehicle-only negative control.

[00681] CD-1 female mice, about 6 weeks old, were used in each study involving mice (n = 5 for all groups). Animals were weighed before dose administration for dose calculation, and 24 hours post-administration for monitoring. TSS and LNP formulations were administered intravenously via tail vein injection with a dosage of 0.01 mpk or 0.03 mpk. Animals were periodically observed for adverse effects for at least 24 hours post-dose. Seven days after treatment, animals were euthanized by cardiac exsanguination under isoflurane anesthesia. Blood was collected by cardiac puncture for Serum TTR ELISA, and liver tissue was collected for downstream analysis.

[00682] Serum TTR results prepared using Serum TTR ELISA – Prealbumin ELISA (Aviva Systems; cat#OKIA00111) according to the manufacturer's protocol are shown in Fig. 29 and Table 35.

Table 35. Serum TTR measurements following treatment.

Guide ID	Dosage (mpk)	Serum TTR (ug/ml)	SD	N
Vehicle		663.5	61.5	5
G021844	0.01	585.5	166.1	5
	0.03	205.8	99.2	5
G021536	0.01	749.2	425.3	5
	0.03	252.6	50.2	4
G027492	0.01	527.4	163.1	4
	0.03	266.0	92.4	5
G027495	0.01	626.9	157.7	5
	0.03	310.0	118.1	5

[00683] Liver biopsy punches weighing about 5mg-15mg were collected for isolation of genomic DNA and total RNA. Genomic DNA was extracted using a DNA isolation kit (ZymoResearch, D3012) and samples were analyzed with NGS sequencing (n=5 for all groups) as described in Example 1. The editing efficiency for LNPs containing the indicated gRNAs are shown in Table 36 and illustrated in Fig. 30.

Table 36. Mean percent indels at the TTR locus in mouse liver samples.

Guide ID	Dosage	Mean	SD	N
Vehicle	0.00	0.1	0.07	5
G021844	0.01	19.7	2.9	5
	0.03	49.6	7.9	5
G021536	0.01	10.7	4.7	5
	0.03	34.4	4.1	4
G027492	0.01	21.1	9.2	4
	0.03	44.6	9.4	5
G027495	0.01	9.3	2.6	4
	0.03	30.2	10.9	5

Example 17. Guide screen with Nme1Cas9 and Nme3Cas9 mRNAs in T cells

[00684] The editing efficiency of one modified gRNA scaffold was tested in T cells with Nme1Cas9 or Nme3Cas9 mRNA using guides with 9 distinct target sequences in the TRAC locus.

[00685] Healthy human donor apheresis was obtained commercially (Hemacare, Donor 3786), and cells were washed and resuspended in CliniMACS® PBS/EDTA buffer (Miltenyi Biotec Cat. 130-070-525) and processed in a MultiMACS™ Cell 24 Separator Plus device (Miltenyi Biotec). T cells were isolated via positive selection using a Straight from Leukopak®

CD4/CD8 MicroBead kit, human (Miltenyi Biotec Cat. 130-122-352). T cells were aliquoted and cryopreserved for use in Cryostor® CS10 (StemCell Technologies Cat. 07930). Upon thawing, T cells were plated at a density of 1.0 x 10^6 cells/mL in T cell growth media (TCGM) composed of CTS OpTmizer T Cell Expansion SFM and T Cell Expansion Supplement (Thermo Fisher Cat. A1048501), 5% human AB serum (GeminiBio, Cat. 100-512), 1X Penicillin-Streptomycin, 1X Glutamax, 10 mM HEPES, 200 U/mL recombinant human interleukin-2 (Peprotech, Cat. 200-02), 5 ng/mL recombinant human interleukin-7 (Peprotech, Cat. 200-07), and 5 ng/mL recombinant human interleukin-15 (Peprotech, Cat. 200-15). T cells were rested in this media for 24 hours, at which time they were activated with T Cell TransAct™, human reagent (Miltenyi, Cat. 130-111-160) added at a 1:100 ratio by volume.

[00686] For Nme1Cas9 guide screening, solutions containing mRNA encoding Nme1Cas9 (mRNA AB) were prepared in P3 buffer. Guide RNAs targeting various sites in the TRAC locus were denatured for 2 minutes at 95°C and incubated at room temperature for 5 minutes. Forty-eight hours post activation, T cells were harvested, centrifuged, and resuspended at a concentration of 12.5 x 10^6 cells/mL in P3 electroporation buffer (Lonza). For each well to be electroporated, 1 x 10^5 cells were mixed with 600 ng of Nme1Cas9 mRNA and 5μM of gRNAs in a final volume of 20 μL of P3 electroporation buffer. This mix was transferred in duplicate to 96-well Nucleofector™ plates and electroporated using the manufacturer's pulse code. Electroporated T cells were immediately rested in CTS OpTmizer T cell growth media without cytokines for 15 minutes before being transferred to new flat-bottom 96-well plates containing an additional CTS OpTmizer T cell growth media supplemented with cytokines. The resulting plates were incubated at 37 °C for 3 days. On day 3 post-electroporation, cells were split 1:2 in 2 U-bottom plates.

[00687] On day 7 post-electroporation, the plated T cells were assayed by flow cytometry to determine surface expression of the T cell receptor. Briefly, T cells were incubated with antibodies against CD3 (BioLegend, Cat. No. 317336), CD4 (BioLegend, Cat. No. 317434), CD8 (BioLegend, Cat. No. 301046), and Viakrome (Beckman Coulter, Cat. No. C36628). Cells were subsequently washed, resuspended in cell staining buffer and processed on a Cytoflex flow cytometer (Beckman Coulter). Flow cytometry data was analyzed using the FlowJo software package. T cells were gated based on size, shape, viability, and the expression of CD8 and CD3. Samples were run in duplicate.

[00688] The CD3 is a cell-surface component of the T cell receptor complex and its presence at the cell surface is used as a surrogate marker for TRAC protein expression. CD3 negative

cell population, and corresponding standard deviation (SD) for each of the indicated gRNAs are shown in Table 37 and illustrated in Fig.31.

Table 37. Mean percent CD3 negative T cells following TRAC editing with Nme1Cas9

Guide ID	Mean	SD
G024103	0.95	0.02
G024104	1.52	0.04
G024108	52.82	0.40
G024109	1.69	0.14
G024110	2.24	0.39
G024111	2.10	0.06
G024112	1.81	0.14
G024113	1.19	0.26
G024114	0.97	0.05

[00689] For screening of guides with Nme3Cas9 mRNA, T cells were prepared as described in this example. Solutions containing mRNA encoding Nme3Cas9 (mRNA Z) were prepared in P3 buffer, as well as controls of Nme1Cas9 (mRNA AB) and Nme2Cas9 (mRNA O). Electroporation of an NmeCas9 (e.g., Nme1Cas9, Nme2Cas9, or Nme3Cas9) gRNA and mRNA was performed as described above. Samples were electroporated in triplicate. On day 3 post electroporation, cells were assayed via flow cytometry as described above.

[00690] The CD3-negative cell population and corresponding standard deviation (SD) for each of the indicated gRNAs are shown in Table 38 and illustrated in Fig. 32.

Table 38. Mean percent CD3 negative T cells following TRAC editing with Nme3Cas9.

Guide ID	Mean	SD
G028844	2.99	0.49
G028845	2.97	0.30
G028846	22.83	1.65
G028847	8.71	1.16
G028848	95.6	0.74
G028849	6.24	0.02
G028850	69.63	3.57
G028851	1.49	0.53
G028852	79.13	3.34
G028853 (Nme1 Control)	97.43	0.20
G021469 (Nme2 Control)	92.46	2.00

Example 18. Expression of codon optimized NmeCas9 mRNAs

[00691] To quantify expression of each mRNA construct, protein expression levels were measured following electroporation of mRNAs encoding Nme1Cas9, Nme2Cas9, or Nme3Cas9 into T cells. All of the NmeCas9 mRNA constructs have the same general structure with sequential SV40 and nucleoplasmin nuclear localization signal coding sequences N-terminal to the NmeCas9 open reading frame. Constructs include a coding sequence for a HiBiT tag C-terminal to the NmeCas9 open reading frame. The components are joined by linkers and the specific sequences are provided herein.

[00692] Healthy human donor apheresis was obtained commercially (Hemacare, Donor 3786), and cells were washed and resuspended in CliniMACS® PBS/EDTA buffer (Miltenyi Biotec Cat. 130-070-525) and processed in a MultiMACS™ Cell 24 Separator Plus device (Miltenyi Biotec). T cells were isolated via positive selection using a Straight from Leukopak® CD4/CD8 MicroBead kit, human (Miltenyi Biotec Cat. 130-122-352). T cells were aliquoted and cryopreserved for future use in Cryostor® CS10 (StemCell Technologies Cat. 07930). Upon thawing, T cells were plated at a density of 1.0 x 10^6 cells/mL in T cell growth media (TCGM) composed of CTS OpTmizer T Cell Expansion SFM and T Cell Expansion Supplement (Thermo Fisher Cat. A1048501), 5% human AB serum (GeminiBio, Cat. 100-512), 1X Penicillin-Streptomycin, 1X Glutamax, 10 mM HEPES, 200 U/mL recombinant human interleukin-2 (Peprotech, Cat. 200-02), 5 ng/mL recombinant human interleukin-7 (Peprotech, Cat. 200-07), and 5 ng/mL recombinant human interleukin-15 (Peprotech, Cat. 200-15). T cells were rested in this media for 24 hours, at which time they were activated with T Cell TransAct™, human reagent (Miltenyi, Cat. 130-111-160) added at a 1:100 ratio by volume.

[00693] Solutions containing mRNA encoding NmeCas9 were prepared in P3 buffer. Guide RNAs targeting the TRAC locus were removed from the storage and denatured for 2 minutes at 95°C and incubated at room temperature for 5 minutes. Forty-eight hours post activation, T cells were harvested, centrifuged, and resuspended at a concentration of 12.5 x 10^6 cells/mL in P3 electroporation buffer (Lonza). Each well to be electroporated contained 1 x 10^5 cells, NmeCas9 mRNA as specified in Table 39, and 1 μM gRNAs (G028853 for Nme1Cas9; G021469 for Nme2Cas9; G028848 for Nme3Cas9) as specified in Table 39 in a final volume of 20 μL of P3 electroporation buffer. NmeCas9 mRNA was tested using a three-fold, five point serial dilution starting at 600 ng mRNA. The appropriate gRNA & mRNA mix was transferred in triplicate to 96-well Nucleofector™ plates and electroporated using the

manufacturer's pulse code. Electroporated T cells were immediately rested in CTS OpTmizer T cell growth media without cytokines for 15 minutes before being transferred to new flat-bottom 96-well plates containing an additional CTS OpTmizer T cell growth media supplemented with cytokines. The resulting plates were incubated at 37 °C for 24 hours prior to HiBiT luminescence assay or 96 hours prior to flow cytometry.

[00694] T cells were harvested for protein expression analysis at 24h post-electroporation. T cells were lysed by Nano-Glo® HiBiT Lytic Assay (Promega). Luminescence was measured using the Biotek Neo2 plate reader. Table 39 and Fig. 33 show the Cas9 protein expression and corresponding standard deviation (SD) in activated cells as relative luminescence units (RLU).

Table 39. Mean luminescence (RLU) as a relative measure of Cas9 protein expression in T cells at 24 hours.

	mRNA (ng)	600	200	66.6	22.2	7.4
mRNA X (Nme1Cas9) G028853	**Mean (RLUs)**	6955.7	2941.0	1893.7	758.3	288.7
	SD	800.5	232.0	268.3	256.0	21.4
mRNA Y (Nme1Cas9) G028853	**Mean (RLUs)**	10999.7	4967.6	2888.7	1423.0	479.3
	SD	1621.8	444.6	451.5	213.3	42.0
mRNA V (Nme2Cas9) G021469	**Mean (RLUs)**	43026.7	15244.0	6522.3	2658.3	1067.3
	SD	7729.3	1288.1	229.0	174.3	127.1
mRNA Z (Nme3Cas9) G028848	**Mean (RLUs)**	19217.3	6488.0	2386.0	1033.3	414.7
	SD	1311.8	521.0	394.3	93.6	50.2

[00695] On day 4 post-editing, T cells were assayed by flow cytometry to determine surface protein expression. Briefly, T cells were incubated for 30 minutes at 4 °C with a mixture of antibodies diluted in cell staining buffer (BioLegend, Cat. No. 420201). Antibodies against CD3 (BioLegend, Cat. No. 317336), CD4 (BioLegend, Cat. No. 317434), CD8 (BioLegend, Cat. No. 301046), and Viakrome (Beckman Coulter, Cat. No. C36628) were diluted at 1:100. Cells were subsequently washed, resuspended in 100 µL of cell staining buffer and processed on a Cytoflex flow cytometer (Beckman Coulter). Flow cytometry data were analyzed using the FlowJo software package. T cells were gated based on size, shape, viability, CD8, and CD3. Samples were run in triplicate. The CD3-negative cell population and corresponding standard deviation (SD) for each of the indicated gRNAs are shown in Table 40 and illustrated in Fig. 34.

Table 40. Percent CD3-negative cells of T cells following TRAC editing.

	mRNA (ng)	600	200	66.7	22.2	7.4
mRNA X (Nme1Cas9) G028853	**Mean**	95.2	94.6	90.3	79.9	58.7
	SD	0.8	1.1	0.6	3.1	4.8
mRNA Y (Nme1Cas9) G028853	**Mean**	97.2	96.2	93.7	88.7	75.0
	SD	0.8	1.1	0.9	1.4	1.3
mRNA V (Nme2Cas9) G021469	**Mean**	87.7	84.6	80.3	66.6	42.7
	SD	3.3	3.9	2.4	1.6	0.1
mRNA Z (Nme3Cas9) G028848	**Mean**	96.6	93.4	85.5	73.6	36.0
	SD	0.1	1.1	2.3	5.8	2.0

Example 19. *In vitro* editing with selected guides in Primary Cynomolgus Monkey Hepatocytes (PCH)

[00696] Three NmeCas9 sgRNAs (G024739, G024741, and G024743) were selected for evaluation in a dose response assay. The tested NmeCas9 sgRNAs targeting the cynomolgus TTR gene include a 24-nucleotide guide sequence.

[00697] Unmodified and modified versions of the guides are provided in Table 41.

Table 41. Unmodified and modified versions of select gRNAs.

Guide ID	Unmodified sequence	Modified sequence
G024739	AGGACCAGCCUCAGACACA AAUACGUUGUAGCUCCCUG AAACCGUUGCUACAAUAAG GCCGUCGAAAGAUGUGCCG CAACGCUCUGCCUUCUGGC AUCGUU (SEQ ID NO: 947)	mA*mG*mG*mAmCCAmGmCCmUCmA GACAmCAAAmUACmGUUGmUmAmG mCUCCCmUmGmAmAmAmCmCGUUm GmCUAmCAAU*AAGmGmCCmGmUmC mGmAmAmAmGmAmUGUGCmCGmCA AmCGCUCUmGmCCmUmUmCmUGGCA UCG*mU*mU (SEQ ID NO: 928)
G024741	CUGCCUCGGACGGCAUCUA GAACUGUUGUAGCUCCCUG AAACCGUUGCUACAAUAAG GCCGUCGAAAGAUGUGCCG CAACGCUCUGCCUUCUGGC AUCGUU (SEQ ID NO: 948)	mC*mU*mG*mCmCUCmGmGAmCGmG CAUCmUAGAmACUmGUUGmUmAmG mCUCCCmUmGmAmAmAmCmCGUUm GmCUAmCAAU*AAGmGmCCmGmUmC mGmAmAmAmGmAmUGUGCmCGmCA AmCGCUCUmGmCCmUmUmCmUGGCA UCG*mU*mU (SEQ ID NO: 929)
G024743	AGGCAGAGGAGGAGCAGA CGAUGAGUUGUAGCUCCCU GAAACCGUUGCUACAAUAA GGCCGUCGAAAGAUGUGCC GCAACGCUCUGCCUUCUGG CAUCGUU (SEQ ID NO: 949)	mA*mG*mG*mCmAGAmGmGAmGGmA GCAGmACGAmUGAmGUUGmUmAmG mCUCCCmUmGmAmAmAmCmCGUUm GmCUAmCAAU*AAGmGmCCmGmUmC mGmAmAmAmGmAmUGUGCmCGmCA AmCGCUCUmGmCCmUmUmCmUGGCA UCG*mU*mU (SEQ ID NO: 930)

[00698] gRNAs and Cas9 mRNA were lipofected, as described below, into primary cynomolgus hepatocytes (PCH). PCH (In Vitro ADMET Laboratories 10136011) were prepared as described in Example 1. PCH were plated at a density of 40,000 cells/well. LNP formulations were prepared as described in Example 1. LNPs were prepared with the lipid composition at a molar ratio of 50% lipid A, 38% cholesterol, 9% DSPC, and 3% PEG2k-DMG. The LNPs were formulated with a lipid amine to RNA phosphate (N:P) molar ratio of about 6 and a gRNA as indicated in Table 41. PCH in 100 uL media were treated with an 8-point, 4-fold dilution series of LNP containing sgRNA, starting at 70 ng, and a fixed 30 ng dose of LNP encapsulating mRNA O by mRNA weight. The sgRNA concentration in each well is indicated in Table 42. The cells were lysed 72 hours post-treatment and NGS analysis was performed as described in Example 1. Dose response of editing efficiency to guide concentration was measured in triplicate samples. Table 42 and Fig. 35 shows mean percent editing and standard deviation (SD) at each guide concentration.

Table 42. Mean percent indels at TTR following editing in PCH.

	G024739		G024741		G024743	
Guide LNP (ng/uL)	Mean	SD	Mean	SD	Mean	SD
0.7	79.0	1.7	63.5	3.7	42.6	1.1
0.2	56.8	2.4	17.4	1.2	25.4	2.3
0.04	27.2	3.6	2.3	0.5	9.8	0.5
0.01	9.5	1.8	0.6	0.1	3.6	0.5
0.003	3.5	0.9	0.3	0.1	0.7	0.3
0.0007	0.9	0.3	0.1	1.3	0.3	0.1
0.0002	0.4	0.1	0.1	0.0	0.0	0.0
0.00004	0.2	0.0	0.1	1.3	0.0	0.0

Example 20. *In vitro* editing of LNPs using mRNA dilution series in PCH

[00699] Modified sgRNAs having the same targeting site in the cynomolgus TTR gene were assayed to evaluate the editing efficiency in PCH of different mRNAs (mRNA O, mRNA AA) and formulation ratios. PCH (In Vitro ADMET Laboratories, 10136011) were prepared, treated, and analyzed as described in this example as in Example 1 unless otherwise noted. PCH were used and plated at a density of 50,000 cells/well. LNP formulations were prepared as described in Example 1. LNPs were prepared with a lipid composition having a molar ratio of 50% lipid A, 38% cholesterol, 9% DSPC, and 3% PEG2k-DMG. The LNPs were formulated

with a lipid amine to RNA phosphate (N:P) molar ratio of about 6 and a gRNA as indicated in Table 43. PCH in 100 uL media were treated with an 8-point, 3-fold serial dilution of mixed (separately formulated) or co-formulated LNP with various ratios of gRNA:mRNA. The top dose was 3 ng/uL total RNA by weight and gRNA:mRNA ratios for the dilution series were as indicated in Table 43. Samples were run in triplicate. Mean percent editing, standard deviation (SD), and a calculated EC50 are shown in Table 43 and in Fig. 36.

Table 43. Mean percent indels at the TTR locus following editing in PCH.

		LNP (ng/uL)								EC50 (ng/uL)
		3	**1**	**0.33**	**0.11**	**0.04**	**0.01**	**0.004**	**0.001**	
G024739:mRNA O LNPs Mixed 2:1	**Mean % editing**	64	64.3	45.7	25.6	6.5	1.6	0.2	0.1	0.17
	SD	6.9	12.8	5.1	8.5	2.0	0.9	0.0	1.3	
G024739:mRNA AA LNPs Mixed 2:1	**Mean % editing**	58.2	69.2	46.5	29.3	7.4	0.6	0.1	0.0	0.13
	SD	4.5	12.2	13.8	7.6	3.3	0.3	0.0	0.0	
G024739:mRNA AA LNPs Mixed 1:2	**Mean % editing**	56.5	67.1	53.4	25.4	5.8	0.7	0.1	0.0	0.13
	SD	4.7	10.9	16.0	11.7	2.4	0.5	0.0	0.0	
G024739:mRNA O Coformulated 2:1	**Mean % editing**	61.3	59.2	47.0	27.2	7.2	0.4	0.1	0.1	0.14
	SD	4.4	9.3	13.2	8.4	2.2	0.2	0.0	0.0	
G024739:mRNA AA Coformulated 2:1	**Mean % editing**	58.2	69.6	56.4	35.3	7.2	1.2	0.2	0.1	0.10
	SD	3.0	14.4	11.4	11.4	3.3	0.4	0.1	1.3	
G024739:mRNA AA Coformulated 1:2	**Mean % editing**	47.0	62.8	56.1	38	12.3	1.3	0.1	0.1	0.07
	SD	5.8	10.5	15.3	13.9	4.3	0.1	0.0	1.3	

Example 21. *In vivo* editing with NmeCas9 gRNA

[00700] The editing efficiency of the modified gRNAs was tested with Nme2Cas9 construct in mice. All Nme sgRNAs tested comprised the same 24 nt guide sequence targeting the mouse TTR gene (mTTR).

[00701] LNPs were generally prepared as described in Example 1 with a cargo of 1:2 by weight of gRNA to mRNA O. The LNPs used were prepared with a molar ratio of 50% Lipid A, 38% cholesterol, 9% DSPC, and 3% PEG2k-DMG. The LNPs were formulated with a lipid amine to RNA phosphate (N:P) molar ratio of about 6. Dose was calculated based on the combined RNA weight of gRNA and mRNA. Transport and storage solution (TSS) used in LNP preparation was dosed in the experiment as a vehicle-only negative control.

[00702] CD-1 female mice, about 6-8 weeks old, were used in each study involving mice. Animals were fed regular chow with standard upkeep. Animals were weighed before dose administration. TSS and LNP formulations were administered intravenously via tail vein injection with a dosage of 0.03 mpk. Animals were periodically observed for adverse effects for at least 24 hours post-dose. Fourteen days after treatment, animals were euthanized by cardiac exsanguination under isoflurane anesthesia; blood for serum preparation and liver tissue were collected for downstream analysis.

[00703] Serum TTR levels shown in Table 44 and Fig. 39 were produced using Serum TTR ELISA – Prealbumin ELISA (Aviva Systems; cat#OKIA00111) according to the manufacturer's protocol for all experimental groups and compared to the negative control (TSS).

Table 44. Serum TTR levels (ug/ml).

Guide ID	Serum TTR (ug/ml)	SD	%TSS	N
TSS	673.7	44.13	100	5
G021536	378.2	83.0	56.1	7
G029377	419.3	83.5	62.2	9
G029384	270.1	63.90	40.1	4
G029392	375.4	58.23	55.7	4
G029391	509.1	115.3	75.6	4
G029390	623.2	144.3	92.5	4

[00704] Liver biopsy punches weighing between 5 and 15 mg were collected for isolation of genomic DNA. Genomic DNA was extracted using a DNA isolation kit (ZymoResearch, D3012) and samples were analyzed with NGS sequencing as described in

Example 1. The editing efficiency for LNPs containing the indicated gRNAs are shown in Table 45 and illustrated in Fig. 40.

Table 45. Mean percent indels at the TTR locus in mouse liver samples

Guide	Mean % editing	SD	N
TSS	0.1	0	5
G021536	27.2	4.58	7
G029377	25.7	6.77	9
G029384	34.9	4.05	4
G029392	20.9	6.14	4
G029391	5.4	2.60	4
G029390	5.5	3.66	4

Example 22. Dose Response Curve for NmeCas9 gRNA in PMH with Nme2Cas9

[00705] The editing efficiency of the modified gRNAs was tested with Nme2Cas9 construct in primary mouse hepatocytes (PMH). All Nme sgRNAs tested comprised the same 24nt guide sequence targeting the mouse TTR gene (mTTR).

[00706] PMH (Gibco, Lot MC931) were thawed and resuspended in hepatocyte thawing medium followed by centrifugation. The supernatant was discarded and the pelleted cells were resuspended in hepatocyte plating medium (William's E Medium (Gibco, Cat. A12176-01)) with plating supplements dexamethasone + cocktail supplement (Gibco, Cat. A15563, Lot 2459010) and FBS content (Gibco, Cat. A13450, Lot 2486425). Cells were counted and plated on Bio-coat collagen I coated 96-well plates (Corning, Ref 356407, Lot 08722018) at a concentration of 15,000 cells/well. Plated cells were allowed to settle and adhere for 4-6 hours in a tissue culture incubator at 37°C and 5% CO2 atmosphere. After incubation cells were checked for monolayer formation and were washed once with hepatocyte maintenance medium (William's E Medium) with plating medium supplement (Gibco, Cat. A15564, Lot 2459014).

[00707] LNPs were generally prepared as described in Example 1 with a cargo of 1:2 by weight of gRNA to mRNA O. The LNPs used were prepared with a molar ratio of 50% Lipid A, 38% cholesterol, 9% DSPC, and 3% PEG2k-DMG. The LNPs were formulated with a lipid

amine to RNA phosphate (N:P) molar ratio of 6. Each LNP was applied to cells using an 8 point 3-fold serial dilution starting at 450 ng of total cargo per 100 µl well at the top dose (300 ng mRNA O and 46.5 nM gRNA (about 150 ng gRNA)) as shown in Table 46. Upon treatment with LNPs, cells were incubated for 24 hours at 37°C in William's E Medium with plating medium supplement (Gibco, Cat. A15564, Lot 2459014) and 3% fetal bovine serum. After 72 hours, cells were harvested and analyzed by NGS as described in Example 1.

[00708] The editing efficiency for LNPs containing the indicated gRNAs, and the corresponding EC50 for each, are shown in Table 46 and illustrated in Fig. 41.

Table 46. Mean percent indels at the TTR locus in primary mouse hepatocytes.

Guide	% indels	nM gRNA								EC50 (nM gRNA)
		46.5	**15.5**	**5.1**	**1.7**	**0.5**	**0.19**	**0.064**	**0.02**	
G021536	**Mean**	97.20	97.83	97.73	96.75	95.55	83.83	48.33	15.53	0.071
	SD	0.63	0.25	0.45	1.70	0.50	2.17	4.99	0.90	
	N	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
G029377	**Mean**	96.65	96.68	96.90	96.73	93.63	83.65	46.88	16.73	0.075
	SD	0.82	1.42	1.04	0.59	2.40	1.92	3.14	1.05	
	N	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
G029380	**Mean**	95.90	97.00	96.08	95.55	88.38	62.00	22.85	5.38	0.136
	SD	2.27	0.99	1.23	1.28	2.04	0.84	1.47	1.05	
	N	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
G029379	**Mean**	97.13	96.75	96.43	95.20	90.65	62.20	22.00	5.33	0.139
	SD	0.49	1.33	1.11	1.16	1.61	1.47	1.64	0.43	
	N	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
G029378	**Mean**	95.88	97.00	96.05	94.90	87.05	53.03	16.28	3.40	0.172
	SD	1.54	0.94	1.15	1.56	2.00	2.00	1.37	0.86	
	N	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
G029381	**Mean**	97.08	96.05	96.65	95.50	87.90	52.28	16.83	3.40	0.175
	SD	0.82	1.95	0.93	0.94	1.71	3.03	2.35	0.48	
	N	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	

Example 23. Dose Response Curve for NmeCas9 gRNA in PMH with Nme2Cas9

[00709] The editing efficiency of the modified gRNAs was tested with Nme2Cas9 construct in primary mouse hepatocytes (PMH). All Nme sgRNAs tested comprised the same 24nt guide sequence targeting the mouse TTR gene (mTTR).

[00710] PMH (Gibco, Lot MC931) were thawed and resuspended in hepatocyte thawing medium followed by centrifugation. The supernatant was discarded and the pelleted cells were resuspended in hepatocyte plating medium (William's E Medium (Gibco, Cat. A12176-01)) with plating supplements dexamethasone + cocktail supplement (Gibco, Cat. A15563, Lot 2459010) and FBS content (Gibco, Cat. A13450, Lot 2486425). Cells were counted and plated on Bio-coat collagen I coated 96-well plates (Corning, Ref 356407, Lot 08722018) at a concentration of 15,000 cells/well. Plated cells were allowed to settle and adhere for 4-6 hours in a tissue culture incubator at 37°C and 5% CO2 atmosphere. After incubation cells were checked for monolayer formation and were washed once with hepatocyte maintenance medium (William's E Medium) with plating medium supplement (Gibco, Cat. A15564, Lot 2459014).

[00711] LNPs were generally prepared as described in Example 1 with a cargo of 1:2 by weight of gRNA to mRNA O. The LNPs used were prepared with a molar ratio of 50% Lipid A, 38% cholesterol, 9% DSPC, and 3% PEG2k-DMG. The LNPs were formulated with a lipid amine to RNA phosphate (N:P) molar ratio of 6. Each LNP was applied to cells using an 8 point 3-fold serial dilution starting at 450 ng of total cargo per 100 µl well at the top dose (300 ng mRNA O and 46.5 nM gRNA (i.e., 150 ng gRNA)) as shown in Table 47. Upon treatment with LNPs, cells were incubated for 24 hours at 37°C in William's E Medium with plating medium supplement (Gibco, Cat. A15564, Lot 2459014) and 3% fetal bovine serum. Samples were run in triplicates After 72 hours, cells were harvested and analyzed by NGS as described in Example 1.

[00712] The editing efficiency for LNPs containing the indicated gRNAs, and the corresponding EC50 for each, as shown in Table 47 and illustrated in Fig. 42.

Table 47. Mean percent indels at the TTR locus in primary mouse hepatocytes.

Guide	% indels	nM gRNA								EC50 (nM gRNA)
		46.5	**15.5**	**5.1**	**1.7**	**0.5**	**0.19**	**0.064**	**0.02**	
G029384	**Mean**	96.70	97.30	96.57	95.37	92.70	78.67	43.77	13.87	0.077
	SD	0.85	0.52	1.71	1.01	1.95	3.73	4.00	1.50	
	N	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	
G021536	**Mean**	97.13	96.91	96.58	95.77	90.42	73.29	36.63	10.49	0.092
	SD	0.00	0.23	0.03	0.76	1.26	1.96	1.53	0.10	
	N	18.00	18.00	18.00	18.00	18.00	18.00	18.00	18.00	

G029383	Mean	96.93	96.83	96.13	94.37	90.50	73.20	34.77	9.07	0.094
	SD	0.90	1.08	2.21	2.75	3.05	2.92	2.23	0.91	
	N	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	
G029388	Mean	96.60	97.03	96.67	95.23	89.63	71.13	34.07	9.90	0.100
	SD	0.95	0.98	2.05	2.80	0.76	2.75	3.74	3.12	
	N	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	
G029392	Mean	96.57	95.87	96.60	95.23	90.30	72.50	31.13	6.87	0.101
	SD	1.47	2.03	1.47	2.72	3.15	1.56	1.74	0.81	
	N	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	
G029382	Mean	96.83	97.37	96.50	95.87	89.43	69.10	33.80	9.87	0.104
	SD	0.67	0.47	1.30	1.12	3.41	4.92	4.06	0.61	
	N	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	
G029386	Mean	97.17	97.20	96.23	95.80	91.70	71.53	32.57	9.43	0.105
	SD	0.55	1.13	0.38	1.32	0.95	0.61	1.62	0.93	
	N	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	
G029385	Mean	96.80	95.90	96.67	94.87	87.83	66.95	25.60	7.20	0.123
	SD	0.80	0.14	1.23	1.53	3.11	2.47	2.52	0.87	
	N	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	
G029387	Mean	94.07	95.65	95.23	94.00	81.90	56.83	22.67	5.97	0.149
	SD	0.15	0.35	0.71	0.56	2.69	1.80	0.47	0.49	
	N	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	
G029391	Mean	95.70	95.77	95.43	94.30	85.40	56.03	19.83	4.70	0.156
	SD	1.40	2.49	2.98	2.96	3.03	2.62	2.40	0.69	
	N	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	
G029389	Mean	96.80	96.40	95.87	94.60	85.53	54.23	17.63	3.40	0.164
	SD	1.14	0.99	2.32	1.93	2.16	4.05	1.75	0.62	
	N	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	
G029390	Mean	96.00	95.40	94.60	93.07	77.60	42.13	11.70	2.20	0.219
	SD	1.49	3.49	3.97	2.97	2.29	4.10	2.49	0.70	
	N	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	

Example 24. Additional Embodiments

[00713] The following numbered items provide additional support for and descriptions of the embodiments herein.

[00714] Item 1 is a guide RNA (gRNA) comprising a guide region and a conserved region, the conserved region comprising one or more of:

(a) a shortened repeat/anti-repeat region, wherein the shortened repeat/anti-repeat region lacks 2-24 nucleotides, wherein

(i) one or more of nucleotides 37-48 and 53-64 is deleted and optionally one or more of nucleotides 37-64 is substituted relative to SEQ ID NO: 500; and

(ii) nucleotide 36 is linked to nucleotide 65 by at least 2 nucleotides; or

(b) a shortened hairpin 1 region, wherein the shortened hairpin 1 lacks 2-10, optionally 2-8 nucleotides, wherein

(i) one or more of nucleotides 82-86 and 91-95 is deleted and optionally one or more of positions 82-96 is substituted relative to SEQ ID NO: 500; and

(ii) nucleotide 81 is linked to nucleotide 96 by at least 4 nucleotides; or

(c) a shortened hairpin 2 region, wherein the shortened hairpin 2 lacks 2-18, optionally 2-16 nucleotides, wherein

(i) one or more of nucleotides 113-121 and 126-134 is deleted and optionally one or more of nucleotides 113-134 is substituted relative to SEQ ID NO: 500; and

(ii) nucleotide 112 is linked to nucleotide 135 by at least 4 nucleotides;

wherein one or both nucleotides 144-145 are optionally deleted relative to SEQ ID NO: 500;

wherein at least 10 nucleotides are modified nucleotides.

[00715] Item 2 is the gRNA of Item 1, wherein the gRNA is a single-guide RNA (sgRNA) and wherein the gRNA comprises (a) a shortened repeat/anti-repeat region, wherein the shortened repeat/anti-repeat region lacks 2-24 nucleotides, wherein

(i) one or more of nucleotides 37-48 and 53-64 is deleted and optionally one or more of nucleotides 37-64 is substituted relative to SEQ ID NO: 500; and

(ii) nucleotide 36 is linked to nucleotide 65 by at least 2 nucleotides.

[00716] Item 3 is the gRNA of Item 1 or 2, wherein the guide region has (i) an insertion of one nucleotide or a deletion of 1-4 nucleotides within positions 1-24 relative to SEQ ID NO: 500, or (ii) a length of 24 nucleotides.

[00717] Item 4 is the gRNA of the immediately preceding Item, wherein the guide region has a length of 25, 24, 23, 22, 21, or 20 nucleotides, optionally wherein the guide region has a length of 25, 24, 23, or 22 nucleotides.

[00718] Item 5 is the gRNA of the immediately preceding Item, wherein the guide region has a length of 23-24 nucleotides.

[00719] Item 6 is the gRNA of any one of the preceding Items, wherein the gRNA further comprises a 3' tail.

[00720] Item 7 is the gRNA of the immediately preceding Item, wherein the 3' tail comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides.

[00721] Item 8 is the gRNA of the immediately preceding Item, wherein the 3' tail comprises 1, 2, 3, 4, or 5 nucleotides.

[00722] Item 9 is the gRNA of any one of Items 6-8, wherein the 3' tail terminates with a nucleotide comprising a uracil or modified uracil.

[00723] Item 10 is the gRNA of any one of Items 6-9, wherein the 3' tail is 1 nucleotide in length.

[00724] Item 11 is the gRNA of any one of Items 6-10, wherein the 3' tail consists of a nucleotide comprising a uracil or a modified uracil.

[00725] Item 12 is the gRNA of any one of Items 6-11, wherein the 3' tail comprises a modification of any one or more of the nucleotides present in the 3' tail.

[00726] Item 13 is the gRNA of any one of Items 6-12, wherein the modification of the 3' tail is one or more of 2'-O-methyl (2'-OMe) modified nucleotide and a phosphorothioate (PS) linkage between nucleotides.

[00727] Item 14 is the gRNA of any one of the preceding Items 6-13, wherein the 3' tail is fully modified.

[00728] Item 15 is the gRNA of any one of the preceding Items, wherein the 3' nucleotide of the gRNA is a nucleotide comprising a uracil or a modified uracil.

[00729] Item 16 is the gRNA of any one of Items 1-5, wherein one or more of nucleotides 144 and 145 are deleted relative to SEQ ID NO: 500.

[00730] Item 17 is the gRNA of any one of Items 1-5, wherein both nucleotides 144 and 145 are deleted relative to SEQ ID NO: 500.

[00731] Item 18 is the gRNA of any one of Items 1-5, wherein the gRNA does not comprise a 3' tail.

[00732] Item 19 is the gRNA of any one of the preceding Items, wherein the shortened repeat/anti-repeat region lacks 2-24 nucleotides.

[00733] Item 20 is the gRNA of any one of the preceding Items, wherein the shortened repeat/anti-repeat region has a length of 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides.

[00734] Item 21 is the gRNA of any one of the preceding Items, wherein the shortened repeat/anti-repeat region lacks 12-24, optionally 18-24 nucleotides, optionally 20-22 nucleotides.

[00735] Item 22 is the gRNA of any one of the preceding Items, wherein the shortened repeat/anti-repeat region has a length of 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides.

[00736] Item 23 is the gRNA of any one of the preceding Items, wherein the shortened repeat/anti-repeat region has a length of 28, 29, 30, 31, 32, 33, or 34 nucleotides, or 30, 31, or 32 nucleotides.

[00737] Item 24 is the gRNA of any one of the preceding Items, wherein nucleotides 37-64 of SEQ ID NO: 500 form the upper stem, and one or more base pairs of the upper stem of the shortened repeat/anti-repeat region are deleted.

[00738] Item 25 is the gRNA of any one of the preceding Items, wherein the upper stem of the shortened repeat/anti-repeat region comprises no more than one, two, three, or four base pairs.

[00739] Item 26 is the gRNA of any one of the preceding Items, wherein all of positions 39-48 and all of positions 53-62 of the upper stem of the shortened repeat/anti-repeat region are deleted, and optionally nucleotides 38 or 63 is substituted.

[00740] Item 27 is the gRNA of any one of the preceding Items, wherein all of positions 38-48 and all of positions 53-63 of the upper stem of the shortened repeat/anti-repeat region are deleted, and optionally nucleotides 37 or 64 is substituted.

[00741] Item 28 is the gRNA of any one of the preceding Items, wherein all of nucleotides 37-48 and 53-64 of the upper stem of the shortened repeat/anti-repeat region are deleted, and optionally nucleotides 36 or 65 is substituted.

[00742] Item 29 is the gRNA of any one of the preceding Items, wherein the shortened repeat/anti-repeat region has a duplex portion 11 base paired nucleotides in length.

[00743] Item 30 is the gRNA of any one of the preceding Items, wherein the shortened repeat/anti-repeat region has a single duplex portion.

[00744] Item 31 is the gRNA of any one of the preceding Items, wherein the upper stem of the shortened repeat/anti-repeat region includes one or more substitutions relative to SEQ ID NO: 500.

[00745] Item 32 is the gRNA of any one of the preceding Items, wherein one or more of nucleotides 49-52 is substituted relative to SEQ ID NO: 500.

[00746] Item 33 is the gRNA of any one of the preceding Items, wherein the shortened repeat/anti-repeat region is unsubstituted.

[00747] Item 34 is the gRNA of any one of the preceding Items, wherein the shortened repeat/anti-repeat region has 12-22 modified nucleotides

[00748] Item 35 is the gRNA of any one of the preceding Items, wherein the shortened hairpin 1 region lacks 2-10 nucleotides, optionally 2-8 or 2-4 nucleotides.

[00749] Item 36 is the gRNA of any one of the preceding Items, wherein the shortened hairpin 1 region has a length of 13, 14, 15, 16, 17, 18, 19, 20, or 21 nucleotides.

[00750] Item 37 is the gRNA of Item any one of the preceding Items, wherein the shortened hairpin 1 region has a duplex portion 4-8, optionally 7-8 base paired nucleotides in length.

[00751] Item 38 is the gRNA of Item any one of the preceding Items, wherein the shortened hairpin 1 region has a single duplex portion.

[00752] Item 39 is the gRNA of any one of the preceding Items, wherein one or two base pairs of the shortened hairpin 1 region are deleted.

[00753] Item 40 is the gRNA of any one of the preceding Items, wherein the stem of the shortened hairpin 1 region is seven or eight base paired nucleotides in length.

[00754] Item 41 is the gRNA of any one of the preceding Items, wherein one or more of positions 85-86 and one or more of nucleotides 91-92 of the shortened hairpin 1 region are deleted.

[00755] Item 42 is the gRNA of any one of the preceding Items, wherein nucleotides 86 and 91 or nucleotides 85 and 92 of the shortened hairpin 1 region are deleted.

[00756] Item 43 is the gRNA of any one of the preceding Items, wherein one or more of nucleotides 82-95 of the shortened hairpin 1 region is substituted relative to SEQ ID NO: 500.

[00757] Item 44 is the gRNA of any one of the preceding Items, wherein one or more of nucleotides 87-90 is substituted relative to SEQ ID NO: 500.

[00758] Item 45 is the gRNA of any one of the preceding Items, wherein the shortened hairpin 1 region is unsubstituted.

[00759] Item 46 is the gRNA of Item any one of the preceding Items, wherein the shortened hairpin 1 region has 6-15 modified nucleotides.

[00760] Item 47 is the gRNA of any one of the preceding Items, wherein the shortened hairpin 2 region lacks 2-18, optionally 2-16 nucleotides.

[00761] Item 48 is the gRNA of any one of the preceding Items, wherein the shortened hairpin 2 region has a length of 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides.

[00762] Item 49 is the gRNA of any one of the preceding Items, wherein the shortened hairpin 2 region has a length of 28, 29, 30, 31, 32, 33, or 34 nucleotides.

[00763] Item 50 is the gRNA of any one of the preceding Items, wherein one or more of nucleotides 113-121 and one or more of nucleotides 126-134 of the shortened hairpin 2 region are deleted.

[00764] Item 51 is the gRNA of any one of the preceding Items, wherein the shortened hairpin 2 region comprises an unpaired region.

[00765] Item 52 is the gRNA of any one of the preceding Items, wherein the shortened hairpin 2 region has two duplex portions.

[00766] Item 53 is the gRNA of any one of the preceding Items, wherein the shortened hairpin 2 region has a duplex portion of 4 base paired nucleotides in length.

[00767] Item 54 is the gRNA of any one of Items 52-53, wherein the shortened hairpin 2 region has a duplex portion of 4-8 base paired nucleotides in length.

[00768] Item 55 is the gRNA of any one of Items 52-54, wherein the shortened hairpin 2 region has a duplex portion of 4-6 base paired nucleotides in length.

[00769] Item 56 is the gRNA of any one of the preceding Items, wherein nucleotides 113-134 of SEQ ID NO: 500 form the upper stem, and the upper stem of the shortened hairpin 2 region comprises one, two, three, or four base pairs.

[00770] Item 57 is the gRNA of any one of the preceding Items, wherein at least one pair of nucleotides 113 and 134, nucleotides 114 and 133, nucleotides 115 and 132, nucleotides 116 and 131, nucleotides 117 and 130, nucleotides 118 and 129, nucleotides 119 and 128, nucleotides 120 and 127, and nucleotides 121 and 126 are deleted.

[00771] Item 58 is the gRNA of any one of the preceding Items, wherein all of positions 113-121 and 126-134 of the shortened hairpin 2 region are deleted.

[00772] Item 59 is the gRNA of any one of the preceding Items, wherein one or more of nucleotides 113-134 of the shortened hairpin 2 region is substituted relative to SEQ ID NO: 500.

[00773] Item 60 is the gRNA of any one of the preceding Items, wherein one or more of nucleotides 122-125 is substituted relative to SEQ ID NO: 500.

[00774] Item 61 is the gRNA of any one of the preceding Items, wherein the shortened hairpin 2 region is unsubstituted.

[00775] Item 62 is the gRNA of Item any one of the preceding Items, wherein the shortened hairpin 2 region has 6-15 modified nucleotides.

[00776] Item 63 is the gRNA of any one of the preceding Items, wherein the guide region of the gRNA comprises at least two modified nucleotides, optionally at least four modified nucleotides.

[00777] Item 64 is the gRNA of any one of the preceding Items, wherein the guide region of the gRNA comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 modified nucleotides, optionally 1, 2, or 3 modified nucleotides.

[00778] Item 65 is the gRNA of any one of the preceding Items, wherein the guide region of the gRNA comprises 4, 5, 6, 7, 8, 9, 10, 11, or 12 modified nucleotides.

[00779] Item 66 is the gRNA of any one of the preceding Items, wherein the guide region of the gRNA comprises 6, 7, 8, 9, 10, 11, or 12 modified nucleotides.

[00780] Item 67 is the gRNA of any one of the preceding Items, wherein the guide region does not comprise a modified nucleotide 3' of the first three nucleotides of the guide region.

[00781] Item 68 is the gRNA of any one of the preceding Items, wherein the guide region does not comprise a modified nucleotide.

[00782] Item 69 is the gRNA of any one of the preceding Items, wherein the gRNA comprises a 5' end modification.

[00783] Item 70 is the gRNA of any one of the preceding Items, wherein the gRNA comprises a 3' end modification.

[00784] Item 71 is the gRNA of any one of the preceding Items, wherein the gRNA comprises a 5' end modification and a 3' end modification.

[00785] Item 72 is the gRNA of any one of the preceding Items, comprising a modification in the upper stem region of the repeat/anti-repeat region.

[00786] Item 73 is the gRNA of any one of the preceding Items, comprising a modification in the hairpin 1 region.

[00787] Item 74 is the gRNA of any one of the preceding Items, comprising a modification in the hairpin 2 region.

[00788] Item 75 is the gRNA of any one of the preceding Items, comprising a 3' end modification, and comprising a modification in the upper stem region of the repeat/anti-repeat region.

[00789] Item 76 is the gRNA of any one of the preceding Items, comprising a 3' end modification, and a modification in the hairpin 1 region.

[00790] Item 77 is the gRNA of any one of the preceding Items, comprising a 3' end modification, and a modification in the hairpin 2 region.

[00791] Item 78 is the gRNA of any one of the preceding Items, comprising a 5' end modification, and comprising a modification in the upper stem region of the repeat/anti-repeat region.

[00792] Item 79 is the gRNA of any one of the preceding Items, comprising a 5' end modification, and a modification in the hairpin 1 region.

[00793] Item 80 is the gRNA of any one of the preceding Items, comprising a 5' end modification, and a modification in the hairpin 2 region.

[00794] Item 81 is the gRNA of any one of the preceding Items, comprising a 5' end modification, a modification in the upper stem region of the repeat/anti-repeat region, and a 3' end modification.

[00795] Item 82 is the gRNA of any one of the preceding Items, comprising a 5' end modification, a modification in the hairpin 1 region, and a 3' end modification.

[00796] Item 83 is the gRNA of any one of the preceding Items, comprising a 5' end modification, a modification in the hairpin 1 region, a modification in the hairpin 2 region, and a 3' end modification.

[00797] Item 84 is the gRNA of any one of the preceding Items, comprising a 5' end modification, a modification in the repeat/anti-repeat region, a modification in the hairpin 1 region, a modification in the hairpin 2 region, and a 3' end modification.

[00798] Item 85 is the gRNA of any one of Items 69-84, wherein the 5' end modification comprises a modified nucleotide selected from a 2'-O-methyl (2'-OMe) modified nucleotide, 2'-O-(2-methoxyethyl) (2'-O-moe) modified nucleotide, a 2'-fluoro (2'-F) modified nucleotide, a phosphorothioate (PS) linkage between nucleotides, or an inverted abasic modified nucleotide.

[00799] Item 86 is the gRNA of any one of the Items 69-85, wherein the 3' end modification comprises a modified nucleotide selected from a 2'-O-methyl (2'-OMe) modified nucleotide, 2'-O-(2-methoxyethyl) (2'-O-moe) modified nucleotide, a 2'-fluoro (2'-F) modified

nucleotide, a phosphorothioate (PS) linkage between nucleotides, or an inverted abasic modified nucleotide .

[00800] Item 87 is the gRNA of any one of the Items 69-86, wherein the 5' end modification comprises any of:

i. a modification of any one or more of the first 1, 2, 3, or 4 nucleotides;
ii. one modified nucleotide;
iii. two modified nucleotides;
iv. three modified nucleotides; and
v. four modified nucleotides.

[00801] Item 88 is the gRNA of any one of Items 69-87, wherein the 5' end modification comprises one or more of:

i. a phosphorothioate (PS) linkage between nucleotides;
ii. a 2'-OMe modified nucleotide;
iii. a 2'-O-moe modified nucleotide;
iv. a 2'-F modified nucleotide; and
v. an inverted abasic modified nucleotide.

[00802] Item 89 is the gRNA of any one of Items 69-88, wherein the 3' end modification comprises any of:

i. a modification of any one or more of the last 4, 3, 2, or 1 nucleotides;
ii. one modified nucleotide;
iii. two modified nucleotides;
iv. three modified nucleotides; and
v. four modified nucleotides.

[00803] Item 90 is the gRNA of any one of Items 69-89, wherein the 3' end modification comprises one or more of:

i. a phosphorothioate (PS) linkage between nucleotides;
ii. a 2'-OMe modified nucleotide;
iii. a 2'-O-moe modified nucleotide;
iv. a 2'-F modified nucleotide; and
v. an inverted abasic modified nucleotide.

[00804] Item 91 is the gRNA of any one of Items 69-90, wherein the 5' end modification comprises at least one PS linkage, and wherein one or more of:

i. there is one PS linkage, and the linkage is between the first and second nucleotides;

ii. there are two PS linkages between the first three nucleotides;

iii. there are PS linkages between any one or more of the first four nucleotides; and

iv. there are PS linkages between any one or more of the first five nucleotides.

[00805] Item 92 is the gRNA of Item 91, wherein the 5' end modification further comprises at least one 2'-OMe, 2'-O-moe, inverted abasic, or 2'-F modified nucleotide.

[00806] Item 93 is the gRNA of any one of the preceding Items, wherein the 5' end modification comprises:

i. a modification of one or more of the first 1-4 nucleotides, wherein the modification is a PS linkage, inverted abasic nucleotide, 2'-OMe, 2'-O-moe, or 2'-F;

ii. a modification to the first nucleotide with 2'-OMe, 2'-O-moe, or 2'-F, and an optional one or two PS linkages to the next nucleotide or the first nucleotide of the 3' tail;

iii. a modification to the first or second nucleotide with 2'-OMe, 2'-O-moe, or 2'-F, and optionally one or more PS linkages;

iv. a modification to the first, second, or third nucleotides with 2'-OMe, 2'-O-moe, or 2'-F, and optionally one or more PS linkages; or

v. a modification to the first, second, third, or forth nucleotides with 2'-OMe, 2'-O-moe, or 2'-F, and optionally one or more PS linkages.

[00807] Item 94 is the gRNA of any one of the preceding Items, wherein the 3' end modification comprises at least one PS linkage, and wherein one or more of:

i. there is one PS linkage, and the linkage is between the last and second to last nucleotides;

ii. there are two PS linkages between the last three nucleotides; and

iii. there are PS linkages between any one or more of the last four nucleotides.

[00808] Item 95 is the gRNA of Item 94, wherein the 3' end modification further comprises at least one 2'-OMe, 2'-O-moe, inverted abasic, or 2'-F modified nucleotide.

[00809] Item 96 is the gRNA of any one of the preceding Items, wherein the 3' end modification comprises:

i. a modification of one or more of the last 1-4 nucleotides, wherein the modification is a PS linkage, inverted abasic nucleotide, 2'-OMe, 2'-O-moe, or 2'-F;

ii. a modification to the last nucleotide with 2'-OMe, 2'-O-moe, or 2'-F, and an optional one or two PS linkages to the next nucleotide or the first nucleotide of the 3' tail;

iii. a modification to the last or second to last nucleotide with 2'-OMe, 2'-O-moe, or 2'-F, and optionally one or more PS linkages;

iv. a modification to the last, second to last, or third to last nucleotides with 2'-OMe, 2'-O-moe, or 2'-F, and optionally one or more PS linkages; or

v. a modification to the last, second to last, third to last, or fourth to last nucleotides with 2'-OMe, 2'-O-moe, or 2'-F, and optionally one or more PS linkages.

[00810] Item 97 is the gRNA of any one of the preceding Items, wherein the modification in the repeat/anti-repeat region, the hairpin 1 region, or the hairpin 2 region comprises a modified nucleotide selected from 2'-O-methyl (2'-OMe) modified nucleotide, 2'-O-(2-methoxyethyl) (2'-O-moe) modified nucleotide, a 2'-fluoro (2'-F) modified nucleotide, or a phosphorothioate (PS) linkage between nucleotides.

[00811] Item 98 is the gRNA of any one of the preceding Items, wherein the modification in the repeat/anti-repeat region, the hairpin 1 region, or the hairpin 2 region comprises a modified nucleotide selected from 2'-O-methyl (2'-OMe) modified nucleotide, a 2'-fluoro (2'-F) modified nucleotide, or a phosphorothioate (PS) linkage between nucleotides.

[00812] Item 99 is the gRNA of any one of the preceding Items, wherein the modification in the repeat/anti-repeat region, the hairpin 1 region, or the hairpin 2 region comprises a modified nucleotide selected from 2'-O-methyl (2'-OMe) modified nucleotide or a phosphorothioate (PS) linkage between nucleotides.

[00813] Item 100 is the gRNA of any one of the preceding Items, wherein at least 20%, 30%, 40%, or 50% of the nucleotides are modified nucleotides.

[00814] Item 101 is the gRNA of Item 100, wherein the gRNA comprises modified nucleotides selected from 2'-O-methyl (2'-OMe) modified nucleotide, 2'-O-(2-methoxyethyl)

(2'-O-moe) modified nucleotide, a 2'-fluoro (2'-F) modified nucleotide, a phosphorothioate (PS) linkage between nucleotides, or combinations thereof.

[00815] Item 102 is the gRNA of Item 100 or 101 comprises modified nucleotides selected from 2'-O-methyl (2'-OMe) modified nucleotide, a 2'-fluoro (2'-F) modified nucleotide, a phosphorothioate (PS) linkage between nucleotides, or combinations thereof.

[00816] Item 103 is the gRNA of any one of the preceding Items, wherein nucleotides 1-3 of the guide region are modified and nucleotides in the guide region other than nucleotides 1-3 are not modified.

[00817] Item 104 is the gRNA of any one of the preceding Items, wherein a 3' tail of nucleotide 144 is present in the gRNA, and comprises 2'-O-Me modified nucleotides at nucleotides 141-144 and two PS linkages between nucleotides 141-142 and 142-143 respectively.

[00818] Item 105 is the gRNA of any one of the preceding Items, wherein one or more positions of 49-52, 87-90, or 122-125 is substituted.

[00819] Item 106is a single guide RNA (sgRNA) comprising any one of SEQ ID NOs: 1-9.

[00820] Item 107 is the gRNA of any one of the preceding Items, comprising a nucleotide sequence having at least 99, 98, 97, 96, 95, 94, 93, 92, 91, 90, 85, 80, 75, or 70% identity to the nucleotide sequence of any one of SEQ ID Nos: 1-9.

[00821] Item 108 is the gRNA of any one of the preceding Items, comprising a nucleotide sequence having at least 99, 98, 97, 96, 95, 94, 93, 92, 91, 90, 85, 80, 75, or 70% identity to the nucleotide sequence of any one of SEQ ID Nos: 1-9, wherein the modification at each nucleotide of the gRNA that corresponds to a nucleotide of the reference sequence identifier in Table 1 is identical to or equivalent to the modification shown in the reference sequence identifier in Table 2.

[00822] Item 109 is the gRNA of any one of the preceding Items, comprising a nucleotide sequence having at least 99, 98, 97, 96, 95, 94, 93, 92, 91, or 90% identity to the sequence from X to the 3' end of the nucleotide sequence of any one of SEQ ID Nos: 1-5, 7, 8, 101-291, and 301-494 where X is the first nucleotide of the conserved region.

[00823] Item 110 is the gRNA of any one of Items 106-109, further comprising a 3' tail comprising a 2'-O-Me modified nucleotide.

[00824] Item 111 is the gRNA of any one of the preceding Items, wherein the gRNA directs a nuclease to a target sequence for binding.

[00825] Item 112 is the gRNA of any one of the preceding Items, wherein the gRNA directs a nuclease to a target sequence for inducing a double-strand break within the target sequence.

[00826] Item 113 is the gRNA of any one of the preceding Items, wherein the gRNA directs a nuclease to a target sequence for inducing a single-strand break within the target sequence.

[00827] Item 114 is the gRNA of any one of Items 111-113, wherein the nuclease is a Nme Cas9.

[00828] Item 115 is the gRNA of any one of the preceding Items, wherein the gRNA comprises a conservative substitution, optionally wherein the conservative substitution maintains at least one base pair.

[00829] Item 116 is a composition comprising a gRNA of any one of the preceding Items, associated with a lipid nanoparticle (LNP).

[00830] Item 117 is an LNP composition comprising a gRNA of any one of the preceding Items.

[00831] Item 118 is a composition comprising the gRNA of any one of Items 1-115, or the composition of any one of Items 116-117, further comprising a nuclease or an mRNA which encodes the nuclease.

[00832] Item 119 is the composition of Item 118, wherein the nuclease is a Cas protein.

[00833] Item 120 is the composition of Item 119, wherein the Cas protein is a Nme Cas9.

[00834] Item 121 is the composition of Item 120, wherein the Nme Cas9 is an Nme1 Cas9, an Nme2 Cas9, or an Nme3 Cas9.

[00835] Item 122 is the composition of any one of Items 118-121, wherein the nuclease has a double strand cleaving activity.

[00836] Item 123 is the composition of any one of Items 118-122, wherein the nuclease has a nickase activity.

[00837] Item 124 is the composition of any one of Items 118-123, wherein the nuclease has a dCas DNA binding domain.

[00838] Item 125 is the composition of any one of Items 118-124, wherein the nuclease is modified.

[00839] Item 126 is the composition of Item 125, wherein the modified nuclease comprises a heterologous functional domain.

[00840] Item 127 is the composition of Item 126 wherein the heterologous functional domain is a deaminase.

[00841] Item 128 is the composition of Item 127, further comprising a UGI or a mRNA encoding a UGI.

[00842] Item 129 is the composition of any one of Items 127-128, wherein the heterologous functional domain is a cytidine deaminase.

[00843] Item 130 is the composition of any one of Items 125-129, wherein the modified nuclease comprises a nuclear localization signal (NLS).

[00844] Item 131 is the composition of any one of Items 118-130, comprising an mRNA which encodes the nuclease.

[00845] Item 132 is the composition of Item 131, wherein the mRNA comprises the sequence of any one of SEQ ID NOs: 636-638.

[00846] Item 133is a pharmaceutical formulation comprising the gRNA of any one of Items 1- 115 or the composition of any one of Items 116-132 and a pharmaceutically acceptable carrier.

[00847] Item 134is a method of modifying a target DNA comprising, delivering a Cas protein or a nucleic acid encoding a Cas protein, and any one or more of the following to a cell:

i. the gRNA of any one of Items 1-115;

ii. the composition of any one of Items 116-132; and

iii. the pharmaceutical formulation of Item 133.

[00848] Item 135 is the method of Item 134, wherein the method results in an insertion or deletion in a gene.

[00849] Item 136 is the method of Item 134 or 135, wherein the method results in at least one base edit.

[00850] Item 137 is the method of any one of Items 134-136, further comprising delivering to the cell a template, wherein at least a part of the template incorporates into a target DNA at or near a double strand break site induced by the Cas protein.

[00851] Item 138 is the gRNA of any one of Items 1-115, the composition of Items 116-132, or the pharmaceutical formulation of Item 133 for use in preparing a medicament for treating a disease or disorder.

[00852] Item 139 is use of the gRNA of any one of Items 1-115, the composition of Items 116-132, or the pharmaceutical formulation of Item 133 in the manufacture of a medicament for treating a disease or disorder.

We claim:

1. A guide RNA (gRNA) comprising a guide region and a conserved region, the conserved region comprising one or more of:

(a) a shortened repeat/anti-repeat region, wherein the shortened repeat/anti-repeat region lacks 2-24 nucleotides, wherein

(i) one or more of nucleotides 37-48 and 53-64 is deleted and optionally one or more of nucleotides 37-64 is substituted relative to SEQ ID NO: 500; and

(ii) nucleotide 36 is linked to nucleotide 65 by at least 2 nucleotides; or

(b) a shortened hairpin 1 region, wherein the shortened hairpin 1 lacks 2-10, optionally 2-8 nucleotides, wherein

(i) one or more of nucleotides 82-86 and 91-95 is deleted and optionally one or more of positions 82-96 is substituted relative to SEQ ID NO: 500; and

(ii) nucleotide 81 is linked to nucleotide 96 by at least 4 nucleotides; or

(c) a shortened hairpin 2 region, wherein the shortened hairpin 2 lacks 2-18, optionally 2-16 nucleotides, wherein

(i) one or more of nucleotides 113-121 and 126-134 is deleted and optionally one or more of nucleotides 113-134 is substituted relative to SEQ ID NO: 500; and

(ii) nucleotide 112 is linked to nucleotide 135 by at least 4 nucleotides;

wherein one or both nucleotides 144-145 are optionally deleted relative to SEQ ID NO: 500;

wherein at least 10 nucleotides are modified nucleotides.

2. The gRNA of claim 1, wherein the gRNA is a single-guide RNA (sgRNA) and wherein the gRNA comprises (a) a shortened repeat/anti-repeat region, wherein the shortened repeat/anti-repeat region lacks 2-24 nucleotides, wherein

(i) one or more of nucleotides 37-48 and 53-64 is deleted and optionally one or more of nucleotides 37-64 is substituted relative to SEQ ID NO: 500; and

(ii) nucleotide 36 is linked to nucleotide 65 by at least 2 nucleotides.

3. The gRNA of claim 1 or 2, wherein the guide region has (i) an insertion of one nucleotide or a deletion of 1-4 nucleotides within positions 1-24 relative to SEQ ID NO: 500, or (ii) a length of 24 nucleotides.

4. The gRNA of claim 3, wherein the guide region has a length of 25, 24, 23, 22, 21, or 20 nucleotides, optionally wherein the guide region has a length of 25, 24, 23, or 22 nucleotides.
5. The gRNA of claim 4, wherein the guide region has a length of 23-24 nucleotides.
6. The gRNA of any one of claims 1-5, wherein the gRNA further comprises a 3' tail.
7. The gRNA of claim 6, wherein the 3' tail comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides.
8. The gRNA of claim 7, wherein the 3' tail comprises 1, 2, 3, 4, or 5 nucleotides.
9. The gRNA of any one of claims 6-8, wherein the 3' tail terminates with a nucleotide comprising a uracil or modified uracil.
10. The gRNA of any one of claims 6-9, wherein the 3' tail is 1 nucleotide in length.
11. The gRNA of any one of claims 6-10, wherein the 3' tail consists of a nucleotide comprising a uracil or a modified uracil.
12. The gRNA of any one of claims 6-11, wherein the 3' tail comprises a modification of any one or more of the nucleotides present in the 3' tail.
13. The gRNA of any one of claims 6-12, wherein the modification of the 3' tail is one or more of 2'-O-methyl (2'-OMe) modified nucleotide and a phosphorothioate (PS) linkage between nucleotides.
14. The gRNA of any one of claims 6-13, wherein the 3' tail is fully modified.
15. The gRNA of any one of claims 1-14, wherein the 3' nucleotide of the gRNA is a nucleotide comprising a uracil or a modified uracil.
16. The gRNA of any one of claims 1-5, wherein one or more of nucleotides 144 and 145 are deleted relative to SEQ ID NO: 500.
17. The gRNA of any one of claims 1-5, wherein both nucleotides 144 and 145 are deleted relative to SEQ ID NO: 500.
18. The gRNA of any one of claims 1-5, wherein the gRNA does not comprise a 3' tail.
19. The gRNA of any one of claims 1-18, wherein the shortened repeat/anti-repeat region lacks 2-24 nucleotides.
20. The gRNA of any one of claims 1-19, wherein the shortened repeat/anti-repeat region has a length of 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides.
21. The gRNA of any one of claims 1-20, wherein the shortened repeat/anti-repeat region lacks 12-24, optionally 18-24 nucleotides, optionally 20-22 nucleotides.
22. The gRNA of any one of claims 1-21, wherein the shortened repeat/anti-repeat region has a length of 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides.

23. The gRNA of any one of claims 1-22, wherein the shortened repeat/anti-repeat region has a length of 28, 29, 30, 31, 32, 33, or 34 nucleotides, or 30, 31, or 32 nucleotides.
24. The gRNA of any one of claims 1-23, wherein nucleotides 37-64 of SEQ ID NO: 500 form the upper stem, and one or more base pairs of the upper stem of the shortened repeat/anti-repeat region are deleted.
25. The gRNA of any one of claims 1-24, wherein the upper stem of the shortened repeat/anti-repeat region comprises no more than one, two, three, or four base pairs.
26. The gRNA of any one of claims 1-25, wherein all of positions 39-48 and all of positions 53-62 of the upper stem of the shortened repeat/anti-repeat region are deleted, and optionally nucleotide 38 or 63 is substituted.
27. The gRNA of any one of claims 1-26, wherein all of positions 38-48 and all of positions 53-63 of the upper stem of the shortened repeat/anti-repeat region are deleted, and optionally nucleotide 37 or 64 is substituted.
28. The gRNA of any one of claims 1-27, wherein all of nucleotides 37-48 and 53-64 of the upper stem of the shortened repeat/anti-repeat region are deleted, and optionally nucleotides 36 or 65 is substituted.
29. The Grna of any one of claims 1-28, wherein the shortened repeat/anti-repeat region has a duplex portion 11 base paired nucleotides in length.
30. The gRNA of any one of claims 1-29, wherein the shortened repeat/anti-repeat region has a single duplex portion.
31. The gRNA of any one of claims 1-29, wherein the shortened repeat/anti-repeat region has a first duplex portion and a second duplex portion.
32. The gRNA of claim 31, wherein the second duplex portion is 2-3 base paired nucleotides in length.
33. The gRNA of claim 31, wherein the first duplex portion is 11 base paired nucleotides in length and the second duplex portion is 3 base paired nucleotides in length.
34. The gRNA of any one of claims 1-33, wherein the upper stem of the shortened repeat/anti-repeat region includes one or more substitutions relative to SEQ ID NO: 500.
35. The gRNA of any one of claims 1-34, wherein one or more of nucleotides 49-52 is substituted relative to SEQ ID NO: 500.
36. The gRNA of any one of claims 1-33, wherein the shortened repeat/anti-repeat region is unsubstituted.
37. The gRNA of any one of claims 1-36, wherein the shortened repeat/anti-repeat region has 12-22 modified nucleotides

38. The gRNA of claim 37, wherein the shortened repeat/anti-repeat region does not comprise a modification at nucleotide 76.
39. The gRNA of claim 37, wherein the shortened repeat/anti-repeat does not comprise a phosphorothioate (PS) modification at nucleotide 76.
40. The gRNA of any one of claims 1-39, wherein the shortened hairpin 1 region lacks 2-10 nucleotides, optionally 2-8 or 2-4 nucleotides.
41. The gRNA of any one of claims 1-40, wherein the shortened hairpin 1 region has a length of 13, 14, 15, 16, 17, 18, 19, 20, or 21 nucleotides.
42. The gRNA of claim any one of claims 1-41, wherein the shortened hairpin 1 region has a duplex portion 4-8, optionally 7-8 base paired nucleotides in length.
43. The gRNA of claim any one of claims 1-41, wherein the shortened hairpin 1 region has a single duplex portion.
44. The gRNA of any one of claims 1-43, wherein one or two base pairs of the shortened hairpin 1 region are deleted.
45. The gRNA of any one of claims 1-44, wherein the stem of the shortened hairpin 1 region is seven or eight base paired nucleotides in length.
46. The gRNA of any one of claims 1-45, wherein one or more of positions 85-86 and one or more of nucleotides 91-92 of the shortened hairpin 1 region are deleted.
47. The gRNA of any one of claims 1-46, wherein nucleotides 86 and 91 or nucleotides 85 and 92 of the shortened hairpin 1 region are deleted.
48. The gRNA of any one of claims 1-47, wherein one or more of nucleotides 82-95 of the shortened hairpin 1 region is substituted relative to SEQ ID NO: 500.
49. The gRNA of any one of claims 1-48, wherein one or more of nucleotides 87-90 is substituted relative to SEQ ID NO: 500.
50. The gRNA of any one of claims 1-48, wherein the shortened hairpin 1 region is unsubstituted.
51. The gRNA of any one of claims 1-49, wherein the shortened hairpin 1 region has 6-15 modified nucleotides.
52. The gRNA of any one of claims 1-50, wherein the shortened hairpin 2 region lacks 2-18, optionally 2-16 nucleotides.
53. The gRNA of any one of claims 1-51, wherein the shortened hairpin 2 region has a length of 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides.
54. The gRNA of any one of claims 1-52, wherein the shortened hairpin 2 region has a length of 28, 29, 30, 31, 32, 33, or 34 nucleotides.

55. The gRNA of any one of claims 1-53, wherein one or more of nucleotides 113-121 and one or more of nucleotides 126-134 of the shortened hairpin 2 region are deleted.
56. The gRNA of any one of claims 1-54, wherein the shortened hairpin 2 region comprises an unpaired region.
57. The gRNA of any one of claims 1-55, wherein the shortened hairpin 2 region has two duplex portions.
58. The gRNA of any one of claims 1-56, wherein the shortened hairpin 2 region has a duplex portion of 4 base paired nucleotides in length.
59. The gRNA of any one of claims 57-58, wherein the shortened hairpin 2 region has a duplex portion of 4-8 base paired nucleotides in length.
60. The gRNA of any one of claims 57-59, wherein the shortened hairpin 2 region has a duplex portion of 4-6 base paired nucleotides in length.
61. The gRNA of any one of claims 1-60, wherein nucleotides 109-138 of SEQ ID NO: 500 form the upper stem, and the upper stem of the shortened hairpin 2 region comprises one, two, three, or four base pairs.
62. The gRNA of any one of claims 1-61, wherein at least one pair of nucleotides 113 and 134, nucleotides 114 and 133, nucleotides 115 and 132, nucleotides 116 and 131, nucleotides 117 and 130, nucleotides 118 and 129, nucleotides 119 and 128, nucleotides 120 and 127, and nucleotides 121 and 126 are deleted.
63. The gRNA of any one of claims 1-62, wherein all of positions 113-121 and 126-134 of the shortened hairpin 2 region are deleted.
64. The gRNA of any one of claims 1-63, wherein one or more of nucleotides 113-134 of the shortened hairpin 2 region is substituted relative to SEQ ID NO: 500.
65. The gRNA of any one of claims 1-64, wherein one or more of nucleotides 122-125 is substituted relative to SEQ ID NO: 500.
66. The gRNA of any one of claims 1-64, wherein the shortened hairpin 2 region is unsubstituted.
67. The gRNA of claim any one of claims 1-66, wherein the shortened hairpin 2 region has 6-15 modified nucleotides.
68. The gRNA of any one of claims 1-67, wherein the guide region of the gRNA comprises at least two modified nucleotides, optionally at least four modified nucleotides.
69. The gRNA of any one of claims 1-68, wherein the guide region of the gRNA comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 modified nucleotides, optionally 1, 2, or 3 modified nucleotides.

70. The gRNA of any one of claims 1-69, wherein the guide region of the gRNA comprises 4, 5, 6, 7, 8, 9, 10, 11, or 12 modified nucleotides.
71. The gRNA of any one of claims 1-70, wherein the guide region of the gRNA comprises 6, 7, 8, 9, 10, 11, or 12 modified nucleotides.
72. The gRNA of any one of claims 1-71, wherein the guide region does not comprise a modified nucleotide 3' of the first three nucleotides of the guide region.
73. The gRNA of any one of claims 1-66, wherein the guide region does not comprise a modified nucleotide.
74. The gRNA of any one of claims 1-72, wherein the gRNA comprises a 5' end modification.
75. The gRNA of any one of claims 1-74, wherein the gRNA comprises a 3' end modification.
76. The gRNA of any one of claims 1-75, wherein the gRNA comprises a 5' end modification and a 3' end modification.
77. The gRNA of any one of claims 1-76, comprising a modification in the upper stem region of the repeat/anti-repeat region.
78. The gRNA of any one of claims 1-77, comprising a modification in the hairpin 1 region.
79. The gRNA of any one of claims 1-78, comprising a modification in the hairpin 2 region.
80. The gRNA of claim 79, wherein the modification in the hairpin 2 region comprises a modification at 1, 2, 3, or 4 nucleotides of nucleotides 106-109.
81. The gRNA of claim 80, wherein the modification in the hairpin 2 region comprises a modification at each of nucleotides 106-109.
82. The gRNA of any one of claims 80 or 81, wherein the modification comprises a 2'-O-methyl (2'-O-Me) modification.
83. The gRNA of any one of claims 1-82, comprising a 3' end modification, and comprising a modification in the upper stem region of the repeat/anti-repeat region.
84. The gRNA of any one of claims 1-83, comprising a 3' end modification, and a modification in the hairpin 1 region.
85. The gRNA of any one of claims 1-83, comprising a 3' end modification, and a modification in the hairpin 2 region.
86. The gRNA of any one of claims 1-85, comprising a 5' end modification, and comprising a modification in the upper stem region of the repeat/anti-repeat region.
87. The gRNA of any one of claims 1-86, comprising a 5' end modification, and a modification in the hairpin 1 region.
88. The gRNA of any one of claims 1-87, comprising a 5' end modification, and a modification in the hairpin 2 region.

89. The gRNA of any one of claims 1-88, comprising a 5' end modification, a modification in the upper stem region of the repeat/anti-repeat region, and a 3' end modification.
90. The gRNA of any one of claims 1-89, comprising a 5' end modification, a modification in the hairpin 1 region, and a 3' end modification.
91. The gRNA of any one of claims 1-90, comprising a 5' end modification, a modification in the hairpin 1 region, a modification in the hairpin 2 region, and a 3' end modification.
92. The gRNA of any one of claims 1-91, comprising a 5' end modification, a modification in the repeat/anti-repeat region, a modification in the hairpin 1 region, a modification in the hairpin 2 region, and a 3' end modification.
93. The gRNA of any one of claims 1-92, wherein the modification in the repeat/anti-repeat region does not comprise a phosphorothioate (PS) modification at nucleotide 76.
94. The gRNA of any one of claims 1-93, wherein the modification in the repeat/anti-repeat region does not comprise a modification at nucleotide 76.
95. The gRNA of any one of claims 74-94, wherein the 5' end modification comprises a modified nucleotide selected from a 2'-O-methyl (2'-OMe) modified nucleotide, 2'-O-(2-methoxyethyl) (2'-O-moe) modified nucleotide, a 2'-fluoro (2'-F) modified nucleotide, a phosphorothioate (PS) linkage between nucleotides, or an inverted abasic modified nucleotide.
96. The gRNA of any one of the claims 74-95, wherein the 3' end modification comprises a modified nucleotide selected from a 2'-O-methyl (2'-OMe) modified nucleotide, 2'-O-(2-methoxyethyl) (2'-O-moe) modified nucleotide, a 2'-fluoro (2'-F) modified nucleotide, a phosphorothioate (PS) linkage between nucleotides, or an inverted abasic modified nucleotide .
97. The gRNA of any one of the claims 74-96, wherein the 5' end modification comprises any of:
    i. a modification of any one or more of the first 1, 2, 3, or 4 nucleotides;
    ii. one modified nucleotide;
    iii. two modified nucleotides;
    iv. three modified nucleotides; and
    v. four modified nucleotides.
98. The gRNA of any one of claims 74-97, wherein the 5' end modification comprises one or more of:
    i. a phosphorothioate (PS) linkage between nucleotides;

ii. a 2'-OMe modified nucleotide;
iii. a 2'-O-moe modified nucleotide;
iv. a 2'-F modified nucleotide; and
v. an inverted abasic modified nucleotide.

99. The gRNA of any one of claims 74-98, wherein the 3' end modification comprises any of:
i. a modification of any one or more of the last 4, 3, 2, or 1 nucleotides;
ii. one modified nucleotide;
iii. two modified nucleotides;
iv. three modified nucleotides; and
v. four modified nucleotides.

100. The gRNA of any one of claims 74-99, wherein the 3' end modification comprises one or more of:
i. a phosphorothioate (PS) linkage between nucleotides;
ii. a 2'-OMe modified nucleotide;
iii. a 2'-O-moe modified nucleotide;
iv. a 2'-F modified nucleotide; and
v. an inverted abasic modified nucleotide.

101. The gRNA of any one of claims 74-100, wherein the 5' end modification comprises at least one PS linkage, and wherein one or more of:
i. there is one PS linkage, and the linkage is between the first and second nucleotides;
ii. there are two PS linkages between the first three nucleotides;
iii. there are PS linkages between any one or more of the first four nucleotides; and
iv. there are PS linkages between any one or more of the first five nucleotides.

102. The gRNA of claim 101, wherein the 5' end modification further comprises at least one 2'-OMe, 2'-O-moe, inverted abasic, or 2'-F modified nucleotide.

103. The gRNA of any one of claims 1-102, wherein the 5' end modification comprises:
i. a modification of one or more of the first 1-4 nucleotides, wherein the modification is a PS linkage, inverted abasic nucleotide, 2'-OMe, 2'-O-moe, or 2'-F;

ii. a modification to the first nucleotide with 2'-Ome, 2'-O-moe, or 2'-F, and an optional one or two PS linkages to the next nucleotide or the first nucleotide of the 3' tail;
iii. a modification to the first or second nucleotide with 2'-Ome, 2'-O-moe, or 2'-F, and optionally one or more PS linkages;
iv. a modification to the first, second, or third nucleotides with 2'-Ome, 2'-O-moe, or 2'-F, and optionally one or more PS linkages; or
v. a modification to the first, second, third, or forth nucleotides with 2'-Ome, 2'-O-moe, or 2'-F, and optionally one or more PS linkages.

104. The gRNA of any one of claims 1-103, wherein the 3' end modification comprises at least one PS linkage, and wherein one or more of:
vi. there is one PS linkage, and the linkage is between the last and second to last nucleotides;
vii. there are two PS linkages between the last three nucleotides; and
viii. there are PS linkages between any one or more of the last four nucleotides.

105. The gRNA of claim 104, wherein the 3' end modification further comprises at least one 2'-Ome, 2'-O-moe, inverted abasic, or 2'-F modified nucleotide.

106. The gRNA of any one of claims 1-105, wherein the 3' end modification comprises:
ix. a modification of one or more of the last 1-4 nucleotides, wherein the modification is a PS linkage, inverted abasic nucleotide, 2'-OMe, 2'-O-moe, or 2'-F;
x. a modification to the last nucleotide with 2'-OMe, 2'-O-moe, or 2'-F, and an optional one or two PS linkages to the next nucleotide or the first nucleotide of the 3' tail;
xi. a modification to the last or second to last nucleotide with 2'-OMe, 2'-O-moe, or 2'-F, and optionally one or more PS linkages;
xii. a modification to the last, second to last, or third to last nucleotides with 2'-OMe, 2'-O-moe, or 2'-F, and optionally one or more PS linkages; or
xiii. a modification to the last, second to last, third to last, or fourth to last nucleotides with 2'-OMe, 2'-O-moe, or 2'-F, and optionally one or more PS linkages.

107. The gRNA of any one of claims 1-106, wherein the modification in the repeat/anti-repeat region, the hairpin 1 region, or the hairpin 2 region comprises a modified nucleotide selected from 2'-O-methyl (2'-OMe) modified nucleotide, 2'-O-(2-methoxyethyl) (2'-O-moe) modified nucleotide, a 2'-fluoro (2'-F) modified nucleotide, or a phosphorothioate (PS) linkage between nucleotides.

108. The gRNA of any one of claims 1-106, wherein the modification in the repeat/anti-repeat region, the hairpin 1 region, or the hairpin 2 region comprises a modified nucleotide selected from 2'-O-methyl (2'-OMe) modified nucleotide, a 2'-fluoro (2'-F) modified nucleotide, or a phosphorothioate (PS) linkage between nucleotides.

109. The gRNA of any one of claims 1-106, wherein the modification in the repeat/anti-repeat region, the hairpin 1 region, or the hairpin 2 region comprises a modified nucleotide selected from 2'-O-methyl (2'-OMe) modified nucleotide or a phosphorothioate (PS) linkage between nucleotides.

110. The gRNA of any one of claims 1-109, wherein the modification in the repeat/anti-repeat region does not comprise a phosphorothioate modification at nucleotide 76.

111. The gRNA of any one of claims 1-110, wherein the modification in the repeat/anti-repeat region does not comprise a modification at nucleotide 76.

112. The gRNA of any one of claims 1-111, wherein at least 20%, 30%, 40%, or 50% of the nucleotides are modified nucleotides.

113. The gRNA of claim 112, wherein the gRNA comprises modified nucleotides selected from 2'-O-methyl (2'-OMe) modified nucleotide, 2'-O-(2-methoxyethyl) (2'-O-moe) modified nucleotide, a 2'-fluoro (2'-F) modified nucleotide, a phosphorothioate (PS) linkage between nucleotides, or combinations thereof.

114. The gRNA of any one of claims 1-113, wherein the modification comprises a modification at 1, 2, 3, or 4 nucleotides of nucleotides 106-109.

115. The gRNA of any one of claims 113 or 114, wherein the modification comprises a modification at each of nucleotides 106-109.

116. The gRNA of any one of claims 114-115, wherein the modification comprises a 2'-O-methyl modification.

117. The gRNA of any one of claims 112-116, wherein the gRNA comprises modified nucleotides selected from 2'-O-methyl (2'-Ome) modified nucleotide, a 2'-fluoro (2'-F) modified nucleotide, a phosphorothioate (PS) linkage between nucleotides, or combinations thereof.

118. The gRNA of any one of claims 1-117, wherein nucleotides 1-3 of the guide region are modified and nucleotides in the guide region other than nucleotides 1-3 are not modified.

119. The gRNA of any one of claims 1-118, wherein a 3' tail of nucleotide 144 is present in the gRNA, and comprises 2'-O-Me modified nucleotides at nucleotides 141-144 and two PS linkages between nucleotides 141-142 and 142-143 respectively.

120. The gRNA of any one of claims 1-120, wherein one or more positions of 49-52, 87-90, or 122-125 is substituted.

121. A single guide RNA (sgRNA) comprising any one of SEQ ID NOs: 1-19 and 21-42.

122. The gRNA of any one of claims 1-121, comprising a nucleotide sequence having at least 99, 98, 97, 96, 95, 94, 93, 92, 91, 90, 85, 80, 75, or 70% identity to the nucleotide sequence of any one of SEQ ID Nos: 1-19 and 21-42.

123. The gRNA of any one of claims 1-121, comprising a nucleotide sequence having at least 99, 98, 97, 96, 95, 94, 93, 92, 91, 90, 85, 80, 75, or 70% identity to the nucleotide sequence of any one of SEQ ID Nos: 1-19 and 21-42, wherein the modification at each nucleotide of the gRNA that corresponds to a nucleotide of the reference sequence identifier in Table 1 is identical to or equivalent to the modification shown in the reference sequence identifier in Table 2.

124. The gRNA of any one of claims 1-122, comprising a nucleotide sequence having at least 99, 98, 97, 96, 95, 94, 93, 92, 91, or 90% identity to the sequence from X to the 3' end of the nucleotide sequence of any one of SEQ ID Nos: 1-5, 7, 8, 11, 12, 13, 15, 16, 18, 19, 21, 23, 24, 26, 27, 28, 30, 31, 33, 34, 35, 37, 39, 41, 101-291, 301-494, 931-946, 951, and 952, where X is the first nucleotide of the conserved region.

125. The gRNA of any one of claims 121-124, further comprising a 3' tail comprising a 2'-O-Me modified nucleotide.

126. The gRNA of any one of claims 1-125, wherein the gRNA directs a nuclease to a target sequence for binding.

127. The gRNA of any one of claims 1-126, wherein the gRNA directs a nuclease to a target sequence for inducing a double-strand break within the target sequence.

128. The gRNA of any one of claims 1-127, wherein the gRNA directs a nuclease to a target sequence for inducing a single-strand break within the target sequence.

129. The gRNA of any one of claims 126-129, wherein the nuclease is a Nme Cas9.

130. The gRNA of any one of claims 1-129, wherein the gRNA comprises a conservative substitution, optionally wherein the conservative substitution maintains at least one base pair.

131. A composition comprising a gRNA of any one of claims 1-130, associated with a lipid nanoparticle (LNP).

132. An LNP composition comprising a gRNA of any one of claims 1-130.

133. A composition comprising the gRNA of any one of claims 1-130, or the composition of any one of claims 131-132, further comprising a nuclease or an mRNA which encodes the nuclease.

134. The composition of claim 133, wherein the nuclease is a Cas protein.

135. The composition of claim 134, wherein the Cas protein is a Nme Cas9.

136. The composition of claim 135, wherein the Nme Cas9 is an Nme1 Cas9, an Nme2 Cas9, or an Nme3 Cas9.

137. The composition of any one of claims 133-136, wherein the nuclease has a double strand cleaving activity.

138. The composition of any one of claims 133-137, wherein the nuclease has a nickase activity.

139. The composition of any one of claims 133-138, wherein the nuclease has a dCas DNA binding domain.

140. The composition of any one of claims 133-139, wherein the nuclease is modified.

141. The composition of claim 140, wherein the modified nuclease comprises a heterologous functional domain.

142. The composition of claim 141, wherein the heterologous functional domain is a deaminase.

143. The composition of claim 142, further comprising a UGI or a mRNA encoding a UGI.

144. The composition of any one of claims 142-143, wherein the heterologous functional domain is a cytidine deaminase.

145. The composition of any one of claims 140-144, wherein the modified nuclease comprises a nuclear localization signal (NLS).

146. The composition of any one of claims 133-145, comprising an mRNA which encodes the nuclease.

147. The composition of claim 146, wherein the mRNA comprises the sequence of any one of SEQ ID NOs: 636-638.

148. A pharmaceutical formulation comprising the gRNA of any one of claims 1- 130 or the composition of any one of claims 131-147 and a pharmaceutically acceptable carrier.

149. A method of modifying a target DNA comprising, delivering a Cas protein or a nucleic acid encoding a Cas protein, and any one or more of the following to a cell:

i. the gRNA of any one of claims 1-130;
ii. the composition of any one of claims 131-147; and
iii. the pharmaceutical formulation of claim 148.

150. The method of claim 149, wherein the method results in an insertion or deletion in a gene.

151. The method of claim 149 or 150, wherein the method results in at least one base edit.

152. The method of any one of claims 149-151, further comprising delivering to the cell a template, wherein at least a part of the template incorporates into a target DNA at or near a double strand break site induced by the Cas protein.

153. The gRNA of any one of claims 1-130, the composition of claims 131-147, or the pharmaceutical formulation of claim 148 for use in preparing a medicament for treating a disease or disorder.

154. Use of the gRNA of any one of claims 1-130, the composition of claims 131-147, or the pharmaceutical formulation of claim 148 in the manufacture of a medicament for treating a disease or disorder.


%Editing
0
5
10
15
RNAWT-145
RNA9-102
RNA7-106
RNA8-106
RNA6-106
RNA6b-110
RNA5-112
RNA4-116
RNA3-122
RNA2-126
ES-100
ES-121
RNAWT-145
RNA17-101
RNA18-103
RNA15-105
RNA16-105
RNA13-107
RNA14-109
RNA12-111
RNA11-113
RNA10-115
RNAWT-145
R10B-111
R10E-109
R10F-113
R10G-113
R10H-113
R10I-113
R10J-113
R19-112
Round 1
Round 2
Round 3

Fig. 1


CR018648
CR018656
Editing %
0
10
20
30
40
TR018227
TR018228
TR018229
TR018230
TR018231
TR018232
TR018233
TR018234
TR018235
TR018236
TR018237
TR018238
TR018239
TR018240
TR018241
TR018242
tracrRNA

Fig. 2


% Editing
0
20
40
60
80
Guide ID
G020031
G020032
G020033
G020034
G020035
G020036
G020037
G020038
G020039
G020040
G020041
G020042
G020043
G020044
G020045
G020046
G020047
G020048
G020049
G020050
G020051
G020052
G020053
G020054
G020055
G020056
G020057
G020058
G020059
G020060
G020061
G020062
G020064
G020066
G020067
G020068
G020069
G020070
G020071
G020072
G020073

Fig. 3


% Editing
100
80
60
40
20
0
Guide ID
G020044
G020054
G020057
G020058
G020063
G020065
G020070
G020073
G020711
G020712
G020713
G020714
G020715
G020716
G020717
G020718
G020719
G020720
G020721
G020722
G020723
G020724
G020725
G020726
G020727
G020728
G020729
G020730
G020731
G020732
G020733
G020734
G020735
G020736
G020737
G020738
G020739
G020740
G020741
G020742
G020743
G020744
G020745
G020746
G020747
G020748
G020749
G020750
G020751
G020752
G020753
G020754
G020755
G020756

Fig. 4


100
80
60
40
20
0
Editing %
0
20
40
60
sgRNA concentration (nM)
SpyCas9 with G000502
mRNA Q with G021320
mRNA Q with G021256

Fig. 5


40
35
30
25
20
15
10
5
0
% Editing
0.01
0.1
1
10
100
Guide concentration (nM)
G017564
G017565
G017566

Fig. 6


50
45
40
35
30
25
20
15
10
5
0
Editing %
0.001
0.01
0.1
1
10
LNP (ng/uL)
mRNA C
mRNA B
mRNA D

Fig. 7


sgRNA:mRNA
1:4
1:2
1:1
2:1
4:1
8:1
% Editing
100
90
80
70
60
50
40
30
20
10
0
0.0001
0.001
0.01
0.1
1
10
LNP (ng/uL)

Fig. 8A


pgRNA:sgRNA
1:4
1:2
1:1
2:1
4:1
8:1
% Editing
100
90
80
70
60
50
40
30
20
10
0
0.0001
0.001
0.01
0.1
1
10
LNP (ng/uL)

Fig. 8B


100
80
60
40
20
0
% Editing
0.000001
0.00001
0.0001
0.001
0.01
0.1
1
gRNA LNP(ng/uL)
G021844
G023416
G023417
G023418
G023414
G023415
G023419
G023413

Fig. 9


Editing of TS-25
% Editing
40
30
20
10
TR018617
TR018618
TR018619
TR018620
TR018621
TR018622
tracrRNA
CR017872
CR017873
CR018473
CR018645
CR018646
CR018647
CR018648
CR018649
crRNA

Fig. 10A


Editing of TS-47
% Editing
40
30
20
10
tracrRNA
TR018617
TR018618
TR018619
TR018620
TR018621
TR018622
CR018650
CR018651
CR018652
CR018653
CR018654
CR018655
CR018656
CR018657
crRNA

Fig. 10B


% Editing
40
35
30
25
20
15
10
5
0
tracrRNA
TR018477
TR018478
TR018479
TR018480
TR018481
TR018482
TR018483
TR018484
TR018485
TR018486
TR018487
TR018488
TR018489
TR018490
TR018491
TR018492
TR018493
TR018494
TR018495
TR018496
TR018497
TR018498
TR018499
TR018500
CR018473
CR018474
CR018475
CR018476
crRNA

Fig. 11



Fig. 12A



Fig. 12B



Fig. 12C



Fig. 12D


40
30
20
10
0
% Editing
0.0
0.5
1.0
1.5
2.0
2.5
ng/uL mRNA
mRNA H
mRNA I
mRNA J
mRNA K
mRNA L
mRNA N
mRNA C

Fig. 13



Fig. 14A



Fig. 14B



Fig. 14C



Fig. 14D



Fig. 14E



Fig. 14F


100
50
0
% Editing
0.0001 0.001 0.01 0.1 1 10 100
ng mRNA LNP
mRNA P (2xNLS) + sgRNA G021536
mRNA P (2xNLS) + pgRNA G021844
mRNA M (1xNLS) + sgRNA G021536
mRNA M (1xNLS) + pgRNA G021844

Fig. 15


100
80
60
40
20
0
% Editing
10-6 10-5 10-4 10-3 10-2 10-1 100 101 102
ng/ul mRNA LNP
mRNA C
mRNA J
mRNA Q
mRNA N
mRNA P
mRNA M
mRNA O

Fig. 16



Fig. 17



Fig. 18A



Fig. 18B



Fig. 18C



Fig. 18D



Fig. 18E



Fig. 18F



Fig. 19



Fig. 20A



Fig. 20B



Fig. 20C



Fig. 20D



Fig. 20E



Fig. 21


Cas9-HiBit sgRNA
Cas9-HiBit pgRNA
Cas9 pgRNA
p=0.03
Percent indels
80
60
40
20
0
TSS
0.03 0.1
0.03 0.1
0.03 0.1
mg/kg

Fig. 22


Nme2Cas9
Cas9 + pgRNA
Base Editor + pgRNA
SpyCas9 base editor + sgRNA
Indel %
C-to-A/G %
C-to-T %
Percent editing
80
60
40
20
0
TSS 0.03 0.1 0.03 0.1 0.03 0.1
MPK

Fig. 23


5'-
1
10
20
30
40
50
60
76
88
100
110
120
130
140
145
-3'
Target-binding region
Bases not amenable to PED replacement
Regions amenable to single or pairwise truncations

Fig. 24


G021536
101-nt sgRNA
5′ –C*C*A*AGUGUCUUCCAGUACGAUUUGG●U* A–A●G ––C–A–Ů–3′
1 5 10 15 20

Fig. 25


100
80
60
40
20
0
% Indels
0.1
1
10
100
ng LNP
G021536
G021844
G027492
G027493
G027494
G027495
G027496

Fig. 26


1000
800
600
400
200
0
Serum TTR (ug/ml)
TSS
G021844
G021536
G027492
G027493
G027494
G027495
G027496

Fig. 27


% Indels
100
80
60
40
20
0
TSS
G021536
G027492
G027493
G027494
G027495
G027496
G021844

Fig. 28


Serum TTR (µg/ml)
1500
1000
500
0
Vehicle
0.01 mpk G021844
0.03 mpkG021844
0.01 mpk G021536
0.03 mpk G021536
0.01mpk G027492
0.03mpk G027492
0.01mpk G027495
0.03mpk G027495

Fig. 29


% Indels
80
60
40
20
0
Vehicle
0.01 mpk G021844
0.03 mpkG021844
0.01 mpk G021536
0.03 mpk G021536
0.01mpk G027492
0.03mpk G027492
0.01mpk G027495
0.03mpk G027495
Vehicle
0.01 mpk G021844
0.03 mpkG021844
0.01 mpk G021536
0.03 mpk G021536
0.01mpk G027492
0.03mpk G027492
0.01mpk G027495
0.03mpk G027495

Fig. 30


CD3- Population (%)
60
40
20
0
CD3-
G024103
G024104
G024108
G024109
G024110
G024111
G024112
G024113
G024114
Nme Guides

Fig. 31


120
100
80
60
40
20
0
CD3- (%)
G028844
G028845
G028846
G028847
G028848
G028849
G028850
G028851
G028852
G028853 (Nme1 Control)
G021469 (Nme2 Control)
Guide ID

Fig. 32


60000
40000
20000
0
Luminescence (RLUs)
600
200
66.6
22.2
7.4
mRNA (ng)
mRNA X
mRNA Y
mRNA V
mRNA Z

Fig. 33


120
100
80
60
40
20
0
CD3- (%)
1
10
100
1000
mRNA (ng)
mRNA X
mRNA Y
mRNA V
mRNA Z

Fig. 34


100
80
60
40
20
0
% Indels
0.00001
0.0001
0.001
0.01
0.1
1
guide LNP (ng/uL)
G024739
G024741
G024743

Fig. 35


100
80
60
40
20
0
% Indels
0.001
0.01
0.1
1
10
LNP (ng/uL)
G024739:mRNA O Mixed 2:1
G024739:mRNA O Coformulated 2:1
G024739:mRNA AA Mixed 2:1
G024739:mRNA AA Coformulated 2:1
G024739:mRNA AA Mixed 1:2
G024739:mRNA AA Coformulated 1:2

Fig. 36


101mer
1 5 10 15 20
5′-C*C*A*AGUGUCUUCCAGUACGAUUUGG•U A- A•G --C-A-Ú*-3′

Fig. 37


105mer
1 5 10 15 20
5′-C*C*A*AGUGUCUUCCAGUACGAUUUGG•U A- A•G --C-A-Ú*-3′

Fig. 38


Serum TTR (ug/mL)
Serum TTR (ug/mL)
1000
800
600
400
200
0
TSS
G021536
G029377
G029384
G029392
G029391
G029390
Guide ID

Fig. 39


Liver editing
Editing (%)
50
40
30
20
10
0
TSS
G021536
G029377
G029384
G029392
G029391
G029390
Guide ID

Fig. 40


100
80
60
40
20
0
Editing %
G029381
G029377
G029378
G029379
G029380
G021536
0.02
0.064
0.19
0.5
1.7
5.1
15.5
46.5
Guide concentration (nM)

Fig. 41


100
80
60
40
20
0
Editing %
0.02
0.064
0.19
0.5
1.7
5.1
15.5
46.5
Guide concentration (nM)
G029384
G029383
G029382
G029385
G029386
G029387
G029388
G029389
G029390
G029391
G029392
G021536

Fig. 42